<SEC-DOCUMENT>0001104659-26-057100.txt : 20260507
<SEC-HEADER>0001104659-26-057100.hdr.sgml : 20260507
<ACCEPTANCE-DATETIME>20260507160522
ACCESSION NUMBER:		0001104659-26-057100
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		81
CONFORMED PERIOD OF REPORT:	20260331
FILED AS OF DATE:		20260507
DATE AS OF CHANGE:		20260507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Corvus Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001626971
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				464670809
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37719
		FILM NUMBER:		26953097

	BUSINESS ADDRESS:	
		STREET 1:		901 GATEWAY BLVD, THIRD FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 900-4520

	MAIL ADDRESS:	
		STREET 1:		901 GATEWAY BLVD, THIRD FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>crvs-20260331x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 11.3.0.1 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 5/7/2026 12:52:07 PM -->
<!-- iXBRL Library version: 1.0.9561.79 -->
<!-- iXBRL Service Job ID: 00000000-0000-0000-0000-000000000000 -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2025" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:crvs="http://www.corvuspharma.com/20260331" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title>Corvus Pharmaceuticals, Inc._March 31, 2026</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" name="us-gaap:AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration" id="Hidden_mkKD2jkV_kmgGThlOZM9jA">http://fasb.org/us-gaap/2025#RelatedPartyMember</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" xs:nil="true" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" name="us-gaap:CommitmentsAndContingencies" id="Hidden_IJ6KV1ib5UaSDg1-LEzK6g"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" xs:nil="true" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden__smBmUS0R0e8VdwDFfJpRA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_f8lQR0w4Tky013YtD5Xtrw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_Ggjt4LQL406hrMZNS22yKA">0</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:EntityCentralIndexKey" id="Tc_4fsmTbNo0Ua9Zq3nEaLmvA_2_1">0001626971</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:CurrentFiscalYearEndDate" id="Tc_hVbF8Ubt7ky3tkVE8s4O_g_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:DocumentFiscalYearFocus" id="Tc_6XZg3WUwoUmjvS2mwhgVAw_4_1">2026</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:DocumentFiscalPeriodFocus" id="Tc_0cJgo-HWAkuCAuL0ETt4XQ_5_1">Q1</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:AmendmentFlag" id="Tc_GaCJY-61e0OrGUF4Skhkbg_6_1">false</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" name="us-gaap:AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration" id="Hidden_y97SYRsuwU6VBvyrhRYUYw">http://fasb.org/us-gaap/2025#RelatedPartyMember</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_FgprKYhvx0GT34f5BC1wWw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" xs:nil="true" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" name="us-gaap:PreferredStockValue" id="Hidden_eNKIckLa0UyHrLM1g_0mcg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" xs:nil="true" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" name="us-gaap:PreferredStockValue" id="Hidden_gYog-BNdUE-FBM0D6OXi_w"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_bQBBXjHiDkurSgRMYzw24g">84090424</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_jqJW3JRuLEelbaPw9XFCKw">74696629</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="crvs-20260331.xsd"/></ix:references><ix:resources><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_FFOllL2fhkyBY8izLXeb2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_2G3cA69Y60Kut3dIpiEj-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0I7JIIL4bUeBisCBXAmQJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rHbcLVDNhk-yPYw6tJnvKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_23_2026_To_1_23_2026_srt_CounterpartyNameAxis_crvs_PuissanceCapitalManagementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_vaIDQou6BEeDZj4w0IamBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:PuissanceCapitalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-23</xbrli:startDate><xbrli:endDate>2026-01-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_23_2026_To_1_23_2026_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_lGZZMu3Hk0q46YOWfhYujg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-23</xbrli:startDate><xbrli:endDate>2026-01-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_-EcyvuEUt0iqD5CMwxh5TA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_JefferiesLlcMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_AtMarketOfferingMember_xtxU8hDdr0aP8Izzn0-FoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:JefferiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_6_2024_To_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonStockSharesAndCommonStockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_qes8akhL1UOvGAi6lmbg1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvs:CommonStockSharesAndCommonStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-06</xbrli:startDate><xbrli:endDate>2024-05-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7NENmaw0i0-q2C5PDhSUwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FLIZWim2CEmiyA6jK8gsKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0whMsvUI40mL2d3_7eOvsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IY-IxZUYbEqP1aoewvItXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1-iFrDRj3UuxNy56xcRv_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bjsu6eUjm0mYlqMaqNdetA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zBkc-2BhYEWNDNtaR_EzxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AWAcFg_V-k6IIf18aUHL0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_tctkN7xylEqaixLGu7rKQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Cb6CWZHa8U-FLgwfn7_C_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MPfkm448p0mSNurWEEYd7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_z2-y6giFRkGYS5lYBANhoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsAndCommonStockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Tlt-RbPRSUqh-Yw0_LG3kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvs:PrefundedWarrantsAndCommonStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_OZWZ5jrEbUGvUd0flVPW_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvs:EquityIncentiveAwardPlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_2sdE3FrdcUCS_x2faPApVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvs:EquityIncentiveAwardPlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2016_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2014Member_HBYSs8y8e0q-y5FdS0ZbgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvs:EquityIncentiveAwardPlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_9SSsEi9c802Zz5UyJSFtsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvs:EquityIncentiveAwardPlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2016_To_3_31_2016_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_i1V10D_o5EOltzgKO-ZZrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvs:EquityIncentiveAwardPlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2016_To_3_31_2016_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_nSKTEU2cHUaYGFDps5DZNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvs:EquityIncentiveAwardPlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2014_To_2_28_2014_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2014Member_ZPEqkJZSKkC77f8CpQy3Og"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvs:EquityIncentiveAwardPlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-02-01</xbrli:startDate><xbrli:endDate>2014-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_23_2026_srt_CounterpartyNameAxis_crvs_PuissanceCapitalManagementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_hqg4T-aXuUSSmEgLg3oLVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:PuissanceCapitalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_23_2026_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_EBLWg8HfXUaxzZXp3DlZnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_IconPlcMember_us-gaap_RelatedPartyTransactionAxis_crvs_ServicesSupportClinicalTrialsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_87RrLXQb50614pVDRnXCIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:IconPlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">crvs:ServicesSupportClinicalTrialsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_crvs_IconPlcMember_us-gaap_RelatedPartyTransactionAxis_crvs_ServicesSupportClinicalTrialsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_m6-TI6NhC0ODOujZoxCV1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:IconPlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">crvs:ServicesSupportClinicalTrialsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_5_2015_To_11_5_2015_srt_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_cxY8H5-g_EGIH2ELcc-HaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:VernalisRAndDLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-11-05</xbrli:startDate><xbrli:endDate>2015-11-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2015_To_12_31_2015_srt_CounterpartyNameAxis_crvs_ScrippsResearchInstituteMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_XMrt33ULGkeQ_-gbvlHdKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:ScrippsResearchInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2017_To_4_30_2017_srt_CounterpartyNameAxis_crvs_MonashLicenseMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_a9cCB_fmJ0qXM_jhei5r1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:MonashLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-04-01</xbrli:startDate><xbrli:endDate>2017-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_R_4AduDylk-cunlIwrPmxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_6C25sOE9Ikmp0oeoupptOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_1OU2yiImZUyepALNkZ8rTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_YgSDQjrssE-QgSvTIuicjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_AIlQrJQUYUCBdCBov2bs-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_66ZNx4o7xE6nChx728HdAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_HK6hD7pbIEy_GhLi3vMwpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_uu4IdM0C2U-qNTnXiqDKRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvs:CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_30_2025_To_6_30_2025_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_sAkMcg3a40yNfpBDpGFwVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvs:CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_13_2026_To_3_13_2026_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_AtMarketOfferingMember_JM0TXSQCVEWG7UWlAYRf6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-03-13</xbrli:startDate><xbrli:endDate>2026-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_23_2026_To_1_23_2026_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_C6QNxTSO-0mAbUm6YypDqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-23</xbrli:startDate><xbrli:endDate>2026-01-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_20_2026_To_1_20_2026_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_AtMarketOfferingMember_pLGqywBb50amw3DDckyXMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-20</xbrli:startDate><xbrli:endDate>2026-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_JefferiesLlcMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_AtMarketOfferingMember_Hon6YB2UOE6cicnSMk7KpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:JefferiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_6_2024_To_8_6_2024_srt_CounterpartyNameAxis_crvs_JefferiesLlcMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_AtMarketOfferingMember_eoj_eqi2mkWRVEknHEdLaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:JefferiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-06</xbrli:startDate><xbrli:endDate>2024-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_6_2024_To_5_6_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Q6hXsJygPUicAUk5ciCrwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-06</xbrli:startDate><xbrli:endDate>2024-05-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_D946TWJ6zkKBuSKvEfvEWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvs:OfficeAndLabSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_n-FcguAxykeAUv9IniliJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7MVQIs275UufJ7lWOSw2jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_22_2024_To_10_22_2024_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_crvs_ThirdYearOfSubleaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_frW_QJfWakWrSN17Dz5hfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">crvs:ThirdYearOfSubleaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvs:OfficeAndLabSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-22</xbrli:startDate><xbrli:endDate>2024-10-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_XaSINNDlBEGGXLQ8_-a_rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvs:OfficeAndLabSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_-5vxilaEUEie4f1HnGwt7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvs:OfficeAndLabSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2wktLQL_MEyMYi3EnlM2xA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_dSaQSn0xTEGxv32ul8LDRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">crvs:AngelPharmaceuticalsLtdEquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__i-TBaMyv0a9A7f3NWezNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_Tb3DXUa7E0uzOGfwD0V8eA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">crvs:AngelPharmaceuticalsLtdEquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_v9GABhLy30GLtxZhg92PdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvs:OfficeAndLabSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_Jyih6nVRJku2Wn342lRYIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvs:OfficeAndLabSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_21_2025_To_2_21_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_N8S53sDar0yqd8bB4rnoJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvs:OfficeAndLabSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-21</xbrli:startDate><xbrli:endDate>2025-02-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_22_2024_To_10_22_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_VpJmf9leeki0mF9gdl0L2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvs:OfficeAndLabSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-22</xbrli:startDate><xbrli:endDate>2024-10-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_YLkw7MG8HEKDEWIWiE4lUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_W8_lVfV_5UW3wioprmLFCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_6ofbkjgS-0e4rwuNdfqWaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">crvs:AngelPharmaceuticalsLtdEquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_2y33YWXdnkGW7dFGwtYxNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">crvs:AngelPharmaceuticalsLtdEquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_ZE_QhKexwEy9f39wgI86gQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">crvs:AngelPharmaceuticalsLtdEquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_23_2026_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_H7SnitH0TUet8vSGLhtCmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">crvs:AngelPharmaceuticalsLtdEquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_R50vtT-u40OjHn3pS5rzEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">crvs:AngelPharmaceuticalsLtdEquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_N1dSKssguEigxjFAegIoIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tU01KvpBW0K_zhL4h7OiVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bzThaTIaykCefde4hKplUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QYcmyFRwzk617SCak5HhVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_StatementClassOfStockAxis_crvs_SharesReservedForEmployeeStockPurchasePlanEquityMember_ANdQEPEp4UGpxOwiSjtfYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:SharesReservedForEmployeeStockPurchasePlanEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_StatementClassOfStockAxis_crvs_SharesAvailableForFutureOptionGrantsEquityMember_laFqZToHYU-XM4gSwg61WA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:SharesAvailableForFutureOptionGrantsEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_StatementClassOfStockAxis_crvs_PreFundedWarrantEquityMember_pG3Yboioek6oDxPenlOLwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:PreFundedWarrantEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_StatementClassOfStockAxis_crvs_OutstandingOptionsEquityMember_-jXcOLXdRUmPSJboXwLFAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:OutstandingOptionsEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_crvs_SharesReservedForEmployeeStockPurchasePlanEquityMember_Nx9PKFTI5ku9GkWFXfmECQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:SharesReservedForEmployeeStockPurchasePlanEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_crvs_SharesAvailableForFutureOptionGrantsEquityMember_uY3rsda1GkefIVaYZOCIXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:SharesAvailableForFutureOptionGrantsEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_crvs_PreFundedWarrantEquityMember_WYZ3KbAX40KHkOolRICzyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:PreFundedWarrantEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_crvs_OutstandingOptionsEquityMember_b0UFSQtEOEulbCh_kct75A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:OutstandingOptionsEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2025_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_54_yHogU40CKupBljfogmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvs:PrefundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonStockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_YFKxpTiNbU6oZe1MFcXljw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvs:CommonStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_t-6dI_GLqkWg5FN5nJrFAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvs:PrefundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Jot-50-Yk0qa7VxZIMl1Sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvs:PrefundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_g8cU3m0E20Wpgrbgr6r3kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_by6XIl09fUeHMa27xYEX5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2TM0kzCyaUqmRGhHtqiKBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1UFe9j-ZmEGRYjbAX_HTFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vIybyFvfXUWOpF0Ttuei1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-i89-0JYT0SuUe9mQLTeMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_XWrNNuJp9kmcv0K4YI0__w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_umpLEYrKtUW8udWfgt4FUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_d-ggcYb3f0OK5oH3EAR0_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_wsU59n8Qhk6UFUREvLUcmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">crvs:AngelPharmaceuticalsLtdEquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_dBO40tK2nky99I0IgRgeFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">crvs:AngelPharmaceuticalsLtdEquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_22_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_KO4XiJ0y0Eewc683WEweWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvs:OfficeAndLabSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_fyY1JRXZxEybfcmX0J6BsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_uG2y5xP9jkqJqpWj4ONRlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_SydJ5hNnoUqd8ueH3lWPpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_eVV0R68k0kqMD0Z_2saoiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_cVDT7uqBXEWvbTkAOn4YWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_0ugRH7hZ0kaz47JCeRx9MQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_6_2024_To_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_xxahbdsvrUmf_bB3pjxXsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvs:PrefundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-06</xbrli:startDate><xbrli:endDate>2024-05-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QuMDHAkYtUGRRN-xmfw_9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JiFN9ck9y06tFohjtNzoVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_7_2026_d2WHpuKgfkqb3D159XpVkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_6_2024_To_8_6_2024_srt_CounterpartyNameAxis_crvs_JefferiesLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_AtMarketOfferingMember_C9TVVV5bD06kEd2FNfIBfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:JefferiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-06</xbrli:startDate><xbrli:endDate>2024-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_srt_StatementScenarioAxis_crvs_AggregatePotentialMilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_aJ4OIsSntUiP4dLNeBCv1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:VernalisRAndDLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">crvs:AggregatePotentialMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_ScrippsResearchInstituteMember_srt_StatementScenarioAxis_crvs_AggregatePotentialMilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_dD5UP8Q5v06xhOLdtmqxlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:ScrippsResearchInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">crvs:AggregatePotentialMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_MonashLicenseMember_srt_StatementScenarioAxis_crvs_AggregatePotentialMilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_6utRsh2k0ky_UVcLFS0XMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:MonashLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">crvs:AggregatePotentialMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_zptfIK_qa0ys8kZeVc8ECg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:VernalisRAndDLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_ScrippsResearchInstituteMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_po2cXNmYykeJqOGtUERulg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:ScrippsResearchInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_MonashLicenseMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_11uvkiG9bE23RyZq6u2HDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:MonashLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_yZROy1gbRU-l_b7CkxhgEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:VernalisRAndDLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_crvs_MonashLicenseMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_qMLGaFcjDk6SK_FVkFPddA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:MonashLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_53gyr3oPf0-E7oFQOdHZ2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:VernalisRAndDLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-01</xbrli:startDate><xbrli:endDate>2017-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_dei_LegalEntityAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_IAkd47amHkiAxCCDntS06Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">crvs:AngelPharmaceuticalsLtdEquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_dei_LegalEntityAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_v9ThojvBS0yKLcEp5NgIDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">crvs:AngelPharmaceuticalsLtdEquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_Z1ifIYrZk0K3l2sseW4akQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_xEp_Nqn3VkmF6ubCOIKCDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_tNZXFjlgt0COhU24eHoxGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonStockSharesAndCommonStockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_oZTsrk4nrkiHDAAiKkO7Zw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvs:CommonStockSharesAndCommonStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_4BVj8xmMz0KGnw09dZm4mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvs:CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_MLeYeQx8wE2unDRlLMuIDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvs:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_zwdjuLpe8Um-MXpoYRfl8Q"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Institution_zA7d4X9tZU-Zo_s_3W3SSg"><xbrli:measure>crvs:Institution</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_HxXZ8IO5D0SV81ta1te2Pw"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:13.8pt;"><a id="_5d7266bc_814a_4ed4_ae5f_cfc87c3f6ae6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">-</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;padding-top:1pt;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:DocumentType" id="Narr_QmMkpakvWkOK_z6yyNdX3A"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"><a id="_16605beb_3c72_423d_b009_c97d1323ab9d"></a><a id="Tc_P-dZd9FQukSuRZlvIrIuUQ_2_0"></a><a id="Tc_Rj0n8j1Xg0uLsUoMM1dZKA_3_1"></a></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:90.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:top;width:9.68%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:90.31%;margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:top;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p></td><td style="vertical-align:top;width:90.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:DocumentQuarterlyReport" id="Tc_Q6EcA9-fKUeMVJJ11Z04IA_3_0"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:90.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Quarterly Period Ended </b><ix:nonNumeric format="ixt:date-monthname-day-year-en" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:DocumentPeriodEndDate" id="Narr_kmBjEOs5nU-h-ihhQJedyA"><b style="font-weight:bold;">March 31, 2026</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><a id="_d463563d_0e7c_4972_a1a3_960078333963"></a><a id="Tc_1XM-CcFRN0-SFyJMI3hnHw_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:90.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:top;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt 0pt 7pt 0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:DocumentTransitionReport" id="Tc_dtL9lwJ7nUm3C8Cy_rGpdA_1_0"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:90.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 7pt 0pt;"><b style="font-size:12pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">For the transition period from          to</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Commission file number: </b><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:EntityFileNumber" id="Narr_1DYlsFYzFkyveTS4BnbutQ"><b style="font-weight:bold;">001-37719</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:EntityRegistrantName" id="Narr_InsPClEHl0yWCXaNWH3BBA"><b style="font-weight:bold;">Corvus Pharmaceuticals, Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:3pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"><a id="_6de74f18_6174_4703_9cdb_b2c853f8b983"></a><a id="Tc_mL58cTtfwEafqXBvmZ9uqg_2_0"></a><a id="Tc_LG-pjYBhH0iedjWOSmcudw_2_2"></a></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:8.1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:EntityIncorporationStateCountryCode" id="Tc_4r3WJxNLTEGeSTF7_pTtMw_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:EntityTaxIdentificationNumber" id="Tc_7DIJrrGBAkOuVsGAa6_bgg_1_2"><b style="font-weight:bold;">46-4670809</b></ix:nonNumeric></p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:middle;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(State or other jurisdiction </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">of incorporation or organization)</p></td><td style="vertical-align:middle;width:33.33%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(IRS Employer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><a id="_2bcf8bbe_d280_41cd_81ee_10d88bbe6625"></a><a id="Tc_dSVeUvo2WUWtiuOPYWJoYA_1_0"></a><a id="Tc_EEW-Cecu7EuPWjkZh6ynxg_2_0"></a><a id="Tc_MT_bDoHxwkClHFbHBxrtJw_2_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:66.66%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:49.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:8.1pt;"><td style="vertical-align:bottom;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:EntityAddressAddressLine1" id="Narr_1OxT6xJwT0SgdFbA4U-FDg"><b style="font-weight:bold;">901 Gateway Boulevard, Third Floor</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:EntityAddressCityOrTown" id="Narr_r3ZXzakQS0C4LR2GkeE5hA"><b style="font-weight:bold;">South San Francisco</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:EntityAddressStateOrProvince" id="Narr_4fKGyWBuL0GvFWh2wpGRsQ"><b style="font-weight:bold;">CA</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:EntityAddressPostalZipCode" id="Tc_eD_aWmr33k6Lo1fJtW5yPg_1_1"><b style="font-weight:bold;">94080</b></ix:nonNumeric></p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:middle;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:middle;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(Zip code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Registrant&#8217;s telephone number, including area code:<b style="font-weight:bold;"> (</b><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:CityAreaCode" id="Narr_hWXDwZQT1EW6VjjvSbkKKg"><b style="font-weight:bold;">650</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:LocalPhoneNumber" id="Narr_ZdpUZuTjHUyw8yAxbHlwNA"><b style="font-weight:bold;">900-4520</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;">Former name, former address and former fiscal year, if changed since last report: N/A</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 7pt 0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><a id="_142fd533_b305_4ece_a9e7_3937e6be35c3"></a><a id="Tc_uzghnbE82ki3rpKN19x9hg_1_0"></a><a id="Tc_0NB49usjfkGnaV74xJ16CA_1_1"></a><a id="Tc_W9lY540IX0iplwrChNVYWA_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;padding:1.45pt;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.97%;border-bottom:1px solid #000000;margin:0pt;padding:1.45pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:23.44%;border-bottom:1px solid #000000;margin:0pt;padding:1.45pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:38.57%;border-bottom:1px solid #000000;margin:0pt;padding:1.45pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:middle;width:37.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.45pt 1.2pt 1.45pt 1.2pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:middle;width:23.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.45pt 1.2pt 1.45pt 1.2pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Trading symbol(s)</p></td><td style="vertical-align:middle;width:38.57%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.45pt 1.2pt 1.45pt 1.2pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr style=""><td style="vertical-align:middle;width:37.97%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.45pt 1.2pt 1.45pt 1.2pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:Security12bTitle" id="Tc_aM5pJYGkq0uoci3pct2brA_2_0">Common Stock, Par Value $0.0001 per share</ix:nonNumeric></p></td><td style="vertical-align:middle;width:23.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.45pt 1.2pt 1.45pt 1.2pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:TradingSymbol" id="Tc_T19lmEd7oUWdXndptY75dA_2_1">CRVS</ix:nonNumeric></p></td><td style="vertical-align:middle;width:38.57%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.45pt 1.2pt 1.45pt 1.2pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:SecurityExchangeName" id="Tc_gbXFjBLKb0KkkmMGgA1gBA_2_2">Nasdaq Global Market</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 7pt 0pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:EntityCurrentReportingStatus" id="Narr_JAz0H8gHxUevlzSepAUpGA">Yes</ix:nonNumeric>&#160;<b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b> &#160;&#160;&#160;&#160;No&#160;<b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 5pt 0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:EntityInteractiveDataCurrent" id="Narr_Co0yrJYexkWSKKPkCYO8TQ">Yes</ix:nonNumeric>&#160;<b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b> &#160;&#160;&#160;&#160;No&#160;<b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.19%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:45.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 7pt 0pt;">Large&#160;accelerated&#160;filer <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:bottom;width:45.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;">Accelerated&#160;filer <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 7pt 0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:EntityFilerCategory" id="Narr_E67gVUULUE-cbHDnmXHh9w">Non-accelerated filer</ix:nonNumeric> <span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:bottom;width:45.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 7pt 0pt;">Smaller&#160;reporting&#160;company <ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:EntitySmallBusiness" id="Narr_hTXFkqr9eEGShFkvKKWrXw"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></ix:nonNumeric></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 4pt 0pt;">Emerging growth company <ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:EntityEmergingGrowthCompany" id="Narr_61TWvdqYS0moEKPbHbX4bQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:45.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 7pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any<span style="white-space:pre-wrap;"> new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange&#160;Act).&#160;&#160;&#160;&#160;Yes&#160;<ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="dei:EntityShellCompany" id="Narr_Y0iFVQmAnkeYf7qpC84tGQ"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric> &#160;&#160;&#160;&#160;No&#160;<span style="font-family:'Segoe UI Symbol';">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;">As of May 7, 2026, <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" format="ixt:num-dot-decimal" scale="0" contextRef="As_Of_5_7_2026_d2WHpuKgfkqb3D159XpVkw" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_wkVYWw1NMUiAJ_C-02FX1g">84,090,424</ix:nonFraction> shares of the registrant&#8217;s common stock, $0.0001 par value per share, were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;padding-top:1pt;text-indent:36pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_49bb7662_3760_4305_98fc_4764d6c01282"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CORVUS PHARMACEUTICALS,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">QUARTERLY REPORT ON FORM&#160;10-Q FOR THE QUARTER ENDED MARCH 31, 2026</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style=""><td colspan="4" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><a href="#PARTIFINANCIALINFORMATION_671322"><b style="font-style:normal;font-weight:bold;">PART&#160;I &#8212; FINANCIAL INFORMATION</b></a></p></td></tr><tr style=""><td style="vertical-align:bottom;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item1UnauditedCondensedFinancialStatemen"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:85.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item1UnauditedCondensedFinancialStatemen"><span style="font-style:normal;font-weight:normal;">Financial Statements (unaudited)</span></a></p></td><td style="vertical-align:bottom;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">3</p></td></tr><tr style=""><td style="vertical-align:bottom;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDBALANCESHEETS_89276"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:bottom;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">3</p></td></tr><tr style=""><td style="vertical-align:bottom;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td><td style="vertical-align:bottom;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">4</p></td></tr><tr style=""><td style="vertical-align:bottom;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#STOCKHOLDERSEQUITY_96157"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity</span></a></p></td><td style="vertical-align:bottom;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">5</p></td></tr><tr style=""><td style="vertical-align:bottom;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#STATEMENTSOFCASHFLOWS_192557"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:bottom;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">6</p></td></tr><tr style=""><td style="vertical-align:bottom;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#NOTESTOCONDENSEDCONSOLIDATEDFINANCIALSTA"><span style="font-style:normal;font-weight:normal;">Notes to Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">7</p></td></tr><tr style=""><td style="vertical-align:bottom;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">21</p></td></tr><tr style=""><td style="vertical-align:bottom;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">37</p></td></tr><tr style=""><td style="vertical-align:bottom;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item4ControlsandProcedures_996727"><span style="font-style:normal;font-weight:normal;">Item&#160;4</span></a>.</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item4ControlsandProcedures_996727"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">38</p></td></tr><tr style=""><td style="vertical-align:bottom;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="4" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><a href="#PARTIIOTHERINFORMATION_177066"><b style="font-style:normal;font-weight:bold;">PART&#160;II &#8212; OTHER INFORMATION</b></a></p></td></tr><tr style=""><td style="vertical-align:bottom;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item1LegalProceedings_213471"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item1LegalProceedings_213471"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">39</p></td></tr><tr style=""><td style="vertical-align:bottom;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#RiskFactors"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#RiskFactors"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">39</p></td></tr><tr style=""><td style="vertical-align:bottom;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:bottom;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">84</p></td></tr><tr style=""><td style="vertical-align:bottom;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_526790"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_526790"><span style="font-style:normal;font-weight:normal;">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:bottom;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">84</p></td></tr><tr style=""><td style="vertical-align:bottom;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item4MineSafetyDisclosures_600075"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item4MineSafetyDisclosures_600075"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">84</p></td></tr><tr style=""><td style="vertical-align:bottom;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item5OtherInformation_876990"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item5OtherInformation_876990"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">84</p></td></tr><tr style=""><td style="vertical-align:bottom;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item6Exhibits_350365"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item6Exhibits_350365"><span style="font-style:normal;font-weight:normal;">Exhibits</span></a></p></td><td style="vertical-align:bottom;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">85</p></td></tr><tr style=""><td style="vertical-align:bottom;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td colspan="3" style="vertical-align:bottom;width:94.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#SIGNATURES_676454"><span style="font-style:normal;font-weight:normal;">SIGNATURES</span></a></p></td><td style="vertical-align:bottom;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">86</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8c130d4c_f641_4351_a5b9_31866e975f4e"></a><a id="PARTIFINANCIALINFORMATION_671322"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">PART I - FINANCIAL INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Item1UnauditedCondensedFinancialStatemen"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Item 1.  Unaudited Condensed Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CORVUS PHARMACEUTICALS, INC.</b></p><a id="CONDENSEDCONSOLIDATEDBALANCESHEETS_89276"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(in thousands, except share and per share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_197d693c_8d6c_4e2b_a0ff_013e875fc05b"></a><a id="Tc_2wMH3Jljt0SGNkIwU51X8g_1_2"></a><a id="Tc_b1VT1CL1XEGvE_VvXrjflg_1_5"></a><a id="Tc_lTE5ovlxukWI3SRxnA-BaA_2_2"></a><a id="Tc_mX3wNrHAPESbyDKuIIMidg_2_5"></a><a id="Tc_bGdg3glyIUCeZv74JdH4hw_3_0"></a><a id="Tc_mJ0yZLRcNE-6lfb7zYWoYg_4_0"></a><a id="Tc_v-vyevtmgEiA0hheXMyjWA_5_0"></a><a id="Tc_OmUtvWfJekaswL8xwsHjKQ_5_2"></a><a id="Tc_i9xJnKtnq0OY9lrsWBging_5_5"></a><a id="Tc_-6M_Uoi45Uy60UeULk-ZdQ_6_0"></a><a id="Tc_aK05sYd3uEqVGhQyEuQKLQ_8_0"></a><a id="Tc_wddC6PLjLEekkVROUJwXsQ_9_0"></a><a id="Tc_noAn2mkewUOgUUJ3VRuLXw_10_0"></a><a id="Tc_8kA02PeeJ02Sn0qqpmD3tw_11_0"></a><a id="Tc_AJ6xwXSo5Eexx5RMDQZiig_12_0"></a><a id="Tc_5KE6LqA_8Ee2dauFJCMN5g_13_0"></a><a id="Tc_jMDllSYDkEec68crEFkymg_14_0"></a><a id="Tc_r3rYbNzKM0G_J5NK47K5Rg_14_2"></a><a id="Tc_GvtgOjSqmUKuKh3hoNh3QQ_14_5"></a><a id="Tc_nCPR1Ezf906QnN73xsJrBQ_16_0"></a><a id="Tc_z9zUK1GPeEaxpEEcjuMlLw_17_0"></a><a id="Tc_wVB4lZpqyUm3eAlz45B_mA_18_0"></a><a id="Tc_yYRg8F_4b0WYx8dH-aNzkw_18_2"></a><a id="Tc_an4scvnQ2Emo5Cf4KeYu3A_18_5"></a><a id="Tc_D7wGNqbXIUWJ3b-TKGJiyw_19_0"></a><a id="Tc_Q3YITbp_eEectkSUTZNL7g_20_0"></a><a id="Tc_YjFJvX-MdkybNXc5PotScw_21_0"></a><a id="Tc_3xQwUdHyGE-Vtw4LHahoUw_22_0"></a><a id="Tc_WFlxw_9EAkWr3wvEouW2fA_23_0"></a><a id="Tc_J6cyGeFJ80Ww1R708JZUzw_24_0"></a><a id="Tc_HZ8uvbMH-Ey4rCJ0wtYvpA_25_0"></a><a id="Tc_rjeCsQFf706PtGnDB0VfMw_26_0"></a><a id="_b6af1b64_9988_4f38_bc02_ecb3e5cd6e7a"></a><a id="_b6af1b64_9988_4f38_bc02_ecb3e5cd6e7a_2"></a><a id="_b6af1b64_9988_4f38_bc02_ecb3e5cd6e7a_3"></a><a id="Tc_9MFUgif9ok2pj_FAFGYVww_27_0"></a><a id="Tc_MgywU3qlo0i-pg-2Nu6p8w_28_0"></a><a id="Tc_VUKCMvsflUuHbP-Mkh2E-w_29_0"></a><a id="Tc_SXjF0cvJxE23veCB5LuKBw_30_0"></a><a id="Tc_OeEKHXhoYUy1GpfUjpvk9Q_31_0"></a><a id="Tc_c3jLEnQFHEOm6ccNL9ZtLw_32_0"></a><a id="Tc_qzlf81UJMU-GsPy9FZQyaQ_32_2"></a><a id="Tc_kLdvt2Uy7ECTQsxVdSa39A_32_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_QIgkJjmSA0mnWeITRncenA_5_3">40,102</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_sA_OT-40uUOKRJFdl6338A_5_6">4,576</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="Tc_PK_JiTnJMkeCp6wIZmltlg_6_3">196,612</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="Tc_MmyBSMv0VUqVin_waOwoOQ_6_6">52,174</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"><span style="-sec-ix-hidden:Hidden_y97SYRsuwU6VBvyrhRYUYw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Accounts receivable - related party</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_MVVEoD7okkiYh34GXGkK5A_7_3">43</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_ogLlwAwRlk2pYKchwvCIPA_7_6">37</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Prepaid and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_PRushlV8Ok6d4Vyols61Xg_8_3">3,189</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_xAeDdx5aHkmHDS9CeEtFQQ_8_6">1,427</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_XTFwl3VHR02j_jDyj9mtzA_9_3">239,946</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_czuy3jO-kESlgKE9kydFeA_9_6">58,214</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_8nzQW7AEK0S_-hTHcWBBRg_10_3">282</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_THgc1ieULky27qChUxJcVg_10_6">220</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Operating lease right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_t_D02v3ALku-5PwlhcguGg_11_3">751</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_d7LsGOpSeke59IEsg3Lvxg_11_6">839</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Investment in Angel Pharmaceuticals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" id="Tc_phZ-euys5EqE8rkIwZSskQ_12_3">10,496</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="3" id="Tc_QA-5G4TONU-yDooJdFHFGA_12_6">10,991</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_VozUM2ygbkKDwzm7krYRuQ_13_3">1,720</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_pgvtl9kUj0yqrNp9zwJkWQ_13_6">855</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_kJtaoTk-vk24ttSvYjn_7g_14_3">253,195</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_Zf5Sb7IhXUOamGqZ-fB5QQ_14_6">71,119</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_9AyP_PbeAkyvqLQrBCFzdA_18_3">4,697</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_BSwaHnn_2k-R3p4ROvd0Kw_18_6">2,491</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_iT2Bn43fn0aE8xAfYhgKPg_19_3">428</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_qoAGfsJL3k2TodTJF0LMKw_19_6">403</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Accrued and other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_bJl-P-eANkyVar7RsX1WKA_20_3">6,985</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_eKzB6yc0ukm9jNFhhz_-qg_20_6">6,486</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_Bz5wqi3ShE-YjJVYIatFiw_21_3">12,110</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_cfGBqoD4fEy9WzJvd50Zzw_21_6">9,380</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_dPTXn3qgtkyT-ghMpNx9Ag_22_3">406</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_vJvHYBML_ESPTgPXmUxJWg_22_6">534</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_0yYYXuH5GU69duzT9Ga41w_23_3">12,516</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_fnKrL8n7yEWqT2I-YbwMTw_23_6">9,914</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Commitments and contingencies <i style="font-style:italic;">(Note&#160;15)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Preferred stock: $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_97qWHT-SeUGZas4xtKlQ_g"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_mcxfi4FZikGTDfChVxYFGA">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_pdTEdBhqAEGb9RnqQjIMFg"><ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_xwHsemi7W0iA4JnbeRRoKg">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March&#160;31,&#160;2026 and December&#160;31,&#160;2025; <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_1PyRHJ07RkeP0kguEFbudQ">0</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_FgprKYhvx0GT34f5BC1wWw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and outstanding at each of March&#160;31,&#160;2026 and December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_eNKIckLa0UyHrLM1g_0mcg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_gYog-BNdUE-FBM0D6OXi_w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Common stock: $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_MwARpLx_g0SfphgAkobVtQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_yzr1rdroLE-chWM3xpeqTw">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_Z_Ce0cpys0mA_A48FBBqcw"><ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_t1pNlhEu1kisoitEMAkvJA">290,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March&#160;31,&#160;2026 and December&#160;31,&#160;2025; <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_7KExFM3VokyPu-49vC04Tw">84,090,424</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_Am-Hc3EjoEedkGbvxhmjhg">74,696,629</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_bQBBXjHiDkurSgRMYzw24g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_jqJW3JRuLEelbaPw9XFCKw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at March&#160;31,&#160;2026 and December&#160;31,&#160;2025, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_uqH6ohbfGEyvW6dIXz_ibA_27_3">8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_3yEceTBoWEWW6kUnblWRUQ_27_6">7</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_XHZXinOxfEKWf-MfFjIs7Q_28_3">667,782</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_GPVC888F7EmWLLd1q0OdWQ_28_6">474,387</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_pIRMygWa6UmEGOuUbGQMPw_29_3">1,126</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_zvbxxQtz_Emcju1YiN-XwQ_29_6">896</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_tITkOCNvm0C6kmBwR4zY1Q_30_3">425,985</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_sOTvL2aJr0ieqBAVvR2COg_30_6">412,293</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_jI9kTlBsvEiND0gXCq9rZA_31_3">240,679</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_4ueeLew8aUW3xLpHR3GR0A_31_6">61,205</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_1xDfZl6iokKrex0I2bzkQA_32_3">253,195</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_LgmUmRN24Ua7U69ngv-Ozw_32_6">71,119</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_45eb922e_ab40_4642_881b_73921259d306"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CORVUS PHARMACEUTICALS, INC.</b></p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(in thousands, except share and per share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_eb43a729_0676_4a3a_9fae_e371a235dcaa"></a><a id="Tc_m7XGbDz6BEGaOqTRNpoI0w_1_2"></a><a id="Tc_vIZ3tN7MdUmZYdpu2DicMw_2_2"></a><a id="Tc_IO5NIXeqAkqX-ZNPJVpPDQ_3_2"></a><a id="Tc_a7aztzoBlUu1fFvpDQZY5Q_3_5"></a><a id="Tc_1cS0ew1wjUGi8ct-wHht9g_4_0"></a><a id="Tc_OqCc-_FRfU2KajJNE3QZrA_5_0"></a><a id="Tc_RZRCK0a0z0mI5bnnuFg4ww_5_2"></a><a id="Tc_hJ1eQ8ekukW8h3MPj9uOZA_5_5"></a><a id="Tc_ypeMXEncDk-H7lDAFMlQ8A_6_0"></a><a id="Tc_ge6lnRZQYEuXiwmOWinafQ_7_0"></a><a id="Tc_-2zrvO0VWE-uoBKtPr1b1w_8_0"></a><a id="Tc_BtdVqhSqwkirK5p08m85Vg_9_0"></a><a id="Tc_OVqBjQvQDU6m1O_vCTWlMQ_10_0"></a><a id="Tc_tWoS3U9tjEK859T5fa6-_Q_10_3"></a><a id="Tc_0wfBWT7jAUCHoSCO5xUT-Q_11_0"></a><a id="Tc_7nn5HBLeXE2DqsOJ0qFZBA_12_0"></a><a id="Tc_myCi8pCsw0-2NGNO5Fq0Vg_13_0"></a><a id="Tc_k_5DTonXk06Dm06zJlS2Eg_13_2"></a><a id="Tc_381qH_2d_EOrA91Jrzw52w_13_5"></a><a id="Tc_4jEmobjGM0WJqtkwP9W_zA_14_0"></a><a id="Tc_o__Yws42tUK4O0sHUNNBmg_14_2"></a><a id="Tc_IwVYYVoK2k2ivVnFolt_YQ_14_5"></a><a id="Tc_5U5HO4cRgUWydD46b-oFvQ_15_0"></a><a id="Tc_WUF4VQZmG0qW6tAdqKOx9Q_15_2"></a><a id="Tc_ju-IOkCgB0Gf2NygBkj49g_15_5"></a><a id="Tc_iIG87n8XTkyAlAexwmhlEA_16_0"></a><a id="Tc_y5a-gs6k8Uipgmv3werRgQ_17_0"></a><a id="Tc_FdUF-9O7KUm5sfaM3vil4w_18_0"></a><a id="Tc_QcsAGKGx50iY-5mJdY2vhg_19_0"></a><a id="Tc_PJ5zz3bpA0SWcfNwBOylTg_20_0"></a><a id="Tc_Ppz6W9EShEKr-ILn2nOmHQ_21_0"></a><a id="Tc_XVaC3iGIkkGjG7aq-bJHJw_21_2"></a><a id="Tc_Xf4RWE5cVUCwpok7eAwrlA_21_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:25.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:25.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_MUcTyuQnekaOlPA_6OSFlg_5_3">11,175</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_oW-fMJV6Y02aQZ543Nvrbg_5_6">7,453</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_IjpMX6FEBkaSBgyM56gQYA_6_3">3,702</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_YCV-kTGwOUGKesO4w5CYRQ_6_6">2,469</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_FHKyp3oYn0KwKIh5OLKZrA_7_3">14,877</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_6rq65DiPV0y3ZudU40l5wg_7_6">9,922</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_B9YFMOBya0-wB6qH3f3-7A_8_3">14,877</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_WlfqJORz2UWlVEtt9ZN-Og_8_6">9,922</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Interest income and other expense, net</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeNet" scale="3" id="Tc_imWBMhvWh0GpeI-V3EerCQ_9_3">1,784</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeNet" scale="3" id="Tc_Y8RE9mIQ6U-GXzZ2agFXww_9_6">525</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Change in fair value of warrant liability</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" sign="-" scale="3" id="Tc_HOdjW1UUPEecjEE4G7XQ4g_10_6">25,129</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss before equity method investment</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" sign="-" scale="3" id="Tc_xI6SC8Q5RkC_HtskZh7BDw_11_3">13,093</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="Tc_HgdDjGvLHU2UNzX8rvFxIg_11_6">15,732</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss from equity method investment</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" sign="-" scale="3" id="Tc_OIDW4H8cj06CAuiHg_6OQQ_12_3">599</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" sign="-" scale="3" id="Tc_Xs8p2ldfZUuM_U2g8WwefA_12_6">539</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net (loss) income</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_HnLwfTcZRkSzl5aebtlywg_13_3">13,692</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_D16ZpxRgAE6-l7mrJiON8A_13_6">15,193</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net (loss) income per share, basic</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_WE-_zGkbOUiwLHT4xN8nKA_14_3">0.15</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_9WdbN8FlKEOMRiLjzRq03A_14_6">0.21</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net loss per share, diluted</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_bAZlC6Ml8UWNVtgFiKjcTg_15_3">0.15</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_AQnvnmHHbUWwoViBO13kEA_15_6">0.13</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Shares used to compute net (loss) income per share, basic</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_IprbQlR0CUO1cBxeaBbiug_16_3">89,996,728</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_DXb6H_g9tk-k3AEJWnm8uQ_16_6">72,126,496</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Shares used to compute net loss per share, diluted</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_PTwvFW1F5UmiU8dxtbU_aA_17_3">89,996,728</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_9Il6cbQvZkO41GZXdFiysg_17_6">75,152,514</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other comprehensive (loss) income:</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Unrealized loss on marketable securities</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" sign="-" scale="3" id="Tc_JW6cVIAkkkuM6824vncZeQ_19_3">334</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" sign="-" scale="3" id="Tc_dz1ZMlCPYEaCPbE4UUnccg_19_6">23</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Cumulative foreign currency translation adjustment</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="Tc_mFaFZ8DgKEeZ6bbs6ym4zA_20_3">104</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="Tc_3xkpqaKq00WopGYsSirfhA_20_6">57</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Comprehensive (loss) income</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_Gt8ApF8KGU2UoTsARzg4YQ_21_3">13,922</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="Tc_uGN7TAMUhUiR7MZ7sJAq9A_21_6">15,227</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a5be6667_8ab4_4587_9702_52d42d9fad4e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CORVUS PHARMACEUTICALS, INC.</b></p><a id="STOCKHOLDERSEQUITY_96157"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(in thousands, except share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_9231e40d_8a65_44b5_9df7_0f6529b4f75c"></a><a id="Tc_8rkaNNJfKUyHVyJtmAjg-w_1_2"></a><a id="Tc_p7H-TpeJ8kiJIjhOJ-NVYQ_2_10"></a><a id="Tc_XFJLosGQPEuO1Z48I8-zLQ_3_7"></a><a id="Tc_V5MVzbIKZ06YA_6GnxnwyA_3_10"></a><a id="Tc_WfWMUuQo1k-FFp5X7URWug_3_16"></a><a id="Tc_EqbqP0-hfEmI3I7rGwnNgw_4_2"></a><a id="Tc_-Ej8j7Da2kK4Pb0Pg_2qqA_4_7"></a><a id="Tc_tkes_BlC7E-Lp2gPSa1__w_4_10"></a><a id="Tc_PVZvoC3mNEy4YmVNFf-rRg_4_13"></a><a id="Tc_kDMg99YCIU-iRYneg94nVA_4_16"></a><a id="Tc_HXz62SNHf0qSWphMA4fBJA_5_2"></a><a id="Tc_h3suV2gjYkOgwfl45TjDRg_5_4"></a><a id="Tc_yNmWIZ2sX0COlP-dVMgi0Q_5_7"></a><a id="Tc_RKzEsc4EwU2Z8Y3NyLVbrA_5_10"></a><a id="Tc_SKy2NSEi7kOBMSlEiDqbwQ_5_13"></a><a id="Tc_Gu_OXwiWDke8cOYUk-5Njw_5_16"></a><a id="Tc_emcuKIvA1EKlnzqiBMQNZA_6_0"></a><a id="Tc_kY1shGYKE0-vZHHE03NakQ_6_4"></a><a id="Tc_-9aEtCPVOUWjrjzYrVE6yw_6_7"></a><a id="Tc_V2qnhi0pmkWGzN3HFIFpqg_6_10"></a><a id="Tc_bhg-1UNOoUGlscGt9Sq9Ew_6_13"></a><a id="Tc_0nHOsQOVM06E_7GHmybVcw_6_16"></a><a id="Tc_bfBqq1aiJUmQSQg9iyT3XQ_7_0"></a><a id="Tc_euidC9mphUeLBdgEEvivXg_7_5"></a><a id="Tc_9zHzhW-BYESNXPM4yNnoHg_7_11"></a><a id="Tc_Y9hA0cbgcE6KqEHuT-8Q7w_7_14"></a><a id="Tc_H2kuVnNMP0OMuqyS6t_3kQ_8_0"></a><a id="Tc_9lGC_n-m0EK1W-4r2SAyUw_8_11"></a><a id="Tc_EBkyEvaLkk6wbiIxZnqahw_8_14"></a><a id="Tc_Ex1vn24oUk2CDUAY0hCk-Q_9_0"></a><a id="Tc__-62LMn3RkWSR_vu7Jhxvw_9_2"></a><a id="Tc_vgor16NRmUWFfjaJOOZe3g_9_5"></a><a id="Tc__T-KQSQX_EuWRsHZTsBjwA_9_11"></a><a id="Tc_DAoYfayxC0KNW_2n45Dtcg_9_14"></a><a id="Tc_oR1xJzVfTEuhIUscto6ERg_10_0"></a><a id="Tc_QhkK3a-L90mMRpvtU49-JQ_10_2"></a><a id="Tc_H61ulVmbtUiQvQcuXACnzQ_10_5"></a><a id="Tc_WwGurVdM2EaO2INKYLoNmg_10_8"></a><a id="Tc_tGlmy8jLpk2hSQgt6asQvQ_10_14"></a><a id="Tc_AV0YUuV3F0WZewwfc2O3bg_11_0"></a><a id="Tc_XCuMlHIKV0qyjTm3Cv6v7Q_11_2"></a><a id="Tc_FyKcD3xcgEii99f2mZ8APg_11_5"></a><a id="Tc_HAY_XgIPqEmBFpwIN8PrGg_11_8"></a><a id="Tc_CryLLyfKWkWONwr10RK71Q_11_14"></a><a id="Tc_JZn_0IPq8ESCN2x1g6iTfg_12_0"></a><a id="Tc_QpRxJ_At10qi8gBG133wEQ_12_2"></a><a id="Tc_U-zDeGNEe0-XsE1HTHse9A_12_5"></a><a id="Tc_Bs_3aeS8uUOb5CibEzkA6w_12_8"></a><a id="Tc_C7OLhQQ20Ee33CM7JWJ2uA_12_11"></a><a id="Tc_E_iZZXe1iUuAmtDfPRP2pQ_13_0"></a><a id="Tc_FrdWEEGqsEi-nUfAo-V4Xw_13_4"></a><a id="Tc_Xm53nB7hJUeKWVnALlgL9w_13_7"></a><a id="Tc_dPNXNTa38Um1FYx4Ykvpdw_13_10"></a><a id="Tc_Z2cTvoGGs0SYZtex8mC3Gg_13_13"></a><a id="Tc_MuIl5ocrZ0KXjsXnJMto_Q_13_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:41.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="16" style="vertical-align:bottom;white-space:nowrap;width:57.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended March 31, 2026</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:41.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:41.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:41.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:41.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tU01KvpBW0K_zhL4h7OiVQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_S6kqRMsK-EKLI2T-kmbXyA_6_2">74,696,629</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tU01KvpBW0K_zhL4h7OiVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_5gYNtZjovUut4z-fAOMUcw_6_5">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1-iFrDRj3UuxNy56xcRv_Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_palI6zhwTEeYP1u5mQ6D2Q_6_8">474,387</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bjsu6eUjm0mYlqMaqNdetA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_EOxRBy6oeU2dPU7wOg6fyQ_6_11">896</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IY-IxZUYbEqP1aoewvItXw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_EvOVdaYmfkiFG8hPzyDtZQ_6_14">412,293</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_HHsWCvzYU0ybDKMndUF_PA_6_17">61,205</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Common stock issued upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0I7JIIL4bUeBisCBXAmQJA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_E1BwUgvWZk-q0NTioaeDqg_7_2">308,017</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QuMDHAkYtUGRRN-xmfw_9A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_RTHwq1o8NkWNR4EVZPJ95A_7_8">1,339</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_IXtkScxvNkWrk2JFWmM0sQ_7_17">1,339</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:10.8pt;text-indent:-10.8pt;margin:0pt;">Issuance of common stock upon follow-on public offering, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_-EcyvuEUt0iqD5CMwxh5TA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_dtaZnRX56kOztQgGntYDuA_8_2">9,085,778</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_-EcyvuEUt0iqD5CMwxh5TA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_DZ7RDMAG9EK7GmpWbw2sbQ_8_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_FFOllL2fhkyBY8izLXeb2Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_jooWYD8CbkyOydWzeQt4dQ_8_8">189,406</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_2G3cA69Y60Kut3dIpiEj-Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_V--JetzT9keYO6rrHhSZzA_8_17">189,407</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QuMDHAkYtUGRRN-xmfw_9A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_qrVwRGhEmUOCq2cMEppWRg_9_8">2,650</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_AbbS-zmnZkqju_rywFO4dw_9_17">2,650</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Unrealized loss on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_n-FcguAxykeAUv9IniliJQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" sign="-" scale="3" id="Tc_z0K61lGVL0-IDjL0fVRc9A_10_11">334</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" sign="-" scale="3" id="Tc_uOGhfh1P9E2HEusoadHERA_10_17">334</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Foreign currency translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_n-FcguAxykeAUv9IniliJQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="Tc_vxMFFATzSkyEHnZVkLdvXQ_11_11">104</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="Tc_NmUxfk74zEa0uADe5eOJ5g_11_17">104</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2wktLQL_MEyMYi3EnlM2xA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_BaEnWM2C9kK4xag7hENHnw_12_14">13,692</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_FsPUBfCWBkmPKFD16gLB6w_12_17">13,692</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_N1dSKssguEigxjFAegIoIg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_ba0ZaKKIA0ukH6kRvG_O3Q_13_2">84,090,424</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_N1dSKssguEigxjFAegIoIg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_AMH5KLEDHUCOZ1yYS_zn8g_13_5">8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FLIZWim2CEmiyA6jK8gsKQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_UEI5NEU-tE2i53le7q9ppQ_13_8">667,782</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0whMsvUI40mL2d3_7eOvsQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_vU_X3bOE60GUD9tnW2sPDA_13_11">1,126</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7NENmaw0i0-q2C5PDhSUwA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_rUu9UB-RKUucMMFwMKL0UQ_13_14">425,985</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_0E2Dy3JgYU2Q3aFZPuTlrA_13_17">240,679</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:13pt;visibility:hidden;">&#8203;</span></p><a id="_2744fd87_5d57_4320_9a2b_319ad7ea27d0"></a><a id="Tc_6_sRPxUhDESrXHXNJsxeNw_1_2"></a><a id="Tc_tQpfJdnje0-PCCqBMVi60w_2_10"></a><a id="Tc_B9j8DCpUOEmKWSRTy8l83Q_3_7"></a><a id="Tc_rLaXlozezUCjslLfa1b78Q_3_10"></a><a id="Tc_0in_i7FUZkCN_sIHqy-HZA_3_16"></a><a id="Tc_n4o0kgXMA0uAhTsh80R-jQ_4_2"></a><a id="Tc__9-y2TMgmUSck50gRg8SMA_4_7"></a><a id="Tc_3GuSHvP8mEyCw321tFgp3g_4_10"></a><a id="Tc_VPxf7b3OaUu4Ftun4qh8Lw_4_13"></a><a id="Tc_yIiWbJ-gjESEt6h7D2Of4A_4_16"></a><a id="Tc_z2DGKaWf6UKrcOcM9D-SHA_5_2"></a><a id="Tc_03vdm0Q-Pky89DNZbZ7Uxg_5_4"></a><a id="Tc_tmVZ4HcMiEi9MeMU5PmUBQ_5_7"></a><a id="Tc_psW_wEoTBUa8qfRImCOsBg_5_10"></a><a id="Tc_OLb3acgdRkKxjSF0b0EFjg_5_13"></a><a id="Tc_BSbTFgq1eEy_0eCE7o8eRQ_5_16"></a><a id="Tc_u9YOyA0On0WoOu8-lhbcdA_6_0"></a><a id="Tc_bvRSYwkAg0yfwWYPOjHbdw_6_4"></a><a id="Tc_bGbsM8GeRUOXQWj66twPfw_6_7"></a><a id="Tc_JQAccBsYYkOiiL_Ma3MDLw_6_10"></a><a id="Tc_HJBtpaEPx0OtPLjJqZUnaA_6_13"></a><a id="Tc_DkvelVwShUK63-CrUONPRg_6_16"></a><a id="Tc_ZDV54LwnS0CGnErKn3TQqg_7_0"></a><a id="Tc_bDEc1PVya0qyZyxFoDOhOw_7_5"></a><a id="Tc_mQyXM2D7eEGcTzp_C7UClw_7_11"></a><a id="Tc_fiLMMgtYFkerWme5_mf1HA_7_14"></a><a id="Tc_zhMbWpNH3kONWoSFf4hQRg_8_0"></a><a id="Tc_zGMef39srEueJVB24col9w_8_2"></a><a id="Tc_nFAZYN6bBke9qg_miELA7w_8_5"></a><a id="Tc_ldgyvGcqwkuerTz4LwSyaw_8_11"></a><a id="Tc_pRBAyHfi0kmjeYy2ds1xKQ_8_14"></a><a id="Tc_wU0S97APBkG4Umgjq3FtiA_9_0"></a><a id="Tc_PNRJRwqiJ0u5Tr18nrwmJg_9_2"></a><a id="Tc_sAZH_Xl2Tk63C7Z26yeZmQ_9_5"></a><a id="Tc_X8y0yopcYESCt3bsWynwcw_9_8"></a><a id="Tc_Z7AUsbclNEy1VsUu5mdovw_9_14"></a><a id="Tc_b7QEBWvaWk6Usk5B8lDviA_10_0"></a><a id="Tc_BFb-lI_g_0Cv9uMCu_XsvQ_10_2"></a><a id="Tc_45N1HY8PB0u59VUGJqJtIA_10_5"></a><a id="Tc_zYX3XjDr50SGsqvarY6b7Q_10_8"></a><a id="Tc_u51CNGZpbECic_d8u6RToA_10_14"></a><a id="Tc_i836nw2AREy1snpidrf0Pg_11_0"></a><a id="Tc_LMJukCL27Um5O4o_AV0cRQ_11_2"></a><a id="Tc_U6RGfYjHSkqTBNOgNKIRTA_11_5"></a><a id="Tc_cI3GdTehdEeKVo41G8QBTQ_11_8"></a><a id="Tc_Up7bgsZLeEOdhdVwZO8A3Q_11_11"></a><a id="Tc_BHtXRsgtEU2hMdwj_s8eFQ_12_0"></a><a id="Tc_cQ1VXZOAkUme_yydrjtyog_12_4"></a><a id="Tc_ppCn_qQ-aUWCM1lUENy-gA_12_7"></a><a id="Tc_v-_jkpydPEOQGdAdtY-f3g_12_10"></a><a id="Tc_ecsTS470LkuDNz8zCWjodA_12_13"></a><a id="Tc_MTMjxf6AmUK-2Ff5EE1gCg_12_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:41.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="16" style="vertical-align:bottom;white-space:nowrap;width:57.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended March 31, 2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:41.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:41.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:41.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:41.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QYcmyFRwzk617SCak5HhVg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_G1YuOKN3o0S0NNDY2FjnsQ_6_2">67,899,779</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QYcmyFRwzk617SCak5HhVg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_JoZZJhaOTk6RcKQ9eiBciA_6_5">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MPfkm448p0mSNurWEEYd7A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ET8eh2ZQG0264JQFktIqZg_6_8">430,859</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_z2-y6giFRkGYS5lYBANhoA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_afN8U9R2E0G3MrbiuNB0Sw_6_11">1,288</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Cb6CWZHa8U-FLgwfn7_C_g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_vV8nlpF_80CKX_hS85B4Pw_6_14">397,010</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2024_g8cU3m0E20Wpgrbgr6r3kw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_2b9yzD1hQ0mZAtxyrCMlMw_6_17">32,568</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Common stock issued upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rHbcLVDNhk-yPYw6tJnvKw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_pGEcfaM6NUaJ9K7DnPEIPA_7_2">269,682</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JiFN9ck9y06tFohjtNzoVg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_omuUKTtIWk6tydHUfVqNig_7_8">279</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_P8M_iyluSEu33rl85tqHAw_7_17">279</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JiFN9ck9y06tFohjtNzoVg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Ogcilocdl0WXnA6tXLAIVA_8_8">1,251</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Pg-vCIR9SUOruO1YRLedZQ_8_17">1,251</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Unrealized loss on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7MVQIs275UufJ7lWOSw2jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" sign="-" scale="3" id="Tc_MJLkvTP9dUmWh8g12Nt19g_9_11">23</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" sign="-" scale="3" id="Tc_fVwA2BB48U6gblSLR3MHtQ_9_17">23</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Foreign currency translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7MVQIs275UufJ7lWOSw2jw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="Tc_VCiel5YdcEevTK2oGs3KQg_10_11">57</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="Tc_grb5P4eMaU692JrQDGsqJw_10_17">57</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">Net income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__i-TBaMyv0a9A7f3NWezNg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_5q1lGXBazkazsh03YBH1zg_11_14">15,193</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_fKWRUMFDAEO-4Q-d1UYkWA_11_17">15,193</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bzThaTIaykCefde4hKplUA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_cDm-OjsOy0ma50EVAaDXUA_12_2">68,169,461</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bzThaTIaykCefde4hKplUA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_8q4C4X5aak2vjy1njwt2fQ_12_5">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AWAcFg_V-k6IIf18aUHL0w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_VKhe9rQBgU6R2sxJSimHzQ_12_8">432,389</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_tctkN7xylEqaixLGu7rKQg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_uMWSPxvhr0mOzIzMvmo7iA_12_11">1,254</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zBkc-2BhYEWNDNtaR_EzxA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_NxgtJfV9tk-ZP-n6nSBMKw_12_14">381,817</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2025_tNZXFjlgt0COhU24eHoxGQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_GuJ9XY0a7EiHKCews4l1hA_12_17">49,325</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_bee1f476_4323_4b1a_82ae_aafce9d2a210"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">CORVUS PHARMACEUTICALS,&#160;INC.</b></p><a id="STATEMENTSOFCASHFLOWS_192557"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_4e03dd47_c1b4_4373_940b_d9bcff330daf"></a><a id="Tc_kcQxFJxTHkyG0jGvwCARUA_1_2"></a><a id="Tc_5-Pvyrg-KE6ZQMH5gXVinw_2_2"></a><a id="Tc_Sf8Vka4EIE-OoeuIzg5fTw_3_2"></a><a id="Tc_GR0oul93GkCFbjmcFX6YnA_3_5"></a><a id="Tc_lFFC0790vkK84esuZM_1-w_4_0"></a><a id="Tc_e66bh6U5H06ulHvDIoqafg_5_0"></a><a id="Tc_ZDp3WiETJkCKAo4hkYCmng_5_2"></a><a id="Tc_UKcEiNGNNkWGGF9WAwG4_w_5_5"></a><a id="Tc_qE9CXBrfcUmRftzq0ByFwg_6_0"></a><a id="Tc_vNSouDSs8kuaXw6Le6oKVQ_7_0"></a><a id="Tc_hmMRH2A80EeIIVKOLrCv8A_8_0"></a><a id="Tc_EA9UzehzN0C6wMb52rd3LQ_9_0"></a><a id="Tc_0d6YNN__5UKBi4bpihtPDg_10_0"></a><a id="Tc_oUpQITCHO02VWc6vuCl_NA_10_3"></a><a id="Tc_jy4bZmW24UaSmY3_qrsMAg_11_0"></a><a id="Tc_c3v3UlieXEuu2BlCYGO7PQ_12_0"></a><a id="Tc_XvRQqoJNIECTbR14gE9WOQ_13_0"></a><a id="Tc_TUQFNvZwA0-_JWqzDBH0Zg_14_0"></a><a id="Tc_dnhaPgDxsUusGsJc89HjXg_15_0"></a><a id="Tc_zBowPgebJUCwPBYb8zU9AQ_16_0"></a><a id="Tc_vlbgn8QfwEe7ksEExMbffQ_17_0"></a><a id="Tc_PkrjA5DpcUOISar091w-RA_18_0"></a><a id="Tc__tXA8d3xeEOvIHCp01yk8w_19_0"></a><a id="Tc_gW_vWvaS-0KtW2lyHsM3yw_20_0"></a><a id="Tc_29VB9oCeiUu3bfh-a513YA_21_0"></a><a id="Tc_I3ET98z7REqBJ9Ge4hqL3A_22_0"></a><a id="Tc_8uZTaOdup0e6mLZoJjvenQ_23_0"></a><a id="Tc_B6MnVFOK1EWX6dGy2EwtxQ_24_0"></a><a id="Tc_xdfl1gBQ40Sos6yOc6uFbA_25_0"></a><a id="Tc_mg4P4cgp_U-zZ1Ioe2YABg_26_0"></a><a id="Tc_KkF519eAwESlY_gxwEEheA_27_0"></a><a id="Tc_nfx8nxo_v0ac91KuvR0kaQ_27_6"></a><a id="Tc_bMEeLODkckOSXj6jj8oFWQ_28_0"></a><a id="Tc_0GNjmHBVA0iSvXl8E87V2Q_29_0"></a><a id="Tc_EM2vMFPp9ESwearWukbYZw_30_0"></a><a id="Tc_zZh-9WENcEGK0N-q1xwvzg_31_0"></a><a id="Tc_mgk6H7EeKU-rnBps603VCQ_32_0"></a><a id="Tc_dpSULFz1yUWQJpWTSVzLeA_32_2"></a><a id="Tc_8Od_NcFNVUS-c6r5ZxRTHg_32_5"></a><a id="Tc_5RvZ8oJXgkOFICRigBnAPA_33_0"></a><a id="Tc_fb-ssh_ZA0mpNmZm2pHM-A_34_0"></a><a id="Tc_Xg-CXgqzAk6bhysxScZ44g_34_2"></a><a id="Tc_cyVw9GYnkE-VZBR0J9Mltg_34_5"></a><a id="Tc_Fem0uzPCukGpbVva9tmSLw_34_6"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:21.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:21.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Cash flows from operating activities</b></p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_SpxC6GTOykyhseGlmn2iUg_5_3">13,692</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="Tc_ulWJk-ZVW0uzJtAaDoBcuA_5_6">15,193</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_OxvSId_M5UWzwsX4XE80QQ_7_3">29</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_FOJ3MAI6_ESlJjznwjtDZw_7_6">22</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Accretion related to marketable securities</p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="Tc_WbWjv5q8wUelqfpUzVzYBA_8_3">17</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="Tc_pqjI9xu1Ck2RuaYPiTMT5A_8_6">291</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_rqhM5tQAtUSn9Ghj9oGQ2A_9_3">2,650</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_80li2zeatk-VPhcDbu6I9A_9_6">1,251</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Change in fair value of warrant liability</p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" sign="-" scale="3" id="Tc_rc0TFg4pjkeUl1jHnzB3pQ_10_6">25,129</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Loss from equity method investment</p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" sign="-" scale="3" id="Tc_a1gPDd8nsECizNUoEoISGQ_11_3">599</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" sign="-" scale="3" id="Tc_Crd41qQ0uECf1YeGXy3x2g_11_6">539</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 24pt;">Accounts receivable - related party</p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_YLkw7MG8HEKDEWIWiE4lUA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_kWL6Lcx0UkeWuzi-44I0sA_13_3">6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_W8_lVfV_5UW3wioprmLFCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_USzV-y-kQUmV7A_HGJp1DQ_13_6">4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 24pt;">Prepaid and other current assets</p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_QP7VGRtfB0q6J6flCFNqbQ_14_3">1,762</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_Ng74OPE_2kKhJI3QpXJf-g_14_6">1,168</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 24pt;">Operating lease right-of-use asset</p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" sign="-" scale="3" id="Tc_BrU3dBB15Ua056eOj-p3uA_15_3">88</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" sign="-" scale="3" id="Tc_YSi2iTg7a0KEYTEVjWzafg_15_6">82</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 24pt;">Other assets</p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" id="Tc_CcKmx_SIjEyiN6RFHFD1NQ_16_3">865</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" sign="-" scale="3" id="Tc_IIcZ_BnlfkKsl2ZyBd4d-Q_16_6">3</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 24pt;">Accounts payable</p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_HyRxQfvJBUedIZfbqhQaUw_17_3">2,206</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_kB8Rj__OIE-w8eZ7aYXWag_17_6">1,274</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 24pt;">Accrued and other liabilities</p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="Tc_NFnPuTSar0etr7ode3TzQQ_18_3">499</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="Tc_PyYvV9BMDk2fuwAT47Ahtg_18_6">146</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 24pt;">Operating lease liability</p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_i8NxHzIxq0-0M1a8HaTJSw_19_3">103</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="Tc_Rw1nb5hMI0ag97HDR1AnDg_19_6">31</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_93kLG_3Qn0ufCCxOcS-iFA_20_3">10,374</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_z2vbpIJK5UCHheMlFz8G0w_20_6">8,263</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Cash flows from investing activities</b></p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Purchases of marketable securities</p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="Tc_h40T4wH4wUyTCJfCsJAOBw_22_3">161,737</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="Tc_98eQZMmxx0qvBShPBclV-Q_22_6">7,708</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Maturities of marketable securities</p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="Tc_eVAmBdJ6sEWYcJU0kOBjDA_23_3">16,982</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="Tc_wwOKRG94c0-lzTXwhvw5fg_23_6">11,987</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_bIVXPyZpR0WG-M5KoDcWyg_24_3">91</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_JbFSzbstikGwxgTy-4PzIQ_24_6">36</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net cash (used in) provided by investing activities</p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_u6BHfllZB0-zUArewTwzeg_25_3">144,846</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_hMo3TBYILUact8IX5JbiqQ_25_6">4,243</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Cash flows from financing activities</b></p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Proceeds from issuance of common stock in connection with follow-on public offering, net</p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_ohMRA9eoFUu33302TR7hKA_27_3">189,407</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Proceeds from exercise of common stock options</p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_FxwkPLcSKkGpvsS5LJOQtA_28_3">1,339</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_5qUFGQHDo0SkVYkDYbugJA_28_6">279</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_vuAJ4lzlrk6Pk1hE8TIq0w_29_3">190,746</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_xLLfXWMoK0a1d31BxGyhQA_29_6">279</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net increase (decrease) in cash and cash equivalents</p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_GQBqclM2REq0LT_mmgw22A_30_3">35,526</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_RpljB1n4gkqM9Y-81C_kmw_30_6">3,741</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Cash and cash equivalents at beginning of the period</p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_r2oW3TOloEOV-Hb6ogjIKg_31_3">4,576</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2024_g8cU3m0E20Wpgrbgr6r3kw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_kuwQztmwwk6xv0FHeOCI3Q_31_6">8,740</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Cash and cash equivalents at end of the period</p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_N9xc-g7RwUGJiqQIRuedkg_32_3">40,102</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2025_tNZXFjlgt0COhU24eHoxGQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_WX18eRiPBEidKWEX3Shl7A_32_6">4,999</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Supplemental disclosures of cash flow information</b></p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:75.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Offering costs recorded to additional paid-in-capital but not paid</p></td><td style="vertical-align:bottom;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="crvs:OfferingCostsAccruedAndChargedToAdditionalPaidInCapital" scale="3" id="Tc_9PH00SmYYE2DCX-TSppzXQ_34_3">553</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CORVUS PHARMACEUTICALS,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="NOTESTOCONDENSEDCONSOLIDATEDFINANCIALSTA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:NatureOfOperations" id="Tb_K7pXwM7pD0O0A3g2kmfbsQ" continuedAt="Tb_K7pXwM7pD0O0A3g2kmfbsQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">1. Organization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Corvus Pharmaceuticals, Inc. (&#8220;Corvus&#8221; or the &#8220;Company&#8221;) was incorporated in Delaware on January 27, 2014 and commenced operations in November 2014. Corvus is a clinical-stage biopharmaceutical company. The Company&#8217;s operations are located in South San Francisco, California.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Corvus Biopharmaceuticals, Ltd. and Corvus Hong Kong Limited. All intercompany accounts and transactions have been eliminated from the condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Registered Direct Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>On May 6, 2024, the Company completed a registered direct offering which resulted in gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_5_6_2024_To_5_6_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Q6hXsJygPUicAUk5ciCrwA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_BrxUMvYe70yqS2pNTQ3gpw">30.6</ix:nonFraction> million. The financing consisted of the sale of <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="Duration_5_6_2024_To_5_6_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Q6hXsJygPUicAUk5ciCrwA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_qiMKwCtxIEKXbaBSlIKs3g">13,512,699</ix:nonFraction> shares of common stock and accompanying common stock warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonStockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_YFKxpTiNbU6oZe1MFcXljw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_CfXn287k50OclXeuh5vHlg">13,078,509</ix:nonFraction> shares of common stock (or pre-funded warrants in lieu thereof) at a combined offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonStockSharesAndCommonStockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_oZTsrk4nrkiHDAAiKkO7Zw" decimals="4" format="ixt:num-dot-decimal" name="crvs:CombinedOfferingPriceForSharesAndWarrants" scale="0" id="Narr_UUOBs1xqIUOJJcF8iC0MLw">1.7312</ix:nonFraction> per share, and the sale of pre-funded warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Jot-50-Yk0qa7VxZIMl1Sg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_ih3TouhekEeQ3h8vlG7X8w">4,144,085</ix:nonFraction> shares of common stock and accompanying common warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_4BVj8xmMz0KGnw09dZm4mg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_88uTQ9FSwU6pFTgw8oSVsg">4,010,927</ix:nonFraction> shares of common stock (or pre-funded warrants in lieu thereof) at a combined offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsAndCommonStockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Tlt-RbPRSUqh-Yw0_LG3kg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_xvVuU1h6F0OBXPzd84LkqA">1.7311</ix:nonFraction> per share. The common warrants had an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_4BVj8xmMz0KGnw09dZm4mg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_4irDIRc8dUCNELCwjYiCpA">3.50</ix:nonFraction> per share of common stock (or $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_4BVj8xmMz0KGnw09dZm4mg" decimals="4" format="ixt:num-dot-decimal" name="crvs:ClassOfWarrantOrRightExercisePricePerPrefundedWarrant" scale="0" id="Narr_5hRFOvAokUqZOMzJopXaIw">3.4999</ix:nonFraction> per pre-funded warrant in lieu thereof), were exercisable at any time after the date of issuance, subject to certain ownership limitations, and expired on June 30, 2025. The pre-funded warrants have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Jot-50-Yk0qa7VxZIMl1Sg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_KC5W23BpbUSofJU5PbTPyg">0.0001</ix:nonFraction> and are exercisable any time after the date of the issuance, subject to certain ownership limitations. As of June 30, 2025, the expiration date of the common warrants, all of the common warrants had been exercised, resulting in proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_6_30_2025_To_6_30_2025_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_sAkMcg3a40yNfpBDpGFwVQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" id="Narr_dYS_FiKqt0SWfup1bmAMHA">54.3</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Follow-on Public Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>On January 23, 2026, the Company completed a follow-on public offering in which the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="Duration_1_23_2026_To_1_23_2026_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_C6QNxTSO-0mAbUm6YypDqg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_MlIQFGqugUWiAhdLax5F7w">9,085,778</ix:nonFraction> shares of common stock at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="As_Of_1_23_2026_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_EBLWg8HfXUaxzZXp3DlZnw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_PhH0e0jnvESvdHwNvs9s_A">22.15</ix:nonFraction> per share, which included <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="Duration_1_23_2026_To_1_23_2026_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_lGZZMu3Hk0q46YOWfhYujg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_MNO-dFV4x0y2-j4ThnKwJg">1,185,101</ix:nonFraction> shares issued pursuant to the underwriters&#8217; exercise of their option to purchase additional shares of common stock. The aggregate net proceeds received by the Company from the offering were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_23_2026_To_1_23_2026_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_C6QNxTSO-0mAbUm6YypDqg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_R_RtpjgSYU60UCKYCxcyAw">189.4</ix:nonFraction> million, net of underwriting discounts and commissions and offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, contract manufacturer and contract research organizations, compliance with government regulations and the need to obtain additional financing to fund operations. Since commencing operations in 2014, the majority of the Company&#8217;s efforts have been focused on the research and development of soquelitinib, ciforadenant and mupadolimab. The Company believes that it will continue to expend substantial resources for the foreseeable future as it continues clinical development of, seek regulatory approval for and, if approved, prepare for the commercialization of soquelitinib, as well as product candidates under the Company&#8217;s other development programs. These expenditures will include costs associated with research and development, conducting preclinical studies and clinical trials, obtaining regulatory approvals, manufacturing and supply, sales and marketing and general operations. In addition, other unanticipated costs may arise. Because the outcome of any clinical trial and/or regulatory approval process is highly uncertain, the Company may not be able to accurately estimate the actual amounts necessary to successfully complete the development, regulatory approval process and commercialization of soquelitinib, or any other product candidates.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_K7pXwM7pD0O0A3g2kmfbsQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred significant losses and negative cash flows from operations in all periods since inception and had an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_KvFQFB1Ek0SSbHhXVPHxOQ">426.0</ix:nonFraction> million as of March 31, 2026. To date, none of the Company&#8217;s product candidates have been approved for sale and therefore the Company has not generated any revenue from sales of commercial products. Management expects operating losses to continue for the foreseeable future. The Company has funded its operations to date primarily through the sale of redeemable convertible preferred stock, common stock, pre-funded warrants and common stock warrants. As of March 31, 2026, the Company had cash, cash equivalents and marketable securities of $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="Narr_FPHNJyCKL0ir9EEXG_QXmQ">236.7</ix:nonFraction> million. Management believes that the Company&#8217;s current cash, cash equivalents and short-term marketable securities will be sufficient to fund its planned operations for at least the next 12 months from the date of the issuance of these condensed consolidated financial statements. To fund all of the Company's ongoing and planned development programs through commercialization, the Company will need to raise additional capital in the future. The Company intends to raise additional capital through private and public equity offerings, debt financings and license and development agreements. However, there can be no assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its operations or on terms acceptable to the Company or at all. If the Company is unsuccessful in its efforts to raise additional capital or if sufficient funds on acceptable terms are not available when needed, the Company could be required to significantly reduce operating expenses and delay, reduce the scope of or eliminate one or more of its development programs, out-license intellectual property rights to its product candidates, sell unsecured assets, or a combination of the above, any of which may have a material adverse effect on the Company&#8217;s business, results of operations, financial condition and/or its ability to fund its obligations on a timely basis or at all. Failure to manage discretionary spending or raise additional capital, as needed, may adversely impact the Company&#8217;s ability to achieve its intended business objectives.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_h7iQmvYOiUSo94M_cpWjzQ" continuedAt="Tb_h7iQmvYOiUSo94M_cpWjzQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">2. Summary of Significant Accounting Policies</b></p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_f38xxQgX-0msnp6fb4AzLA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The Company&#8217;s functional and reporting currency is the U.S. dollar, except for its investment in its equity method investee which is the Chinese renminbi (RMB). The accompanying condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and discharge of liabilities in the normal course of business.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="crvs:UnauditedInterimFinancialInformationPolicyTextBlock" id="Tb_GPO6XF_bgki77M62gF958g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Unaudited Interim Financial Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The accompanying interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for fair statement of the condensed consolidated financial statements presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The condensed consolidated balance sheet as of December 31, 2025 was derived from audited financial statements, but does not include all disclosures required by GAAP. The condensed consolidated results of operations for the three months ended March 31, 2026 are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements and the related notes for the year ended December 31, 2025 included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 12, 2026.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:UseOfEstimates" id="Tb_ejveAPN5q0Og2t6U2I0Dnw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The preparation of the Company&#8217;s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from such estimates.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_h7iQmvYOiUSo94M_cpWjzQ_cont1" continuedAt="Tb_h7iQmvYOiUSo94M_cpWjzQ_cont2"><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:EquityMethodInvestmentsPolicy" id="Tb_6jarc9NDR0GL0Ivevq1Mqg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Investments in Equity Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The Company uses the equity method of accounting for its equity investment if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The Company&#8217;s proportionate share of the net income (loss) resulting from the equity method investment is reported under the line item captioned &#8220;income (loss) from equity method investment&#8221; in the condensed consolidated statements of operations and comprehensive loss and the carrying value of the equity method investments is reported under the line captioned &#8220;Investment in Angel Pharmaceuticals&#8221; in the condensed consolidated balance sheets. The Company&#8217;s equity method investments are reported at cost and adjusted each period for the Company&#8217;s share of the investee&#8217;s income or loss and the foreign currency translation adjustment as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>For equity method investees with a functional currency different than the Company&#8217;s reporting currency, the Company follows the guidance under Accounting Standards Codification (&#8220;ASC&#8221;) 830-10-15-5, pursuant to which, the foreign currency financial statements of a foreign investee accounted for by the equity method should be translated to the reporting entity&#8217;s reporting currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The Company evaluates equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable. Factors considered by the Company when reviewing an equity method investment for impairment include the length of time (duration) and the extent (severity) to which the fair value of the equity method investment has been less than cost, the investee&#8217;s financial condition and near-term prospects and the intent and ability to hold the investment for a period of time sufficient to allow for anticipated recovery. An impairment that is other-than-temporary is recognized in the period identified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>See Note 6, &#8220;Equity Method Investment,&#8221; for further information.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_FKX-fjYIwUWxSvJ-atF5ew" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk and Other Risks and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:ConcentrationRiskCreditRiskUninsuredDeposits" id="Narr_Ex-1AP7yMEyzeyV19zfazw">Substantially all of the Company&#8217;s cash and cash equivalents are deposited in accounts with <ix:nonFraction unitRef="Unit_Standard_Institution_zA7d4X9tZU-Zo_s_3W3SSg" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="INF" format="ixt-sec:numwordsen" name="crvs:NumberOfFinancialInstitutionsInWhichCashAndCashEquivalentsAreDeposited" scale="0" id="Narr_FdqbESBG5Ey2HML_D3jDBQ">two</ix:nonFraction> financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company maintains its cash with an accredited financial institution and accordingly, such funds are subject to minimal credit risk. The Company&#8217;s marketable securities consist of investments in U.S. Treasury securities and U.S. government agency securities, which can be subject to certain credit risks. However, the Company mitigates the risks by investing in high-grade instruments, limiting its exposure to any one issuer, and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities.</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company is subject to a number of risks similar to other early stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, and protection of proprietary technology. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="crvs:SignificantAccountingPoliciesPolicyTextBlock" id="Tb_tI-6DrE1eEaFO-JLCprdXQ" continuedAt="Tb_tI-6DrE1eEaFO-JLCprdXQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Significant Accounting Policies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There have been no material changes to the Company&#8217;s significant accounting policies during the three months ended March 31, 2026 from those discussed in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 12, 2026.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_h7iQmvYOiUSo94M_cpWjzQ_cont2"><ix:continuation id="Tb_tI-6DrE1eEaFO-JLCprdXQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_IG5Edo71tkOurSKulJeN7A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2023, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative, which modifies the disclosure or presentation requirements related to variety of FASB Accounting Standard Codification topics. The effective date for each amendment will be the date on which the SEC&#8217;s removal of that related disclosure from Regulation S-X or Regulation S-K is effective. If by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the associated amendment will be removed from the Codification and will not become effective for any entities. The Company is currently evaluating the effect of adopting this ASU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expense. This update requires entities to disaggregate operating expenses into specific categories, such as salaries and wages, depreciation, and amortization, to provide enhanced transparency into the nature and function of expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, with early adoption permitted. ASU 2024-03 may be applied retrospectively or prospectively. The Company is currently evaluating the impact of ASU 2024-03 on its financial statement presentation and disclosures.</p></ix:nonNumeric></ix:continuation><a id="_1ef6e51c_4186_41ed_892b_65d25ec57510"></a><a id="Tc_p0TXyxWTDUmL0f0wKs1n7w_1_2"></a><a id="Tc_4C-tI8yOCUCsnTTl3bU6cw_2_2"></a><a id="Tc_bkvuVGdhxUS-kErbKGXD_g_3_2"></a><a id="Tc_xBXvdGiM-0msl0v6MTU7yQ_3_5"></a><a id="Tc_QhIqAEDXjkibFJlZ508idQ_4_0"></a><a id="Tc_iEEFnyx1dkOvkmcL5SHaMQ_5_0"></a><a id="Tc_ddWVCQQbvEKP6YJaDcmh-A_5_2"></a><a id="Tc_QG8aQ_fUt0y1kMmRB43oMA_5_5"></a><a id="Tc_q3jIrzB7zEuMCCUBHrxdKw_6_0"></a><a id="Tc_RL1nwHBg1EePzuttnOTuhA_6_3"></a><a id="Tc_rzokXTZZi0CKR3XycrAQ3A_7_0"></a><a id="Tc_oyJtUeBh5E2RhuYg2z7Xdw_7_2"></a><a id="Tc_Vl42ON7uqEGOGHhjMKdUxw_7_5"></a><a id="Tc_EMWiKwNENU6AZFIDmtwCQw_8_0"></a><a id="Tc__JzSvUz8A0atZrRVxh27sw_9_0"></a><a id="Tc_XkDkwZzUCkilipq6MsY_rw_10_0"></a><a id="Tc_7_sQ85gOMEKUshf1kf85Cg_10_3"></a><a id="Tc_-rtTcn7n4EKl6bzzNbuUkA_11_0"></a><a id="Tc_o_WtllTAokemuzFne0KJVA_13_0"></a><a id="Tc_U2Rq7LslpkiVigyEkPAEHg_13_2"></a><a id="Tc_9_fNa2thSkWVD5XLkXujfg_13_5"></a><a id="Tc__Whmi2LH1Uqi1MD53qQYMw_14_0"></a><a id="Tc_p16NGwYYUkS-PFpHF95zcQ_14_2"></a><a id="Tc_ykws1eMt0kq4GuTZyUhJpw_14_5"></a><a id="Tc_MYqiZKzay0m_ekKNY3QDrQ_1_2"></a><a id="Tc_a5SsMPvX0E6r_uIwtXM9Cw_2_2"></a><a id="Tc_a20vkBcyG0aROB4NGwELfg_3_2"></a><a id="Tc_ydJm2gpnAESotT0AD4ubxA_3_4"></a><a id="Tc_mzsVvYCtsUG0EJazOgPCqA_4_0"></a><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:EarningsPerShareTextBlock" id="Tb_ddzhK8BDr0ShdEsyzM0-XA" continuedAt="Tb_ddzhK8BDr0ShdEsyzM0-XA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">3. Net Loss per Share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_tPJfTkf__UC-Z4ODGxeb1A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The following table shows the calculation of net (loss) income per share (in thousands, except share and per share data):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:25.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:25.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Net loss attributable to common stockholders, basic</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_N9CRsXxzI0iNZGm01mZL_Q_5_3">13,692</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="Tc_2cMHUAvc4kCOrXEhgmwdXg_5_6">15,193</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Gain from change in fair value of warrant liability</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" scale="3" id="Tc_i0Lsn-7fZkifj6KxZPApOw_6_6">25,129</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Net loss - basic and diluted</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_EN6opVegE0G5CrcPKJPVSA_7_3">13,692</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_5AIdsTF43kapsl2YkI3c1g_7_6">9,936</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Weighted average common shares and pre-funded warrants outstanding used to compute basic and diluted net (loss) income per share</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_iAy2e8vu_0miiGH1unHi8w_9_3">89,996,728</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_KeXriQ3dOkm8HzhRW5xVrQ_9_6">72,126,496</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Weighted average shares issuable upon the exercise of common warrants</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" scale="0" id="Tc_6UBGDvhmFUmiAPgPdyDfiw_10_6">3,026,018</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Weighted average common shares and prefunded warrants outstanding used to compute diluted net loss per share</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_9Lkt4zIV-UeAZZlDAFp7Hg_11_3">89,996,728</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_kSP_HPP1qEi0j-tZ41chpQ_11_6">75,152,514</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net (loss) income per share, basic</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_qnCYTm0xjUqjf9eiY-ccCg_13_3">0.15</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_M6A-fSjdi0iGHqCRYkhxRw_13_6">0.21</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net loss per share, diluted</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_baz_FUXSsEeaIdmJB3lH7g_14_3">0.15</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_MPXE6wLwDEekbGinsJATig_14_6">0.13</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Weighted average common shares outstanding used in the calculation of basic and diluted net loss per share for the three months ended March 31, 2026 and 2025 includes <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="INF" format="ixt:num-dot-decimal" name="crvs:CommonSharesIssuableUponConversionOfPreFundedWarrants" scale="0" id="Narr_9AIQhUI0OUCIGr3WGc2wxA">8,275,913</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_3_31_2025_tNZXFjlgt0COhU24eHoxGQ" decimals="INF" format="ixt:num-dot-decimal" name="crvs:CommonSharesIssuableUponConversionOfPreFundedWarrants" scale="0" id="Narr_yC4LgAP7Kk--pXOeCGAuPw">4,144,085</ix:nonFraction> shares of common stock issuable upon conversion of pre-funded warrants, respectively. Refer to Note 9, &#8220;Warrants&#8221; for further details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Shares issuable upon exercise of common warrants used in the calculation of diluted net loss per share for the three months ended March 31, 2025 were calculated using the treasury stock method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The amounts in the table below were excluded from the calculation of diluted net loss per share, due to their anti-dilutive effect:</p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_R5jv-1evA0SIX8FkuNJHeA" continuedAt="Tb_R5jv-1evA0SIX8FkuNJHeA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:73.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:73.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:73.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:73.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Outstanding options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_fyY1JRXZxEybfcmX0J6BsQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ST2pr1JHCU-MnHAG_K8YRg_4_2">13,066,326</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_uG2y5xP9jkqJqpWj4ONRlg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_l4VcjCA7I0uGSllOwrTo2A_4_4">11,575,683</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><ix:continuation id="Tb_ddzhK8BDr0ShdEsyzM0-XA_cont1"><ix:continuation id="Tb_R5jv-1evA0SIX8FkuNJHeA_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_efaf009d_6ce2_4fcd_a5ec_0e9e40f9e02f"></a><a id="Tc_A9ooev71B0O0V5Y7bGdrTQ_1_2"></a><a id="Tc_GXG3yyKf90e9e3Co7H-fag_2_2"></a><a id="Tc_npG6bnB1u0mNzoXCTRPdmQ_3_2"></a><a id="Tc_GjEy-ga_JEiYQsQ3W-Kdrg_3_5"></a><a id="Tc_2X4mB13jgEa1JI71pC-UMQ_4_0"></a><a id="Tc_1Ud0frqSREC1sQmpX0Vw6g_4_2"></a><a id="Tc_YKvA2tZ6nUm0vWfM1OOxdA_4_5"></a><a id="Tc_JgpqbfDdX0-RoQLa84HElw_5_0"></a><a id="Tc_-5Z20GPOu0-apkesi6fNBQ_6_0"></a><a id="Tc_vvTbFH5tsku1KAsBbUv4fQ_7_0"></a><a id="Tc_1b7aZcdyhk2snIDys_K9Fw_8_0"></a><a id="Tc_iv-9DdVbqkCykiTa5b5ojQ_9_0"></a><a id="Tc_2Rvtuz8UbE2aIbETZQfccQ_10_0"></a><a id="Tc_-LuZdOHM4EG4uu9XMQC03g_11_0"></a><a id="Tc_ll9T9CF4I0-Ks02_N-IMeQ_12_0"></a><a id="Tc_Dm86UkEbwkmP6dcvKBMF-w_13_0"></a><a id="Tc_cQc8PJztmECABTh1cctCGg_13_2"></a><a id="Tc_fCq604Fi4ESMR30kNCmlkQ_13_5"></a><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:SegmentReportingDisclosureTextBlock" id="Tb_6fS73Z3ViEqTUSilWO-LQA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">4. Segments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The Company views its operations and manages its business in <ix:nonFraction unitRef="Unit_Standard_pure_zwdjuLpe8Um-MXpoYRfl8Q" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_lhMdfOQ3uE6f38VtrLF9FQ"><ix:nonFraction unitRef="Unit_Standard_pure_zwdjuLpe8Um-MXpoYRfl8Q" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_jL9F7RkRIk-1O1uM0fPcAA">one</ix:nonFraction></ix:nonFraction> operating segment, that of the development and commercialization of drugs and antibodies that target critical elements of the immune system. The Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;) is made up of the Chief Executive Officer and Chief Financial Officer. The CODM assesses performance for the segment and decides how to allocate resources based on consolidated net loss that is reported on the consolidated statement of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total consolidated assets. Managing and allocating resources on a consolidated basis enables the CODM to assess the overall level of resources available and how to best deploy these resources across functions and programs that are in line with the Company&#8217;s long-term company-wide strategic goals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="Tb_qaUfeIKQM0uZqXw3Lti1cw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The following table presents reportable segment net loss, including significant expense categories, attributable to the Company&#8217;s reportable segment for the three months ended March 31, 2026 and 2025 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Compensation and benefits, excluding stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold" scale="3" id="Tc_13QLE4--qkSLAG4eDqDZOw_4_3">3,027</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold" scale="3" id="Tc_HhgmmlQf7EWW8vrLMCqlbg_4_6">2,239</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_IE3j77P_3ESSlg1PuFpLOA_5_3">2,650</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_BzlRanmm4EiTKdkeIEWvQg_5_6">1,251</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Drug manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="crvs:SegmentDrugManufacturingCosts" scale="3" id="Tc_kjSkT5SgqU2oQrO9qXYGeQ_6_3">431</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="crvs:SegmentDrugManufacturingCosts" scale="3" id="Tc_sMrKbVv7nUeMvk7adJ1rpg_6_6">1,830</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Clinical trials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" id="Tc_7lSreRP70USRpQuNR9fgoA_7_3">5,043</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" id="Tc_MXM7_wrcZ02O_qy786zIAQ_7_6">1,927</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Outside general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" id="Tc_7gJ4JSLVIUSmA_tArmjgyg_8_3">1,244</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" id="Tc_gR2D5niWjkOlrlmFL_uGcw_8_6">946</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Facilities and insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="crvs:FacilitiesAndInsurance" scale="3" id="Tc_XB2jVlvoaEi09Fycb-Kmcw_9_3">558</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="crvs:FacilitiesAndInsurance" scale="3" id="Tc_0ShVXZxySUy0blkGtdHwvA_9_6">780</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other segment items (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralExpense" scale="3" id="Tc_vHRpbb1WI02RfLwX9x1D2w_10_3">1,924</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralExpense" scale="3" id="Tc_UrLEZK7KZ0SqofqqshXHZQ_10_6">949</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total segment expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_oj_57xTYYUGnpyD_FRW5YA_11_3">14,877</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_xZKHCL8_fEevR-8_2yJSjQ_11_6">9,922</ix:nonFraction></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Non-operating income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_XQDJZr-Uw0CsYH-AUv_jjg_12_3">1,185</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_qy_Yt9Z9rEOwaMPIYcH_ng_12_6">25,115</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_6APwYmHgY0Wv9zRWrJDqVA_13_3">13,692</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_5yZL0ulBeE-pItxNMcPwuA_13_6">15,193</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><div style="margin-top:3pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Includes consulting, non-clinical research and laboratory supplies.</span></td></tr></table><div style="margin-top:3pt;"></div></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_mQ1ddGvXTUi_ANiXWYy_IQ" continuedAt="Tb_mQ1ddGvXTUi_ANiXWYy_IQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">5. Fair Value Measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Financial assets and liabilities are measured and recorded at fair value. The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2&#8212;Inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3&#8212;Unobservable inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">There have been no transfers of assets and liabilities between levels of hierarchy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b9d6e4c9_0f48_496a_88cd_6f7625fbc35f"></a><a id="Tc_E4wc28Vl0EOH-yLoo6jBpg_1_2"></a><a id="Tc_sGl0E07YYUOOmFlb2eEqLw_2_2"></a><a id="Tc_NzDPcnYLv0GVw3ZURsKYKw_2_11"></a><a id="Tc_-z03kYnXQUmJAeu8N79jaA_3_2"></a><a id="Tc_LqazaQQdf0idIUCe5V6U7Q_3_5"></a><a id="Tc_cTyBjR75BESUK1AXqLMLQw_3_8"></a><a id="Tc_vsoMuR0KtkS_jBm2uDlibA_3_11"></a><a id="Tc_XEwOIurE3ES1jHtJRLvzkQ_4_0"></a><a id="Tc_lDfL4FXU-U6WOWN6bVw6Vg_5_0"></a><a id="Tc_HQKaMOHFZUiXdaFONdCpmA_5_2"></a><a id="Tc_02qFSs8imE2hOOUxc2p9pg_5_5"></a><a id="Tc_p-SO3O7LcEuCPCkXGfu-Qg_5_6"></a><a id="Tc_kbk-FBLs6k-N2tvy0VHOjg_5_8"></a><a id="Tc_u-qZcWjIwUiBjp1cZW0t3w_5_9"></a><a id="Tc_5bfXk6VT30uDMc9mo9l5lA_5_11"></a><a id="Tc_TDUYZP5H0UGGESguyuOaOA_6_0"></a><a id="Tc_fu_zxKhexUuLZVt90K8hjQ_6_3"></a><a id="Tc_GwiLyQbaHkSXy-9_HlAqCQ_6_9"></a><a id="Tc__QamFaZPbE-OwdEIGdCC1g_7_2"></a><a id="Tc_2pqVXWfQ_EyDJQIUlSNIng_7_5"></a><a id="Tc_pQKRLHKu9ECOq6IJactTag_7_8"></a><a id="Tc_lJdlX-Whj0uOQl78wMB9jw_7_9"></a><a id="Tc_62l2dH3CIkyC-yJ5mIfnsw_7_11"></a><a id="_5c1dd3ec_1269_4ec7_bcb1_75242d62396c"></a><a id="Tc_Xf1Ixd73b0mc-8GxknqPLA_1_2"></a><a id="Tc_IhLlVktwUE-O-BX0I-O04g_2_2"></a><a id="Tc_k35t6KIUqEOP3cPrTi74rA_2_11"></a><a id="Tc_dcv_vza9fUqEG5M6qWyu2g_3_2"></a><a id="Tc_2b8Z2_rnoUqsGWw8Aw09tA_3_5"></a><a id="Tc_c2PP-PorzUWse7ObqOiQXg_3_8"></a><a id="Tc_9UiPbZrYU0CLjzMuRa_5KA_3_11"></a><a id="Tc_TZAxMqR35USjXnZLDKGGzQ_4_0"></a><a id="Tc_s3si7EH2qECORn3-6kCeLQ_5_0"></a><a id="Tc_aHuZ0RIXN0mwXcMZZQZFBA_5_2"></a><a id="Tc_rwTV9gzEhkqsIuZoL9Qrjw_5_5"></a><a id="Tc_JP-XhouvOUS_44dwNN9j_g_5_6"></a><a id="Tc_iZNTxlDLCEqUpInxBZ1bWg_5_8"></a><a id="Tc_HPc-JkJqAkSQUgHfbwiLJg_5_9"></a><a id="Tc_4fgzKiObG0ObvgMthPii5w_5_11"></a><a id="Tc_2Clp0HAjb0GJS6wm8PRjwQ_6_0"></a><a id="Tc_svJp1ogbR0Wqg3NNE7fzPQ_6_3"></a><a id="Tc_sF5_iOfZSUqf8YFAEaW4vA_6_9"></a><a id="Tc_i03VUnVAgUq7SuxC0Sju_g_7_2"></a><a id="Tc_xzIcVAnNXkGDJ1eBfh5MLA_7_5"></a><a id="Tc_EcKoAd6-ZE643LZOCEBLGQ_7_8"></a><a id="Tc_8izKBAze_Uivb8I1qC1kcg_7_9"></a><a id="Tc_BAyJA5wTpEyz9X0JoCStIQ_7_11"></a><a id="_556044ce_7c46_4fa9_bb4b_38bae74c6d7d"></a><a id="Tc_IQJxQUPsY0ivj7cmC2E4Ww_1_2"></a><a id="Tc_9uVfFQSBGEWmI-9VmxXo-g_2_5"></a><a id="Tc_cKMfDfElukehYclRaIk2Vg_2_8"></a><a id="Tc_t5OQdrFJGUyzDmcBiw9-ZA_3_2"></a><a id="Tc_TJdkSNyBwkCzJlZii7p4FQ_3_5"></a><a id="Tc_MEKcEXf-IkeKmvQPqbXkQQ_3_8"></a><a id="Tc_MdV5o2gk5UqP8gziGNAf4A_3_11"></a><a id="Tc_Fw8t7LbIrky-WB95FQw7JQ_4_2"></a><a id="Tc_q9lc2jrVYU27shk1yOJKrA_4_5"></a><a id="Tc_cCwfgcfmKUCm5KwIXXV9aA_4_8"></a><a id="Tc_o6hvCaJfT0q0vMXPn8Wyfw_4_11"></a><a id="Tc_vvefLIljYUmyzxd-yMD8ig_5_0"></a><a id="Tc_CxuEwlYE7UqNzP6UESeVCw_5_2"></a><a id="Tc_kkt4gdd8IEe9HH4XIp4Stw_5_5"></a><a id="Tc_ZslIz5Ted0OvR5GFKQ-jQA_5_8"></a><a id="Tc_F9t0WTpvNkGqvnT7j9Qq4w_5_11"></a><a id="Tc_f_3aTQuLMEOCIp2kdUGeYg_6_0"></a><a id="Tc_5EDj-2Wcf0Wesw57aDuxkQ_7_2"></a><a id="Tc_aRbmXxRJPUeQSzIswHOnTA_7_5"></a><a id="Tc_rtWItigXU0mm2CRjbSUz_w_7_8"></a><a id="Tc_3cb38PVAdESE6tFywUlUbw_7_11"></a><a id="_0c927464_7784_4845_9a92_7d2993ee0c7e"></a><a id="Tc_N9OSLOhN8kupNQINRNHwZQ_1_2"></a><a id="Tc_l0ednyGjLUCL0WjLomTv0w_2_5"></a><a id="Tc_iyhXbuPVgEugcB17EJsvMA_2_8"></a><a id="Tc_SoBFQKZGxUaf55-Zg3t6zA_3_2"></a><a id="Tc_8H1ORZMlakSloK5P0zX4JQ_3_5"></a><a id="Tc_naC4ygQcHE-sqvxvhXxJyA_3_8"></a><a id="Tc_cAmcsGPwa0iWzc5HfmZ3uw_3_11"></a><a id="Tc_6GCVQ7M8tEiFzA-oNZXULA_4_2"></a><a id="Tc_OA6bJeTO7kCodTJYjR8vAQ_4_5"></a><a id="Tc_H4yJVny1V0aQqjnXhgZAzA_4_8"></a><a id="Tc_4WOJvE7UIkqIw1D2CV1qdw_4_11"></a><a id="Tc_sAgxVXfDcEyb7Unfr-HGBQ_5_0"></a><a id="Tc_6krZde-1DESt_GjonWxHgg_5_2"></a><a id="Tc_8uv9DyrH3kaSelQEj95W3g_5_5"></a><a id="Tc_ltQJuYH1D0ijUgMtVCH-6g_5_8"></a><a id="Tc_AvWkpcpPPkC_UnlcB8niSA_5_9"></a><a id="Tc_L09Mt0tnvk-gO8tiNsDupQ_5_11"></a><a id="Tc_3vfcW0BK4UKTGd-eeUoVhg_6_0"></a><a id="Tc_F1StBSsyzU-RfRBNtuFm6Q_6_9"></a><a id="Tc_3-cHwFvuXUWJ02A5Yy7dNw_7_2"></a><a id="Tc_wRTrQ_8qtE-kTLYcm6e1DQ_7_5"></a><a id="Tc_wrNYnz5jkUCX1gy_gfVjtQ_7_8"></a><a id="Tc_EKZhYO7BwkCvwvVPnpkrBw_7_9"></a><a id="Tc_zNVJ62nyYESO3mp4ICounQ_7_11"></a><a id="_84c70dbf_3ce3_4eff_8c3d_996edd911d3a"></a><a id="Tc_OjoTYc6tNEGpL4vGnDGtSA_1_2"></a><a id="Tc_sVzMckwE50OcCwnsD0HuMg_2_5"></a><a id="Tc_QKawLEDhjECWQ-MWZE8OvA_3_2"></a><a id="Tc_Rd5RoqlU3UuLLmZS0vvpYA_3_5"></a><a id="Tc_a_6K-b4Dck6S_8GVUtRy7g_3_8"></a><a id="Tc_r1XxsXTPBkycH16BSANMUw_4_0"></a><a id="Tc_AZv65xw-6E-1LkZzq5fBOA_4_2"></a><a id="Tc_iJnlyMuj8EGEypqc-d4hVA_4_5"></a><a id="Tc_ftZ-5iMvrkO7ahDEPL4QpA_4_8"></a><a id="Tc_33RX8_tXrEiCxCpAL55zVQ_5_0"></a><a id="Tc_stCsxBtj2kCaJtQ0ETzx5w_6_2"></a><a id="Tc_hHjkbfpeNUOMrFAkO9YSmg_6_5"></a><a id="Tc_40EjROeZCkeh4i5GohNEWQ_6_8"></a><ix:continuation id="Tb_mQ1ddGvXTUi_ANiXWYy_IQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company&#8217;s Level 2 investments are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar investments, issuer credit spreads, benchmark investments, prepayment/default projections based on historical data and other observable inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="Tb_3bF2iaIDb0G23EF4PmuJRQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The following tables present information as of March 31, 2026 and December 31, 2025 about the Company&#8217;s assets that are measured at fair value on a recurring basis and indicate the level of the fair value hierarchy the Company utilized to determine such fair values (in&#160;thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;width:43.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2026</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;width:32.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measured&#160;Using</b></p></td><td style="vertical-align:bottom;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vIybyFvfXUWOpF0Ttuei1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_tAVOJvg6jUycRAmQn3RK8w_5_3">39,106</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-i89-0JYT0SuUe9mQLTeMA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_bQj9ROKoTU6BcLEAsLhJoA_5_12">39,106</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1UFe9j-ZmEGRYjbAX_HTFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="Tc_5rQxo2wcEkeGRBxz6wfP-A_6_6">196,612</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-i89-0JYT0SuUe9mQLTeMA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="Tc_rdC3Tu6r-EiBi0cU6YzclQ_6_12">196,612</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vIybyFvfXUWOpF0Ttuei1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc__t3jOBzLEkSehAtzRU0bDQ_7_3">39,106</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1UFe9j-ZmEGRYjbAX_HTFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_597XN0Oob0uevEqwNODN1w_7_6">196,612</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-i89-0JYT0SuUe9mQLTeMA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_d9jv0iLhREijn3nrIiGOjA_7_12">235,718</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:normal;width:43.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:normal;width:32.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measured&#160;Using</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_umpLEYrKtUW8udWfgt4FUQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_IaN0v6gVrUK1r2PLr-kQog_5_3">4,163</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_d-ggcYb3f0OK5oH3EAR0_w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_ukXVyuvJGE2kk_gSGjWJvg_5_12">4,163</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_XWrNNuJp9kmcv0K4YI0__w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="Tc_mqBqwx3WmU-efGYpmh1-7w_6_6">52,174</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_d-ggcYb3f0OK5oH3EAR0_w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="Tc_5JVOYhJTVkyCCI-3xd6JiA_6_12">52,174</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_umpLEYrKtUW8udWfgt4FUQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_WL88Q_ATxUqh2hzmKtWAxA_7_3">4,163</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_XWrNNuJp9kmcv0K4YI0__w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_2fwr-Xyc5kWt2roXYHIMGw_7_6">52,174</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_d-ggcYb3f0OK5oH3EAR0_w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_awpN79pkBkCm6CS800vp9A_7_12">56,337</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="Tb_fHMEMrdCkEKRBtHksSF2bQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of March 31, 2026 and December 31, 2025, the fair value of available for sale marketable securities by type of security were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:38.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2026</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:59.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">U.S. Treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_Z1ifIYrZk0K3l2sseW4akQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="Tc_qO5vfv6ulEG_yydGlyTrJQ_5_3">164,862</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_Z1ifIYrZk0K3l2sseW4akQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_rlP-bz2CsE2CQlUPs1d2bQ_5_6">53</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_Z1ifIYrZk0K3l2sseW4akQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_WjWDc7szqUaNdfG04nCpwA_5_9">237</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_Z1ifIYrZk0K3l2sseW4akQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="Tc_29JvD2edjUOfiJfT1RQEdg_5_12">164,678</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">U.S. Government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_xEp_Nqn3VkmF6ubCOIKCDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="Tc_TQvMk84POU2l9HiA4M1L1g_6_3">32,021</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_xEp_Nqn3VkmF6ubCOIKCDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_Tk6vWkgod0OLdd7xEuefQQ_6_6">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_xEp_Nqn3VkmF6ubCOIKCDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_bkIM-LBEE0utuws9gc5jvA_6_9">88</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_xEp_Nqn3VkmF6ubCOIKCDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="Tc__110bAL6Bk-SH51U_sMuPQ_6_12">31,934</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:59.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="Tc_yXYJaMF0sEOc03a0yq_HcA_7_3">196,883</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_DedKCjtgFkmUQmdgxTaeRw_7_6">54</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_AEtsalyPW0m2nZpHY-H9hA_7_9">325</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="Tc_oC1x32-OdU6hmLT3bm4BbQ_7_12">196,612</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:36.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">U.S. Treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_by6XIl09fUeHMa27xYEX5w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="Tc_D6mb8zgQLECgolQzmDojDA_5_3">38,622</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_by6XIl09fUeHMa27xYEX5w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_c05Y99AmG0avBSt9Clt9oQ_5_6">53</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_by6XIl09fUeHMa27xYEX5w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="Tc_VLlxmRUZz06iwEaiHerMxQ_5_12">38,675</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">U.S. Government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2TM0kzCyaUqmRGhHtqiKBw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="Tc_yhuNG8LwlEuyJxvGd6K6rg_6_3">13,489</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2TM0kzCyaUqmRGhHtqiKBw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_2B5KhP6Uq0Cq63_M-R4OcA_6_6">10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2TM0kzCyaUqmRGhHtqiKBw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="Tc_h9Ltn6t-CUGMLUkZDYoBiA_6_12">13,499</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="Tc_jSXltk0uUUKH2H2ojUbj8w_7_3">52,111</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_LIhH3nm_uEaDaB6wQvLwGQ_7_6">63</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="Tc_uq6hFWBubU28wF_OK6oIZw_7_12">52,174</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="color:#ee0000;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="Tb_XqD0Ux5HkkGM5XQGwTmiAw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of March 31, 2026, all of the Company&#8217;s marketable securities are considered available for current operations and the remaining maturity by type of security is as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="color:#ee0000;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maturities&#160;by&#160;Period at Amortized Cost</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">than</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">1 Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">1-2 years</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">U.S. Treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_Z1ifIYrZk0K3l2sseW4akQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="Tc_vHImPEEtPUW-WtB7rHlEgg_4_3">164,862</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_Z1ifIYrZk0K3l2sseW4akQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="3" id="Tc_AuEVHbo8hkOT4wpNn1U2FQ_4_6">95,749</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_Z1ifIYrZk0K3l2sseW4akQ" decimals="-3" format="ixt:num-dot-decimal" name="crvs:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" scale="3" id="Tc_q_iyV2vKpU6d3D5uuDyViw_4_9">69,113</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">U.S. Government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_xEp_Nqn3VkmF6ubCOIKCDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="Tc_RAoUpbN-2UeCx6yqH7qAKQ_5_3">32,021</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_xEp_Nqn3VkmF6ubCOIKCDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="3" id="Tc_mLKqi7pprUqu0kAAq9BjVA_5_6">12,943</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_xEp_Nqn3VkmF6ubCOIKCDQ" decimals="-3" format="ixt:num-dot-decimal" name="crvs:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" scale="3" id="Tc_BeZDG692nE6fqrhMWS_JBw_5_9">19,078</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:middle;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="Tc_Wrzyl4v2TEqduVKksqGb_w_6_3">196,883</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="3" id="Tc_aYlgYm_8O0uesJJwQ4_7cg_6_6">108,692</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="crvs:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" scale="3" id="Tc_wA6Whjw9tECsy5lKzmL8Qg_6_9">88,191</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="color:#ee0000;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_9j3gRzLG0Eqq9rOdx7aVLg_1_3"></a><a id="Tc_U4O8jDKI8kOvzg2b-ZrDPQ_1_6"></a><a id="Tc_qNkTdwZ4sEmMDg0AOpD5ag_2_0"></a><a id="Tc_x9JmuzmGjEO-ek5mrczSjg_2_2"></a><a id="Tc_aDdSCY0BMUyERfIkTFIW9w_2_5"></a><a id="Tc_mU4B57RTk0aJGOectJvoxA_3_2"></a><a id="Tc_bcCCk1vcRkyDygtSjy6rjg_4_0"></a><a id="Tc_WwJ8KYrYW06Jd69N699w4g_4_2"></a><a id="Tc_ESHo34Ydj0qtdk5wfsfSjA_4_5"></a><a id="Tc_nx4eLBzOLki1TXgs3oMIYw_5_0"></a><a id="Tc_pN2OrEJ_Ok6HzCM17hOERg_6_0"></a><a id="Tc_rFzt3WKIik2xstoxg6cdOg_7_0"></a><a id="Tc_RHnboOPTqEGmvI007oR5aw_8_0"></a><a id="Tc_DIjCxQYAvUC6LNP9YF7jYQ_1_3"></a><a id="Tc_XMnXFYvA40GVilNK1-iELg_2_3"></a><a id="Tc_1cFCDoBl0EWtYPRpxofkWA_3_0"></a><a id="Tc_0LyK3dM7aUyR-k48Vnhw6Q_3_3"></a><a id="Tc_w5uDPKzri0KSpBEg1dFlDQ_3_6"></a><a id="Tc_KeoSB_Q6LECF1iNFehYrvw_5_0"></a><a id="Tc_1hUQFuQ1PEii6pyF8moWxQ_5_3"></a><a id="Tc_mxIB3H3BHU-GCZ_SwxhvKA_5_4"></a><a id="Tc_USKDXjTUoUSgbhNZpx3MWg_5_6"></a><a id="Tc_zDX0eFbHrEGZP2xwIqw-TQ_5_7"></a><a id="Tc_Xge7KHrtOkuumrTpwk76Hw_6_0"></a><a id="Tc_SdjbSifC0UCFktfsqrK5-w_6_4"></a><a id="Tc_EZaMr7eoa0OWz1Cs7rNm2w_6_7"></a><a id="Tc_5Kh_bVGXf06cJa6wnJcm1g_7_0"></a><a id="Tc_JCwcVScdzkOIKvqg2h--tw_8_0"></a><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="Tb_fGD6W6BlB0mCyqFS_nsb-g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">6. Equity Method Investment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Angel Pharmaceuticals Co. Ltd. (&#8220;Angel Pharmaceuticals&#8221;) is a corporate venture in the People&#8217;s Republic of China designed to develop, manufacture, and commercialize soquelitinib, ciforadenant and mupadolimab compounds for distribution within the countries of China, Taiwan, Macao, and Hong Kong based on intellectual property licenses contributed to Angel Pharmaceuticals by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, the Company&#8217;s ownership interest in Angel Pharmaceuticals was approximately <ix:nonFraction unitRef="Unit_Standard_pure_zwdjuLpe8Um-MXpoYRfl8Q" contextRef="As_Of_3_31_2026_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_ZE_QhKexwEy9f39wgI86gQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="Narr_vv-i-Z4Hnkm9hSKru9v99g"><ix:nonFraction unitRef="Unit_Standard_pure_zwdjuLpe8Um-MXpoYRfl8Q" contextRef="As_Of_12_31_2025_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_R50vtT-u40OjHn3pS5rzEA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="Narr_DGWIIlsTmUqbgfemg9-VEQ">49.7</ix:nonFraction></ix:nonFraction>%, excluding <ix:nonFraction unitRef="Unit_Standard_pure_zwdjuLpe8Um-MXpoYRfl8Q" contextRef="Duration_1_1_2026_To_3_31_2026_dei_LegalEntityAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_IAkd47amHkiAxCCDntS06Q" decimals="2" format="ixt:num-dot-decimal" name="crvs:EmployeeStockOwnershipPlanEsopEquityReservePercentage" scale="-2" id="Narr_vbbyFlGkYkGiHei4myBLeA"><ix:nonFraction unitRef="Unit_Standard_pure_zwdjuLpe8Um-MXpoYRfl8Q" contextRef="Duration_1_1_2025_To_12_31_2025_dei_LegalEntityAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_v9ThojvBS0yKLcEp5NgIDw" decimals="2" format="ixt:num-dot-decimal" name="crvs:EmployeeStockOwnershipPlanEsopEquityReservePercentage" scale="-2" id="Narr_GukjNznNM0SaYT2jsMC93w">7</ix:nonFraction></ix:nonFraction>% of Angel Pharmaceuticals&#8217; equity reserved for issuance under the Angel Pharmaceuticals Employee Stock Ownership Plan, and is accounted for as an equity method investment. The Company recognized its share of loss in Angel Pharmaceuticals for the total amount of $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_6ofbkjgS-0e4rwuNdfqWaw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" sign="-" scale="6" id="Narr_TeiI_sT-a0iXgYJBqa9S7g">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_2y33YWXdnkGW7dFGwtYxNQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" sign="-" scale="6" id="Narr_nCLTmD7c8EWjCRrQbVtJeA">0.5</ix:nonFraction> million as loss from equity method investment in the condensed consolidated statement of operations for the three months ended March 31, 2026 and 2025, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary Financial Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Summary financial information for Angel Pharmaceuticals is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:EquityMethodInvestmentsTextBlock" id="Group_kvemLDOiikSQ8whOQalung" continuedAt="Group_kvemLDOiikSQ8whOQalung_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:67.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Balance Sheet Data</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2025</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr style=""><td style="vertical-align:bottom;width:67.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_wsU59n8Qhk6UFUREvLUcmQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_CXA-8YPfoEWEofDBmU4fOg_4_3">10,286</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_dBO40tK2nky99I0IgRgeFA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_4OdPE57CHE61jHWJ3k676Q_4_6">11,033</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_wsU59n8Qhk6UFUREvLUcmQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" id="Tc_QvdlZaF6REeOsd2p7B0B7g_5_3">798</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_dBO40tK2nky99I0IgRgeFA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" id="Tc_SmcwGMXPz0SQPuCyjbYdDg_5_6">904</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_wsU59n8Qhk6UFUREvLUcmQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_cGLy5fiCBEuqkwWHotkQPg_6_3">863</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_dBO40tK2nky99I0IgRgeFA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_w2kVPvn_FEup3tFbIVClaA_6_6">1,049</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_wsU59n8Qhk6UFUREvLUcmQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_VbYNOE2zS0KV1mK7VgUtwg_7_3">143</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_dBO40tK2nky99I0IgRgeFA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_AapER5xAJEOdRV8DdC2HKg_7_6">229</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stockholders' equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_wsU59n8Qhk6UFUREvLUcmQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_0bEJWhMDWEi80DqbZ93-hA_8_3">10,078</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_dBO40tK2nky99I0IgRgeFA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_tf4kjobaJUGzdvUthIqsBg_8_6">10,659</ix:nonFraction></p></td></tr></table></ix:nonNumeric><ix:continuation id="Group_kvemLDOiikSQ8whOQalung_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Statement&#160;of&#160;Operations&#160;Data</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_dSaQSn0xTEGxv32ul8LDRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_xh1t7Ej4Dkq_3kBJNQCGEw_7_4">768</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_Tb3DXUa7E0uzOGfwD0V8eA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_3u4lo_NUE0espasGKSqsUA_7_7">686</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Share of loss from investments accounted for using the equity method</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" sign="-" scale="3" id="Tc_YYrR8dYMUkeFvmgdZDyUHg_8_4">599</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" sign="-" scale="3" id="Tc_Ew65Xl5-Bk6kvk30OdGv9Q_8_7">539</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Tb_-NwrlrjdG0Wu8bS84vI-1w" continuedAt="Tb_-NwrlrjdG0Wu8bS84vI-1w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">7. License and Collaboration Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Scripps Licensing Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2014, the Company entered into a license agreement with The Scripps Research Institute (&#8220;Scripps&#8221;), pursuant to which it was granted a non-exclusive, world-wide license for all fields of use under Scripps&#8217; rights in certain know-how and technology related to a mouse hybridoma clone expressing an anti-human CD73 antibody, and to progeny, mutants or unmodified derivatives of such hybridoma and any antibodies expressed by such hybridoma, from which we developed CPI-006. Scripps also granted the Company the right to grant sublicenses in conjunction with other proprietary rights the Company holds, or to others collaborating with or performing services for the Company. Under this license agreement, Scripps has agreed not to grant any additional commercial licenses with respect to such materials, other than march-in rights granted to the U.S. government.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Upon execution of the agreement, the Company made a one time cash payment to Scripps of $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2015_To_12_31_2015_srt_CounterpartyNameAxis_crvs_ScrippsResearchInstituteMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_XMrt33ULGkeQ_-gbvlHdKA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Narr_RdoLPSx-O0KdWZKWx9mHSg">10,000</ix:nonFraction> in 2015 and is also obligated to pay a minimum annual fee to Scripps of $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_ScrippsResearchInstituteMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_po2cXNmYykeJqOGtUERulg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" scale="0" id="Narr_UJcEY2LP-k-036Jjj97gig">25,000</ix:nonFraction>. The one time cash payment was recorded as research and development expense as technological feasibility of the asset had not been established and there was no alternative future use. A minimum annual fee payment is due on each anniversary of the effective date of the agreement </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_-NwrlrjdG0Wu8bS84vI-1w_cont1" continuedAt="Tb_-NwrlrjdG0Wu8bS84vI-1w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">for the term of the agreement. The Company is also required to make performance based cash payments upon successful completion of clinical and sales milestones. The aggregate potential milestone payments are $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_ScrippsResearchInstituteMember_srt_StatementScenarioAxis_crvs_AggregatePotentialMilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_dD5UP8Q5v06xhOLdtmqxlA" decimals="-5" format="ixt:num-dot-decimal" name="crvs:LicenseAgreementMilestonePayment" scale="6" id="Narr_uaPOhfflsUWjvQTdDLlyOQ">2.5</ix:nonFraction> million as of March 31, 2026. The Company is also required to pay royalties on net sales of licensed products (including CPI-006) sold by it, its affiliates and its sublicensees at a rate in the low single digits. In addition, should the Company sublicense the rights licensed under the agreement, it has agreed to pay a percentage of sublicense revenue received at specified rates that start at double digit percentages and decrease to single digit percentages based on the elapsed time from the effective date of the agreement and the time of entry into such sublicense. To date, <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_ScrippsResearchInstituteMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_po2cXNmYykeJqOGtUERulg" decimals="0" format="ixt-sec:numwordsen" name="crvs:LicenseAgreementMilestonePayment" scale="0" id="Narr_bcA1Fi0nnkGAiMMS8Ho43A">no</ix:nonFraction> milestone payments have been made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s license agreement with Scripps will terminate upon expiration of its obligation to pay royalties to Scripps under the license agreement. The Company&#8217;s license agreement with Scripps is terminable by the consent of the parties, at will by the Company upon providing <ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_ScrippsResearchInstituteMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_po2cXNmYykeJqOGtUERulg" format="ixt-sec:durwordsen" name="crvs:ResearchAndDevelopmentArrangementContractTerminationNoticePeriod" id="Narr_-QZ31wnJPkOuHnDLnCxv0Q">90 days</ix:nonNumeric> written notice to Scripps, or by Scripps for certain material breaches, or if the Company undergoes a bankruptcy event. In addition, Scripps may terminate the license on a product by product basis, or the entire agreement, if the Company fails to meet specified diligence obligations related to the development and commercialization of licensed products. Scripps may also terminate the agreement after the third anniversary of the effective date of the agreement if it reasonably believes, based on reports the Company provides to Scripps, that the Company has not used commercially reasonable efforts as required under the agreement, subject to a specified notice and cure period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Vernalis Licensing Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In February 2015, the Company entered into a license agreement with Vernalis (R&amp;D) Limited (&#8220;Vernalis&#8221;), which was subsequently amended as of November 5, 2015, and, pursuant to which the Company was granted an exclusive, worldwide license under certain patent rights and know-how, including a limited right to grant sublicenses, for all fields of use to develop, manufacture and commercialize products containing certain adenosine receptor antagonists, including ciforadenant. Pursuant to this agreement, the Company made a one-time cash payment to Vernalis in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_11_5_2015_To_11_5_2015_srt_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_cxY8H5-g_EGIH2ELcc-HaQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_KYwUiagBwEylwfdh5F56Qw">1.0</ix:nonFraction> million, which was recorded as research and development expense as technological feasibility of the asset had not been established and there was no alternative future use. The Company is also required to make cash milestone payments to Vernalis upon the successful completion of clinical and regulatory milestones for licensed products depending on the indications for which such licensed products are developed and upon achievement of certain sales milestones. In February 2017, the Company made a milestone payment of $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_53gyr3oPf0-E7oFQOdHZ2A" decimals="-5" format="ixt:num-dot-decimal" name="crvs:LicenseAgreementMilestonePayment" scale="6" id="Narr_oH2NyYNmoU2MUUMnvehc0A">3.0</ix:nonFraction> million to Vernalis following the expansion of a cohort of patients with renal cell cancer treated with single agent ciforadenant in the Company&#8217;s Phase 1/1b clinical trial. During the three months ended March 31, 2026 and 2025, <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_yZROy1gbRU-l_b7CkxhgEg" decimals="0" format="ixt-sec:numwordsen" name="crvs:LicenseAgreementMilestonePayment" scale="0" id="Narr_vEjqAyv4WEaZ2toQeOc5ug"><ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_zptfIK_qa0ys8kZeVc8ECg" decimals="0" format="ixt-sec:numwordsen" name="crvs:LicenseAgreementMilestonePayment" scale="0" id="Narr_ELLoI-U-2EKl4jTTUHE0bQ">no</ix:nonFraction></ix:nonFraction> clinical or regulatory milestones were completed or paid to Vernalis, and the aggregate potential milestone payments were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_srt_StatementScenarioAxis_crvs_AggregatePotentialMilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_aJ4OIsSntUiP4dLNeBCv1A" decimals="-6" format="ixt:num-dot-decimal" name="crvs:LicenseAgreementMilestonePayment" scale="6" id="Narr_TxJxpRSILUGesoU4MeYugw">220</ix:nonFraction> million for all indications as of March 31, 2026. The Company has also agreed to pay Vernalis tiered incremental royalties based on the annual net sales of licensed products containing ciforadenant on a product by product and country by country basis, subject to certain offsets and reductions. The tiered royalty rates for products containing ciforadenant range from the mid single digits up to the low double digits on a country by country net sales basis. The royalties on other licensed products that do not include ciforadenant also increase with the amount of net sales on a product-by-product and country by country basis and range from the low single digits up to the mid single digits on a country by country net sales basis. The Company is also obligated to pay to Vernalis certain sales milestones as indicated above when worldwide net sales reach specified levels over an agreed upon time period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The agreement will expire on a product-by-product and country-by-country basis upon the expiration of the Company&#8217;s payment obligations to Vernalis in respect of a particular product and country. Both parties have the right to terminate the agreement for an uncured material breach by the other party. The Company may also terminate the agreement at its convenience by providing <ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_zptfIK_qa0ys8kZeVc8ECg" format="ixt-sec:durwordsen" name="crvs:ResearchAndDevelopmentArrangementContractTerminationNoticePeriod" id="Narr_1UJ1fluf-EqiE0hxNWEIHA">90 days</ix:nonNumeric> written notice, provided that the Company has not received notice of its own default under the agreement at the time the Company exercises such termination right. Vernalis may also terminate the agreement if the Company challenges a licensed patent or undergoes a bankruptcy event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_-NwrlrjdG0Wu8bS84vI-1w_cont2" continuedAt="Tb_-NwrlrjdG0Wu8bS84vI-1w_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Monash License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2017, the Company entered into a license agreement with Monash University (&#8220;Monash&#8221;), pursuant to which the Company was granted an exclusive, sublicensable worldwide license under certain know-how, patent rights and other intellectual property rights controlled by Monash to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon execution of the agreement, the Company made a one time cash payment to Monash of $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_4_1_2017_To_4_30_2017_srt_CounterpartyNameAxis_crvs_MonashLicenseMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_a9cCB_fmJ0qXM_jhei5r1Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Narr_6KKaQ4RB30WGO4V_CfoNhw">275,000</ix:nonFraction> and reimbursed Monash for certain patent prosecution costs incurred prior to execution of the agreement. The Company recorded these payments as research and development expenses for the year ended December 31, 2017. The Company is also obligated to pay an annual license maintenance fee to Monash of $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_4_1_2017_To_4_30_2017_srt_CounterpartyNameAxis_crvs_MonashLicenseMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_a9cCB_fmJ0qXM_jhei5r1Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" scale="0" id="Narr_LLHmbctO70mAdxgSs9zfoQ">25,000</ix:nonFraction> until a certain development milestone is met with respect to the licensed product, after which no further maintenance fee will be due. The Company is also required to make development and sales milestone payments to Monash with respect to the licensed products. During the three months ended March 31, 2026 and 2025, <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_crvs_MonashLicenseMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_qMLGaFcjDk6SK_FVkFPddA" decimals="0" format="ixt-sec:numwordsen" name="crvs:LicenseAgreementMilestonePayment" scale="0" id="Narr_zrLkubgCfEy1AwmFFd4a7Q"><ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_MonashLicenseMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_11uvkiG9bE23RyZq6u2HDA" decimals="0" format="ixt-sec:numwordsen" name="crvs:LicenseAgreementMilestonePayment" scale="0" id="Narr_SwCxs_ifV0KpxwattsviRA">no</ix:nonFraction></ix:nonFraction> development or sales milestones were completed or paid to Monash, and the aggregate potential milestones were $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_MonashLicenseMember_srt_StatementScenarioAxis_crvs_AggregatePotentialMilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_6utRsh2k0ky_UVcLFS0XMg" decimals="-5" format="ixt:num-dot-decimal" name="crvs:LicenseAgreementMilestonePayment" scale="6" id="Narr_zgj72-EnmU27vTz8WA_rXg">45.1</ix:nonFraction> million as of March 31, 2026. The Company is also required to pay to Monash tiered royalties on net sales of licensed products sold by it, its affiliates and its sublicensees at a rate ranging in the low single digits. In addition, should the Company sublicense its rights under the agreement, the Company has agreed to pay a percentage of sublicense revenue received at specified rates that are currently at low double digit percentages and decrease to single digit percentages based on the achievement of development milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The term of the Company&#8217;s agreement with Monash continues until the expiration of its obligation to pay royalties to Monash thereunder. The license agreement is terminable at will by the Company upon providing <ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_MonashLicenseMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_11uvkiG9bE23RyZq6u2HDA" format="ixt-sec:durwordsen" name="crvs:ResearchAndDevelopmentArrangementContractTerminationNoticePeriod" id="Narr_i9zqJIY7gUa2qDj-6pKmBQ">30 days</ix:nonNumeric> written notice to Monash, or by either party for material breaches by the other party. In addition, Monash may terminate the entire agreement or convert the license to a non-exclusive license if the Company has materially breached its obligation to use commercially reasonable efforts to develop and commercialize a licensed product, subject to a specified notice and cure mechanism.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_-NwrlrjdG0Wu8bS84vI-1w_cont3"></ix:continuation><a id="Tc_f9rPqsSOMUy3uVj51kpndA_1_2"></a><a id="Tc_1q_UeHhEZkaFGGwUbknABg_1_5"></a><a id="Tc_VvyBOwlx-0SS2Do7UIgOAQ_2_2"></a><a id="Tc_CPGvO43RZ0C5LaTwbTdqsg_2_5"></a><a id="Tc_eXjD9DsP3Ua15rtnotri4w_3_0"></a><a id="Tc_dmkFMGJ7qkGz3RmHhv_2PQ_4_0"></a><a id="Tc_rnwSLWY8m0q1Os3eQKdTAQ_4_2"></a><a id="Tc_xag28gjHpk-YaejHnPUl_Q_4_5"></a><a id="Tc_XSJYR00jK0yAwzFGSeeh1g_5_0"></a><a id="Tc_FLPmsVaaqUqFgVEJWC8ASw_6_0"></a><a id="Tc_L-2jIGii6UC3tg7iFQKAXQ_7_0"></a><a id="Tc_rHQh9Idfh06TJdfM6e4XCw_8_0"></a><a id="Tc_8wZc5lH0-UG6x6_N-A3Scg_9_2"></a><a id="Tc_sxKrSw9y3UuGF_LfF3oY5Q_9_5"></a><a id="Tc_iXvId8LPVUiss9d8QUXqSA_10_0"></a><a id="Tc_4gHer_sYiUuqup-IH6Ur8A_11_0"></a><a id="Tc_McsPBG97tkqr-jClCIxUHQ_11_2"></a><a id="Tc_LzTyUw-CQUiozB0pvRUjkA_11_5"></a><a id="Tc_Vc6ZIBsRm0e8dY7kBEgDCg_12_0"></a><a id="Tc_LJT7FBOykkOfAWkyd4VfBg_13_0"></a><a id="Tc_nNN2MmqoPkGEW2os5gRq2A_14_0"></a><a id="Tc_L9WedZMZQ0iW4eWnZ428ag_14_6"></a><a id="Tc_ZjPEOe8nEUidkiGTVUe6ng_16_0"></a><a id="Tc_gBt2efb4o0icki7dT8NMfw_17_2"></a><a id="Tc_1I9guTaNbUa7gRMddD0EVw_17_5"></a><a id="Tc_xCc_LVIank2p4YXx6dpuBA_18_0"></a><a id="Tc_PX-HJNe9XEKsCsTI0ytAlA_19_0"></a><a id="Tc_xMnaA4t1DkqtmR9KHbbumw_19_2"></a><a id="Tc_F0WTuHSATkqz8Gpq8gsyHQ_19_5"></a><a id="Tc_B6R5opD8QkC3A1sy8fkmdA_20_0"></a><a id="Tc_OoLWW_F9N0yEyR7Qz1zRiA_21_0"></a><a id="Tc_MgYmUs8EQEicQUEG5RzgAA_22_0"></a><a id="Tc_1n0Gx2HY6Euvpi7UFqQjWQ_23_0"></a><a id="Tc_5R0TTqeLLEKoB9ohfSOv9w_24_2"></a><a id="Tc_49awuP3I_0Cj8K9bhoeu0A_24_5"></a><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="Tb_he-nVDrEc0O05UX4ZwJB0w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">8. Balance Sheet Components (in thousands)</b></p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="srt:ScheduleOfCondensedBalanceSheetTableTextBlock" id="Tb_z0LYv6qH8ECL1x1LTXtXaQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Prepaid and Other Current Assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Interest receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestReceivable" scale="3" id="Tc_LDKDLWzqlUiT9mtzkkjMyg_4_3">1,155</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestReceivable" scale="3" id="Tc_YwkhEkZrh0GILWTmOa9FQw_4_6">337</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Prepaid research and development manufacturing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="Tc_wZcNB6eEYEudHFkOkkdC2Q_5_3">1,564</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="Tc_vP06TTqYn0ahhnPUZrFqyw_5_6">599</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Prepaid facility expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidRent" scale="3" id="Tc_IL6qsoXxIEe4bNLfKvCwfA_6_3">34</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidRent" scale="3" id="Tc_gEm1bjhG4UOLyoRUSi0B3A_6_6">35</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidInsurance" scale="3" id="Tc_rwFvDe4DD0KGNignKXduwQ_7_3">69</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidInsurance" scale="3" id="Tc_YpJPcxIqf0C9EnI0n8VDRg_7_6">138</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_NZBLIRttk0CABSNlVF-tgA_8_3">367</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_Zdsdb4JXvkSNaEgR2jQmgw_8_6">318</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_H_jsvud-D02jJXXBAVxLAA_9_3">3,189</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_wMfoOD19G0-Gvyew6QKjSw_9_6">1,427</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Property and Equipment</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_6C25sOE9Ikmp0oeoupptOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_gWDj3ZicDEyNOVuUkaJb2w_11_3">2,713</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_66ZNx4o7xE6nChx728HdAQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_RYIDSZFym0e1SviuC2qLww_11_6">2,646</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Computer equipment and purchased software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_YgSDQjrssE-QgSvTIuicjQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_7kuQEhbFcE-eVWfEQlgiaA_12_3">190</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_HK6hD7pbIEy_GhLi3vMwpg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_k7eCc1K9ZE2Jkkkrl4EIIQ_12_6">190</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_R_4AduDylk-cunlIwrPmxA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_9WG1A-2yn0aNn2ruP7db9g_13_3">33</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_AIlQrJQUYUCBdCBov2bs-A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_hhfK1dwVTEahimnbjA7RmQ_13_6">33</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_1OU2yiImZUyepALNkZ8rTQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_YDOuo_dzo0GXAqCm72cxIg_14_3">23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_YGOEOFj7DkyNAO7Sd2giyA_15_3">2,959</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_y9qKYDRFWUGJCDoi2H0odA_15_6">2,869</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Less: accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_7IUiJhxLIkWaPYQ4nAFfbw_16_3">2,677</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_WBFOH6660UeM296x9fUp2g_16_6">2,649</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_yffE4Z5EHkiXvt7g0pyryw_17_3">282</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_X1-DN8HXBEGNbUKh-Jckpw_17_6">220</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Accrued and Other Liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued clinical trial expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="crvs:AccruedLiabilitiesClinicalTrialCurrent" scale="3" id="Tc_ozcNd_EPMku6d0SJh37tpA_19_3">3,300</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="crvs:AccruedLiabilitiesClinicalTrialCurrent" scale="3" id="Tc_bgWIDAIJk0m7hnsRXzHyCQ_19_6">3,566</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued manufacturing expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="crvs:AccruedLiabilitiesManufacturingCurrent" scale="3" id="Tc_UaU0fnFUMUSjYfXs0G4nJg_20_3">1,794</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="crvs:AccruedLiabilitiesManufacturingCurrent" scale="3" id="Tc_WTxzARpeqEq0RiU2BtgKiw_20_6">1,812</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Personnel related </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_uN1nQXAguUKHydRgy5E5nw_21_3">1,381</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_08GRs6yphkagieXXcZGM_g_21_6">641</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued legal and accounting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_wqTawbwlqEajHI1j0E1iIA_22_3">304</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc__Law-VZCE0S_NcD3V4kCTg_22_6">229</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_ZLteTAu6VECsO7rw4wqICQ_23_3">206</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_8I8kPn4FXEalrwurwjxowA_23_6">238</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_nx6UBmIg_EWXm6B4Oric9g_24_3">6,985</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_jogQwegC3ECtVSpU8oKcQQ_24_6">6,486</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the three months ended March 31, 2026 and 2025, the Company recorded approximately $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" id="Narr_V6FDhVf-9UGGmP6j9Gqj5A">29,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" id="Narr_g9SgpGbI7UqVt0e9Zmk27A">22,000</ix:nonFraction> in depreciation expense, respectively.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="crvs:WarrantsAndRightsNoteDisclosureTextBlock" id="Tb_uvGRnerGKkO4d-BgLvKH6Q" continuedAt="Tb_uvGRnerGKkO4d-BgLvKH6Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">9. Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 6, 2024, the company completed a registered direct offering in which the Company sold an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="Duration_5_6_2024_To_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonStockSharesAndCommonStockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_qes8akhL1UOvGAi6lmbg1w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_fdVAkSsN1UCo9car9emC-A">13,512,699</ix:nonFraction> shares of common stock and common warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonStockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_YFKxpTiNbU6oZe1MFcXljw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_YyZusWQNXE-Y769gihKLAA">13,078,509</ix:nonFraction> shares of common stock (or pre-funded warrants in lieu thereof) at a combined offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonStockSharesAndCommonStockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_oZTsrk4nrkiHDAAiKkO7Zw" decimals="4" format="ixt:num-dot-decimal" name="crvs:CombinedOfferingPriceForSharesAndWarrants" scale="0" id="Narr_maNDEkBM2k-8H67FJyJD0g">1.7312</ix:nonFraction> per share and common warrant, and pre-funded warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Jot-50-Yk0qa7VxZIMl1Sg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_pVRBaOx8n0yZzwzrDOwAOg">4,144,085</ix:nonFraction> shares of common stock and common warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_4BVj8xmMz0KGnw09dZm4mg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_oj1-87WAEEG6FUKtPBc0sQ">4,010,927</ix:nonFraction> shares of common stock (or pre-funded warrants in lieu thereof), at a combined offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsAndCommonStockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Tlt-RbPRSUqh-Yw0_LG3kg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_Di-yWYaTekCMGxAN_d44IA">1.7311</ix:nonFraction> per share underlying each pre-funded warrant and common warrant, which equals the offering price per share and common warrant less the $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Jot-50-Yk0qa7VxZIMl1Sg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_WdN3FMLi2k6zOjbidvttPw">0.0001</ix:nonFraction> exercise price per share of the pre-funded warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The pre-funded warrants have an exercise price per share of common stock equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Jot-50-Yk0qa7VxZIMl1Sg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_tyn0PzBbBE6iJ_zQxOz72A">0.0001</ix:nonFraction> per share. The exercise price and the number of shares of common stock issuable upon exercise of the pre-funded warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. The pre-funded warrants are exercisable at any time after the date of issuance. In accordance with accounting guidance discussed in Note 2, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_5_6_2024_To_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_xxahbdsvrUmf_bB3pjxXsA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="6" id="Narr_zdnbrQOJ2UmDMOQVgYLQ9A">5.0</ix:nonFraction> million to additional paid-in capital upon issuance of the pre-funded warrants on May 6, 2024. In May 2025, an additional <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_5_31_2025_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_54_yHogU40CKupBljfogmQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_349YLcAIcEiiXEPV7ziHTA">4,131,828</ix:nonFraction> pre-funded warrants were issued in connection with the exercise of common warrants. As of March 31, 2026, <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_t-6dI_GLqkWg5FN5nJrFAw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_2o9zY-31gkm7sYCZU58b_w">none</ix:nonFraction> of the pre-funded warrants have been exercised and <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_t-6dI_GLqkWg5FN5nJrFAw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_5OH4GnI0h06BY5FBEEe3oA">8,275,913</ix:nonFraction> pre-funded warrants remain outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The common warrants had an exercise price per share of common stock equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_4BVj8xmMz0KGnw09dZm4mg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_seeesWTIk0WeOU6pJMxarg">3.50</ix:nonFraction> per share (or $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_4BVj8xmMz0KGnw09dZm4mg" decimals="4" format="ixt:num-dot-decimal" name="crvs:ClassOfWarrantOrRightExercisePricePerPrefundedWarrant" scale="0" id="Narr_q4E_D5ipjkK5d9a9KYxeCA">3.4999</ix:nonFraction> per pre-funded warrant). The exercise price and the number of shares of common stock (or pre-funded warrants in lieu thereof) issuable upon exercise of the common warrants were subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_uvGRnerGKkO4d-BgLvKH6Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">common stock. The common warrants were exercisable at any time after the date of issuance and had an expiration date of June 30, 2025. In accordance with accounting guidance discussed in Note 2, &#8220;Summary of Significant Accounting Policies,&#8221; the Company recorded a decrease in fair value of warrant liability of $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_MLeYeQx8wE2unDRlLMuIDQ" decimals="-5" format="ixt:num-dot-decimal" name="crvs:ChangeInFairValueOfWarrantLiabilities" sign="-" scale="6" id="Narr_oxVvGCHLkEm0MiREOGf73Q">25.1</ix:nonFraction> million to other income in its condensed consolidated statement of operations and comprehensive loss for the three months ended March 31, 2025. As of June 30, 2025, the expiration date of the common warrants, all of the common warrants had been exercised, resulting in proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_uu4IdM0C2U-qNTnXiqDKRw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" id="Narr_0h7Kq1jcfEGXaf9JP1TazQ">54.3</ix:nonFraction> million.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_0knmeuKzfUO0ebAr7Y1_7g_1_2"></a><a id="Tc_WE9Y3qEa5kG42gEMI5HSMg_1_4"></a><a id="Tc_H9DwYqHUvECBPiHgKcR-rg_2_2"></a><a id="Tc_zTsmY-56KEqHO-laZieC6w_2_4"></a><a id="Tc_yz5nXfVrfU-UFT8J9QzQrg_3_0"></a><a id="Tc_mTlpDilcvUGn_99otx0Uaw_4_0"></a><a id="Tc_lccdcGZmqUOZJoM05H5cxg_5_0"></a><a id="Tc_2o-Xqx1Z3UicDJP3zgEldA_6_0"></a><a id="Tc_knveDba7Hky7Yu5fG5uMKQ_7_0"></a><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="crvs:CommonStockNoteDisclosureTextBlock" id="Tb_yPKfRt0vgkO76gAGqrLetA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">10. Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of March 31, 2026, the amended and restated certificate of incorporation authorizes the Company to issue <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="Narr_3G6cbrMSkEyvzaQG4hFLvQ">290</ix:nonFraction>&#160;million shares of common stock and <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="Narr_mjjD3d93qEGI3uNm_MvfVQ">10</ix:nonFraction> million shares of preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:CommonStockVotingRights" id="Narr_S5zsYkhN-U6fJDcHXDDYyQ">Each share of common stock is entitled to one vote.</ix:nonNumeric> Common stockholders are entitled to dividends if and when declared by the board of directors. As of March 31, 2026, <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DividendsCommonStock" scale="3" id="Narr_l95CgOqVI0qiSqH_K1pOQQ">no</ix:nonFraction> dividends on common stock had been declared.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">On August 6, 2024, the Company entered into an Open Market Sale Agreement<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> (the &#8220;2024 Sales Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) to sell shares of the Company&#8217;s common stock, from time-to-time, with aggregate gross sales proceeds of up to $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_8_6_2024_To_8_6_2024_srt_CounterpartyNameAxis_crvs_JefferiesLlcMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_AtMarketOfferingMember_eoj_eqi2mkWRVEknHEdLaA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_Lp0GJvbZP0yzJIVkfjPy7w">100.0</ix:nonFraction> million, through an at-the-market equity offering program under which Jefferies will act as its sales agent. The issuance and sale of shares of common stock by the Company pursuant to the 2024 Sales Agreement are deemed an &#8220;at-the-market&#8221; offering under the Securities Act of 1933, as amended. Jefferies is entitled to compensation for its services up to <ix:nonFraction unitRef="Unit_Standard_pure_zwdjuLpe8Um-MXpoYRfl8Q" contextRef="Duration_8_6_2024_To_8_6_2024_srt_CounterpartyNameAxis_crvs_JefferiesLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_AtMarketOfferingMember_C9TVVV5bD06kEd2FNfIBfg" decimals="INF" format="ixt:num-dot-decimal" name="crvs:UnderwritingCommitmentsPercentage" scale="-2" id="Narr_PkvSjdGyCUq15LOcDGFmkw">3.0</ix:nonFraction>% of the gross proceeds of any shares of common stock sold through Jefferies under the 2024 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">On January 20, 2026, in connection with the January 2026 financing, as further described in Note 1, the Company suspended the offering of any shares of its common stock under the 2024 Sales Agreement and, on March 13, 2026, the Company entered into an Amended and Restated Open Market Sale Agreement<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup>, dated March 13, 2026 (the &#8220;Amended Sales Agreement&#8221;), with Jefferies, which amends and restates the 2024 Sales Agreement to increase the maximum aggregate offering price of shares of the Company&#8217;s common stock from $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_20_2026_To_1_20_2026_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_AtMarketOfferingMember_pLGqywBb50amw3DDckyXMA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_ujK5RNTHakqtMu0c-d__jA">100.0</ix:nonFraction> million to $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_3_13_2026_To_3_13_2026_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_AtMarketOfferingMember_JM0TXSQCVEWG7UWlAYRf6Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_FHMsq1g6tkGS-1w1GmYmLg">200.0</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">During the three months ended March 31, 2026, the Company did <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_JefferiesLlcMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_AtMarketOfferingMember_xtxU8hDdr0aP8Izzn0-FoA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_SK8glwjhEUaFePxsVQZBjw">no</ix:nonFraction>t sell any shares of common stock under its at-the-market offering program. As of March 31, 2026, $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_JefferiesLlcMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_AtMarketOfferingMember_Hon6YB2UOE6cicnSMk7KpA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_M0qAmS3GdUChKEsFbp1cxg">200.0</ix:nonFraction> million remained available for sale under the Amended Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company has reserved shares of common stock for issuance as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:ScheduleOfOptionsIndexedToIssuersEquityTextBlock" id="Tb_TwMQk7VKk0eIbEu_A6DHdQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Pre-funded warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_3_31_2026_us-gaap_StatementClassOfStockAxis_crvs_PreFundedWarrantEquityMember_pG3Yboioek6oDxPenlOLwA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_ww1SOYCha06aGaojTFgguQ_3_2">8,275,913</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_crvs_PreFundedWarrantEquityMember_WYZ3KbAX40KHkOolRICzyw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_qkH3bfJUzEKj-Zw2MlM0sw_3_4">8,275,913</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Shares available for future option grants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_3_31_2026_us-gaap_StatementClassOfStockAxis_crvs_SharesAvailableForFutureOptionGrantsEquityMember_laFqZToHYU-XM4gSwg61WA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc__8WXJMKv30ep7kB0GspBJg_4_2">6,649,034</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_crvs_SharesAvailableForFutureOptionGrantsEquityMember_uY3rsda1GkefIVaYZOCIXg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_lfqMUretn0WhLGwE-KT63g_4_4">3,007,335</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Outstanding options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_3_31_2026_us-gaap_StatementClassOfStockAxis_crvs_OutstandingOptionsEquityMember_-jXcOLXdRUmPSJboXwLFAQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_dHa3EJUrC0eP2SQL9lYBFA_5_2">13,066,326</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_crvs_OutstandingOptionsEquityMember_b0UFSQtEOEulbCh_kct75A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_q95zmSmnhEKe5VZaO10hSw_5_4">14,028,177</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Shares reserved for employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_3_31_2026_us-gaap_StatementClassOfStockAxis_crvs_SharesReservedForEmployeeStockPurchasePlanEquityMember_ANdQEPEp4UGpxOwiSjtfYw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_wSTFWyv3EEGZFv1NpUAb4Q_6_2">400,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_crvs_SharesReservedForEmployeeStockPurchasePlanEquityMember_Nx9PKFTI5ku9GkWFXfmECQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_rOwF70OnqE6WeEYQOeWjZQ_6_4">400,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_5XxIGd1KcEquEjcsBr5AnA_7_2">28,391,273</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_ILWdQ9aChESRB6k7ebDwcg_7_4">25,711,425</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="crvs:EquityIncentivePlansDisclosureTextBlock" id="Tb_PFNCk9BR3Eqd4eRW32RFbg" continuedAt="Tb_PFNCk9BR3Eqd4eRW32RFbg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">11. Stock Option Plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In February 2014, the Company adopted the 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;), which was subsequently amended in November 2014, July 2015 and September 2015, under which it granted incentive stock options (&#8220;ISOs&#8221;) or non-qualified stock options (&#8220;NSOs&#8221;). Terms of stock agreements, including vesting requirements, are determined by the board of directors or a committee authorized by the board of directors, subject to the provisions of the 2014 Plan. In general, awards granted by the Company vest over <ix:nonNumeric contextRef="Duration_2_1_2014_To_2_28_2014_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2014Member_ZPEqkJZSKkC77f8CpQy3Og" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_B1ssn0d0pkK0Mg1aQu8pAg">four years</ix:nonNumeric> and have a maximum exercise term of <ix:nonNumeric contextRef="Duration_2_1_2014_To_2_28_2014_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2014Member_ZPEqkJZSKkC77f8CpQy3Og" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_5h9js8hNjE-dDcP-Jutj6g">10 years</ix:nonNumeric>. The 2014 Plan provides that grants must be at an exercise price of <ix:nonFraction unitRef="Unit_Standard_pure_zwdjuLpe8Um-MXpoYRfl8Q" contextRef="Duration_2_1_2014_To_2_28_2014_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2014Member_ZPEqkJZSKkC77f8CpQy3Og" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr_ZVRZc_lrEUSBkhmaiSIAjQ">100</ix:nonFraction>% of fair market value of the Company&#8217;s common stock as determined by the board of directors on the date of the grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In connection with the consummation of the IPO in March 2016, the 2016 Equity Incentive Award Plan (the &#8220;2016 Plan&#8221;) became effective. Under the 2016 Plan, ISOs, NSOs, stock purchase rights and other stock-based awards </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_fE1KA3wcbEWGv-87o-WbFQ_1_4"></a><a id="Tc_R1JZUSZyakiwmCdcE9Fiiw_2_6"></a><a id="Tc_YeNtQtj4Dk-SwZUsk189vg_3_2"></a><a id="Tc_XvrXe0QDUkm3q74d1srPdg_3_6"></a><a id="Tc_BR0K0OgKbU6onmXGRiR0zA_4_2"></a><a id="Tc_pHjDqFOyKk-VwC492QnfIA_4_4"></a><a id="Tc_UJq3kNKMx0yjH1jlSd59RA_4_6"></a><a id="Tc_EaiT20I8pkCIAbz_YJordA_5_2"></a><a id="Tc_pwqDRj8p0UWvLzuS3C4Egg_5_4"></a><a id="Tc_oml6Ce2LAUmOlBOW6GlI0w_5_6"></a><a id="Tc__FizK-tXukqYtwW6P8lWAA_6_0"></a><a id="Tc_81Nw-qd1FkWp0z75KepVNw_6_6"></a><a id="Tc_4dh-U_EeSkWWB6cCg9nsdQ_7_0"></a><a id="Tc_mLi3reOCzE-skRvn73kmqg_7_4"></a><a id="Tc_OKO1KQlpjEG2PNsHAaByMA_7_7"></a><a id="Tc_bechm81lY0-E_pCez0Q4Qg_8_0"></a><a id="Tc_KshmGpdlmUKbyTackSYRDQ_9_0"></a><a id="Tc_KZbrSxnVOUu_OwFFCE1P4Q_9_2"></a><a id="Tc_1Sh2lGnRG0qFezm32d7afg_10_0"></a><a id="Tc_i8npDnYnh0OwzoHpLKwucA_11_0"></a><a id="Tc_VoIVdVNiQEqY54PxYBFOew_11_6"></a><ix:continuation id="Tb_PFNCk9BR3Eqd4eRW32RFbg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">may be granted. Terms of stock agreements, including vesting requirements, are determined by the board of directors or a committee authorized by the board of directors, subject to the provisions of the 2016 Plan. In general, awards granted by the Company vest over <ix:nonNumeric contextRef="Duration_3_1_2016_To_3_31_2016_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_nSKTEU2cHUaYGFDps5DZNw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_-8If3gMCu02g1O5scG11lg">four years</ix:nonNumeric> and have a maximum exercise term of <ix:nonNumeric contextRef="Duration_3_1_2016_To_3_31_2016_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_nSKTEU2cHUaYGFDps5DZNw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_j8hL_PDqJEGuN0gsuf1OGg">10 years</ix:nonNumeric>. The 2016 Plan provides that grants must be at an exercise price of <ix:nonFraction unitRef="Unit_Standard_pure_zwdjuLpe8Um-MXpoYRfl8Q" contextRef="Duration_3_1_2016_To_3_31_2016_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_nSKTEU2cHUaYGFDps5DZNw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr_mYb_7J3ViUm65NpScdFALg">100</ix:nonFraction>% of fair market value of the Company&#8217;s common stock as determined by the board of directors on the date of the grant. In conjunction with adopting the 2016 Plan, the 2014 Plan was terminated and <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_3_31_2016_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2014Member_HBYSs8y8e0q-y5FdS0ZbgA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_MCiLk-dTr02VbfM4XQoMIw">no</ix:nonFraction> further awards will be granted under the 2014 Plan. Options outstanding under the 2014 Plan as of the effective date of the 2016 Plan that are forfeited or lapse unexercised may be re-issued under the 2016 Plan, up to a maximum of <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="Duration_3_1_2016_To_3_31_2016_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_i1V10D_o5EOltzgKO-ZZrA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_nV0gB67ZDUii-Q10VTfsSA">1,136,229</ix:nonFraction> shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Activity under the Company&#8217;s stock option plans is set forth below:</p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_eqRaYtCxSkq4FIiQXxrLBw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;Outstanding</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">&#8209;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Available</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">for&#160;Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Balance at December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_2sdE3FrdcUCS_x2faPApVA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Tc_XucXXvAhJ0qYH5gQUlFgzg_6_2">3,007,335</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_2sdE3FrdcUCS_x2faPApVA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_18tJ_BReEkW-JlvgLeWBZw_6_4">14,028,177</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_2sdE3FrdcUCS_x2faPApVA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_HPxSVl0lb0enDjzg-0ccEA_6_7">5.20</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Additional shares authorized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_9SSsEi9c802Zz5UyJSFtsQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Tc_J878ekErQkWruMoXsIFFqw_7_2">2,987,865</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_9SSsEi9c802Zz5UyJSFtsQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_EJ1CZkuDUkaSkBhjasY1Sw_8_2">7,500</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_9SSsEi9c802Zz5UyJSFtsQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_XVcw-VRJqU-0QRr-_F11Tg_8_4">7,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_9SSsEi9c802Zz5UyJSFtsQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_TSOnx3zA6EG2p6FTme1aqg_8_7">14.63</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Options exercised </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_9SSsEi9c802Zz5UyJSFtsQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_gCQIp1cj506kQ5NjWo6aMw_9_4">308,017</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_9SSsEi9c802Zz5UyJSFtsQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_HWHNkr3xQkGjDU0yNFss9Q_9_7">4.35</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_9SSsEi9c802Zz5UyJSFtsQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" scale="0" id="Tc_8ZieV-T-vky9xkYca6r8ag_10_2">661,334</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_9SSsEi9c802Zz5UyJSFtsQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_4Ht0047oi0iI4dhUcCfCDw_10_4">661,334</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_9SSsEi9c802Zz5UyJSFtsQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_f3SI2He0EUCbfc7obklqqg_10_7">14.23</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Balance at March&#160;31,&#160;2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_OZWZ5jrEbUGvUd0flVPW_Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Tc_B1kz28NarEWO7CNZshJxLg_11_2">6,649,034</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="As_Of_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_OZWZ5jrEbUGvUd0flVPW_Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_Z9qZdO4eykq-7Im1DpR0_A_11_4">13,066,326</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="As_Of_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_OZWZ5jrEbUGvUd0flVPW_Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_8Wb13jCbQUiMV46h5n_vbA_11_7">4.76</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_612082e7_baf5_4f1b_ac11_dbd3d5a4800d"></a><a id="Tc_VFA6IvXuJEek27jdIATyQQ_1_2"></a><a id="Tc_qPN-gm-iH0S8kTrtEzKoaQ_2_2"></a><a id="Tc_DF6r1ycCeESU_7jK8GuVMA_3_2"></a><a id="Tc_88LGlopQeUidvfJXzs8B1Q_3_5"></a><a id="Tc_o6EuCTLBoUaNDJc7V9InGg_4_0"></a><a id="Tc_AWDaNqBB-EuKe2f5dgQp3w_4_2"></a><a id="Tc_n9NlAiDumEOZlf15n86Oiw_4_5"></a><a id="Tc_ncdGCUOwrUGutVJD3OZF8A_5_0"></a><a id="Tc_ztxMso-AJkCtj5nYtFwstw_6_0"></a><a id="Tc_tmdC1az5FEyF49DqcMwQ0Q_6_2"></a><a id="Tc_KaZL0ByKPEKdSxZN2_Jrkw_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_5p7aRHOMK06a8bAMREhKKA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">12. Stock-Based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_KK5pPa0UCkmvnKubU2Qd2Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company&#8217;s results of operations include expenses relating to employee and non-employee stock-based awards as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:74.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:21.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:21.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_SydJ5hNnoUqd8ueH3lWPpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_ibt-7FWSuUSe2oCYyR2bIA_4_3">1,077</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_cVDT7uqBXEWvbTkAOn4YWw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_BtAb-t0HdEugA7IL7h4olw_4_6">528</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_eVV0R68k0kqMD0Z_2saoiw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_PRqJAaAhZ0KCZ_DEt_bRvA_5_3">1,573</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_0ugRH7hZ0kaz47JCeRx9MQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_bzX9dou-Y02ePO3nyG9tRA_5_6">723</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_CKbHJNYZeEaJ7t5WaypU3Q_6_3">2,650</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_7w7SxUvoTkS2fi6BP7Su1A_6_6">1,251</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_a5w46kUsqkW9gKqOyZaEcA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">13. Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the three months ended March 31, 2026 and 2025, the Company recorded <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Narr_Z90yJyin5Eq8vCgYea5Q3Q"><ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Narr_k1IXwJweXkG2h9s6yZeKUg">no</ix:nonFraction></ix:nonFraction> income tax benefits for the net operating losses (NOLs) incurred due to the uncertainty of realizing a benefit from those items. The Company continues to maintain a full valuation allowance against its net deferred tax assets.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_5yYVSILaxUqA0TLXOcgGeg" continuedAt="Tb_5yYVSILaxUqA0TLXOcgGeg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">14. Facility Lease</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">On October 22, 2024, the Company entered into an operating sub-sublease agreement, pursuant to which the Company sub-leased approximately <ix:nonFraction unitRef="Unit_Standard_sqft_HxXZ8IO5D0SV81ta1te2Pw" contextRef="As_Of_10_22_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_KO4XiJ0y0Eewc683WEweWg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_F_m755rbaEyT31bSNwTO7w">20,916</ix:nonFraction> square feet of office and lab space. The sub-sublease has a term of <ix:nonNumeric contextRef="As_Of_10_22_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_KO4XiJ0y0Eewc683WEweWg" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_CF3Mch_56EiO04wBtCtYCw">three years</ix:nonNumeric> commencing on February 21, 2025 with an <ix:nonNumeric contextRef="Duration_10_22_2024_To_10_22_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_VpJmf9leeki0mF9gdl0L2g" format="ixt:fixed-true" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Narr_SXPGXk-11E20t9k950tC_A">option to extend</ix:nonNumeric> at fair market value for an additional <ix:nonNumeric contextRef="As_Of_10_22_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_KO4XiJ0y0Eewc683WEweWg" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_CVMH7A6daEC6qR5pSy9lKg">27</ix:nonNumeric> months. The Company records rent expense on a straight-line basis over the effective term of the lease, including any free rent periods and incentives. As the interest rate implicit in lease arrangements is typically not readily available, in calculating the present value of the lease payments, the Company has utilized its incremental borrowing rate, which is determined based on the prevailing market rates for collateralized debt with maturity dates commensurate with the term of its lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company&#8217;s obligation for the payment of base rent for the premises began on the commencement date and is initially $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_10_22_2024_To_10_22_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_VpJmf9leeki0mF9gdl0L2g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesRentExpenseMinimumRentals" scale="0" id="Narr_Lf0g-YQqkEucyqciZ1YvQw">33,833</ix:nonFraction> per month, up to monthly base rent of $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_10_22_2024_To_10_22_2024_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_crvs_ThirdYearOfSubleaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_frW_QJfWakWrSN17Dz5hfg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesRentExpenseMinimumRentals" scale="0" id="Narr_VXf59lKWYEaiT737ND-8MA">47,200</ix:nonFraction> during the third year of the sub-sublease. In addition </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:5.75pt;"><a id="Tc_rdgP9xrFYkqFl371cO-y0g_1_4"></a><a id="Tc_NNymVTrYCki-Y6vc80C4dg_2_2"></a><a id="Tc_NPoRnypdDUG7UbE-TVKcaA_2_4"></a><a id="Tc_DyqyBjSGGEuBjrMFIRwSFw_3_2"></a><a id="Tc_GMGX0xxJLkeKd3RssUjgcw_3_4"></a><a id="Tc_A3Da4LO9hUmL1PRTF3hWGg_3_7"></a><a id="Tc_-hDsejkmaE6FSpHoSb9nvw_4_0"></a><a id="Tc__7xOTYIW-UGcK3-sgEyCOA_5_0"></a><a id="Tc_rZlitWhcAE6jBk4CmJFb0Q_5_2"></a><a id="Tc_jlREa1JRqE2snBZArLeEKw_5_4"></a><a id="Tc_4avdKYnqck2iTXZ1CjzTcw_5_7"></a><a id="Tc_ER6gNgv_w0mXoVHtNxTyug_6_0"></a><a id="Tc_rAymU2U_z0urI4PlVtRMzw_6_2"></a><a id="Tc_TVXs4Zqiuk6UIqCvm5bpEg_7_0"></a><a id="Tc_KuO3FZXySUuUgRvsc5HOdA_7_4"></a><a id="Tc_jazax5Tu-0661h3h6bxamw_7_7"></a><a id="Tc_g8TNrBDri0erof4dgttYow_8_0"></a><a id="Tc_ygY2VOzluECsn22s-URXdw_9_0"></a><a id="Tc_W2M4vnFHHUeuczvkd2nKmQ_9_4"></a><a id="Tc_VQ8j4x0Tn0unXigxEwkmBA_9_7"></a><a id="Tc_ry7UNLDiFUCgR1kEXxeySg_9_8"></a><a id="Tc_pIT6XUamDUGx5Q25E0zWZg_10_0"></a><a id="Tc_5F4IZCzSVkKnG7HL-9I8eA_10_5"></a><a id="Tc_6lCf58sdJ0meZnrJ8G_new_10_8"></a><a id="Tc__do_cUaXIkOWV8XpPDSvNg_11_0"></a><a id="_9d4f7e36_53ea_4720_9bc0_537a022197d2"></a><a id="Tc_w3IkWdTke0WNoYpSII7NXg_1_0"></a><a id="Tc_b5E5fo-m3EKVpbXqvMuK7Q_2_0"></a><a id="Tc_nRqQ0To1f0OMJNZywd1blw_2_2"></a><a id="Tc_gpzSMZdguEStQduWt3YTsg_3_0"></a><a id="Tc_snSE8R7QrkKXvbZs0EE38Q_4_0"></a><a id="Tc_GBPMwqQrJEmZeJbdHntBxg_5_0"></a><a id="Tc_ttGVyi_HFkqITc6Sp6hSwg_6_0"></a><a id="Tc_GQOKS4aRPUW4oTLfHiJfqg_6_2"></a><a id="Tc_z7BbNGaI206OYzSlD96vnQ_1_0"></a><a id="Tc_E9ZZLde_HEq58XF53UHDTQ_2_0"></a><a id="Tc_0UvnOKBsqE6mpnkNQ_vbGA_2_2"></a><a id="Tc_KOFC_6bVd0Odv2UkvkQKSA_3_0"></a><a id="Tc_xzwQ6E17LkSjuciXR0lFMQ_4_0"></a><a id="Tc_fVdjyJfE2UeEOX1F4uuFSg_5_0"></a><a id="Tc_V82bunzj3ECOclN3023o6A_6_0"></a><a id="Tc_HVL1JaLbHE6NCU9bkvbcpA_6_2"></a><ix:continuation id="Tb_5yYVSILaxUqA0TLXOcgGeg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">to base rent, the Company is obligated to pay its proportionate share of taxes, insurance and operating expenses. In November 2024, the Company paid the sublandlord $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_11_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_D946TWJ6zkKBuSKvEfvEWw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidRent" scale="0" id="Narr_1waq8hRybEKZ-QYyN-ygSw">231,235</ix:nonFraction> in prepaid rent, which was applied to the monthly base rent and the Company&#8217;s proportionate share of additional expenses for the first three months of the term of the sub-sublease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Although the <ix:nonNumeric contextRef="Duration_2_21_2025_To_2_21_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_N8S53sDar0yqd8bB4rnoJA" format="ixt:fixed-false" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate" id="Narr_0d8-nOAH5U-HJ28BolLZvw">non-cancellable</ix:nonNumeric> lease term commenced on February 21, 2025, for purposes of determining the right-of-use asset balance, in accordance with ASC Topic 842, the Company used November 25, 2024 as the commencement date, the date on which the sublandlord granted the Company access to the premises. The sub-sublease is a net lease, as the non-lease components (i.e., common area maintenance) are paid separately from rent based on actual costs incurred. Therefore, the non-lease components were not included in the right-of-use asset and liability and are reflected as an expense in the period incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of March 31, 2026 and December 31, 2025, the right-of-use asset under the operating lease was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_v9GABhLy30GLtxZhg92PdA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_eXKcsXWm1kiPUv847jdqjg"><ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_Jyih6nVRJku2Wn342lRYIg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_oDj7pP1Ia0OJlFvaBomOTA">0.8</ix:nonFraction></ix:nonFraction> million. <ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:LeaseCostTableTextBlock" id="Group_m-yHoJ5Rc0K0bbIp3V7eRw" continuedAt="Group_m-yHoJ5Rc0K0bbIp3V7eRw_2" escape="true">The elements of lease expense under the operating lease for the three months ended March 31, 2026 were as follows (in thousands):</ix:nonNumeric></p><ix:continuation id="Group_m-yHoJ5Rc0K0bbIp3V7eRw_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:20.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Statements of operations and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;width:20.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">comprehensive loss location</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Costs of operating lease</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Operating lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Research and development,<br/>General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_XaSINNDlBEGGXLQ8_-a_rg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_urUsWM_V_UWjF4LBq7aKgA_5_5">230</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_-5vxilaEUEie4f1HnGwt7g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_jXVuS-XuXkW4KCGHdLLeNw_5_8">113</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Costs of non-lease components (previously common area maintenance)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Research and development,<br/>General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_XaSINNDlBEGGXLQ8_-a_rg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_7-ilndUgtEmcE0jbzpJkZQ_6_5">61</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_-5vxilaEUEie4f1HnGwt7g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_R1hzGoVAQEyi-oNZrH97tw_6_8">22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" id="Tc_JDukXNyxm06nzJDZ39Lg0A_7_5">291</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" id="Tc_NCWyg6YHY0-OtAyyb_pZsg_7_8">135</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Other Information</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Operating cash flows used for operating lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_MgIbfgVG7ESzfe9__siezw_9_5">188</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_BPkEpNjp8kypI_XS45Mkng">1.9</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_3_31_2025_tNZXFjlgt0COhU24eHoxGQ" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_Wurams_i20WWl23yncWhew">2.9</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_zwdjuLpe8Um-MXpoYRfl8Q" contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_FNex6-USUEerbLB-cWkX6Q_11_5">11.7</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_zwdjuLpe8Um-MXpoYRfl8Q" contextRef="As_Of_3_31_2025_tNZXFjlgt0COhU24eHoxGQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_exjzWNVVBEaVegoUCSGZTQ_11_8">11.7</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">As of March 31, 2026, minimum rental commitments under this lease were as follows (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Group__eZ4x-Z1yEON54GRI2FMkA" continuedAt="Group__eZ4x-Z1yEON54GRI2FMkA_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31 (in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2026*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_v9GABhLy30GLtxZhg92PdA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_khD_GQgeF0eHRfSVtSPJ6A_2_3">358</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_v9GABhLy30GLtxZhg92PdA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_rNb1ggyBp0OXX2daauTrgw_3_3">566</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_v9GABhLy30GLtxZhg92PdA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_PWexeEYjVkiJl9pvZog4vw_4_3">924</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_v9GABhLy30GLtxZhg92PdA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_Hhh4k7UIyUGZxVQ6P9R17A_5_3">90</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_v9GABhLy30GLtxZhg92PdA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_HJSIogXRoUO2qNn7XKzxig_6_3">834</ix:nonFraction></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">* Remainder of the year</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>As of December 31, 2025, minimum rental commitments under this lease were as follows (in thousands):</p><ix:continuation id="Group__eZ4x-Z1yEON54GRI2FMkA_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31 (in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_Jyih6nVRJku2Wn342lRYIg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_MGn23iz04Ei5DmmgkEyT4A_2_3">486</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_Jyih6nVRJku2Wn342lRYIg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_qmvYwm5Q3E2McwpMUZ-UOQ_3_3">566</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_Jyih6nVRJku2Wn342lRYIg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_nTusVZDj1EO5B9KFxXbL1w_4_3">1,052</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_Jyih6nVRJku2Wn342lRYIg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_9RvOrQ0YhE64fdCe39rNhA_5_3">115</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_Jyih6nVRJku2Wn342lRYIg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_Qry10sec9UuSf9DK67Wr4A_6_3">937</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_qXXbgcH18U-N-Qm4ymfeDA" continuedAt="Tb_qXXbgcH18U-N-Qm4ymfeDA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">15. Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Pursuant to the Company&#8217;s license agreements with each of Vernalis, Scripps and Monash, it has obligations to make future milestone and royalty payments to the respective parties. However, because these amounts are contingent, </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_qXXbgcH18U-N-Qm4ymfeDA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">they have not been included on the Company&#8217;s balance sheet. For further discussion of the Vernalis, Scripps and Monash licensing agreements, see Note 7, &#8220;License and Collaboration Agreements.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Indemnifications</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware law. There have been no claims to date and the Company has a directors and officers insurance policy that may enable it to recover a portion of any amounts paid for future claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Legal Proceedings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is not a party to any material legal proceedings.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_Rl5VdH52GkKDNkXxuICZaA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">16. Related Party Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As part of the January 2026 follow-on public offering, <ix:nonFraction unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A" contextRef="Duration_1_23_2026_To_1_23_2026_srt_CounterpartyNameAxis_crvs_PuissanceCapitalManagementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_vaIDQou6BEeDZj4w0IamBw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_7zaZ0NNyf0CZU3iDUIB-5g">30,000</ix:nonFraction> shares of common stock, at the public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA" contextRef="As_Of_1_23_2026_srt_CounterpartyNameAxis_crvs_PuissanceCapitalManagementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_hqg4T-aXuUSSmEgLg3oLVg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_5dXadeEQxECr5ofWmRdjzA">22.15</ix:nonFraction> per share, were sold to Puissance Capital Management, a related party. Ted Wang, Ph.D., a Co-Founder, General Manager and Director of Angel Pharmaceuticals, of which the Company holds a <ix:nonFraction unitRef="Unit_Standard_pure_zwdjuLpe8Um-MXpoYRfl8Q" contextRef="As_Of_1_23_2026_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_H7SnitH0TUet8vSGLhtCmw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="Narr_DJcIMMDCZEqF6p43mfatYw">49.7</ix:nonFraction>% ownership interest, is the founder of Puissance Capital Management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2021, Linda S. Grais, M.D., J.D., a member of the Company&#8217;s Board of Directors, was appointed as a non-executive member of the Board of Directors of ICON plc (&#8220;ICON&#8221;), effective upon completion of ICON&#8217;s acquisition of PRA Health Sciences, Inc. ICON is a clinical research organization and provides services to support the Company&#8217;s clinical trials. During the three months ended March 31, 2026 and 2025, the Company recorded approximately $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_IconPlcMember_us-gaap_RelatedPartyTransactionAxis_crvs_ServicesSupportClinicalTrialsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_87RrLXQb50614pVDRnXCIw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Narr_AfM23MdmNkqs4QdcaEPhqQ">123,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA" contextRef="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_crvs_IconPlcMember_us-gaap_RelatedPartyTransactionAxis_crvs_ServicesSupportClinicalTrialsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_m6-TI6NhC0ODOujZoxCV1Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Narr_FT3NAOM9tEumBZ-kvblsSw">94,000</ix:nonFraction>, respectively, in clinical trial expenses under its agreements with ICON.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2ffb478b_ad68_4643_b3ac_199abc38edd9"></a><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Item 2.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and related notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q and with our audited condensed consolidated financial statements and notes for the year ended December 31, 2025, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March 12, 2026.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">This discussion and other parts of this report contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this report entitled &#8220;Risk Factors.&#8221; Except as may be required by law, we assume no obligation to update these forward-looking statements or the reasons that results could differ from these forward-looking statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. We believe our proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our lead product candidate, soquelitinib (formerly CPI-818), is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (&#8220;ITK&#8221;), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. Based on the proposed mechanism of action, we believe soquelitinib has the potential to be utilized to inhibit the production of a number of inflammatory cytokines involved in diseases such as atopic dermatitis, hidradenitis suppurativa, asthma, psoriasis and fibrotic diseases. In preclinical studies, Soquelitinib has affected T cell differentiation leading to enhanced function of T cells involved in tumor cell eradication. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since the immune cells targeted by our product candidates play a role in many diseases, our strategy is to leverage our research and development capabilities by evaluating our product candidates in clinical trials where there is an understanding of the role of specific T cells in the target indication and where we believe such product candidates have the broadest potential. We believe this strategy has enabled us to move rapidly from preclinical to clinical trials in diverse disease areas, each with large unmet needs. We are enrolling patients in a potentially registrational Phase 3 clinical trial of soquelitinib for relapsed peripheral T cell lymphomas. Soquelitinib is also being evaluated in a randomized, placebo-controlled Phase 2 trial in patients with atopic dermatitis. We have two additional product candidates which are in clinical development for the treatment of various solid tumors, also based on modulation of immune function.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:175.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Product Candidate Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Our product candidate pipeline and anticipated milestones include the following:</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><img src="crvs-20260331x10q007.jpg" alt="Graphic" style="display:inline-block;height:174.95pt;left:0%;padding-bottom:0.55pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:7.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">A Phase 1b/2 clinical trial in atopic dermatitis is being conducted by Angel Pharmaceuticals, the Company&#8217;s partner in China.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:7.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:7pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:7pt;font-style:normal;font-weight:normal;">The Company did not conduct Phase 1 studies for these specific indications, but is planning to initiate Phase 2 studies for these indications based on the Phase 1 Atopic Dermatitis study.</span></td></tr></table><div style="margin-top:3pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;"><span style="font-size:7pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Soquelitinib (CPI-818), ITK Inhibitor.</span> Soquelitinib is an investigational selective, orally bioavailable, covalent inhibitor of ITK. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells, which are lymphocytes that play a vital role in immune responses. T cell lymphomas are malignancies of T cells that proliferate and spread throughout the body. These lymphomas often have uncontrolled tonic signaling through the T cell receptor pathway, which involves ITK. Inhibition of ITK with soquelitinib could result in blockade of this signaling pathway and control the growth of the malignancy. In addition, one of the key survival mechanisms of both lymphomas and solid tumors is believed to be the reprogramming of normal T cells to create an environment in the tissues that inhibits an anti-tumor immune response and favors tumor growth. We believe highly selective inhibitors of this enzyme will facilitate induction of normal T cell anti-tumor immunity and may be useful in the treatment of solid tumors as well as lymphomas. A normal functioning immune system maintains balance between inflammation, needed to fight infection or eliminate noxious agents, and suppression of inflammation necessary when the inflammatory signals are eliminated. This balance is restored through the action of T regulatory cells, which dampen inflammatory responses. ITK plays a vital role in the function of these regulatory T cells where it acts to modulate immune responses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In ITK genetic knockout mice, which completely lack expression of ITK, T cells exhibit defects in T helper cell differentiation and cytokine secretion but retain the ability to differentiate into cytotoxic T cells that secrete IL-2 and interferon gamma (&#8220;IFNg&#8221;), which are the cells responsible for tumor rejection. We believe that skewing T helper cell differentiation to favor cytotoxic T cells, known as Th1 skewing, may be beneficial in treating T cell lymphomas and many other types of cancer. Mice with genetic knock-out of ITK also demonstrate a reduction in Th2 and Th17 cells, which produce the cytokines that are often responsible for autoimmunity and allergy such as interleukin (Il) Il-4, Il-5, Il-13, Il-17 and many others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">We have designed and developed soquelitinib to covalently target the cysteine amino acid residue at position 442 in the ITK protein. We believe this irreversible targeting of ITK has the potential to provide a potent, selective and prolonged duration of activity without the need for high systemic exposures and thereby improve the therapeutic window. This approach was previously used by our cofounders to generate ibrutinib. Selective inhibition of ITK can block the production and function of Th2 and Th17 helper T cells, potentially leading to a biasing toward the differentiation of na&#239;ve T cells into Th1 helper T cells. Th1 cells lead to the generation of killer T cells that can eliminate tumor cells or viral infected cells. Th1 cells produce interferon gamma and tumor necrosis factor that are cytokines known to destroy cancer cells. We believe, based on our preclinical and Phase 1/1b data from our T cell lymphoma </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">clinical trial, that soquelitinib has the potential to reprogram normal immune responses that also could be beneficial for the treatment of certain autoimmune, inflammatory and allergic diseases. Overactive Th2 and Th17 cells are known to play a role in autoimmune, inflammatory and allergic diseases, which can potentially be ameliorated by selective ITK inhibition by blocking Th2 and Th17 function and their production of inflammatory cytokines such as IL4, IL5, IL13, IL17 and others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:8pt 0pt 12pt 0pt;">In December 2024, we and our academic collaborators published results describing the chemistry, enzymology and preclinical anti-tumor activity of soquelitinib in the journal npj Drug Discovery. Key results from the publication include that soquelitinib:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Selectively bound to and inhibited ITK function while sparing other closely related kinases, including resting lymphocyte kinase.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:8pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Inhibited Th2 T cell function and the production of various Th2 cytokines leading to Th1 skewing and production of interferon gamma and tumor necrosis factor, which are important cytokines in tumor rejection. Th2 cytokines have been previously implicated in promoting tumor growth and are also involved in autoimmune and allergic diseases. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:8pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Activated cytotoxic killer cells and increases infiltration of these cells into tumors.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:8pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reduced and reversed T cell exhaustion resulting in a more potent and prolonged immune response. T cell exhaustion is often a major reason for resistance to immune checkpoint therapy.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:8pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Led to in vivo anti-tumor activity in several mouse tumor models, including colon, renal, melanoma, B cell and T cell tumor.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Soquelitinib for treatment of T cell lymphomas.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Soquelitinib is currently being studied both in cancer and in immune mediated diseases. A Phase 1/1b clinical trial was conducted in patients with relapsed T cell lymphomas that was designed to select the optimal dose of soquelitinib and evaluate its safety, pharmacokinetics (&#8220;PK&#8221;), target occupancy, immunologic effects, biomarkers and efficacy. The study is now complete, however, some of the patients remain on therapy and are continuing to receive follow-up monitoring. The trial enrolled 75 patients (27 in the dose escalation portion and 48 in dose expansion portion) with various T cell lymphomas, including peripheral T cell lymphoma (&#8220;PTCL&#8221;), T follicular helper cell lymphoma, natural killer cell T cell lymphoma, cutaneous T cell lymphoma, anaplastic large cell lymphoma and adult T cell lymphoma/leukemia. The median number of prior therapies was three (range 1-18), with only 31% achieving an objective response to their most recent prior therapy. In the dose escalation portion, patients received a twice-daily dose of soquelitinib of 100 mg, 200 mg, 400 mg or 600 mg, and the 200 mg twice-daily dose (&#8220;200 mg BID&#8221;) was selected for the dose expansion portion based on biomarker studies indicating that doses of 200 mg or higher achieved complete occupancy of the ITK target with the drug. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Final data from the Phase 1/1b clinical trial were presented at the American Society of Hematology Annual Meeting (&#8220;ASH&#8221;) in December 2025. Key highlights from the data supporting the ongoing registration Phase 3 trial in relapsed/refractory PTCL include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">No dose limiting toxicities or significant adverse events were observed in any patients in all dose cohorts up to 600 mg twice-daily, including no myelosuppression or immunosuppression;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Objective and durable tumor responses were seen in the 200 mg twice-daily cohort (N=36) with 6 patients experiencing complete responses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In the 200 mg twice-daily cohort, it was determined that patients with between &#8805;1 and &#8804;3 prior therapies and an adequate peripheral blood lymphocyte count (N=24) were most likely to be responders to therapy. </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In this patient population:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:64.8pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Objective responses were seen in 9 of 24 patients including 6 complete responses and 3 partial responses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:64.8pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Median progression free survival (&#8220;PFS&#8221;) was 6.2 months, including an 18-month PFS of 30%; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:64.8pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Median overall survival (&#8220;OS&#8221;) was 28.1 months, including a 24-month OS of 67%</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Key highlights from the data supporting soquelitinib&#8217;s proposed mechanism of action (Th1 skewing and blocking Th2 and Th17 differentiation) and development in immune and inflammatory diseases include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In vitro studies demonstrated that at appropriate doses, soquelitinib produced Th1 skewing, which is an immunologic property resulting from the blockade of Th2 differentiation and a shift to Th1;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Biomarker studies evaluating blood samples and tumor biopsies showed an increase in Th1 in blood and tumor samples and a reduction in serum IL-5, consistent with inhibiting Th2 and Th17 cells; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">For six patients, paired tumor biopsies were compared at baseline and day 8 and showed an increase in intratumor Th1 cells with treatment analyzed using RNA sequencing.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2023, we completed an End-of-Phase/Pre-Phase 3 meeting with the Food and Drug Administration (&#8220;FDA&#8221;) regarding our plans to conduct a potentially registrational Phase 3 clinical trial of soquelitinib in relapsed PTCL. The FDA provided feedback on our proposed registration trial, including the proposed endpoints. We initiated this clinical trial in the third quarter of 2024. The clinical trial is designed to enroll a total of 150 patients with relapsed PTCL that have received &#8805; 1 prior therapy and&#8804;3 prior therapies. Patients are being randomized 1:1 to soquelitinib 200 mg two-times a day or one of the standard of care chemotherapies. The standard of care agent is selected based on the physician&#8217;s choice of either belinostat or pralatrexate. The primary endpoint is progression-free survival. Secondary endpoints include objective response rate, overall survival and duration of response. Leading academic and private medical centers with significant experience in lymphoma research are participating in the trial, including investigators who have conducted other Phase 3 clinical trials in T cell lymphoma and authored many peer-reviewed articles on lymphomas. There are currently no FDA fully approved agents for the treatment of relapsed PTCL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA has granted Fast Track designation to soquelitinib for the treatment of adult patients with relapsed or refractory PTCL after at least two lines of systemic therapy. In addition to Fast Track designation, soquelitinib has also been granted FDA orphan drug designation for the treatment of T cell lymphoma.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Soquelitinib for treatment of atopic dermatitis.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:8pt 0pt 12pt 0pt;">In November 2023, we announced the posting of preclinical data on soquelitinib in bioRxiv that demonstrated that ITK&#8217;s selective inhibition produced therapeutic benefits in several autoimmune and allergy preclinical models, including psoriasis, asthma, pulmonary fibrosis, scleroderma and graft versus host disease. The mechanism of action involves the inhibition of Th2 and Th17 cells and their subsequent production of cytokines such as IL-4, IL-5, IL-17 and other cytokines involved in these diseases. The novel mechanism is a result of ITK inhibition and blockade of formation of Th2 and Th17 cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In April 2024, we initiated a randomized, double-blind, placebo-controlled Phase 1 clinical trial with soquelitinib in patients with moderate to severe atopic dermatitis that previously failed one prior topical or systemic therapy. The clinical trial was planned to enroll 64 patients into one of four dosing cohorts in a 3:1 ratio (12 active and 4 placebo) to receive either soquelitinib or placebo. The cohorts were designed to sequentially enroll and to examine 100 mg oral twice per day, 200 mg oral once per day, 200 mg oral twice per day and 400 mg oral once per day. Patients would be treated for 28 days and are then followed for an additional 30 days with no therapy. The primary endpoints included safety and tolerability, and efficacy, measured by improvement in Eczema Area and Severity Index (&#8220;EASI&#8221;) </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">score, Investigator Global Assessment (&#8220;IGA&#8221;), reduction in itch and various cytokine biomarkers. EASI scores are also evaluated by the percent of patients that achieve a specified percent reduction in EASI score &#8211; EASI 50 for patients that achieved a 50% reduction; EASI 75 for a 75% reduction; and EASI 90 for a 90% reduction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of May 6, 2025, enrollment into cohorts 1, 2 and 3 had been completed and we reported interim data for a total of 48 patients. These data covered 32 patients receiving soquelitinib and 12 receiving placebo with 28-day follow-up, and four additional patients receiving soquelitinib with 15-day follow-up from cohort 3. These four patients had not yet completed the 28-day treatment course. The percent reduction in mean EASI scores at 28 days for the combined cohort 1 and 2 group was 54.6% for patients receiving soquelitinib and 30.6% for patients receiving placebo. In cohort 3, the 200 mg BID cohort, the percent reduction in mean EASI score at 28 days was 71.1% for patients receiving soquelitinib and 42.1% for patients receiving placebo.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 20, 2026, we announced positive results from cohort 4 of our randomized, blinded, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. Based on the encouraging results from cohorts 1-3, cohort 4 was prospectively redesigned to support and potentially extend the clinical results obtained in the initial cohorts. Cohort 4 was expanded to enroll 24 patients randomized 1:1 to receive soquelitinib 200 mg BID (the same dose as cohort 3) or placebo, and the treatment period was extended to 56 days from the 28-day treatment period used for cohorts 1-3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The cohort 4 data demonstrated favorable safety and efficacy results consistent with results from cohorts 1-3, including a deepening of responses in cohort 4 over the 8-week treatment period compared to the 4-week treatment period. The results also showed clinical activity in patients who had received prior systemic therapies, including patients resistant to therapies like dupilumab and JAK inhibitors. We believe the data to-date also support the novel proposed mechanism of action with ITK inhibition, which is designed to act upstream and regulate multiple T cell functional pathways. We believe the immune rebalancing shown thus far by soquelitinib shows its potential in a wide range of inflammatory and immune diseases. Based on these positive results, we have initiated a Phase 2 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis that have failed at least one prior topical or systemic therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of January 15, 2026, enrollment in cohort 4 was completed and all soquelitinib treated patients (n=12) had completed the 56-day treatment course. Of the 12 enrolled placebo patients, 10 were evaluable at day 56, as two patients were non-compliant and missed the day 56 visit; these two patients completed additional follow up at later time points. Patients in cohort 4 had similar baseline characteristics compared to patients in cohort 3, with patients in these cohorts having more advanced disease with a higher mean baseline EASI score compared to patients in cohorts 1 and 2. The mean baseline EASI in cohort 4 was 25.7 for the patients treated with soquelitinib and 21.9 for patients that received placebo. Across all four cohorts (n=72), 35% of patients had received prior systemic therapies (n=25), including 50% of patients (n=12) in cohort 4. Overall, all four cohorts showed meaningful responses in the soquelitinib treatment groups compared to placebo for clinically significant endpoints of EASI 75 and IGA 0 or 1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At day 56, the mean percent reduction in EASI for patients receiving soquelitinib in cohort 4 (n=12) was 72%, compared to 40% for patients receiving placebo (n=10). The kinetics of response demonstrated continuous improvement from day 28 to day 56 with widening separation of the response curve compared to the placebo. Two placebo patients experienced disease flares requiring therapy during the 56-day treatment period compared to none in the soquelitinib group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Figure 1 below summarizes the efficacy results for cohorts 1 through 4 evaluating EASI 75, EASI 90 and IGA 0 or 1. Cohort 3 and 4 results appear similar, with cohort 4 exhibiting higher frequency of EASI 75 and 90. EASI 75, EASI 90 and IGA 0 or 1 for cohort 4 was achieved in 75%, 25% and 33% of patients receiving soquelitinib, respectively, compared to 20%, 0% and 0%, respectively, for the placebo group. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:214.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Figure 1: Percent Patients Achieving Endpoints EASI 75, EASI 90 and IGA 0 or 1 at Day 28 (cohorts 1-3) or at Day 56 (cohort 4) of Treatment.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><img src="crvs-20260331x10q008.jpg" alt="Graphic" style="display:inline-block;height:214pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:468pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Figure 2 below shows the kinetics of response for cohort 4 patients receiving soquelitinib and placebo. Separation of the curves was seen at the first visit on day 15 and continuously increased out to day 56. At day 56, the difference in the curves is statistically significant, p=0.035. The disease control continued in the 30-day post treatment follow up period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:271.3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Figure 2: Percent Reduction in Mean EASI for Cohort 4.</b><i style="font-style:italic;"> Mean percent change in&#160;EASI&#160;over time is shown. Treatment beginning is designated &#8220;Baseline&#8221; and days post-baseline are shown. Screening to baseline data are shown and demonstrate relative disease stability. The study blinding remained in effect for the entire 86-day period. Numbers at the top of the graphs indicate numbers of patients evaluated at the various time points. As of January 15, 2026, not all patients had completed the 30-day post treatment follow up.</i></p><div style="height:259.85pt;left:0%;position:relative;top:0pt;width:468pt;z-index:251660288;"><div style="height:259.85pt;left:0pt;padding-bottom:0pt;position:relative;width:468pt;"><img src="crvs-20260331x10q009.jpg" alt="Graphic" style="height:259.85pt;width:468pt;"/></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Figure 3A and 3B below show the response curves for soquelitinib and placebo patients across all patients in cohorts 1-4 and in patients in cohorts 3-4 only, also segmented into sub-groups by those who had or had not received prior systemic therapies. Across all four cohorts, 25 patients (35% of all patients) received prior systemic therapies with dupilumab being the most common prior systemic therapy (n=11). Other prior systemic therapies included JAK inhibitors, corticosteroids and investigational agents. The response curves are nearly identical for soquelitinib treated patients, regardless of their history of prior systemic therapy. Placebo patients who had prior systemic therapy had a lesser reduction in EASI compared to placebo patients who had not received prior systemic therapy. These Phase 1 results show separation of the curves for patients receiving soquelitinib compared to placebo and demonstrate that soquelitinib was similarly active in both systemic treatment na&#239;ve or experienced patients. Also, prior systemic therapy experienced patients appeared to have worse disease. The two placebo patients who achieved EASI 75 had not received prior systemic therapy. None of the seven placebo patients who had received prior systemic therapy achieved EASI 75 or EASI 50; whereas, three of the five soquelitinib treated patients who received prior systemic therapy achieved EASI 75.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:448.8pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Figure 3A, 3B: Percent Reduction in Mean EASI for Cohorts 1-4&#8211; Breakout of Patients with or without Prior Systemic Therapy</b><span style="font-style:italic;font-weight:bold;">.</span><i style="font-style:italic;"> In Figure 3A, mean percent change in&#160;EASI&#160;over time is shown for all patients in Cohort 1-4 (left) and for those who received prior therapy (right). In Figure 3B, similar analysis is shown for patients in cohort 3 and 4; these patients received the 200 mg twice daily dose. In all charts, treatment beginning is designated &#8220;Baseline&#8221; and weeks post-baseline are shown. Placebo patients include cohorts 1-4. Soquelitinib cohorts 3 and 4 are combined (200 mg twice daily doses used in both of these cohorts). </i></p><div style="height:210.4pt;left:0%;position:relative;top:0pt;width:468pt;z-index:251658240;"><div style="height:210.4pt;left:0pt;padding-bottom:0pt;position:relative;width:468pt;"><img src="crvs-20260331x10q010.jpg" alt="Graphic" style="height:210.4pt;width:468pt;"/></div></div><div style="height:211.5pt;left:0%;position:relative;top:0pt;width:468pt;z-index:251659264;"><div style="height:211.4pt;left:0pt;padding-bottom:0.1pt;position:relative;width:468pt;"><img src="crvs-20260331x10q011.jpg" alt="Graphic" style="height:211.4pt;width:468pt;"/></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Figure 4 below shows longer follow up from cohort 3 patients, who also received the 200 mg twice-daily dose. The data show maintenance or improvement in EASI out to 3 months beyond the treatment period and an increase of circulating Treg cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:289.85pt;"><div style="height:258pt;left:0%;position:relative;top:0pt;width:468pt;z-index:251661312;"><div style="height:257.4pt;left:0pt;padding-bottom:0.6pt;position:relative;width:468pt;"><img src="crvs-20260331x10q012.jpg" alt="Graphic" style="height:257.4pt;width:468pt;"/></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Figure 4:</b> <b style="font-weight:bold;">Percent Reduction in Mean EASI for Cohort 3 and percent change in Treg cells for cohorts 1-3.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Reduction in serum IL-4 cytokine was observed in cohorts 3 and 4, both during the treatment period and in the post treatment period, including a dose dependent response with cohort 4 patients showing the largest reductions in IL-4 out to day 86. Biomarker data from cohorts 1 through 3 shows a reduction in serum IL-5 cytokine for cohorts 1 through 3 compared to placebo, including a dose dependent response with cohort 3 patients showing the largest reductions in IL-5 compared to placebo. The reduction in serum IL-5 occurred as early as day 8 of therapy. Serum IL-17 and TARC levels also were lower. Circulating Th2 cells were measured (n=6 cohorts 1 and 2) by scRNA seq technology and demonstrated a reduction in these cells with treatment. As noted above, circulating Tregs cells increased in patients in cohort 3 and were associated with a prolonged treatment effect. These results are consistent with soquelitinib&#8217;s observed ability to block Th2 and Th17 cells and their secreted cytokines, such as IL-4, IL-5, IL-17 and the effects on T reg cells. This biomarker data suggest that soquelitinib induced an immune system rebalancing involving Th1, Th2, Th17 and Treg cells. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of January 15, 2026, no new safety signals had been observed. Reported adverse events occurred in 41.7% of soquelitinib patients and 50% of placebo patients; all were Grade 1-2 and did not result in any dose modifications or interruptions. No severe or serious adverse events were reported. No significant lab abnormalities were seen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2026, we initiated a Phase 2 clinical trial of soquelitinib for the treatment of atopic dermatitis. The trial is anticipated to enroll approximately 200 patients with moderate-to-severe atopic dermatitis that have failed at least one prior topical or systemic therapy. The trial is anticipated to enroll four cohorts of 50 patients each, with soquelitinib doses of: 200 mg once per day; 200 mg twice per day; and 400 mg once per day; along with a placebo group. The treatment period is anticipated to be 12 weeks with a 30-day follow-up period with no treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Angel Pharmaceuticals, our partner in China, is enrolling a Phase 1b/2 clinical trial evaluating soquelitinib in patients with moderate-to-severe atopic dermatitis. This is a blinded, placebo-controlled trial that is planned to evaluate a 12-week treatment regimen in 48 patients utilizing soquelitinib doses of 100 mg twice per day, 200 mg once per day, 200 mg twice per day and 400 mg once per day. The patient eligibility and endpoints are similar to those used previously in our Phase 1 clinical trial. Depending on the results from the Phase 1b portion of the study, an additional 60-90 patients will be enrolled in the Phase 2 portion of the study. The trial is open at several leading dermatology centers in China who </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">have been involved in global registration trials. The study is being conducted in close collaboration with Corvus. Results from the initial cohorts are anticipated late this year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Beyond our current and planned clinical trials for soquelitinib, we also continue to advance our next-generation ITK inhibitor preclinical product candidates, which were designed to deliver precise T-cell modulation that is optimized for specific immunology indications. The next-generation ITK inhibitor candidates are part of our ongoing business development efforts to maximize the potential of our ITK inhibitor programs and other programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have issued patents covering composition of matter and uses of our ITK inhibitors and hold exclusive worldwide rights (except for greater China) for all indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Ciforadenant Adenosine A2A Receptor Antagonist.</span> Our second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor&#8217;s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. In 2018, we published preclinical findings in animal tumor models demonstrating that treatment with anti-CTLA4 antibody combined with ciforadenant provided synergistic anti-tumor activity based on a novel proposed mechanism of action. We are collaborating with the Kidney Cancer Research Consortium to evaluate ciforadenant in an open label Phase 1b/2 clinical trial as a first line therapy for metastatic RCC in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1). The efficacy endpoints for the trial are deep response rate, defined as CR plus PRs of greater than 50% tumor volume reduction as well as progression free survival. The clinical trial is planned to enroll up to 60 patients. The protocol defined pre-specified statistical threshold for efficacy is a 50% increase above the 32% deep response rate seen with previous ipilimumab/nivolumab combination trials in RCC conducted by investigators at the Kidney Cancer Research Consortium. Interim results from this trial were reported at the European Society of Clinical Oncology meeting in October 2025. The deep response rate was 34%, demonstrating an improvement compared to historical data for the combination of ipilimumab and nivolumab alone, though not statistically significant at this point in time. Patients with stable or responding disease continue to be followed. No further trials are planned.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mupadolimab, B Cell Activating Anti-CD73 Antibody.</span> Our third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73. In both preclinical and in vivo studies, mupadolimab has demonstrated binding to various immune cells and the enhancement of immune responses by activating B cells. While we believe mupadolimab has the potential to be an important new therapeutic agent with a novel proposed mechanism of action to support its development for the treatment of a broad range of cancers and infectious diseases, we are waiting to initiate a potential Phase 2 randomized clinical trial in order to prioritize the development of our other two lead product candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To date, the majority of our efforts have been focused on the research, development and advancement of soquelitinib, ciforadenant, and mupadolimab, and we have not generated any revenue from product sales and, as a result, we have incurred significant losses. We expect to continue to incur significant research and development and general and administrative expenses related to our operations. Our net loss for the&#160;three months ended March 31, 2026 was $13.7 million, and net income for the three months ended March 31, 2025 was $15.2 million, which includes non-operating income of $25.1 million associated with a change in fair value of warrant liability. As of March&#160;31, 2026, we had an accumulated deficit of $426.0&#160;million. We expect our losses will increase as we continue our development of, seek regulatory approval for and, if approved, begin to commercialize soquelitinib, ciforadenant and mupadolimab, and as we develop other product candidates. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since our inception and through March 31, 2026, we have funded our operations primarily through the sale and issuance of stock, including through our initial public offering (&#8220;IPO&#8221;) in March 2016 and subsequent follow-on public offerings, including a follow-on public offering of common stock which was completed on January 23, 2026 and resulted in aggregate net proceeds of approximately $189.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">On August 6, 2024, we entered into an Open Market Sale Agreement<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> (the &#8220;2024 Sales Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) to sell shares of our common stock, from time-to-time, with aggregate gross sales proceeds of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">up to $100.0 million, through an at-the-market equity offering program under which Jefferies will act as our sales agent. The issuance and sale of shares of common stock pursuant to the 2024 Sales Agreement are deemed an &#8220;at-the-market&#8221; offering under the Securities Act of 1933, as amended. Jefferies is entitled to compensation for its services of up to 3.0% of the gross proceeds of any shares of common stock sold through Jefferies under the 2024 Sales Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the January 2026 follow-on public offering, we suspended the at-the-market offering with respect to the 2024 Sales Agreement and, on March 13, 2026, entered into an Amended and Restated Open Market Sale Agreement<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> (the &#8220;Amended Sales Agreement&#8221;), with Jefferies, which amends and restates the 2024 Sales Agreement to increase the maximum aggregate offering price of shares of our common stock from $100.0 million to $200.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the three months ended March 31, 2026, we did not sell any shares of common stock under our at-the-market offering program. As of March 31, 2026, $200.0 million remained available for sale under the Amended Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our three product candidates, soquelitinib, ciforadenant and mupadolimab, are in clinical development by us and/or our partner, Angel Pharmaceuticals. Except for Greater China, we own the world-wide rights to these product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result of our ongoing development efforts, we anticipate needing to spend substantial resources for the foreseeable future. Consequently, we will need additional financing to support our continuing operations. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity or debt financings or other sources, which may include collaborations with third parties. Such financing could result in dilution to stockholders and may include the imposition of debt covenants and repayment obligations or other restrictions that may affect our business. If we raise additional capital through strategic collaboration agreements, we may have to relinquish valuable rights to our product candidates, including potential future revenue streams. Adequate additional financing may not be available to us on acceptable terms, or at all. For example, the trading prices for our and other biopharmaceutical companies&#8217; stock have been highly volatile as a result of factors such as the impacts of pandemics and increases in inflation rates or interest rates or the broad imposition of tariffs and other trade controls. As a result, we may face difficulties raising capital through sales of our common stock and any such sales may be on unfavorable terms. Our inability to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenue to achieve profitability, and we may never do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026, we had capital resources consisting of cash, cash equivalents and marketable securities of approximately $236.7 million. Based on our currently available cash resources and our currently planned level of operations and cash flows, we expect that our cash resources will be sufficient to enable us to advance our programs into the second quarter of 2028. In accordance with applicable accounting standards, we evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern for at least the next 12 months from the date of the issuance of the condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q and concluded that our existing cash, cash equivalents and marketable securities are sufficient to fund our operations for at least the next 12 months from issuance of the condensed consolidated financial statements. However, the Company will need to continue to raise additional capital to fund its operations. See &#8220;Risk Factors&#8212;Risks Related to Our Limited Operating History, Financial Condition and Need for Additional Capital.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently have no manufacturing capabilities and do not intend to establish any such capabilities. We have no commercial manufacturing facilities for our product candidates. As such, we are dependent on third parties to supply our product candidates according to our specifications, in sufficient quantities, on time, in compliance with appropriate regulatory standards and at competitive prices.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our significant accounting policies are described in Note 2 to our consolidated financial statements for the year ended December&#160;31, 2025 included in our Annual Report on Form&#160;10-K filed with the SEC on March 12, 2026. There have been no material changes to our significant accounting policies during the three months ended March 31, 2026 from those discussed in our Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Components of Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To date, we have not generated any revenues. We do not expect to receive any revenues from any product candidates that we develop unless and until we obtain regulatory approval and commercialize our products or enter into revenue-generating collaboration agreements with third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Our research and development expenses consist primarily of costs incurred to conduct research and development of our product candidates. We record research and development expenses as incurred. Research and development expenses include:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee-related expenses, including salaries, benefits, travel and non-cash stock-based compensation expense;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">external research and development expenses incurred under arrangements with third parties, such as contract research organizations, preclinical testing organizations, contract manufacturing organizations, academic and non-profit institutions and consultants;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs to acquire technologies to be used in research and development that have not reached technological feasibility and have no alternative future use;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">license fees; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other expenses, which include direct and allocated expenses for laboratory, facilities and other costs.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We plan to increase our research and development expenses substantially as we continue the development and potential commercialization of our product candidates. Our current planned research and development activities include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enrollment and completion of our ongoing Phase 3 potentially registrational clinical trial for soquelitinib in PTCL;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of our ongoing Phase 1 clinical trial for soquelitinib in atopic dermatitis;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of our Phase 1b/2 clinical trial with ciforadenant in collaboration with the Kidney Cancer Research Consortium;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enrollment and completion of our Phase 2 clinical trial for soquelitinib in atopic dermatitis;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a potential clinical trial for soquelitinib in asthma;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a potential clinical trial for soquelitinib in hidradenitis suppurativa;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">process development and manufacturing of drug supply of soquelitinib; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preclinical studies under our other programs in order to select development product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to our product candidates that are in clinical development, we believe it is important to continue substantial investment in potential new product candidates to build the value of our product candidate pipeline and our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Our expenditures on current and future preclinical and clinical development programs are subject to numerous uncertainties related to timing and cost to completion. The duration, costs and timing of clinical trials and development of product candidates will depend on a variety of factors, including many of which are beyond our control. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time consuming, and the successful development of our product candidates is uncertain. The risks and uncertainties associated with our research and development projects are discussed more fully in &#8220;Risk Factors.&#8221; As a result of these risks and uncertainties, we are unable to determine with any degree of certainty the duration and completion costs of our research and development projects or if, when or to what extent we will generate revenues from the commercialization and sale of any of our product candidates that obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses include personnel costs, expenses for outside professional services and allocated expenses. Personnel costs consist of salaries, benefits and stock-based compensation. Outside professional services consist of legal, accounting and audit services and other consulting fees. Allocated expenses consist of rent expense related to our office and research and development facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research and development and potential commercialization of one or more of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Comparison of the periods below as indicated (in thousands)</i>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:65.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:18.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,175</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,453</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,722</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,702</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,469</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,233</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,877</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,922</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,955</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (14,877)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (9,922)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,955)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Interest income and other expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,784</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 525</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,259</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Change in fair value of warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25,129</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (25,129)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Income (loss) before equity method investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (13,093)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,732</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (28,825)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss from equity method investment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (599)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (539)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (60)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (13,692)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,193</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (28,885)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Research and development expenses for the three months ended March 31, 2026 and 2025 consisted of the following costs by program as well as unallocated employee costs and overhead costs (specific program costs consist solely of external costs) (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:67.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Soquelitinib</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,696</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,249</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,447</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 51</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 50</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Unallocated employee and overhead costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,428</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,154</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,274</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,175</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,453</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,722</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the three months ended March 31, 2026,&#160;the increase in soquelitinib costs of $2.4 million as compared to the three months ended March 31, 2025, primarily consisted of an increase of $3.0 million in clinical trial expenses and an increase of $0.7 million in other outside service costs, which were partially offset by a decrease of $1.3 million in drug manufacturing costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the three months ended March 31, 2026, the increase other programs costs were negligible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the three months ended March 31, 2026, the increase in unallocated costs of $1.3 million as compared to the three months ended March 31, 2025, primarily consisted of an increase of $1.3 million in personnel and related costs and an increase of $0.1 million in other outside service costs, which were partially offset by a decrease of $0.1 million in facilities related costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General and Administrative Expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the three months ended March 31, 2026, the increase in general and administrative expenses of $1.2 million as compared to the three months ended March 31, 2025, primarily consisted of an increase of $1.0 million in personnel and related costs and an increase of $0.2 million in outside service costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Interest Income and Other Expense, net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the three months ended March 31, 2026, the increase in interest income and other expense, net of $1.3 million as compared to the three months ended March 31, 2025, primarily consisted of an increase in interest income earned due to an increase in cash equivalents and marketable securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Change in fair value of warrant liabilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the three months ended March 31, 2026, the change in fair value of warrant liability was zero as all common warrants had been exercised as of June 30, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the three months ended March 31, 2025, the change in fair value of warrant liability of $25.1 million represents a decrease in the fair value of common warrants from December 31, 2024 to March 31, 2025, which was primarily due to a decrease in the market price of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Loss from equity method investment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the three months ended March 31, 2026, the increase in loss from equity method investment of $0.1 million as compared to the three months ended March 31, 2025, primarily consisted of an increase in Angel Pharmaceuticals&#8217; loss for the three months ended March 31, 2026.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026, we had cash, cash equivalents and marketable securities of $236.7&#160;million, and an accumulated deficit of<span style="color:#ff0000;"> </span>$426.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since our inception and through March 31, 2026, we have funded our operations primarily through the sale and issuance of preferred and common stock, including through our IPO in March 2016, in which we raised net proceeds of approximately $70.6 million, a follow-on offering of our common stock in March 2018, in which we raised net proceeds of approximately $64.9 million, a follow on offering of our common stock in February 2021, in which we raised net proceeds of approximately $32.0 million, and a registered direct offering in May 2024, in which we sold shares of our common stock, pre-funded warrants and common stock warrants for net proceeds of approximately $30.3 million and proceeds of $54.3 million from the exercise of common stock warrants. On January 23, 2026, we completed a follow-on offering of common stock, which resulted in aggregate net proceeds of approximately $189.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the January 2026 follow-on offering, we suspended the at-the-market offering with respect to the 2024 Sales Agreement and, on March 13, 2026, entered into the Amended Sales Agreement, with Jefferies, which amends and restates the 2024 Sales Agreement to increase the maximum aggregate offering price of shares of our common stock from $100.0 million to $200.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the three months ended March 31, 2026, we did not sell any shares of common stock under our at-the-market offering program. As of March 31, 2026, $200.0 million remained available for sale under the Amended Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Funding Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since our inception, we have incurred significant losses and negative cash flows from operations. We have an accumulated deficit of $426.0 million through March 31, 2026. We do not expect positive cash flows from operations in the foreseeable future, if ever. Historically, we have incurred operating losses as a result of ongoing efforts to develop our product candidates, including conducting ongoing research and development, clinical and preclinical studies and providing general and administrative support for these operations. We do not have any products approved for sale, and we do not expect to generate any meaningful revenue unless and until we obtain regulatory approval of and commercialize any of our current and future product candidates and/or enter into additional significant collaboration agreements with third parties, and we do not know when, or if, either will occur. We expect to continue to incur net operating losses for at least the next several years and we expect the losses to increase as we advance soquelitinib, as well as any other product candidates, through clinical development, seek regulatory approval, prepare for and, if approved, proceed to commercialization and continue our research and development efforts. We are subject to all the risks typically related to the development of new product candidates, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. We do not yet have a sales organization or commercial infrastructure and, accordingly, we will need to incur significant expenses to develop a sales organization and commercial infrastructure in advance of generating any commercial product sales. Moreover, we incur substantial costs associated with operating as a public company. We anticipate that we will need substantial additional funding in connection with our continuing operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Until we can generate a sufficient amount of revenue from the commercialization of our product candidates or from additional significant collaboration or license agreements with third parties, if ever, we expect to finance our future cash needs through private and public equity offerings and potential future collaboration, license and development agreements. Adequate funding may not be available to us on acceptable terms, or at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we will be required to significantly reduce our operating expenses and may have to significantly delay, scale back or discontinue the development of one or more of our current or future product candidates. If we raise additional funds by issuing equity or convertible debt securities, it could result in dilution to our existing stockholders and increased fixed payment obligations. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. If we incur indebtedness, we could become subject to covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term, but we may have to relinquish valuable rights to our product candidates or grant licenses on terms that are not favorable to us. Any of the foregoing could significantly harm our business, financial condition and prospects. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to incur substantial additional losses in the future as we conduct our planned research and development activities. We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our planned operating and capital needs into the second quarter of 2028. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially based on a number of factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to estimate the exact amount of our operating capital requirements. Our future capital requirements depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress, timing, costs and results of clinical trials for soquelitinib, including the potentially registrational clinical trial for soquelitinib, and to a lesser extent, the timing, costs and results of the clinical trials for ciforadenant and mupadolimab;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, progress, costs and results of preclinical and clinical development activities for our other product candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and scope of preclinical and clinical programs we decide to pursue;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in prosecuting, maintaining and enforcing patent and other intellectual property rights;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost and timing of regulatory approvals;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our efforts to enhance operational systems and hire additional personnel, including personnel to support development of our product candidates and satisfy our obligations as a public company; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other factors described in the section of this Quarterly Report on Form 10-Q entitled &#8220;Risk Factors.&#8221;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Summary of Statement of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The following table summarizes our cash flows for the periods indicated (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net cash provided by (used in):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (10,374)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (8,263)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (144,846)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,243</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 190,746</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 279</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net increase (decrease) in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 35,526</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,741)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flows from Operating Activities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Cash used in operating activities during the three months ended March 31, 2026 was $10.4 million, which primarily consisted of a net loss of $13.7 million, adjusted by net non-cash transactions of $3.3 million, that primarily </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">consisted of $2.7 million of stock-based compensation expense and $0.6 million of loss from equity method investment; an increase of $1.8 million in prepaid and other current assets; an increase of $0.9 million in other assets; an increase of $2.2 million in accounts payable; and an increase of $0.5 million in accrued and other current liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash used in operating activities during the three months ended March 31, 2025 was $8.3 million, which primarily consisted of a net income of $15.2 million, adjusted by net non-cash transactions of $23.6 million, that primarily consisted of $1.3 million of stock-based compensation expense, $0.5 million of loss from equity method investment and a decrease of $25.1 million in the fair value of warrant liability; an increase of $1.2 million in prepaid and other current assets; a decrease of $1.3 million in accounts payable; an increase of $0.1 million in accrued and other current liabilities; and a decrease of $0.1 million in operating lease liability net of operating lease right-of-use assets amortization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flows from Investing Activities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the three months ended March 31, 2026. net cash flows used in investing activities was $144.8 million, which primarily consisted of purchases of marketable securities of $161.7 million and purchases of property and equipment of $0.1 million, which were partially offset by maturities of marketable securities of $17.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the three months ended March 31, 2025. net cash flows provided by investing activities was $4.2 million, which primarily consisted of maturities of marketable securities of $12.0 million, which were partially offset by purchases of marketable securities of $7.7 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flows from Financing Activities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the three months ended March 31, 2026, cash provided by financing activities was $190.7 million, which primarily consisted of net proceeds of $189.4 million from the January 2026 follow-on public offering and proceeds of $1.3 million from the exercise of stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the three months ended March 31, 2025, cash provided by financing activities was $0.3 million, which primarily consisted of proceeds from the exercise of stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Contractual Obligations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There have been no material changes outside the ordinary course of our business to our contractual obligations during the three months ended March 31, 2026, as compared to those disclosed in our Annual Report on Form&#160;10-K filed with the SEC on March 12, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Critical Accounting Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There have been no changes to our critical accounting estimates during the three months ended March 31, 2026, as compared to those disclosed in our Annual Report on Form 10-K filed with the SEC on March 12, 2026.</p><a id="_0368776b_2992_4005_9929_b2c1c3da03ad"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Item 3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures about Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">We are exposed to market risk related to changes in interest rates. We had cash and cash equivalents and marketable securities of $236.7 million as of March 31, 2026 and cash, cash equivalents and marketable securities of $56.8 million as of December&#160;31, 2025, which consisted of bank deposits, money market investments, U.S. Treasury securities and U.S. government agency securities. Such interest-earning instruments carry a degree of interest rate risk; however, historical fluctuations of interest income have not been significant. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate 10% increase in interest rates would not have a material effect on the fair market value of our portfolio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9709292c_c619_47cf_8cfa_c75098eab92b"></a><a id="Item4ControlsandProcedures_996727"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Item 4.&#160;&#160;&#160;&#160;Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules&#160;and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Due to the inherent limitations of control systems, including the possibility of human error and the circumvention or overriding of the controls and procedures, not all misstatements may be prevented or detected. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As required by Rule&#160;13a-15(b)&#160;under the Exchange Act, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2026 the end of the period covered by this Quarterly Report on Form&#160;10-Q. Based upon such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Changes in Internal Controls Over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form&#160;10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_77776295_26ea_4edc_be4f_27c3e78b38dc"></a><a id="PARTIIOTHERINFORMATION_177066"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">PART&#160;II &#8212; OTHER INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Item1LegalProceedings_213471"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Item 1 &#8212; Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">We are not currently a party to any material litigation or legal proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_231a419f_90f2_4be9_8aeb_0c1a6afb3787"></a><a id="RiskFactors"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Item 1A &#8212; Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Our business involves significant risks, some of which are described below. You should consider carefully the risks and uncertainties described below, together with all of the other information in this Quarterly Report on Form 10-Q, including our unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Risk Factor Summary</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading &#8220;Risk Factors&#8221; and should be carefully considered, together with other information in this Quarterly Report on Form 10-Q and our other filings with the Securities and Exchange Commission (&#8220;SEC&#8221;) before making investment decisions regarding our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="margin-bottom:14pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, other operations or commercialization efforts.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our product candidates are in various stages of development and may fail or suffer delays that materially and adversely affect their commercial viability. If we are unable to advance our product candidates through clinical development, obtain regulatory approval and ultimately commercialize such product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results. Any product candidate we or any of our existing or potential future collaborators advance into clinical trials, including </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">soquelitinib, ciforadenant and mupadolimab</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, may not have favorable results in later clinical trials, if any, or receive regulatory approval.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any termination or suspension of, or delays in the commencement or completion of, our planned clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our product candidates are subject to extensive regulation, compliance with which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are conducting and plan to conduct clinical trials for </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">soquelitinib</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, ciforadenant and mupadolimab, and we and Angel Pharmaceuticals may in the future, conduct additional clinical trials of product candidates at sites </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outside the United States, and the Food and Drug Administration (&#8220;FDA&#8221;) may not accept data from trials conducted in foreign locations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we encounter difficulties enrolling subjects in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The occurrence of serious complications or side effects in connection with use of our product candidates, either in clinical trials or post-approval, could lead to discontinuation of our clinical development programs, refusal of regulatory authorities to approve our product candidates or, post-approval, revocation of marketing authorizations or refusal to approve new indications, which could severely harm our business, prospects, results of operations and financial condition.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not be successful in our efforts to identify or discover additional product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely, and expect to continue to rely, on third parties to conduct our clinical trials. If these third parties do not meet our deadlines or otherwise conduct the trials as required, our clinical development programs could be delayed or unsuccessful and we may not be able to obtain regulatory approval for or commercialize our product candidates when expected, or at all.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely on third parties to conduct some or all aspects of our manufacturing, research and preclinical and clinical testing, and these third parties may not perform satisfactorily.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We, or our third-party manufacturers, may be unable to successfully scale-up manufacturing of our product candidates in sufficient quality and quantity, which would delay or prevent us from developing our product candidates and commercializing approved products, if any.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to commercialize our product candidates or if we experience significant delays in obtaining regulatory approval for, or commercializing, any or all of our product candidates, our business will be materially and adversely affected.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our products may be delayed and, as a result, our stock price may decline.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We face competition from entities that have developed or may develop product candidates for cancer, including companies developing novel treatments and technology platforms. If these companies develop technologies or product candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize product candidates may be adversely affected.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">An active, liquid and orderly market for our common stock may not be sustained.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The trading price of the shares of our common stock could be highly volatile, and investors in our common stock could incur substantial losses</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Limited Operating History, Financial Condition and Need for Additional Capital</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">We are a clinical-stage biopharmaceutical company that has never generated revenue from the sale of our product candidates. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. To date, we have focused primarily on developing our lead product candidates, soquelitinib, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ciforadenant and mupadolimab, and researching additional product candidates. We have incurred significant operating losses since we were founded in January&#160;2014 and have not yet generated any revenue from sales. If our product candidates are not approved, we may never generate any revenue. We incurred a net loss of $15.3 million, $62.3 million and $27.0 million for the years ended December 31, 2025, 2024 and 2023, respectively. During the three months ended March 31, 2026 and 2025, we recorded a net loss of $13.7 million and net income of $15.2 million, respectively. We had an accumulated deficit of $426.0&#160;million as of March 31, 2026. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase as we continue our development of, seek regulatory approval for and, if approved, begin to commercialize soquelitinib, and as we develop other product candidates. Even if we achieve profitability in the future, we may not be able to sustain it in subsequent periods. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; equity and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, other operations or commercialization efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since our inception, the majority of our efforts have been focused on the research and development of soquelitinib, ciforadenant and mupadolimab. We believe that we will continue to expend substantial resources for the foreseeable future as we continue clinical development of, seek regulatory approval for and, if approved, prepare for the commercialization of soquelitinib, as well as product candidates under our other development programs. These expenditures will include costs associated with research and development, conducting preclinical studies and clinical trials, obtaining regulatory approvals, manufacturing and supply, sales and marketing and general operations. In addition, other unanticipated costs may arise. Because the outcome of any clinical trial and/or regulatory approval process is highly uncertain, we may not be able to accurately estimate the actual amounts necessary to successfully complete the development, regulatory approval process and commercialization of soquelitinib, ciforadenant and mupadolimab or any other product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on our planned expenditures and capital expenditures requirements, our cash, cash equivalents and marketable securities of $236.7 million as of March 31, 2026, we expect that our existing capital resources will be sufficient to fund our operations into the second quarter of 2028. As a result, we do not expect our existing capital resources to be sufficient to enable us to fund the completion of all of our ongoing and planned clinical trials and remaining development programs through commercialization. In addition, while Angel Pharmaceuticals has received outside investment of approximately $41.0 million in connection with its formation and licensing of certain of our intellectual property, such cash is not available for our use. Our operating plan may change as a result of many factors, including those described below as well as others currently unknown to us, and we will need to seek additional funds, through public or private equity, and debt financings or other sources, such as strategic collaborations. Such financing would result in dilution to stockholders, imposition of debt covenants and repayment obligations or other restrictions that may affect our business. If we raise additional capital through strategic collaboration agreements, we may have to relinquish valuable rights to our product candidates, including possible future revenue streams. For example, in October 2020 we formed Angel Pharmaceuticals with a group of investors in China to create a new China-based biopharmaceutical company with a mission to bring innovative quality medicines to Chinese patients for treatment of serious diseases including cancer, autoimmune diseases and infectious diseases. We granted Angel Pharmaceuticals a license to rights to develop and commercialize our three clinical-stage candidates &#8211; soquelitinib, ciforadenant and mupadolimab &#8211; in greater China and Angel Pharmaceuticals obtained global rights to our Bruton&#8217;s tyrosine kinase (&#8220;BTK&#8221;) inhibitor preclinical programs. In addition, additional funding may not be available to us on acceptable terms, or at all, and any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The amount and timing of any expenditures needed to implement our development and commercialization programs will depend on numerous factors, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the type, number, scope, progress, expansions, results of and timing of our ongoing and planned clinical trials of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">soquelitinib (including the potential registration trial), ciforadenant and mupadolimab</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and any of </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our planned preclinical studies and clinical trials of other product candidates which we are pursuing or may choose to pursue in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the need for, and the progress, costs and results of, any additional clinical trials of soquelitinib, ciforadenant and mupadolimab or any of our other product candidates we may initiate based on the results of our planned clinical trials or discussions with the FDA or other regulatory agencies, including any additional trials the FDA or other regulatory agencies may require;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of obtaining or maintaining manufacturing for soquelitinib, ciforadenant and mupadolimab and our other product candidates, including commercial manufacturing if any product candidate is approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of establishing sales and marketing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to achieve sufficient market acceptance, coverage and reimbursement from third-party payors and adequate market share for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and timing of establishing collaborations, license agreements and other partnerships;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether the FDA or other regulatory agencies accepts data from any clinical trials of our product candidates conducted by Angel Pharmaceuticals in China;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs associated with any new product candidates that we may develop, in-license or acquire;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Angel Pharmaceuticals&#8217; ability to develop and commercialize product candidates in China;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic conditions, such as rising inflation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effect of competing technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to attract, hire and retain qualified personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain partnering arrangements for development; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with being a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Several of these factors are outside of our control and if we are unable to obtain funding on a timely basis, or at all, we will be unable to complete the clinical trials for soquelitinib, ciforadenant and mupadolimab and our other product candidates, and we may be required to significantly curtail some or all of our activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the Discovery and Development of Our Product Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our product candidates are in various stages of development and may fail or suffer delays that materially and adversely affect their commercial viability. If we are unable to advance our product candidates through clinical development, obtain regulatory approval and ultimately commercialize such product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">We have invested a significant portion of our efforts and financial resources in the development of our most advanced product candidates, soquelitinib, ciforadenant and mupadolimab. We have no products on the market and our ability to achieve and sustain profitability depends on obtaining regulatory approvals for and successfully </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">commercializing our product candidates, either alone or with third parties. Before obtaining regulatory approval for the commercial distribution of our product candidates, we or our collaborators must conduct extensive preclinical tests and clinical trials to demonstrate sufficient safety and efficacy of our product candidates in patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result, we may not have the financial resources to continue development of, or to modify existing or enter into new collaborations for, a product candidate if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, product candidates, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">negative or inconclusive results from our clinical trials, the clinical trials of our collaborators, including Angel Pharmaceuticals, or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product-related side effects experienced by participants in our clinical trials, the clinical trials of our collaborators or by individuals using drugs or therapeutic biologics similar to our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in submitting Investigational New Drug Applications (&#8220;INDs&#8221;) or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conditions imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in enrolling research subjects in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">high drop-out rates of research subjects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inadequate supply or quality of product candidate components or materials or other supplies necessary for the conduct of our clinical trials or the clinical trials of our collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">greater than anticipated clinical trial costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay in the development, approval or certification of companion diagnostic tests for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">varying interpretations of data by the FDA and similar foreign regulatory agencies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We could find that the product candidates we or our collaborators pursue are not safe or effective. Furthermore, if one or more of our product candidates generally prove to be ineffective, unsafe or commercially unviable, the development of our entire platform and pipeline could be delayed, potentially permanently. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Of the large number of drugs in development in the pharmaceutical industry, only a small percentage result in the submission of a NDA or Biologics License Application (&#8220;BLA&#8221;) to the FDA or comparable marketing applications </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">to foreign regulatory authorities, and even fewer are approved for commercialization. Furthermore, even if we do receive regulatory approval to market soquelitinib, ciforadenant or mupadolimab, any such approval may be subject to limitations on the indicated uses for which we may market the product. Accordingly, even if we are able to obtain the requisite financing to continue to fund our development programs, we cannot assure our stockholders that soquelitinib, ciforadenant or mupadolimab will be successfully developed or commercialized. If we or any of our existing or potential future collaborators are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize soquelitinib, ciforadenant or mupadolimab, we may not be able to generate sufficient revenue to continue our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results. Any product candidate we or any of our existing or potential future collaborators advance into clinical trials, including </span><span style="font-style:italic;font-weight:bold;">soquelitinib, ciforadenant and mupadolimab</span><span style="font-style:italic;font-weight:bold;">, may not have favorable results in later clinical trials, if any, or receive regulatory approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under our collaboration with Angel Pharmaceuticals, Angel Pharmaceuticals is responsible for the clinical development and commercialization, including all related expenses, of the licensed pipeline programs in greater China, and for the pre-clinical BTK program globally. Clinical trials conducted by Angel Pharmaceuticals will be subject to many of the same risks as our ongoing clinical programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot be certain that our ongoing or planned clinical trials or any other future clinical trials will be successful. Any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies with respect to clinical trials may change and additional government regulations may be enacted. For instance, the regulatory landscape related to clinical trials in the European Union (&#8220;EU&#8221;) has evolved. The EU Clinical Trials Regulation (&#8220;CTR&#8221;) which was adopted in April 2014 and repealed the EU Clinical Trials Directive, became applicable on January 31, 2022. While the EU Clinical Trials Directive required a separate CTA to be submitted in each member state in which the clinical trial takes place, to both the competent national health authority and an independent ethics committee, the CTR introduced a centralized process and only requires the submission of a single application for multi-center trials. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. The CTR transition period ended on January 31, 2025, and all clinical trials (and related applications) are now fully subject to the provisions of the CTR. Compliance with the CTR requirements by us, our collaborators and third-party service providers, such as contract research organizations (&#8220;CROs&#8221;), may impact our developments plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may also be impacted.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any termination or suspension of, or delays in the commencement or completion of, our planned clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Before we can initiate clinical trials in the United States or in foreign countries for any of our product and development candidates, we must submit the results of preclinical testing to the FDA or foreign regulatory authorities along with other information, including information about product candidate chemistry, manufacturing and controls and our proposed clinical trial protocol, as part of an IND or similar application. In addition, we may rely in part on preclinical, clinical and quality data generated by CROs and other third parties for regulatory submissions for our product candidates. If these third parties do not make timely regulatory submissions for our product candidates, it will delay our plans for our clinical trials. If those third parties do not make this data available to us, we will likely have to develop all necessary preclinical and clinical data on our own, which will lead to significant delays and increase development costs of the product candidate. In addition, the FDA or foreign regulatory authorities may require us to conduct additional preclinical testing for any product candidate before it allows us to initiate clinical testing under any IND or similar application, which may lead to additional delays and increase the costs of our preclinical development. Delays in the completion of our planned clinical trials for product candidates could significantly affect our product development costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While we initiated several clinical trials, we do not know whether any of our other planned trials will begin on time in the future or whether any of our trials will be completed on schedule, if at all. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or foreign regulatory authorities failing to grant permission to proceed or placing a clinical trial on hold;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subjects failing to enroll or remain in our trial at the rate we expect;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subjects choosing an alternative treatment for the indication for which we are developing soquelitinib, ciforadenant and mupadolimab or other product candidates, or participating in competing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of adequate funding to continue the clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subjects experiencing severe or unexpected drug-related adverse effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a facility manufacturing soquelitinib, ciforadenant or mupadolimab, any of our other product candidates or any of their components being ordered by the FDA or other regulatory authorities to temporarily or permanently shut down due to violations of Good Manufacturing Practice (&#8220;GMP&#8221;) regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes to our manufacturing process that may be necessary or desired;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any failure or delay in reaching an agreement with CROs and clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, Good Clinical Practice (&#8220;GCP&#8221;) or regulatory requirements or other third parties not performing data collection or analysis in a timely or accurate manner;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one or more Institutional Review Boards (&#8220;IRBs&#8221;) or other reviewing bodies refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing its approval of the trial; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients failing to complete a trial or return for post-treatment follow-up.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, we could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Safety Monitoring Board for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs or other reviewing bodies for reexamination, which may impact the costs, timing or successful completion of a clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed or adversely affected. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. See also the risk factor below titled &#8220;<i style="font-style:italic;">If we encounter difficulties enrolling subjects in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. For example, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. Further, if one or more clinical trials are delayed, our competitors may be able to bring products to market before we do, and the commercial viability of soquelitinib, ciforadenant and mupadolimab or other product candidates could be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"><span style="font-style:italic;font-weight:bold;">Interim &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may publicly disclose interim, top-line or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data has been received and fully evaluated. Top-line or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the top-line or preliminary data we previously published. As a result, top-line and preliminary data should be viewed with caution until the final data are available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:6pt 0pt 12pt 0pt;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the interim, top-line or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, results of operations, prospects or financial condition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our product candidates are subject to extensive regulation, compliance with which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The clinical development, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of our product candidates are subject to extensive regulation by the FDA in the United States and by comparable authorities in foreign markets. In the United States, we are not permitted to market our product candidates until we receive regulatory approval from the FDA. The process of obtaining regulatory approval is expensive, often takes many years and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and patient population. Approval policies or regulations may change, and the FDA and comparable authorities have substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, regulatory approval is never guaranteed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA or comparable foreign regulatory authorities, including in China, can delay, limit or deny approval of a product candidate for many reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such authorities may disagree with the design or implementation of our or any of our existing or potential future collaborators&#8217; clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we or any of our existing or potential future collaborators may be unable to demonstrate to the satisfaction of the FDA or other regulatory authorities that a product candidate is safe, pure, potent or effective for any indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such authorities may not accept clinical data from trials which are conducted at clinical facilities or in countries where the standard of care is potentially different from that of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we or any of our existing or potential future collaborators may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval may be granted only for indications that are significantly more limited than what we apply for and/or with other significant restrictions on distribution and use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such authorities may find deficiencies in the manufacturing processes or facilities of third-party manufacturers with which we or any of our existing or potential future collaborators contract for clinical and commercial supplies; or</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval policies or regulations of such authorities may significantly change in a manner rendering our or any of our existing or potential future collaborators&#8217; clinical data insufficient for approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">With respect to foreign markets, approval procedures vary among countries and, in addition to the foregoing risks, may involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of certain marketed pharmaceuticals may result in increased cautiousness by the FDA and comparable foreign regulatory authorities, including in China, in reviewing new drugs based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our existing or potential future collaborators from commercializing our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are conducting and plan to conduct clinical trials for soquelitinib, ciforadenant and mupadolimab, and we and Angel Pharmaceuticals may in the future conduct additional clinical trials of product candidates at sites outside the United States, and the FDA may not accept data from trials conducted in foreign locations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>We are conducting oncology clinical trials with soquelitinib in North America, Australia and South Korea and with ciforadenant in North America in collaboration with the Kidney Cancer Research Consortium. In addition, Angel Pharmaceuticals has initiated clinical trials in China for soquelitinib and mupadolimab and plans to initiate a clinical trial for ciforadenant. The acceptance of study data from clinical trials conducted outside the U.S. or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, if the trials were not subject to an IND, the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the applicable jurisdiction. If the FDA or such foreign regulatory authority does not accept the data from our or Angel Pharmaceuticals&#8217; clinical trials for soquelitinib, ciforadenant or mupadolimab, or any other product candidates, it would likely result in the need for additional trials, which would be costly and time-consuming and delay or permanently halt our development of soquelitinib, ciforadenant or mupadolimab or any other product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we encounter difficulties enrolling subjects in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, the risk that enrolled patients will not complete a clinical trial, our ability to recruit clinical trial investigators with the appropriate competencies and experience, competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating. We will be required to identify and enroll a sufficient number of subjects for each of our clinical trials. Potential subjects for any planned clinical trials may not be adequately diagnosed or identified with the diseases which we are targeting or may not meet the entry criteria for our studies. We also may encounter difficulties in identifying and enrolling subjects with a stage of disease appropriate for our planned clinical trials. We may not be able to initiate or continue clinical trials if we are unable to locate a sufficient number of eligible subjects to participate in the clinical trials required by the FDA or other foreign regulatory agencies. In addition, the process of finding and diagnosing subjects may prove costly.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If patients are unwilling to participate in our studies for any reason, including the existence of competitive clinical trials for similar patient populations, the availability of approved therapies or negative perceptions of the safety or efficacy of our product candidates, the timeline for recruiting subjects, conducting studies and obtaining regulatory approval of our product candidates may be delayed. Our inability to enroll a sufficient number of subjects for any of our future clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe we have appropriately considered the above factors in our trials when determining expected clinical trial timelines, but we cannot assure our stockholders that our assumptions are correct or that we will not experience delays in enrollment, which would result in the delay of completion of such trials beyond our expected timelines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The occurrence of serious complications or side effects in connection with use of our product candidates, either in clinical trials or post-approval, could lead to discontinuation of our clinical development programs, refusal of regulatory authorities to approve our product candidates or, post-approval, revocation of marketing authorizations or refusal to approve new indications, which could severely harm our business, prospects, results of operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries and discomforts, to their study doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. It is possible that as we test our product candidates in larger, longer and more extensive clinical programs with different dosing regimens and in combination with other immunotherapies, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by subjects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Side effects are often only detectable after investigational products are tested in large-scale, Phase&#160;3 clinical trials or, in some cases, after they are made available to patients on a commercial scale after approval. Results of our current clinical trials and any future clinical trials we undertake could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. Drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw approvals of such product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require additional warnings on the label;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for harm caused to patients; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">A Fast Track designation from the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive regulatory approval. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July 29, 2024, the FDA granted Fast Track designation for soquelitinib for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma after at least two lines of systemic therapy. Depending on the data from our preclinical and clinical studies, we may decide to seek additional Fast Track designations for some or all of our other product candidates. The Fast Track program is intended to expedite or facilitate the process for reviewing product candidates that meet certain criteria. Specifically, drugs and biologics are eligible for Fast Track designation if they are intended, alone or in combination with one or more drugs or biologics, to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a Fast Track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once a BLA or NDA is submitted, the application may be eligible for priority review. An NDA or BLA submitted for a Fast Track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the application on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA or BLA, the FDA agrees to accept sections of the NDA or BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA has broad discretion whether or not to grant this designation. Even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track designation for any of our product candidates, such product candidates may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may also withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Furthermore, such a designation does not increase the likelihood that soquelitinib or any other product candidate that may be granted Fast Track designation will receive regulatory approval in the U.S. Many product candidates that have received Fast Track designation have ultimately failed to obtain approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be successful in our efforts to identify or discover additional product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The success of our business depends primarily upon our ability to develop and commercialize soquelitinib, ciforadenant and mupadolimab. Although soquelitinib, ciforadenant and mupadolimab are currently in clinical development, our research programs may fail to identify other potential product candidates, or advance them into and through clinical development for a number of reasons. Our research methodology may be unsuccessful in identifying other potential product candidates or our other potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval. It may also take greater human and financial resources to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through our research programs than we will possess, thereby limiting our ability to diversify and expand our product candidate portfolio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Reliance on Third Parties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely, and expect to continue to rely, on third parties to conduct our clinical trials. If these third parties do not meet our deadlines or otherwise conduct the trials as required, our clinical development programs could be delayed or unsuccessful and we may not be able to obtain regulatory approval for or commercialize our product candidates when expected, or at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">We do not have the ability to conduct all aspects of our preclinical testing or clinical trials ourselves. As a result, we are dependent on third parties to conduct our ongoing and planned clinical trials for soquelitinib, ciforadenant and mupadolimab and expect to continue to be dependent on third parties to conduct any additional future clinical trials of soquelitinib, ciforadenant and mupadolimab and preclinical and clinical trials for our other product candidates. The timing of the initiation and completion of these trials will therefore be controlled by such third parties and may occur at </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">times substantially different from our estimates. Specifically, we use and rely on medical institutions, clinical investigators, CROs and consultants to conduct our trials in accordance with our clinical protocols and regulatory requirements. Such CROs, investigators and other third parties play a significant role in the conduct of these trials and subsequent collection and analysis of data, and we will control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA, the competent authorities of the EU member states and comparable foreign regulatory authorities for all of our product candidates in clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs or trial sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. In addition, our clinical trials must be conducted with product produced under cGMP or similar regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There is no guarantee that any such CROs, investigators or other third parties will devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed or terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA or foreign regulatory authorities conclude that the financial relationship may have affected the interpretation of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any NDA, BLA or other applications we submit to the FDA or foreign regulatory authorities. Any such delay or rejection could prevent us from commercializing soquelitinib, ciforadenant and mupadolimab or our other product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely on third parties to conduct some or all aspects of our manufacturing, research and preclinical and clinical testing, and these third parties may not perform satisfactorily.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not expect to independently conduct all aspects of our manufacturing, research and preclinical and clinical testing. We currently rely, and expect to continue to rely, on third parties with respect to these items. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our stated study plans and protocols, we may not be able to complete, or may be delayed in completing, the preclinical and clinical studies required to support future IND or other submissions and approval of our product candidates. Furthermore, any of these third parties may terminate its engagement with us at any time. If we need to enter into alternative arrangements, it could delay our product development activities, and we may not be able to negotiate alternative arrangements on commercially reasonable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We and our contract manufacturers are subject to significant regulation with respect to manufacturing our products and the contract manufacturers on which we rely may not continue to meet regulatory requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not currently have nor do we plan to acquire the infrastructure or internal capability to manufacture our clinical drug supplies for use in the conduct of our trials, and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. We currently rely on several different manufacturers who supply different parts of the ciforadenant and soquelitinib molecules, on one manufacturer for mupadolimab drug substance and on other third-party manufacturers to produce our other product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All entities involved in the preparation of therapeutics for clinical studies or commercial sale, including our existing contract manufacturers for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical studies must be manufactured in accordance with cGMP requirements. These regulations govern manufacturing processes and procedures, including record keeping, and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of an NDA or BLA on a timely basis and must adhere to the FDA&#8217;s Good Laboratory Practice regulations and cGMP regulations enforced by the FDA through its facilities inspection program. Our facilities and quality systems and the facilities and quality systems of some or all of our third-party contractors must successfully complete a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates or any of our other potential products. In addition, the regulatory authorities may, at any time, audit or inspect our manufacturing facilities or those of our third-party contractors involved with the preparation of our product candidates or the associated quality systems for compliance with the regulations applicable to the activities being conducted. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with cGMPs. Similar requirements must be complied with in foreign jurisdictions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The regulatory authorities also may, at any time following approval of a product for sale, audit the manufacturing facilities of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement and that may include the temporary or permanent suspension of a clinical study or commercial sales or the temporary or permanent closure of a facility. Such violations could also result in civil and/or criminal penalties, and the FDA or foreign regulatory authorities may impose regulatory sanctions including, among other things, refusal to approve a pending application for a new drug product or biologic product, revocation of a pre-existing approval or closing one or more manufacturing facilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, if supply from an approved manufacturer is interrupted, there could be a significant disruption in commercial supply. An alternative manufacturer would need to be qualified through an NDA or BLA supplement which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Changing manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We, or our third-party manufacturers, may be unable to successfully scale-up manufacturing of our product candidates in sufficient quality and quantity, which would delay or prevent us from developing our product candidates and commercializing approved products, if any.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In order to conduct clinical trials of our product candidates, we will need to manufacture them in large quantities. We, or any manufacturing partners, may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If we or any manufacturing partners are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing and clinical trials of that product candidate may be delayed or become infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the supply chain for the manufacturing of our product candidates is complicated and can involve several parties. If we were to experience any supply chain issues, our product supply could be seriously disrupted. We expect that the logistical challenges associated with our supply chain will grow more complex as we expand enrollment in our clinical trials for soquelitinib, ciforadenant and mupadolimab and as we commence any clinical trials for additional product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because we rely on third parties to research and develop and to manufacture our product candidates, we must share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s independent discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. For example, any academic institution that we may collaborate with in the future will likely expect to be granted rights to publish data arising out of such collaboration. In the future we may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Commercialization of Our Product Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to commercialize our product candidates or if we experience significant delays in obtaining regulatory approval for, or commercializing, any or all of our product candidates, our business will be materially and adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ability to generate product revenue will depend heavily on our ability to successfully develop and commercialize our product candidates. We do not expect that such commercialization of any of our product candidates will occur for at least the next few years, if ever. Our ability to commercialize our product candidates effectively will depend on several factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful completion of preclinical studies and clinical trials, including the ability to demonstrate safety and efficacy of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">managing the complexity of our clinical trial designs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt of marketing approvals from the FDA and similar foreign regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing commercial manufacturing capabilities by making arrangements with third-party manufacturers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully launching commercial sales of any approved products, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of any approved products by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing market share while competing with other therapies;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a continued acceptable safety profile of any approved products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining compliance with post-approval regulation and other requirements; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">qualifying for, identifying, registering, maintaining, enforcing and defending intellectual property rights and claims covering our product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we experience significant delays or an inability to commercialize our product candidates, our business, financial condition and results of operations will be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our products may be delayed and, as a result, our stock price may decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials and the submission of regulatory filings. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones will be based on a variety of assumptions, and the actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet these milestones as publicly announced, the commercialization of our products may be delayed and, as a result, our stock price may decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any approved products could be subject to restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Following potential approval of any of our product candidates, the FDA or foreign regulatory authorities may impose significant restrictions on a product&#8217;s indicated uses or marketing or impose ongoing requirements for potentially costly and time consuming post-approval studies, post-market surveillance or clinical trials. Following approval, if any, of soquelitinib, ciforadenant and mupadolimab or any other product candidate, such candidate will also be subject to ongoing FDA or foreign regulatory authorities&#8217; requirements governing the labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, recordkeeping and reporting of safety and other post-market information. If we or a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requesting recall or withdrawal of the product from the market or suspension of manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we or the manufacturing facilities for soquelitinib, ciforadenant and mupadolimab or any other product candidate that may receive regulatory approval, if any, fail to comply with applicable regulatory requirements, a regulatory agency may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issue warning letters or untitled letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek an injunction or impose civil or criminal penalties or monetary fines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspend or withdraw regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspend any ongoing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refuse to approve pending applications or supplements or applications filed by us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspend or impose restrictions on operations, including costly new manufacturing requirements; or</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seize or detain products, refuse to permit the import or export of product or request that we initiate a product recall.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA has the authority to require a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) as part of an NDA or BLA or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. Similar risks exist in foreign jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, if soquelitinib, ciforadenant and mupadolimab or any of our other product candidates is approved, our product labeling, advertising and promotion will be subject to regulatory requirements and continuing regulatory review. The FDA and foreign regulatory authorities strictly regulate the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the FDA or foreign regulatory authorities as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, the FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Disruptions at the&#160;FDA&#160;and other government agencies caused by funding shortages, staff reductions or policy changes could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The ability of the FDA and foreign regulatory authorities to review and/or approve new products can be affected by a variety of factors, including government budget and funding levels, staff reductions, statutory, regulatory, and policy changes, the FDA&#8217;s or foreign regulatory authorities&#8217; ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s or foreign regulatory authorities&#8217; ability to perform routine functions. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs and biologics or modifications to approved drugs or biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, the U.S. government has shut down several times and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. In addition, the current U.S. Presidential administration has issued certain policies and Executive Orders directed towards reducing the employee headcount and costs associated with U.S. administrative agencies, including the FDA, and it remains unclear the degree to which these efforts may limit or otherwise adversely affect the FDA&#8217;s ability to conduct routine activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If a prolonged government shutdown occurs, or if funding shortages, staffing reductions or policy changes prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, such events could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we receive regulatory approval we still may not be able to successfully commercialize soquelitinib, ciforadenant and mupadolimab or any other product candidate, and the revenue that we generate from sales, if any, could be limited.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if soquelitinib, ciforadenant and mupadolimab or any of our other product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors or the medical community. The degree of market acceptance of our product candidates will depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">demonstration of clinical efficacy and safety compared to other more-established products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the indications for which our product candidates are approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the limitation of our targeted patient population and other limitations or warnings contained in any FDA-approved labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of a new formulation by healthcare providers and their patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain sufficient third-party coverage and reimbursement from government healthcare programs, including Medicare and Medicaid, private health insurers and other third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of patients to pay out-of-pocket in the absence of third-party coverage and reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any adverse effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pricing and cost-effectiveness;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of market introduction of our product candidates as well as competitive drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effectiveness of our or any of our existing or potential future collaborators&#8217; sales and marketing strategies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unfavorable publicity relating to the product candidate.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors or patients, we may not generate sufficient revenue from that product candidate and may not become or remain profitable. Our efforts to educate the medical community and third-party payors regarding the benefits of soquelitinib, ciforadenant and mupadolimab or any of our other product candidates may require significant resources and may never be successful.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Successful commercial sales of any approved products will depend on the availability of adequate coverage and reimbursement from government health administration authorities, private health insurers and other third-party payors. Each third-party payor separately decides which products it will cover and establishes the reimbursement level, and there is no guarantee that any of our product candidates that may be approved for marketing by regulatory authorities will receive adequate coverage or reimbursement levels. Obtaining and maintaining coverage approval for a product candidate is time-consuming, costly and may be difficult. We may be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of coverage and reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or limited, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for drugs and biologics. Even if we obtain coverage for a given product, the resulting reimbursement rates may be inadequate and may affect the demand for, or the price of, any product candidate for which we obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize our product candidates and affect the prices we may obtain.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system, including cost-containment measures that may reduce or limit coverage and reimbursement for newly approved drugs and biologics and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For example, in March&#160;2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively referred to as the &#8220;ACA&#8221;), was enacted with a goal of reducing the cost of healthcare and substantially changing the way healthcare is financed by both governmental and private insurers. The ACA, among other things, subjected biological products to potential competition by lower-cost biosimilars; addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program; extended the rebate program to individuals enrolled in Medicaid managed care organizations; established annual fees and taxes on manufacturers of certain prescription drugs; and established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities and conduct comparative clinical effectiveness research, along with funding for such research.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Other legislative changes have been proposed and adopted in the U.S. since the ACA was enacted. On March 11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminated the statutory Medicaid drug rebate cap, beginning January 1, 2024. The rebate was previously capped at 100% of a drug&#8217;s average manufacturer price (&#8220;AMP&#8221;). On August 16, 2022, the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare, with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (which began in 2025). The IRA permits the Secretary of the Department of Health and Human Services (&#8220;HHS&#8221;) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has issued and will continue to issue guidance implementing the IRA. CMS has published the negotiated prices for the initial ten drugs, which went into effect in 2026, and the subsequent 15 drugs, which will first be effective in 2027, as well as the next set of 15 drugs that will be subject to negotiation, although the Medicare drug price </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">negotiation program is currently subject to legal challenges. While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The One Big Beautiful Bill Act, which was enacted in July 2025, imposes significant reductions in the funding of the Medicaid program. Such reductions are expected to decrease the number of persons enrolled in Medicaid and reduce the services covered by Medicaid, which could adversely affect our sales of any product candidate that we may commercialize.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Trump administration is pursuing a two-fold strategy to reduce drug costs in the U.S. President Trump has threatened to impose significant tariffs on pharmaceutical manufacturers that do not adopt pricing policies such as most favored nation pricing, which would tie the price for drugs in the U.S. to the lowest price in a group of other countries. In response, multiple manufacturers entered into confidential pricing agreements with the federal government. In April 2026, the Trump administration issued a proclamation imposing tariffs on imports of patented pharmaceuticals, biologics and associated ingredients into the U.S., beginning July 31, 2026. Any manufacturers that entered into a company-specific agreement with the government prior to the proclamation will not be subject to any additional tariffs until January 20, 2029. The Trump administration is also pursuing traditional regulatory pathways to impose drug pricing policies, and published two proposed regulations in December 2025, referred to as Globe and Guard. If finalized, these regulations would implement mandatory payment models under which manufacturers of eligible drugs would be required to pay rebates to the federal government on a portion of the units of their drugs that are reimbursed by Medicare, with the rebate amount based on most favored nation pricing. While the impact of the Globe and Guard proposed regulations, if finalized, cannot yet be determined, it is likely to be significant. Even proposals or executive actions that are ultimately deemed unlawful could negatively impact the U.S. pharmaceutical sector and our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure, drug price reporting and other transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Some states have enacted legislation creating so-called prescription drug affordability boards, which ultimately may attempt to impose price limits on certain drugs in these states.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect that these new laws and other healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the EU, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved. In markets outside of the United States and EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. Further, EU pharmaceutical legislation is currently undergoing a complete review process, with proposed revisions not expected to become applicable prior to the end of 2027. These revisions may have a significant impact on the pharmaceutical industry and our business in the long term.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 13, 2021, Regulation No 2021/2282 on Health Technology Assessment (&#8220;HTA&#8221;) amending Directive 2011/24/EU, was adopted. The Regulation entered into force in January 2022 and has been applicable since January 2025, with phased implementation based on the type of product, i.e., oncology and advanced therapy medicinal products as of 2025, orphan medicinal products as of 2028, and all other medicinal products by 2030. The Regulation intends to boost cooperation among EU member states in assessing health technologies, including new medicinal products, and provide the basis for cooperation at the EU level for joint clinical assessments in these areas. It will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the highest potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, and ethical) aspects of health technology, and making decisions on pricing and reimbursement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States, the EU or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The ACA includes a subtitle called the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until twelve years from the date on which the reference product was first licensed. During this twelve-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Mupadolimab, which we evaluated in a Phase&#160;1/1b oncology clinical trial is regulated by the FDA as a biological product. We believe that mupadolimab and any of our future product candidates, if approved as a biological product under a BLA, should qualify for the twelve-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Jurisdictions in addition to the United States have established abbreviated pathways for regulatory approval of biological products that are biosimilar to earlier approved reference products. For example, the EU has had an established regulatory pathway for biosimilars since 2006. Moreover, the extent to which a biosimilar, once approved, could be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products will depend on a number of marketplace factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may fail to obtain orphan drug designations from the FDA for our product candidates, and even if we obtain such designations, we may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug or biologic intended to treat a rare disease or condition, which is defined as one occurring in a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug or biologic will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">orphan drug exclusivity, which means that the FDA may not approve any other applications, including a full NDA or BLA, to market the same drug or biologic for the same approved indication or use within such disease or condition for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity in the relevant indication or where the manufacturer is unable to assure sufficient product quantity to meet the needs relating to the approved indication or use of patients with the relevant disease or condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 7, 2024, the FDA granted orphan drug designation for soquelitinib for the treatment of T cell lymphoma. We also believe many of the targeted indications of our other product candidates could qualify for orphan drug designation. As a result, we may seek to obtain additional orphan drug designations in the future. Even if we obtain such designations, we may not be the first to obtain marketing approval of our product candidate for the orphan-designated disease or condition due to the uncertainties associated with developing pharmaceutical products. In addition, exclusive marketing rights in the United States may be limited if we seek approval for a disease or condition broader than the orphan-designated disease or condition or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs relating to the approved indication or use of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same indications and uses. Even after an orphan product is approved, the FDA can subsequently approve the &#8220;same drug,&#8221; as defined by the FDA, for the same indication or use if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval process. In addition, while we may seek orphan drug designation for our other product candidates, we may never receive such designations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because we have limited financial and managerial resources, we are currently focusing on soquelitinib and ciforadenant. As a result, we may forgo or delay pursuit of opportunities with other product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may form additional strategic alliances and collaborative partnerships in the future, and we may not realize the benefits of such alliances.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may form strategic alliances, create joint ventures or collaborations or enter into licensing arrangements with third parties that we believe will complement or augment our existing business, including for the continued development or commercialization of our product candidates. These relationships may result in or include non-recurring and other charges, increased near- and long-term expenditures, the issuance of securities that dilute our existing stockholders or disruptions to our management and business. In addition, we face significant competition in seeking appropriate strategic partners, and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because third parties may view the risk of failure in future clinical trials as too significant or the commercial opportunity for our product candidates as too limited. We cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Even if we are successful in our efforts to establish strategic alliances or collaborative partnerships, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such strategic alliances or collaborative partnerships if, for example, development or approval of a product candidate is delayed, the safety of a product candidate is questioned or sales of an approved product candidate are unsatisfactory. In addition, any existing or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">potential future strategic alliances or collaborative partnerships may be terminable by our strategic partners, and we may not be able to adequately protect our rights under these agreements. Furthermore, strategic partners may negotiate for certain rights to control decisions regarding the development and commercialization of our product candidates, if approved, and may not conduct those activities in the same manner as we do. Any termination of strategic alliances or collaborative partnerships we enter into in the future, or any delay in entering into collaborative partnership agreements related to our product candidates, could delay the development and commercialization of our product candidates and reduce their competitiveness if they reach the market, which could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2020, we formed Angel Pharmaceuticals with a group of investors in China to create a new China-based biopharmaceutical company with a mission to bring innovative quality medicines to Chinese patients for treatment of serious diseases including cancer, autoimmune diseases and infectious diseases. We granted Angel Pharmaceuticals a license to rights to develop and commercialize our three clinical-stage candidates &#8211; soquelitinib, ciforadenant and mupadolimab &#8211; in greater China and obtained global rights to our BTK inhibitor preclinical programs. While certain of our executive officers and directors will initially be on the board of directors of Angel Pharmaceuticals, we have limited control over it and so we will be subject to many of the same risks set forth above with respect to all collaborations. Additionally, any actions taken by the Chinese government to implement trade policy changes, financial restrictions, or increased regulatory scrutiny on U.S. companies could negatively impact Angel Pharmaceuticals. For instance, China has previously taken or threatened to take trade and other actions in retaliation against U.S. policies, and is likely to continue to do so. Past or future developments in this regard may have a material adverse effect on the economies, financial markets, and currency exchange rates in China and the United States. Tensions between the United States and China have increased over the past few years as a result of disputes in areas including trade policy, intellectual property, cybersecurity and data privacy, due to the current U.S. Presidential Administration&#8217;s imposition of tariffs and other trade controls, as well as due to geopolitical conflicts such as the war between Ukraine and Russia and conflicts or tensions in the Middle East and Venezuela. Our interests in Angel Pharmaceuticals could be harmed if relations between the United States and China worsen or if either government imposes additional policies, tariffs or sanctions and our business could encounter increased regulatory scrutiny in China, as well as adverse media or public attention in China, as a result of the deteriorating bilateral relationship.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Angel Pharmaceuticals will also be subject to many of the same risks that are set forth in this &#8220;Risk Factors&#8221; section pertaining to operations, government regulation, and intellectual property, which may adversely affect Angel Pharmaceuticals&#8217; ability to develop and commercialize products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We face competition from entities that have developed or may develop product candidates for cancer and immune diseases, including companies developing novel treatments and technology platforms. If these companies develop technologies or product candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize product candidates may be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our competitors have developed, are developing or will develop product candidates and processes competitive with our product candidates. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments that enter the market. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop product candidates. In particular, there is intense and rapidly evolving competition in the immunology therapeutics field. Our competitors include larger and better funded pharmaceutical, biopharmaceutical, biotechnological and therapeutics companies. Moreover, we also compete with universities and other research institutions that may be active in oncology research and could be in direct competition with us. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites, registering subjects for clinical trials and in identifying and in-licensing new product candidates. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In oncology, there are large pharmaceutical companies with approved products or products in late-stage development that target kinases and immune checkpoints. There is also intense competition in the areas of inflammation </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">and autoimmune diseases. Several drugs and biologics have been approved or are in late stage development for treatment of atopic dermatitis and other inflammatory diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cancer therapies are sometimes characterized as first-line, second-line or third-line, which refers to the number of prior therapies required to be used prior to administration of the relevant therapy, and the FDA commonly approves new therapies initially for later-line uses. When cancer is detected early enough, first line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever first-line therapy, usually chemotherapy, hormone therapy, surgery or a combination of these, proves unsuccessful, second-line therapy may be administered. Second-line therapies often consist of more chemotherapy, radiation, antibody drugs, tumor targeted small molecules or a combination of these. Third-line therapies can include bone marrow transplantation, antibody and small molecule targeted therapies, more invasive forms of surgery and new technologies. In markets with approved therapies, we expect to initially seek approval of our product candidates as a later stage therapy for patients who have failed other approved treatments. Subsequently, for those drugs that prove to be sufficiently beneficial, if any, we would expect to seek approval as a second-line therapy and potentially as a first-line therapy, but there is no guarantee that our product candidates, even if approved, would be approved for second-line or first-line therapy. In addition, we may have to conduct additional clinical trials prior to gaining approval for second-line or first-line therapy. Similarly, products to treat immune diseases may be indicated for early stage or more advanced recurrent diseases. In dermatology, treatments may be administered by topical or systemic routes. Our products may require additional clinical trials to gain approval for these additional indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our projections of both the number of people who have the cancers and immune diseases that we are targeting, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. In addition, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. Even if we obtain significant market share for our product candidates, we may never achieve profitability without obtaining regulatory approval for additional indications, including use as a first or second-line therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have no sales, marketing or distribution capabilities, and we may have to invest significant resources to develop these capabilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">We have no internal sales, marketing or distribution capabilities. If soquelitinib, ciforadenant and mupadolimab or any of our other product candidates ultimately receives regulatory approval, we may not be able to effectively market and distribute the product candidate. We may have to seek collaborators or invest significant amounts of financial and management resources to develop internal sales, distribution and marketing capabilities, some of which will be committed prior to any confirmation that soquelitinib, ciforadenant and mupadolimab or any of our other product candidates will be approved, if at all. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms or at all. Even if </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">we determine to perform sales, marketing and distribution functions ourselves, we could face a number of additional related risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to attract and build an effective marketing department or sales force;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of establishing a marketing department or sales force may exceed our available financial resources and the revenue generated by soquelitinib, ciforadenant and mupadolimab or any other product candidates that we may develop, in-license or acquire; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our direct sales and marketing efforts may not be successful.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Governments may impose price controls, which may adversely affect our future profitability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We intend to seek approval to market our product candidates in both the United States and in foreign jurisdictions. In some foreign countries, particularly in the EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product candidate. To obtain reimbursement or pricing approval in some countries, we may be required to conduct clinical trials to compare the cost-effectiveness of our product candidates to other available therapies, which is time-consuming and costly. If reimbursement of our future products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Business Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our results of operations may fluctuate significantly, which makes our future results of operations difficult to predict and could cause our results of operations to fall below expectations or any guidance we may provide.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our quarterly and annual results of operations may fluctuate significantly, which makes it difficult for us to predict our future results of operations. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and cost of, and level of investment in, research, development and commercialization activities relating to our product candidates, which may change from time to time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">coverage and reimbursement policies with respect to our product candidates, if approved, and potential future drugs that compete with our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of manufacturing our product candidates, which may vary depending on the quantity of production and the terms of our agreements with manufacturers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the level of demand for any approved products (if any), which may vary significantly;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">macroeconomic conditions such as increased interest and inflationary pressures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future accounting pronouncements or changes in our accounting policies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and success or failure of clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual results of operations. As a result, comparing our results of operations on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or results of operations fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are dependent on the services of our President and Chief Executive Officer, Richard A. Miller, M.D., and other key executives, and if we are not able to retain these members of our management or recruit additional management, clinical and scientific personnel, our business will suffer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are dependent on the principal members of our management and scientific staff. The loss of service of any of our management could harm our business. In addition, we are dependent on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. If we are not able to retain our management, particularly our President and Chief Executive Officer, Dr.&#160;Miller, and to attract, on acceptable terms, additional qualified personnel necessary for the continued development of our business, we may not be able to sustain our operations or grow. Although we have executed employment agreements with each member of our current executive management team, including Dr.&#160;Miller, these agreements are terminable at will with or without notice and, therefore, we may not be able to retain their services as expected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We will need to expand and effectively manage our managerial, operational, financial and other resources in order to successfully pursue our clinical development and commercialization efforts. We may not be able to attract or retain qualified management and scientific and clinical personnel in the future due to the intense competition for qualified personnel among pharmaceutical, biotechnology and other businesses, particularly in the San Francisco Bay Area. Our industry has experienced a high rate of turnover of management personnel in recent years. If we are not able to attract, integrate, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, we do not currently maintain &#8220;key person&#8221; life insurance on the lives of our executives or any of our employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may encounter difficulties in managing our growth and expanding our operations successfully.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We will need to grow our organization substantially to continue development and pursue the potential commercialization of soquelitinib, ciforadenant and mupadolimab and our other product candidates. As we seek to advance soquelitinib, ciforadenant and mupadolimab and other product candidates, we will need to expand our financial, development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with various strategic partners, suppliers and other third parties. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to various federal and state healthcare laws and regulations, and our failure to comply with these laws and regulations could harm our results of operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Although we do not currently have any products on the market, if we obtain FDA or foreign approval for any of our product candidates and begin commercializing those products in the United States or abroad, our operations may be </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">directly, or indirectly through our customers and third-party payors, subject to various U.S. federal, state and foreign healthcare laws and regulations. These laws will affect our operations, sales and marketing practices, and our relationships with physicians and other customers and third-party payors. Such laws include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal False Claims Act, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; in addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Physician Payment Sunshine Act, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the government information related to payments or other &#8220;transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiology assistants and certified nurse midwives) and teaching hospitals, and requires applicable manufacturers and group purchasing organizations to report annually to the government ownership and investment interests held by the physicians described above and their immediate family members. Manufacturers are required to submit reports to the government by the 90th day of each calendar year; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; and state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Ensuring that our internal operations and business arrangements with third-parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of such laws or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We and our current and any existing or future collaborators, third-party manufacturers and suppliers will or may use biological materials and may use hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We and our current and any existing or future collaborators, third-party manufacturers or suppliers will or may use biological materials and may use hazardous materials, including chemicals and biological agents and compounds that could be dangerous to human health and safety of the environment. Our operations and the operations of our third-party manufacturers and suppliers also produce hazardous waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product development efforts. In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. In the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of soquelitinib, ciforadenant and mupadolimab or our other product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We face an inherent risk of product liability as a result of the clinical testing of soquelitinib, ciforadenant and mupadolimab, and the planned clinical testing of our other product candidates and will face an even greater risk if we commercialize our product candidates. For example, we may be sued if soquelitinib, ciforadenant and mupadolimab or our other product candidates allegedly cause injury or are found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or cease the commercialization of our product candidates. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for soquelitinib, ciforadenant and mupadolimab or our other product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injury to our reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a diversion of management&#8217;s time and our resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to trial participants or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize soquelitinib, ciforadenant and mupadolimab or our other product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decline in our stock price.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have product liability insurance coverage in an amount and on terms and conditions that are customary for similarly situated companies and that are satisfactory to our board of directors. Our inability to retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of soquelitinib, ciforadenant and mupadolimab or our other product candidates. Although we plan to maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies will also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We and any of our existing or potential future collaborators will be required to report to regulatory authorities if any products that may be approved in the future cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we and any of our existing or potential future collaborators are successful in commercializing our products, the FDA and foreign regulatory authorities would require that we and any of our existing or potential future collaborators report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We and any of our existing or potential future collaborators or CROs may fail to report adverse events within the prescribed timeframe. If we or any of our existing or potential future collaborators or CROs fail to comply with such reporting obligations, the FDA or a foreign regulatory authority could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of our products or delay in approval or clearance of future products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct involving the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of fines and other sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions of licenses granted to us by other companies. The patent protection, prosecution and enforcement for some of our product candidates may be dependent on third parties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">We currently are heavily reliant upon licenses of certain patent rights and proprietary technology from third parties that is important or necessary to the development of our technology and products, including technology related to our product candidates. For example, we rely on our license agreement with Vernalis for rights with respect to the intellectual property covering ciforadenant. Further, we rely on our license agreement with The Scripps Research Institute for rights related to our lead development candidate for our anti-CD73 program, mupadolimab. These and other licenses we may enter into in the future may not provide adequate rights to use such intellectual property and technology </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">in all relevant fields of use or in all territories in which we may wish to develop or commercialize our technology and products in the future. As a result, we may not be able to develop and commercialize our technology and products in fields of use and territories for which we are not granted rights pursuant to such licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Licenses to additional third-party technology that may be required for our development programs may not be available in the future or may not be available on commercially reasonable terms, which could have a material adverse effect on our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In some circumstances, we may not have the right to control the preparation, filing, prosecution and enforcement of patent applications, or to maintain the patents, covering technology that we license from third parties. In addition, some of our agreements with our licensors require us to obtain consent from the licensor before we can enforce patent rights, and our licensor may withhold such consent or may not provide it on a timely basis. Therefore, we cannot be certain that our licensors or collaborators will prosecute, maintain, enforce and defend such intellectual property rights in a manner consistent with the best interests of our business, including by taking reasonable measures to protect the confidentiality of know-how and trade secrets, or by paying all applicable prosecution and maintenance fees related to intellectual property registrations for any of our product candidates. We also cannot be certain that our licensors have drafted or prosecuted the patents and patent applications licensed to us in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could cause us to lose rights in any applicable intellectual property that we in-license, and as a result our ability to develop and commercialize products or product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product candidates, proprietary technologies and their uses as well as our ability to operate without infringing upon the proprietary rights of others. We generally seek to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates, proprietary technologies and their uses that are important to our business. There can be no assurance that our patent applications or those of our licensors will result in additional patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents issued will not be infringed, designed around or invalidated by third parties. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. This failure to properly protect the intellectual property rights relating to our product candidates could have a material adverse effect on our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While we have rights to issued composition-of-matter patents in the United States and corresponding issued patents in certain foreign territories covering soquelitinib, mupadolimab and ciforadenant, we cannot be certain that the claims in any of our patent applications covering composition-of-matter of our other product candidates will be considered patentable by the United States Patent and Trademark Office (&#8220;USPTO&#8221;), courts in the United States or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our issued composition-of-matter patents will not be found invalid or unenforceable if challenged.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our existing or potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patent applications may not result in any patents being issued;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use and sell our potential product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The patent prosecution process is also expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents, if issued, or the patent rights that we license from others, may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical products, or limit the duration of the patent protection of our products and product candidates. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In addition, we rely on the protection of our trade secrets, including unpatented know-how, technology and other proprietary information to maintain our competitive position. Although we have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors. Despite these efforts, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates and future approved products or impair our competitive position. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, reexaminations, inter partes review (&#8220;IPR&#8221;) proceedings and post-grant review (&#8220;PGR&#8221;) proceedings before the USPTO and/or corresponding foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. As the biotechnology industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published we may be unaware of third-party patent applications that, if issued as patents, may be infringed by commercialization of soquelitinib, ciforadenant and mupadolimab or our other product candidates, and we cannot be certain that we were the first to file&#160;a patent application related to a product candidate or technology. Moreover, because patent applications can take many years to issue, there may be currently-pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. Any claims of patent infringement asserted by third parties would be time consuming and could:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">result in costly litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">divert the time and attention of our technical personnel and management;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cause development delays;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prevent us from commercializing soquelitinib, ciforadenant and mupadolimab or our other product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require us to develop non-infringing technology, which may not be possible on a cost-effective basis; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although no third party has asserted a claim of patent infringement against us as of the date of this Annual Report on Form 10-K, others may hold proprietary rights that could prevent soquelitinib, ciforadenant and mupadolimab or our other product candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities relating to our product candidates or processes could subject us to potential liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or market soquelitinib, ciforadenant and mupadolimab or our other product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. Moreover, even if we or our future strategic partners were able to obtain a license, the rights may be </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">nonexclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we cannot be certain that we could redesign our product candidates or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing soquelitinib, ciforadenant and mupadolimab or our other product candidates, which could harm our business, financial condition and results of operations. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity and could prohibit us from marketing or otherwise commercializing our product candidates and technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Competitors may infringe our intellectual property rights or those of our licensors. To prevent infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in a patent infringement proceeding, a court may decide that a patent we own or in-license is not valid, is unenforceable and/or is not infringed. If we or any of our existing or potential future collaborators were to initiate legal proceedings against a third party to enforce a patent directed at one of our product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before the USPTO, even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable, and prior art could render our patents or those of our licensors invalid. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. Such a loss of patent protection would have a material adverse impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Interference proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring our product candidates to market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September&#160;16, 2011, the Leahy-Smith America Invents Act (&#8220;Leahy-Smith Act&#8221;) was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March&#160;2013 to a &#8220;first to file&#8221; system in which the first inventor to file&#160;a patent application will be entitled to the patent. Third parties are allowed to submit prior art before the issuance of a patent by the USPTO, and may become involved in post-grant proceedings including opposition, derivation, reexamination, inter-partes review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently have rights to the intellectual property, through licenses from third parties and under patents that we own, to develop our product candidates. Because our programs may require the use of proprietary rights held by third parties, the growth of our business will depend in part on our ability to acquire, in-license or use these proprietary rights. For example, our product candidates may require specific formulations to work effectively and efficiently and the rights to these formulations may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have collaborated with U.S. academic institutions and may in the future collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements with these institutions. These institutions may provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of that program and our business and financial condition could suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may fail to comply with any of our obligations under existing agreements pursuant to which we license or have otherwise acquired intellectual property rights or technology, which could result in the loss of rights or technology that are material to our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. We are party to various agreements that we depend on for rights to use various technologies that are material to our business, including intellectual property rights covering ciforadenant and methods relating to its use and manufacture. In each of these cases, our rights to use the licensed intellectual property are subject to the continuation of and our compliance with the terms of these agreements. Disputes may arise regarding our rights to intellectual property licensed to us from a third party, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sublicensing of patent and other rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ownership of inventions and know-how resulting from the creation or use of intellectual property by us, alone or with our licensors and collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope and duration of our payment obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our rights upon termination of such agreement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope and duration of exclusivity obligations of each party to the agreement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If disputes over intellectual property and other rights that we have licensed or acquired from third parties prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. If we fail to comply with our obligations under current or future licensing agreements, these agreements may be terminated or the scope of our rights under them may be reduced and we might be unable to develop, manufacture or market any product that is licensed under these agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As is common in the pharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other pharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we do not obtain patent term extension for our product candidates, our business may be materially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Depending upon the timing, duration and specifics of potential FDA marketing approval of soquelitinib, ciforadenant, mupadolimab, or other product candidates, one or more of our U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984 (&#8220;Hatch-Waxman Amendments&#8221;). The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, we may not be </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. In addition, Congress may pass patent reform legislation that is unfavorable to us. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While we have issued patents directed at soquelitinib, mupadolimab and ciforadenant in the United States and certain foreign territories, and pending patent applications directed at soquelitinib, ciforadenant, mupadolimab and other product candidates in other foreign countries, filing, prosecuting and defending patents on soquelitinib, ciforadenant, mupadolimab and our other product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">competing products in violation of our proprietary rights. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to make adenosine antagonists that are similar to our product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that our pending patent applications will not lead to issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued patents that we own or have exclusively licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not develop additional proprietary technologies that are patentable; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of others may have an adverse effect on our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Should any of these events occur, they could significantly harm our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">An active, liquid and orderly market for our common stock may not be sustained.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Although our common stock is listed on The Nasdaq Global Market (&#8220;Nasdaq&#8221;), an active trading market for our common stock may not be sustained on Nasdaq or any other exchange in the future. The lack of an active market may impair our stockholders&#8217; ability to sell their shares at the time they wish to sell them or at a price that they consider reasonable. If an active market for our common stock is not sustained, it may also be difficult for our stockholders to sell shares without depressing the market price for the shares or at all. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other businesses, applications or technologies using our shares as consideration, which, in turn, could materially adversely affect our business. In any event, we have a limited </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">public float and, as a result, our common stock has been and will likely continue to be less liquid than many other listed companies and trading may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The trading price of the shares of our common stock could be highly volatile, and investors in our common stock could incur substantial losses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our stock price has been volatile. The stock market in general and the market for stock of pharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by those factors discussed in this &#8220;Risk Factors&#8221; section and many others, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to enroll subjects in our planned clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of the clinical trials, and the results of trials of our competitors or those of other companies in our market sector;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory approval of soquelitinib, ciforadenant, mupadolimab and our other product candidates, or limitations to specific label indications or patient populations for its use, or changes or delays in the regulatory review process;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Angel Pharmaceuticals&#8217; ability to develop and commercialize product candidates in China;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory developments in the United States and foreign countries; including changes in the policies of the U.S. or Chinese governments resulting in sanctions instituted by either government;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the structure of healthcare payment systems, especially in light of current reforms to the U.S. healthcare system;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success or failure of our efforts to acquire, license or develop additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">innovations or new products developed by us or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing, supply or distribution delays or shortages;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes to our relationship with any manufacturers, suppliers, collaborators or other strategic partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">achievement of product sales and profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">variations in our financial results or those of companies that are perceived to be similar to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market conditions in the pharmaceutical sector and issuance of securities analysts&#8217; reports or recommendations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of political instability, natural disasters, war and/or events of terrorism, such as the military conflict between Ukraine and Russia, and the corresponding tensions created from such conflict between Russia, the United States and countries in Europe as well as other countries such as China, and conflicts and tensions in the Middle East and Venezuela;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading volume of our common stock;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an inability to obtain additional funding on favorable terms, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our stock by insiders and stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic, industry and market conditions, other events or factors such as tariffs, trade controls, interest rates, inflationary pressures and the occurrence of a recession or even depression, many of which are beyond our control;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additions or departures of key personnel; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">intellectual property, product liability or other litigation against us.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result of this volatility, investors may experience losses on their investment in our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, in the past, stockholders have initiated class action lawsuits against pharmaceutical companies following periods of volatility in the market prices of these companies&#8217; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to adhere to the listing requirements of the Nasdaq Global Market our common stock could be delisted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are unable to comply with the listing requirements of the Nasdaq Global Market, our stock could be delisted for such failure. If our common stock is delisted from Nasdaq, we could be required to list on the over-the-counter (&#8220;OTC&#8221;) market, which may adversely affect the price and trading liquidity of our common stock. Delisting from the Nasdaq may have other negative results, including the potential loss of confidence in us by employees and partners, the loss of institutional investor interest, fewer business development opportunities and greater difficulty in obtaining financing on favorable terms or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026, our executive officers, directors, holders of 5% or more of our capital stock based on publicly available filings made with the SEC and their respective affiliates beneficially owned approximately 25% of our outstanding common stock. Therefore, these stockholders have the ability to influence us through their ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that our stockholders may feel are in their best interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We do not currently intend to pay dividends on our common stock, and, consequently, our stockholders&#8217; ability to achieve a return on their investment will depend on appreciation, if any, in the price of our common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have never declared or paid any cash dividend on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which stockholders have purchased their shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">reduce the market price of our common stock. Moreover, certain holders of shares of our common stock have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We have registered and intend to continue to register all shares of common stock that we may issue under our equity compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are a smaller reporting company and the reduced reporting requirements applicable to smaller reporting companies may make our common stock less attractive to investors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a smaller reporting company, which allows us to take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not smaller reporting companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (&#8220;Sarbanes-Oxley&#8221;), reduced disclosure obligations regarding executive compensation in our Annual Report and our periodic reports and proxy statements and providing only two years of audited financial statements in our Annual Report and our periodic reports. We will remain a smaller reporting company so long as (a) the aggregate market value of our outstanding common stock held by non-affiliates as of the last business day our most recently completed second fiscal quarter is less than $250 million or (b) (1) we have less than $100 million in annual revenues during our most recently completed fiscal year and (2) the aggregate market value of our outstanding common stock held by non-affiliates as of the last business day our most recently completed second fiscal quarter is less than $700 million. We cannot predict whether investors will find our common stock less attractive if we rely on certain or all of these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile and may decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely consolidated financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to Section&#160;404 of Sarbanes-Oxley, if and when we no longer qualify as a smaller reporting company, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules&#160;governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To continue to comply with the requirements of being a reporting company under the Exchange Act, as we continue to grow, we will need to upgrade our systems including information technology; implement additional financial and management controls, reporting systems and procedures; and hire additional accounting and finance staff. If we or, if required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot assure our stockholders that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begin its Section&#160;404 reviews, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could significantly reduce the value of our shares to a potential acquiror or delay or prevent changes in control or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">changes in our management without the consent of our board of directors. The provisions in our charter documents include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the exclusive right of our board of directors, unless the board of directors grants such right to the stockholders, to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the required approval of at least 66 2/3% of the shares entitled to vote to remove a director for cause, and the prohibition on removal of directors without cause;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the required approval of at least 66 2/3% of the shares entitled to vote to adopt, amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an exclusive forum provision providing that the Court of Chancery of the State of Delaware will be the exclusive forum for certain actions and proceedings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the requirement that a special meeting of stockholders may be called only by the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of us.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are also subject to the anti-takeover provisions contained in Section&#160;203 of the Delaware General Corporation Law. Under Section&#160;203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine. This provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. Alternatively, if a court were to find this provision in our amended and restated certificate of incorporation and amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition. This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General Risks</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such regulatory approvals for any of our product candidates. To obtain separate regulatory approval in many other countries we must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among other things, clinical trials, commercial sales, pricing and distribution of our product candidates. If we obtain regulatory approval of our product candidates and ultimately commercialize our product candidates in foreign markets, we would be subject to additional risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and the reduced protection of intellectual property rights in some foreign countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes to applicable U.S. or foreign tax laws and regulations may have a material adverse effect on our business, financial condition and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are subject to evolving and complex tax laws in the United States and the foreign jurisdictions in which we operate. New income, sales, use or other tax laws, statutes, rules, regulations, or ordinances could be enacted at any time, or interpreted, changed, modified, or applied adversely to us, any of which could adversely affect our business operations and financial performance. We expect the scope and extent of regulation in the jurisdictions in which we conduct our business, or where our management is located, as well as regulatory oversight and supervision, to generally continue to increase. Generally, future changes in applicable U.S. or foreign tax laws and regulations, or their interpretation and application could have an adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our information technology systems, or those of any of our existing or potential future collaborators, CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">We maintain sensitive company data on our information technology systems, including our intellectual property, proprietary business information, clinical trial data, and personal information (collectively, &#8220;Confidential Information&#8221;) of customers and our employees and contractors. We face a number of threats to our networks from unauthorized access, security breaches and other system disruptions. Despite the implementation of security measures, our information technology and other internal computer systems and those of our current and any future CROs and other </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">contractors, consultants and collaborators are vulnerable to damage from cyberattacks, &#8220;phishing&#8221; attacks, computer viruses and malware (e.g., ransomware), malicious code, misconfigurations, &#8220;bugs&#8221; or other vulnerabilities, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures, including from diverse threat actors, such as state-sponsored organizations, opportunistic hackers and hacktivists. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage or disrupt, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques &#8211; including artificial intelligence &#8211; that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. As a result of the continued hybrid working environment, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our and our service providers&#8217; employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. There can also be no assurance that our and our current and future CROs&#8217; and other contractors&#8217;, consultants&#8217; and collaborators&#8217; cybersecurity risk management program and processes, including policies, controls or procedures, will be fully implemented, complied with or effective in protecting our systems, networks and Confidential Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We and certain of our service providers are from time to time, subject to cyberattacks and security incidents. While we do not believe that we have experienced any significant system failure, accident or security breach to date, any such security breach may compromise Confidential Information stored on our networks, or those of our vendors, and may result in significant data losses or theft of our Confidential Information. Further, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, such a breach may require notification to governmental agencies, or affected individuals pursuant to applicable data privacy and security laws. We would also be exposed to a risk of loss, including financial assets or litigation and potential liability, which could materially adversely affect our business, reputation, financial condition, results of operations and prospects. We also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of Confidential Information, we could incur liability and the further development and commercialization of our product candidates could be delayed or otherwise harmed. Any adverse impact to the availability, integrity or confidentiality of our or third-party systems or Confidential Information can result in legal claims or proceedings (such as class actions), regulatory investigations and enforcement actions, fines and penalties, negative reputational impacts that cause us to lose customers, and/or significant incident response, system restoration or remediation and future compliance costs. Our existing general liability and cyber liability insurance policies may not cover, or may cover only a portion of, any potential claims related to security breaches to which we are exposed, or may not be adequate to indemnify us for all or any portion of liabilities that may be imposed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in and failures to comply with U.S. and foreign privacy and data protection laws, regulations and standards may adversely affect our business, operations and financial performance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are subject to or affected by numerous federal, state and foreign laws and regulations, as well as regulatory guidance, governing the collection, use, disclosure, retention, and security of personal data, such as information that we collect about patients and healthcare providers in connection with clinical trials in the United States and abroad. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. This evolution may create uncertainty in our business, affect our or our collaborators&#8217;, service providers&#8217; and contractors&#8217; ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Certain states have also adopted comparable privacy and security laws and regulations, which govern the privacy, processing and protection of health-related and other personal information. Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly obtain, use, or disclose individually identifiable health information that was provided to us by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, the California Consumer Privacy Act, as amended by the California Privacy Rights Act (collectively, the &#8220;CCPA&#8221;) requires covered businesses that process the personal information of California residents to, among other things: provide certain disclosures to California residents regarding the business&#8217;s collection, use, and disclosure of their personal information; receive and respond to requests from California residents to access, delete, and correct their personal information, or to opt out of certain disclosures of their personal information; and enter into specific contractual provisions with service providers that process California resident personal information on the business&#8217;s behalf. Similar laws have been proposed in other states and are continuing to be proposed at the state and federal level, and if passed, such laws may have potentially conflicting requirements that would make compliance challenging.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our operations abroad may also be subject to increased scrutiny or attention from data protection authorities. Many countries in these regions have established or are in the process of establishing privacy and data security legal frameworks with which we, our collaborators, service providers, including our CRO, and contractors must comply. For example, the General Data Protection Regulation (the &#8220;GDPR&#8221;), which went into effect in May 2018, imposes strict requirements for processing the personal data of individuals within the EEA, including clinical trial data. The GDPR has and will continue to increase compliance burdens on us, including by mandating potentially burdensome documentation requirements and granting certain rights to individuals to control how we collect, use, disclose, retain and process information about them. The processing of sensitive personal data, such as physical health condition, may impose heightened compliance burdens under the GDPR and is a topic of active interest among foreign regulators. The GDPR provides for robust regulatory enforcement and fines of up to &#8364;20 million or 4% of the annual global revenue of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EEA and the United States remains uncertain. Case law from the Court of Justice of the European Union (&#8220;CJEU&#8221;) states that reliance on the standard contractual clauses &#8211; a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism &#8211; alone may not necessarily be sufficient in all circumstances and that transfers must be assessed on a case-by-case basis. On July 10, 2023, the European Commission adopted its Adequacy Decision in relation to the new EU-US Data Privacy Framework (&#8220;DPF&#8221;), rendering the DPF effective as a GDPR transfer mechanism to U.S. entities self-certified under the DPF. Additionally, the U.S. Department of Justice recently issued a final rule that went into effect in April 2025, known as the &#8220;Data Security Program&#8221; (the &#8220;DSP Rule&#8221;). The DSP Rule places restrictions, and in some cases prohibitions, on certain transactions that could grant access of sensitive personal data to certain foreign actors with connections to &#8220;countries of concern&#8221;, such as China, which the DSP Rule refers to as &#8220;covered persons,&#8221; and may create operational challenges and legal risks for our business. As regulators issue further guidance on personal data export mechanisms and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines. If we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, from January 1, 2021, we had to comply with the GDPR and the United Kingdom (&#8220;UK&#8221;) GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law, the latter regime having the ability to separately fine up to the greater of &#163;17.5 million or 4% of global turnover. On October 12, 2023, the UK Extension to the DPF came into effect (as approved by the UK Government), as a data transfer mechanism from the UK to U.S. entities self-certified under the DPF.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As we expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us or our collaborators, service </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">providers and contractors to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing processing of personal information could result in negative publicity, diversion of management time and effort and proceedings against us by governmental entities or others. In many jurisdictions, enforcement actions and consequences for noncompliance are rising.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and pandemics, and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our corporate headquarters and laboratory are located in the San Francisco Bay Area. This location has in the past experienced severe earthquakes and other natural disasters. Earthquakes, extreme weather conditions, or other natural disasters, power-shortages, telecommunications failures, fires, medical epidemics and pandemics, and other natural or manmade disasters could severely disrupt our operations or those of our collaboration partners and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure (such as the manufacturing facilities of our third-party contract manufacturers) or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If any of our suppliers of the drug substance we use for the development of our product candidates are unable to provide such drug substance, our business could be disrupted and seriously harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently rely on several different manufacturers who supply different parts of the ciforadenant molecule and soquelitinib molecule, on one manufacturer for mupadolimab drug substance and on other third-party manufacturers to produce our other product candidates. Our ability to obtain clinical supplies of soquelitinib, ciforadenant and mupadolimab or our other product candidates could be disrupted if the operations of these suppliers were affected by a man-made or natural disaster or other business interruption. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses<span style="font-size:12pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our ability to use net operating loss carryforwards and other tax attributes may be limited.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve profitability. Generally, to the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire. As of December 31, 2025, we had federal net operating loss (&#8220;NOL&#8221;) carryforwards of approximately $285.9 million and state NOL carryforwards of approximately $353.7 million available to offset future taxable income. If not utilized, certain of our federal and state NOL carryforwards will begin to expire in various years beginning in 2035. As of December 31, 2025, we also had $11.1 million of federal research and development tax credit, $1.5 million of federal orphan drug credit, and $5.8 million of state research and development tax credit carryforwards available to offset future income taxes. The federal research and development tax credits will begin to expire in 2036, if not utilized. The state research and development tax credits have no expiration date. Utilization of NOL carryforwards and credits may be subject to an annual limitation due to the &#8220;ownership change&#8221; provisions under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;). An &#8220;ownership change&#8221; is generally defined as a cumulative change in stock ownership of certain significant stockholders over a rolling three year period in excess of 50 percentage points by value. Similar provisions under state tax law may also apply. We may have experienced ownership changes in the past, and we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside our control. Such ownership changes could result in the expiration of certain of our NOL carryforwards and other tax attributes before they can be utilized. As a result, even if we attain profitability, we may be unable to use a material portion of our NOL carryforwards and other tax attributes to offset future taxable income.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, under the Tax Act, as modified by the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;), NOL carryforwards arising in tax years beginning after December 31, 2020 are limited to 80% of taxable income. Under the Tax Act, federal NOL carryforwards arising in tax years beginning after December 31, 2017 may be carried forward indefinitely. Under the CARES Act, federal NOL carryforwards arising in tax years beginning after December 31, 2017 and before January 1, 2021 may be carried back to each of the five tax years preceding the tax year of such loss. The changes in the carryforward and carryback periods as well as the limitation on use of NOL carryforwards may significantly impact our ability to use NOL carryforwards, particularly for tax years beginning after December 31, 2020, as well as the timing of any such use, and could adversely affect our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research or reports or publish unfavorable research or reports about our business, our stock price and trading volume could decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our target studies and results of operations fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f1cf53c1_e512_43de_bc79_99062a2f408c"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Item&#160;2.</b>&#160;&#160;&#160;<b style="font-weight:bold;">Unregistered Sales of Equity Securities and Use of Proceeds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recent Sales of Unregistered Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">None</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Proceeds from Registered Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Not applicable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Repurchases of Shares or of Company Equity Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">None</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_196b6bfc_3012_4657_91e2_051c49c40ed0"></a><a id="Item3DefaultsUponSeniorSecurities_526790"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Item</b>&#160;<b style="font-weight:bold;">3.</b>&#160;&#160;&#160;<b style="font-weight:bold;">Defaults Upon Senior Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">None</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2a2ab4c1_8799_4785_9931_ec0c76e44e43"></a><a id="Item4MineSafetyDisclosures_600075"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Item</b>&#160;<b style="font-weight:bold;">4.</b>&#160;&#160;&#160;<b style="font-weight:bold;">Mine Safety Disclosures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Not applicable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_105b73b2_1ad1_465d_b777_9f1f09ffd4af"></a><a id="Item5OtherInformation_876990"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Item</b>&#160;<b style="font-weight:bold;">5.</b>&#160;&#160;&#160;<b style="font-weight:bold;">Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Rule 10b5-1 Trading Arrangements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">During the quarter ended March 31, 2026, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) <ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_fNNH7WRRRkq7CeF6UDCPzg"><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_thvp3Z72Ek-7-0NN5uf_Iw">adopted</ix:nonNumeric></ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" format="ixt:fixed-false" name="crvs:Rule10b51ArrModifiedFlag" id="Narr_ohvm1PZ5fESAxV_aCHSQrw"><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" format="ixt:fixed-false" name="crvs:NonRule10b51ArrModifiedFlag" id="Narr_zMpd8GlMMEe5k0V-GTbxNA">modified</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr_MXS14G6hKEGjkhMXEQmuVQ"><ix:nonNumeric contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_FZKx0mOflE-cWWpWb1WC_w">terminated</ix:nonNumeric></ix:nonNumeric> a &#8220;Rule 10b5-1 trading arrangement&#8221; or a &#8220;non-Rule 10b5-1 trading arrangement&#8221;, as each term is defined in Item 408(a) of Regulation S-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_5649bd21_15bf_46df_8505_40ebb9f31d67"></a><a id="Item6Exhibits_350365"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Item</b>&#160;<b style="font-weight:bold;">6.</b>&#160;&#160;&#160;<b style="font-weight:bold;">Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXHIBIT&#160;INDEX</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style=""><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.91%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.77%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"/></tr><tr style=""><td style="vertical-align:bottom;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:51.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:28.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated&#160;by&#160;Reference</b></p></td><td style="vertical-align:bottom;width:1.04%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="border-bottom-color:transparent;border-bottom-style:solid;border-bottom-width:1px;color:#000000;font-style:normal;font-weight:normal;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;margin-top:0pt;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;text-align:left;vertical-align:bottom;width:8.26%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b></p></td></tr><tr style=""><td style="vertical-align:top;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:top;width:51.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;Description</b></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:top;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:top;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:top;width:8.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:top;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Herewith</b></p></td></tr><tr style=""><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1626971/000110465916108304/a16-7289_1ex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Certificate of Incorporation.</span></a></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">3/29/2016</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1626971/000110465916108304/a16-7289_1ex3d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws.</span></a></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">3/29/2016</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1626971/000110465926027390/tm268518d4_ex1-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Open Market Sale Agreement</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">SM</sup><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, dated March 13, 2026, by and between Corvus Pharmaceuticals, Inc. and Jefferies LLC.</span></a></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">3/13/2026</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">1.1</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;">31.1</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="crvs-20260331xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer required by Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a).</span></a></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">X</p></td></tr><tr style=""><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;">31.2</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="crvs-20260331xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer required by Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a).</span></a></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">X</p></td></tr><tr style=""><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;">32.1*</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="crvs-20260331xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification required by Rule&#160;13a-14(b)&#160;or Rule&#160;15d-14(b)&#160;and Section&#160;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350).</span></a></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">X</p></td></tr><tr style=""><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;">101.INS</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">X</p></td></tr><tr style=""><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document.</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">X</p></td></tr><tr style=""><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;">101.CAL</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">X</p></td></tr><tr style=""><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;">101.DEF</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Inline XBRL Taxonomy Extension Definitions Linkbase Document.</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">X</p></td></tr><tr style=""><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;">101.LAB</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document.</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">X</p></td></tr><tr style=""><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;">101.PRE</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">X</p></td></tr><tr style=""><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The cover page of Corvus Pharmaceuticals, Inc.&#8217;s Quarterly Report on Form 10-Q for the three months ended March 31, 2026, formatted in Inline XBRL (contained in Exhibit 101).</p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">X</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;">The certification attached as Exhibit&#160;32.1 that accompanies this Quarterly Report on Form&#160;10-Q is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Corvus Pharmaceuticals,&#160;Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form&#160;10-Q, irrespective of any general incorporation language contained in such filing.</p></td></tr></table><a id="_013749"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_952feaf0_219a_4dfc_9ece_cd126e43e071"></a><a id="SIGNATURES_676454"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style=""><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">CORVUS PHARMACEUTICALS,&#160;INC.</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Date: May 7, 2026</p></td><td style="vertical-align:bottom;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">/s/ Richard. A. Miller</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Richard A. Miller, M.D.</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">President, Chief Executive Officer and Director</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Date: May 7, 2026</p></td><td style="vertical-align:bottom;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">/s/ Leiv Lea</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Leiv Lea</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Chief Financial Officer</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">(Principal Financial and Accounting Officer)</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>crvs-20260331xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 5/7/2026 12:52:05 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Richard A. Miller, M.D. President and Chief Executive Officer of Corvus Pharmaceuticals,&#160;Inc., certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">1.&#160;&#160;&#160;&#160;I have reviewed this Quarterly Report on Form&#160;10-Q of Corvus Pharmaceuticals,&#160;Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s)&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;">(a)&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;">(b)&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;">(c)&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;">(d)&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s)&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;">(a)&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;">(b)&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:43.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May 7, 2026</p></td><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:43.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Richard A. Miller</p></td></tr><tr style=""><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:43.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Richard A. Miller, M.D. </p></td></tr><tr style=""><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:43.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr style=""><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>crvs-20260331xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 5/7/2026 12:52:05 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Leiv Lea, Chief Financial Officer of Corvus Pharmaceuticals,&#160;Inc., certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">1.&#160;&#160;&#160;&#160;I have reviewed this Quarterly Report on Form&#160;10-Q of Corvus Pharmaceuticals,&#160;Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s)&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;">(a)&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;">(b)&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;">(c)&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;">(d)&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s)&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;">(a)&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;">(b)&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:43.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May 7, 2026</p></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:43.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Leiv Lea</p></td></tr><tr style=""><td style="vertical-align:top;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leiv Lea</p></td></tr><tr style=""><td style="vertical-align:top;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr style=""><td style="vertical-align:top;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal Financial and Accounting Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>crvs-20260331xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 5/7/2026 12:52:05 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION&#160;1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In connection with the Quarterly Report of Corvus Pharmaceuticals,&#160;Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the fiscal quarter ended March 31, 2026, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Richard A. Miller, President and Chief Executive Officer of the Company, and Leiv Lea, Chief Financial Officer of the Company, respectively, do each hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:49.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:50.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Richard A. Miller</p></td><td style="vertical-align:top;width:49.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:50.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Richard A. Miller, M.D.</p></td><td style="vertical-align:top;width:49.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:50.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:top;width:49.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:50.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td><td style="vertical-align:top;width:49.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:50.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:50.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May 7, 2026</p></td><td style="vertical-align:top;width:49.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:50.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:50.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Leiv Lea</p></td><td style="vertical-align:top;width:49.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:50.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leiv Lea</p></td><td style="vertical-align:top;width:49.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:50.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:top;width:49.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:50.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td><td style="vertical-align:top;width:49.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:50.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style=""><td style="vertical-align:top;width:50.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May 7, 2026</p></td><td style="vertical-align:top;width:49.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">This certification accompanies the Report on Form&#160;10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Corvus Pharmaceuticals,&#160;Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Report on Form&#160;10-Q), irrespective of any general incorporation language contained in such filing.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>crvs-20260331x10q007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 crvs-20260331x10q007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %> \L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]0I[J5)G4
M-@ ^E,^VS?W_ -!3;K_CXD^M14$D_P!MF_O_ *"C[;-_?_05!10!/]MF_O\
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M< P7$@SWVR8]:^]_V+#G]DKX1?\ 8MVG_H)H ]IHHHH$%%%% !1110 4444
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M\%!_!_@+0?B+\)_&DMU:Q^.;CQSH,-S)=ZEE[;3HV<Y2%GQ%$64%G"@$KR:
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M&(_,PSL=Y+,0,X[DFNWUW1/BAX=_;7_9T?XG^,?#_B:-UUYK-M%TIK 6RK9
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MVKD+PP!&/TPDSYCYY.XYQ]: &T444""I(_\ 52_0?SJ.I(_]5+]!_.@!@!)
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MV9I__0KWO_@5'_A7RW11_J_EW_/O\7_F'^M>;_\ /W_R6/\ D?4G_#9FG_\
M0KWO_@5'_A1_PV9I_P#T*][_ .!4?^%?+=%'^K^7?\^_Q?\ F'^M>;_\_?\
MR6/^1]2?\-F:?_T*][_X%1_X4?\ #9FG_P#0KWO_ (%1_P"%?+=%'^K^7?\
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M )A_K7F__/W_ ,EC_D?4G_#9FG_]"O>_^!4?^%'_  V9I_\ T*][_P"!4?\
MA7RW11_J_EW_ #[_ !?^8?ZUYO\ \_?_ "6/^1]2?\-F:?\ ]"O>_P#@5'_A
M1_PV9I__ $*][_X%1_X5\MT4?ZOY=_S[_%_YA_K7F_\ S]_\EC_D?4G_  V9
MI_\ T*][_P"!4?\ A1_PV9I__0KWO_@5'_A7RW11_J_EW_/O\7_F'^M>;_\
M/W_R6/\ D?4G_#9FG_\ 0KWO_@5'_A7H'PI^/>B_%"ZGL4@DTK4T^9+6Y=6,
MR=RA'4CN.O>OANI[&^N-+O8+NTGDMKJ!Q)%-$VUD8="#6%?AS!3IN-)<LNCN
MW^;.K"\7YC2K1E7DIQZJR7XI;GZ645Y#\"_CI;_$>R73-3:.V\20)ED'"W2C
MJZ#U]5[=1Q7KU?F6)PU7"571K*S1^T8/&4<?1CB,/*\7^'D_,****Y3M"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVF/9?M$_&>YLHP?#][I6@RVEU9^&9- L;EA',&>&U?H!P-W4]:^XZ "BBB@
MHHHH *0]#2TAZ&@#X(^.W_)7_%7_ %]C_P!%I7"5W?QV_P"2O^*O^OL?^BTK
MA*_=,%_NM+_#'\D?S%F/^^U_\<O_ $IA11178>>%%%% !1110 4444 %%%%
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MIPE52:BE^!^ X[(<SJ8NM.%!M.4FMMFWYG@U%>\_\,>>*_\ H,:-_P!]2_\
MQ%'_  QYXK_Z#&C?]]2__$5U?VSE_P#S]7XG%_J[FO\ SX?X?YG@U%>\_P##
M'GBO_H,:-_WU+_\ $4?\,>>*_P#H,:-_WU+_ /$4?VSE_P#S]7XA_J[FO_/A
M_A_F>#45[S_PQYXK_P"@QHW_ 'U+_P#$4?\ #'GBO_H,:-_WU+_\11_;.7_\
M_5^(?ZNYK_SX?X?YG@U%>\_\,>>*_P#H,:-_WU+_ /$4?\,>>*_^@QHW_?4O
M_P 11_;.7_\ /U?B'^KN:_\ /A_A_F>#45[S_P ,>>*_^@QHW_?4O_Q%'_#'
MGBO_ *#&C?\ ?4O_ ,11_;.7_P#/U?B'^KN:_P#/A_A_F>#45[S_ ,,>>*_^
M@QHW_?4O_P 11_PQYXK_ .@QHW_?4O\ \11_;.7_ //U?B'^KN:_\^'^'^9X
M-17O/_#'GBO_ *#&C?\ ?4O_ ,11_P ,>>*_^@QHW_?4O_Q%']LY?_S]7XA_
MJ[FO_/A_A_F>#45[S_PQYXK_ .@QHW_?4O\ \11_PQYXK_Z#&C?]]2__ !%'
M]LY?_P _5^(?ZNYK_P ^'^'^9X-17O/_  QYXK_Z#&C?]]2__$4?\,>>*_\
MH,:-_P!]2_\ Q%']LY?_ ,_5^(?ZNYK_ ,^'^'^9X-17O/\ PQYXK_Z#&C?]
M]2__ !%'_#'GBO\ Z#&C?]]2_P#Q%']LY?\ \_5^(?ZNYK_SX?X?YG@U%>\_
M\,>>*_\ H,:-_P!]2_\ Q%'_  QYXK_Z#&C?]]2__$4?VSE__/U?B'^KN:_\
M^'^'^9X-17O/_#'GBO\ Z#&C?]]2_P#Q%'_#'GBO_H,:-_WU+_\ $4?VSE__
M #]7XA_J[FO_ #X?X?YG@U%>\_\ #'GBO_H,:-_WU+_\11_PQYXK_P"@QHW_
M 'U+_P#$4?VSE_\ S]7XA_J[FO\ SX?X?YG@U%>\_P##'GBO_H,:-_WU+_\
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MHHHK<T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
MY36_BIX2\.>.-#\':GK]C9>)]<1Y-.TN:4+-=*@)8HO?&UOR- '5T5GQ^(-,
MEUN31TU"U?5HX!<O8K,IG6(G D*9R%)XSC&:OY'K0 M%)D>M<YX(^(OAWXCV
MNJ7/AW4X]3@TS49])NWC5E$5U"0)8SN R5)'(X]#0!TE%)G->/>$_P!L'X,>
M./$-KH>B_$CP]?:K=2>5!:K>JKRO_<7=C<WL.30![%129'K10 M%)D>M&1ZT
M +15#6]?TSPUILFH:OJ%KIEA&55[F\F6*-2Q"J"S$ 9) 'N:P[CXI^%;/QS<
M>#Y]9MX/$-MI)UR:SDROEV0<QF9G(VA0P(ZY[]* .KHKDM0^+'A+3-2\)V$V
MN6K7'BMY(]%\EC*EZ4C\QMCJ"N O.20*ZP$'H: %HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *0]#2TAZ&@#XJ^,R@_%+Q+P/^/H=O\ IFE<9M7^Z/RK
MM/C+_P E2\2_]?0_]%I7&5^%XW_>JO\ BE^;/SZO_&GZO\Q-J_W1^5&U?[H_
M*EHKC,!-J_W1^5&U?[H_*EHH 3:O]T?E1M7^Z/RI:* $VK_='Y4;5_NC\J6B
M@!-J_P!T?E1M7^Z/RI:* $VK_='Y4;5_NC\J6B@!-J_W1^5&U?[H_*EHH 3:
MO]T?E1M7^Z/RI:* $VK_ '1^5&U?[H_*EHH 3:O]T?E1M7^Z/RI:* $VK_='
MY4J_(P9?E8'((X(-%% 'TM\$/C>-:6#P_P"()P-0 "6MY(<"<=E8_P!_W[_7
MK[E7Y\*Q5@RDA@<@@X(-?2WP0^-XUM8/#_B"<#40 EM>.<"X'96/]_W[_7K^
MBY)G?/;"XIZ]'W\GY]GU]=_I\!C^:U&L]>C_ $/<:***^[/H0HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ."^-/Q9M_@SX.
MBUV?2+[77GU&STNWT_3C$)II[F=((E!D=4 WNN26&*X/4?VM=,\-:1XJ;Q/X
M2U_PUX@\.PV5W<Z#>BW>>>VNKD6\4\,D<K12)YFY6P^5*D$=,P_MK:/J.N_"
MG0K/299K6_?QCX>,=U;VXN&MB-3@/G>6>&"?>PW''/%><?M'? "ZT7X(_$CQ
M#KNOZI\0/&&MV^E:5)=36L< BL8M2A<00P0*-H+22.S9))YR * /K#1_%FB^
M(1?'3-6LM0^PRM!=?9;A)/(D'5'VD[2/0X-1Z+XTT#Q'875]I6M:?J-G:L5G
MN+2ZCECB(&2&920,#GFOE#XMZ)#\,?B'\9)?"W@"VU/39_AOIBRZ)9V+QVEZ
MQOKV*0R)"H,FR%RS!<N47 ZBN$BT#1O%GB#XMVLTM]?^#=5^'^FQW%[X)\+2
M:?&[I?W(W06_S?:/*4C=][*!D((&* /NO1_&6@^(-%EUC3-9T_4-*BW;[VUN
MDDA7;][+J2!COSQ4^@>(]*\5:;'J.C:E::K82$A+FRG6:-B#@X920<5\$W]K
MK'BKX7?$"#P_IFF:IH%EK_AV\U#Q3X:\,26R:[8QS W:/8-E)WMTCC,BQY61
M&V8R"M>]?LEZ/H\&N?$+6=!UJ]US3M1GL@]TF@II.F23QPL'>U1<;VVF-9'
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M. <TOCS6;GX=W_Q[T?Q9:ZC=>(_%GP]TZ'3S9Z=-=#5+B'3KR&YV-&C*2LC
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MXGZCXB^/GQ-^*&D^#/$OB#_A6^MZ/8:'XBTVT\S3K!=.D:74X[B;/R^89V&
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MP4445H4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:*VD>=H?(CC"L%1CRJDT ?6X*YZG\S3MHS_]>ODOQ5\%] M_CS\/_!W@Z_\
M%%E?V<J^*-?NW\5:G<+!I\#[8;=DDG9";FXPN"/]7#-7UH.E "T444 %%%%
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M^%']D7__ #XW/_?EO\*^_,?7\Z,?7\Z/]5(_\_O_ "7_ ((?V.OY_P /^"?
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M-&7*;F9@ 3D7/%/[+?ASQ3K6O2R:SKECX?\ $5]%J6N^&+.XB73]3N$$8WR
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M\U^I]M@L1+$TN::L_P PHHHKW3T HHHH **** "BBB@ HHHH **** "BBB@
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M7TC^R/KUCKOP4L1I^@6/AN&PU'4M->QTF5I;#S8+V:.62U9N3"[JSH,  -M
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MEG?>*M<U6]62Z>#STGN[N5SMWNP@1 JCDL..IKZYHH :JA5    Z#TI<4M%
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MXP? 2R\6?!37/ O@RPT;PM]OFM9E6"U6VM@T=U#,Q98EZE8B,XZD4 )X?_:
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MQ7H_A_X;7^D?'7QGXXDN;9]/US1M*TV"W3=YL;VLEX[LW&,$7*8P2?E.<<4
M>3?&+XA_%_X9VVK^-[B\T&VTBUU^WTO2/!HM#/<ZQ:RW,4"N+E904N)/,=UC
M$9"A0&SR0[0OVL=!\(_&3XO>&?'OBVVT^+2-:M8-'M)H"#';/I]M(W*)\V97
MD.6)/..F*+_X5?&F_P#C#>^--2A\">(H[.X=/#=K?:G>PQZ1;'*[UB6V96N7
M4_-,22 =J;5SN]0^&?POU#P3\0?BEK]W=V\]MXLUFVU*UB@+;X4CL;>V97R
M,EH6(QG@COQ0!R_[-/Q1\2?$S]FY?&#21^)=?FGUDV(;9;)=B&^N8[6,D !
M4CB7<1[GG-<I:_%?XD?"KXB>&-*\?:OHOB6+6]!U+6M4L-'TYK>30OLD*2DJ
M_FOYL)9S"&8*2VTCJ0/0?A!\,/%'P@^!EUX9LKK2;[Q3'<:M>64T[2BS,MS>
M7%Q")"%W[1YR!L#/!QV-<-\'_@G\2O#]]JR^.[?PCKDGB6&6'Q'XCMM2NY-1
MND:-U6.*-[=4BA4MA8E8*H)/S,22 9WPX^,_Q*M[[X/Z[XONM&U#0OBE$_DZ
M586;02Z+,]D][:QB8R-YX:.-T<E5P^"..*MVOCSXO^#/&WPS@\8:GH%Y=>.;
M^:RNO">F6)\W1HUMII_/CN?-/GK$8XTD8HH)D&W&0"O@3]G?XAZ5=_#>R\1Z
M[H&HZ#\,[>9?#_V1)EN-2G%H]I;2789=L0CAD;(C+[F.> ,5/\(OA7\8O#'C
MZ3Q1XSB\#^(=:U&3R=0UV'4+S[1;66_<+6S@:W"11KQ\N[+L-SL3C !3\57/
MQ=\$_$GX=^&X/B7IWB2_\0:F7N=//AA+<1:9 !)>3M()V*X!CC7CEYD'K7T^
M.E>;^#?AEJ%C\7/&?CWQ!=6UY?:@D&E:-%;EB+#2XAO*$D#]Y+.TDCXR,+$,
MG;7I- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 FT'L*-H]!2T4 )M'H*-H]!2T4 )M'H*-H]!2T4 )M'H*-H]!2T4 )M'H
M*-H]!2T4 )M'H*-H]!2T4 )M'H*-H]!2T4 ( !TXI:** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@"K)9R/(S"ZD0$_= &!^E,^PR_\_DOY+_A5VB@"E]AE_P"?R7\E_P */L,O
M_/Y+^2_X5=HH I?89?\ G\E_)?\ "C[#+_S^2_DO^%7:* *7V&7_ )_)?R7_
M  H^PR_\_DOY+_A5VB@"E]AE_P"?R7\E_P */L,O_/Y+^2_X5=HH I?89?\
MG\E_)?\ "C[#+_S^2_DO^%7:* *7V&7_ )_)?R7_  H^PR_\_DOY+_A5VB@"
ME]AE_P"?R7\E_P */L,O_/Y+^2_X5=HH I?89?\ G\E_)?\ "C[#+_S^2_DO
M^%7:* *7V&7_ )_)?R7_  H^PR_\_DOY+_A5VB@"E]AE_P"?R7\E_P */L,O
M_/Y+^2_X5=HH I?89?\ G\E_)?\ "C[#+_S^2_DO^%7:* *7V&7_ )_)?R7_
M  H^PR_\_DOY+_A5VB@"E]AE_P"?R7\E_P */L,O_/Y+^2_X5=HH I?89?\
MG\E_)?\ "C[#+_S^2_DO^%7:* *7V&7_ )_)?R7_  H^PR_\_DOY+_A5VB@"
ME]AE_P"?R7\E_P */L,O_/Y+^2_X5=HH I?89?\ G\E_)?\ "C[#+_S^2_DO
M^%7:* *7V&7_ )_)?R7_  H^PR_\_DOY+_A5VB@"E]AE_P"?R7\E_P */L,O
M_/Y+^2_X5=HH I?89?\ G\E_)?\ "C[#+_S^2_DO^%7:* *7V&7_ )_)?R7_
M  H^PR_\_DOY+_A5VB@"E]AE_P"?R7\E_P */L,O_/Y+^2_X5=HH I?89?\
MG\E_)?\ "C[#+_S^2_DO^%7:* *7V&7_ )_)?R7_  H^PR_\_DOY+_A5VB@"
ME]AE_P"?R7\E_P */L,O_/Y+^2_X5=HH I?89?\ G\E_)?\ "C[#+_S^2_DO
M^%7:* *7V&7_ )_)?R7_  H^PR_\_DOY+_A5VB@"E]AE_P"?R7\E_P */L,O
M_/Y+^2_X5=HH I?89?\ G\E_)?\ "C[#+_S^2_DO^%7:* *7V&7_ )_)?R7_
M  H^PR_\_DOY+_A5VB@"E]AE_P"?R7\E_P */L,O_/Y+^2_X5=HH I?89?\
MG\E_)?\ "C[#+_S^2_DO^%7:* *7V&7_ )_)?R7_  H^PR_\_DOY+_A5VB@"
ME]AE_P"?R7\E_P */L,O_/Y+^2_X5=HH I?89?\ G\E_)?\ "C[#+_S^2_DO
M^%7:* *7V&7_ )_)?R7_  H^PR_\_DOY+_A5VB@"E]AE_P"?R7\E_P */L,O
M_/Y+^2_X5=HH I?89?\ G\E_)?\ "C[#+_S^2_DO^%7:* *7V&7_ )_)?R7_
M  H^PR_\_DOY+_A5VB@"E]AE_P"?R7\E_P */L,O_/Y+^2_X5=HH I?89?\
MG\E_)?\ "C[#+_S^2_DO^%7:* *7V&7_ )_)?R7_  H^PR_\_DOY+_A5VB@"
ME]AE_P"?R7\E_P */L,O_/Y+^2_X5=HH I?89?\ G\E_)?\ "C[#+_S^2_DO
M^%7:* *7V&7_ )_)?R7_  H^PR_\_DOY+_A5VB@"E]AE_P"?R7\E_P */L,O
M_/Y+^2_X5=HH I?89?\ G\E_)?\ "C[#+_S^2_DO^%7:* *7V&7_ )_)?R7_
M  H^PR_\_DOY+_A5VB@"E]AE_P"?R7\E_P */L,O_/Y+^2_X5=HH I?89?\
MG\E_)?\ "C[#+_S^2_DO^%7:* *7V&7_ )_)?R7_  H^PR_\_DOY+_A5VB@"
ME]AE_P"?R7\E_P */L,O_/Y+^2_X5=HH I?89?\ G\E_)?\ "C[#+_S^2_DO
M^%7:* *7V&7_ )_)?R7_  H^PR_\_DOY+_A5VB@"E]AE_P"?R7\E_P */L,O
M_/Y+^2_X5=HH I?89?\ G\E_)?\ "C[#+_S^2_DO^%7:* *7V&7_ )_)?R7_
M  H^PR_\_DOY+_A5VB@"E]AE_P"?R7\E_P */L,O_/Y+^2_X5=HH I?89?\
MG\E_)?\ "C[#+_S^2_DO^%7:* *7V&7_ )_)?R7_  JQ%$T:!3*SD?Q'&34M
M% !1110 4444 %%%% !1110 44TR*" 6&2<#WI001D'- "T444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %(>!2TAZ&@#YQ^(GQZ\3^
M&?&^LZ59BQ^RVL_EQ^9 6;&U3R=P]37.?\-+^,?33O\ P';_ .+KG/C+_P E
M2\2_]?0_]%I7&5^/8O,\;#$5(QJM)2?7S/B:V+KQJR2F]V>K?\-+^,?33O\
MP';_ .+H_P"&E_&/IIW_ (#M_P#%UY317+_:N._Y_2^\Q^N8C^=GJW_#2_C'
MTT[_ ,!V_P#BZ/\ AI?QCZ:=_P" [?\ Q=>4T4?VKCO^?TOO#ZYB/YV>K?\
M#2_C'TT[_P !V_\ BZ/^&E_&/IIW_@.W_P 77E-%']JX[_G]+[P^N8C^=GJW
M_#2_C'TT[_P';_XNC_AI?QCZ:=_X#M_\77E-%']JX[_G]+[P^N8C^=GJW_#2
M_C'TT[_P';_XNC_AI?QCZ:=_X#M_\77E-%']JX[_ )_2^\/KF(_G9ZM_PTOX
MQ]-._P# =O\ XNC_ (:7\8^FG?\ @.W_ ,77E-%']JX[_G]+[P^N8C^=GOOP
M_P#VE;R?6UMO$Z6R6,V%6YMXRGDMZL"3E??M7T1%*D\221N'C<!E93D$>HK\
M^J]D^"?QK?PK)%HFMRM)H[G;#<,<FV/H?]C^7TKZ;)\^E&7L,9*Z>TGT]?+S
MZ>FWJX+,6G[.N]'U_P SZDHID4J3Q))&X>-P&5E.01ZBGU^B[GTX4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 ,DE2%"SL%4=R<4BW$3Q^8LBE.FX'BOGG]NZYM[7X)Z<
M;U+J;3G\5Z#%>6]F)&EGMVU&%98U6/YV+(67:O)S@<U\^?$NPO\ 0?AS\8-1
M\ Z-XC\+?#8Z;H:65EKOVJR\[5AJB>=);I.?-BC,1A1S@*S= <'(!^AM%?/4
M/QA\;>#O%OQ%\-^+M0\*/<:1X8M_$NG:H?-L+*W$TES#Y-TS,YVJ\"GS5 )5
MC\@/%<AI'[37CV6/XAZ3IECI_C[7](\,VGB#2'TO2[FP2X:6::&2+R969I0G
ME;U9#\XRH :@#ZTHKY//[5>L:+\+]<U;^V_#WB[5AKFG:%I[Z=IMY:S6TUVZ
MH?MM@V^9#'EW"*2T@4 !2:]-^ 'Q-\4^.;[Q5IGB2PEDCTF2V:RUX:+=:5#J
M,<J,6407&65XV0AL,P(=#D$D  ]BR,XS2U\C^//!FK>$?B+X0MM&\>>(O$?Q
M9U?Q-'J5Q"E](NGV^B?:BUPLUEN,4=NEOF)7(WO+M(;)(':_'G4/'$'QW^">
MG^&?%%OHFG:G?:C%=6L]D\Z3F.PEE_>!94W+M7"K_"^&R<;: /H%F"*2Q  [
MFG5\=?$#XO\ C;Q%\(OC)K6L6V@S>&] \1S>']/L(EN8[BX\G5((A+++'*I7
M"DC:A^8@$D#*GH_VA?VE=?\ A/KGB2YTO5_#=[8^'5LY9O#T=I<W5],DC+YW
MGS(1':':^8PP?=@$[0: /J .&+ $$KP1Z4JL'S@@X..*\3^"%U//\:?V@(Y9
MI)(X?$U@D2.Y*QJ=&L20H/09)/'<FO,?#GQ@\6V1T+1O"EIHME>^)/B9XFT*
M:34/M,T21V_VV43 &0MO)MU)0$*<E5" Y !]=,P7&3C)P*&8*!D@9..:^3XO
MC!XB\23^#=.\2VFEWFLZ5\6)?"L][8BXMX91%87$T=RD0ERK%60%':1<[N#\
MI')^%?%_C>U^'%U>>+M<LO%P?XQ1:);*UO<6K6P77FA=@RW!)0#;Y<9^5 NU
MO,% 'V[368(,L0!ZFOE_XC_M+:]X*^(4L5MJ_AS5=&@\3:=H$VBV%I<SW44=
MS-# TDUV"(H9E>4MY)4C: -VYL#S\>+O'-E\,/C/J/B?7;+Q59:?\2+32+:R
MDM[BW,.=2TY"4D2XW+&JRY6,<!@22RL5H ^XJ*^7?&_[0_CJPTWXJ>-M"@T0
M>#/AQJDFGW>E7D,K7VIK;Q12WDB3!PL.!*1&I1]Q3DJ&%5/B7^T#\2=(N?C?
MJGAX^'$\/?#>*TOXX;^UF>XU&-]/BNY(2RN!&<.VV3#<D IP20#ZL9@N,D#)
MP,TM>,_M!>*#I^@?#BY2SBN%U'QIH5L4FDE3RQ+<#YP8W7++V#94]U(XKS.Y
M_:%^)=M9^)?%3+X<'A;0/B&?"3Z<+:8W=Y:MJ,5H)1+YFV.1/.!QM8/M/W,B
M@#ZQ)Q2,ZKC) R<#W->:_&SP9'XLT_2[G5_&5YX3\'Z3)->ZU%973637L8C(
M17ND=7AC1B7;:<M@#('7Y7U'7O%VA?#?X9:JD?B+Q#I<WQ=67PM97MUMU*\T
M8VMSY"2/,R%@S"1T\YLF,Q[N<4 ?>1=0X7(W$9 I20.]?+6D>/?$GBO]LGP-
M#K7A#6?!4*>#M:9;;4KNVE6Z/VFP^8""6097I\V#\_'>M']IWPE;V$'B/Q7K
MWCCQ+'//8QZ=X2\.>'+V6SF74=K[?+2)_P#2II9"G#J514.1C<: /I0D#O02
M!7R+I?ASQ7\8OB/>^#O'7BG6]&U#PGX!T6>8>']1>R#ZQ=BX^T7A:(CS-C6R
MA5;*<ME3FJFAZK#\3/V?_ 'Q8^*/CO7-+T=O"ELKZ1H=W-8276J.Q#7*M P>
M:63"+'  1DGAMV  ?8N0!UI:^"K?Q%\1=8U[X=?#_P"(5GXTUZ_L/ D6N:EI
M7A.Z^Q7=W>RW4D*&[N5DB"^3%",J'4-*Y^]MQ7U)^S5XDM/$WP?TB:TUK6-=
M%K-=6,L_B&(1ZC#)#<21O;W('!EB*^66_BV;N<YH ]1HHHH **** "BBB@ H
MHHH **** "BBB@ KXI^/?[4_C+P1^U/IMAHE[!'\,_"<^CV/C.-XD+>;JDDJ
M1-O(RHB41.<$?>YS7VJ1D5\->)?^";P^)7A_XN:KXQUPS_$/Q?JEWJ&G75AJ
M%Q'I]HF%^PQRQ8'F>65&25.!TZ4 >S?$?]KFQ\$?%R[^'VE^#=?\7ZSIMG;W
M^IC1Q"6@AF;"&.-Y%><@?,1&K8%>?W?[5?Q N?C_ /&'P&OA*:PT3PUX;DU&
MQU3$1DMG%O,\=Q*#(=T<K(H10NX$_.!SC,^._P"Q]\2OCCH^AV>I7O@0ZG#I
M-A;2^)FMKF/5]+O(@OGS6L\8!E1V5F5)-FW<:[?6OV9/&$7QO\9>+-&US2;K
M0_%_@\>'-334Q*+R.>*WDCAEC*J5*LS*7W<XW8SQ0!S/[+'[:-[XXTGX4>&_
M&GA_7H_$'B[0KB]M/$=S:Q0V>ISVR>9<"-5;*@+T8J >W!!*^%_^"CNB^)-,
M\&:HOPT\:QZ7XLN)].TN[2VAD6YOHV8?9T DRQ.S&_[@).3\K8TO '[(OB;P
ME>_LW37.KZ5*OPRT?5=.U,1-)FZ>ZMA$C0Y09 (R=VWCIFL3X>_L4>*_"/PX
M_9^\.W6MZ--=?#KQ1<:YJ,L32[+F*229@D.4R6 E'W@!P>: /2_"'[6UOXT^
M&?B3Q'IW@/Q1-KWA_7I/#=_X6CMXWO8KQ2N<L'\L1@.K&0L% SFNK^!WQ[LO
MC=I/B9K?1K[0=;\-ZI+H^IZ5?M&[PW"(K_*\3,CJP8893ZUX-XO_ &+/&NL>
M&O'=GI_B#1@^N_$X^.%TZZEN$L[^Q,:H;&[,:A@"5W':&7*KU[>G?LG_ +/6
ML_ 4_$-M7ET/;XFU\ZO;6N@1216]K&843RPC@8P5/3.1SQG  /,M4UC0-1\,
M_"ZRN_%-]9>.=5TBRU5M5NM1EAMM,5KGSKF<+D*\TDADA6,YR%QA45J^A?@S
M>W$[>.;22XDN;.Q\47L%H\A+$1LL4K(">RRRRJ/0+CM7=:1HUEH-BMEI]M':
M6BN[K#$,*I=R[8';+,3^-&E:/9:';/;V-NEM"\TMPRH/O22.7D8^I9F8D^IH
M NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(>AI
M:0]#0!\5_&7_ )*EXE_Z^A_Z+2N,KL_C+_R5+Q+_ -?0_P#1:5QE?A>-_P!Z
MJ_XI?FS\^K_QI^K_ #"BBBN,P"BBB@ HHHH **** "BBB@ HHHH ***?##)<
M3)%$C22N0JH@R6)Z "@#V3X'?&:;P[=6_A_5F>?2YG$=O+@LUNQ/"^ZD_E]*
M^H:\>^"GP4C\)11:UK42R:TXS%"W(M0?_9_?M7L-?L&24L51PJCB7Z+JEV?^
M73\OML!"M"BE5?IY(****^@/2"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .0^)WPST[XIZ+IV
MF:G<7-O#8ZO8:Q&UJ5#&6TN$GC4Y!^4M& >^,X(H^*_PTT[XN> ]1\*:I<7-
MM8WS0/)+:E1(#%/',N"P(^]& >.A-87[0?Q4U+X0^!;35]'TFVUG4[W6=.T:
MWM;RY:WA\R[NH[=6=U1R ID!.%/2O,?%_P"U?X@^%^G>-K'QEX2T^S\4>'=/
MT[6(HM/U5I[&\LKJ]^R>8)FB5HVC</N5D[ @X.0 >B?$G]G'PU\4]5\4WVLW
M%^K>(-"M="G2VE5!%';W,ES%+&=I(D$DF><K\HXZYS8/V9K676?$&M:GXU\4
MZEKVMZ-;Z-/J@NHK:>&.&=YXWA\J-1&P9SP 5/<')SU/ACX\^ O%]OXCGTSQ
M/830^'4\W5)'D\M;6+#,)6+8_=D(Y#CY3M.#Q4.@?M"?#WQ)H6NZQ9^)[);#
M0X5N-1EN&,/V:)@2DCAP"$;:VUL8.#@G% ',C]EC0M2TWQ0/$&OZWX@U[Q#+
M83W'B":2&"[MY+%S)9/!Y,:I&T3LS [3DD[LCBNW^'7PYF\#-JMS?^*-;\5Z
MIJ<D;SWFL3)A51=J)%%&J1QJ!DG:H+$DDGC%'0OC_P" /$/A/6?$EIXFLQI.
MC$+J,TY,+6I(!42(X#*6!&W(^;(QG-;'P_\ B?X:^*.ESW_AK58M2AMY?(N%
M4%)(), [9$8!D)!! (&00>AH \M\)?LM:AX*\3:KK6F_%7Q8+K5[\7^HM/!8
M2O=D'B-Y&MR_EJN55 P"@G:!DUZ%\2?A1:_$34/"^J#5M0T+6O#=\]]I^H:=
MY9=2\+PRQLLB,K(\<C*1C(X(((KSJ[_:BU#3=8M+^^^'^K67P_N]>3P[#XCG
MGB20W#W/V6.4VI/F"!IL*'ZX(;;M.:]2^(?Q4\+_  KT^TO/$^KPZ7'>3_9K
M9'!:2>3!)5$4%F( ).!P 2>* .2U/]F[P_JGP[\8^#I;_45T_P 3ZY/KMU,K
M)YL<TMTERRH=N H>, 9!.,\YYK%\=?LF:+XX?QO;GQ1XBTG1/&$Z7VJZ/830
MK!+=JD4?G!FB,@RD$8*;MIV].HJ[X(_:>\,Z]\/M4\8:S=V>D:/#XCU#0;&:
M.<SB_P#(N9(HGB 7+-(L>\(H.!GKC-5O&'[8'P^\*#P'.FHOJFG^+;Z>RM[R
MQA>5(#%%*TA<*I(*O%Y93&X,W(PK$ '=>&OA;9^%/B-XN\66.HWP/B=K>>^T
MV0HUN+B*%(!,GR[U8Q11J1N*_+G )-<YHW[..@:)J^@ZA#?Z@\NC^*-4\50J
M[)M:YOEN%E1OE^XHN7V@<\+DGG.UJ'QX\":7XYC\(77B.TAUYYX[0VS$X2XD
M :.%GQM61@5(0D,=PP.15WXA_%_PA\*1IQ\5ZY;:-_:+2I:"X)S.T:;W5 !R
MVWG'4]LT <S%^SCX?AU:/4!?:@94\:2>-PI9-OVQ[5K8Q_=_U6UB<=<]ZI?\
M,QZ*)-4A&N:O_95YXKM?&,6FEHC%:7\5U]JD\MMF[9++RRL3C^';733_ !Y\
M!VOCJ+P?+XDLX]?DD2 6K,<"9U#)"7QM$C @A"=Q!''-%S\>? =IX[7P=+XD
MLTU\W"V7V8L<+<,H98"^-HE*D$(3N((XYH XG4OV2]%U"XU"%?%/B*UT&[\2
MQ>+/[#AFA%LE^MVEV[9\O>R/*FXHS$ L2,8&+^L?LPZ+JR>,[3^W-7M]&\4Z
MQ::_=:7&T)BAOH+BWF,L3&/>!(;6,,I8CEB "<U4^+G[6'A'X=376DZ?J%EK
M7BBUU33M-FTL3%-CW-U#"REPI7S$2;S/+^]A>PYKL-?^/G@'POXTB\*:IXFL
M;/7'>*)K=W.(I)/]4DCXVHSY&U6(+9&,YH YCQ;^RWH'BW6O$$CZYK>G^'O$
MUU'>Z_X:LYHELM3F18UW.2AD0.L4:R"-U#A>>ISJ^(OV>M!\2Z=\6+.XO;^.
M+XC0)!J9B9 ;=5LTM!Y.5X^1 ?FSS[<5TFJ?%KPGHUGXQNKS6K>"#P@ =<=L
MXLLP+.-_'_/-U;C/!KF/#'[1OAGQ3\;O$GPRMA<KK6C6]O.96A?RIC(LK,JM
MC V"(')X.\;<X. #H_''PNTWQYIGAJRO;BYACT'5['6;=H"H+RVKAXU;(/RD
MCG&#Z$5S-S^SAX?NO!WB#PXU_J L]9\5#Q;/(&3>ES]MBN]B_+CR]\2C!!."
M><\U=U#XYZ%X9UWQQ#XCU/2=(TCPS+IL,MX;PM(C7@ 03H4 BR[*%.Y@0<G;
M6W\/_B[X2^*)U9?#&M6^J2Z5*L-Y%'E7A+ E"58 [6 )5NC '!- '-_'7X"Q
M?'.+0(;KQ3K&@VND71O?LFG+;R6]W*-IC,\<T;K((R"RJ1MR<D$A<1GX"R:M
M:>&4\3>-==\4W/A_Q%#XCL[J^CM8W$D<,D2PL(HD4Q_O7;INR>N.*UOA/\4Y
M?B3JWQ$LY=/2P'A3Q-+X?1UE+_:%2VMI_-(P-I/V@C;S]W.>:>_QZ\!IX[_X
M0X^)+0:_]I^Q?9\G;]IV;_(WXV^;MY\O.[':@"_J/PPTW4OBIH7CR2>Y75-(
MTJ\TF&%2ODM%<20R.S#&=P-NF,'')K@_&W[-5QXL^+,OQ M/B)XET/5A:K9V
MD%M%9S06$6T"06ZS0.8S(1EV!W-G&=H "_#G]KCP'\0-$\8ZL;Y]&L/#&H36
M5W/J,;1(524Q)(I( /F,,!/O9(!&3BO1? /Q)\.?$[1Y-3\-:I%J=M#,;>;8
M"KPR@ E)$8!D;#*<, <$'H: . \7?LU6_BV[LM4_X3;Q-I'B+^QUT'5-9TN6
MWBGU6S#,VV8&(HKAG<J\:JR[VQUK)\2?LDZ?J.O>$+_0O&.O>%+7PEID>EZ+
MIEC':SVMDJKL\U$GA?\ ?% %\S[V,@$9.8H?VI+]-9T6\U#P!JVF>!-:UY/#
MMAX@N9XEE>Y>=K>*1[0GS$ADE7:KGG#*Q4 YI)?VL!%XBEN?^$0OS\/(?$G_
M  B<GBW[1%L6_P#/%MN\C._R!<$0^;_>[;>: .CUO]GI]:_L'5/^$Z\1V/C7
M2+6:Q'BJT%JEU=VTD@=H9XS"874$*5^0%2,@\G/:?#'X:Z1\)_"%OX>T8W,M
MO'+-<RW5[+YMQ=7$TC2S32O@;G=W9B< <\   5Y3XN_:EO\ PC>ZSJUSX U9
M?A[HNL+HE_XDEGBB<2F=+=IH[9B))(%ED52XZX)4,!FF_%_X_?$/X2:;KNMW
M7PPAO?#FGS^7!=Q^((%FNPT@CA"0[=V^1F153KE@* /H.BH+"::XLK>6X@-M
M.\:M)"6#>6Q RN1P<'(S[5/0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !2'H:6D/- 'Q7\9?^2I>)?^OH?^BTKC*^LO%/[/.B>*_$-_J]
MQJ%]%/=R>8Z1E-H. .,K[5E_\,L>'O\ H*:E^<?_ ,37Y=B<@QU6O4J1BK-M
M[KJSY&KEN(G4E)+1M]3YAHKZ>_X98\/?]!34OSC_ /B:/^&6/#W_ $%-2_./
M_P")KF_U<S#^5?>C+^S,3V7WGS#17T]_PRQX>_Z"FI?G'_\ $T?\,L>'O^@I
MJ7YQ_P#Q-'^KF8?RK[T']F8GLOO/F&BOI[_AECP]_P!!34OSC_\ B:/^&6/#
MW_04U+\X_P#XFC_5S,/Y5]Z#^S,3V7WGS#17T]_PRQX>_P"@IJ7YQ_\ Q-'_
M  RQX>_Z"FI?G'_\31_JYF'\J^]!_9F)[+[SYAHKZ>_X98\/?]!34OSC_P#B
M:/\ AECP]_T%-2_./_XFC_5S,/Y5]Z#^S,3V7WGS#17T]_PRQX>_Z"FI?G'_
M /$T?\,L>'O^@IJ7YQ__ !-'^KF8?RK[T']F8GLOO/F2&&2XF2*)&DE<A51!
MDL3T %?4GP4^"D?A&&+6M:B636G&8H6Y%J#_ .S^_:MOP+\#/#_@75CJ4+3W
M]VHQ$]V5(B]2H '/O7HU?391D/U67M\59R6RZ+S]?R_+UL%EWLG[2MOT0444
M5]H>Z%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'B'[7G@/5?B/\ #+2-&TBWOYYF\4Z'
M/,^F/LN(((]0A>:9&_A*(&;=VQGM7$_&_P#9CL](^!?CRV\,V>L>+_%NOG38
MKF[U:[:^O;F"&^A<1 MP(T7S6VJ .6)R:^I.M!&: /F#XU^%/'MO\2OB=KW@
MOP\-1N;GX?Z=IVGO/;I+#/.E_=M-$J.0KR+#)N5&^4DJ#P:X8_#K7?&/BWXC
MZGK'@SQIXN\/:KX'L-/6'7W@LKV^FCO[B21(=@C$3H'$B*P4[@,<,*^V,"C
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MG7O]V#_OH_X4>=>_W8/^^C_A0!?HJAYU[_=@_P"^C_A1YU[_ '8/^^C_ (4
M7Z*H>=>_W8/^^C_A1YU[_=@_[Z/^% %^BJ'G7O\ =@_[Z/\ A1YU[_=@_P"^
MC_A0!?HJAYU[_=@_[Z/^%'G7O]V#_OH_X4 7Z*H>=>_W8/\ OH_X4>=>_P!V
M#_OH_P"% %^BJ'G7O]V#_OH_X4>=>_W8/^^C_A0!?HJAYU[_ '8/^^C_ (4>
M=>_W8/\ OH_X4 7Z*H>=>_W8/^^C_A1YU[_=@_[Z/^% %^BJ'G7O]V#_ +Z/
M^%'G7O\ =@_[Z/\ A0!?HJAYU[_=@_[Z/^%'G7O]V#_OH_X4 7Z*H>=>_P!V
M#_OH_P"%'G7O]V#_ +Z/^% %^BJ'G7O]V#_OH_X4>=>_W8/^^C_A0!?HJAYU
M[_=@_P"^C_A1YU[_ '8/^^C_ (4 7Z*H>=>_W8/^^C_A1YU[_=@_[Z/^% %^
MBJ'G7O\ =@_[Z/\ A1YU[_=@_P"^C_A0!?HJAYU[_=@_[Z/^%'G7O]V#_OH_
MX4 7Z*H>=>_W8/\ OH_X4>=>_P!V#_OH_P"% %^BJ'G7O]V#_OH_X4HFO,<K
)#G_>/^% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>crvs-20260331x10q008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 crvs-20260331x10q008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &L Z@# 2(  A$! Q$!_\0
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MJ$9UR3N& ,D^E 'LM%?*'_#?D_\ T;=\?/\ PBC_ /'J/^&_)_\ HV[X^?\
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MW?'S_P (H_\ QZC_ (;\G_Z-N^/G_A%'_P"/4 ?5]%?*'_#?D_\ T;=\?/\
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MX)_:\_: ^)'P&^)_AW1]8\3>+?#/PN&A*LGCC0/#]GJ$]SJF[;_I/FQF*-<
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MPWY/_P!&W?'S_P (H_\ QZC_ (;\G_Z-N^/G_A%'_P"/4 ?5]%?*'_#?D_\
MT;=\?/\ PBC_ /'J/^&_)_\ HV[X^?\ A%'_ ./4 ?5]%?*'_#?D_P#T;=\?
M/_"*/_QZC_AOR?\ Z-N^/G_A%'_X]0!]7T5\H?\ #?D__1MWQ\_\(H__ !ZC
M_AOR?_HV[X^?^$4?_CU 'U?17RA_PWY/_P!&W?'S_P (H_\ QZC_ (;\G_Z-
MN^/G_A%'_P"/4 ?5]%?*'_#?D_\ T;=\?/\ PBC_ /'J/^&_)_\ HV[X^?\
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M117RO_PWE-_T;I\=_P#PC#_\=H_X;RF_Z-T^._\ X1A_^.T70<K/JBBOE?\
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MOA5XP\/ZA=?%_P ;^)?#7AQBVC>%[N\,5I;C&%638?WBKP0N%&0,@C(,\O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "L:3_6-]36S6-)_K&^IK6F8U.@VBBBMC ****
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M6K110!Y=^RQ_R;%\(/\ L3]'_P#2*&O4:\N_98_Y-B^$'_8GZ/\ ^D4->HT
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !6-)_K&^IK9K&D_UC?4UK3,:G0;1116Q@%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 4==_Y FH_]>\G_ *":_$9_OM]:_;G7?^0)J/\
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M[?6OJ<DVJ?+]3P<TWA\_T$HHHKZ<\(_7S]F?_D@'@'_L$0?^@UZ97F?[,_\
MR0#P#_V"(/\ T&O3*_-:_P#%GZO\S[:E_#CZ(****Q-0HHHH **** "BBB@
MHHHH **** -NBBBN0[0HHHH 1E# @@$'@@]ZH:=X=TK2+6>VL-,L[*WG):6&
MWMTC20GJ6  !S[UH44 5-+TBPT.T6UTZRM]/M5)(@M8EC0$]3M4 5;HHH \N
M_98_Y-B^$'_8GZ/_ .D4->HUY=^RQ_R;%\(/^Q/T?_TBAKU&@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:QI/]8WU-:TS&IT&T445L8!1110 4444 %%%% !1110 4444 %%%% !1110
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MHKR#T@HHHH **** "BBB@ K&D_UC?4ULUC2?ZQOJ:UIF-3H-HHHK8P"BBB@
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M/_Z10UZC7EW[*^?^&8/A!G@_\(=H^<?]>4->HT %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%4==UFV\.:)?ZK>LRV=C;R7,S(I9@B*6; ').!TH O4
M5\<_#'_@HB?&_P 0?".E:[\*?$'@SPCXUO)+#PMXGO[E)!J$RMMVR0!08<G
M'SOR?0$T?%/_ (*)'X>^,_%,&G?"?Q'XD\!^$+U+#Q)XOAG2".SE9MI\J!E)
MF4$@9W)W[8) /L:BJ.A:U9^)-$T_5M/E\^PO[>.ZMY<$;XW4,K8/J"#5Z@ H
MHHH **** "BBB@ HHHH **** "BBB@ K\@/VQ/\ DY7QW_U^+_Z*2OU_K\@/
MVQ/^3E?'?_7XO_HI*^DR+^/+T_5'A9O_  8^OZ,\;HHHK[<^4/N[_@EQ_K_B
M5_NZ;_.ZK[UKX*_X)<?Z_P")7^[IO\[JOO6OSO-O]\G\OR1]MEO^ZP^?YL**
M**\@](**** "BBB@ HHHH *QI/\ 6-]36S6-)_K&^IK6F8U.@VBBBMC ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH HZ[_ ,@34?\ KWD_
M]!-?B,_WV^M?MSKO_($U'_KWD_\ 037XC/\ ?;ZU]3DFU3Y?J>#FF\/G^@E%
M%%?3GA'Z^?LS_P#) / /_8(@_P#0:],KS/\ 9G_Y(!X!_P"P1!_Z#7IE?FM?
M^+/U?YGVU+^''T04445B:A165XK\2V7@SPSJNO:DTBV&FVLEW.8D+OL12QVJ
M.2<#@=Z^=OAE^VR_C+Q[X:T'Q'\.-9\%Z=XL#MX<U6[N$F6^"\_O(PJF+(Z<
MMU'8YJE"4E=$.23LSZ>HKY6^(7[=0\#>*-?$/PWUO5O WAW4AI&L>+(YUCCM
M[G< RQQ%?W@!8<[UZCU&?J'3[^'5-/MKVW;?;W,2S1MC&58 @_D:)0E%78U)
M2T18HHHJ2@HHHH **** ,GXM?#CPE\5/ 6IZ!XVTNWU;P](GG317";A&4^82
M+Z,N,@U^2_@SQ;\ _"&G6?A_3?V4O%GQ A:"YU"PUS6W1KW4K-96S<8BB52B
MY !4< #)/4_K!\:/BKX+^#OP_P!1\0>/=7AT?P]M^S2R2AF:5G! C15!9F//
M 'J>@)KX3^$_P]TO]H+P3H,GP ^/,R^+?AY=7EMIESK6E[;BRTB\15%G+&1E
MU0Q?)* 1P5P.W(=I]P_L[^([+Q=\#O!.LZ;X>B\)Z;>Z9#-:Z+"ZNEG"1^[0
M%>"-N.GK7HE<3\%/AJGP=^$_A7P4FH2:J-$L([1KV5=K3L!\SXR<9))QDXKM
MJ "BBB@ HHHH \N_98_Y-B^$'_8GZ/\ ^D4->HUY=^RQ_P FQ?"#_L3]'_\
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MBB@#X^_X*A>5!X>^#U]?Z-?:_H.G^,[:\U2PL;5KEI;9%)<%!URN1@X'/6O
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MN(ZPHHHH **** "OD#]L/]K7QE\!/B1I>@^';32+BRNM)COG:_@DD<2--,A
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M]01,8?@8+ YSCL5^ITE3BJ?-'?\ KR_4B-23GRO;^O/]#Z/HHHKE.D*QI/\
M6-]36S6-)_K&^IK6F8U.@VBBBMC **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH HZ[_ ,@34?\ KWD_]!-?B,_WV^M?MSKO_($U'_KWD_\
M037XC/\ ?;ZU]3DFU3Y?J>#FF\/G^@E%%%?3GA'Z^?LS_P#) / /_8(@_P#0
M:Y;XE_MP?!3X0^-G\)>*?&]O8:]&RK-;1VTTX@) ($CQHRH<$'YB.M=3^S/_
M ,D \ _]@B#_ -!KY=_:+TCPO'KOQ"^#?P;\(6_B3XK?$LFZ\4WUR6EMM)@D
M)S<3ROD1D;G,<:GY6PP7.T-^:8AVJS]7^9]O02<(W[(^E/B]^U5\,/@7X<\/
M:]XP\3)8Z3X@!.F7%M;2W0N5"*^Y1$K';M=3GI\P]:V/@C\>_!/[1/A2[\2>
M M6?6-'M;U]/EGDM9;<K.L<<C+ME52?EE0Y QS[&OD'XM?LYBX^)'[/WPWT/
MXRVG@;Q3X.\.O#IB/ILEU=SNL862XB)Q$,B(C#,",< \"O7_ -A+XO>,/B%H
M7Q \,>-]5A\3:OX(\0RZ,OB.WC")J$0&5) XWJ0V<=F7OR>>[N;M*US4^/'[
M0WB7X9^.SHVE6^G2VHMHYMUS$[/N;.>0XXX]*\Z_X;'\;_\ /GHW_@/)_P#'
M*J?M=_\ )7&_Z\8?_9J\4K]<RW*\%5P=*<Z2;:5S\9S/-L=1QM6G3JM)2=D>
M[?\ #8_C?_GST;_P'D_^.5Z;^S[\?O$?Q2\:W>DZO;Z?%;16#W*M:Q.K;A)&
MHY+'C#G]*^/*]Y_8S_Y*EJ/_ &")?_1T-3FF68.C@JM2G22:6Y659KCJV.I4
MZE5M-ZH^SZ***_*#]A"BBB@ HHHH YKXS67C^7PY#>_#S7]%T;6+&4SR6_B&
MU,EE?1X(,4DBD/#S@AU!QCD&OB#X_>)K_P"('CKP/KOQ!TSPW\,O%NG6USI$
M,7Q TT:WX.U(2NK&:VO5^2*8>7TD4-@XS@9/U+^U_P# 76_CYX,\/Z?HG]BW
M[:5JJ:C/H7B5YTTW5$".OE3F#YQM+!U(!&Y1D&LS]F']F.?X9> O%^A>,](\
M+C3?$6H"['A30UFN-(L8Q"D92,7(W,7*%V) &X\ 5R':=[^S3\)A\$O@SH7A
M/^UK?6C UQ=-=6, @M=T\[SE;>($B.%3)M50<8 ]:]0KF_A]\.O#WPK\,P^'
M?"VG+I.B02220V4<C,D)=B[!-Q)5=Q)"C@9P !@5TE !1110 4444 >7?LL?
M\FQ?"#_L3]'_ /2*&O4:\N_98_Y-B^$'_8GZ/_Z10UZC0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4V1/,C9=Q3<"-R]1[BG5X-^U7^
MTO<_LX6'ARYMM!BUPZM+/&RRW)A\ORPAR,*<YW_I6U*E.O-4Z:NV95*D:4'.
M;T1Y7%_P2A^#,$]S/'JOC>.:YD,T\BZ^P:5R<EF.SYB3W/->B_&/]@WX3?'+
M4M'U+Q'8:E'JNFV,>F"_TZ_>WFN;9  L<Q'#C'? //7I7@__  ]!U/\ Z$"T
M_P#!FW_QNC_AZ#J?_0@6G_@S;_XW7I?V1C/Y/Q7^9P_VEA?YOP9]P> ? >@_
M##P=I/A7PSIT>E:%I< M[2TBR0BCGJ<DDDDDDY)))ZUT%?'OP&_;RO\ XR_%
MC0O!TW@^WTN/4C,#=I?-(8_+@DE^Z4&<[,=>]?85<&(PU7#24*JL]SLHUZ>(
MCS4W=!1117,;A7B'QT_9!\#_ +0WBG3-?\4W6N1WVFVHM;9=-O\ R(XUWLY8
M#:?F);!.>BKZ5ZSXMUMO#7A76=76(3MI]E-=B(MM#F-"VW/;.,5\L?\ #=E]
M_P!"C;_^!K?_ !%>O@<NQF-3GA8WMYI?FSQL?FF"P#C#%RM?5:-_DCTOPI^Q
MM\.?"_P\\2^"9(=4U[0/$#I)=Q:S?-.ZL@^1HW !0@\Y'<5>^!_[)OP]_9_U
M6^U7PQ97DVKWD0MWU#5+IKF9(00?*0GA5R!T'.!D\"O)O^&[+[_H4;?_ ,#6
M_P#B*/\ ANR^_P"A1M__  -;_P"(KTGD&;--.&_]Y?YGE+B3*%9JIM_=E_D?
M7M%<Q\-/&#^/O VD>()+9;-[^+S# K[PGS$8S@9Z5T]?-5*<J4W3GNG9_(^J
MIU(U81J0V:NO1A11169H%%%% !7YJ?\ !3#_ )+AX?\ ^Q=A_P#2FYK]*Z_-
M3_@IA_R7#P__ -B[#_Z4W->YDW^]KT9Y.:?[L_5'R/1117WY\:?4'_!.G_DX
M?_N#W7_H4=?J'7Y>?\$Z?^3A_P#N#W7_ *%'7ZAU\%G7^]?)'V&5?[O\V%%%
M%>">P%%%5=3U6RT2QEO=1O+>PLXL&2XNI5CC3) &68@#D@?C0!:HK'UGQEH'
MAU;=M6US3=,6X4M";R[CA$H&,E=Q&1R.GJ*-#\8Z!XGEECT?7--U:2(!I$L;
MN.8H#T)"DX%.SW%=;&Q1112&%%%% !1110 5^0'[8G_)ROCO_K\7_P!%)7Z_
MU^0'[8G_ "<KX[_Z_%_]%)7TF1?QY>GZH\+-_P"#'U_1GC=%%%?;GRA]W?\
M!+C_ %_Q*_W=-_G=5]ZU\%?\$N/]?\2O]W3?YW5?>M?G>;?[Y/Y?DC[;+?\
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M [  5LZ+\7IO@M^R;\-]=ATU-5>:WM;/R9)3& &BD;=D _W,8]ZXK_AO^_\
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M(/2/ OVU?^20VO\ V%8?_1<M?#-?<W[:O_)(;7_L*P_^BY:^&:_7^%_^1?\
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MG/"/N_XK?\F/_"[_ *Z67_I//7RQ7U/\5O\ DQ_X7?\ 72R_])YZ^6*O)_\
M=Y?XI?F?I&"_@1] K4\*_P#(T:/_ -?D/_H8K+K4\*_\C1H__7Y#_P"ABO:G
M\+.U['T?^UU_R5L_]>$'_LU>*5[7^UU_R5L_]>$'_LU>*495_N-'_"C^;,W_
M .1A7_Q,*]Y_8S_Y*EJ/_8(E_P#1T->#5[S^QG_R5+4?^P1+_P"CH:C./]PK
M>A>2_P#(QH^I]GT445^*G[L%%%% !1110!MT445R':%%%% !1110 4444 >7
M?LL?\FQ?"#_L3]'_ /2*&O4:\N_98_Y-B^$'_8GZ/_Z10UZC0 4444 %%%%
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M/_KU/_H;5Z17F_[.7_)$_"?_ %ZG_P!#:O2*_ ,?_O=7_%+\V?T;EW^Y4?\
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MY?\ )$_"?_7J?_0VKTBOP#'_ .]U?\4OS9_1N7?[E1_PQ_)!1117">@%%%%
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M3FBBBOYZ/Z4"L:3_ %C?4ULUC2?ZQOJ:UIF-3H-HHHK8P"OQ$US_ )#6H?\
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M?#/XA_#KP-X=\)Z7XU\,3:9H6FVVEVLEWX6N'F:*")8D,C+J*@L509(4#.<
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MWWXX_P"CB/$W_@-/_P#)E'_#OOQQ_P!'$>)O_ :?_P"3*EUL2U9T_P#R8W6
MRA.ZQG_E-_YGVM17C7PV^%7Q+^&?@O3_  W;_$?1M<ALO,VW^M^'+FXNY=\C
M2'?(-17.-^!P,  =JZ;^Q?BC_P!#CX0_\).Z_P#EG73%MI-JS/!JQA&I*-.7
M-%-V=K771VZ7['?T5P']B_%'_H<?"'_A)W7_ ,LZ/[%^*/\ T./A#_PD[K_Y
M9U1D=_17 ?V+\4?^AQ\(?^$G=?\ RSH_L7XH_P#0X^$/_"3NO_EG0!W]?#G_
M  5"_P"0%\/O^OF]_P#08:^I/[%^*/\ T./A#_PD[K_Y9UY5\>?V5_%G[0]I
MH]OXC\?Z+9)I3RR0G2_#,T98R!0V[??/G[@QC'>N_ UH8?$1JSV5_P CCQ=*
M5:A*G#=_YGY845]W_P##K9_^BG+_ .$__P#=5'_#K9_^BG+_ .$__P#=5?7_
M -LX3N_N/F?[+Q/9?>>#?L.?\G2^"/\ >O/_ $BGKK_VL_\ DX3QA_UVA_\
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M^6= '?U^0'[8G_)ROCO_ *_%_P#125^H']B_%'_H<?"'_A)W7_RSKYP^)/\
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M !5_A+J?^95NO_EE6L#&IT.ZHK@_[&^)W_0W^$O_  E;K_Y94?V-\3O^AO\
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MN\?4L.F3USB@#[R\4>*-)\%>'-2U[7;^#2M&TZ![F[O;EML<,:C+,3]*\/\
M@G^W?\(OC[XU;PGX8UB]BUQXVEM;?4["2V^V(N2QA9AAL 9P<'!X!YQ5_:D\
M-:W^TM^QUJD?A31[ZVU;5K6QU>VT+6(Q;74HBGBN&M94R0DC+&4VDD;B 3BO
M'-2^._C+]H.-M!^'?P!\1^%_%&E^&-1MH?%/BW3X].?1KMK8K%'8R'<&#.@7
M.4_A.  : /M[5O$>GZ/I&IZE-<*]OIT$ES<"$AV1$4LW [X!XK$^%OQ3\/\
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M\O\ V"O#U_X6_9B\/Z9J6FW.D7<.IZR39W<#0.B-JETR'8P! *E2..001P:
M/5_#_P 3] \3>)_%6A6-RS7?AFX@M-1ED7;"D\L8E6)7)^9@C(2.V]?6NB_M
M.S\II?M<'E(VUG\Q=H/H3GK7YJ?$'P=K7C3]F?XNZ,NF:AJ^O2_&NX;4+>QA
M>681_;4(8! 2$$)C(/0+CM72?$#]FZ>+QO\ '[PAX.^#<'BSPK>CPY?6/AB:
M_FT?3;B=8Y!<31SK)&-ZX4L%?D_>!).0#[S\1>//#GA+P]J.NZQKEAIVD:?$
M9[J\GN$6.%!W8YX]O4\"O,8?VP/AW=_!KPY\3+2?5;_0O$=Z^G:-9V>FRSZA
MJ%RLLL1BBMD!=FS!*<>BYKYU_9<_9%M]*LO&-KXY_9PT/X>V$L,%S;)#XFFU
MM+VXB,A0/$]Q*!L+;AD8)(ZD#&=\./'WB?\ 9S_X)]_#H6'P[U#6?'[ZIJ=K
MIME=Z'<SC27?4;QOMD\<<;2)&L; X4;GWJ%R": /J7PE^UA\//&=MX5FL;^\
MA_X2'5Y] @BO;-X)+7488S(]I<HP#0R[1PK#G(]17L5?G!XE\-Z%X<_9>\#V
MV@7^M:SXPO\ XK:7?WNKZWH]UI5Q?ZS+(KSS)#<1QL$\GY%*+MPF.H:OT?H
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M6D4D\I49.U06.!WX%?-/A:&V3_@H%HB^&X9[?1(OA1"MQ%)&\92/[8/LZNK
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MC;([8KK)[R"U*":>.(N<*)'"[C[9ZU^>'C_X WWC'6?VC=0\7^%;KQ#XALO
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M\GQ UIM(Y^7[-YB!MOMYXN.G?-?2U4M40]&%%%%,#;HHHKD.T**** "BBB@
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M4A. 3Z4 >">'/VV/AOXI^)=OX/L1KQ2[U*;1K'Q'-I$L>CWU_$,R6T-T1AY
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MP<5[9^P7;:7;?$S]H7^P_#]SX7T5M?LFL]*NK4VKV\9MB0ODG_5<$$1X!4$
M@8P$F)QT+%I_P5(^#5Q>K'/:>+;"P%S]FEU:XT4FTA._86=T=CM!ZX!/M75?
M'7X^?"62P\:Q^+['5M0C^%>I:-J]S+80@O'=7!B-I);,'!8XN K=/E9QR#S^
M<>B?##Q[#\.[WPU)X8_: FUR34Y);;PM_8LH\'W+FY#QBX5Y%_=M@%SM SSG
M'-?2'QM^'WCR_M/VIKQO!.M75[JO_"$S6MMI.F33+>O -/-RMIM4^:(RD@.T
MG;L.<8-3=V+Y5<^I/@7^VQ\.?C_XON?"VB+K>C:_';?:X;#Q!IQM'NH@2':+
ME@VWC()!^88SAL>^5\=^&_&FO_M,?M-_#+Q)8?"OQIX"\/\ @>WU*:_U3QKI
M0TZ:Z>Y@\F.WA3<Q=007)S@$#('!/V)5HS:L%(Z[T922 1C(.#2T50C \!^!
MM'^&OA+3O#6@6[6NDV",D,;R-(WS,79F9B2S,S,Q).2236_110 4444 ;=%%
M%<AVA1110 4444 %%%% !1110 4444 %%%% '/\ CCP'H?Q'T+^Q_$%E]NL!
M<07:HLKQ,DT,BRQ.KH0RLKHI!!'2N@HHH **** $(R"/7TKGO 7P^T#X9>'4
MT/PW8#3]-6>:Y,9E>5GEED:21V=R69F=V.23UQT KHJ* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KQ7Q3^QQ\)/&?C/4?$^K>&9I]2U.Z@O=0BCU6
M\BL[V:$@Q//:I*(92"H/SH>G->U44 (JA%"J J@8  P *6BB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *\:\=?L@?"CXD>+]2\3:_X;GN=4U3[/\
MVD(-5O+>WU#R#F$7,$4JQ3!>F)%;CCI7LM% $=O;Q6EO%!#&L4,2A$C0855
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MT3\5_%_PY\:_%OPU9^%H_ ?AZYOS:Z#?Q3G4-2M+)G$TIN5D"0NPC<HAC8<
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M@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ;=%%%<AVA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %8TG^L;ZFMFLIX)"[$(W4]JU@8U.A#14GV>7_GFWY4?9Y?\ GFWY
M5K=&-F1T5)]GE_YYM^5'V>7_ )YM^5%T%F1T5)]GE_YYM^5'V>7_ )YM^5%T
M%F1T5)]GE_YYM^5'V>7_ )YM^5%T%F1T5)]GE_YYM^5'V>7_ )YM^5%T%F1T
M5)]GE_YYM^5'V>7_ )YM^5%T%F1T5)]GE_YYM^5'V>7_ )YM^5%T%F1T5)]G
ME_YYM^5'V>7_ )YM^5%T%F1T5)]GE_YYM^5'V>7_ )YM^5%T%F1T5)]GE_YY
MM^5'V>7_ )YM^5%T%F1T5)]GE_YYM^5'V>7_ )YM^5%T%F1T5)]GE_YYM^5'
MV>7_ )YM^5%T%F1T5)]GE_YYM^5'V>7_ )YM^5%T%F1T5)]GE_YYM^5'V>7_
M )YM^5%T%F1T5)]GE_YYM^5'V>7_ )YM^5%T%F1T5)]GE_YYM^5'V>7_ )YM
M^5%T%F1T5)]GE_YYM^5'V>7_ )YM^5%T%F1T5)]GE_YYM^5'V>7_ )YM^5%T
M%F1T5)]GE_YYM^5%%T%F:]%%%<IV!17A#_"/XI_\+\O/%<?Q(D3P4\;1P:&\
M4+.HVEU5C]G&8Q*S#;NW[0#YI^X/*O!?PS/@[XX>";3PQXV\1^-?B!9WTTWQ
M"UJ>_GDTY[=X)"8IH"Q@A<R&/RHH@'4<M\HH ^S**\?^.?QD\1?#_P 5> O"
MO@_PY:^)_$OBJYND2WO+IK:&W@@A+O/(X5B$5VB!^4G#' )P*\9\:_&7Q5\5
M_#&D_#_5M-@\->-G^)-AX9U:/1KYY;=[> 1:E--!*51RC0( 58!N6!&#0!]C
M45\>ZK^W7=V'Q;L- BM?!=WHUYXDM_#L>FVGB87.O.9;@0+<B"&-H F6W;#+
MN X.#P.U_P"&@?B=XHU'4==\$_#6RUWX=:;J[:4]W-J;1ZIJ(CF\FXN+2W$9
M0QQR"0?.ZLPC) Y% 'T;17PKXG_X*=Z+IOBC4Y]*_P"$2OO"6F:I_9DEK-KC
MIKM\HE$3W%M;"$QE 2S*KR*S*N>,UO>,/C9\0?"_Q9^-_CGPIX8LO$O@_P '
MVUA87SZEJSVH9+>W-U<K:1A'#3 W1#%]@_=J,DX% 'V917SMX@_:&\=>+?$V
MK:5\)/!FEZ_;:!907>KZGXCU)[*#S9H1.EG!Y<<A>;RV1B6VHN\ FO3_ (>?
M%K2_'?P;TCXBO&^E:7>:4-4GCN&!-JH0M*K$<'8589'!QF@#NJ*^6/ O[4_Q
M$OI_A1JWC'X>Z7X?\(?$*>/3[.:WU5Y;^UN9+>2>-I83&%$3K$V,.6 P6QTK
M"M/V[[J?XNZ%X?%IX,O='UGQ!'H$&GZ5XE%[KD(DD,:74D44;0>6.&8+,2H/
MJ* /L2BOB'P]\3?&GB!?B%J'C>RTV_\ #GBSX@6O@[0K&RUF\C(6"7R+EHV5
M8RD86WGERK9=Q(& 4#-/_AYUH]YXJBN--'A.\\(2:Q'I4=H-<D_X2"='N%@%
MTEJ(3'Y>6W[#('V#.!0!]U45\B_$7]L#X@Z#;_%3Q#X:\!:)JG@7X?:FVGW6
MJ:CK$D$^H/&(UGBMXDB<&1)7=/F*J< #)R*NZE\5_B7;?M#?%+5;/1;+6_"'
M@;PQ"G]AV%[.U]<74T1ND01>5Y?GL @;YCM0IC<6( !]6T5X#^S/\?/%OQJN
M;^35=)\*RZ-% )$U7PKK;W0MI]V#:75O/%%-%*!D_<V_*1G-4/C#^T3X[\+?
M$#Q=X<\$^#M(UJS\+^'8M>U36=:U-[.VM=WG,83L1V9S'%N4 8YRQ48R ?1M
M%?,GP_\ VH?'&O:QX,O?%'@;3/#'A3Q7H%UK5GC57GU&W2W@29GGC\H(L;"1
M0N&+#(W $XKB9/VFO$'PT\#?#,:+X4T/0(O&^GS>))M8\8ZY>QZ5!-<2B5;4
M7)CF99G67>%<HB@$+@   'VC17R_\6?VI/&WP_B\!VK>%?#GAS4-?L#=7=YX
MMUMXM+@N P46<=W;Q2HTKYW*6*J5QSG(')_%#]OV?P-XBTWPE+IOA/PKXOBT
MF#4];A\8^(O)M+227.VU@EMXY3.Y"EMP 0*R9.3@ 'V917S%H'[6'B;XP:/X
M,B^%/@_3]7U[6M&_MO47US4FMM/TN'S7A"M+'&[R-)+%*J;4Y"%C@9QJ_L=:
MOKWC;3OB5XV\0VDVG:EK/BRZMH]-DNC/'9QV:):F)&Z%1-%<'< -V0<4 ?1%
M%?GS<_$SXJ^+?AEK.JZC96NJ3>,OB=:Z3X?TW1-6F5Y[>SN'2ZB625$6&!EL
M'(<9R'D9E' /I'B']N;4OA1H/Q C^)'A_0]-\2^'=9T_1+*+2M6=]/O)[RW%
MP@:>6)#&(HR6D8KP!P"2,@'U]17S;^RQ^UPGQ\\6>)?"UXWAJ\U71[.WU!=1
M\'ZG+?Z?-%*[H4+RQ1NDB%1D%<$."#5?XK^ -.^//[5&D>$/$$NHR^%_#?A.
M75;JST[5;JP,EW<W216Y=[>2-B EO.0,]10!]-45\AZ7XA7]E?XG_$OPYH^J
M7FM>"M.\)V7B*UTGQ!KF5TV]EN9K<0"]NWRD<H1'VN[$;25!+ &AX+_;GU[Q
M);_$>RCTGPCXDUCPUX1N?%=I<>#]:FOK%Q"<?9)W>&-EF/4;0P(!YH ^RZ*\
MG\+_ !M;QYX^\.:#X>M+:[LI= BU_6[QI"?L,<Z VD*@=9)"7?!Z)&3_ !+G
MRS]L+1?%WC;QSX*T32_AOXB^('A6PM+S4M1M='UXZ''-<DI';HUV)8V^1?/?
M8I))9.,<T ?5=%?GCXH^(4_B_P *?"KX;?![PAXPD\.ZO;:CKFNZ!:ZV\6I[
M;>Z:WDLY=1N9F:&/[2) SAR2(U5, XKZ@_9 >T;X2S+8MKMM;1:M>0?V+XCN
M3=7>BO&^R2R,[,S3(DBN5<L25<>E 'MU%?/.B?M.:EKW@S31;Z+9CQUJ/C&^
M\)0Z09F,2FTO)(Y[ACC=L2WC\UO=E4'YA7!ZS^TIJ'P_\"1>,?#WA?3[>/QE
MXJU**XUOQ#JM[_9-E';.UO'<7$BI,T"RBW4*L:+&"P/!)) /L*BOE_5?C=KF
MOCP!!J_AG1[;Q1+8ZUXC@:W\0R2Z6BV4 6"Y$UOGS+>9KA<"1"5&3LW**[/]
MCN?QQ=? /0=1^(#V;:OJ7F:I%+;W<MPY@N6^T*)FD1=KKYK)L7*JJ( Q[ 'M
MM%?'.F_MY75W\7?#OAXVG@R_T?7=?30H+#1O$HOM;MM[E4N9HHXS!Y8P&8),
MQ /<BK=O^U[\1M6M=7\4:9\/=&E^'NG>,6\,QZA<:O(E[J<?VX6:RVL*Q,I.
M\G(=UST&<&@#Z[HKY-^+G[3OQ#C\&_$OQ/X,\#Z?=_#[PK'>V,VM7^J-!?7D
MT*M'-+9PK&RLD4H*G>ZEBC!>>*]3\#2W'P&_9:T";6G.H:CX?\-P/>F^OXX#
M<70A4R!IYW")NE)&YFP,]^E 'K]%?(/PN_;HG\3>(_$VF:[#X/U"'2O"]YXI
M^V>"];DU&.VCMVC5K>Y,D,860^8,%"P.#63XB_;H\8>!/!'@K6?&/AGPEX2O
M?&]I'<:);:QKLL"P*L0DN)KQO);RXQOB$:1[W;?\P7!% 'VI17B?[+/[1D7[
M1'AG7KIDTDW^AZC_ &=<W.@7K7FG7),22K)!*Z(Q7$F"&4$%2#7G'C3]K'XD
MV=U\6=2\*^ -$U+P;\/+]K6ZU;4]6DMY+\QPQO-#;QK$VZ56<CYBJ_=&2<B@
M#ZSHKYX\7?'GXDZMXD\46GPR\!Z1KND^$U1-6U#7=6:S^T7/E"9[6U5(WW.B
M,F6D*IEL9X-8'A/XF^.?C%^TAX&U3P_'IUO\.XO!L.N7=K=7\Z7&;]L1L8EC
MV/(GD2*H+ ;6=L@X4@'U-17B'QJ^*6F^#OB-HT-U8B[;P_X<UGQ?/<?;)8A:
M);Q+$FZ-"$D$@EF'SA@ICR & (X/PW^U?X]TK5_ UU\2_ VB^#?"_BC1K[5@
M\.KO<W]A':6JW$TL\7E!1&588"LS+N ;!X(!]5T5\V>'/VB/BA/;Z1XMU_X8
MVFG?#;6;2>]AN[74VFU+38%@>>*6]A\L(BR*H'R.Q4N,^^7^R7\2-<M=/\!^
M!]5A>_O]0\'/XXUO5;J5C)!)>W9>"  YQ\KR<'H(P* /J>BOF31OVGO'/Q T
MKPII_@?P5I>I>+=>M[S5W_M/47M]-T_2X[J2&WGED5'=GF"H51$/);LN:\5T
MO]KJ_P#A1=^-/$_B>VTO2?&/C/Q=<:'8Z?K^N-%I6G0:7;Q13RM,J,=GGO*!
MLCW/N7(X. #]!:*^2? W[<=SX^\$-'H.A:/XE\?S>(%\.6%IH>JM+I-Y*;<7
M#7*W+QJZP1Q%B^4W KMP216K\&?%WCCQ]^U=XJM_&>EVNAW?@KPQ;:;<6VD:
MA)=6$]S>3FX\Z,LJ,088H1\Z!@0XZ$$@'U#15#7]$M/$VA:CH^H+*]AJ%M):
M7"PSO YCD4JP62,JZ'!.&4AAU!!&:^,?A-^R[\-_&_QJ^+]M):>('\*>%[VQ
MT>P@/B[5]HN1;+/=.6^U;F^:9$(8D#9P!DY /MVBOAWX,_M%_$+2=.T3Q1-X
M4L;[P!X]^($]E:ZA=ZO(=1:&ZNG2">&W$900111J2&<$A&(4 YJ"Y_X*=:-+
MXOFDL%\+-X0M]9&D&UN=:=?$%RGGB%KJ&T6(Q^7G+!7D#LH!P,XH ^Z:*\ U
M7]I^;1K/XDVD^CP2>)]!\3Q>&=#TF.9MVJS7%O!-:D\97/G.7P"%2)F[5W'Q
MA^*MY\)_ MC?Q:(WB/Q3J5S!I>FZ+9RB,7=]+P$\QN$C&&8L>BJ30!Z/17PK
M\2?BM\1=,^*NIZA\0?#EA8R> O U_K"V/AW69Y;+4KB^E2UM8]^R.17PMPO*
MY!P5/.1WNM?&_P <>#?"_BJ'P!X!T^^\!?#:P>RU34M4UR5;FXEMK?=<1V0=
M9&E,( R\[KO8$;B<T ?5M%>!?#77IO@-^Q3I?B77#-?W^B^%'UV^2XF9WEN6
MA:YDCWL2>9'*CTXKRWQK^W'XN^&ND>$_^$P\/>#_  EK7B^S2^TNVUO7I8(K
M&!8P9I+YA"Q4EV18XXA(Q!)8KM(H ^SZ*^'M>_:8\;?M"?"GPI;_  ^3P[!K
M]_XXB\/W]Q:ZS<?8;A8%%VYMYTAWF&2*-E8E0R@D8)XKUR;]IC5XOA=\5?%B
M:#9RR>%-;DT#2H1.PCU.Y3R(B=V,A3<RM&,#HOK0!]"T5\W^)/VD/&D'C?XF
M6>B>%=)E\(_#Z.&?5_$.IWLD*%5M3<W,42(C;YE4IA3M4 Y9OF454^&W[2'Q
M-UKQO\,=.\:?#W1_#.E^/+&YN+.*VUA[C4+5H+=9G>:+R@BHVY0 &8KN ;!X
M(!]-T5\J_MNR>-_%&L_#'X>>%SIT6E>)-3FN-7>YU6[T^1[:TA:>2-I;="Z0
MLHP65@V[RU& Q(I^'/VF?&.C>$/#/BZT^'UC:?!&6]L]%L;V[UF:36VM))5M
MH+WR70AHR2C8:4RE3DY)S0!];45X3\,_C9XX^*_Q.\5Z?I'A72[7P)X:\07&
MBW.NWU[(L]UY42[OLT2H0["8E6+,JA<8+-D#EO'WQ8N/#_[1GCO5]\<^C?#W
MP3;$V=QJ,=E!+J%_<NRK)+*RQK^[MH^6Y <X!) (!]/T5\5^'OV\-<UC3/B/
M +7P/JVJ>&_"=QXIMK_PUKD][IRK$ZJ;:X=H$99CNRH0,K8(R.M8%O\ MA^(
MO@%X*\!?#KQ7J'@Y?B7_ &%'JNKZAXKU^X@LXHY&/E(\@@>62Y< EE";4/\
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M>O/'[VLNMZB'U-)+>[EN9&AN6^T*)FD12LBF5DV+E55% 8T >U4444 %%%%
M!1110 4444 8'CW0M5\3^"M;TC0];;PWJ]]:26]KJZ0>>UG(RD"4)N7<5SD#
M<.>]>-_LW_L[>/\ X$?8],U'XJV7B?PE;0R Z1!X3AT^6:=L$W$MR)G=W)R6
M+9+$Y)KLO$?[4/PF\(_$&'P-K/C_ $33_%DLB1#2YKD"17< HCG[J,01@,03
MD>HJ+Q]^U5\(_A=KD^C>*_'^C:%JT$D<4EE=S$2JSJ&7Y0"<88'=T&>2* .
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M#G%=IX1\8:)X^\-V'B#PYJMKK>B7Z>9;7]E*)(I5!(.&'H001V((/(H \/\
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M^+_B/0KZ;3=/\&^'/#,&MZKK=U-L\B:>:185+$[ AC@E;)Y)QCW ,O\ 9&^
MK?L__!O2M%U&0WGBN[CCN=<OWD\QYK@1K&J;NZ11HD2@<83/<YD^*'P3\;^*
MO&$NM^#?B_K/@6WO[>.UU+3/L,6HV[HF[#VPE8?9I2'(9U#!L*2N1SO?#?\
M:/\ AC\7=/U>^\(>-M(URUTA/,OY(9]OV5,$[W#8(7 /S=.#S4/@+]IOX4_%
M!-<?POX]T35TT.%KG47BN@JVT(^]*Q; \L8Y?[H]: .(U3]DN;P]IWA8_"WQ
MU?\ P[UG0M/ETIM0>QBU-;^VEF\^7SXI"H:4S%I!(",,[<'.*]4^$_PRT_X1
M^"K;P]I]W=ZD5EFNKK4=0</<7ES-(TDT\A  W.[,>  ,X'2L/P)^TO\ "_XH
M6&OWGA'QII?B&+086N-16REW-!&H)+E3@E?E.&'!QUKE/V9/VLO"GQ^\-Z-;
MMKVB)X]GTU-3U#P[I]P7:T1_F ^;[Q"LF[!."><4 7? O[,MCX%^+7CWX@0:
MRUYJFOR32:3!/:_N=$,ZQFZ*#?\ O#-+%&[,=IPBKV)/.R?LK^*M!\%^#=%\
M$_%J_P#"\^B:,-%OOM&DQZA8:I&6+/*]G+)M24L6^<,3AL'< *[[PI^T[\*?
M'/CV?P5H'CW1=6\40EPVFVMP&<E/OA3]UR,'(4DC!]*ZSX@?$;PQ\*O#%QXB
M\7ZY9>'M$MR%DO;Z4(FX]%'=F/91DGTH \%T#]AS3/#'A_5M&T_Q;?)9W/@>
MX\&6;O:IYMG]HFEFN;H$,%)=Y5Q&JH%5  ?3VK0_A]-%\([?P1X@U=]9D.D'
M2;S4[2W6R:93$8V=(U+"([3P 3BLC2?VD_A?KGPZF\>6'C?2;GPA!<):3:ND
MW[F&9F551^,H<NG# <,#TYI? O[2/PO^)>G^(+_PQXYT;6+'P^N_5+F&Y CM
M$P3O=FP-F%;YNG!YH \?^'/[%OB'P3JG@$ZA\5I=;T+P1+(VD:(GAZWLX-IL
MY;:)IFC?=+-'YBOYIZE#\H+9'?Z#^S5;:!\+/AIX(@UK-GX2U>VUF[F^QX_M
M.:)Y)F^7?^ZW7,BS9R^-F.<Y&EX0_:E^%WQ)TCQ)>>#?&ND^(WT&TEO+V&TF
M.^.-%)+E2 2O&-PR/>M+X.?%NW^(7@'3M4U::RT[7ETBSU76+",LB:>+F 3H
M&+]!L)R<_P )Z4 >/>)/V*M<UJQUWPU:?%S5M,^'6HZO_;,?A:+2X2$DDO!=
M7,,EQN#R0R,9<)\NTR DN%*M[%\>O@U;?'/X8WOA&;4Y=&9YK>ZMKV.!)Q#/
M!*LL1>)_EE3<@W(V PR,CK6)XB_:]^#7A%]!36OB)HVEOKEM'>Z>EU*R-+ Y
M(24@C*(V#AGP#@UH>(/C9I'A7QGK_P#;'B/PUIG@[0-%MK_4[JYN9%N[:>XE
M<0%LKY0A=(WVD.79A@*!R0#RW_AC77]:L_%K>*OBG<>(M4\1>'D\.27(T.&T
MAL[?[1YL@MX8I $61?E())S\VXX"UZ-\8?@;JGCG5_#GB+P7XQD^'OBW0K>>
MQMM1CTV*_A>TF,9DA>!RH/,2%2&&TCOG%=+\*_C7X%^-VD7&I^!?$]AXFLK:
M3RIY+*0DQ/U =2 RY'3(YKR7Q7^VMX7T7XB_%/PC92VEU=^!/"\NN7#F5RTU
MR@D+VVT+@! L63NR3,H X- 'LWPS\"R_#SPK%I5SX@U?Q3?-(]Q=:MK5P99I
MYG.6('W8TSPL: *H  [D^?3_ +-GVCX.7G@,^(R#J7B!M<U+4A8_-=!M1^VO
M#L\SY05"P[MQ^49P>E:?P<_:7\ ?%^W>PTGQCH6J>)M.T^.[UFQTZZ#K:G:O
MFL">&C5SMW D#(R>:T?AK^T?\,?C%KNHZ-X*\;Z1XEU33T,EQ:V$^]U0$*7'
M]Y<D#<N1R.>: //?&'[*&MZYXF\4#0OBGJ_A/P/XMN3=Z_X<L-/@::>5D6.7
M[/>-\]N)%4;@%;J<$9X[7X>_ QOAO\4==\1:7KQ'AK4=(L=+@\-&R7%F;5 D
M;I<;MQ7;O_=[<9<G)XI/C]\5M?\ AQ9>%]-\):1I^K^*_%.JC2--76;IK:PA
MD\J25GFD56;&V)@%4%F) %5_V<OC#KGQ7TKQ5:>)]+TO3O$7A?69-%OI-"O&
MN].N)%CCDWP2,JM@"0*RL,JRD'T !C?%7]F*?XG>(_'VKMXK_LZ7Q1H&G^&X
MD_L[S?L5G#=//<KGS5\PSB1D_AV<'Y\8K8\?_LX:1\3/')U;7;^2;0AX1O\
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M0COM+D?=X]G_ &H]-U.R_9G\7Z1X1\/W6K7$FGQZ9#H^C0@S?99)(X9A#'D
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M0LM2TZT\+3VDERS+<"9K>25G$(C BY<, ,J.G<_%!?&_A/1/V@?"%G\%M?\
M&/B;QE<71M/$UO9QRZ?+ITL2PVX:4MO+P*3B%5)W MP"37WI10!X5\9O NKZ
M/^R+J/@3PO9SW.J2:%;^';>*RB,C()%2W=\+_"JLS$]  37#:/\ "R\\+ZY\
M>O'4'A6[NM2T_2(O#'A&SDM"\TEG::<"!;#&666:9ER."8R.@KZNHH \B@\/
M:[\)_P!E%-$\*Z?)J/B?0/!_V73K.,8>>\BL]L8[<M(!^=>5?"#X7+KOB[X,
M2:IX.U2PT#P/X$\RUBU_3_+>#4Y98XCE?F F2.WE;;DD"93UQ7UE10!^<_C+
MX0^.=3\+?#SQQJFA?$+3[2;Q!XA\1:KHO@2*W77-.N[VX!LW\F=&#*D*LAP-
MR[\YY)KZ8_8\^$>I_#KPMXCUW7?^$DCUSQ9J(U&X@\5:G!>WR(D:Q1&9H(8D
M20HBEE&_' +$YQ] 4A&01Z^E 'P#HVKZ]X\T+XP:-H7PDU/7]6^*&MZE;67C
M-XH'T@:<&^QQRW$Q?<@B6)Y%BV98X*\M70>/?!/C[3/!/Q-OM*\/ZY=)=^)-
M)T:5;/2X;O4Y=%L+6.)[BT@N!LE=IO,="0>'+#D9K[$\%>"M%^'7A73?#?AV
MP33-$TZ+R;6T1V<1KDG&YB6/))R23S6W0!^<&F_"+XE>,-,^+FLS^'_'^I&Y
MTO0K2RL_'36PU+5M/BOC<7EN@@5(HRT:LGDDD_-AC\_'<_'/PAXC_:7^%6MZ
MGI'P<UOP7!82:=8P).+>R\1ZEI27*2WUO# =T<2A40QB0L&93\F,!ON:B@#\
M[;+X)>--<\$?$?Q9H^G?%6XU>[\+2>#M L_B)>VGVN5;N:,2DVMO IABCVJ=
MS.1C>=H S7?-X/\ %?Q<@@MO!WPNU3X36/@SPEJ^CZ7)K\<%O-/J%S:^1%%
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J1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>crvs-20260331x10q009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 crvs-20260331x10q009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (( Z@# 2(  A$! Q$!_\0
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M(#$"@)*R,-Q7/(P>!0!]!G]JR^!P?@[\0 ?>+3__ )+H_P"&K+W_ *(]X_\
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M75@T?2H])TRU\22MJ*W\[VM_>V2?8[D6Y\I+:-I?WC$$%\!1G.XX!OW/Q_\
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ML^GW?]?(/K4^R-#_ (:RNO\ HC_C_P#[]:?_ /)='_#65U_T1_Q__P!^M/\
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M_%&*/[/I]W_7R#ZU/LC0_P"&LKK_ *(_X_\ ^_6G_P#R71_PUE=?]$?\?_\
M?K3_ /Y+K/Q1BC^SZ?=_U\@^M3[(T/\ AK*Z_P"B/^/_ /OUI_\ \ET?\-97
M7_1'_'__ 'ZT_P#^2ZS\48H_L^GW?]?(/K4^R-#_ (:RNO\ HC_C_P#[]:?_
M /)='_#65U_T1_Q__P!^M/\ _DNL_%&*/[/I]W_7R#ZU/LC0_P"&LKK_ *(_
MX_\ ^_6G_P#R71_PUE=?]$?\?_\ ?K3_ /Y+K/Q1BC^SZ?=_U\@^M3[(T/\
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M'_#65U_T1_Q__P!^M/\ _DNL_%&*/[/I]W_7R#ZU/LC0_P"&LKK_ *(_X_\
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M$KZOHH^N5_YOP0?5Z?8^4/\ A'/CC_T3GPQ_X5S_ /R)1_PCGQQ_Z)SX8_\
M"N?_ .1*^KZ*/KE?^;\$'U>GV/E#_A'/CC_T3GPQ_P"%<_\ \B4?\(Y\<?\
MHG/AC_PKG_\ D2OJ^BCZY7_F_!!]7I]CY0_X1SXX_P#1.?#'_A7/_P#(E'_"
M.?''_HG/AC_PKG_^1*^KZ*/KE?\ F_!!]7I]CY0_X1SXX_\ 1.?#'_A7/_\
M(E'_  CGQQ_Z)SX8_P#"N?\ ^1*^KZ*/KE?^;\$'U>GV/E#_ (1SXX_]$Y\,
M?^%<_P#\B4?\(Y\<?^B<^&/_  KG_P#D2OJ^BCZY7_F_!!]7I]CY0_X1SXX_
M]$Y\,?\ A7/_ /(E'_".?''_ *)SX8_\*Y__ )$KZOHH^N5_YOP0?5Z?8^4/
M^$<^./\ T3GPQ_X5S_\ R)1_PCGQQ_Z)SX8_\*Y__D2OJ^BCZY7_ )OP0?5Z
M?8^4/^$<^./_ $3GPQ_X5S__ ")1_P (Y\<?^B<^&/\ PKG_ /D2OJ^BCZY7
M_F_!!]7I]CY0_P"$<^./_1.?#'_A7/\ _(E'_".?''_HG/AC_P *Y_\ Y$KZ
MOHH^N5_YOP0?5Z?8^4/^$<^./_1.?#'_ (5S_P#R)7&^*_ 'QM@\9^'/%T_@
M/PS'!HT5S"UNOBMBTOG)L!!-J,8ZU]PUS'Q%_P"18F_WU_G43Q-6I'ED]"HT
M81=TCX.UKX9>-]9U'49QX#33++5)/-U+2=,^(4EO97[D89I8EM>K  -M*[AU
MS6CK'@?QAK:7<<WPIT.&&YL(--:&U\9F)%MXG#QHBBU^7! Y':OH2BN4V/*-
M2USXJ:MIUU8W/PUT!K>YB:&0+XO()5A@X/V7CBL"ST/Q]8-X5,/PQT4'PS"8
M--W>-&.Q3'Y9W_Z+\_R]S7NU% 'SD/AQXN_M:2\;X8:>]N\TEU_9+_$"<Z<D
M[@AY5MOL^P.<G)Z9.<9YJGI'PF\5Z-<P3)\.(+PV]C-IENFH?$6>X2"TD7:T
M$:O;D(F.F.1@<\5],T4 ?-]K\-O&%MH6J:2WPUL+FUU*TM[&Y:Y\>/)*T,&?
M*4.;7(VAL9] /2K^N^#?&OB.[U6ZO/A?I/VO46MGDN+?QS)#+%);Y\F2%TM@
M8W7<>0>>]?0-% 'SYHG@WQQH5YIM[#\-=.N;^PNI;U;V^\>2W$\T\B>6SRN]
ML2YV\8X ["DTKP5XWT/6=.U6P^&FFVM[8S74T;1^.G"R?:&W2I(OV7#H6 (4
M],"OH2B@#S'_ (2SXM?]$W\/_P#A6_\ W+1_PEGQ:_Z)OX?_ /"M_P#N6O3J
M* /,?^$L^+7_ $3?P_\ ^%;_ /<M'_"6?%K_ *)OX?\ _"M_^Y:].HH \Q_X
M2SXM?]$W\/\ _A6__<M'_"6?%K_HF_A__P *W_[EKTZB@#S'_A+/BU_T3?P_
M_P"%;_\ <M'_  EGQ:_Z)OX?_P#"M_\ N6O3J* /,?\ A+/BU_T3?P__ .%;
M_P#<M'_"6?%K_HF_A_\ \*W_ .Y:].HH \Q_X2SXM?\ 1-_#_P#X5O\ ]RT?
M\)9\6O\ HF_A_P#\*W_[EKTZB@#S'_A+/BU_T3?P_P#^%;_]RT?\)9\6O^B;
M^'__  K?_N6O3J* /,?^$L^+7_1-_#__ (5O_P!RT?\ "6?%K_HF_A__ ,*W
M_P"Y:].HH \Q_P"$L^+7_1-_#_\ X5O_ -RT?\)9\6O^B;^'_P#PK?\ [EKT
MZB@#S'_A+/BU_P!$W\/_ /A6_P#W+1_PEGQ:_P"B;^'_ /PK?_N6O3J* /F?
M]H/7_B'J'P\,&N>"M'TC37O[7S+NU\1?:I$_>#&(_(7/YBBN[_:F_P"232_]
MA"T_]&"B@#ZL^+?Q1LOA%X4CUR]TS4-8\Z^M=.@L=+2-IYI[B58HE7S'1>68
M<EA7GNK_ +6NC^&;/7$U_P '>*M#UW2[>TNUT*[M[<W-Y#<W:6D3P,DS1-^^
MD56!<%<@D8(K5_:D\"ZO\1/A]I&D:+'>M<CQ+H]U+-ITRQ7%O!%>Q/+,CG[I
M1%+9Y/'0UYY\>_V9H(_A1XKN=(3Q-XX\6ZDVE6TUS>ZFUQ?M8P:E#</#;L61
M8P LC_)M)8 YR!0!Z;X?_:*T2\O_ !!I_B;1]8\ :AHFEG7+J#Q''"H-@&96
MN$DADD1E5D(89W#CCD5G:'^TS:WE_H#:WX*\4>$M \0W$=II&O:S;PI;W$TG
M^I21$E:6W,O 3S47)(4X8@'P^X_9]U?X@WWCZP\*>'_$_A'0?$'@^XTJ[O/'
MNH-=SW&H"97LU@WS331PH#/YOS!&\Q<*64FN^\=:OXL^/GA71_  ^'6O^%;^
M74=.GU[4=5BB2RTV&VN(IY3;SJY%R[-$$C\L'[^YMN"* /8OB;\5]/\ AJ-'
MM6T_4-?U_6IVMM*T/241KJ\=4+N1O941$4;F=V"J,<Y(!K^ /C%8^,;;Q NJ
M:3J/@W5/#[JFJ6&O+'']G5DWI*)D=HI(V7)#JY *L#@@BN4^->B:WH?Q,^'_
M ,1])T.\\3V6@1:CIVJ:9IH5[Q;>[6(BXAC8CS"CP(&0'<5<D E<'B_B9)X[
M^.'AB2\;X=70\':3K^E7\'AS52D&IZ]:PNS78D@=_+5 QB:.*0@N86W8#**
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ME 'LGQ2^*\'PZ?1--M=(O/$OBC7II(-*T.P9$DN#&F^61I)"$CB1<%G8\;E
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MDBL<\#S<#D-CA_V8?AEXX^'%_P#$K_A+M2LKVUU/Q";K3EL]-2T62,6T$?G
M+*^U6V!!&<;?*)R=W'GC?#J^\86^I>%SHT.H7>D?%Z+7M3MK@H1)I\DPN8[@
MJW#+Y;JHQG)B8=5- 'O.K?%'PA-9>%M?MYK+Q%HM]JB6%KKFG2174%I<2[HD
M8NI.W<Y$)8<@R ' )KE?VT?^36OB3_V")/YBO,?'WP\U/P]\-?BYX<%A'IES
MXU\=6P\-P0E0)C*EB/-54^[M:&>1L@$"-F/K7IO[:'_)K7Q)_P"P1+_,4 8L
M/^IC_P!Q?Y"GTR'_ %,?^XO\A3Z "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 5PWQA^,?ASX(>#Y_$/B.:40KE8+2UC,MQ=2!2WEQH.IP">P
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MHH **** "BBB@ HHHH **** $P/2EHHH **** "BBB@ HHHH **** "BBB@
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M10 4444 %%%% !1110 4444 %%%% !7,?$7_ )%B;_?7^==/7,?$7_D6)O\
M?7^= 'D=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 >1?M3?\DFE_["%I_Z,%%'[4W_ "2:7_L(
M6G_HP44 ?<%%%% !1110 4444 %%%% !1110 4444 %>*?MH_P#)K7Q)_P"P
M1)_,5[77BG[:/_)K7Q)_[!$G\Q0!B0_ZF/\ W%_D*?3(?]3'_N+_ "%/H **
M** "BBB@ HHHH **** "BBB@ HHHH *='_K%^HIM.C_UB_44 >_I]Q?I3J:G
MW%^E.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KF/B+_ ,BQ-_OK_.NGKF/B+_R+$W^^O\Z
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M;%CAO)B5,_7 KSX5:[Q$J4DK))];Z\W^1WSIT%0C4BW=MKI;2W^9/1117H'
M%%%% !1110 4444 %%%% !1110 4Z/\ UB_44VG1_P"L7ZB@#W]/N+]*=34^
MXOTIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*-C^9!K3M_">AVG^HT73H<?W+2,?^RT?\)D?^?C_ / 8_P#R0?\ ";'^=_\
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MT4H)[-6G%^C7+^;:ZZGH.:6O-3\._&&AJ/[ ^(%Y,B'Y;;7[6.\4CT+J%?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZU7E'PX^.?@CXA^)IM/^']O-XALYGDN-1\0:39;=,CE"@?/<D*LTK848CWD
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M7PL5?^$0 P,&]O>,<?\ 'S)5;7O@SX7UJ\-_#9/HNJYR-1T>4VD^?4E,!O\
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M5]GUZI-;^HM%%%=AR!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P 4OS.W%;P_PQ_(****[CB"BBB@ HHHH **** "BBB@ KF/B+_R+$W^^O\
M.NGKF/B+_P BQ-_OK_.@#R.BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /(OVIO^232_P#80M/_
M $8**/VIO^232_\ 80M/_1@HH ^X**** "BBB@!#TKX+^._B+5;CXL^+[KQ!
M\3?&/A'3O#_B72+6XTK1=5?3;2U\/74"1G4"RK\^+J1BTI)"^45.!7U]\;_B
M%+\)_@]XU\9P6J7MQH.CW6HQ6\A(65XHF958CG!(&<=J^8EL?CCXL^)/A_X9
M>(?BC96\.M>'IO$]YK^A>'K>"\CC5XXCIR++YD9AWS*V]EWD*5/7- 'KW[&F
MK_VM\()UC\0:EXQL[/7-1L[3Q3JEZ]W)K,"7#!+E9&)RI'R#;\F8R5X(KW:O
M'/V3_%^K>+/A%'#KTEM<ZQH>JZCH%S=VEJEK%<FTNI(5E$2 +'N55)5> 2<<
M5['0 4444 %%%% !7BG[:/\ R:U\2?\ L$2?S%>UUXI^VC_R:U\2?^P1)_,4
M 8D/^IC_ -Q?Y"GTR'_4Q_[B_P A3Z "BBB@ HHHH **** "BBB@ HHHH **
M** "G1_ZQ?J*;3H_]8OU% 'OZ?<7Z4ZFI]Q?I3J "BBB@ HHHH **** "BBB
M@ HHHH *;(<(?I3JY_Q5X1;Q0;?;KFKZ-Y.[/]EW(B\S./O94YQCCZUK2C&4
MTIRLN^YK3C&4DIRLN^YA_!0C_A!5Y_YB.H?^EDU=Y7 >%_A!!X2GMC9^)_$D
MEM#,T_V2>^5X9&9R[[ALR068D\]Z[^NS,)4JF(G5HRNI-O:UKLZ\?*E4Q$ZM
M*5U)M[6W9#=V<&H6TMO=0QW%O*I5XI5#*X/4$'@BO)[[X$W'A2\EU/X::Y)X
M0NG8R2:1(IGTJX/4AH"?W>?[T9&,]*]>HJ,-C:^$NJ4M'NGK%^J=T_FM.A&&
MQM?"W5*6CW3UB_5/1_<>067QVN/"EW%IOQ,T*3PA<NVR/6(F-QI-P<X&)@,Q
M$_W9 /K7K-I>6^H6T=S:SQW-O*NZ.:%PZ./4$<$4E[8VVI6LMM=P175M*I62
M&9 Z./0@\$5Y-=_ J[\'7,FH_#'77\)S,V^31;@&XTFX/<&$G,1/K&1CTKO_
M -@QO_3F?S<'^<H_^3+T1W?[#C/^G,_FX/\ .4?_ "9>B/8**\AT_P"/$OAB
M[BTSXEZ')X,O'81QZHK&?2KAO]F<#]WG^[(!]:]8M;N"^MX[BVFCN()%#)+$
MP97!Z$$<$5P8G!5\)9U8Z/9K6+])*Z?R9PXG!U\+9U8Z/9K5/T:T?R9-1117
M"<04444 %%%% ''>"_\ D:O&G_7_ !?^B$KL:X[P7_R-7C3_ *_XO_1"5V-<
M&"_@_.7_ *4SMQ?\7Y1_])04445WG$%)BEHH CGMX[F)HIHUEC889' 8'Z@U
MR.M?!SP3X@YO/#&FF3.?-A@$,@/^^F&_6NRHK"KAZ-=6K04EYI/\S>EB*U!W
MI3<7Y-K\CS8_!*VL"'T+Q/XDT!EZ)!J+3Q?C'-O%+_PC?Q*T>4-8^+],UN(#
M_4ZSIGEM_P!]PL/Y5Z117%_9N'C_  KP_P ,I)?<G;\#L_M'$2_B6G_BBF_O
M:O\ B>;#Q=\1-(=EU+P/;:K&/^6^B:FIS_VSF"G]:5?CGI-EE=<T7Q!X<9>&
M-_I<C1C_ (''N7'XUZ128S1]5Q,/X==O_$DU^'*_Q#ZSAI_Q*"7^%M/\>9?@
M<KHGQ6\'>(E']G^)=,N'/ C^TJDG_?#$']*ZE)%D4,K!E(R"#D&L+6O 7AOQ
M%&RZGH.FW^[J9[5&;\\9KEI/@'X7@^;2&U3P[*/NOI.I30@?\!W%?TI<V/I[
MQC/T;B_N:E_Z4'+@9[2E'U2E^*<?R-2SN(C\6=1B$B&3^RXODW#=_K#VKM*^
M.=*^"'Q!TOXWS7%EJ$$UW:R?;EU._N"WG1$D*) OS$G&T@?RKWL?$CQ3X<PO
MB?P1=M$,AK_P_(+V+ZF/B11^!KQLLS64HU'BZ,J=I2ULVM^K2T]7IYGL9EED
M8RI_5:T:EXK2Z3VZ)O7Y:^1Z717)>&OBOX3\62"'3M;MFN\X-G.3#<*?0QOA
ML_A769KZBE7I5X\]*2DNZ=SYJK1JT)<E6+B^S5A:***V,0HHHH **** "BBB
M@ KF/B+_ ,BQ-_OK_.NCG,@A<PJK2X.T.<*3VR0#7D/Q&\5>*[.&UTJ[T?1P
M][N9)(=0E8+LY.<Q"N6OB88>W/?731-[Z+8Z:.'G7OR6T[M+;7J<]15>Q:Z>
MW!O(X8I\\K Y=?S(!_2K%=$9<R3,)+E;044451(4444 %%%% !1110 4444
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MKTKTB@ HHHH **** "O%/VT?^36OB3_V")/YBO:Z\4_;1_Y-:^)/_8(D_F*
M,2'_ %,?^XO\A3Z9#_J8_P#<7^0I] !1110 4444 %%%% !1110 4444 %%%
M% !3H_\ 6+]13:='_K%^HH ]_3[B_2G4U/N+]*=0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!7O]/M=4LY;2\MXKNUE4K)#.@=''H0>#
M7DUU\#+[P7<27_PPUY_"[LQ>30KL&XTF<^GED[H2?6,CZ5[#17?AL=7PEU2E
M[KWB]8OUB]'^:Z'=AL;7PMU3E[KW3UB_5/1_IT/(M/\ CR?#=Y#I?Q)T67P5
M?N=D>HEO.TNY/^Q< 80G^[( 1ZUZQ;W,5Y!'-!*DT,BADDC8,K ]""."*CU'
M3;35[*:SOK:&\M)E*203H'1QZ%3P:\GNO@AJ7@F:2^^&&OMX<))=M OPUQI4
MQ[@(3NA)]4/X5W6P.-V_<S^;@_SE'Y\R\TCLM@L9M^YG\W!_G*/_ ),O-(]A
MHKR33?CTF@W\6D_$71IO!&I.VR.]E;SM,N6_Z9W(&%SZ.%(KU>"XBNH4EAD6
M6)QN5T8%6'J".M>?B<%7PC7M8Z/9K5/T:NG\F<.)P=?"M>UCH]GNGZ-:/Y,D
MKF/B#X#MOB'HJ:;=:AJ&FQI*LWFZ;,(I"1GC)!XYKIZ0]*XM.J3]4FON>C,*
M56=":J4W:2V/FWP7^S[INH>*O%5M)XE\2*FEW\4<12\0%P84?YSL^8Y.,^E?
M2,:"-%4$D* ,GK7 _#S_ )';XA?]A.'_ -)HZ] KOQM.E2J\M*G&*Y8OW8QC
MO%-WLE?4]?-L77Q-:*K2O:,;?.,6_O"BBBN \,**** "BBB@ HHHH **** "
MBBB@#C[/_DJFH?\ 8+B_]&&NPKC[/_DJFH?]@N+_ -&-785PX3X9_P"*7YG;
MBMX?X8_D8/B3P)X>\81>7K.C6>HXZ//$"Z_1NH_ UR1^#]YH/S>$?%VK:$H.
M5LKI_MUH/;9)\P'T:O2Z*57 X:M+GE#WNZTE]ZL_Q'2QN(HQY(S]WL]5]SNO
MP/-/^$D^(OAC(U;PU9>)[5>MUH-QY4V/4P2]3[!JNZ7\</"E[="SOKR;P]J!
M.W['KD#6CY]B_P I_ FN^JEJNC6&N6C6NHV5O?6[=8KF)9%/X$5C]6Q5+^#6
MNNTU?\59_-\QM]8PU7^-2L^\7;\'=?)<I9AGCN8EEBD66-AE70@@CV(J2O.)
M_@9HUE*\_AJ_U/PA<MS_ ,2FZ982?>%LH?R%1E/B?X7)VR:1XUM%' <'3[L_
MB-T9/Y4?6Z]+_>*+]8^\ONTE]T6'U6A5_@5EZ2]U_?K'[Y(]+HKS>+XXZ5IL
M@A\4:5JWA&;'W]2M2UN3[31[D_,BNYT?7]-\06JW.F7]MJ%NPR);659%_,&N
MFCC,/B'RTYIOMU7JGJOFCFK82OAUS5(-+OT?HUH_DR_11178<@5Y-\8_^1C\
M._[EQ_Z#7K->3?&/_D8_#O\ N7'_ *#7!C?@C_BA_P"E([L'\<O\,_\ TEG*
MT445WG"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'WO_ ".GHKER/&H_CT%O^ S#^M)GQJ/X= ;_ (%.*/KW_3J?_@/_  1_4O\
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MW408H?56ZJ?<$&MZBM*=2=&:J4Y-26S6C-*=2=*2G3DTUU6C/'?^%3>,/A^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 5S'Q%_P"18F_WU_G73US'Q%_Y%B;_ 'U_G0!Y'1110 4444 %%%%
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M_P!3'_N+_(4^F0_ZF/\ W%_D*?0 4444 %%%% !1110 4444 %%%% !1110
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M 4444 %>*?MH_P#)K7Q)_P"P1)_,5[77BG[:/_)K7Q)_[!$G\Q0!B0_ZF/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH **** "BBB@ HHHH **** "BBB@ HHHH *YCXB_\BQ-_OK_ #KIZYCXB_\
M(L3?[Z_SH \CHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ$^(&O>![WPC=:=XJN[>9+37/M"/8F.W6(3 QJ0YX.8^ <#D<BO:O%GBW1_
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MV\L_$WCF3^SWC>&UNO%%S+;D)C:C1DX9, #:>,<4 <]^V$(QX?\ AY)J&?\
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M7<ES#+,69S<LS38;J 2QQZ59^&?P_LOAAX6LO#NG:AJFHV%H<0/J]V;F:-.
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MDDG))/)))/6N7M?@+X3M-#\?Z3'!=?8_'%Q/<ZP#<MN=Y85B?8?X!L4=.AH
M^7=)TS7OAQXR_9Y\9IXZ\5ZYK/CO]WX@@U759);*Z$NG/<82UXCB".!L"*,
M<Y.37'ZMX;U[QI^R)XF^/<_Q3\::7X]G@O[^/^SM=EM[&S2.>2-;%;93Y87:
M@4G&_<<YS7VO??!'PS>IX!WP7#'P.R/HP-PV$*P&!?,_O_(3U[\U\/\ Q/\
MV9_$WCQ_%?ABV^">MZ3K6N:C+(=2L_%FWP>K/)QJ7V3SMPF"88Q^4?G&?>@#
M[X\*W,MY\--(GGD>:>7287DDD8LS,8%)))ZDGO7PI^S)X&^.GB;]D.&/P7X^
M\*Z3H=T-4CMM.O\ 0)7N5!NIPX-T)BH).[#>4< C@XK] -%T2/2?#ECI)8R1
M6UK':[NA8*@3/Z5\^Z=^P)\/-)TQM*M-?\>VNALTA;1[?Q=>Q6;!V+.OE(X&
MUBQR!UR: /%O!OB?1_%7A?\ 8[N-"T=] T^U\03Z>-/>?S_+>"VN8I")<#S
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M(Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M /;L_7\J,_7\J\1_X8M^#W_0JS_^#J__ /C]'_#%OP>_Z%6?_P '5_\ _'Z
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M[=GZ_E1GZ_E7B/\ PQ;\'O\ H59__!U?_P#Q^C_ABWX/?]"K/_X.K_\ ^/T
M>W9^OY49^OY5XC_PQ;\'O^A5G_\ !U?_ /Q^C_ABWX/?]"K/_P"#J_\ _C]
M'MV?K^5<U\0P7\,S!5).]>@]Z\V_X8M^#W_0JS_^#J__ /C]>5^-OV5_AC9?
M'?X=Z!#H%PFD:E;Z@]W:'6+XK,8XMR$YF['F@#T/R9/^>;_]\FCR9/\ GF__
M 'R:M_\ #$'P5_Z$P_\ @VOO_C]'_#$'P5_Z$P_^#:^_^/T 5/)D_P">;_\
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MK?\ PQ!\%?\ H3#_ .#:^_\ C]'_  Q!\%?^A,/_ (-K[_X_0!4\F3_GF_\
MWR:/)D_YYO\ ]\FK?_#$'P5_Z$P_^#:^_P#C]'_#$'P5_P"A,/\ X-K[_P"/
MT 5/)D_YYO\ ]\FCR9/^>;_]\FK?_#$'P5_Z$P_^#:^_^/T?\,0?!7_H3#_X
M-K[_ ./T 5/)D_YYO_WR:/)D_P">;_\ ?)JW_P ,0?!7_H3#_P"#:^_^/T?\
M,0?!7_H3#_X-K[_X_0!4\F3_ )YO_P!\FCR9/^>;_P#?)JW_ ,,0?!7_ *$P
M_P#@VOO_ (_1_P ,0?!7_H3#_P"#:^_^/T 5/)D_YYO_ -\FCR9/^>;_ /?)
MJW_PQ!\%?^A,/_@VOO\ X_1_PQ!\%?\ H3#_ .#:^_\ C] %3R9/^>;_ /?)
MH\F3_GF__?)JW_PQ!\%?^A,/_@VOO_C]'_#$'P5_Z$P_^#:^_P#C] %3R9/^
M>;_]\FCR9/\ GF__ 'R:M_\ #$'P5_Z$P_\ @VOO_C]'_#$'P5_Z$P_^#:^_
M^/T 5/)D_P">;_\ ?)H\F3_GF_\ WR:M_P##$'P5_P"A,/\ X-K[_P"/T?\
M#$'P5_Z$P_\ @VOO_C] %3R9/^>;_P#?)H\J3^XW_?)JW_PQ!\%?^A,/_@VO
MO_C]<-\<?V/OA)X6^$GBG5M,\+/9ZA:6320SIJM[E&!'(S-0!Q_[4\;K\)9B
M48#^T+3DC_IH**]@\%?L<?!ZWL-#U;_A#(9[V.&&Y5KF]NIT\S8#N*/*5/)[
M@T4 >_4444 %%%% !1110 4444 %%%% !113)MWE/M(5L'!/04 .S2U^>]I
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MPG^*_A]-7\.OXCTGP^-7M-=^'^L3W-KY9F$;(7=$>*5&*^H97!&.17H?B/\
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MU#QU9W5O;V]Y'X=\?7$5]=0(Q93<0WD<CAXW. 8R<HP]Z^DZ "BBB@ HHHH
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3 HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>crvs-20260331x10q010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 crvs-20260331x10q010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &E Z@# 2(  A$! Q$!_\0
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M&Y;#DX. ">E '1T5YII_[2?PPUJR\27&D^._#^K#P[$\VI)9ZE"YMU7J6^;
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MA0?FQWQG%2ZK\>/ASHFJQ:9?>.?#UOJ,MZ-.6T;4HO-^TG_ED5#9#\C@^HH
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M;?#BY\'Z/=P>'K&]VVUPT%O]VU+?O4B52H5F&0#T&3Q0!Q'[$:7$?[+W@,7
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MWM=%UN>QB#RRWGF.RQ,-S$1(,GLM:?\ PSQIO_0Y>/\ _P *^^_^.5>\,_\
M)>_'?_8#T;_T;J%>D4 >4_\ #/&F_P#0Y>/_ /PK[[_XY1_PSQIO_0Y>/_\
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MY>/_ /PK[[_XY1_PSQIO_0Y>/_\ PK[[_P".5ZM10!Y3_P ,\:;_ -#EX_\
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M\:;_ -#EX_\ _"OOO_CE'_#/&F_]#EX__P#"OOO_ (Y7JU% 'E/_  SQIO\
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M /\ "OOO_CE'_#/&F_\ 0Y>/_P#PK[[_ ..5ZM10!Y3_ ,,\:;_T.7C_ /\
M"OOO_CE'_#/&F_\ 0Y>/_P#PK[[_ ..5ZM10!Y3_ ,,\:;_T.7C_ /\ "OOO
M_CE'_#/&F_\ 0Y>/_P#PK[[_ ..5ZM10!Y3_ ,,\:;_T.7C_ /\ "OOO_CE'
M_#/&F_\ 0Y>/_P#PK[[_ ..5ZM10!Y3_ ,,\:;_T.7C_ /\ "OOO_CE'_#/&
MF_\ 0Y>/_P#PK[[_ ..5ZM10!Y3_ ,,\:;_T.7C_ /\ "OOO_CE'_#/&F_\
M0Y>/_P#PK[[_ ..5ZM10!Y3_ ,,\:;_T.7C_ /\ "OOO_CE'_#/&F_\ 0Y>/
M_P#PK[[_ ..5ZM10!Y3_ ,,\:;_T.7C_ /\ "OOO_CE'_#/&F_\ 0Y>/_P#P
MK[[_ ..5ZM10!Y3_ ,,\:;_T.7C_ /\ "OOO_CE'_#/&F_\ 0Y>/_P#PK[[_
M ..5ZM10!Y3_ ,,\:;_T.7C_ /\ "OOO_CE'_#/&F_\ 0Y>/_P#PK[[_ ..5
MZM10!Y3_ ,,\:;_T.7C_ /\ "OOO_CE'_#/&F_\ 0Y>/_P#PK[[_ ..5ZM10
M!Y3_ ,,\:;_T.7C_ /\ "OOO_CE'_#/&F_\ 0Y>/_P#PK[[_ ..5ZM10!Y3_
M ,,\:;_T.7C_ /\ "OOO_CE'_#/&F_\ 0Y>/_P#PK[[_ ..5ZM10!Y3_ ,,\
M:;_T.7C_ /\ "OOO_CE'_#/&F_\ 0Y>/_P#PK[[_ ..5ZM10!Y3_ ,,\:;_T
M.7C_ /\ "OOO_CE'_#/&F_\ 0Y>/_P#PK[[_ ..5ZM10!Y3_ ,,\:;_T.7C_
M /\ "OOO_CE'_#/&F_\ 0Y>/_P#PK[[_ ..5ZM10!Y3_ ,,\:;_T.7C_ /\
M"OOO_CE'_#/&F_\ 0Y>/_P#PK[[_ ..5ZM10!Y3_ ,,\:;_T.7C_ /\ "OOO
M_CE'_#/&F_\ 0Y>/_P#PK[[_ ..5ZM10!Y3_ ,,\:;_T.7C_ /\ "OOO_CE'
M_#/&F_\ 0Y>/_P#PK[[_ ..5ZM10!Y3_ ,,\:;_T.7C_ /\ "OOO_CE'_#/&
MF_\ 0Y>/_P#PK[[_ ..5ZM10!Y3_ ,,\:;_T.7C_ /\ "OOO_CE'_#/&F_\
M0Y>/_P#PK[[_ ..5ZM10!\_?%?X-Q>$/ACXLUS3?&WCV+4--TJYO+=W\5WCJ
MLD<3,I*LY!&0.",&BO0_C_\ \D-^('_8!OO_ $0]% '?4444 %%%% !1110
M4444 >;^&?\ DO?CO_L!Z-_Z-U"O2*\W\,_\E[\=_P#8#T;_ -&ZA7I% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!Y5XO_ .3@/A__ ->&H_\ H*5ZK7E7B_\ Y. ^'_\ UX:C_P"@
MI7JM !1110!Y1^T-_P @CP?_ -C/8_\ M2O5E^Z*\I_:&_Y!'@__ +&>Q_\
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MT<4\;AX5XX64TJDM4KZL]-HHHIG:%%%% !1110 4444 %%%% !1110 4444
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MB@#@?C__ ,D-^('_ & ;[_T0]%'Q_P#^2&_$#_L WW_HAZ* .^HHHH ****
M"BBB@!LB"1&1NC#!KR+X9?L_R?#[Q#IUY=>*[S7M+T*SN-/\/Z;/:11#3[>9
MT9@\B#=,P6-(U8XP@.022U>OT4 >7Z386VJ_&WXAV=Y!'<VEQX?T>*6&5=R.
MC2:@"I'<$5P^K?#/5_@#JMUK_@&9X_"MRPDU'17B-PENPX\U5'SF/'WMIW+U
M 8?+7H'AG_DO?CO_ + >C?\ HW4*]'(R,'I6-6E&M'EE^#LU\T<\Z2<XUH64
MX[.R>^Z:>Z?5?-6:37!^$_BYINN&RMM21='OKM0UJ6E$EK>@]&MYQ\L@/]WA
MO5:[RO)?%?P_?PB;Z]T;24U[PO>,9=5\*,@89/+7%H#PLG<QC ?J,-UG\-SZ
MG8Z-;ZOX)U/_ (2[PQ(,KI5],1<P@<%(IFYRO3RY>01C<*X^>OAM*BYX]TO>
M7JEOZQU_N]3LH5:.+E[)_NZJ^RW[LO.,GT\I;=9;7]4HKGO"_CO2?%C2P6LD
MEOJ,'_'QIMXABN8#_M1GG'^T,J>QKH:[:=6%:*G3=T%2G.E+DJ*S"BBBM3,*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*O%
M_P#R<!\/_P#KPU'_ -!2O5:\J\7_ /)P'P__ .O#4?\ T%*]5H *\A^)?P!D
M\>^);O4K+Q3=Z!::K;166M64%K%,+Z&-MRA7?F)L?*6&<KV!YKUZB@#R+X\V
MD6G^'?!%K"NV&'Q)I\:+Z* X _(5#\6_@CH/B"\/B4>'K;5[I1F^LB"C74?=
MXV4@I,O4,"">E7/VAO\ D$>#_P#L9['_ -J5ZLOW12:35F=6&Q-3"SYX/?1K
MNGNF>):!\.M<M](M]4^&WQ)U*/3I%WQZ5XF3^UK08_Y9[V*W$>.A'F''I6C_
M ,+0\>>#OE\8_#RXO[5>&U;P9/\ ;XC_ +36SA)U^BA_J:V==LI_AOK$_B+3
M(6ET*Z??JUC$,F$_\_,8_P#0P.HY]:[VSO(-1M(;JVE2>WE4/'(AR&!Z$&LO
M96^!V_K^MC?$044JD/>A+;NNZ=NJ_%:G(>"_C3X)\?SM:Z+XAM)]03B339R;
M>\C/?=!(%D'XK7:YKF/&?PP\)_$.W$7B3P]I^L!?N274"M+&?5)/O(?=2#7%
M'X*>(/"8#^!/B#J^DQ)]W2=?_P")O8X[*/,(F0?[LOX47J1W5_3_ "?^9QVA
M+9V]?Z_0]=HKR+_A9'Q$\&G;XM^'[:U:+][5?!=Q]K'U:TEV2CZ(9/QKHO!W
MQQ\#^.KLV.F>(+9=57A]*O@UI>H?0P2A7_2FJL&[7L_/03IR6NYW=%)FEK4S
M"BBB@ KD/B)KOB3PWI-SJ>BV&E7UK9VTEQ<+J%Y+ YV MA-D3@Y [XKKZYOX
ME?\ )//$W_8,N?\ T6U1._*[%1W5Q/!.I>(]6L1=:[9:79I+&DD TZZEF)!&
M3NWQIC\,UTM9?A?_ )%S3/\ KVC_ /016I3CL@EN%%%%42%%%% !1110 444
M4 %%%% 'GWQ4_P"0W\._^QB7_P!([FO0!T%>?_%3_D-_#O\ [&)?_2.YKT =
M!64?BE_70TE\,1:***U,PHHHH **** "BBB@ HHHH CN(%NK>6%]P212C;&*
MM@C!P1@@^XYKQ^Q^&&CK\5-0TS[7KYL;?2+.[CA;Q#?D+*T]PK-_KN<B-!@\
M<=.37LE</9?\EJUC_L7['_TINZQJ13<;HU@VD[';CBEKG8?B+X4N-?ET*+Q/
MHTFMPEA)IJ7\1N4*C+ Q;MPP.O'%'AWXC>$_%\UQ#H7B?1M:EMT\R:/3M0BG
M:)?5@C':/<UIS1VN1ROL=%16!X7\?^&/'!NQX=\1:5KQM'V7 TV]CN/);L&V
M,<=#U]*+3X@>%[_Q%+H%KXDTBYUV(LLFEQ7T372%?O Q!MPQWXXHYH[W#E?8
MWZ*J-JUBFIIIK7EN-1>(W"VAE7SFC!"EPF<E02!G&,D"K542+16!KWQ \,>%
MM5L-,UGQ%I6DZC?G%I:7M['#+<'.,(K,"W/''>M^DFGHAV:"BHY+B**2.-Y$
M1Y"0BLP!8@9.!WX&:DIB"BJNHZK9:1%'+?WEO9122I CW$JQJTCL%1 21EF8
M@ =22 *LYH X+X__ /)#?B!_V ;[_P!$/11\?_\ DAOQ _[ -]_Z(>B@#OJJ
MZGJEGHMA-?:A=P6-E N^6XN9%CCC7U9F( 'UJU7FGQ@F^']K>:!/\0M/CN-.
MCDD-O>:G;/-I=K+\H#3D@Q1L<_(\H &&PP)Y .A\*?%;P5X[NY;7PWXNT+Q!
M<Q9,D.EZE#<NF.I*HQ('O755\Q>#]=M/C'\49]#UWX:Z9;V%B)Y['4[6TN(;
MW2_*E40N;ORDB/GK\Z&VE;Y1SN&2/IV@ HHHH **** /-_#/_)>_'?\ V ]&
M_P#1NH5Z17F_AG_DO?CO_L!Z-_Z-U"O2* "O.O$G@S4O#&LW'BGP9&C7DQWZ
MEH;OL@U(#JRGI'.!T?HW1O4>BT4'/7H1KQM+1K5-;I]U_5GL[HX.WB\+_&72
M(=1B26*^M',8F3-MJ&G3#[T9(^9&!ZJ<@]>0:C_MCQ/X!^76H9/%&B+TU2PA
M O(5]9H!PX']Z/G_ &:E\9> [QM7'BCPK/%IWB:- DR2Y%MJ40Z13@?^.R#Y
ME]QD5J>"?'EGXSM[B,0RZ;K%DPBO]*NL">UD]#C[RGJKCAAT[@<-3"QE+VE-
M\L^ZZ^JV?YKHT:X7,:E-K"8Q*7;L_.+WB^KC\[21KZ'K^G>)=.CO]+O8;^TD
M^[+ ^X9[@^A'<'D5H5QVN?#>WN=1DU?0[N3PYKK\O=V:@QW'M/$?ED'N<,.Q
M%4[?XB7?AJ:.S\:V*:268)'K-L2^GS$],L>86/\ =?CT8U"Q4J/NXI<O]Y?"
M_P#Y'YZ=$V>G]6C6UPKO_=?Q?_;?+7ND=[13(Y4FC5XV#HP#*RG((/0@T^O1
M//"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*O%__
M "<!\/\ _KPU'_T%*]5KRKQ?_P G ?#_ /Z\-1_]!2O5: "BBB@#RC]H;_D$
M>#_^QGL?_:E>K+]T5Y3^T-_R"/!__8SV/_M2O5E^Z* $90ZE6 92,$'H:\X
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MF=NK7=FMR3[_ +W=S[UVVC>$=#\.P+#I6C:?ID*]([.UCA4?@H%'[U]E^/\
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MD#HP]"#P:X#6?V=/ACKTZW%WX%T-;I5VK=6UDEO,G^[)'M93[@YJO9271/\
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M)+%;1MPBLRKUR0%500H H 7PS_R7OQW_ -@/1O\ T;J%>D5YOX9_Y+WX[_[
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M0KL_RCH'QB\/$\Q:TO\ O:%>_P#QJC^T,'_S]C]Z#ZAB_P#GU+[F=O17%?\
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MGLJ:_I^J>&),[2^I6I\@GVFCW1_FPH^O4HZ5KP_Q*R_\"^'[F'U*K+^%:?\
MA=W]WQ?@=S15+2]:T_7+87&G7UM?V[=);659%/XJ2*NUW1DI+FB[HXI1<7:2
MLPHHHJB0KAOB;H%I<:8U^7NXKKS(8]\%[-$-I< C:K@=/:NYKE_B-_R+3?\
M7Q!_Z,%<..A&>'FI*^C.W!RE#$0Y7;5'"ZQH]KH?QU^']M:"41?8M2;$T[S-
MDJG\3L3^M>Q5Y5XO_P"3@/A__P!>&H_^@I7JM=D8Q@E&*LCDE)S?-)W84445
M1)Y1^T-_R"/!_P#V,]C_ .U*]67[HKRG]H;_ )!'@_\ [&>Q_P#:E>K+]T4
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M110 4444 %%%% ' _'__ )(;\0/^P#??^B'HH^/_ /R0WX@?]@&^_P#1#T4
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MHZYRW_Y*%?\ _8+MO_1T]!TT?AJ>GZHZ.BBB@Y@HHHH **** "BBB@ HHHH
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M)+*&_P!2T_3;*RF1BGV6\DEDR&(P0T:C''K0<[KQC55*SN_)V^_8ZRBBB@Z
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MQ_A3L']GXK_GVSO**X/_ (6Y:_\ 0L^+/_!#<?X4?\+<M?\ H6O%G_@AN/\
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MSSB@'- 'G'AG_DO?CO\ [ >C?^C=0KTBO-_#/_)>_'?_ & ]&_\ 1NH5Z10
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M;_T=/0=5!M1J6_E_5%?6/A9X5UNY-U/HUO#>Y+?;++-M<;O7S(RK9]\UG_\
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MR7##H9&4 N>>I)H XKPS_P E[\=_]@/1O_1NH5Z17F_AG_DO?CO_ + >C?\
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M]T5Y3^T-_P @CP?_ -C/8_\ M2O5E^Z* %HHHH **** "BBB@ HHHH ****
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M?$/BS1]:T_P=X6N/#&GP:=I,MK+*DKVI\V5WGD!(%HHPH'WC7T1110 4444
M%%%% 'F_AG_DO?CO_L!Z-_Z-U"O2*\W\,_\ )>_'?_8#T;_T;J%>D4 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3_$^D:!J-MXXN&TV6V=[MIH<+<2LH$LCS++(ARQV[F! ;D ]Z\,_\E[\=_\
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MK^FB8L<G?M?=^N:]D7[HH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#QKQ__P F[_$[_KSUK^<U%'C_
M /Y-W^)W_7GK7\YJ*#JQ7\>?JSV6BBB@Y0HHHH **** $QSF@#%+10!YOX9_
MY+WX[_[ >C?^C=0KTBO-_#/_ "7OQW_V ]&_]&ZA7I% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!C:?X&L?[#5KO^TO*0B+'D-Y6\;N?GQC@X- 'T'FC->8?\,Q?"S_ *$;1_\
MOR?\:/\ AF+X6?\ 0C:/_P!^3_C0!Z?FC->8?\,Q?"S_ *$;1_\ OR?\:/\
MAF+X6?\ 0C:/_P!^3_C0!Z?FC->8?\,Q?"S_ *$;1_\ OR?\:/\ AF+X6?\
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M_P!"-H__ 'Y/^-'_  S%\+/^A&T?_OR?\: /3\T9KS#_ (9B^%G_ $(VC_\
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M\-O&WA#PSJ.C7'@O5M7NO%6AP65N]HL,D6F2B8L8[AMX\M4#!LC(R,#FOMC
M(QCBC /:@#QSXT64NG>#OA_:2G?-!K^FQ.PYR55P3^E>Q+T%8WC#P3H/C_1S
MI7B+2;36=.,BR_9KR,.F]?NM@]",\&O&H?V8/!/_  MBZ=_ MA_PCG]CQB,E
M#Y/VGSFW87=][;MYQTQ0![_FC->8?\,Q?"S_ *$;1_\ OR?\:/\ AF+X6?\
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M-'_#,7PL_P"A&T?_ +\G_&@#T_-&:\P_X9B^%G_0C:/_ -^3_C1_PS%\+/\
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M&Z!\8/#_ (F^)>N>"-.-Q/JNC6R7-W.(L6Z[FQY:OGYG&02 .,C)YKN*\/\
MA7^SO?\ PL^)LNLP>*[[5M _LDV26U^MOY[2M-YK.[1P)NR23NW;B>O%>X4
M%%%% !1110 4444 %%%% !1110!S_COQMIOP\\+WNO:J93:6J@F.WC\R65B<
M*B+W8D@ 50^&WQ%3XC:5<W?]@:SX=FMIC#)::Q BL3C.Y'B=XY%]T<X((.#6
M5\?/A:WQB^&.J>&8Y;>.><QRQ"[#&!W1PP23;SL.,''8]ZR?@%\*+_X91>(Y
M;S3M!\/QZM=I<0Z#X9+FPL@J;24+)'\SGEL(HX'7K0!ZU1110 4444 %%%%
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M)4MC=M9PN[@8'NL2&.-59RY P6;&3[\4 /HHHH **** "BBB@ HHHH ****
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M%M901>'?"\\T]HLL*,LETS2QQD2."B8"_=B4LS-T* /;**** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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C **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>crvs-20260331x10q011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 crvs-20260331x10q011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &G Z@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4L5RGQ5^
M)&D?!_X<>(O&FNLXTK1+*2]G6( NX4<(F2!N8X49(Y85UE?GC_P5O^,>FV>B
M> OA'=:E)IUEXFU.+4->N((FE>WTV&4#.Q>6R^7  Y,% 'U5^RW^U#X6_:O^
M']SXJ\,6U[80VMZ]A<66HA!/%(JJP)V,PPRN""#Z^E>QXK\K?V.OCS\/?!'[
M>OBGPU\.KZ0_#+XA6T1L(9;.6U6TU"*/<L860 X.)E!Q_P M$':OU2!R,T &
M*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4
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M+2/BGX.T_P 2:(\ILKL,##<IY<]O*C%)894R=LB.K(P[%3UZUTU "8HQ2T4
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MQOA;X;:O??'KQ)\0?$,$4$4%FFC:#;K(LC+;YWRS''W2[8 7J .: /7****
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M /CM>MT4 >2?\*]^*W_16H/_  E;?_X[1_PKWXK?]%:@_P#"5M__ ([7K=%
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MI%>;^&?^2]^._P#L":-_Z-OZ](H **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"2%>/_ /L!WG_HIJ*/VAO^2%>/_P#L!WG_ **:B@#T*BBB@ HHHH ****
M"BFNX12S< #)KR_X=_'_ $KXB^(H-,@T/6M*M]0MIK[1M2U&&-+?5K>*14DD
MAVNS+@NI"R*C,C!@".@!:\,_\E[\=_\ 8$T;_P!&W]>D5Y59:S8^'OC-\1M2
MU*ZBLK"U\/Z1-/<3-M2-%DU LQ/H #74_#KXJ^$_BQI$NI^$];M]9LXI3#(T
M6Y61QSAD8!AP01D<CI5J$W%S2T77H0YQ4E%O7L=91114%A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+<F\M!JWBF;6H(%\PH)$A:5HR!)&P#E20R'#9!KW*@ HHHH **** /-_#/\
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M/6K-;?4=1,L!1#+&F4VC)"J.?6BM[7_^38_BA_NZ]_Z-FHK.DDH*Q=1WDSZ
MKSK]H?2M*UKX)^,;36];@\.:4^G2-<:G=1^9# JX;,B?\M$) #)_$"5[UZ+7
MD?[2NH6,OP\U+P[J!$$.M6-Q''=KJ5E:2QS($:,1?:G53(6Y4\A2H+8XK4S/
M&?V4K.75?B=+J&I7>G17=C!J\MI;:1X?U.T66.^O8[B3S)[N")0D9"+'"N3\
MS,2<<?85?-7[.'CWQ=XD\;3V.N^)=3UFRCT]W6*^O_#TXWAXP&QI[&;.">2-
MG)SSMKZ5H *0G%+6%XU\$:-\0_#\^B:]:&]TV<JTD(FDB)*D$?-&RL.0.AH
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M]%9QCRMN^Y;E=)6"BBBM" HHHH **** "BBB@ HHHH *XBP_Y+3KO_8 T_\
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M\HZG@J?Y5I4II+VE/6/XKR?Z/K]Z4PJ-ODG\7Y^:_K0WJY77O^1X\,?6X_\
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M@K&-S_WS1]=C'^)"4?\ MUO\8W7XA]3E+^'.,O\ MY+\)6?X&GH'_(W>)/\
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M_(V:**3-<AD+124M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA5YK^TAXCU'PE\#O&6K:3J<VD:E;:>[6]W:PB6=7) "Q*58>8V=JD@@,RDC
MKTJO-OVC[[2-.^!OC2;7M.EU?2#ILD=S917C69F5L+M,ZD&%<L-T@^ZN3VH
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M6.:;<@4$<97D\]\5VU%%84:*HIQ3;]?,VK5G6:;27H%%%%=!@%%%% !1110
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M /CRG_ZYM_(US'PE'_%O-&_W'_\ 1C5T]_\ \>4__7-OY&N8^$O_ "3S1O\
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MF_AG_DO?CO\ [ FC?^C;^O2*\W\,_P#)>_'?_8$T;_T;?UZ10 4444 %%%%
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M*** "BBB@ HHHH **** "BBB@#D_&=U"NK>%5::-675>07 (_P!'FKJHW61
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MP_QB_P"1,/\ U^6O_HY:Z_3]2M-6LXKNRN8;RUE7='/!('1QZAAP:Y#XQ?\
M(F'_ *_+7_T<M305JL4^Y=76G+T,+Q;_ ,G!^ ?^P;J7\HZ]5KRKQ;_R<'X!
M_P"P;J7\HZ]5KG-@HHHH \I_:$_Y!O@K_L:++_T&2O55^Z*\J_:$_P"0;X*_
M[&BR_P#09*]57[HH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N>MO\
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M@31O_1M_7I%>;^&?^2]^._\ L":-_P"C;^O2* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "N.^+?B[5O W@34=9T31WUO4+<+MMD1WP"<,Y5 78*.2%Y
M/:NQK"\:>#[/QUH$VDWT]Y:Q.RNL]A<M!-&ZG*LKKT(/KD>HK6DXJ<7-:7U,
MZBDX-0W/$M _:/USQ-HFE6VD)X;U?Q!JVJ-I]K/;S7,=M"JIO=KB&1%FC8#C
M9U/K5_2/V@-?7QOIOA#6-*TV/65UG^S;^:TDD,!C:(R)+%NY!/0JV<5T;_LV
M>%Y].N8Y[S6;C59[Q;]M<DOL7ZS!=H99 H &WC&W!!Y%9&G?LF>&],AV1>(/
M$HE2^&HPW@U "[BFV;2?.";F!'9L@=L5Z_M,"[Z6^77OOMY67?R/,Y,8K:_C
M_7YGH7Q*\;2>!O#\%W;VZ75[=WD-C;12,0ADD; +$<X R:XGPW\3?&WC'5+O
M4M)TK0O^$2LM1?3YA=W4L=ZZQ\23+P4 !Z(>2.]=+XF^%[ZMX(L-$@U:[N;O
M3KJ&\M[[593<2/)&^1YC#!;@D51F_9^\+W/B4ZQ(=1CCDNA?S:/%?R#3I+G'
M^M,'0M^GM7)3EAXTVI:O7I_P4=-15Y3O';3K_P !G/\ B?\ :=TBR\,ZI?:5
M87K74=I)=Z<VH6QCM]02.0(YC922<9/!"D]LUIZ?^T;H5U:)&^F:Q_;9N4L_
M['2T!N))6C\S*#?M*[><EA^=._X9I\'M#>02'5)K::%[>""6^9DLHW<.ZP _
M<!(]_2KE_P#L_P#AF]N+FZ274[+4);F.[COK2\,<T$B1^6#&P' *\$$$&M6\
M#:R3_JW]/\#-+%WO='.Z[^U;X<L=-EFTK1]<UVZ33VU P6UGA8D5BI$SDXC(
M8$'.?;-:OA7]HO0_$NO:9H)T[4K76KN"&:6VDCC'D>8F\9!?>RX_B52!W(K1
MTWX ^$=*MKVW@M[H0WFF?V5,K7+-OB+%BV>N\L22V:IQ?LZ>&/[8T34;JZU?
M4I-'\HVT=[>^8@:,;4;[N00.RD ]P:&\#9I)^H)8NZ;:+OCKXFZEX3\?>$=#
MBT4/I>L7#0W&JW$RJD>$+;44'<3QR2 !5W6OC!X'MM)OY?\ A(M(U3R8F+V5
MI>PSRR]M@C5B222!C'>MGQ'X(TSQ3J>B7U\LK3:1<-<VP1\*6*[3N'\0P>E9
MVJ?!OP)K-I+;7O@[0KB"4Y=&TZ$;CG/.%!ZUS1EAVH\R::WMZ^?D;N-9.7*U
MKM?T_P SYY\#+!XAF\-:OH]E-\+]0\0W5W;L?#MP1$EQ$<JLUJX:!]R]2%!R
M#S3/VG_B[\2?@UX,LK;6](T;Q1;75Y'Y.M6/G6W,;!]LL'S!6;'!5R.O%>P^
M&?V>M"\$ZUH']@00Z?HFE3W%]]F )DEN91@$MTVJ.@]ZZ'XQJ#X,((S_ *9:
M]?\ KLM>G]:I/$P:CS1OL]]W;75Z*VEVC@^KU%0FN;EEY;;*^FWX7.&L_$,_
MBWXI_"G6KFPDTR>_T.^N'LY?O1%EB)4U[C7E7BW_ ).#\ _]@W4OY1UZK7@R
M:;;2LCV8II)-W"BBBI&>4_M"?\@WP5_V-%E_Z#)7JJ_=%>5?M"?\@WP5_P!C
M19?^@R5ZJOW10 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<];?\C]J/
M_8-MO_1L];TJ&2-T#M&6! =<97W&:YN+P0\6HM?#Q#J[7+QI$[%H,,BEB 1Y
M7JS?G732Y;2YI6NO/NBXVL[LZ>BBBN8@**** "BBB@ HHHH **** "D/2EI#
MTH \9^)'_)N7Q)_Z\]6_G)11\2/^3<OB3_UYZM_.2BNG$_QI^I<_B9[/1117
M,0%%%% !116'XR\4KX-T&?5'TS5-76(J/LFCV;75PV3C*QKR<9R?04 ;>:*^
M*M4\?^([WX\R>);?5]3L_#\/BW3M%-O<:M+#=0++:1@V7]D$^6\;RRH[3-^]
M7+L%*Q@UT_[/7B"[F\5_#J]3Q9J>O:GXK\/ZAJ'B2QO-6>[B@N(Y8<.D)8K;
M^7([P!4"C'!!*YH ]G\,_P#)>_'?_8$T;_T;?UZ17F_AG_DO?CO_ + FC?\
MHV_KTB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KA_C%_R)A_Z_+7_T<M=Q7"?&2>-/!Q5I$5OMEJ<%@/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !2'I2TAZ4 >,_$C_ )-R^)/_ %YZ
MM_.2BCXD?\FY?$G_ *\]6_G)173B?XT_4N?Q,]GHHHKF("BBB@ HHHH P)?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/^BF^//_  :0?_(] 'J>1ZBC(]17EG_"C+S_ **;X\_\&D'_ ,CT?\*,O/\
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M .1Z/^%&7G_13?'G_@T@_P#D>@#U/(]11D>HKRS_ (49>?\ 13?'G_@T@_\
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M?]%-\>?^#2#_ .1Z/^%&7G_13?'G_@T@_P#D>@#U/(]11D>HKRS_ (49>?\
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MHXH ^@LCU%&1ZBO+/^%&7G_13?'G_@T@_P#D>C_A1EY_T4WQY_X-(/\ Y'H
M]3R/449'J*\L_P"%&7G_ $4WQY_X-(/_ )'H_P"%&7G_ $4WQY_X-(/_ )'H
M ]3R/449'J*\L_X49>?]%-\>?^#2#_Y'H_X49>?]%-\>?^#2#_Y'H ]3R/44
M9'J*\L_X49>?]%-\>?\ @T@_^1Z/^%&7G_13?'G_ (-(/_D>@#U/(]11D>HK
MRS_A1EY_T4WQY_X-(/\ Y'H_X49>?]%-\>?^#2#_ .1Z /4\CU%&1ZBO+/\
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M//\ P:0?_(]'_"C+S_HIOCS_ ,&D'_R/0!ZGD>HHR/45Y9_PHR\_Z*;X\_\
M!I!_\CT?\*,O/^BF^//_  :0?_(] 'J>1ZBC(]17EG_"C+S_ **;X\_\&D'_
M ,CT?\*,O/\ HIOCS_P:0?\ R/0!ZGD>HHR/45Y9_P *,O/^BF^//_!I!_\
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MPHR\_P"BF^//_!I!_P#(]'_"C+S_ **;X\_\&D'_ ,CT >IY'J*,CU%>6?\
M"C+S_HIOCS_P:0?_ "/0?@;>#_FIGCS_ ,&D'_R/0!H_M#$?\**\?\_\P.\_
M]%-17F7@;X.WWQ/\%:S;^)?B#XXN;:;4-1TV6V;48HUEMTN)(E4@0 \H!D@\
M]:* /I"BBB@ HHHH **** .0\;_%CPS\/-0TVPUN\N8[_4HYI;6ULM.N;V65
M(MGF-L@C<A5\Q,D@#YA6OX3\7:/XZ\.6.O:#?Q:GI%\GF6]U#G:XR5(P0"""
M""I ((((!%>(_M&>$=>U;XH> M:TZ/QC'IEAINJVUU>>"GMQ=1O*UJ8T83<%
M&\ISP#R@Z5X)XP^$?Q&OOAEHGAB7P!=74HTG6$TR^N+2+4+^*:>[9X!<8NH[
M>UNF0K))= /\[,%*D$, ?H!GFL[7/$.G>&K)+O4[I;.V>>&U61P2#++(L<:\
M#JSNH_&OC1?A;\1(_BY-J&EZ)J@UB]ARVK:Q;)ML2=(\GSH-0CG#%!,%4V<T
M;X?=(NW.^H?A!\&/&-AITF=(UZQ9#H,=[I]WI-MI]O-/!J,,LTVY;F1KB6.-
M9=T^ )%8?,Y   /MJPOXM2M5N(5E6-BP FA>)N"0<JX!'(/;D<C@U8SSBOB/
M5OV>/%NO>'/%=SJ/AN^N]>M_"K0Z%))>CS(=0_M*^F4Q'S<)*$>W(?@@$#.-
MPK5\&?"KQQ;?M''5M7BUR.Z3Q'<W[:O:Z5;_ &>?3VC(CBDO6N-YAV;4^SB+
M<KKN Q\Y /LBBD'04M !1110 4444 %%%% !7">*OCEX$\$^++/PUK?B6ST_
M6KH(4MI-QV!VVH9& *QAFX4N5R<XSBN[KYU^,MCJWBOX@-X;D\"ZLO@>Y6WF
MUG5='LH)9M;96)2U9S(K1PIR78@L0VU<9+4 ?15%)2T %%%% !1110 4444
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MBHI4:C<22@A9.GELA/J#CGD5#\4/@5XML;J&QL-!U)O UO?:L+;2].TZ+5!
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MZ;&TJPV=K.T27%RQ.(M^ !G[S9V@A21['0 4444 %%%% !1110 4F!G-+10
M4444 %%%% !1110 4444 %%%% !1110 @ '08HI:* "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /+?B/\/?&>L>()=2\,^*-.CL+RS^PWN@>)=.>^T]AG(FC1)$*R<D$'*L,9
M Q7FB_L<7&GZ,NC:?XGMH;&?0)=(N7?3=K)*;@W$<L**X5(Q(Q'EG/R@ $8S
M110!H77[-WC+5_$#>--3\:Z3-XW@NK2\L6AT=TTZ%H$DC:-HO.+NKK*V3O!4
M].E<?\2?@GJC:9X9\'7&M2ZGXOUSQ+-JLNLZ?:I:006LBJMW$5:4MM\H,@ W
M$Y!//-%% 'T3\1OAI:^._AAJG@Z&8:5!<V7V2VN(X]WV4@ 1LJY'W<#'/:O.
M9/V5;.5?A;NUQV;P>V;PFW'_ !-LGS&#?-\F9L2=_2BB@#D;/]B&PM_%M_*\
MGAJ31+F[NKW[4?#RMK),^XF,W32%0JLQ(<(&QQGO5?PW^PW;:?X>U31KZ3PC
M';2Z;_945SI/AE;>YN(]R[GN9#*Q=BJ[2J;5.23Z444 >Y?"3X7M\);#4]%L
MM1%QX9-R9M)TXQ%3IL3<M K;CNC#9*C VY(Y&,=]110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>crvs-20260331x10q012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 crvs-20260331x10q012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (# Z@# 2(  A$! Q$!_\0
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MM)>*]4GM/%L6C6*>&4\ :AXAN-*-ZX=KFWNC$=I,0)R4"KG'RN20&&#MZ_\
M'[XA>'8?$K77@?0 ^@Z'!XHN576I2#82;_W*GRN;D&)^?]7P.>: /I/_ (:Z
MT;_H0OB+_P"$O-_C1_PUUHW_ $(7Q%_\)>;_ !KYKE_:LFE^),NC6/APWNB6
M^LQZ+,T4-Y)?,Q9%>X0) ;?RT:3E6E#;58\< W-,^/7C'4[C2KC_ (1/18-&
MUK5]2\/:=-_:DC7'VRV6Y\N25?*VK"YM6!P2RYS@]* /HC_AKK1O^A"^(O\
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M0!=_X:ZT;_H0OB+_ .$O-_C1_P -=:-_T(7Q%_\ "7F_QJE@>@HP/04 7?\
MAKK1O^A"^(O_ (2\W^-'_#76C?\ 0A?$7_PEYO\ &J6!Z"C ]!0!=_X:ZT;_
M *$+XB_^$O-_C1_PUUHW_0A?$7_PEYO\:I8'H*,#T% %W_AKK1O^A"^(O_A+
MS?XT?\-=:-_T(7Q%_P#"7F_QJE@>@HP/04 7?^&NM&_Z$+XB_P#A+S?XT?\
M#76C?]"%\1?_  EYO\:I8'H*,#T% %W_ (:ZT;_H0OB+_P"$O-_C1_PUUHW_
M $(7Q%_\)>;_ !JE@>@HP/04 7?^&NM&_P"A"^(O_A+S?XT?\-=:-_T(7Q%_
M\)>;_&J6!Z"C ]!0!=_X:ZT;_H0OB+_X2\W^-'_#76C?]"%\1?\ PEYO\:I8
M'H*,#T% %W_AKK1O^A"^(O\ X2\W^-'_  UUHW_0A?$7_P )>;_&J6!Z"C ]
M!0!=_P"&NM&_Z$+XB_\ A+S?XT?\-=:-_P!"%\1?_"7F_P :I8'H*,#T% %W
M_AKK1O\ H0OB+_X2\W^-'_#76C?]"%\1?_"7F_QJE@>@HP/04 7?^&NM&_Z$
M+XB_^$O-_C1_PUUHW_0A?$7_ ,)>;_&J6!Z"C ]!0!=_X:ZT;_H0OB+_ .$O
M-_C1_P -=:-_T(7Q%_\ "7F_QJE@>@HP/04 7?\ AKK1O^A"^(O_ (2\W^-'
M_#76C?\ 0A?$7_PEYO\ &J6!Z"C ]!0!=_X:ZT;_ *$+XB_^$O-_C1_PUUHW
M_0A?$7_PEYO\:I8'H*,#T% %W_AKK1O^A"^(O_A+S?XT?\-=:-_T(7Q%_P#"
M7F_QJE@>@HP/04 7?^&NM&_Z$+XB_P#A+S?XT?\ #76C?]"%\1?_  EYO\:I
M8'H*,#T% %W_ (:ZT;_H0OB+_P"$O-_C1_PUUHW_ $(7Q%_\)>;_ !JE@>@H
MP/04 7?^&NM&_P"A"^(O_A+S?XT?\-=:-_T(7Q%_\)>;_&J6!Z"C ]!0!=_X
M:ZT;_H0OB+_X2\W^-'_#76C?]"%\1?\ PEYO\:I8'H*,#T% %W_AKK1O^A"^
M(O\ X2\W^-'_  UUHW_0A?$7_P )>;_&J6!Z"C ]!0!=_P"&NM&_Z$+XB_\
MA+S?XT?\-=:-_P!"%\1?_"7F_P :I8'H*,#T% %W_AKK1O\ H0OB+_X2\W^-
M'_#76C?]"%\1?_"7F_QJE@>@HP/04 7?^&NM&_Z$+XB_^$O-_C1_PUUHW_0A
M?$7_ ,)>;_&J6!Z"C ]!0!=_X:ZT;_H0OB+_ .$O-_C1_P -=:-_T(7Q%_\
M"7F_QJE@>@H(&#P* /3_ (4?%G1_C#H-]JFCVVI62V-_+IMU:ZM9M:W$,\84
MLK1MR.'4Y]Z*\[_9)_X\/BE_V/6H?^B;:B@#WFBBB@ HHHH **** "BBB@ H
MHHH **** "OF;]LR\U/3M:^#5SH^E+K>H1^*9_+L6NUM1+G2[P']XP(7 )/(
MYQCO7TS7SU^U/_R./P3_ .QJN/\ TTWM 'CGAJY\=>%)=<DL/A3AM9U*75KK
MS?%]LX,\BHK;?W7RKA%X^M9&J>'?$^M6/BVSOOA$;BW\3W4=[?K_ ,)G;HPF
MCCB2-XF6,&,KY,; @Y##->^#I10!X=X%A\?^ ?[1EMOA]JNKW^H2))=:CKGC
MZ&\N9-B[47<T8"JHZ!0.I)R>:N7]SXZU'QEHGB>;X59U71[>ZMK4KXOMA'LN
M/+\W<OE?,?W*8/;GUKV6B@#YYN?!WB:Y\'1^&_\ A55W;VL&I2:Q:W=KXX@A
MO+2\>9YC-%,L8*,&E<#MM8J<BLMOACXHQIL\7@'Q';:S937,W]NP?$E%U&?[
M0$$Z2S^62R/Y<?R@ #8NW&*^FJ* /EY/A!K,&B6FDV_PMU.VL;?2;[0_+C\>
M0?O;.[D:26*0F(E]KL61CRIQR:Z/7O#GBOQ&/$(O/A1*1KNA1>';SR_&5LN;
M2/S-H7]U\K_O7^;Z>E>_44 ?. \ ^)D\3#6(OAIJ]M&U[%J<^D6_Q"CCTVYO
M(PH2XEMU0!G^1">0K%06!-7['PQXIT^RT&TB^%$IAT36+C7;0/XRMB?M,WG^
M9O/E?,G^DRX7MQZ5] 44 >)^ !X[^&WA2R\.Z5\,;B;3++<MLM_XSMIWBC)R
M(PQBSL7HH[#BMR\\9?$NYL[B$?"N%3+$\8)\56O&5(S_ *OWKU"B@#PNP^ W
MQ2NOA3X3\):S\,(Y+KP_;VPM=6TSQE#;7%M<Q)M$\#B(E#@D8.002""#447[
M-WQ"GT[7H=7^'%_XBU#6X8;:]U?5/'-N]VT$4HECAC*P*D48<;MJ*,DDG)K[
MYA_U,?\ NBGUU?6:G?\ !&/L8'QO8^ _BIIWBK7/$,/PGA_M'64MH[HMXPMR
MA$"NL>U?)^7AVSZ\4QOA[\4F\9OXH/PGB_M5M,_L@G_A,+?R_(\WS?N^3][=
MW].*^RZ*KZW6[_@B?84^Q\'S_L_?$%_"7A;0;;X87FECPP@CTC4]-\>16]]:
MC84;$RP_,&4X8$$$8XX%9MQ^R_XXE%GY/PUUFPDAL)-+N)[/XD^7-J-L\K2O
M'=2>66E!D=VSD'YB 0.*_0*BI>)J/_AD5[&!\ W/[,GC>YM+.U/PMO([:VT:
MST(Q1>.X%2:UM9EFM_,'D89T=>&X."1WK=UWX+?$7Q%)XEDO/A/\WB&[L;V]
M,?C.W7]Y:%##L_<_*/W:Y'?GUK[AHI_6JO?\$'L8'P=IG[/GQ T?Q&-4M?AE
MJ$=O'=3WT&B_\+"7^S+:XFW>;+';>7M4DNYP<J"Q( )J0?L_^.CX?\.Z*_PB
M\W3M"TJZT6TC?QK!DVUQ"(95<B'+$H,!N,'FONVBE]:J?TD'L8'QWX8\'?%W
MPKX>T[1X/AD;V"Q@6WCGO_&=O-.R*,+O?R1N(&!GT K4_LWXQ_\ 1*+3_P *
MRW_^-5]845:QE9:7_!$_5Z?8^3_[-^,?_1*+3_PK+?\ ^-4?V;\8_P#HE%I_
MX5EO_P#&J^L**?UVOW_!"^KT^Q\G_P!F_&/_ *)1:?\ A66__P :H_LWXQ_]
M$HM/_"LM_P#XU7UA11]=K]_P0?5Z?8^3_P"S?C'_ -$HM/\ PK+?_P"-4?V;
M\8_^B46G_A66_P#\:KZPHH^NU^_X(/J]/L?)_P#9OQC_ .B46G_A66__ ,:H
M_LWXQ_\ 1*+3_P *RW_^-5]844?7:_?\$'U>GV/AOQYX:^+Q\4>!]?G^&5G!
M!H5]=3/%_P )3;LTWFVDD( /EC&"V<\],5Q_B/P)XUUS7-5U.R\#Z[X8?6<'
M5[?0/'MM;0Z@0NS>Z^2=DA4!3)&58@#)XK[>^*G_ ""+/_KX_P#9&KS*N6I4
ME5ES2W-XQ4%9'SI>> M<NM+NM-B^#OV'3I_#H\+_ &6S\8VT:1V(D+A4_='#
M[B?GY/K7=/XM^([V+6I^%47E-$83_P 59:YV[=O7R^N*]1HK,H\$TS0O%NDZ
M;X&L;?X4RB#P:P;2MWC*V+ BW>W_ 'A\KY_DD;TYP>U9=OX \2VWB1M5C^&.
MJI:M>RZG_80^(,8TH7<@823_ &8)MW-N8D9VY8G;FOH^B@#Y@\-?";7_  Q=
MZ7-#\-M;OXM*L+G2K"TU+XAQ7%O:64\?EO;Q1M'A4VXQ_$,#D@8JUIWPW\1Z
M?X7U?03\,M1O+/5-'M]!N);SQS;2S?9(#)Y2A_)X*B5EW>@4=J^E:* /GGQ+
MX.\2^++[5KV^^%%PE[J"V/\ I5IXW@@FM9+/?]GF@=8P8Y%\Q_F!YS@C'%+X
M=\)>+?#FJ:1JB?#34M2U73;RYOUO]5\>PW4T\\\(AD:5GCY&P *H"JN.!7T+
M10!\\Z/X/\4Z!JN@ZC8?"Z\MKO1IK^6!D\;VX65;R;SKB*5?*P\9DPP4XQM7
MGBN\_P"$X^)7_1*H?_"KM?\ XW7I5% 'FO\ PG'Q*_Z)5#_X5=K_ /&Z/^$X
M^)7_ $2J'_PJ[7_XW7I5% 'FO_"<?$K_ *)5#_X5=K_\;H_X3CXE?]$JA_\
M"KM?_C=>E44 >:_\)Q\2O^B50_\ A5VO_P ;H_X3CXE?]$JA_P#"KM?_ (W7
MI5% 'FO_  G'Q*_Z)5#_ .%7:_\ QNC_ (3CXE?]$JA_\*NU_P#C=>E44 >:
M_P#"<?$K_HE4/_A5VO\ \;H_X3CXE?\ 1*H?_"KM?_C=>E44 >:_\)Q\2O\
MHE4/_A5VO_QNC_A./B5_T2J'_P *NU_^-UZ510!YK_PG'Q*_Z)5#_P"%7:__
M !NC_A./B5_T2J'_ ,*NU_\ C=>E44 >:_\ "<?$K_HE4/\ X5=K_P#&Z/\
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M .%7:_\ QNC_ (3CXE?]$JA_\*NU_P#C=>E44 >:_P#"<?$K_HE4/_A5VO\
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M(?"C2_BR/A?J][X2M-=\-6'PNN-)1-0MHYHK74-]I&8"CYQ*OE3)G'&UAD4
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M%%% !1110 4444 %%%% !1110!#>WL&FV5Q=W4R6]K;QM---(<+&B@EF)[
M$GZ5YUIWQ\T'6O .I^+=+T_6-3L;75'T>"UM[,_:KV<2)&GEQM@JKLXPS[0!
M\S8%>E,-RD$9SV->-BR\>> / GQ N/#7AY-7\3:EXIOKW3;66XC5#;SR)B=M
MSJ"%4,WEE@20 <9H [?X??$6/QW_ &Q;3:-J/AS6M'N$M]0TC5!&9H"\8DC8
M/&S(Z.AR&5CT/I775YM\#-(OM'T'4DU7P[K&C:M<W?VJ]O\ 7+RVN;G5)W4;
MIR8&944!518Q@*H 48%>DT %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQX"@<FN+U+]HCPOI?A?P3J]PEX)O%PLVT_38XM]PJ7#H@DEQ\J(AD4,Q.,G
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M?^FF]KZ$KY[_ &J#_P 5E\$_^QJN/_33>T .'2B@=** "BBB@ HHHH ****
M"BBB@ HHHH ]_A_U,?\ NBI*9#_J8_\ =%/H **** "BBB@ HHHH **** "D
MI:* "BBB@ HHHH **** "BBB@#B?BI_R"+3_ *^/_9&KS*O3?BI_R"+/_KX_
M]D:O,J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH  *Z?3/A]J.JV$%W#+;K',NY0[$''OQ7,#K7M/@S_D5M-_ZXB@#AO\
MA5^J_P#/:T_[[;_XFC_A5^J_\]K3_OMO_B:]3HH \L_X5?JO_/:T_P"^V_\
MB:/^%7ZK_P ]K3_OMO\ XFO4Z* /+/\ A5^J_P#/:T_[[;_XFC_A5^J_\]K3
M_OMO_B:]3HH \L_X5?JO_/:T_P"^V_\ B:/^%7ZK_P ]K3_OMO\ XFO4Z* /
M+/\ A5^J_P#/:T_[[;_XFC_A5^J_\]K3_OMO_B:]3KYC_:]^#5Y<>!?B'\2-
M,^)_Q%\,ZGH_AR[OK72]!\0-:Z<);:V=T)A"_P 3*-V&&?:@#TG_ (5?JO\
MSVM/^^V_^)H_X5?JO_/:T_[[;_XFO%? .GV'[-?P.T_XY>+/B+\3O&=L/#EG
M>:AI6JZY]OM@UR(-TD<#A1N5GXRV0N[J:]+N/VL]#TWPK%K&J^#O&FD75_J
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M]U8-<:=:S-=RJHFG9_,954QJ9%1D7A2P(( !]*_\*OU7_GM:?]]M_P#$T?\
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M:;@&:1EP>.H(H T_^%7ZK_SVM/\ OMO_ (FC_A5^J_\ /:T_[[;_ .)KS?\
M99^,-]\7OC=\>+AI->M-'T^ZT:WM-#U^)X)=,E^Q$7$7DL2$)D4DE<JQPP)!
M!KZ;H \L_P"%7ZK_ ,]K3_OMO_B:/^%7ZK_SVM/^^V_^)KU.B@#RS_A5^J_\
M]K3_ +[;_P")H_X5?JO_ #VM/^^V_P#B:]3HH \L_P"%7ZK_ ,]K3_OMO_B:
M/^%7ZK_SVM/^^V_^)KU.B@#RS_A5^J_\]K3_ +[;_P")K'\0^%KOPV(#=/$_
MG;MOE,3TQG.0/6O:Z\^^+/W=+^LO_LM 'GM(>AI:0]#0!:_9&_Y!?Q._['G4
MO_1<%%'[(W_(+^)W_8\ZE_Z+@HH ]ZHHHH **** "BBB@ HHHH **** .3^*
M/A?7/&?@J]T;P_XDF\):A=O"C:O:Q!YX8?-4S"+/"R-&'57YVE@V#C%?(.N_
M$#Q#X$\.?&2?X;^,O$&N>"[&#2]$T_7==O6U(6VN3WWV:[-G<2[FD2*.6(MD
MLBR@@=& ^I_CW\,=5^,?PNU?PAI/BNX\&2ZF$BFU2UM_.D\C<#)$!O0@.HV$
MA@=K,.]>>:5^R]XAN_A7K_P\\6?$*#6/"][I\=EIEKHOAJWTC^R7C</'+%Y;
ML&VLJ$*1C*\YR: #X=66H_"K]I!O ,/B?Q!XC\.ZMX4DUM8_$>H/?S6UW!=Q
MPNT<K_,%D6<$IG:&3Y0H)%+^U/\ \CC\$_\ L:KC_P!--[74_#'X->(?#_CZ
M]\<>./&$7C#Q.^EIHMI)9:4-.MK6T$GFOB(22%I)) K,Q;'R*%4 <\M^U/\
M\CC\$_\ L:KC_P!--[0 X=**!THH **** "BBB@ HHHH **** "BBB@#Z A_
MU,?^Z*?3(?\ 4Q_[HI] !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% '$_%3_D$6?\ U\?^R-7F5>F_%3_D$6?_ %\?^R-7F5 !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444  ZU[3X,_Y%
M;3?^N(KQ8=:]I\&?\BMIO_7$4 ;5%%% !1110 4444 %%%% !7G'[26BW_B/
M]GCXH:3I5G-J.IWWA?4[6UL[9"\L\KVLBHB*.K,Q  ]37H]% 'RK\=_ 7B37
M?^">Z>%-/T*_OO$O_"-Z-;'2(("USYL;VID39URH1LCMM-)^V?\ !_5?&?B/
MX5>-+;0==\4:/X3NKY-6T?POJ,EEJC6]U D8FMGCDC9FC9!F-6!=6(]:^JL#
M&.U&,T ?GS)^SQ%\5M!^*DOA_P !^*_ MK=>#IM$TWQ+\2M?O7OKB>2596MQ
M;7$T@BMLQKF1L'<W (S5_P".'QI\0^,O _PD\-ZA\)_$_A&\M_&WAJ+5+K6K
M6*"RMI8[N+$=I(';[1N92%,8P$R21TK[D\3>&-*\9>'=2T'6[&'4M'U*WDM+
MNSG7*31.I5E/L037CO@S]CCP1X1\0Z'JD^I^*?$T/AZ03:%I?B/79KZQTEU7
M:CP0OQN53A6?<5[$4 =5^TUH>H>)OV</BGH^DV<VHZIJ'A;5+6TL[9"\L\KV
MLBHB*.2S,0 .Y->/_!CP!XCT?]HSPCJ]_H%_9Z9;?!W3M'FO9X"L<=ZETK/;
M%NT@ R5]!7U7CC%&* /@;6O@;X_OV^*.N:=X6N[N\T;XRVGC?3M*N5$)UNSM
MX8U=8&<A6)#.5)."R8ZUZ5\0OB#X\^.OA7QOIV@?"O7-!\.Q^#-:MY[GQ7IG
MV;4[N_FMF2WMK&(.6()!WL1M;Y #GK]7X'I1@#L* /BKXJ? #Q3X]_8J^!VE
MVVB:A<:]X*.@:S?^&X;EK"^NEMK;R[BVCE#*89P)&*G<"&3 YQ5/X8_#*S\2
M?&'P]K?ACX4?$+24\.VE]=KX@^)^O:B/LEZ\)BBAM;:6XD$N_<1(Y 7:."3B
MON'%  '08H _*_Q_\,OB#\2?V=]>T+6/ WQC\0?%G[$[7D.I7IM/#EK(K[W-
MG!!(L$Z[01%$J.22N<8)KVWXV^"GE^*KZ]J'P]^)VC7<^CV":7XT^$MS(;VX
M*QD26VH6Y8*K1O\ =+H05."PQ@?<>T>@H*@]0#0!^>WBCX,?$_5]*^"GQ ^)
MV@^*O&%[H]AJ>E>(-/\ "FH&SUR"">;?9W&+66,2R"-$69$;DG.&(->R?LH?
M#>TLOB/XL\9V/P[\5>#].EL(-*L=3\<:W>76K:@@<R2!K:>:3R8D;;L)(8EF
MX )KZEP/2@ #H,4 >&?%?PKK.J_M3_ ;6[/2[NZT?2;?Q"M_?11%H;4RVL"Q
M"1OX=[*P'J0:\$\$_";QE9?\$K-9\$3^%M5@\82Z9K$::&]JPO&>349WC'E]
M<LC*P]017W=BC QC'% '/>%[.XM? 6E6TT+QW,>FPQO$XPRN(0"I'KGBOA/P
M!<?$BV_8HA^!!^#'BN#QGJ^D7>C07ES:)%I,,-S+*/M-Q<%OW11)"S1E=Y91
M@$,#7Z'4FT>@H ^%O'O[,GC'Q7/\>/"FF64K_;_!7A;3M(U*^4I:ZC<V+2N\
M7F'@[BB*WIY@S75^/O%_C3]I4> ?"-C\)?%?A"XLO$NEZWKVI^)K5+>QT^*S
MG6=T@E#M]I=V0(I08PQ)(KZ^Q0 !V% 'QU\-O$/C']ERW\>>"KOX5^+O&LUY
MXCU/6=!U;P_:1W-GJ,5W(946XE+C[.ZLQ1RXQ@9!-<C\+?@MXZ_9-U'X4^,]
M1\+7_C6"S\(7OAK7M,\+0K=76ES7&H&_22&+<#+&&8PML.1M!&17WF0#V%!
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MS386,TXN[7$KY7YG^9OF//S'GFCZE!JZ;#ZQ).S1]D?\+B\/?]1#_P  )O\
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M00"?N^I'YU)<?%K0;.,27'VVWC+!0\UG(BY/09( S[5Y!I/_ "-MM_UXS?\
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M>OVI_P#D<?@G_P!C5<?^FF]KZ%KYZ_:G_P"1Q^"?_8U7'_IIO: '#I10.E%
M!1110 4444 %%%% !1110 4444 ?0$/^IC_W13Z9#_J8_P#=%/H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XGXJ?\@BS_Z^/_9&KS*O
M3?BI_P @BS_Z^/\ V1J\RH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ '6O:?!G_(K:;_UQ%>+#K7M/@S_ )%;3?\ KB*
M-JBO!_VQOB[XR^#/PNAUOP;8PR7#79BO-1N--GU&.PA$,KJ[00$.V^1(XMV=
MJ&7<W K=_9D^*'B'XO?#NX\0Z_I_V))-2GCTV?[!-8F\LAM,4QAF^=>6=,G
M;R]P #"@#UNBBB@!K]!]1_.ODK_@FK_R2/Q]_P!E UO_ -&)7UJ_0?4?SKY*
M_P"":O\ R2/Q]_V4#6__ $8E 'UO17*^./B5HG@'2C>ZA<>:2_E);VY#R._H
M!GC&.2>E'@CXDZ)X]TH7NGW'ED/Y3V]P0DJ/Z$9YSG@CK7G_ -H83ZQ]4]JO
M:6ORWUL=_P!0Q7U?ZU[-^SO:]M+G5453UG4#I.D7MZ(_--M!)-LSC=M4G'Z5
M\U6_[7.K6?A+2-=O=)\.ZF-7\-WFO0V>A:T]Q/9F"P:\V7*&(;4.WRC(.CL@
MP=W'H' ?4-(RAE(/0C%?.7A_]K6-['5I]0M]%UP6FA0ZTO\ PB&IF^*R2RI%
M%:2AD7RY9'D 0Y(.UR0NWGO=+^)GB?1_&7AS0?&OA[3M,7Q'YT6GW>D:B]TD
M=S'$TS6\P>*,Y,:2,LBY4F-@0.,@%RV^!^D6=O%!#JNKI%$@1!YL1P ,#GR_
M:F0? C0K5I6@O;^!I3F0Q"W0R'U;$0W?C5;6_B7XIU'Q;XDT3P7X;T_6#X;2
M$7\NIZDUIY]S)$)EMH0L3_-Y;1L7?:H,BCGYB+7_  OKPO::YI^AZH]YI>M3
MFT@N;:2TDECT^ZN54P6MQ<1AH8Y7+ !2_)*X^\N=_;U?YG]YG[.'9#U^"&CH
M5*ZEJ:E%V*5: ;5]!^ZX' XZ<4O_  I/23()/[4U3S ,!]\.X#N,^5G%<W%^
MUY\,Y[-KJ+4]3DMQ;7%XLB:)>D206\ACN94Q%\R0L,2,.%R,]14WAO\ :6\/
M:MXS\0^'+\2:=-9:TND6%YY$TEI=E[."YAS.$\M))!*P6,MD[!CE@*/;U?YG
M]X>SA_*C:E^!>B30-!)?:A+ QRT3B!D;G/*F+!YYILGP&T"7R=]W?2>2,1;T
MMSY8]%S#\OX8K)\-?M0^!];DTFS.IS2WEY'IS//:Z9=FSB:^4&T#S-$%C$I(
M5=^TY(! -:T/[1/@*2XU%)-::UM[*"[N#?W5I-#:7$=J2+IH)V0)-Y1&&\LM
MCWH]O5_F?WA[.'9"K\"=#642B^U 2@ "0"W# #H ?*SQDX],T]?@?HZ%2NI:
MFI4DJ08!C/7'[KC/?UJ/X8_&FR^*'B[Q;I%A8W=I!H4=BQ>_MIK6X9KB-Y,/
M#*BLF%52#W#>U>DT>WJ_S/[P]G#LCS:'X#Z#;H4AO+Z%"_F%8UMU!?\ O8$7
MWO?K3V^!FB,RLU_J+,K^8"?()#]-P/E?>]^M>C44>WJ_S/[P]G#LCSV'X+:7
M!>K=)J^K"=8VB#>9#]TD$C'E^H%37?P>TR_C6.ZU&_NXU.X)<);2*#Z@-"1G
MWJQXBTNZD\5Z9%%K>J6L%Z9C)#!,@5=B C;E#CFNR1=B*N2V!C+=364I.;O)
MW9E1J<TIPY;<KM^%_P!3B'^$MC(07U;4G(4J"WD' (P0/W70CM3E^%5FBA5U
MG554# 4&  #TQY5=O14G2<,OPDL$2-5U74E2+_5J!;@)QCY1Y7'!(XI@^#^F
M+=/<C4;\73KM:<);B1E]"WDY(]LUWE% 'G\?P6T:&)XH[NZCB<$-&D-JJL#U
M! AP<]_6ID^$>GQ! FJ:B@1MRA1;C:>F1B+@^]=U10!P,GP;TF98EDOKV18F
MWQAXK9A&W7*YA^4^XJ4_"2P8L3JNI$LXD.1;\L.C']UR>!SUXKN:* .%C^$E
MA"KK%JNI1!V+-Y8MUW,>K'$7)/KUKK](TR+1=*LM/MRY@M($@C+G+;54*,GN
M<"K=% !1110 4444 %%%% !7GWQ9^[I?UE_]EKT&O/OBS]W2_K+_ .RT >>T
MAZ&EI#T- %K]D;_D%_$[_L>=2_\ 1<%%'[(W_(+^)W_8\ZE_Z+@HH ]ZHHHH
M **** "BBB@ HHHH **** "BBB@ KYZ_:G_Y''X)_P#8U7'_ *:;VOH0$'I7
MSW^U/_R./P3_ .QJN/\ TTWM #ATHH'2B@ HHHH **** "BBB@ HHHH ****
M /H"'_4Q_P"Z*?3(?]3'_NBGT %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 <3\5/^019_]?'_ +(U>95Z;\5/^019_P#7Q_[(U>94 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 #K7M
M/@S_ )%;3?\ KB*\6'6O:?!G_(K:;_UQ% 'SQ^W)JU]<^$_#UAH>IF1[36X9
MM9TJR\:6_AJ>:U>"<(K7+NK+EP'51][RSV!(ZS]CAQ)\)9B+2\LO^)G,/+OO
M&,?BB3[J<_;$9@!_TSSE>O\ %7EG[;/@JUT>XG\9>(?$_@+1/#-U]FMC9Z_\
M.H_$5[=7423%"IW;Y"J/+M&W"*9#D FO5/V.]-TK2?A9>VFE:KX;U:.'5[F.
M>3POX970+>*90BM&]JO208&7_B!7&1@T >HS_$7PU;>.[3P7)K5H/%5U:27\
M6DB3=.;="H:0J/NKE@ 3C/.,X..&L_VL?A1?>%=4\2Q>+X?["TZ6&":^DM+B
M.-Y)79(UBW1@S%F1@!'NZ&LGQY\$;W6?C[H_C31=/TNTC/AS5]-U*^==DTUS
M.+9;8R;-KR*JPL,[@5  !&:\ \&_LJ?%'PCI%AJ&G:!HFCQ^'=9T35+'P/;^
M)+FYL;N>TCN(KNXBFF5OLWG+/'M3!QY(W')S0!]M^&O%&D^-?#FFZ]H6H0:K
MH^HPI<VEY;/NCFC;!5E-?+W_  36_P"21^/O^R@:W_Z,2K'AG]B[6KOX4>"=
M%U3XJ>./ NJZ5%=27EIX!UO['9O+=7<MTR_-&2XC,QC1L#Y5'%9?_!+W3CH_
MP-\8V)NKB^-MXYU>$W5V^^:;:T:[W;NQQDGN2: /H3Q[\%?#WC?3I(EMHM*O
MFE\X7UI"H<L>N[IN!SW[\T> O@KX>\$:>D36T6JWPE\XWUW"I<,.FWKM QVK
MR3]HS]M_PY\'] G3P_;OXA\3B[:R6SN+>>W@A9<[W>1D 8#& $)SGJ!S1^SI
M^V_X<^,.@01Z_;OX>\3&[6R:SM[>>X@F9L;'214(4'.,.1C'4CFM/]2]/[8^
MIJ^U[:^O+_[=;YV.C_6.MR?V?]8?+O:_X7_2]O(^CM7T\:MI5Y9&0Q"YA>'>
M!DKN4C./QKSO3_@'H>D_!*[^'M@MM8M=^'#X>GU>UL8XI90;8P&9E7&3SNP3
MU[UZ'K5Y)I^CWUU$T"20022*UU)Y<0*J2"[?PKQR>PS7RKI'[0'C3P;I=Y>^
M*[F_36X?#U[?2Z!XAT5+.&XO(8Q)G3[NWW130+\V]6=G$9$F?E85F<YZ-)^S
M0?$2K'XK\1K?Q6^@/H%H-$TX::T2M)!)Y[/YDC/*KVT+)R%4ACM.ZNDT;X4:
MU<>+?#^O>+_%O_"2S:!%)_9UO;Z:EC&+B2-HGN90'??)Y;.HQM0;V(7)&.7\
M0:[XZ^$]]X0DUCQ9#XIC\073Z1=6YTR*W6VNVM9YXYK;9\WE@P,ICD,AVL&W
M?*=W>? SQ5J'CCX+^!?$.K3)/JNJZ'97MU*B!%>62%&<A1P 23P.E &1XC^$
MVO/XJU_6_"/C(^%I-?MXH]0AETQ+U?/C41I<PEG79+Y85#NWH0B';D<X47[-
MLUEJ\PL_&6H?\(_?7^E:GJ=E?6Z7-W>7-@L*HQNF(8"3[+;F3*L24.TKN-1>
M'M:\>>/]+U+Q?I_BRR\/VD&MW5I:Z)?:>AM3:VMV]M)]ID/[T2R>4[!D953<
M@VM@[L+Q_P#M0:E9^#?%>IZ1X=N;'3#::[::!XC>:*42ZCI]M<R-YEL>4C+6
MD^QB3N\OE5##(!MZ7^RY;Z9X=L=*'B.>06WAK6/#GF_95!9;^9)3-C=P4*8"
M]#GJ*BL/V8+BVUAQ<>+Y+GPW)KEGXA?21IR)(;JVLX+>(>?O)\O=;1RLNW)(
MVA@,YIZ)^T[JL>G+I>K^#IH_&<W]E1Z=IR:C"T=^;V*9XW:51B';]EN"XPVT
M(-I?<!2ZY^TSKTFGO8:)X(9_%$6G:M=7UK>ZG''#I[V#QQR@N%/FAFGB9-H&
MY6YV'(  _P ._LE6OA_PC=Z$GB>XF6X/AT^>;105_LIH2O&[GS?)&?[N>,XJ
MA;_L5: EIJNF2ZC =(N;?4;>U:'3$6_M_M;E]QN69MQC)(7:B;A@/OQ7I/@W
MQ5XP\6_ ?PYX@MK/2X_&.J:-:79AO)G^QI-+&C,[%%W%0&+;5&3C;D?>JQ\
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M1M0T:[MM6N+?5!JFLC5[BXO%2(M*]V !(=AC0@*NPQE,#95C]M+3?&NN^ M
MTOP5IUE=W=SJVZ:YOM#BU=+4QVT\L#>3+\B;YTAB\YN$\P&G_L0ZUXG\0?!V
M[O?$XU S2ZS=M9RZCX?BT.2:W)5M_P!DC "9D:7);)9@S9((H ^@J*** &OT
M'U'\Z^2O^":O_)(_'W_90-;_ /1B5]:OT'U'\Z^2O^":W_)(_'W_ &4#6_\
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M %%%% !1110!Q/Q4_P"019_]?'_LC5YE7IOQ4_Y!%G_U\?\ LC5YE0 4444
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M:^>OVI_^1Q^"?_8U7'_IIO: '#I10.E% !1110 4444 %%%% !1110 4444
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M$FF^(K>UD$4[Z?<+)Y3$9 <#E<CD9'(Y&17DO[4__(X_!/\ [&JX_P#33>T
M.'2B@=** "BBB@ HHHH **** "BBB@ HHHH ^@(?]3'_ +HI],A_U,?^Z*?0
M 4444 -==Z,O3(Q7PE\'/A)KWPT_:DTZPU.^BM%CDF=;F!B8[Q6C=EBXZ%E!
M;:W]P^U?=]>%^.?"MWXI\2?$!M+.W7M+BTG5-+?GBYA6=E7Z.-R'V<TFCY+/
ML#'$SPV(LW.G*Z2ZV3DUZOE21[F.E+6'X(\5VOCGPEI6O67%O?VZS!#UC8_>
M0^ZL"I]P:W*9]33G&K!5(.Z:NO1A1110:!1110 4444 %%%% !1110 4444
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M\[0!6#_P2]TN'0_@;XRTZV:5K>T\<ZO;QF9R[E4:-1N8\DX R>] 'V'1110
M4444 %%%% !1110 4444 %9?B/Q-IOA+2I-1U6[2TM4(&YN2['HJJ.68]E&2
M:Q_%GC^'0KR/2--M7UOQ).NZ'3+=@"J_\])7Z11_[1Z]@35;P[X!F;58]?\
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M"\+$YCT3=LN;U>QN6'W%/_/)3G^\>U>A6EI!I]K%;6T,=O;Q*$CBB4*J*.@
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M/*QW[GDQ:^QO_A?Q?=I+_MT]2HIL<BRHKHP=&&0RG((]:=3/5"BBB@ HHHH
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  .M>T^#/\
MD5M-_P"N(KQ8=:]I\&?\BMIO_7$4 ?+/[1FM7NI?'JP\$:19ZCI5QXALH+"]
MO))+BYL]3@G,D;!K'RS#+'"H/F2>=!*H?Y6. #[?^S]\/[_X=>%M0T_5M,2V
MU62^,UQJ0UNYU9]3/EHJSM-=9F4A55!&Y;8(P Q&#7J&.:6@ HHHH :_0?4?
MSKY*_P"":O\ R2/Q]_V4#6__ $8E?6K]!]1_.ODK_@FK_P DC\??]E UO_T8
ME 'UO1110 4444 %%%% !1110 4444 %%%% !1110 4444 )C/K^=+110 44
M44 %%%% !1110 4444 87C+P1HGQ T?^R_$&GQZE8>:LWD2,RC>N<'*D'C)K
M.\!_";PE\,1=#POHD&CK=!%E6!G(8+G:,,QQC<>GK77457-*W+?0KFE:U] H
MHHJ20HHHH **** "O/OBS]W2_K+_ .RUZ#7GWQ9^[I?UE_\ 9: //:0]#2TA
MZ&@"U^R-_P @OXG?]CSJ7_HN"BC]D;_D%_$[_L>=2_\ 1<%% 'O5%%% !111
M0 AKYCT[XD_'+XB^(/%C^%[OX<^&M)T?6[K2(].\0PWD^H!87*K++Y<B*OF#
M$B@#[C*<G-?3AZ5\!7'PPT33_B#X^?QU^S/XA^)VI7WB*\N[3Q4WV.1[VV=\
MQ(%FNE*K$N(U"C!5 <*210!]R>##K9\+:8?$EQIUUKODC[9-I".EH\G<Q!R6
M"_4DUM5R7PGLK'3OAQX>MM,\+S^"K".T58?#]RJ+)8+SB)@C,H(]F(]ZZV@
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M0?\ @TO?_CU'_#LS]FS_ *)I!_X-+W_X]0!])_V[IW_/];?]_E_QH_MW3O\
MG^MO^_R_XU\H^-O^":O[/=GX-UZ?2OAG&VIQ:?</:B+4+UW\T1,4VKYIR=V,
M#')KSW]DO_@G5\(?$_[.O@G5/B+\,9HO&MS:R-J::E<7MI<"032 ;XO,78=H
M7C:.,'O0!]X?VYIW_/\ 6W_?Y?\ &C^W-._Y_K;_ +_+_C7S9_P[,_9L_P"B
M:0?^#2]_^/4?\.S/V;/^B:0?^#2]_P#CU 'TG_;FG?\ /];?]_E_QH_MS3O^
M?ZV_[_+_ (U\V?\ #LS]FS_HFD'_ (-+W_X]1_P[,_9L_P"B:0?^#2]_^/4
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M44SZ$**** "BBB@ HHHH XGXJ?\ ((L_^OC_ -D:O,J]-^*G_((L_P#KX_\
M9&KS*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M****  =:]I\&?\BMIO\ UQ%>+#K7M/@S_D5M-_ZXB@#:HHHH **** "BBB@
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M1J\RKTWXJ?\ ((L_^OC_ -D:O,J "BBB@ HHHH **** "BBB@ HHHH ****
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M"NMH **** "BBB@ KYZ_:G_Y''X)_P#8U7'_ *:;VOH6OGK]J?\ Y''X)_\
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MK<?"'65O?#VB:/KOCJZTN2QLX;AY)K6WAU$,LS%L?-]EW@*!AMF20"#[]<?
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M91@E2"P8&N0_:G_Y''X)_P#8U7'_ *:;V@!PZ44#I10 4444 %%%% !1110
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M%E)!?AMN/X@*\[\.Q? *VO\ X<7'@EM,779HI4T=O#Q!N;B!K5_-^V^7EFB
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MUHPT:\*$>Y1@54@,"?EX=?I[3/#FE:-=WMU8:99V-S>OYEU-;6Z1O.W]YV4
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M0?%?4/C?\0;7Q5HEC9^&HY+'R&CU6>:.WS:9(M0UL@E#/@N=PVL2.:]\HHH
M**** "BBB@ HHHH **** "BBB@ KS[XL_=TOZR_^RUZ#7GWQ9^[I?UE_]EH
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MW+P6;[?++P".+<57S'0=<;J^[Z2@#Y^^&5QJ?Q/_ &C-1^(:^&=>\-^'=/\
M"R:! ?$>GO87%W<R7?VB4I#)A]D:I&N\@!F<[<@9IG[4_P#R./P3_P"QJN/_
M $TWM?0M?/7[4_\ R./P3_[&JX_]--[0 X=**!THH **** "BBB@ HHHH **
M** "BBB@#Z A_P!3'_NBGTR'_4Q_[HI] !1110 4444 %%%% !1110 4444
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MG_A,=:_Z",W_ ([_ (4?\)CK7_01F_\ '?\ "L:B@LV?^$QUK_H(S?\ CO\
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M_A,=:_Z",W_CO^%8U% &S_PF.M?]!&;_ ,=_PH_X3'6O^@C-_P"._P"%8U%
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M?_I$CKOV1O\ D%_$[_L>=2_]%P44?LC?\@OXG?\ 8\ZE_P"BX**#O/>J***
M"BBB@#D?BQ\0/"OPO^'VL>)/&MW#9^&;2(+>23PF9&61A&J% "6W,ZKC!SNK
MY)\5>.M6\>V/@SX>>!?@;H'@WP1XIU)ETV_\=6$26IFBA>[,Z:5"=Q^6(E3(
MRY8KD=:^M/BSXG\*^$O ]W>^-((;GP[+/;6,\%Q:_:8Y&GGC@B5H\$,#)(@Y
M&!G)Z5\_ZO\ LL?#X?$DV7PO\7:M\,_'/A=%UN/3=,9KK3+872S0K*;*<-"
MZK,N(BAQGIQ0!])>!=&U;P_X0TK3M=UE?$&L6\"I=:FEHMJMQ)W81*2$'8*#
MP!6]7!_ GQM+\1OA#X5\23ZC!J\VHV2S/?6UF]I'.<D%Q"[,T><?=).*[R@
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MG?1W^S%=EV+E%%%!Z04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN);?]%8"FQ_#VZL6_P")=XNUZS3/$<TJ7*#_ +^*3^M,/;8R'QT4_P##*_\
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MTB+_ +S 5R!^$'A)OOZ4TG^_=3'_ -GIR?"'P:A_Y%^U8_[;2-_-J!>TQ_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>0#[&!S7SW^U/_R./P3_ .QJN/\ TTWM7_A3?Z_X#^.GB3X9:KXGU+Q?I/\
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MS0RJ4>-QE64C!!'<$5S'@/X4^#?A=%>1>#_"NC^%X[QD:Y32+*.V$Q4$*7"
M9P"<9]375T4 ?/%E^R_J6E_L^^$_!5EXAMH?%7A35QKVD:R]JSVZW2W<TRB2
M+<"4:.>2)@"#AR1SBJ5[^S#XG\8Z7XRUOQ-XHTZ#XB:S>:5>Z;?:39/]ATE]
M,D\VS58Y&+R R-(TFXC<)" !@5]*44 >1_"KX6^*-,^('B'Q]X]U;2]2\4:E
M86VD6]OHEO)#:65G"\DFU?,8NSO)*S,3C@*!TS7%?MBZQ9^&-2^$6N:K/]BT
M>P\42M=7KHQC@#:9>(I<@' +,JCW(KZ1I&4,,$ CT- 'QBO[3'PL,AC'CG2C
M(H!*!GW 'H2-OL:=_P -*?"__H=M,_.3_P")KZ \/>&-0M?V@O&FM36+II-Y
MX?TBVM[HJ-DDL4U\TB#W421D_P"\*])\B/\ N+^0H ^-O^&E/A?_ -#MIGYR
M?_$T?\-*?"__ *';3/SD_P#B:^R?(C_N+^0H\B/^XOY"@#XV_P"&E/A?_P!#
MMIGYR?\ Q-'_  TI\+_^AVTS\Y/_ (FOLGR(_P"XOY"CR(_[B_D* /C;_AI3
MX7_]#MIGYR?_ !-'_#2GPO\ ^AVTS\Y/_B:^R?(C_N+^0H\B/^XOY"@#XV_X
M:4^%_P#T.VF?G)_\31_PTI\+_P#H=M,_.3_XFOLGR(_[B_D*/(C_ +B_D* /
MC;_AI3X7_P#0[:9^<G_Q--D_:8^%D,;22>.=*C11DL[.H'U)6OLOR(_[B_D*
M\S_:5\+ZAXL^!7C31]%L'U#5+RP:*WMH5&^1MRG S]* ,B/]L/X-+&H/Q!T?
M@ ?ZUO\ XFG?\-B_!K_HH.C_ /?UO\*]A\B/^XOY"CR(_P"XOY"@#Q[_ (;%
M^#7_ $4'1_\ OZW^%'_#8OP:_P"B@Z/_ -_6_P *]A\B/^XOY"CR(_[B_D*
M/'O^&Q?@U_T4'1_^_K?X4Q/VRO@M+NV?$317VL5;;,3M8=0>.#[5[(8(\'Y%
M_P"^17EWP)\*ZEX</Q#_ +5L'L_M_C#4;^U\U1^]@D\O9(OL<'\J ,__ (;%
M^#7_ $4'1_\ OZW^%'_#8OP:_P"B@Z/_ -_6_P *]A\B/^XOY"CR(_[B_D*
M/'O^&Q?@U_T4'1_^_K?X4?\ #8OP:_Z*#H__ '];_"O8?(C_ +B_D*/(C_N+
M^0H \;;]LKX++(L;?$71%D<$JAF.6QUP,<XI_P#PV+\&O^B@Z/\ ]_6_PK0\
M<^%-2U'X^?"[6;73WFTK3;'6H[RZ51LA:5+81!O][8^/H:]1\B/^XOY"@#Q[
M_AL7X-?]%!T?_OZW^%'_  V+\&O^B@Z/_P!_6_PKV'R(_P"XOY"CR(_[B_D*
M /'O^&Q?@U_T4'1_^_K?X4?\-B_!K_HH.C_]_6_PKV'R(_[B_D*/(C_N+^0H
M \>_X;%^#7_10='_ ._K?X4?\-B_!K_HH.C_ /?UO\*]A\B/^XOY"CR(_P"X
MOY"@#Q[_ (;%^#7_ $4'1_\ OZW^%'_#8OP:_P"B@Z/_ -_6_P *]A\B/^XO
MY"CR(_[B_D* /G'XA_M:?!_5;"U@MOB!H\DZR^9Y2R,6V[2-V O3) S[UPG_
M  TI\+_^AVTS\Y/_ (FOH"Z\,:@_[1VEZXMBYT>+PI>63W>T;%G:\MG6/ZE4
M8_@:])\B/^XOY"@#XV_X:4^%_P#T.VF?G)_\31_PTI\+_P#H=M,_.3_XFOLG
MR(_[B_D*/(C_ +B_D* /C;_AI3X7_P#0[:9^<G_Q-'_#2GPO_P"AVTS\Y/\
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M/^XOY"CR(_[B_D* /C;_ (:4^%__ $.VF?G)_P#$T?\ #2GPO_Z';3/SD_\
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M?"__ *';3/SD_P#B:^R?(C_N+^0H\B/^XOY"@#XV_P"&E/A?_P!#MIGYR?\
MQ-'_  TI\+_^AVTS\Y/_ (FOLGR(_P"XOY"CR(_[B_D* /C;_AI3X7_]#MIG
MYR?_ !-'_#2GPO\ ^AVTS\Y/_B:^R?(C_N+^0H\B/^XOY"@#XV_X:4^%_P#T
M.VF?G)_\31_PTI\+_P#H=M,_.3_XFOLGR(_[B_D*/(C_ +B_D* /C;_AI3X7
M_P#0[:9^<G_Q-'_#2GPO_P"AVTS\Y/\ XFOLGR(_[B_D*/(C_N+^0H ^-O\
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MQK\!]"O_ !#J,FKZM!=:AILNH3*JR7*VM]/;)(X4 ;RD2EB!R<F@#V*BBB@
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M69D&3\A.WD\5F^'_ -F?X6^%K#5;+2_ VCVMKJ@B6[B$&X2)%()(D^8G:B.
MRHN%!&0*]-HH X?XC_!+P-\7&LG\7^&;'7);,.L$UPI$D:MC>@=2&V-@97.T
MXY%1>+_@-\/O'FAZ1H^M^$M,N]-T=?+TZ!(?)^QIMVE(C'M**5 !4$ @#(-=
M[10!S&@_#'PGX6O-)NM'\.Z=ID^DZ>VE6+VENL?V:T9U=H4QT0LB,1W*@UI>
M&?"VD>#=(32]#T^WTO3DEEF6VMDV('DD:21L>K.[,?=C6K10 4444 %%%% '
M$_$3X*^!OBS<:?/XO\,:?X@GT]9%M9;R+<T(?;O"D$$!MJY]<"J;?L]_#<^
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M/!+.2Q/KS4?P\^%/A+X4:=<V/A/0K71(+J7S[@P F2=\!0TCL2SD  #<3@#
MKK** "BBB@ HHHH **** "N0^)'PB\&?%_3K2P\:>&]/\2V5I*9X(-1B\Q(Y
M-I7<!ZX)&?>NOHH \RTK]F;X5Z'X/U7PKI_@/1+/P]JDJ3WFGPVH6*:1,;)"
M.S+@888((X-=1X!^&WACX7:*VD^%=%M=$L'E:>2.V4YED;&7=B2SL< ;F).
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
G%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>crvs-20260331.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.3.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/7/2026 12:52:15 PM-->
<!--Modified on: 5/7/2026 12:52:15 PM-->
<xsd:schema targetNamespace="http://www.corvuspharma.com/20260331" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:attributeFormDefault="unqualified" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:crvs="http://www.corvuspharma.com/20260331" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2025" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureNetLossPerShareCalculationOfEarningsPerShareDetails" id="DisclosureNetLossPerShareCalculationOfEarningsPerShareDetails">
        <link:definition>99940301 - Disclosure - Net Loss per Share - Calculation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureSegmentsDetails" id="DisclosureSegmentsDetails">
        <link:definition>99940401 - Disclosure - Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails" id="DisclosureFairValueMeasurementsRecurringDetails">
        <link:definition>99940501 - Disclosure - Fair Value Measurements - Recurring (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsCurrentOperationsAndRemainingMaturityDetails" id="DisclosureFairValueMeasurementsCurrentOperationsAndRemainingMaturityDetails">
        <link:definition>99940503 - Disclosure - Fair Value Measurements - Current Operations and The Remaining Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPrepaidsAndOtherCurrentAssetsDetails" id="DisclosureBalanceSheetComponentsPrepaidsAndOtherCurrentAssetsDetails">
        <link:definition>99940801 - Disclosure - Balance Sheet Components - Prepaids and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails" id="DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails">
        <link:definition>99940802 - Disclosure - Balance Sheet Components - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsAccrualsAndOtherLiabilitiesDetails" id="DisclosureBalanceSheetComponentsAccrualsAndOtherLiabilitiesDetails">
        <link:definition>99940803 - Disclosure - Balance Sheet Components - Accruals and Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails" id="DisclosureFacilityLeaseLeaseCostDetails">
        <link:definition>99941402 - Disclosure - Facility Lease - Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails" id="DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails">
        <link:definition>99941403 - Disclosure - Facility Lease - Minimum Rental Commitments San Francisco Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>995200090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureFacilityLeaseTables" id="DisclosureFacilityLeaseTables">
        <link:definition>99931403 - Disclosure - Facility Lease (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureOrganizationDetails" id="DisclosureOrganizationDetails">
        <link:definition>99940101 - Disclosure - Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>99940201 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" id="DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails">
        <link:definition>99940302 - Disclosure - Net Loss per Share - Anti-Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsAvailableForSaleDetails" id="DisclosureFairValueMeasurementsAvailableForSaleDetails">
        <link:definition>99940502 - Disclosure - Fair Value Measurements - Available For Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentInvestmentInAngelPharmaceuticalsDetails" id="DisclosureEquityMethodInvestmentInvestmentInAngelPharmaceuticalsDetails">
        <link:definition>99940601 - Disclosure - Equity Method Investment - Investment in Angel Pharmaceuticals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfBalanceSheetInformationDetails" id="DisclosureEquityMethodInvestmentSummaryOfBalanceSheetInformationDetails">
        <link:definition>99940602 - Disclosure - Equity Method Investment - Summary of Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfIncomeStatementInformationDetails" id="DisclosureEquityMethodInvestmentSummaryOfIncomeStatementInformationDetails">
        <link:definition>99940603 - Disclosure - Equity Method Investment - Summary of Income Statement Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails" id="DisclosureLicenseAndCollaborationAgreementsDetails">
        <link:definition>99940701 - Disclosure - License and Collaboration Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails" id="DisclosureWarrantsNarrativeDetails">
        <link:definition>99940901 - Disclosure - Warrants - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails" id="DisclosureCommonStockStockIssuanceAgreementDetails">
        <link:definition>99941001 - Disclosure - Common Stock - Stock Issuance Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureCommonStockCommonSharesReservedForIssuanceDetails" id="DisclosureCommonStockCommonSharesReservedForIssuanceDetails">
        <link:definition>99941002 - Disclosure - Common Stock - Common Shares Reserved for Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionActivityDetails" id="DisclosureStockOptionPlansStockOptionActivityDetails">
        <link:definition>99941101 - Disclosure - Stock Option Plans - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionsActivityDetails" id="DisclosureStockOptionPlansStockOptionsActivityDetails">
        <link:definition>99941102 - Disclosure - Stock Option Plans - Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureStockBasedCompensationExpenseAllocationDetails" id="DisclosureStockBasedCompensationExpenseAllocationDetails">
        <link:definition>99941201 - Disclosure - Stock-Based Compensation - Expense Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails" id="DisclosureFacilityLeaseLesseeInformationDetails">
        <link:definition>99941401 - Disclosure - Facility Lease - Lessee Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>99941601 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureOrganization" id="DisclosureOrganization">
        <link:definition>995210101 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995210201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>995210301 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureSegments" id="DisclosureSegments">
        <link:definition>995210401 - Disclosure - Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>995210501 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureEquityMethodInvestment" id="DisclosureEquityMethodInvestment">
        <link:definition>995210601 - Disclosure - Equity Method Investment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreements" id="DisclosureLicenseAndCollaborationAgreements">
        <link:definition>995210701 - Disclosure - License and Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponents" id="DisclosureBalanceSheetComponents">
        <link:definition>995210801 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureWarrants" id="DisclosureWarrants">
        <link:definition>995210901 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureCommonStock" id="DisclosureCommonStock">
        <link:definition>995211001 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureStockOptionPlans" id="DisclosureStockOptionPlans">
        <link:definition>995211101 - Disclosure - Stock Option Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>995211201 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>995211301 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureFacilityLease" id="DisclosureFacilityLease">
        <link:definition>995211401 - Disclosure - Facility Lease</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>995211501 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>995211601 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>99930303 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureSegmentsTables" id="DisclosureSegmentsTables">
        <link:definition>99930403 - Disclosure - Segments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>99930503 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentTables" id="DisclosureEquityMethodInvestmentTables">
        <link:definition>99930603 - Disclosure - Equity Method Investment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsTables" id="DisclosureBalanceSheetComponentsTables">
        <link:definition>99930803 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureCommonStockTables" id="DisclosureCommonStockTables">
        <link:definition>99931003 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureStockOptionPlansTables" id="DisclosureStockOptionPlansTables">
        <link:definition>99931103 - Disclosure - Stock Option Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>99931203 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxesComponentsOfEarningBeforeIncomeTaxesAndIncomeTaxesBenefitsDetails" id="DisclosureIncomeTaxesComponentsOfEarningBeforeIncomeTaxesAndIncomeTaxesBenefitsDetails">
        <link:definition>99941301 - Disclosure - Income Taxes - Components of Earning Before Income Taxes and Income Taxes Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="crvs-20260331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="crvs-20260331_cal.xml" xlink:title="Calculation Links, all" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="crvs-20260331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="crvs-20260331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="https://xbrl.org/2023/calculation-1.1" schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd" />
  <xsd:element name="CommonStockWarrantsMember" id="crvs_CommonStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CombinedOfferingPriceForSharesAndWarrants" id="crvs_CombinedOfferingPriceForSharesAndWarrants" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ClassOfWarrantOrRightExercisePricePerPrefundedWarrant" id="crvs_ClassOfWarrantOrRightExercisePricePerPrefundedWarrant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ResearchAndDevelopmentArrangementContractTerminationNoticePeriod" id="crvs_ResearchAndDevelopmentArrangementContractTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AccruedLiabilitiesClinicalTrialCurrent" id="crvs_AccruedLiabilitiesClinicalTrialCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccruedLiabilitiesManufacturingCurrent" id="crvs_AccruedLiabilitiesManufacturingCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NumberOfFinancialInstitutionsInWhichCashAndCashEquivalentsAreDeposited" id="crvs_NumberOfFinancialInstitutionsInWhichCashAndCashEquivalentsAreDeposited" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ScrippsResearchInstituteMember" id="crvs_ScrippsResearchInstituteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EquityIncentiveAwardPlan2014Member" id="crvs_EquityIncentiveAwardPlan2014Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EquityIncentiveAwardPlan2016Member" id="crvs_EquityIncentiveAwardPlan2016Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="VernalisRAndDLimitedMember" id="crvs_VernalisRAndDLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FollowOnPublicOfferingMember" id="crvs_FollowOnPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AtMarketOfferingMember" id="crvs_AtMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MonashLicenseMember" id="crvs_MonashLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="JefferiesLlcMember" id="crvs_JefferiesLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonStockSharesAndCommonStockWarrantsMember" id="crvs_CommonStockSharesAndCommonStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PrefundedWarrantsAndCommonStockWarrantsMember" id="crvs_PrefundedWarrantsAndCommonStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AngelPharmaceuticalsLtdEquityMethodInvesteeMember" id="crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SignificantAccountingPoliciesPolicyTextBlock" id="crvs_SignificantAccountingPoliciesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="UnauditedInterimFinancialInformationPolicyTextBlock" id="crvs_UnauditedInterimFinancialInformationPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CommonSharesIssuableUponConversionOfPreFundedWarrants" id="crvs_CommonSharesIssuableUponConversionOfPreFundedWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ChangeInFairValueOfWarrantLiabilities" id="crvs_ChangeInFairValueOfWarrantLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PreFundedWarrantEquityMember" id="crvs_PreFundedWarrantEquityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SharesAvailableForFutureOptionGrantsEquityMember" id="crvs_SharesAvailableForFutureOptionGrantsEquityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OutstandingOptionsEquityMember" id="crvs_OutstandingOptionsEquityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SharesReservedForEmployeeStockPurchasePlanEquityMember" id="crvs_SharesReservedForEmployeeStockPurchasePlanEquityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SegmentDrugManufacturingCosts" id="crvs_SegmentDrugManufacturingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OrganizationTable" id="crvs_OrganizationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OrganizationLineItems" id="crvs_OrganizationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsAndRightsNoteDisclosureTextBlock" id="crvs_WarrantsAndRightsNoteDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CommonStockNoteDisclosureTextBlock" id="crvs_CommonStockNoteDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EquityIncentivePlansDisclosureTextBlock" id="crvs_EquityIncentivePlansDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="FacilitiesAndInsurance" id="crvs_FacilitiesAndInsurance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EmployeeStockOwnershipPlanEsopEquityReservePercentage" id="crvs_EmployeeStockOwnershipPlanEsopEquityReservePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LicenseAgreementMilestonePayment" id="crvs_LicenseAgreementMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AggregatePotentialMilestonePaymentsMember" id="crvs_AggregatePotentialMilestonePaymentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OfficeAndLabSpaceLeaseMember" id="crvs_OfficeAndLabSpaceLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ThirdYearOfSubleaseMember" id="crvs_ThirdYearOfSubleaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PrefundedWarrantsMember" id="crvs_PrefundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommonWarrantsMember" id="crvs_CommonWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PuissanceCapitalManagementMember" id="crvs_PuissanceCapitalManagementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ServicesSupportClinicalTrialsMember" id="crvs_ServicesSupportClinicalTrialsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IconPlcMember" id="crvs_IconPlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="UnderwritingCommitmentsPercentage" id="crvs_UnderwritingCommitmentsPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OfferingCostsAccruedAndChargedToAdditionalPaidInCapital" id="crvs_OfferingCostsAccruedAndChargedToAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" id="crvs_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="Rule10b51ArrModifiedFlag" id="crvs_Rule10b51ArrModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NonRule10b51ArrModifiedFlag" id="crvs_NonRule10b51ArrModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>crvs-20260331_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.3.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/7/2026 12:52:15 PM-->
<!--Modified on: 5/7/2026 12:52:15 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <link:roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureNetLossPerShareCalculationOfEarningsPerShareDetails" roleURI="http://www.corvuspharma.com/role/DisclosureNetLossPerShareCalculationOfEarningsPerShareDetails" />
  <link:roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureSegmentsDetails" roleURI="http://www.corvuspharma.com/role/DisclosureSegmentsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureFairValueMeasurementsRecurringDetails" roleURI="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails" />
  <link:roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureFairValueMeasurementsCurrentOperationsAndRemainingMaturityDetails" roleURI="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsCurrentOperationsAndRemainingMaturityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureBalanceSheetComponentsPrepaidsAndOtherCurrentAssetsDetails" roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPrepaidsAndOtherCurrentAssetsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails" roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails" />
  <link:roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureBalanceSheetComponentsAccrualsAndOtherLiabilitiesDetails" roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsAccrualsAndOtherLiabilitiesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureFacilityLeaseLeaseCostDetails" roleURI="http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails" />
  <link:roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails" roleURI="http://www.corvuspharma.com/role/DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails" />
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <link:calculationLink xlink:role="http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_639137551343688372" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_639137551343688372" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_639137551343688372" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_639137551343688372" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments_639137551343688372" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_EquityMethodInvestments_639137551343688372" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_639137551343688372" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_639137551343688372" order="4" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_639137551343693549" order="5" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_639137551343693549" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_639137551343693549" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_639137551343693549" xlink:to="us-gaap_AccountsReceivableNetCurrent_639137551343693549" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_639137551343693549" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_639137551343693549" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_639137551343693549" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639137551343693549" order="4" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_639137551343693549" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639137551343693549" xlink:to="us-gaap_PreferredStockValue_639137551343693549" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639137551343693549" xlink:to="us-gaap_CommonStockValue_639137551343693549" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639137551343693549" xlink:to="us-gaap_AdditionalPaidInCapital_639137551343693549" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639137551343693549" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_639137551343693549" order="4" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639137551343693549" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_639137551343693549" order="5" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_639137551343693549" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_639137551343693549" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_639137551343693549" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_639137551343693549" xlink:to="us-gaap_LiabilitiesCurrent_639137551343693549" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_639137551343693549" xlink:to="us-gaap_AccountsPayableCurrent_639137551343693549" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_639137551343693549" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_639137551343693549" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_639137551343693549" xlink:to="us-gaap_AccruedLiabilitiesCurrent_639137551343693549" order="3" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_639137551343693549" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_639137551343693549" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_639137551343693549" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_639137551343693549" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_639137551343693549" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_639137551343693549" xlink:to="us-gaap_InvestmentIncomeNet_639137551343693549" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_639137551343693549" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_639137551343693549" order="2" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_639137551343693549" xlink:to="us-gaap_OperatingIncomeLoss_639137551343693549" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_639137551343693549" xlink:to="us-gaap_OperatingExpenses_639137551343693549" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_639137551343693549" xlink:to="us-gaap_ResearchAndDevelopmentExpense_639137551343693549" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_639137551343693549" xlink:to="us-gaap_GeneralAndAdministrativeExpense_639137551343693549" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_639137551343693549" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_639137551343693549" order="3" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_639137551343693549" order="1" use="optional" weight="1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639137551343693549" xlink:to="us-gaap_ProfitLoss_639137551343693549" order="1" use="optional" weight="1" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639137551343693549" xlink:to="us-gaap_DepreciationDepletionAndAmortization_639137551343693549" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639137551343693549" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_639137551343693549" order="3" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639137551343693549" xlink:to="us-gaap_ShareBasedCompensation_639137551343693549" order="4" use="optional" weight="1" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639137551343693549" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_639137551343693549" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639137551343693549" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_639137551343693549" order="6" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639137551343693549" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_639137551343693549" order="7" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639137551343693549" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_639137551343693549" order="8" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639137551343693549" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_639137551343693549" order="9" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639137551343693549" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639137551343693549" order="10" use="optional" weight="-1" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639137551343693549" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_639137551343693549" order="11" use="optional" weight="1" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639137551343693549" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_639137551343693549" order="12" use="optional" weight="1" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639137551343693549" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_639137551343693549" order="13" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_639137551343693549" order="2" use="optional" weight="1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_639137551343693549" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_639137551343693549" order="1" use="optional" weight="-1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_639137551343693549" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_639137551343693549" order="2" use="optional" weight="1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_639137551343693549" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_639137551343693549" order="3" use="optional" weight="-1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_639137551343693549" order="3" use="optional" weight="1" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639137551343693549" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_639137551343693549" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_639137551343693549" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639137551343693549" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_639137551343693549" order="2" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.corvuspharma.com/role/DisclosureNetLossPerShareCalculationOfEarningsPerShareDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Net Loss per Share - Calculation of Earnings Per Share (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_639137551343743749" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xlink:label="us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount_639137551343743749" order="2" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639137551343743749" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_639137551343743749" order="2" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.corvuspharma.com/role/DisclosureSegmentsDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Segments (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense_639137551343743749" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingExpenses_639137551343743749" order="2" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralExpense" xlink:label="us-gaap_OtherGeneralExpense_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_639137551343743749" xlink:to="us-gaap_OtherGeneralExpense_639137551343743749" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_FacilitiesAndInsurance" xlink:label="crvs_FacilitiesAndInsurance_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_639137551343743749" xlink:to="crvs_FacilitiesAndInsurance_639137551343743749" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_639137551343743749" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_639137551343743749" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_639137551343743749" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_639137551343743749" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_SegmentDrugManufacturingCosts" xlink:label="crvs_SegmentDrugManufacturingCosts_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_639137551343743749" xlink:to="crvs_SegmentDrugManufacturingCosts_639137551343743749" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:label="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_639137551343743749" xlink:to="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_639137551343743749" order="6" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_639137551343743749" xlink:to="us-gaap_ShareBasedCompensation_639137551343743749" order="7" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Fair Value Measurements - Recurring (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_639137551343743749" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetsFairValueDisclosure" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_639137551343743749" order="2" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsCurrentOperationsAndRemainingMaturityDetails" xlink:type="extended" xlink:title="99940503 - Disclosure - Fair Value Measurements - Current Operations and The Remaining Maturity (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_639137551343743749" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:label="crvs_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="crvs_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_639137551343743749" order="2" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPrepaidsAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Balance Sheet Components - Prepaids and Other Current Assets (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InterestReceivable_639137551343743749" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_639137551343743749" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidRent_639137551343743749" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance_639137551343743749" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_639137551343743749" order="5" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="99940802 - Disclosure - Balance Sheet Components - Property and Equipment (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_639137551343743749" order="1" use="optional" weight="-1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_639137551343743749" order="2" use="optional" weight="1" priority="2" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsAccrualsAndOtherLiabilitiesDetails" xlink:type="extended" xlink:title="99940803 - Disclosure - Balance Sheet Components - Accruals and Other Liabilities (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_AccruedLiabilitiesClinicalTrialCurrent" xlink:label="crvs_AccruedLiabilitiesClinicalTrialCurrent_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="crvs_AccruedLiabilitiesClinicalTrialCurrent_639137551343743749" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_AccruedLiabilitiesManufacturingCurrent" xlink:label="crvs_AccruedLiabilitiesManufacturingCurrent_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="crvs_AccruedLiabilitiesManufacturingCurrent_639137551343743749" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_639137551343743749" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_639137551343743749" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_639137551343743749" order="5" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails" xlink:type="extended" xlink:title="99941402 - Disclosure - Facility Lease - Lease Cost (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="LeaseCost" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="us-gaap_OperatingLeaseCost_639137551343743749" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="us-gaap_VariableLeaseCost_639137551343743749" order="2" use="optional" weight="1" priority="2" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.corvuspharma.com/role/DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails" xlink:type="extended" xlink:title="99941403 - Disclosure - Facility Lease - Minimum Rental Commitments San Francisco Lease (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_639137551343743749" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_639137551343743749" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_639137551343743749" order="2" use="optional" weight="1" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>crvs-20260331_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.3.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/7/2026 12:52:15 PM-->
<!--Modified on: 5/7/2026 12:52:15 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureOrganizationDetails" roleURI="http://www.corvuspharma.com/role/DisclosureOrganizationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" roleURI="http://www.corvuspharma.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureFairValueMeasurementsRecurringDetails" roleURI="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureFairValueMeasurementsAvailableForSaleDetails" roleURI="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsAvailableForSaleDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureFairValueMeasurementsCurrentOperationsAndRemainingMaturityDetails" roleURI="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsCurrentOperationsAndRemainingMaturityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureEquityMethodInvestmentInvestmentInAngelPharmaceuticalsDetails" roleURI="http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentInvestmentInAngelPharmaceuticalsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureEquityMethodInvestmentSummaryOfBalanceSheetInformationDetails" roleURI="http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfBalanceSheetInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureEquityMethodInvestmentSummaryOfIncomeStatementInformationDetails" roleURI="http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfIncomeStatementInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureLicenseAndCollaborationAgreementsDetails" roleURI="http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails" roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureWarrantsNarrativeDetails" roleURI="http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureCommonStockStockIssuanceAgreementDetails" roleURI="http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureCommonStockCommonSharesReservedForIssuanceDetails" roleURI="http://www.corvuspharma.com/role/DisclosureCommonStockCommonSharesReservedForIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureStockOptionPlansStockOptionActivityDetails" roleURI="http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureStockOptionPlansStockOptionsActivityDetails" roleURI="http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionsActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureStockBasedCompensationExpenseAllocationDetails" roleURI="http://www.corvuspharma.com/role/DisclosureStockBasedCompensationExpenseAllocationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureFacilityLeaseLesseeInformationDetails" roleURI="http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureFacilityLeaseLeaseCostDetails" roleURI="http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails" roleURI="http://www.corvuspharma.com/role/DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.corvuspharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="crvs-20260331.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_1" xlink:title="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_1" xlink:title="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_1" xlink:to="us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_1 To us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1" xlink:title="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_1" xlink:title="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1 To us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_1" xlink:title="us-gaap_CreditFacilityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_1" xlink:title="us-gaap_CreditFacilityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CreditFacilityAxis_1" xlink:to="us-gaap_CreditFacilityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CreditFacilityAxis_1 To us-gaap_CreditFacilityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_1" xlink:title="us-gaap_OptionIndexedToIssuersEquityTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" xlink:title="us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis_1" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_OptionIndexedToIssuersEquityTypeAxis_1 To us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1" xlink:title="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_1" xlink:title="srt_EquityMethodInvesteeNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1" xlink:to="srt_EquityMethodInvesteeNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1 To srt_EquityMethodInvesteeNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityNameAxis_1 To us-gaap_IncomeTaxAuthorityNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:label="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_1" xlink:title="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="us-gaap_DeferredTaxAssetDomain_1" xlink:title="us-gaap_DeferredTaxAssetDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_1" xlink:to="us-gaap_DeferredTaxAssetDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_1 To us-gaap_DeferredTaxAssetDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_1" xlink:title="us-gaap_LeaseContractualTermAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_1" xlink:title="us-gaap_LeaseContractualTermDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LeaseContractualTermAxis_1" xlink:to="us-gaap_LeaseContractualTermDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LeaseContractualTermAxis_1 To us-gaap_LeaseContractualTermDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:title="us-gaap_ConcentrationRiskByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_1" xlink:title="us-gaap_ConcentrationRiskTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:to="us-gaap_ConcentrationRiskTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByTypeAxis_1 To us-gaap_ConcentrationRiskTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_1" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByBenchmarkAxis_1 To us-gaap_ConcentrationRiskBenchmarkDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis_1" xlink:title="srt_ConsolidationItemsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_1" xlink:title="srt_ConsolidationItemsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidationItemsAxis_1" xlink:to="srt_ConsolidationItemsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidationItemsAxis_1 To srt_ConsolidationItemsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis_1" xlink:title="us-gaap_DisposalGroupClassificationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain_1" xlink:title="us-gaap_DisposalGroupClassificationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DisposalGroupClassificationAxis_1" xlink:to="us-gaap_DisposalGroupClassificationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DisposalGroupClassificationAxis_1 To us-gaap_DisposalGroupClassificationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1 To us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationDocumentAxis" xlink:label="dei_DocumentInformationDocumentAxis_1" xlink:title="dei_DocumentInformationDocumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentDomain" xlink:label="dei_DocumentDomain_1" xlink:title="dei_DocumentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_DocumentInformationDocumentAxis_1" xlink:to="dei_DocumentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_DocumentInformationDocumentAxis_1 To dei_DocumentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended" xlink:title="995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_AtMarketOfferingMember" xlink:label="crvs_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="crvs_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_FollowOnPublicOfferingMember" xlink:label="crvs_FollowOnPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="crvs_FollowOnPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProfitLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_OfferingCostsAccruedAndChargedToAdditionalPaidInCapital" xlink:label="crvs_OfferingCostsAccruedAndChargedToAdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="crvs_OfferingCostsAccruedAndChargedToAdditionalPaidInCapital" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureOrganizationDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - Organization (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_OrganizationTable" xlink:label="crvs_OrganizationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="crvs_OrganizationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_FollowOnPublicOfferingMember" xlink:label="crvs_FollowOnPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="crvs_FollowOnPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="crvs_OrganizationTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_CommonStockWarrantsMember" xlink:label="crvs_CommonStockWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="crvs_CommonStockWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_CommonStockSharesAndCommonStockWarrantsMember" xlink:label="crvs_CommonStockSharesAndCommonStockWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="crvs_CommonStockSharesAndCommonStockWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_CommonWarrantsMember" xlink:label="crvs_CommonWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="crvs_CommonWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_PrefundedWarrantsMember" xlink:label="crvs_PrefundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="crvs_PrefundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_PrefundedWarrantsAndCommonStockWarrantsMember" xlink:label="crvs_PrefundedWarrantsAndCommonStockWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="crvs_PrefundedWarrantsAndCommonStockWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_OrganizationLineItems" xlink:label="crvs_OrganizationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="crvs_OrganizationLineItems" xlink:to="crvs_OrganizationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="crvs_OrganizationLineItems" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_CombinedOfferingPriceForSharesAndWarrants" xlink:label="crvs_CombinedOfferingPriceForSharesAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="crvs_CombinedOfferingPriceForSharesAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_ClassOfWarrantOrRightExercisePricePerPrefundedWarrant" xlink:label="crvs_ClassOfWarrantOrRightExercisePricePerPrefundedWarrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="crvs_ClassOfWarrantOrRightExercisePricePerPrefundedWarrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="99940302 - Disclosure - Net Loss per Share - Anti-Dilutive Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_CommonSharesIssuableUponConversionOfPreFundedWarrants" xlink:label="crvs_CommonSharesIssuableUponConversionOfPreFundedWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="crvs_CommonSharesIssuableUponConversionOfPreFundedWarrants" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Fair Value Measurements - Recurring (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsAvailableForSaleDetails" xlink:type="extended" xlink:title="99940502 - Disclosure - Fair Value Measurements - Available For Sale (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsCurrentOperationsAndRemainingMaturityDetails" xlink:type="extended" xlink:title="99940503 - Disclosure - Fair Value Measurements - Current Operations and The Remaining Maturity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:label="crvs_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="crvs_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentInvestmentInAngelPharmaceuticalsDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Equity Method Investment - Investment in Angel Pharmaceuticals (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember" xlink:label="crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_EmployeeStockOwnershipPlanEsopEquityReservePercentage" xlink:label="crvs_EmployeeStockOwnershipPlanEsopEquityReservePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="crvs_EmployeeStockOwnershipPlanEsopEquityReservePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfBalanceSheetInformationDetails" xlink:type="extended" xlink:title="99940602 - Disclosure - Equity Method Investment - Summary of Balance Sheet Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember" xlink:label="crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:to="crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_AssetsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_LiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfIncomeStatementInformationDetails" xlink:type="extended" xlink:title="99940603 - Disclosure - Equity Method Investment - Summary of Income Statement Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember" xlink:label="crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:to="crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - License and Collaboration Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_AggregatePotentialMilestonePaymentsMember" xlink:label="crvs_AggregatePotentialMilestonePaymentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="crvs_AggregatePotentialMilestonePaymentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_ScrippsResearchInstituteMember" xlink:label="crvs_ScrippsResearchInstituteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="crvs_ScrippsResearchInstituteMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_VernalisRAndDLimitedMember" xlink:label="crvs_VernalisRAndDLimitedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="crvs_VernalisRAndDLimitedMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_MonashLicenseMember" xlink:label="crvs_MonashLicenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="crvs_MonashLicenseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_LicenseAgreementMilestonePayment" xlink:label="crvs_LicenseAgreementMilestonePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="crvs_LicenseAgreementMilestonePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_ResearchAndDevelopmentArrangementContractTerminationNoticePeriod" xlink:label="crvs_ResearchAndDevelopmentArrangementContractTerminationNoticePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="crvs_ResearchAndDevelopmentArrangementContractTerminationNoticePeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="99940802 - Disclosure - Balance Sheet Components - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DepreciationAndAmortization" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Warrants - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_CommonStockSharesAndCommonStockWarrantsMember" xlink:label="crvs_CommonStockSharesAndCommonStockWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="crvs_CommonStockSharesAndCommonStockWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_CommonWarrantsMember" xlink:label="crvs_CommonWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="crvs_CommonWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_PrefundedWarrantsAndCommonStockWarrantsMember" xlink:label="crvs_PrefundedWarrantsAndCommonStockWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="crvs_PrefundedWarrantsAndCommonStockWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_PrefundedWarrantsMember" xlink:label="crvs_PrefundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="crvs_PrefundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_CombinedOfferingPriceForSharesAndWarrants" xlink:label="crvs_CombinedOfferingPriceForSharesAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="crvs_CombinedOfferingPriceForSharesAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_ClassOfWarrantOrRightExercisePricePerPrefundedWarrant" xlink:label="crvs_ClassOfWarrantOrRightExercisePricePerPrefundedWarrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="crvs_ClassOfWarrantOrRightExercisePricePerPrefundedWarrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_ChangeInFairValueOfWarrantLiabilities" xlink:label="crvs_ChangeInFairValueOfWarrantLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="crvs_ChangeInFairValueOfWarrantLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Common Stock - Stock Issuance Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_AtMarketOfferingMember" xlink:label="crvs_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="crvs_AtMarketOfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_JefferiesLlcMember" xlink:label="crvs_JefferiesLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="crvs_JefferiesLlcMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_UnderwritingCommitmentsPercentage" xlink:label="crvs_UnderwritingCommitmentsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="crvs_UnderwritingCommitmentsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureCommonStockCommonSharesReservedForIssuanceDetails" xlink:type="extended" xlink:title="99941002 - Disclosure - Common Stock - Common Shares Reserved for Issuance (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_PreFundedWarrantEquityMember" xlink:label="crvs_PreFundedWarrantEquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="crvs_PreFundedWarrantEquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_SharesAvailableForFutureOptionGrantsEquityMember" xlink:label="crvs_SharesAvailableForFutureOptionGrantsEquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="crvs_SharesAvailableForFutureOptionGrantsEquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_OutstandingOptionsEquityMember" xlink:label="crvs_OutstandingOptionsEquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="crvs_OutstandingOptionsEquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_SharesReservedForEmployeeStockPurchasePlanEquityMember" xlink:label="crvs_SharesReservedForEmployeeStockPurchasePlanEquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="crvs_SharesReservedForEmployeeStockPurchasePlanEquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionActivityDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - Stock Option Plans - Stock Option Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_EquityIncentiveAwardPlan2014Member" xlink:label="crvs_EquityIncentiveAwardPlan2014Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="crvs_EquityIncentiveAwardPlan2014Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_EquityIncentiveAwardPlan2016Member" xlink:label="crvs_EquityIncentiveAwardPlan2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="crvs_EquityIncentiveAwardPlan2016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionsActivityDetails" xlink:type="extended" xlink:title="99941102 - Disclosure - Stock Option Plans - Stock Options Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_EquityIncentiveAwardPlan2016Member" xlink:label="crvs_EquityIncentiveAwardPlan2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="crvs_EquityIncentiveAwardPlan2016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureStockBasedCompensationExpenseAllocationDetails" xlink:type="extended" xlink:title="99941201 - Disclosure - Stock-Based Compensation - Expense Allocation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails" xlink:type="extended" xlink:title="99941401 - Disclosure - Facility Lease - Lessee Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_OfficeAndLabSpaceLeaseMember" xlink:label="crvs_OfficeAndLabSpaceLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BuildingMember" xlink:to="crvs_OfficeAndLabSpaceLeaseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_ThirdYearOfSubleaseMember" xlink:label="crvs_ThirdYearOfSubleaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="crvs_ThirdYearOfSubleaseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_PrepaidRent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails" xlink:type="extended" xlink:title="99941402 - Disclosure - Facility Lease - Lease Cost (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_OfficeAndLabSpaceLeaseMember" xlink:label="crvs_OfficeAndLabSpaceLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BuildingMember" xlink:to="crvs_OfficeAndLabSpaceLeaseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseCostAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_OperatingLeasePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails" xlink:type="extended" xlink:title="99941403 - Disclosure - Facility Lease - Minimum Rental Commitments San Francisco Lease (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_OfficeAndLabSpaceLeaseMember" xlink:label="crvs_OfficeAndLabSpaceLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BuildingMember" xlink:to="crvs_OfficeAndLabSpaceLeaseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended" xlink:title="99941601 - Disclosure - Related Party Transactions - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_FollowOnPublicOfferingMember" xlink:label="crvs_FollowOnPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="crvs_FollowOnPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember" xlink:label="crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_ServicesSupportClinicalTrialsMember" xlink:label="crvs_ServicesSupportClinicalTrialsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="crvs_ServicesSupportClinicalTrialsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_IconPlcMember" xlink:label="crvs_IconPlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="crvs_IconPlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_PuissanceCapitalManagementMember" xlink:label="crvs_PuissanceCapitalManagementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="crvs_PuissanceCapitalManagementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>crvs-20260331_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.3.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/7/2026 12:52:15 PM-->
<!--Modified on: 5/7/2026 12:52:15 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document And Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Act File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration" xlink:label="us-gaap_AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration" xlink:to="us-gaap_AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, after Allowance for Credit Loss, Current, Related Party [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Method Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment in Angel Pharmaceuticals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 15)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock: $0.0001 par value; 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; 0 shares issued and outstanding at each of March 31, 2026 and December 31, 2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock: $0.0001 par value; 290,000,000 shares authorized at March 31, 2026 and December 31, 2025; 84,090,424 and 74,696,629 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">R&amp;D expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total segment expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income and other expense, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of warrant liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before equity method investment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Equity Method Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from equity method investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share of loss from investments accounted for using the equity method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from equity method investment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (loss) income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net income (loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (loss) income per share, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares used to compute net (loss) income per share, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares and pre-funded warrants outstanding used to compute basic net (loss) income per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares used to compute net loss per share, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares and pre-funded warrants outstanding used to compute diluted net (loss) income per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive (loss) income:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized loss on marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative foreign currency translation adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive (loss) income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AOCI Attributable to Parent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Registered Direct Offering</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_FollowOnPublicOfferingMember" xlink:label="crvs_FollowOnPublicOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_FollowOnPublicOfferingMember" xlink:to="crvs_FollowOnPublicOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_FollowOnPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secondary offering of stock to the public.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_FollowOnPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Follow-on Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_FollowOnPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Follow-on Public Offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over-Allotment Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over-Allotment Option</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_AtMarketOfferingMember" xlink:label="crvs_AtMarketOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_AtMarketOfferingMember" xlink:to="crvs_AtMarketOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of stock through an at-the-market equity offering program under a sales agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At-the-market offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024 Sales Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock issued upon exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding Options, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock issued upon exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds from sale of stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares issued in transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized loss on marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related and Nonrelated Parties [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related and Nonrelated Parties [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion (Amortization) of Discounts and Premiums, Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion related to marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Noncurrent Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Current Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Debt Securities, Available-for-Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturities of marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash (used in) provided by investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock in connection with follow-on public offering, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of common stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase (decrease) in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at beginning of the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosures of cash flow information</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_OfferingCostsAccruedAndChargedToAdditionalPaidInCapital" xlink:label="crvs_OfferingCostsAccruedAndChargedToAdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_OfferingCostsAccruedAndChargedToAdditionalPaidInCapital" xlink:to="crvs_OfferingCostsAccruedAndChargedToAdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_OfferingCostsAccruedAndChargedToAdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents equity issuance costs that have been recognized as a reduction to additional paid-in capital but have not yet been paid in cash as of the reporting period. These amounts are accrued as liabilities and disclosed as non-cash financing activities in the statement of cash flows.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_OfferingCostsAccruedAndChargedToAdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering Costs Accrued and Charged to Additional Paid-in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_OfferingCostsAccruedAndChargedToAdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering costs recorded to additional paid-in-capital but not paid</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Method Investment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Method Investments and Joint Ventures Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Method Investment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and Collaboration Agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and Collaboration Agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Components</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Balance Sheet Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Components</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_WarrantsAndRightsNoteDisclosureTextBlock" xlink:label="crvs_WarrantsAndRightsNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_WarrantsAndRightsNoteDisclosureTextBlock" xlink:to="crvs_WarrantsAndRightsNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_WarrantsAndRightsNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for warrants and rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_WarrantsAndRightsNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants And Rights Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_WarrantsAndRightsNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_CommonStockNoteDisclosureTextBlock" xlink:label="crvs_CommonStockNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_CommonStockNoteDisclosureTextBlock" xlink:to="crvs_CommonStockNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_CommonStockNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_CommonStockNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_CommonStockNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_CompensationRelatedCostsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Plans</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_EquityIncentivePlansDisclosureTextBlock" xlink:label="crvs_EquityIncentivePlansDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_EquityIncentivePlansDisclosureTextBlock" xlink:to="crvs_EquityIncentivePlansDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_EquityIncentivePlansDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for equity incentive plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_EquityIncentivePlansDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plans Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_EquityIncentivePlansDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Facility Lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Facility Lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:label="crvs_UnauditedInterimFinancialInformationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:to="crvs_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for the presentation of interim (unaudited) financial statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unaudited Interim Financial Information [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unaudited Interim Financial Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsPolicy" xlink:to="us-gaap_EquityMethodInvestmentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Method Investments [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments in Equity Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations of Credit Risk and Other Risks and Uncertainties</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_SignificantAccountingPoliciesPolicyTextBlock" xlink:label="crvs_SignificantAccountingPoliciesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_SignificantAccountingPoliciesPolicyTextBlock" xlink:to="crvs_SignificantAccountingPoliciesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_SignificantAccountingPoliciesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of changes to significant accounting policies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_SignificantAccountingPoliciesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_SignificantAccountingPoliciesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of net (loss) income per share, basic and diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of antidilutive securities excluded from calculation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of segment net loss (income) by significant expense category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value of assets measured at fair value on a recurring basis, by level of fair value hierarchy</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value of available for sale marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments Classified by Contractual Maturity Date [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of remaining maturity by type of security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Method Investments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of financial information of Angel Pharmaceuticals Co.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Balance Sheet [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of balance sheet components</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOptionsIndexedToIssuersEquityTextBlock" xlink:label="us-gaap_ScheduleOfOptionsIndexedToIssuersEquityTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOptionsIndexedToIssuersEquityTextBlock" xlink:to="us-gaap_ScheduleOfOptionsIndexedToIssuersEquityTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOptionsIndexedToIssuersEquityTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Options Indexed to Issuer's Equity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOptionsIndexedToIssuersEquityTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of common stock shares reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of expenses relating to employee and non-employee stock-based awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Facility Lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Minimum rental commitments</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_OrganizationTable" xlink:label="crvs_OrganizationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_OrganizationTable" xlink:to="crvs_OrganizationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_OrganizationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Presentation of information about the organization and basis of presentation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_OrganizationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_CommonStockWarrantsMember" xlink:label="crvs_CommonStockWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_CommonStockWarrantsMember" xlink:to="crvs_CommonStockWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_CommonStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to common stock warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_CommonStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_CommonStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock warrants</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_CommonStockSharesAndCommonStockWarrantsMember" xlink:label="crvs_CommonStockSharesAndCommonStockWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_CommonStockSharesAndCommonStockWarrantsMember" xlink:to="crvs_CommonStockSharesAndCommonStockWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_CommonStockSharesAndCommonStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The transaction group, which details the sale of common stock equity and the accompanying warrants to purchase common stock in connection with the company's Registered Direct Offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_CommonStockSharesAndCommonStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Shares and Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_CommonStockSharesAndCommonStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock and Common Warrants</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_CommonWarrantsMember" xlink:label="crvs_CommonWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_CommonWarrantsMember" xlink:to="crvs_CommonWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_CommonWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to common warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_CommonWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Warrants [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_CommonWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common warrants</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_PrefundedWarrantsMember" xlink:label="crvs_PrefundedWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_PrefundedWarrantsMember" xlink:to="crvs_PrefundedWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_PrefundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to pre-funded warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_PrefundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prefunded Warrants [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_PrefundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-funded warrants</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_PrefundedWarrantsAndCommonStockWarrantsMember" xlink:label="crvs_PrefundedWarrantsAndCommonStockWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_PrefundedWarrantsAndCommonStockWarrantsMember" xlink:to="crvs_PrefundedWarrantsAndCommonStockWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_PrefundedWarrantsAndCommonStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The transaction group, which details the sale of pre-funded warrants, and common warrants, to purchase common stock in connection with the company's Registered Direct Offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_PrefundedWarrantsAndCommonStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prefunded Warrants and Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_PrefundedWarrantsAndCommonStockWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-funded and Common Warrants</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_OrganizationLineItems" xlink:label="crvs_OrganizationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_OrganizationLineItems" xlink:to="crvs_OrganizationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_OrganizationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_OrganizationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public Offerings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Common Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants issued to purchase common shares</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_CombinedOfferingPriceForSharesAndWarrants" xlink:label="crvs_CombinedOfferingPriceForSharesAndWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_CombinedOfferingPriceForSharesAndWarrants" xlink:to="crvs_CombinedOfferingPriceForSharesAndWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_CombinedOfferingPriceForSharesAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Combined price per unit of share and warrants issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_CombinedOfferingPriceForSharesAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Combined Offering Price For Shares And Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_CombinedOfferingPriceForSharesAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Combined offering price per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Combined offering price per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of warrants</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_ClassOfWarrantOrRightExercisePricePerPrefundedWarrant" xlink:label="crvs_ClassOfWarrantOrRightExercisePricePerPrefundedWarrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ClassOfWarrantOrRightExercisePricePerPrefundedWarrant" xlink:to="crvs_ClassOfWarrantOrRightExercisePricePerPrefundedWarrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ClassOfWarrantOrRightExercisePricePerPrefundedWarrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price expressed as price per unit of pre-funded warrants outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ClassOfWarrantOrRightExercisePricePerPrefundedWarrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price Per Prefunded Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ClassOfWarrantOrRightExercisePricePerPrefundedWarrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of pre-funded warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the exercise of common stock warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, and Short-Term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price of stock issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRiskUninsuredDeposits" xlink:label="us-gaap_ConcentrationRiskCreditRiskUninsuredDeposits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRiskUninsuredDeposits" xlink:to="us-gaap_ConcentrationRiskCreditRiskUninsuredDeposits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRiskUninsuredDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Uninsured Deposits</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_NumberOfFinancialInstitutionsInWhichCashAndCashEquivalentsAreDeposited" xlink:label="crvs_NumberOfFinancialInstitutionsInWhichCashAndCashEquivalentsAreDeposited" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_NumberOfFinancialInstitutionsInWhichCashAndCashEquivalentsAreDeposited" xlink:to="crvs_NumberOfFinancialInstitutionsInWhichCashAndCashEquivalentsAreDeposited_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_NumberOfFinancialInstitutionsInWhichCashAndCashEquivalentsAreDeposited_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of financial institutions in which cash and cash equivalents are deposited.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_NumberOfFinancialInstitutionsInWhichCashAndCashEquivalentsAreDeposited_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Financial Institutions In Which Cash and Cash Equivalents Are Deposited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_NumberOfFinancialInstitutionsInWhichCashAndCashEquivalentsAreDeposited_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of financial institutions in which cash and cash equivalents are deposited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share, Basic and Diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to common stockholders, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xlink:label="us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xlink:to="us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant, Down Round Feature, Decrease in Net Income to Common Shareholder, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain from change in fair value of warrant liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to common stockholders, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract" xlink:label="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract" xlink:to="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Undistributed Earnings (Loss) Available to Common Shareholders, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares issuable upon the exercise of the common warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Security, Excluded EPS Calculation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Excluded from the calculation of diluted net loss per share, due to anti-dilutive effect</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total shares of common stock equivalents</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_CommonSharesIssuableUponConversionOfPreFundedWarrants" xlink:label="crvs_CommonSharesIssuableUponConversionOfPreFundedWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_CommonSharesIssuableUponConversionOfPreFundedWarrants" xlink:to="crvs_CommonSharesIssuableUponConversionOfPreFundedWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_CommonSharesIssuableUponConversionOfPreFundedWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares issuable upon conversion of pre-funded warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_CommonSharesIssuableUponConversionOfPreFundedWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares issuable upon conversion of pre-funded warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_CommonSharesIssuableUponConversionOfPreFundedWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares issuable upon conversion of pre-funded warrants (included in calculation of basic and diluted EPS)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:label="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:to="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation Expense, Excluding Cost of Good and Service Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation and benefits, excluding stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_SegmentDrugManufacturingCosts" xlink:label="crvs_SegmentDrugManufacturingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_SegmentDrugManufacturingCosts" xlink:to="crvs_SegmentDrugManufacturingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_SegmentDrugManufacturingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The aggregate costs incurred for the operating segment in the production of goods for sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_SegmentDrugManufacturingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment drug manufacturing costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_SegmentDrugManufacturingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Drug manufacturing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical trial</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outside general and administrative</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_FacilitiesAndInsurance" xlink:label="crvs_FacilitiesAndInsurance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_FacilitiesAndInsurance" xlink:to="crvs_FacilitiesAndInsurance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_FacilitiesAndInsurance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The expense in the period incurred with respect to protection provided by facilities and insurance entities against risks other than risks associated with production (which are allocated to cost of sales).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_FacilitiesAndInsurance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Facilities And Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_FacilitiesAndInsurance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Facilities and insurance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralExpense" xlink:label="us-gaap_OtherGeneralExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralExpense" xlink:to="us-gaap_OtherGeneralExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other General Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherGeneralExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other segment items</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-operating income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1 Inputs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 2 Inputs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">US Treasury Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">US Treasury Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">US Government Agencies Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">US Government Agencies Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available for sale marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current operations and the remaining maturity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of available for sale marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Unrealized Gains</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Unrealized Losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less than 1 Year</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:label="crvs_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:to="crvs_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less than 1-2 Year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Method Investment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment, Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember" xlink:label="crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember" xlink:to="crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Angel Pharmaceuticals, Ltd., an equity method investee of Corvus Pharmaceuticals.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Angel Pharmaceuticals LTD Equity Method Investee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Angel Pharmaceuticals, Ltd</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">All Entities [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Equity Method Investments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Method Investment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Method Investment, Ownership Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity ownership interest</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_EmployeeStockOwnershipPlanEsopEquityReservePercentage" xlink:label="crvs_EmployeeStockOwnershipPlanEsopEquityReservePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_EmployeeStockOwnershipPlanEsopEquityReservePercentage" xlink:to="crvs_EmployeeStockOwnershipPlanEsopEquityReservePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_EmployeeStockOwnershipPlanEsopEquityReservePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The Percentage of employee stock ownership plan (ESOP), equity reserve.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_EmployeeStockOwnershipPlanEsopEquityReservePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Ownership Plan (ESOP), Equity Reserve, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_EmployeeStockOwnershipPlanEsopEquityReservePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity reserved under employee stock ownership plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Method Investment, Nonconsolidated Investee [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Method Investment, Nonconsolidated Investee [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity method investee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development, Contract to Perform for Others [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Terms [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_AggregatePotentialMilestonePaymentsMember" xlink:label="crvs_AggregatePotentialMilestonePaymentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_AggregatePotentialMilestonePaymentsMember" xlink:to="crvs_AggregatePotentialMilestonePaymentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_AggregatePotentialMilestonePaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The member represent the Aggregate Potential Milestone Payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_AggregatePotentialMilestonePaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Potential Milestone Payments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_AggregatePotentialMilestonePaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate potential milestone payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_ScrippsResearchInstituteMember" xlink:label="crvs_ScrippsResearchInstituteMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ScrippsResearchInstituteMember" xlink:to="crvs_ScrippsResearchInstituteMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ScrippsResearchInstituteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to the Scripps Research Institute.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ScrippsResearchInstituteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scripps Research Institute</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_VernalisRAndDLimitedMember" xlink:label="crvs_VernalisRAndDLimitedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_VernalisRAndDLimitedMember" xlink:to="crvs_VernalisRAndDLimitedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_VernalisRAndDLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Vernalis (R&amp;D) Limited.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_VernalisRAndDLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vernalis (R&amp;D) Limited</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_MonashLicenseMember" xlink:label="crvs_MonashLicenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_MonashLicenseMember" xlink:to="crvs_MonashLicenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_MonashLicenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to Monash License.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_MonashLicenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Monash University</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Arrangement, Contract to Perform for Others [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and Collaboration Agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual licensing fee</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_LicenseAgreementMilestonePayment" xlink:label="crvs_LicenseAgreementMilestonePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_LicenseAgreementMilestonePayment" xlink:to="crvs_LicenseAgreementMilestonePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_LicenseAgreementMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount purchased during the period under the license agreement milestone payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_LicenseAgreementMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_LicenseAgreementMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_ResearchAndDevelopmentArrangementContractTerminationNoticePeriod" xlink:label="crvs_ResearchAndDevelopmentArrangementContractTerminationNoticePeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ResearchAndDevelopmentArrangementContractTerminationNoticePeriod" xlink:to="crvs_ResearchAndDevelopmentArrangementContractTerminationNoticePeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ResearchAndDevelopmentArrangementContractTerminationNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of the research and development arrangement contract termination notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ResearchAndDevelopmentArrangementContractTerminationNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Arrangement Contract Termination Notice Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ResearchAndDevelopmentArrangementContractTerminationNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Early termination notice period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid research and development manufacturing expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRent" xlink:to="us-gaap_PrepaidRent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid facility expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid insurance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer equipment and purchased software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction in Progress [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction in progress</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization, Nonproduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation expense</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_AccruedLiabilitiesClinicalTrialCurrent" xlink:label="crvs_AccruedLiabilitiesClinicalTrialCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_AccruedLiabilitiesClinicalTrialCurrent" xlink:to="crvs_AccruedLiabilitiesClinicalTrialCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_AccruedLiabilitiesClinicalTrialCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of accrued liabilities clinical trial current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_AccruedLiabilitiesClinicalTrialCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities Clinical Trial Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_AccruedLiabilitiesClinicalTrialCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued clinical trial expense</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_AccruedLiabilitiesManufacturingCurrent" xlink:label="crvs_AccruedLiabilitiesManufacturingCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_AccruedLiabilitiesManufacturingCurrent" xlink:to="crvs_AccruedLiabilitiesManufacturingCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_AccruedLiabilitiesManufacturingCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of accrued liabilities manufacturing current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_AccruedLiabilitiesManufacturingCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities Manufacturing Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_AccruedLiabilitiesManufacturingCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued manufacturing expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel related</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued legal and accounting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital adjustment from warrant issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants outstanding</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_ChangeInFairValueOfWarrantLiabilities" xlink:label="crvs_ChangeInFairValueOfWarrantLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ChangeInFairValueOfWarrantLiabilities" xlink:to="crvs_ChangeInFairValueOfWarrantLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ChangeInFairValueOfWarrantLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense (income) related to adjustment to fair value of warrant liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ChangeInFairValueOfWarrantLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of warrant liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ChangeInFairValueOfWarrantLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of warrant liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock, Class of Stock [Table]</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_JefferiesLlcMember" xlink:label="crvs_JefferiesLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_JefferiesLlcMember" xlink:to="crvs_JefferiesLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_JefferiesLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Jefferies LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_JefferiesLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Jefferies LLC</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_JefferiesLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Jefferies LLC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="us-gaap_ScenarioPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario, Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockVotingRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Voting Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockVotingRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Voting rights of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends on common stock</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_UnderwritingCommitmentsPercentage" xlink:label="crvs_UnderwritingCommitmentsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_UnderwritingCommitmentsPercentage" xlink:to="crvs_UnderwritingCommitmentsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_UnderwritingCommitmentsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of compensation due to broker for  underwriting commitments. Percent is calculated based on proceeds from securities sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_UnderwritingCommitmentsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriting Commitments, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_UnderwritingCommitmentsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales agent fee percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_PreFundedWarrantEquityMember" xlink:label="crvs_PreFundedWarrantEquityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_PreFundedWarrantEquityMember" xlink:to="crvs_PreFundedWarrantEquityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_PreFundedWarrantEquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative instrument whose primary underlying risk is tied to share prices.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_PreFundedWarrantEquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-funded Warrant Equity [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_PreFundedWarrantEquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-funded warrants</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_SharesAvailableForFutureOptionGrantsEquityMember" xlink:label="crvs_SharesAvailableForFutureOptionGrantsEquityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_SharesAvailableForFutureOptionGrantsEquityMember" xlink:to="crvs_SharesAvailableForFutureOptionGrantsEquityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_SharesAvailableForFutureOptionGrantsEquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_SharesAvailableForFutureOptionGrantsEquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Available for Future Option Grants Equity [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_SharesAvailableForFutureOptionGrantsEquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares available for future option grants</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_OutstandingOptionsEquityMember" xlink:label="crvs_OutstandingOptionsEquityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_OutstandingOptionsEquityMember" xlink:to="crvs_OutstandingOptionsEquityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_OutstandingOptionsEquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_OutstandingOptionsEquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding Options Equity [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_OutstandingOptionsEquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding options</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_SharesReservedForEmployeeStockPurchasePlanEquityMember" xlink:label="crvs_SharesReservedForEmployeeStockPurchasePlanEquityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_SharesReservedForEmployeeStockPurchasePlanEquityMember" xlink:to="crvs_SharesReservedForEmployeeStockPurchasePlanEquityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_SharesReservedForEmployeeStockPurchasePlanEquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_SharesReservedForEmployeeStockPurchasePlanEquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Reserved for Employee Stock Purchase Plan Equity [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_SharesReservedForEmployeeStockPurchasePlanEquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares reserved for employee stock purchase plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_EquityIncentiveAwardPlan2014Member" xlink:label="crvs_EquityIncentiveAwardPlan2014Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_EquityIncentiveAwardPlan2014Member" xlink:to="crvs_EquityIncentiveAwardPlan2014Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_EquityIncentiveAwardPlan2014Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entity's 2014 plan under which it may grant stock-based awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_EquityIncentiveAwardPlan2014Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2014 Plan</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_EquityIncentiveAwardPlan2016Member" xlink:label="crvs_EquityIncentiveAwardPlan2016Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_EquityIncentiveAwardPlan2016Member" xlink:to="crvs_EquityIncentiveAwardPlan2016Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_EquityIncentiveAwardPlan2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entity's 2016 Equity Incentive Award Plan under which it may grant stock-based awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_EquityIncentiveAwardPlan2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2016 Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum exercise term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of common stock grants, percentage of stock fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Available for Grant, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Available for Grant, Opening Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares available for future option grants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Available for Grant, Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited or unexercised shares under expired stock plan subject to re-issuance under current stock plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Other Share Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Available for Grant, Increase from Options Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding Options, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding Options, Opening Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding Options, Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding Options, Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding Options, Weighted Average Exercise Price, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding Options, Weighted Average Exercise Price, Opening Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding Options, Weighted Average Exercise Price, Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding Options, Weighted Average Exercise Price, Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding Options, Weighted Average Exercise Price, Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Income Location, Balance [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Income Location, Balance [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Building [Member]</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_OfficeAndLabSpaceLeaseMember" xlink:label="crvs_OfficeAndLabSpaceLeaseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_OfficeAndLabSpaceLeaseMember" xlink:to="crvs_OfficeAndLabSpaceLeaseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_OfficeAndLabSpaceLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information related to office and lab space lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_OfficeAndLabSpaceLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office And Lab Space Lease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_OfficeAndLabSpaceLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office and lab space lease</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_ThirdYearOfSubleaseMember" xlink:label="crvs_ThirdYearOfSubleaseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ThirdYearOfSubleaseMember" xlink:to="crvs_ThirdYearOfSubleaseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ThirdYearOfSubleaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information related to third year of sublease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ThirdYearOfSubleaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third Year of Sublease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ThirdYearOfSubleaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third year of sublease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of Real Estate Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of leased facility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option to Extend</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease extension period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Rent Expense, Minimum Rentals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sublease initial base monthly rent expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Existence of Option to Terminate [true false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option to terminate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs of operating lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs of non-lease components (previously common area maintenance)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Description [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating cash flows used for operating lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Rental Commitments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: imputed interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Domain]</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_ServicesSupportClinicalTrialsMember" xlink:label="crvs_ServicesSupportClinicalTrialsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_ServicesSupportClinicalTrialsMember" xlink:to="crvs_ServicesSupportClinicalTrialsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_ServicesSupportClinicalTrialsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to services to support clinical trials.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_ServicesSupportClinicalTrialsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Services Support Clinical Trials [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_ServicesSupportClinicalTrialsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Support clinical trials</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_IconPlcMember" xlink:label="crvs_IconPlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_IconPlcMember" xlink:to="crvs_IconPlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_IconPlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to ICON plc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_IconPlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Icon Plc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_IconPlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICON plc</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_PuissanceCapitalManagementMember" xlink:label="crvs_PuissanceCapitalManagementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_PuissanceCapitalManagementMember" xlink:to="crvs_PuissanceCapitalManagementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_PuissanceCapitalManagementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Puissance Capital Management.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_PuissanceCapitalManagementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Puissance Capital Management [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_PuissanceCapitalManagementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Puissance Capital Management</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_NonRule10b51ArrModifiedFlag" xlink:label="crvs_NonRule10b51ArrModifiedFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_NonRule10b51ArrModifiedFlag" xlink:to="crvs_NonRule10b51ArrModifiedFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_NonRule10b51ArrModifiedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_NonRule10b51ArrModifiedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Rule 10b5-1 Arr Modified [Flag]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_NonRule10b51ArrModifiedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Rule 10b5-1 Arrangement Modified</label>
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_Rule10b51ArrModifiedFlag" xlink:label="crvs_Rule10b51ArrModifiedFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvs_Rule10b51ArrModifiedFlag" xlink:to="crvs_Rule10b51ArrModifiedFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="crvs_Rule10b51ArrModifiedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="crvs_Rule10b51ArrModifiedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rule 10b5-1 Arr Modified Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="crvs_Rule10b51ArrModifiedFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rule 10b5-1 Arrangement Modified</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>crvs-20260331_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.3.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/7/2026 12:52:15 PM-->
<!--Modified on: 5/7/2026 12:52:15 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#StatementCondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureOrganization" roleURI="http://www.corvuspharma.com/role/DisclosureOrganization" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureNetLossPerShare" roleURI="http://www.corvuspharma.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureSegments" roleURI="http://www.corvuspharma.com/role/DisclosureSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureFairValueMeasurements" roleURI="http://www.corvuspharma.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureEquityMethodInvestment" roleURI="http://www.corvuspharma.com/role/DisclosureEquityMethodInvestment" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureLicenseAndCollaborationAgreements" roleURI="http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureBalanceSheetComponents" roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureWarrants" roleURI="http://www.corvuspharma.com/role/DisclosureWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureCommonStock" roleURI="http://www.corvuspharma.com/role/DisclosureCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureStockOptionPlans" roleURI="http://www.corvuspharma.com/role/DisclosureStockOptionPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureStockBasedCompensation" roleURI="http://www.corvuspharma.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureIncomeTaxes" roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureFacilityLease" roleURI="http://www.corvuspharma.com/role/DisclosureFacilityLease" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureRelatedPartyTransactions" roleURI="http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.corvuspharma.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureSegmentsTables" roleURI="http://www.corvuspharma.com/role/DisclosureSegmentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureEquityMethodInvestmentTables" roleURI="http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureBalanceSheetComponentsTables" roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureCommonStockTables" roleURI="http://www.corvuspharma.com/role/DisclosureCommonStockTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureStockOptionPlansTables" roleURI="http://www.corvuspharma.com/role/DisclosureStockOptionPlansTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.corvuspharma.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureFacilityLeaseTables" roleURI="http://www.corvuspharma.com/role/DisclosureFacilityLeaseTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureOrganizationDetails" roleURI="http://www.corvuspharma.com/role/DisclosureOrganizationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureNetLossPerShareCalculationOfEarningsPerShareDetails" roleURI="http://www.corvuspharma.com/role/DisclosureNetLossPerShareCalculationOfEarningsPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" roleURI="http://www.corvuspharma.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureSegmentsDetails" roleURI="http://www.corvuspharma.com/role/DisclosureSegmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureFairValueMeasurementsRecurringDetails" roleURI="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureFairValueMeasurementsAvailableForSaleDetails" roleURI="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsAvailableForSaleDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureFairValueMeasurementsCurrentOperationsAndRemainingMaturityDetails" roleURI="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsCurrentOperationsAndRemainingMaturityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureEquityMethodInvestmentInvestmentInAngelPharmaceuticalsDetails" roleURI="http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentInvestmentInAngelPharmaceuticalsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureEquityMethodInvestmentSummaryOfBalanceSheetInformationDetails" roleURI="http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfBalanceSheetInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureEquityMethodInvestmentSummaryOfIncomeStatementInformationDetails" roleURI="http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfIncomeStatementInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureLicenseAndCollaborationAgreementsDetails" roleURI="http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureBalanceSheetComponentsPrepaidsAndOtherCurrentAssetsDetails" roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPrepaidsAndOtherCurrentAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails" roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureBalanceSheetComponentsAccrualsAndOtherLiabilitiesDetails" roleURI="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsAccrualsAndOtherLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureWarrantsNarrativeDetails" roleURI="http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureCommonStockStockIssuanceAgreementDetails" roleURI="http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureCommonStockCommonSharesReservedForIssuanceDetails" roleURI="http://www.corvuspharma.com/role/DisclosureCommonStockCommonSharesReservedForIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureStockOptionPlansStockOptionActivityDetails" roleURI="http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureStockOptionPlansStockOptionsActivityDetails" roleURI="http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionsActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureStockBasedCompensationExpenseAllocationDetails" roleURI="http://www.corvuspharma.com/role/DisclosureStockBasedCompensationExpenseAllocationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureIncomeTaxesComponentsOfEarningBeforeIncomeTaxesAndIncomeTaxesBenefitsDetails" roleURI="http://www.corvuspharma.com/role/DisclosureIncomeTaxesComponentsOfEarningBeforeIncomeTaxesAndIncomeTaxesBenefitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureFacilityLeaseLesseeInformationDetails" roleURI="http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureFacilityLeaseLeaseCostDetails" roleURI="http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails" roleURI="http://www.corvuspharma.com/role/DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="crvs-20260331.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="995200090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_639137551344221992" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_639137551344221992" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_639137551344221992" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_639137551344221992" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentTransitionReport_639137551344221992" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_639137551344221992" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_639137551344221992" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_639137551344221992" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_639137551344221992" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_639137551344221992" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_639137551344221992" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_639137551344221992" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_639137551344221992" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_639137551344221992" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_639137551344221992" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_639137551344221992" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_639137551344221992" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_639137551344221992" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_639137551344221992" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_639137551344221992" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_639137551344221992" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_639137551344221992" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_639137551344221992" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityShellCompany_639137551344221992" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_639137551344221992" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_639137551344221992" order="26" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_639137551344221992" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_639137551344221992" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_639137551344221992" order="29" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_639137551344221992" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639137551344221992" xlink:to="us-gaap_AssetsCurrentAbstract_639137551344221992" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639137551344221992" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_639137551344221992" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639137551344221992" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_639137551344221992" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639137551344221992" xlink:to="us-gaap_AccountsReceivableNetCurrent_639137551344221992" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration" xlink:label="us-gaap_AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639137551344221992" xlink:to="us-gaap_AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration_639137551344221992" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639137551344221992" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639137551344221992" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639137551344221992" xlink:to="us-gaap_AssetsCurrent_639137551344221992" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639137551344221992" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_639137551344221992" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639137551344221992" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_639137551344221992" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639137551344221992" xlink:to="us-gaap_EquityMethodInvestments_639137551344221992" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639137551344221992" xlink:to="us-gaap_OtherAssetsNoncurrent_639137551344221992" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639137551344221992" xlink:to="us-gaap_Assets_639137551344221992" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639137551344221992" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639137551344221992" xlink:to="us-gaap_LiabilitiesCurrentAbstract_639137551344221992" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639137551344221992" xlink:to="us-gaap_AccountsPayableCurrent_639137551344221992" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639137551344221992" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_639137551344221992" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639137551344221992" xlink:to="us-gaap_AccruedLiabilitiesCurrent_639137551344221992" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639137551344221992" xlink:to="us-gaap_LiabilitiesCurrent_639137551344221992" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639137551344221992" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_639137551344221992" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639137551344221992" xlink:to="us-gaap_Liabilities_639137551344221992" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639137551344221992" xlink:to="us-gaap_CommitmentsAndContingencies_639137551344221992" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639137551344221992" xlink:to="us-gaap_StockholdersEquityAbstract_639137551344221992" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639137551344221992" xlink:to="us-gaap_PreferredStockValue_639137551344221992" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639137551344221992" xlink:to="us-gaap_CommonStockValue_639137551344221992" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639137551344221992" xlink:to="us-gaap_AdditionalPaidInCapital_639137551344221992" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639137551344221992" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_639137551344221992" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639137551344221992" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_639137551344221992" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639137551344221992" xlink:to="us-gaap_StockholdersEquity_639137551344221992" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639137551344221992" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_639137551344221992" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_639137551344221992" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_639137551344221992" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_639137551344221992" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_639137551344221992" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_639137551344221992" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_639137551344221992" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_639137551344221992" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_639137551344221992" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_639137551344221992" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_639137551344221992" xlink:to="us-gaap_ResearchAndDevelopmentExpense_639137551344221992" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_639137551344221992" xlink:to="us-gaap_GeneralAndAdministrativeExpense_639137551344221992" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_639137551344221992" xlink:to="us-gaap_OperatingExpenses_639137551344221992" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_639137551344221992" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeNet_639137551344221992" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_639137551344221992" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_639137551344221992" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_639137551344221992" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_639137551344221992" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_639137551344221992" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_639137551344221992" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639137551344221992" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_639137551344221992" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_639137551344221992" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_639137551344221992" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_639137551344221992" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_639137551344221992" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_639137551344221992" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_639137551344221992" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended" xlink:title="995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_639137551344221992" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639137551344221992" xlink:to="us-gaap_StatementEquityComponentsAxis_639137551344221992" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639137551344221992" xlink:to="us-gaap_CommonStockMember_639137551344221992" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639137551344221992" xlink:to="us-gaap_AdditionalPaidInCapitalMember_639137551344221992" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639137551344221992" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_639137551344221992" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639137551344221992" xlink:to="us-gaap_RetainedEarningsMember_639137551344221992" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639137551344221992" xlink:to="us-gaap_EquityComponentDomain_639137551344221992" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639137551344221992" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639137551344221992" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639137551344221992" xlink:to="us-gaap_PrivatePlacementMember_639137551344221992" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_FollowOnPublicOfferingMember" xlink:label="crvs_FollowOnPublicOfferingMember_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639137551344221992" xlink:to="crvs_FollowOnPublicOfferingMember_639137551344221992" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639137551344221992" xlink:to="us-gaap_OverAllotmentOptionMember_639137551344221992" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_AtMarketOfferingMember" xlink:label="crvs_AtMarketOfferingMember_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639137551344221992" xlink:to="crvs_AtMarketOfferingMember_639137551344221992" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639137551344221992" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639137551344221992" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639137551344221992" xlink:to="us-gaap_StatementLineItems_639137551344221992" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639137551344221992" xlink:to="us-gaap_StockholdersEquity_639137551344221992" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639137551344221992" xlink:to="us-gaap_CommonStockSharesIssued_639137551344221992" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639137551344221992" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_639137551344221992" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_639137551344221992" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_639137551344221992" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639137551344221992" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_639137551344221992" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_639137551344221992" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639137551344221992" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639137551344221992" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_639137551344221992" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639137551344221992" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_639137551344221992" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639137551344221992" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_639137551344221992" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639137551344221992" xlink:to="us-gaap_NetIncomeLoss_639137551344221992" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_6391375513442219921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639137551344221992" xlink:to="us-gaap_StockholdersEquity_6391375513442219921" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_6391375513442219921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639137551344221992" xlink:to="us-gaap_CommonStockSharesIssued_6391375513442219921" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable_639137551344221992" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639137551344221992" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639137551344221992" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639137551344221992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639137551344221992" xlink:to="us-gaap_RelatedPartyDomain_639137551344221992" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639137551344221992" xlink:to="us-gaap_RelatedPartyMember_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639137551344221992" xlink:to="us-gaap_StatementLineItems_639137551344378787" order="2" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639137551344378787" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_639137551344378787" xlink:to="us-gaap_ProfitLoss_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_639137551344378787" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639137551344378787" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639137551344378787" xlink:to="us-gaap_DepreciationDepletionAndAmortization_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639137551344378787" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_639137551344378787" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639137551344378787" xlink:to="us-gaap_ShareBasedCompensation_639137551344378787" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639137551344378787" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_639137551344378787" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639137551344378787" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_639137551344378787" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639137551344378787" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639137551344378787" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639137551344378787" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639137551344378787" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639137551344378787" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639137551344378787" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_639137551344378787" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639137551344378787" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_639137551344378787" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639137551344378787" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_639137551344378787" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639137551344378787" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_639137551344378787" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639137551344378787" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_639137551344378787" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_639137551344378787" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_639137551344378787" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639137551344378787" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639137551344378787" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639137551344378787" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639137551344378787" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_639137551344378787" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639137551344378787" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_639137551344378787" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_639137551344378787" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_639137551344378787" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639137551344378787" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_639137551344378787" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_639137551344378787" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_639137551344378787" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_639137551344378787" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_639137551344378787" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_639137551344378787" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639137551344378787" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_639137551344378787" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639137551344378787" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639137551344378787" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6391375513443787871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639137551344378787" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6391375513443787871" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639137551344378787" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_639137551344378787" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_OfferingCostsAccruedAndChargedToAdditionalPaidInCapital" xlink:label="crvs_OfferingCostsAccruedAndChargedToAdditionalPaidInCapital_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_639137551344378787" xlink:to="crvs_OfferingCostsAccruedAndChargedToAdditionalPaidInCapital_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureOrganization" xlink:type="extended" xlink:title="995210101 - Disclosure - Organization" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="995210201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="995210301 - Disclosure - Net Loss per Share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureSegments" xlink:type="extended" xlink:title="995210401 - Disclosure - Segments" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="995210501 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_3" xlink:to="us-gaap_FairValueDisclosuresTextBlock_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureEquityMethodInvestment" xlink:type="extended" xlink:title="995210601 - Disclosure - Equity Method Investment" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreements" xlink:type="extended" xlink:title="995210701 - Disclosure - License and Collaboration Agreements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract_2" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponents" xlink:type="extended" xlink:title="995210801 - Disclosure - Balance Sheet Components" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_2" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureWarrants" xlink:type="extended" xlink:title="995210901 - Disclosure - Warrants" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_WarrantsAndRightsNoteDisclosureTextBlock" xlink:label="crvs_WarrantsAndRightsNoteDisclosureTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="crvs_WarrantsAndRightsNoteDisclosureTextBlock_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureCommonStock" xlink:type="extended" xlink:title="995211001 - Disclosure - Common Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_1" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_CommonStockNoteDisclosureTextBlock" xlink:label="crvs_CommonStockNoteDisclosureTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_1" xlink:to="crvs_CommonStockNoteDisclosureTextBlock_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureStockOptionPlans" xlink:type="extended" xlink:title="995211101 - Disclosure - Stock Option Plans" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract_1" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_EquityIncentivePlansDisclosureTextBlock" xlink:label="crvs_EquityIncentivePlansDisclosureTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract_1" xlink:to="crvs_EquityIncentivePlansDisclosureTextBlock_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="995211201 - Disclosure - Stock-Based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="995211301 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_6" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureFacilityLease" xlink:type="extended" xlink:title="995211401 - Disclosure - Facility Lease" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="995211501 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="995211601 - Disclosure - Related Party Transactions" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_3" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:label="crvs_UnauditedInterimFinancialInformationPolicyTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="crvs_UnauditedInterimFinancialInformationPolicyTextBlock_639137551344378787" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_639137551344378787" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsPolicy_639137551344378787" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_639137551344378787" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_SignificantAccountingPoliciesPolicyTextBlock" xlink:label="crvs_SignificantAccountingPoliciesPolicyTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="crvs_SignificantAccountingPoliciesPolicyTextBlock_639137551344378787" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_639137551344378787" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="99930303 - Disclosure - Net Loss per Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_639137551344378787" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureSegmentsTables" xlink:type="extended" xlink:title="99930403 - Disclosure - Segments (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="99930503 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_4" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_4" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_639137551344378787" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_4" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_639137551344378787" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentTables" xlink:type="extended" xlink:title="99930603 - Disclosure - Equity Method Investment (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="EquityMethodInvestmentsAndJointVenturesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsTables" xlink:type="extended" xlink:title="99930803 - Disclosure - Balance Sheet Components (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_3" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureCommonStockTables" xlink:type="extended" xlink:title="99931003 - Disclosure - Common Stock (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOptionsIndexedToIssuersEquityTextBlock" xlink:label="us-gaap_ScheduleOfOptionsIndexedToIssuersEquityTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_2" xlink:to="us-gaap_ScheduleOfOptionsIndexedToIssuersEquityTextBlock_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureStockOptionPlansTables" xlink:type="extended" xlink:title="99931103 - Disclosure - Stock Option Plans (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract_2" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="99931203 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureFacilityLeaseTables" xlink:type="extended" xlink:title="99931403 - Disclosure - Facility Lease (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_639137551344378787" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureOrganizationDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - Organization (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_OrganizationTable" xlink:label="crvs_OrganizationTable_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="crvs_OrganizationTable_639137551344378787" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_OrganizationTable_639137551344378787" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639137551344378787" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639137551344378787" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639137551344378787" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639137551344378787" xlink:to="us-gaap_PrivatePlacementMember_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_FollowOnPublicOfferingMember" xlink:label="crvs_FollowOnPublicOfferingMember_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639137551344378787" xlink:to="crvs_FollowOnPublicOfferingMember_639137551344378787" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639137551344378787" xlink:to="us-gaap_OverAllotmentOptionMember_639137551344378787" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_OrganizationTable_639137551344378787" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639137551344378787" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639137551344378787" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639137551344378787" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_CommonStockWarrantsMember" xlink:label="crvs_CommonStockWarrantsMember_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639137551344378787" xlink:to="crvs_CommonStockWarrantsMember_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_CommonStockSharesAndCommonStockWarrantsMember" xlink:label="crvs_CommonStockSharesAndCommonStockWarrantsMember_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639137551344378787" xlink:to="crvs_CommonStockSharesAndCommonStockWarrantsMember_639137551344378787" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_CommonWarrantsMember" xlink:label="crvs_CommonWarrantsMember_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639137551344378787" xlink:to="crvs_CommonWarrantsMember_639137551344378787" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_PrefundedWarrantsMember" xlink:label="crvs_PrefundedWarrantsMember_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639137551344378787" xlink:to="crvs_PrefundedWarrantsMember_639137551344378787" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_PrefundedWarrantsAndCommonStockWarrantsMember" xlink:label="crvs_PrefundedWarrantsAndCommonStockWarrantsMember_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639137551344378787" xlink:to="crvs_PrefundedWarrantsAndCommonStockWarrantsMember_639137551344378787" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_OrganizationLineItems" xlink:label="crvs_OrganizationLineItems_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_OrganizationTable_639137551344378787" xlink:to="crvs_OrganizationLineItems_639137551344378787" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvs_OrganizationLineItems_639137551344378787" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_639137551344378787" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_639137551344378787" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639137551344378787" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_CombinedOfferingPriceForSharesAndWarrants" xlink:label="crvs_CombinedOfferingPriceForSharesAndWarrants_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_639137551344378787" xlink:to="crvs_CombinedOfferingPriceForSharesAndWarrants_639137551344378787" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_639137551344378787" xlink:to="us-gaap_SharesIssuedPricePerShare_639137551344378787" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_639137551344378787" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639137551344378787" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_ClassOfWarrantOrRightExercisePricePerPrefundedWarrant" xlink:label="crvs_ClassOfWarrantOrRightExercisePricePerPrefundedWarrant_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_639137551344378787" xlink:to="crvs_ClassOfWarrantOrRightExercisePricePerPrefundedWarrant_639137551344378787" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_639137551344378787" xlink:to="us-gaap_ProceedsFromWarrantExercises_639137551344378787" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_639137551344378787" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_639137551344378787" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_639137551344378787" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_639137551344378787" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_639137551344378787" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_639137551344378787" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_639137551344378787" xlink:to="us-gaap_SaleOfStockPricePerShare_639137551344378787" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_639137551344378787" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_639137551344378787" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRiskUninsuredDeposits" xlink:label="us-gaap_ConcentrationRiskCreditRiskUninsuredDeposits_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRiskUninsuredDeposits_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_NumberOfFinancialInstitutionsInWhichCashAndCashEquivalentsAreDeposited" xlink:label="crvs_NumberOfFinancialInstitutionsInWhichCashAndCashEquivalentsAreDeposited_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="crvs_NumberOfFinancialInstitutionsInWhichCashAndCashEquivalentsAreDeposited_639137551344378787" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureNetLossPerShareCalculationOfEarningsPerShareDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Net Loss per Share - Calculation of Earnings Per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_2" xlink:to="us-gaap_EarningsPerShareBasicAbstract_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_639137551344378787" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_639137551344378787" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount" xlink:label="us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_639137551344378787" xlink:to="us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount_639137551344378787" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_639137551344378787" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_639137551344378787" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract" xlink:label="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_639137551344378787" xlink:to="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract_639137551344378787" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract_639137551344378787" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract_639137551344378787" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_639137551344378787" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract_639137551344378787" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_639137551344378787" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_639137551344378787" xlink:to="us-gaap_EarningsPerShareBasic_639137551344378787" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_639137551344378787" xlink:to="us-gaap_EarningsPerShareDiluted_639137551344378787" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="99940302 - Disclosure - Net Loss per Share - Anti-Dilutive Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_639137551344378787" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_639137551344378787" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_639137551344378787" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_639137551344378787" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_639137551344378787" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_639137551344378787" xlink:to="us-gaap_EmployeeStockOptionMember_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_639137551344378787" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_639137551344378787" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_639137551344378787" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_CommonSharesIssuableUponConversionOfPreFundedWarrants" xlink:label="crvs_CommonSharesIssuableUponConversionOfPreFundedWarrants_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_639137551344378787" xlink:to="crvs_CommonSharesIssuableUponConversionOfPreFundedWarrants_639137551344378787" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureSegmentsDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Segments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:label="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_ShareBasedCompensation_639137551344378787" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_SegmentDrugManufacturingCosts" xlink:label="crvs_SegmentDrugManufacturingCosts_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="crvs_SegmentDrugManufacturingCosts_639137551344378787" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_639137551344378787" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_639137551344378787" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_FacilitiesAndInsurance" xlink:label="crvs_FacilitiesAndInsurance_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="crvs_FacilitiesAndInsurance_639137551344378787" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralExpense" xlink:label="us-gaap_OtherGeneralExpense_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_OtherGeneralExpense_639137551344378787" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_OperatingExpenses_639137551344378787" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_NonoperatingIncomeExpense_639137551344378787" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_NetIncomeLoss_639137551344378787" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_NumberOfOperatingSegments_639137551344378787" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Fair Value Measurements - Recurring (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639137551344378787" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639137551344378787" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_639137551344378787" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_639137551344378787" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_639137551344378787" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_639137551344378787" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639137551344378787" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_639137551344378787" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_639137551344378787" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639137551344378787" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639137551344378787" xlink:to="us-gaap_FairValueInputsLevel1Member_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639137551344378787" xlink:to="us-gaap_FairValueInputsLevel2Member_639137551344378787" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639137551344378787" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639137551344378787" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639137551344378787" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_639137551344378787" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_639137551344378787" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_639137551344378787" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_639137551344378787" xlink:to="us-gaap_AssetsFairValueDisclosure_639137551344378787" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsAvailableForSaleDetails" xlink:type="extended" xlink:title="99940502 - Disclosure - Fair Value Measurements - Available For Sale (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_639137551344378787" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable_639137551344378787" xlink:to="us-gaap_FinancialInstrumentAxis_639137551344378787" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_639137551344378787" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639137551344378787" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639137551344378787" xlink:to="us-gaap_USTreasurySecuritiesMember_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639137551344378787" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_639137551344378787" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable_639137551344378787" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_639137551344378787" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_639137551344378787" xlink:to="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_639137551344378787" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_639137551344378787" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_639137551344378787" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_639137551344378787" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_639137551344378787" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_639137551344378787" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_639137551344378787" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_639137551344378787" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_639137551344378787" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsCurrentOperationsAndRemainingMaturityDetails" xlink:type="extended" xlink:title="99940503 - Disclosure - Fair Value Measurements - Current Operations and The Remaining Maturity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable_639137551344535078" xlink:to="us-gaap_FinancialInstrumentAxis_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_639137551344535078" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639137551344535078" xlink:to="us-gaap_USTreasurySecuritiesMember_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_639137551344535078" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable_639137551344535078" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_639137551344535078" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_639137551344535078" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:label="crvs_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_639137551344535078" xlink:to="crvs_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo_639137551344535078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentInvestmentInAngelPharmaceuticalsDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Equity Method Investment - Investment in Angel Pharmaceuticals (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="EquityMethodInvestmentsAndJointVenturesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable_639137551344535078" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable_639137551344535078" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_639137551344535078" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_639137551344535078" xlink:to="srt_EquityMethodInvesteeNameDomain_639137551344535078" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember" xlink:label="crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain_639137551344535078" xlink:to="crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable_639137551344535078" xlink:to="dei_LegalEntityAxis_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_639137551344535078" xlink:to="dei_EntityDomain_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember" xlink:label="crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_6391375513445350781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_639137551344535078" xlink:to="crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_6391375513445350781" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable_639137551344535078" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_639137551344535078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_639137551344535078" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_EmployeeStockOwnershipPlanEsopEquityReservePercentage" xlink:label="crvs_EmployeeStockOwnershipPlanEsopEquityReservePercentage_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_639137551344535078" xlink:to="crvs_EmployeeStockOwnershipPlanEsopEquityReservePercentage_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_639137551344535078" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_639137551344535078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfBalanceSheetInformationDetails" xlink:type="extended" xlink:title="99940602 - Disclosure - Equity Method Investment - Summary of Balance Sheet Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="EquityMethodInvestmentsAndJointVenturesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable_639137551344535078" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable_639137551344535078" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_639137551344535078" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_639137551344535078" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember" xlink:label="crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_639137551344535078" xlink:to="crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable_639137551344535078" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_639137551344535078" xlink:to="us-gaap_AssetsCurrent_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_639137551344535078" xlink:to="us-gaap_AssetsNoncurrent_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_639137551344535078" xlink:to="us-gaap_LiabilitiesCurrent_639137551344535078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_639137551344535078" xlink:to="us-gaap_LiabilitiesNoncurrent_639137551344535078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_639137551344535078" xlink:to="us-gaap_StockholdersEquity_639137551344535078" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfIncomeStatementInformationDetails" xlink:type="extended" xlink:title="99940603 - Disclosure - Equity Method Investment - Summary of Income Statement Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_1" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable_639137551344535078" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_639137551344535078" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:label="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_639137551344535078" xlink:to="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember" xlink:label="crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_639137551344535078" xlink:to="crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable_639137551344535078" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_639137551344535078" xlink:to="us-gaap_NetIncomeLoss_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_639137551344535078" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - License and Collaboration Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_639137551344535078" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_639137551344535078" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_639137551344535078" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_639137551344535078" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_639137551344535078" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_639137551344535078" xlink:to="us-gaap_LicenseAgreementTermsMember_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_639137551344535078" xlink:to="srt_StatementScenarioAxis_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_639137551344535078" xlink:to="srt_ScenarioUnspecifiedDomain_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_AggregatePotentialMilestonePaymentsMember" xlink:label="crvs_AggregatePotentialMilestonePaymentsMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639137551344535078" xlink:to="crvs_AggregatePotentialMilestonePaymentsMember_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_639137551344535078" xlink:to="srt_CounterpartyNameAxis_639137551344535078" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639137551344535078" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639137551344535078" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_ScrippsResearchInstituteMember" xlink:label="crvs_ScrippsResearchInstituteMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639137551344535078" xlink:to="crvs_ScrippsResearchInstituteMember_639137551344535078" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_VernalisRAndDLimitedMember" xlink:label="crvs_VernalisRAndDLimitedMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639137551344535078" xlink:to="crvs_VernalisRAndDLimitedMember_639137551344535078" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_MonashLicenseMember" xlink:label="crvs_MonashLicenseMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639137551344535078" xlink:to="crvs_MonashLicenseMember_639137551344535078" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_639137551344535078" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_639137551344535078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_639137551344535078" xlink:to="us-gaap_ResearchAndDevelopmentExpense_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_639137551344535078" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_LicenseAgreementMilestonePayment" xlink:label="crvs_LicenseAgreementMilestonePayment_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_639137551344535078" xlink:to="crvs_LicenseAgreementMilestonePayment_639137551344535078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_ResearchAndDevelopmentArrangementContractTerminationNoticePeriod" xlink:label="crvs_ResearchAndDevelopmentArrangementContractTerminationNoticePeriod_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_639137551344535078" xlink:to="crvs_ResearchAndDevelopmentArrangementContractTerminationNoticePeriod_639137551344535078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPrepaidsAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Balance Sheet Components - Prepaids and Other Current Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" xlink:to="us-gaap_InterestReceivable_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" xlink:to="us-gaap_PrepaidRent_639137551344535078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" xlink:to="us-gaap_PrepaidInsurance_639137551344535078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" xlink:to="us-gaap_OtherAssetsCurrent_639137551344535078" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639137551344535078" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="99940802 - Disclosure - Balance Sheet Components - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639137551344535078" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639137551344535078" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639137551344535078" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639137551344535078" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_639137551344535078" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_639137551344535078" xlink:to="us-gaap_EquipmentMember_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_639137551344535078" xlink:to="us-gaap_ComputerEquipmentMember_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_639137551344535078" xlink:to="us-gaap_LeaseholdImprovementsMember_639137551344535078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_639137551344535078" xlink:to="us-gaap_ConstructionInProgressMember_639137551344535078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_639137551344535078" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_639137551344535078" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_639137551344535078" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_639137551344535078" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_639137551344535078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_639137551344535078" xlink:to="us-gaap_DepreciationAndAmortization_639137551344535078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsAccrualsAndOtherLiabilitiesDetails" xlink:type="extended" xlink:title="99940803 - Disclosure - Balance Sheet Components - Accruals and Other Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_AccruedLiabilitiesClinicalTrialCurrent" xlink:label="crvs_AccruedLiabilitiesClinicalTrialCurrent_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="crvs_AccruedLiabilitiesClinicalTrialCurrent_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_AccruedLiabilitiesManufacturingCurrent" xlink:label="crvs_AccruedLiabilitiesManufacturingCurrent_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="crvs_AccruedLiabilitiesManufacturingCurrent_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_639137551344535078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_639137551344535078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_639137551344535078" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_639137551344535078" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Warrants - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_1" xlink:to="us-gaap_ClassOfWarrantOrRightTable_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639137551344535078" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639137551344535078" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639137551344535078" xlink:to="us-gaap_PrivatePlacementMember_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639137551344535078" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639137551344535078" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_CommonStockSharesAndCommonStockWarrantsMember" xlink:label="crvs_CommonStockSharesAndCommonStockWarrantsMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639137551344535078" xlink:to="crvs_CommonStockSharesAndCommonStockWarrantsMember_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_CommonWarrantsMember" xlink:label="crvs_CommonWarrantsMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639137551344535078" xlink:to="crvs_CommonWarrantsMember_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_PrefundedWarrantsAndCommonStockWarrantsMember" xlink:label="crvs_PrefundedWarrantsAndCommonStockWarrantsMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639137551344535078" xlink:to="crvs_PrefundedWarrantsAndCommonStockWarrantsMember_639137551344535078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_PrefundedWarrantsMember" xlink:label="crvs_PrefundedWarrantsMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639137551344535078" xlink:to="crvs_PrefundedWarrantsMember_639137551344535078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639137551344535078" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_639137551344535078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639137551344535078" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639137551344535078" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_CombinedOfferingPriceForSharesAndWarrants" xlink:label="crvs_CombinedOfferingPriceForSharesAndWarrants_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639137551344535078" xlink:to="crvs_CombinedOfferingPriceForSharesAndWarrants_639137551344535078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639137551344535078" xlink:to="us-gaap_SharesIssuedPricePerShare_639137551344535078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639137551344535078" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639137551344535078" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_ClassOfWarrantOrRightExercisePricePerPrefundedWarrant" xlink:label="crvs_ClassOfWarrantOrRightExercisePricePerPrefundedWarrant_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639137551344535078" xlink:to="crvs_ClassOfWarrantOrRightExercisePricePerPrefundedWarrant_639137551344535078" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639137551344535078" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_639137551344535078" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639137551344535078" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_639137551344535078" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639137551344535078" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_639137551344535078" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_ChangeInFairValueOfWarrantLiabilities" xlink:label="crvs_ChangeInFairValueOfWarrantLiabilities_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639137551344535078" xlink:to="crvs_ChangeInFairValueOfWarrantLiabilities_639137551344535078" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639137551344535078" xlink:to="us-gaap_ProceedsFromWarrantExercises_639137551344535078" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Common Stock - Stock Issuance Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_639137551344535078" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639137551344535078" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639137551344535078" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639137551344535078" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639137551344535078" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_AtMarketOfferingMember" xlink:label="crvs_AtMarketOfferingMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639137551344535078" xlink:to="crvs_AtMarketOfferingMember_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639137551344535078" xlink:to="srt_CounterpartyNameAxis_639137551344535078" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639137551344535078" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639137551344535078" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_JefferiesLlcMember" xlink:label="crvs_JefferiesLlcMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639137551344535078" xlink:to="crvs_JefferiesLlcMember_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639137551344535078" xlink:to="srt_RangeAxis_639137551344535078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639137551344535078" xlink:to="srt_RangeMember_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639137551344535078" xlink:to="srt_MaximumMember_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639137551344535078" xlink:to="srt_StatementScenarioAxis_639137551344535078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_639137551344535078" xlink:to="srt_ScenarioUnspecifiedDomain_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639137551344535078" xlink:to="us-gaap_ScenarioPlanMember_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639137551344535078" xlink:to="us-gaap_ClassOfStockLineItems_639137551344535078" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639137551344535078" xlink:to="us-gaap_CommonStockSharesAuthorized_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639137551344535078" xlink:to="us-gaap_PreferredStockSharesAuthorized_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639137551344535078" xlink:to="us-gaap_CommonStockVotingRights_639137551344535078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639137551344535078" xlink:to="us-gaap_DividendsCommonStock_639137551344535078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639137551344535078" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_639137551344535078" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639137551344535078" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639137551344535078" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_UnderwritingCommitmentsPercentage" xlink:label="crvs_UnderwritingCommitmentsPercentage_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639137551344535078" xlink:to="crvs_UnderwritingCommitmentsPercentage_639137551344535078" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639137551344535078" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_639137551344535078" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureCommonStockCommonSharesReservedForIssuanceDetails" xlink:type="extended" xlink:title="99941002 - Disclosure - Common Stock - Common Shares Reserved for Issuance (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639137551344535078" xlink:to="us-gaap_StatementClassOfStockAxis_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_639137551344535078" xlink:to="us-gaap_ClassOfStockDomain_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_PreFundedWarrantEquityMember" xlink:label="crvs_PreFundedWarrantEquityMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_639137551344535078" xlink:to="crvs_PreFundedWarrantEquityMember_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_SharesAvailableForFutureOptionGrantsEquityMember" xlink:label="crvs_SharesAvailableForFutureOptionGrantsEquityMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_639137551344535078" xlink:to="crvs_SharesAvailableForFutureOptionGrantsEquityMember_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_OutstandingOptionsEquityMember" xlink:label="crvs_OutstandingOptionsEquityMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_639137551344535078" xlink:to="crvs_OutstandingOptionsEquityMember_639137551344535078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_SharesReservedForEmployeeStockPurchasePlanEquityMember" xlink:label="crvs_SharesReservedForEmployeeStockPurchasePlanEquityMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_639137551344535078" xlink:to="crvs_SharesReservedForEmployeeStockPurchasePlanEquityMember_639137551344535078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_639137551344535078" xlink:to="us-gaap_ClassOfStockLineItems_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_639137551344535078" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionActivityDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - Stock Option Plans - Stock Option Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639137551344535078" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639137551344535078" xlink:to="us-gaap_PlanNameAxis_639137551344535078" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_639137551344535078" xlink:to="us-gaap_PlanNameDomain_639137551344535078" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_EquityIncentiveAwardPlan2014Member" xlink:label="crvs_EquityIncentiveAwardPlan2014Member_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_639137551344535078" xlink:to="crvs_EquityIncentiveAwardPlan2014Member_639137551344535078" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_EquityIncentiveAwardPlan2016Member" xlink:label="crvs_EquityIncentiveAwardPlan2016Member_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_639137551344535078" xlink:to="crvs_EquityIncentiveAwardPlan2016Member_639137551344535078" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639137551344535078" xlink:to="srt_RangeAxis_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639137551344535078" xlink:to="srt_RangeMember_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639137551344535078" xlink:to="srt_MaximumMember_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639137551344535078" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639137551344535078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639137551344535078" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639137551344535078" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639137551344535078" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_639137551344535078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639137551344535078" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_639137551344535078" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639137551344535078" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_639137551344535078" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionsActivityDetails" xlink:type="extended" xlink:title="99941102 - Disclosure - Stock Option Plans - Stock Options Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639137551344535078" xlink:to="us-gaap_AwardTypeAxis_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_639137551344535078" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639137551344535078" xlink:to="us-gaap_EmployeeStockOptionMember_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639137551344535078" xlink:to="us-gaap_PlanNameAxis_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_639137551344535078" xlink:to="us-gaap_PlanNameDomain_639137551344535078" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_EquityIncentiveAwardPlan2016Member" xlink:label="crvs_EquityIncentiveAwardPlan2016Member_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_639137551344535078" xlink:to="crvs_EquityIncentiveAwardPlan2016Member_639137551344535078" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639137551344535078" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639137551344535078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639137551344535078" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639137551344535078" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639137551344535078" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_639137551344535078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6391375513445350781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639137551344535078" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6391375513445350781" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639137551344535078" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_639137551344535078" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639137551344535078" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_639137551344535078" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639137551344535078" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_639137551344535078" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639137551344535078" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_639137551344535078" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6391375513445350781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639137551344535078" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6391375513445350781" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639137551344535078" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_639137551344535078" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639137551344535078" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_639137551344535078" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639137551344535078" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_639137551344535078" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639137551344535078" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_639137551344535078" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6391375513445350781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639137551344535078" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6391375513445350781" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureStockBasedCompensationExpenseAllocationDetails" xlink:type="extended" xlink:title="99941201 - Disclosure - Stock-Based Compensation - Expense Allocation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_639137551344535078" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_639137551344535078" xlink:to="us-gaap_IncomeStatementLocationAxis_639137551344535078" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_639137551344535078" xlink:to="us-gaap_IncomeStatementLocationDomain_639137551344535078" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_639137551344535078" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_639137551344535078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_639137551344535078" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_639137551344535078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_639137551344535078" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_639137551344535078" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_639137551344691281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_639137551344535078" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_639137551344691281" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureIncomeTaxesComponentsOfEarningBeforeIncomeTaxesAndIncomeTaxesBenefitsDetails" xlink:type="extended" xlink:title="99941301 - Disclosure - Income Taxes - Components of Earning Before Income Taxes and Income Taxes Benefits (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_IncomeTaxExpenseBenefit_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails" xlink:type="extended" xlink:title="99941401 - Disclosure - Facility Lease - Lessee Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_639137551344693998" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639137551344693998" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_639137551344693998" xlink:to="us-gaap_BuildingMember_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_OfficeAndLabSpaceLeaseMember" xlink:label="crvs_OfficeAndLabSpaceLeaseMember_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BuildingMember_639137551344693998" xlink:to="crvs_OfficeAndLabSpaceLeaseMember_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_639137551344693998" xlink:to="srt_StatementScenarioAxis_639137551344693998" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_639137551344693998" xlink:to="srt_ScenarioUnspecifiedDomain_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_ThirdYearOfSubleaseMember" xlink:label="crvs_ThirdYearOfSubleaseMember_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_639137551344693998" xlink:to="crvs_ThirdYearOfSubleaseMember_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_639137551344693998" xlink:to="srt_RangeAxis_639137551344693998" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639137551344693998" xlink:to="srt_RangeMember_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639137551344693998" xlink:to="srt_MaximumMember_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_639137551344693998" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_639137551344693998" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_639137551344693998" xlink:to="us-gaap_LesseeDisclosureAbstract_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_639137551344693998" xlink:to="us-gaap_AreaOfRealEstateProperty_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_639137551344693998" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_639137551344693998" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_639137551344693998" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_639137551344693998" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_639137551344693998" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_639137551344693998" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_639137551344693998" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals_639137551344693998" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_639137551344693998" xlink:to="us-gaap_PrepaidRent_639137551344693998" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_639137551344693998" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_639137551344693998" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_639137551344693998" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_639137551344693998" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails" xlink:type="extended" xlink:title="99941402 - Disclosure - Facility Lease - Lease Cost (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_639137551344693998" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_639137551344693998" xlink:to="us-gaap_IncomeStatementLocationAxis_639137551344693998" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_639137551344693998" xlink:to="us-gaap_IncomeStatementLocationDomain_639137551344693998" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_639137551344693998" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_639137551344693998" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639137551344693998" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639137551344693998" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_639137551344693998" xlink:to="us-gaap_BuildingMember_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_OfficeAndLabSpaceLeaseMember" xlink:label="crvs_OfficeAndLabSpaceLeaseMember_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BuildingMember_639137551344693998" xlink:to="crvs_OfficeAndLabSpaceLeaseMember_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_639137551344693998" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_639137551344693998" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_639137551344693998" xlink:to="us-gaap_LeaseCostAbstract_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_639137551344693998" xlink:to="us-gaap_OperatingLeaseCost_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_639137551344693998" xlink:to="us-gaap_VariableLeaseCost_639137551344693998" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_639137551344693998" xlink:to="us-gaap_LeaseCost_639137551344693998" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_639137551344693998" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract_639137551344693998" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_639137551344693998" xlink:to="us-gaap_OperatingLeasePayments_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_639137551344693998" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_639137551344693998" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_639137551344693998" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_639137551344693998" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails" xlink:type="extended" xlink:title="99941403 - Disclosure - Facility Lease - Minimum Rental Commitments San Francisco Lease (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_639137551344693998" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639137551344693998" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_639137551344693998" xlink:to="us-gaap_BuildingMember_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_OfficeAndLabSpaceLeaseMember" xlink:label="crvs_OfficeAndLabSpaceLeaseMember_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BuildingMember_639137551344693998" xlink:to="crvs_OfficeAndLabSpaceLeaseMember_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_639137551344693998" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_639137551344693998" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_639137551344693998" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_639137551344693998" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_639137551344693998" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_639137551344693998" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_639137551344693998" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_639137551344693998" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_639137551344693998" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_639137551344693998" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_639137551344693998" xlink:to="us-gaap_OperatingLeaseLiability_639137551344693998" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended" xlink:title="99941601 - Disclosure - Related Party Transactions - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_2" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639137551344693998" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639137551344693998" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_FollowOnPublicOfferingMember" xlink:label="crvs_FollowOnPublicOfferingMember_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639137551344693998" xlink:to="crvs_FollowOnPublicOfferingMember_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639137551344693998" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_639137551344693998" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_639137551344693998" xlink:to="srt_EquityMethodInvesteeNameDomain_639137551344693998" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember" xlink:label="crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain_639137551344693998" xlink:to="crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639137551344693998" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639137551344693998" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639137551344693998" xlink:to="us-gaap_RelatedPartyDomain_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639137551344693998" xlink:to="us-gaap_RelatedPartyMember_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639137551344693998" xlink:to="us-gaap_RelatedPartyTransactionAxis_639137551344693998" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_639137551344693998" xlink:to="us-gaap_RelatedPartyTransactionDomain_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_ServicesSupportClinicalTrialsMember" xlink:label="crvs_ServicesSupportClinicalTrialsMember_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_639137551344693998" xlink:to="crvs_ServicesSupportClinicalTrialsMember_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639137551344693998" xlink:to="srt_CounterpartyNameAxis_639137551344693998" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639137551344693998" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_IconPlcMember" xlink:label="crvs_IconPlcMember_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639137551344693998" xlink:to="crvs_IconPlcMember_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_PuissanceCapitalManagementMember" xlink:label="crvs_PuissanceCapitalManagementMember_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639137551344693998" xlink:to="crvs_PuissanceCapitalManagementMember_639137551344693998" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639137551344693998" xlink:to="us-gaap_RelatedPartyTransactionLineItems_639137551344693998" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639137551344693998" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639137551344693998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639137551344693998" xlink:to="us-gaap_SaleOfStockPricePerShare_639137551344693998" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639137551344693998" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_639137551344693998" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639137551344693998" xlink:to="us-gaap_ResearchAndDevelopmentExpense_639137551344693998" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_NonRule10b51ArrModifiedFlag" xlink:label="crvs_NonRule10b51ArrModifiedFlag_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="crvs_NonRule10b51ArrModifiedFlag_639137551344693998" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="crvs-20260331.xsd#crvs_Rule10b51ArrModifiedFlag" xlink:label="crvs_Rule10b51ArrModifiedFlag_639137551344693998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="crvs_Rule10b51ArrModifiedFlag_639137551344693998" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>May 07, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Corvus Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-37719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-4670809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">901 Gateway Boulevard, Third Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">900-4520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CRVS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,090,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001626971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 40,102<span></span>
</td>
<td class="nump">$ 4,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">196,612<span></span>
</td>
<td class="nump">52,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration', window );">Accounts Receivable, after Allowance for Credit Loss, Current, Related Party [Extensible Enumeration]</a></td>
<td class="text">Related Party [Member]<span></span>
</td>
<td class="text">Related Party [Member]<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">$ 3,189<span></span>
</td>
<td class="nump">$ 1,427<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">239,946<span></span>
</td>
<td class="nump">58,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">751<span></span>
</td>
<td class="nump">839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Angel Pharmaceuticals</a></td>
<td class="nump">10,496<span></span>
</td>
<td class="nump">10,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,720<span></span>
</td>
<td class="nump">855<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">253,195<span></span>
</td>
<td class="nump">71,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,697<span></span>
</td>
<td class="nump">2,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">428<span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other liabilities</a></td>
<td class="nump">6,985<span></span>
</td>
<td class="nump">6,486<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">12,110<span></span>
</td>
<td class="nump">9,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">406<span></span>
</td>
<td class="nump">534<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">12,516<span></span>
</td>
<td class="nump">9,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 15)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock: $0.0001 par value; 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; 0 shares issued and outstanding at each of March 31, 2026 and December 31, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock: $0.0001 par value; 290,000,000 shares authorized at March 31, 2026 and December 31, 2025; 84,090,424 and 74,696,629 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">667,782<span></span>
</td>
<td class="nump">474,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,126)<span></span>
</td>
<td class="num">(896)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(425,985)<span></span>
</td>
<td class="num">(412,293)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">240,679<span></span>
</td>
<td class="nump">61,205<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 253,195<span></span>
</td>
<td class="nump">$ 71,119<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates status and type of related party for accounts receivable, after allowance for credit loss, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">290,000,000<span></span>
</td>
<td class="nump">290,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">84,090,424<span></span>
</td>
<td class="nump">74,696,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">84,090,424<span></span>
</td>
<td class="nump">74,696,629<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 11,175<span></span>
</td>
<td class="nump">$ 7,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,702<span></span>
</td>
<td class="nump">2,469<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">14,877<span></span>
</td>
<td class="nump">9,922<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(14,877)<span></span>
</td>
<td class="num">(9,922)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income and other expense, net</a></td>
<td class="nump">1,784<span></span>
</td>
<td class="nump">525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,129<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before equity method investment</a></td>
<td class="num">(13,093)<span></span>
</td>
<td class="nump">15,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="num">(599)<span></span>
</td>
<td class="num">(539)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (13,692)<span></span>
</td>
<td class="nump">$ 15,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) income per share, basic</a></td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="nump">$ 0.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used to compute net (loss) income per share, basic</a></td>
<td class="nump">89,996,728<span></span>
</td>
<td class="nump">72,126,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used to compute net loss per share, diluted</a></td>
<td class="nump">89,996,728<span></span>
</td>
<td class="nump">75,152,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">$ (334)<span></span>
</td>
<td class="num">$ (23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Cumulative foreign currency translation adjustment</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">$ (13,922)<span></span>
</td>
<td class="nump">$ 15,227<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Common Stock </div>
<div>Follow-on Public Offering</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Follow-on Public Offering</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Follow-on Public Offering</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430,859<span></span>
</td>
<td class="num">$ (1,288)<span></span>
</td>
<td class="num">$ (397,010)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,568<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,899,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,193<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432,389<span></span>
</td>
<td class="num">(1,254)<span></span>
</td>
<td class="num">(381,817)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,325<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,169,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">474,387<span></span>
</td>
<td class="num">(896)<span></span>
</td>
<td class="num">(412,293)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,205<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,696,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,696,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued (in shares)</a></td>
<td class="nump">9,085,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(334)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,692)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,692)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 667,782<span></span>
</td>
<td class="num">$ (1,126)<span></span>
</td>
<td class="num">$ (425,985)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,679<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance (in shares) at Mar. 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,090,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,090,424<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (13,692)<span></span>
</td>
<td class="nump">$ 15,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion related to marketable securities</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(291)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,650<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,129)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="nump">599<span></span>
</td>
<td class="nump">539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other current assets</a></td>
<td class="num">(1,762)<span></span>
</td>
<td class="nump">1,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Operating lease right-of-use asset</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other assets</a></td>
<td class="num">(865)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,206<span></span>
</td>
<td class="num">(1,274)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">499<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(103)<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(10,374)<span></span>
</td>
<td class="num">(8,263)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(161,737)<span></span>
</td>
<td class="num">(7,708)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">16,982<span></span>
</td>
<td class="nump">11,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(144,846)<span></span>
</td>
<td class="nump">4,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in connection with follow-on public offering, net</a></td>
<td class="nump">189,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of common stock options</a></td>
<td class="nump">1,339<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">190,746<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">35,526<span></span>
</td>
<td class="num">(3,741)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of the period</a></td>
<td class="nump">4,576<span></span>
</td>
<td class="nump">8,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of the period</a></td>
<td class="nump">40,102<span></span>
</td>
<td class="nump">4,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_OfferingCostsAccruedAndChargedToAdditionalPaidInCapital', window );">Offering costs recorded to additional paid-in-capital but not paid</a></td>
<td class="nump">553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">$ (6)<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_OfferingCostsAccruedAndChargedToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents equity issuance costs that have been recognized as a reduction to additional paid-in capital but have not yet been paid in cash as of the reporting period. These amounts are accrued as liabilities and disclosed as non-cash financing activities in the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_OfferingCostsAccruedAndChargedToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">1. Organization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Corvus Pharmaceuticals, Inc. (&#8220;Corvus&#8221; or the &#8220;Company&#8221;) was incorporated in Delaware on January 27, 2014 and commenced operations in November 2014. Corvus is a clinical-stage biopharmaceutical company. The Company&#8217;s operations are located in South San Francisco, California.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Corvus Biopharmaceuticals, Ltd. and Corvus Hong Kong Limited. All intercompany accounts and transactions have been eliminated from the condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Registered Direct Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>On May 6, 2024, the Company completed a registered direct offering which resulted in gross proceeds of approximately $30.6 million. The financing consisted of the sale of 13,512,699 shares of common stock and accompanying common stock warrants to purchase 13,078,509 shares of common stock (or pre-funded warrants in lieu thereof) at a combined offering price of $1.7312 per share, and the sale of pre-funded warrants to purchase 4,144,085 shares of common stock and accompanying common warrants to purchase 4,010,927 shares of common stock (or pre-funded warrants in lieu thereof) at a combined offering price of $1.7311 per share. The common warrants had an exercise price of $3.50 per share of common stock (or $3.4999 per pre-funded warrant in lieu thereof), were exercisable at any time after the date of issuance, subject to certain ownership limitations, and expired on June 30, 2025. The pre-funded warrants have an exercise price of $0.0001 and are exercisable any time after the date of the issuance, subject to certain ownership limitations. As of June 30, 2025, the expiration date of the common warrants, all of the common warrants had been exercised, resulting in proceeds of $54.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Follow-on Public Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>On January 23, 2026, the Company completed a follow-on public offering in which the Company sold 9,085,778 shares of common stock at a price of $22.15 per share, which included 1,185,101 shares issued pursuant to the underwriters&#8217; exercise of their option to purchase additional shares of common stock. The aggregate net proceeds received by the Company from the offering were approximately $189.4 million, net of underwriting discounts and commissions and offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, contract manufacturer and contract research organizations, compliance with government regulations and the need to obtain additional financing to fund operations. Since commencing operations in 2014, the majority of the Company&#8217;s efforts have been focused on the research and development of soquelitinib, ciforadenant and mupadolimab. The Company believes that it will continue to expend substantial resources for the foreseeable future as it continues clinical development of, seek regulatory approval for and, if approved, prepare for the commercialization of soquelitinib, as well as product candidates under the Company&#8217;s other development programs. These expenditures will include costs associated with research and development, conducting preclinical studies and clinical trials, obtaining regulatory approvals, manufacturing and supply, sales and marketing and general operations. In addition, other unanticipated costs may arise. Because the outcome of any clinical trial and/or regulatory approval process is highly uncertain, the Company may not be able to accurately estimate the actual amounts necessary to successfully complete the development, regulatory approval process and commercialization of soquelitinib, or any other product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred significant losses and negative cash flows from operations in all periods since inception and had an accumulated deficit of $426.0 million as of March 31, 2026. To date, none of the Company&#8217;s product candidates have been approved for sale and therefore the Company has not generated any revenue from sales of commercial products. Management expects operating losses to continue for the foreseeable future. The Company has funded its operations to date primarily through the sale of redeemable convertible preferred stock, common stock, pre-funded warrants and common stock warrants. As of March 31, 2026, the Company had cash, cash equivalents and marketable securities of $236.7 million. Management believes that the Company&#8217;s current cash, cash equivalents and short-term marketable securities will be sufficient to fund its planned operations for at least the next 12 months from the date of the issuance of these condensed consolidated financial statements. To fund all of the Company's ongoing and planned development programs through commercialization, the Company will need to raise additional capital in the future. The Company intends to raise additional capital through private and public equity offerings, debt financings and license and development agreements. However, there can be no assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its operations or on terms acceptable to the Company or at all. If the Company is unsuccessful in its efforts to raise additional capital or if sufficient funds on acceptable terms are not available when needed, the Company could be required to significantly reduce operating expenses and delay, reduce the scope of or eliminate one or more of its development programs, out-license intellectual property rights to its product candidates, sell unsecured assets, or a combination of the above, any of which may have a material adverse effect on the Company&#8217;s business, results of operations, financial condition and/or its ability to fund its obligations on a timely basis or at all. Failure to manage discretionary spending or raise additional capital, as needed, may adversely impact the Company&#8217;s ability to achieve its intended business objectives.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">2. Summary of Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The Company&#8217;s functional and reporting currency is the U.S. dollar, except for its investment in its equity method investee which is the Chinese renminbi (RMB). The accompanying condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and discharge of liabilities in the normal course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Unaudited Interim Financial Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The accompanying interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for fair statement of the condensed consolidated financial statements presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The condensed consolidated balance sheet as of December 31, 2025 was derived from audited financial statements, but does not include all disclosures required by GAAP. The condensed consolidated results of operations for the three months ended March 31, 2026 are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements and the related notes for the year ended December 31, 2025 included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 12, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The preparation of the Company&#8217;s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from such estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Investments in Equity Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The Company uses the equity method of accounting for its equity investment if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The Company&#8217;s proportionate share of the net income (loss) resulting from the equity method investment is reported under the line item captioned &#8220;income (loss) from equity method investment&#8221; in the condensed consolidated statements of operations and comprehensive loss and the carrying value of the equity method investments is reported under the line captioned &#8220;Investment in Angel Pharmaceuticals&#8221; in the condensed consolidated balance sheets. The Company&#8217;s equity method investments are reported at cost and adjusted each period for the Company&#8217;s share of the investee&#8217;s income or loss and the foreign currency translation adjustment as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>For equity method investees with a functional currency different than the Company&#8217;s reporting currency, the Company follows the guidance under Accounting Standards Codification (&#8220;ASC&#8221;) 830-10-15-5, pursuant to which, the foreign currency financial statements of a foreign investee accounted for by the equity method should be translated to the reporting entity&#8217;s reporting currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The Company evaluates equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable. Factors considered by the Company when reviewing an equity method investment for impairment include the length of time (duration) and the extent (severity) to which the fair value of the equity method investment has been less than cost, the investee&#8217;s financial condition and near-term prospects and the intent and ability to hold the investment for a period of time sufficient to allow for anticipated recovery. An impairment that is other-than-temporary is recognized in the period identified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>See Note 6, &#8220;Equity Method Investment,&#8221; for further information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk and Other Risks and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Substantially all of the Company&#8217;s cash and cash equivalents are deposited in accounts with two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company maintains its cash with an accredited financial institution and accordingly, such funds are subject to minimal credit risk. The Company&#8217;s marketable securities consist of investments in U.S. Treasury securities and U.S. government agency securities, which can be subject to certain credit risks. However, the Company mitigates the risks by investing in high-grade instruments, limiting its exposure to any one issuer, and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company is subject to a number of risks similar to other early stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, and protection of proprietary technology. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Significant Accounting Policies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There have been no material changes to the Company&#8217;s significant accounting policies during the three months ended March 31, 2026 from those discussed in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 12, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2023, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative, which modifies the disclosure or presentation requirements related to variety of FASB Accounting Standard Codification topics. The effective date for each amendment will be the date on which the SEC&#8217;s removal of that related disclosure from Regulation S-X or Regulation S-K is effective. If by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the associated amendment will be removed from the Codification and will not become effective for any entities. The Company is currently evaluating the effect of adopting this ASU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expense. This update requires entities to disaggregate operating expenses into specific categories, such as salaries and wages, depreciation, and amortization, to provide enhanced transparency into the nature and function of expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, with early adoption permitted. ASU 2024-03 may be applied retrospectively or prospectively. The Company is currently evaluating the impact of ASU 2024-03 on its financial statement presentation and disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">3. Net Loss per Share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The following table shows the calculation of net (loss) income per share (in thousands, except share and per share data):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:25.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:25.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Net loss attributable to common stockholders, basic</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (13,692)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,193</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Gain from change in fair value of warrant liability</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (25,129)</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Net loss - basic and diluted</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (13,692)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (9,936)</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Weighted average common shares and pre-funded warrants outstanding used to compute basic and diluted net (loss) income per share</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 89,996,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72,126,496</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Weighted average shares issuable upon the exercise of common warrants</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,026,018</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Weighted average common shares and prefunded warrants outstanding used to compute diluted net loss per share</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 89,996,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75,152,514</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net (loss) income per share, basic</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (0.15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.21</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net loss per share, diluted</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (0.15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (0.13)</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Weighted average common shares outstanding used in the calculation of basic and diluted net loss per share for the three months ended March 31, 2026 and 2025 includes 8,275,913 and 4,144,085 shares of common stock issuable upon conversion of pre-funded warrants, respectively. Refer to Note 9, &#8220;Warrants&#8221; for further details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Shares issuable upon exercise of common warrants used in the calculation of diluted net loss per share for the three months ended March 31, 2025 were calculated using the treasury stock method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The amounts in the table below were excluded from the calculation of diluted net loss per share, due to their anti-dilutive effect:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:73.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:73.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:73.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:73.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Outstanding options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,066,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,575,683</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">4. Segments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The Company views its operations and manages its business in one operating segment, that of the development and commercialization of drugs and antibodies that target critical elements of the immune system. The Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;) is made up of the Chief Executive Officer and Chief Financial Officer. The CODM assesses performance for the segment and decides how to allocate resources based on consolidated net loss that is reported on the consolidated statement of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total consolidated assets. Managing and allocating resources on a consolidated basis enables the CODM to assess the overall level of resources available and how to best deploy these resources across functions and programs that are in line with the Company&#8217;s long-term company-wide strategic goals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The following table presents reportable segment net loss, including significant expense categories, attributable to the Company&#8217;s reportable segment for the three months ended March 31, 2026 and 2025 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Compensation and benefits, excluding stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,239</p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,650</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,251</p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Drug manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,830</p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Clinical trials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,927</p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Outside general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,244</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 946</p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Facilities and insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 558</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 780</p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other segment items (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,924</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 949</p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total segment expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,877</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,922</p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Non-operating income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (1,185)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (25,115)</p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,692</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (15,193)</p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><div style="margin-top:3pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Includes consulting, non-clinical research and laboratory supplies.</span></td></tr></table><div style="margin-top:3pt;"></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">5. Fair Value Measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Financial assets and liabilities are measured and recorded at fair value. The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2&#8212;Inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3&#8212;Unobservable inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">There have been no transfers of assets and liabilities between levels of hierarchy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company&#8217;s Level 2 investments are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar investments, issuer credit spreads, benchmark investments, prepayment/default projections based on historical data and other observable inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The following tables present information as of March 31, 2026 and December 31, 2025 about the Company&#8217;s assets that are measured at fair value on a recurring basis and indicate the level of the fair value hierarchy the Company utilized to determine such fair values (in&#160;thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;width:43.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2026</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;width:32.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measured&#160;Using</b></p></td><td style="vertical-align:bottom;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,106</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,106</p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 196,612</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 196,612</p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,106</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 196,612</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 235,718</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:normal;width:43.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:normal;width:32.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measured&#160;Using</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,163</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,163</p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,174</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,174</p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,163</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,174</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56,337</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of March 31, 2026 and December 31, 2025, the fair value of available for sale marketable securities by type of security were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:38.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2026</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:59.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">U.S. Treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164,862</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (237)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164,678</p></td></tr><tr style=""><td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">U.S. Government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (88)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,934</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:59.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 196,883</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (325)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 196,612</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:36.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">U.S. Treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,622</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,675</p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">U.S. Government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,489</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,499</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,174</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="color:#ee0000;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of March 31, 2026, all of the Company&#8217;s marketable securities are considered available for current operations and the remaining maturity by type of security is as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="color:#ee0000;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maturities&#160;by&#160;Period at Amortized Cost</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">than</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">1 Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">1-2 years</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">U.S. Treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164,862</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 95,749</p></td><td style="vertical-align:bottom;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69,113</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">U.S. Government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,943</p></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,078</p></td></tr><tr style=""><td style="vertical-align:middle;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 196,883</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108,692</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,191</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="color:#ee0000;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Equity Method Investment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">6. Equity Method Investment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Angel Pharmaceuticals Co. Ltd. (&#8220;Angel Pharmaceuticals&#8221;) is a corporate venture in the People&#8217;s Republic of China designed to develop, manufacture, and commercialize soquelitinib, ciforadenant and mupadolimab compounds for distribution within the countries of China, Taiwan, Macao, and Hong Kong based on intellectual property licenses contributed to Angel Pharmaceuticals by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2026 and December 31, 2025, the Company&#8217;s ownership interest in Angel Pharmaceuticals was approximately 49.7%, excluding 7% of Angel Pharmaceuticals&#8217; equity reserved for issuance under the Angel Pharmaceuticals Employee Stock Ownership Plan, and is accounted for as an equity method investment. The Company recognized its share of loss in Angel Pharmaceuticals for the total amount of $0.6 million and $0.5 million as loss from equity method investment in the condensed consolidated statement of operations for the three months ended March 31, 2026 and 2025, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary Financial Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Summary financial information for Angel Pharmaceuticals is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:67.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Balance Sheet Data</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2025</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr style=""><td style="vertical-align:bottom;width:67.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,286</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,033</p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 798</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 904</p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,049</p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 143</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 229</p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stockholders' equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,659</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Statement&#160;of&#160;Operations&#160;Data</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (768)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (686)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Share of loss from investments accounted for using the equity method</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (599)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (539)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478156/740-323-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 323<br> -Publisher FASB<br> -URI https://asc.fasb.org/323/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>License and Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaboration Agreements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">7. License and Collaboration Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Scripps Licensing Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2014, the Company entered into a license agreement with The Scripps Research Institute (&#8220;Scripps&#8221;), pursuant to which it was granted a non-exclusive, world-wide license for all fields of use under Scripps&#8217; rights in certain know-how and technology related to a mouse hybridoma clone expressing an anti-human CD73 antibody, and to progeny, mutants or unmodified derivatives of such hybridoma and any antibodies expressed by such hybridoma, from which we developed CPI-006. Scripps also granted the Company the right to grant sublicenses in conjunction with other proprietary rights the Company holds, or to others collaborating with or performing services for the Company. Under this license agreement, Scripps has agreed not to grant any additional commercial licenses with respect to such materials, other than march-in rights granted to the U.S. government.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Upon execution of the agreement, the Company made a one time cash payment to Scripps of $10,000 in 2015 and is also obligated to pay a minimum annual fee to Scripps of $25,000. The one time cash payment was recorded as research and development expense as technological feasibility of the asset had not been established and there was no alternative future use. A minimum annual fee payment is due on each anniversary of the effective date of the agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">for the term of the agreement. The Company is also required to make performance based cash payments upon successful completion of clinical and sales milestones. The aggregate potential milestone payments are $2.5 million as of March 31, 2026. The Company is also required to pay royalties on net sales of licensed products (including CPI-006) sold by it, its affiliates and its sublicensees at a rate in the low single digits. In addition, should the Company sublicense the rights licensed under the agreement, it has agreed to pay a percentage of sublicense revenue received at specified rates that start at double digit percentages and decrease to single digit percentages based on the elapsed time from the effective date of the agreement and the time of entry into such sublicense. To date, no milestone payments have been made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s license agreement with Scripps will terminate upon expiration of its obligation to pay royalties to Scripps under the license agreement. The Company&#8217;s license agreement with Scripps is terminable by the consent of the parties, at will by the Company upon providing 90 days written notice to Scripps, or by Scripps for certain material breaches, or if the Company undergoes a bankruptcy event. In addition, Scripps may terminate the license on a product by product basis, or the entire agreement, if the Company fails to meet specified diligence obligations related to the development and commercialization of licensed products. Scripps may also terminate the agreement after the third anniversary of the effective date of the agreement if it reasonably believes, based on reports the Company provides to Scripps, that the Company has not used commercially reasonable efforts as required under the agreement, subject to a specified notice and cure period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Vernalis Licensing Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In February 2015, the Company entered into a license agreement with Vernalis (R&amp;D) Limited (&#8220;Vernalis&#8221;), which was subsequently amended as of November 5, 2015, and, pursuant to which the Company was granted an exclusive, worldwide license under certain patent rights and know-how, including a limited right to grant sublicenses, for all fields of use to develop, manufacture and commercialize products containing certain adenosine receptor antagonists, including ciforadenant. Pursuant to this agreement, the Company made a one-time cash payment to Vernalis in the amount of $1.0 million, which was recorded as research and development expense as technological feasibility of the asset had not been established and there was no alternative future use. The Company is also required to make cash milestone payments to Vernalis upon the successful completion of clinical and regulatory milestones for licensed products depending on the indications for which such licensed products are developed and upon achievement of certain sales milestones. In February 2017, the Company made a milestone payment of $3.0 million to Vernalis following the expansion of a cohort of patients with renal cell cancer treated with single agent ciforadenant in the Company&#8217;s Phase 1/1b clinical trial. During the three months ended March 31, 2026 and 2025, no clinical or regulatory milestones were completed or paid to Vernalis, and the aggregate potential milestone payments were approximately $220 million for all indications as of March 31, 2026. The Company has also agreed to pay Vernalis tiered incremental royalties based on the annual net sales of licensed products containing ciforadenant on a product by product and country by country basis, subject to certain offsets and reductions. The tiered royalty rates for products containing ciforadenant range from the mid single digits up to the low double digits on a country by country net sales basis. The royalties on other licensed products that do not include ciforadenant also increase with the amount of net sales on a product-by-product and country by country basis and range from the low single digits up to the mid single digits on a country by country net sales basis. The Company is also obligated to pay to Vernalis certain sales milestones as indicated above when worldwide net sales reach specified levels over an agreed upon time period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The agreement will expire on a product-by-product and country-by-country basis upon the expiration of the Company&#8217;s payment obligations to Vernalis in respect of a particular product and country. Both parties have the right to terminate the agreement for an uncured material breach by the other party. The Company may also terminate the agreement at its convenience by providing 90 days written notice, provided that the Company has not received notice of its own default under the agreement at the time the Company exercises such termination right. Vernalis may also terminate the agreement if the Company challenges a licensed patent or undergoes a bankruptcy event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Monash License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2017, the Company entered into a license agreement with Monash University (&#8220;Monash&#8221;), pursuant to which the Company was granted an exclusive, sublicensable worldwide license under certain know-how, patent rights and other intellectual property rights controlled by Monash to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon execution of the agreement, the Company made a one time cash payment to Monash of $275,000 and reimbursed Monash for certain patent prosecution costs incurred prior to execution of the agreement. The Company recorded these payments as research and development expenses for the year ended December 31, 2017. The Company is also obligated to pay an annual license maintenance fee to Monash of $25,000 until a certain development milestone is met with respect to the licensed product, after which no further maintenance fee will be due. The Company is also required to make development and sales milestone payments to Monash with respect to the licensed products. During the three months ended March 31, 2026 and 2025, no development or sales milestones were completed or paid to Monash, and the aggregate potential milestones were $45.1 million as of March 31, 2026. The Company is also required to pay to Monash tiered royalties on net sales of licensed products sold by it, its affiliates and its sublicensees at a rate ranging in the low single digits. In addition, should the Company sublicense its rights under the agreement, the Company has agreed to pay a percentage of sublicense revenue received at specified rates that are currently at low double digit percentages and decrease to single digit percentages based on the achievement of development milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The term of the Company&#8217;s agreement with Monash continues until the expiration of its obligation to pay royalties to Monash thereunder. The license agreement is terminable at will by the Company upon providing 30 days written notice to Monash, or by either party for material breaches by the other party. In addition, Monash may terminate the entire agreement or convert the license to a non-exclusive license if the Company has materially breached its obligation to use commercially reasonable efforts to develop and commercialize a licensed product, subject to a specified notice and cure mechanism.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Components</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">8. Balance Sheet Components (in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Prepaid and Other Current Assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Interest receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 337</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Prepaid research and development manufacturing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,564</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 599</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Prepaid facility expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 138</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 367</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 318</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,189</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,427</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Property and Equipment</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,713</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,646</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Computer equipment and purchased software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,959</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,869</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Less: accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (2,677)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (2,649)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 282</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 220</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Accrued and Other Liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued clinical trial expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,566</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued manufacturing expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,794</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,812</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Personnel related </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,381</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 641</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued legal and accounting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 229</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 206</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,985</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,486</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the three months ended March 31, 2026 and 2025, the Company recorded approximately $29,000 and $22,000 in depreciation expense, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_WarrantsAndRightsNoteDisclosureTextBlock', window );">Warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">9. Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 6, 2024, the company completed a registered direct offering in which the Company sold an aggregate of 13,512,699 shares of common stock and common warrants to purchase up to 13,078,509 shares of common stock (or pre-funded warrants in lieu thereof) at a combined offering price of $1.7312 per share and common warrant, and pre-funded warrants to purchase up to 4,144,085 shares of common stock and common warrants to purchase up to 4,010,927 shares of common stock (or pre-funded warrants in lieu thereof), at a combined offering price of $1.7311 per share underlying each pre-funded warrant and common warrant, which equals the offering price per share and common warrant less the $0.0001 exercise price per share of the pre-funded warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The pre-funded warrants have an exercise price per share of common stock equal to $0.0001 per share. The exercise price and the number of shares of common stock issuable upon exercise of the pre-funded warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. The pre-funded warrants are exercisable at any time after the date of issuance. In accordance with accounting guidance discussed in Note 2, the Company recorded $5.0 million to additional paid-in capital upon issuance of the pre-funded warrants on May 6, 2024. In May 2025, an additional 4,131,828 pre-funded warrants were issued in connection with the exercise of common warrants. As of March 31, 2026, none of the pre-funded warrants have been exercised and 8,275,913 pre-funded warrants remain outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The common warrants had an exercise price per share of common stock equal to $3.50 per share (or $3.4999 per pre-funded warrant). The exercise price and the number of shares of common stock (or pre-funded warrants in lieu thereof) issuable upon exercise of the common warrants were subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">common stock. The common warrants were exercisable at any time after the date of issuance and had an expiration date of June 30, 2025. In accordance with accounting guidance discussed in Note 2, &#8220;Summary of Significant Accounting Policies,&#8221; the Company recorded a decrease in fair value of warrant liability of $25.1 million to other income in its condensed consolidated statement of operations and comprehensive loss for the three months ended March 31, 2025. As of June 30, 2025, the expiration date of the common warrants, all of the common warrants had been exercised, resulting in proceeds of $54.3 million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_WarrantsAndRightsNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for warrants and rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_WarrantsAndRightsNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_CommonStockNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">10. Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of March 31, 2026, the amended and restated certificate of incorporation authorizes the Company to issue 290&#160;million shares of common stock and 10 million shares of preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Each share of common stock is entitled to one vote. Common stockholders are entitled to dividends if and when declared by the board of directors. As of March 31, 2026, no dividends on common stock had been declared.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">On August 6, 2024, the Company entered into an Open Market Sale Agreement<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> (the &#8220;2024 Sales Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) to sell shares of the Company&#8217;s common stock, from time-to-time, with aggregate gross sales proceeds of up to $100.0 million, through an at-the-market equity offering program under which Jefferies will act as its sales agent. The issuance and sale of shares of common stock by the Company pursuant to the 2024 Sales Agreement are deemed an &#8220;at-the-market&#8221; offering under the Securities Act of 1933, as amended. Jefferies is entitled to compensation for its services up to 3.0% of the gross proceeds of any shares of common stock sold through Jefferies under the 2024 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">On January 20, 2026, in connection with the January 2026 financing, as further described in Note 1, the Company suspended the offering of any shares of its common stock under the 2024 Sales Agreement and, on March 13, 2026, the Company entered into an Amended and Restated Open Market Sale Agreement<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup>, dated March 13, 2026 (the &#8220;Amended Sales Agreement&#8221;), with Jefferies, which amends and restates the 2024 Sales Agreement to increase the maximum aggregate offering price of shares of the Company&#8217;s common stock from $100.0 million to $200.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">During the three months ended March 31, 2026, the Company did not sell any shares of common stock under its at-the-market offering program. As of March 31, 2026, $200.0 million remained available for sale under the Amended Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company has reserved shares of common stock for issuance as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Pre-funded warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,275,913</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,275,913</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Shares available for future option grants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,649,034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,007,335</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Outstanding options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,066,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,028,177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Shares reserved for employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 400,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 400,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,391,273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,711,425</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_CommonStockNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_CommonStockNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Stock Option Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_EquityIncentivePlansDisclosureTextBlock', window );">Stock Option Plans</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">11. Stock Option Plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In February 2014, the Company adopted the 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;), which was subsequently amended in November 2014, July 2015 and September 2015, under which it granted incentive stock options (&#8220;ISOs&#8221;) or non-qualified stock options (&#8220;NSOs&#8221;). Terms of stock agreements, including vesting requirements, are determined by the board of directors or a committee authorized by the board of directors, subject to the provisions of the 2014 Plan. In general, awards granted by the Company vest over four years and have a maximum exercise term of 10 years. The 2014 Plan provides that grants must be at an exercise price of 100% of fair market value of the Company&#8217;s common stock as determined by the board of directors on the date of the grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In connection with the consummation of the IPO in March 2016, the 2016 Equity Incentive Award Plan (the &#8220;2016 Plan&#8221;) became effective. Under the 2016 Plan, ISOs, NSOs, stock purchase rights and other stock-based awards </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">may be granted. Terms of stock agreements, including vesting requirements, are determined by the board of directors or a committee authorized by the board of directors, subject to the provisions of the 2016 Plan. In general, awards granted by the Company vest over four years and have a maximum exercise term of 10 years. The 2016 Plan provides that grants must be at an exercise price of 100% of fair market value of the Company&#8217;s common stock as determined by the board of directors on the date of the grant. In conjunction with adopting the 2016 Plan, the 2014 Plan was terminated and no further awards will be granted under the 2014 Plan. Options outstanding under the 2014 Plan as of the effective date of the 2016 Plan that are forfeited or lapse unexercised may be re-issued under the 2016 Plan, up to a maximum of 1,136,229 shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Activity under the Company&#8217;s stock option plans is set forth below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;Outstanding</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">&#8209;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Available</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">for&#160;Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Balance at December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,007,335</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,028,177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.20</p></td></tr><tr style=""><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Additional shares authorized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,987,865</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (7,500)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.63</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Options exercised </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (308,017)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.35</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 661,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (661,334)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.23</p></td></tr><tr style=""><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Balance at March&#160;31,&#160;2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,649,034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,066,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.76</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_EquityIncentivePlansDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity incentive plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_EquityIncentivePlansDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">12. Stock-Based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company&#8217;s results of operations include expenses relating to employee and non-employee stock-based awards as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:74.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:21.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:21.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,077</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,573</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 723</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,650</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">13. Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the three months ended March 31, 2026 and 2025, the Company recorded no income tax benefits for the net operating losses (NOLs) incurred due to the uncertainty of realizing a benefit from those items. The Company continues to maintain a full valuation allowance against its net deferred tax assets.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Facility Lease<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Facility Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Facility Lease</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">14. Facility Lease</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">On October 22, 2024, the Company entered into an operating sub-sublease agreement, pursuant to which the Company sub-leased approximately 20,916 square feet of office and lab space. The sub-sublease has a term of three years commencing on February 21, 2025 with an option to extend at fair market value for an additional 27 months. The Company records rent expense on a straight-line basis over the effective term of the lease, including any free rent periods and incentives. As the interest rate implicit in lease arrangements is typically not readily available, in calculating the present value of the lease payments, the Company has utilized its incremental borrowing rate, which is determined based on the prevailing market rates for collateralized debt with maturity dates commensurate with the term of its lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company&#8217;s obligation for the payment of base rent for the premises began on the commencement date and is initially $33,833 per month, up to monthly base rent of $47,200 during the third year of the sub-sublease. In addition </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">to base rent, the Company is obligated to pay its proportionate share of taxes, insurance and operating expenses. In November 2024, the Company paid the sublandlord $231,235 in prepaid rent, which was applied to the monthly base rent and the Company&#8217;s proportionate share of additional expenses for the first three months of the term of the sub-sublease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Although the non-cancellable lease term commenced on February 21, 2025, for purposes of determining the right-of-use asset balance, in accordance with ASC Topic 842, the Company used November 25, 2024 as the commencement date, the date on which the sublandlord granted the Company access to the premises. The sub-sublease is a net lease, as the non-lease components (i.e., common area maintenance) are paid separately from rent based on actual costs incurred. Therefore, the non-lease components were not included in the right-of-use asset and liability and are reflected as an expense in the period incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of March 31, 2026 and December 31, 2025, the right-of-use asset under the operating lease was approximately $0.8 million. The elements of lease expense under the operating lease for the three months ended March 31, 2026 were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:20.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Statements of operations and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;width:20.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">comprehensive loss location</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Costs of operating lease</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Operating lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Research and development,<br/>General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 113</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Costs of non-lease components (previously common area maintenance)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Research and development,<br/>General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 291</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Other Information</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Operating cash flows used for operating lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 188</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1.9 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2.9 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">11.7%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">11.7%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">As of March 31, 2026, minimum rental commitments under this lease were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31 (in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2026*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 358</p></td></tr><tr style=""><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 566</p></td></tr><tr style=""><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 924</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (90)</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 834</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">* Remainder of the year</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>As of December 31, 2025, minimum rental commitments under this lease were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31 (in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 486</p></td></tr><tr style=""><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 566</p></td></tr><tr style=""><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,052</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (115)</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 937</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">15. Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Pursuant to the Company&#8217;s license agreements with each of Vernalis, Scripps and Monash, it has obligations to make future milestone and royalty payments to the respective parties. However, because these amounts are contingent, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">they have not been included on the Company&#8217;s balance sheet. For further discussion of the Vernalis, Scripps and Monash licensing agreements, see Note 7, &#8220;License and Collaboration Agreements.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Indemnifications</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware law. There have been no claims to date and the Company has a directors and officers insurance policy that may enable it to recover a portion of any amounts paid for future claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Legal Proceedings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is not a party to any material legal proceedings.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">16. Related Party Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As part of the January 2026 follow-on public offering, 30,000 shares of common stock, at the public offering price of $22.15 per share, were sold to Puissance Capital Management, a related party. Ted Wang, Ph.D., a Co-Founder, General Manager and Director of Angel Pharmaceuticals, of which the Company holds a 49.7% ownership interest, is the founder of Puissance Capital Management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2021, Linda S. Grais, M.D., J.D., a member of the Company&#8217;s Board of Directors, was appointed as a non-executive member of the Board of Directors of ICON plc (&#8220;ICON&#8221;), effective upon completion of ICON&#8217;s acquisition of PRA Health Sciences, Inc. ICON is a clinical research organization and provides services to support the Company&#8217;s clinical trials. During the three months ended March 31, 2026 and 2025, the Company recorded approximately $123,000 and $94,000, respectively, in clinical trial expenses under its agreements with ICON.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (13,692)<span></span>
</td>
<td class="nump">$ 15,193<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_NonRule10b51ArrModifiedFlag', window );">Non-Rule 10b5-1 Arrangement Modified</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_Rule10b51ArrModifiedFlag', window );">Rule 10b5-1 Arrangement Modified</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_NonRule10b51ArrModifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>N/A</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_NonRule10b51ArrModifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_Rule10b51ArrModifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>N/A</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_Rule10b51ArrModifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The Company&#8217;s functional and reporting currency is the U.S. dollar, except for its investment in its equity method investee which is the Chinese renminbi (RMB). The accompanying condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and discharge of liabilities in the normal course of business.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_UnauditedInterimFinancialInformationPolicyTextBlock', window );">Unaudited Interim Financial Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Unaudited Interim Financial Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The accompanying interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for fair statement of the condensed consolidated financial statements presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The condensed consolidated balance sheet as of December 31, 2025 was derived from audited financial statements, but does not include all disclosures required by GAAP. The condensed consolidated results of operations for the three months ended March 31, 2026 are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements and the related notes for the year ended December 31, 2025 included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 12, 2026.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The preparation of the Company&#8217;s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from such estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Investments in Equity Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Investments in Equity Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The Company uses the equity method of accounting for its equity investment if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The Company&#8217;s proportionate share of the net income (loss) resulting from the equity method investment is reported under the line item captioned &#8220;income (loss) from equity method investment&#8221; in the condensed consolidated statements of operations and comprehensive loss and the carrying value of the equity method investments is reported under the line captioned &#8220;Investment in Angel Pharmaceuticals&#8221; in the condensed consolidated balance sheets. The Company&#8217;s equity method investments are reported at cost and adjusted each period for the Company&#8217;s share of the investee&#8217;s income or loss and the foreign currency translation adjustment as applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>For equity method investees with a functional currency different than the Company&#8217;s reporting currency, the Company follows the guidance under Accounting Standards Codification (&#8220;ASC&#8221;) 830-10-15-5, pursuant to which, the foreign currency financial statements of a foreign investee accounted for by the equity method should be translated to the reporting entity&#8217;s reporting currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The Company evaluates equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable. Factors considered by the Company when reviewing an equity method investment for impairment include the length of time (duration) and the extent (severity) to which the fair value of the equity method investment has been less than cost, the investee&#8217;s financial condition and near-term prospects and the intent and ability to hold the investment for a period of time sufficient to allow for anticipated recovery. An impairment that is other-than-temporary is recognized in the period identified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>See Note 6, &#8220;Equity Method Investment,&#8221; for further information.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk and Other Risks and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Substantially all of the Company&#8217;s cash and cash equivalents are deposited in accounts with two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company maintains its cash with an accredited financial institution and accordingly, such funds are subject to minimal credit risk. The Company&#8217;s marketable securities consist of investments in U.S. Treasury securities and U.S. government agency securities, which can be subject to certain credit risks. However, the Company mitigates the risks by investing in high-grade instruments, limiting its exposure to any one issuer, and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company is subject to a number of risks similar to other early stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, and protection of proprietary technology. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_SignificantAccountingPoliciesPolicyTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Significant Accounting Policies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There have been no material changes to the Company&#8217;s significant accounting policies during the three months ended March 31, 2026 from those discussed in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 12, 2026.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2023, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative, which modifies the disclosure or presentation requirements related to variety of FASB Accounting Standard Codification topics. The effective date for each amendment will be the date on which the SEC&#8217;s removal of that related disclosure from Regulation S-X or Regulation S-K is effective. If by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the associated amendment will be removed from the Codification and will not become effective for any entities. The Company is currently evaluating the effect of adopting this ASU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expense. This update requires entities to disaggregate operating expenses into specific categories, such as salaries and wages, depreciation, and amortization, to provide enhanced transparency into the nature and function of expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, with early adoption permitted. ASU 2024-03 may be applied retrospectively or prospectively. The Company is currently evaluating the impact of ASU 2024-03 on its financial statement presentation and disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_SignificantAccountingPoliciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of changes to significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_SignificantAccountingPoliciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_UnauditedInterimFinancialInformationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the presentation of interim (unaudited) financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_UnauditedInterimFinancialInformationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of net (loss) income per share, basic and diluted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The following table shows the calculation of net (loss) income per share (in thousands, except share and per share data):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:25.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:25.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Net loss attributable to common stockholders, basic</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (13,692)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,193</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Gain from change in fair value of warrant liability</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (25,129)</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Net loss - basic and diluted</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (13,692)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (9,936)</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Weighted average common shares and pre-funded warrants outstanding used to compute basic and diluted net (loss) income per share</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 89,996,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72,126,496</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Weighted average shares issuable upon the exercise of common warrants</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,026,018</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Weighted average common shares and prefunded warrants outstanding used to compute diluted net loss per share</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 89,996,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75,152,514</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net (loss) income per share, basic</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (0.15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.21</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net loss per share, diluted</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (0.15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (0.13)</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:73.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:73.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:73.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:73.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Outstanding options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,066,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,575,683</p></td><td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of segment net loss (income) by significant expense category</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The following table presents reportable segment net loss, including significant expense categories, attributable to the Company&#8217;s reportable segment for the three months ended March 31, 2026 and 2025 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Compensation and benefits, excluding stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,239</p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,650</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,251</p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Drug manufacturing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,830</p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Clinical trials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,927</p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Outside general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,244</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 946</p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Facilities and insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 558</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 780</p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other segment items (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,924</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 949</p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total segment expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,877</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,922</p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Non-operating income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (1,185)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (25,115)</p></td><td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,692</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (15,193)</p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><div style="margin-top:3pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Includes consulting, non-clinical research and laboratory supplies.</span></td></tr></table><div style="margin-top:3pt;"></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value of assets measured at fair value on a recurring basis, by level of fair value hierarchy</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The following tables present information as of March 31, 2026 and December 31, 2025 about the Company&#8217;s assets that are measured at fair value on a recurring basis and indicate the level of the fair value hierarchy the Company utilized to determine such fair values (in&#160;thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;width:43.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2026</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;width:32.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measured&#160;Using</b></p></td><td style="vertical-align:bottom;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,106</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,106</p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 196,612</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 196,612</p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,106</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 196,612</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 235,718</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:normal;width:43.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:normal;width:32.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measured&#160;Using</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,163</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,163</p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,174</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,174</p></td></tr><tr style=""><td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,163</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,174</p></td><td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56,337</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of fair value of available for sale marketable securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of March 31, 2026 and December 31, 2025, the fair value of available for sale marketable securities by type of security were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:38.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2026</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:59.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">U.S. Treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164,862</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (237)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164,678</p></td></tr><tr style=""><td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">U.S. Government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (88)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,934</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:59.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 196,883</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (325)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 196,612</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:36.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2025</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">U.S. Treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,622</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,675</p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">U.S. Government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,489</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,499</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,174</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of remaining maturity by type of security</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of March 31, 2026, all of the Company&#8217;s marketable securities are considered available for current operations and the remaining maturity by type of security is as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="color:#ee0000;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maturities&#160;by&#160;Period at Amortized Cost</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">than</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">1 Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">1-2 years</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">U.S. Treasury securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164,862</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 95,749</p></td><td style="vertical-align:bottom;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69,113</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">U.S. Government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,943</p></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,078</p></td></tr><tr style=""><td style="vertical-align:middle;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 196,883</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108,692</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88,191</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="color:#ee0000;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Schedule of financial information of Angel Pharmaceuticals Co.</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:67.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Balance Sheet Data</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2025</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr style=""><td style="vertical-align:bottom;width:67.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,286</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,033</p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 798</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 904</p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,049</p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 143</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 229</p></td></tr><tr style=""><td style="vertical-align:bottom;width:67.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stockholders' equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,659</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Statement&#160;of&#160;Operations&#160;Data</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (768)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (686)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Share of loss from investments accounted for using the equity method</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (599)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (539)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Components</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock', window );">Schedule of balance sheet components</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Prepaid and Other Current Assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Interest receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 337</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Prepaid research and development manufacturing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,564</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 599</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Prepaid facility expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 138</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 367</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 318</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,189</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,427</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Property and Equipment</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,713</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,646</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Computer equipment and purchased software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,959</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,869</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Less: accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (2,677)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (2,649)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 282</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 220</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Accrued and Other Liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued clinical trial expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,566</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued manufacturing expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,794</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,812</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Personnel related </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,381</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 641</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Accrued legal and accounting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 229</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 206</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,985</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,486</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOptionsIndexedToIssuersEquityTextBlock', window );">Schedule of common stock shares reserved for future issuance</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Pre-funded warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,275,913</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,275,913</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Shares available for future option grants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,649,034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,007,335</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Outstanding options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,066,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,028,177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Shares reserved for employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 400,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 400,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,391,273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,711,425</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOptionsIndexedToIssuersEquityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the freestanding option contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock. Includes disclosure on the strike price and the number of shares to which the contract is indexed, the settlement date or dates of the contract, and the issuer's accounting for the contract. If the terms of the contract provide settlement alternatives, those settlement alternatives are disclosed, including who controls the settlement alternatives, and the maximum number of shares that could be required to be issued, to net share settle the contract, if applicable. If a contract does not have a fixed or determinable maximum number of shares that could be required to be issued, the fact that a potentially infinite number of shares that may be required to be issued to settle the contract is disclosed. Disclosure also includes the contract's current fair value for each settlement alternative and how changes in the price of the issuer's equity instruments affect those settlement amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOptionsIndexedToIssuersEquityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Stock Option Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;Outstanding</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">&#8209;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Available</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">for&#160;Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Balance at December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,007,335</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,028,177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.20</p></td></tr><tr style=""><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Additional shares authorized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,987,865</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (7,500)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.63</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Options exercised </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (308,017)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.35</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Options forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 661,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (661,334)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.23</p></td></tr><tr style=""><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Balance at March&#160;31,&#160;2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,649,034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,066,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.76</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of expenses relating to employee and non-employee stock-based awards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company&#8217;s results of operations include expenses relating to employee and non-employee stock-based awards as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:74.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:21.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:21.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,077</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,573</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 723</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,650</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Facility Lease (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Facility Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of components of lease expense</a></td>
<td class="text">The elements of lease expense under the operating lease for the three months ended March 31, 2026 were as follows (in thousands):<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:20.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Statements of operations and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="5" style="vertical-align:bottom;width:20.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">comprehensive loss location</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Costs of operating lease</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Operating lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Research and development,<br/>General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 113</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Costs of non-lease components (previously common area maintenance)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Research and development,<br/>General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 291</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Other Information</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="color:#ff0000;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Operating cash flows used for operating lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 188</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1.9 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2.9 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">11.7%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">11.7%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Minimum rental commitments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31 (in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2026*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 358</p></td></tr><tr style=""><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 566</p></td></tr><tr style=""><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 924</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (90)</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 834</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">* Remainder of the year</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31 (in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 486</p></td></tr><tr style=""><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 566</p></td></tr><tr style=""><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,052</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (115)</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 937</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 23, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>May 06, 2024</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>May 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Public Offerings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 425,985<span></span>
</td>
<td class="nump">$ 412,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Public Offerings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,512,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Registered Direct Offering | Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Public Offerings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,078,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Registered Direct Offering | Common Stock and Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Public Offerings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,512,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_CombinedOfferingPriceForSharesAndWarrants', window );">Combined offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Registered Direct Offering | Common warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Public Offerings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,010,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_ClassOfWarrantOrRightExercisePricePerPrefundedWarrant', window );">Exercise price of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.4999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Registered Direct Offering | Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Public Offerings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,144,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,131,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Registered Direct Offering | Pre-funded and Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Public Offerings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Combined offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=crvs_FollowOnPublicOfferingMember', window );">Follow-on Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Public Offerings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common shares issued in transaction</a></td>
<td class="nump">9,085,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 189,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price of stock issued</a></td>
<td class="nump">$ 22.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Public Offerings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common shares issued in transaction</a></td>
<td class="nump">1,185,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ClassOfWarrantOrRightExercisePricePerPrefundedWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price expressed as price per unit of pre-funded warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ClassOfWarrantOrRightExercisePricePerPrefundedWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_CombinedOfferingPriceForSharesAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Combined price per unit of share and warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_CombinedOfferingPriceForSharesAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=crvs_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=crvs_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=crvs_CommonStockSharesAndCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=crvs_CommonStockSharesAndCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=crvs_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=crvs_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=crvs_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=crvs_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=crvs_PrefundedWarrantsAndCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=crvs_PrefundedWarrantsAndCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=crvs_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=crvs_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>Institution</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRiskUninsuredDeposits', window );">Concentration Risk, Credit Risk, Uninsured Deposits</a></td>
<td class="text">Substantially all of the Company&#8217;s cash and cash equivalents are deposited in accounts with two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company maintains its cash with an accredited financial institution and accordingly, such funds are subject to minimal credit risk. The Company&#8217;s marketable securities consist of investments in U.S. Treasury securities and U.S. government agency securities, which can be subject to certain credit risks. However, the Company mitigates the risks by investing in high-grade instruments, limiting its exposure to any one issuer, and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_NumberOfFinancialInstitutionsInWhichCashAndCashEquivalentsAreDeposited', window );">Number of financial institutions in which cash and cash equivalents are deposited</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_NumberOfFinancialInstitutionsInWhichCashAndCashEquivalentsAreDeposited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of financial institutions in which cash and cash equivalents are deposited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_NumberOfFinancialInstitutionsInWhichCashAndCashEquivalentsAreDeposited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRiskUninsuredDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of credit risk that arises from having significant balances in excess of the Federal Deposit Insurance Corporation or other insurance limits on deposits in financial institutions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRiskUninsuredDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Calculation of Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders, basic</a></td>
<td class="num">$ (13,692)<span></span>
</td>
<td class="nump">$ 15,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount', window );">Gain from change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,129)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders, diluted</a></td>
<td class="num">$ (13,692)<span></span>
</td>
<td class="num">$ (9,936)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares and pre-funded warrants outstanding used to compute basic net (loss) income per share</a></td>
<td class="nump">89,996,728<span></span>
</td>
<td class="nump">72,126,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Weighted average shares issuable upon the exercise of the common warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,026,018<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares and pre-funded warrants outstanding used to compute diluted net (loss) income per share</a></td>
<td class="nump">89,996,728<span></span>
</td>
<td class="nump">75,152,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) income per share, basic</a></td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="nump">$ 0.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-26<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in net income available to common shareholder for down round feature triggered for warrant classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-12B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Anti-Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Excluded from the calculation of diluted net loss per share, due to anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_CommonSharesIssuableUponConversionOfPreFundedWarrants', window );">Common shares issuable upon conversion of pre-funded warrants (included in calculation of basic and diluted EPS)</a></td>
<td class="nump">8,275,913<span></span>
</td>
<td class="nump">4,144,085<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Excluded from the calculation of diluted net loss per share, due to anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares of common stock equivalents</a></td>
<td class="nump">13,066,326<span></span>
</td>
<td class="nump">11,575,683<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_CommonSharesIssuableUponConversionOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common shares issuable upon conversion of pre-funded warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_CommonSharesIssuableUponConversionOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold', window );">Compensation and benefits, excluding stock-based compensation</a></td>
<td class="nump">$ 3,027<span></span>
</td>
<td class="nump">$ 2,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,650<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_SegmentDrugManufacturingCosts', window );">Drug manufacturing</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">1,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Clinical trial</a></td>
<td class="nump">5,043<span></span>
</td>
<td class="nump">1,927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Outside general and administrative</a></td>
<td class="nump">1,244<span></span>
</td>
<td class="nump">946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_FacilitiesAndInsurance', window );">Facilities and insurance</a></td>
<td class="nump">558<span></span>
</td>
<td class="nump">780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralExpense', window );">Other segment items</a></td>
<td class="nump">1,924<span></span>
</td>
<td class="nump">949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total segment expense</a></td>
<td class="nump">14,877<span></span>
</td>
<td class="nump">9,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Non-operating income, net</a></td>
<td class="num">(1,185)<span></span>
</td>
<td class="num">(25,115)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 13,692<span></span>
</td>
<td class="num">$ (15,193)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_FacilitiesAndInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense in the period incurred with respect to protection provided by facilities and insurance entities against risks other than risks associated with production (which are allocated to cost of sales).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_FacilitiesAndInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_SegmentDrugManufacturingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred for the operating segment in the production of goods for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_SegmentDrugManufacturingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Other employee benefit expense includes, but is not limited to, service component of net periodic benefit cost for defined benefit plan. Excludes compensation cost in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general expenses not normally included in Other Operating Costs and Expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Recurring (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">$ 196,612<span></span>
</td>
<td class="nump">$ 52,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">39,106<span></span>
</td>
<td class="nump">4,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">196,612<span></span>
</td>
<td class="nump">52,174<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">235,718<span></span>
</td>
<td class="nump">56,337<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1 Inputs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">39,106<span></span>
</td>
<td class="nump">4,163<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">39,106<span></span>
</td>
<td class="nump">4,163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2 Inputs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">196,612<span></span>
</td>
<td class="nump">52,174<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">$ 196,612<span></span>
</td>
<td class="nump">$ 52,174<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Available For Sale (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Fair value of available for sale marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">$ 196,883<span></span>
</td>
<td class="nump">$ 52,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">196,612<span></span>
</td>
<td class="nump">52,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Fair value of available for sale marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">164,862<span></span>
</td>
<td class="nump">38,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">164,678<span></span>
</td>
<td class="nump">38,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Fair value of available for sale marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">32,021<span></span>
</td>
<td class="nump">13,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">$ 31,934<span></span>
</td>
<td class="nump">$ 13,499<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Current Operations and The Remaining Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Current operations and the remaining maturity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">$ 196,883<span></span>
</td>
<td class="nump">$ 52,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Less than 1 Year</a></td>
<td class="nump">108,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo', window );">Less than 1-2 Year</a></td>
<td class="nump">88,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Current operations and the remaining maturity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">164,862<span></span>
</td>
<td class="nump">38,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Less than 1 Year</a></td>
<td class="nump">95,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo', window );">Less than 1-2 Year</a></td>
<td class="nump">69,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Current operations and the remaining maturity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">32,021<span></span>
</td>
<td class="nump">$ 13,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Less than 1 Year</a></td>
<td class="nump">12,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo', window );">Less than 1-2 Year</a></td>
<td class="nump">$ 19,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investment - Investment in Angel Pharmaceuticals (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Jan. 23, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="nump">$ 599<span></span>
</td>
<td class="nump">$ 539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember', window );">Angel Pharmaceuticals, Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_EmployeeStockOwnershipPlanEsopEquityReservePercentage', window );">Equity reserved under employee stock ownership plan</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember', window );">Angel Pharmaceuticals, Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity ownership interest</a></td>
<td class="nump">49.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.70%<span></span>
</td>
<td class="nump">49.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_EmployeeStockOwnershipPlanEsopEquityReservePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Percentage of employee stock ownership plan (ESOP), equity reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_EmployeeStockOwnershipPlanEsopEquityReservePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity Method Investment - Summary of Balance Sheet Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">$ 239,946<span></span>
</td>
<td class="nump">$ 58,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="nump">12,110<span></span>
</td>
<td class="nump">9,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="nump">240,679<span></span>
</td>
<td class="nump">61,205<span></span>
</td>
<td class="nump">$ 49,325<span></span>
</td>
<td class="nump">$ 32,568<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember', window );">Angel Pharmaceuticals, Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">10,286<span></span>
</td>
<td class="nump">11,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Non-current assets</a></td>
<td class="nump">798<span></span>
</td>
<td class="nump">904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="nump">863<span></span>
</td>
<td class="nump">1,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Non-current liabilities</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="nump">$ 10,078<span></span>
</td>
<td class="nump">$ 10,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investment - Summary of Income Statement Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (13,692)<span></span>
</td>
<td class="nump">$ 15,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of loss from investments accounted for using the equity method</a></td>
<td class="num">(599)<span></span>
</td>
<td class="num">(539)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember', window );">Angel Pharmaceuticals, Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (768)<span></span>
</td>
<td class="num">$ (686)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 05, 2015</div></th>
<th class="th"><div>Apr. 30, 2017</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>License and Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">R&amp;D expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,175,000<span></span>
</td>
<td class="nump">$ 7,453,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">Licensing Agreement | Scripps Research Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>License and Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">R&amp;D expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Annual licensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_LicenseAgreementMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_ResearchAndDevelopmentArrangementContractTerminationNoticePeriod', window );">Early termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">Licensing Agreement | Vernalis (R&amp;D) Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>License and Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">R&amp;D expense</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_LicenseAgreementMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_ResearchAndDevelopmentArrangementContractTerminationNoticePeriod', window );">Early termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">Licensing Agreement | Monash University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>License and Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">R&amp;D expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Annual licensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_LicenseAgreementMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_ResearchAndDevelopmentArrangementContractTerminationNoticePeriod', window );">Early termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">Licensing Agreement | Aggregate potential milestone payments | Scripps Research Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>License and Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_LicenseAgreementMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">Licensing Agreement | Aggregate potential milestone payments | Vernalis (R&amp;D) Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>License and Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_LicenseAgreementMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">Licensing Agreement | Aggregate potential milestone payments | Monash University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>License and Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_LicenseAgreementMilestonePayment', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_LicenseAgreementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount purchased during the period under the license agreement milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_LicenseAgreementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ResearchAndDevelopmentArrangementContractTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of the research and development arrangement contract termination notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ResearchAndDevelopmentArrangementContractTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=crvs_ScrippsResearchInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=crvs_ScrippsResearchInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=crvs_VernalisRAndDLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=crvs_VernalisRAndDLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=crvs_MonashLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=crvs_MonashLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=crvs_AggregatePotentialMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=crvs_AggregatePotentialMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Prepaids and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Components</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">$ 1,155<span></span>
</td>
<td class="nump">$ 337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid research and development manufacturing expenses</a></td>
<td class="nump">1,564<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid facility expenses</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">$ 3,189<span></span>
</td>
<td class="nump">$ 1,427<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2,959,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,869,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(2,677,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,649,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">282,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">29,000<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,713,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,646,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and purchased software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Accruals and Other Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Components</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_AccruedLiabilitiesClinicalTrialCurrent', window );">Accrued clinical trial expense</a></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="nump">$ 3,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_AccruedLiabilitiesManufacturingCurrent', window );">Accrued manufacturing expense</a></td>
<td class="nump">1,794<span></span>
</td>
<td class="nump">1,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Personnel related</a></td>
<td class="nump">1,381<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and accounting</a></td>
<td class="nump">304<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other liabilities</a></td>
<td class="nump">$ 6,985<span></span>
</td>
<td class="nump">$ 6,486<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_AccruedLiabilitiesClinicalTrialCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued liabilities clinical trial current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_AccruedLiabilitiesClinicalTrialCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_AccruedLiabilitiesManufacturingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued liabilities manufacturing current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_AccruedLiabilitiesManufacturingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>May 06, 2024</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>May 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=crvs_CommonWarrantsMember', window );">Common warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (25.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,512,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Registered Direct Offering | Common Stock and Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,512,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_CombinedOfferingPriceForSharesAndWarrants', window );">Combined offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Registered Direct Offering | Common warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,010,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_ClassOfWarrantOrRightExercisePricePerPrefundedWarrant', window );">Exercise price of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.4999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of common stock warrants</a></td>
<td class="nump">$ 54.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Registered Direct Offering | Pre-funded and Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Combined offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Registered Direct Offering | Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,144,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,131,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Additional Paid-in Capital adjustment from warrant issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,275,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ChangeInFairValueOfWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ChangeInFairValueOfWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_ClassOfWarrantOrRightExercisePricePerPrefundedWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price expressed as price per unit of pre-funded warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_ClassOfWarrantOrRightExercisePricePerPrefundedWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_CombinedOfferingPriceForSharesAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Combined price per unit of share and warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_CombinedOfferingPriceForSharesAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=crvs_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=crvs_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=crvs_CommonStockSharesAndCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=crvs_CommonStockSharesAndCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=crvs_PrefundedWarrantsAndCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=crvs_PrefundedWarrantsAndCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=crvs_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=crvs_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Stock Issuance Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 13, 2026</div></th>
<th class="th"><div>Jan. 20, 2026</div></th>
<th class="th"><div>Aug. 06, 2024</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,000,000<span></span>
</td>
<td class="nump">290,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Voting rights of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each share of common stock is entitled to one vote.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends on common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,407,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=crvs_AtMarketOfferingMember', window );">2024 Sales Agreement | Maximum | Scenario plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=crvs_AtMarketOfferingMember', window );">2024 Sales Agreement | Jefferies LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=crvs_AtMarketOfferingMember', window );">2024 Sales Agreement | Jefferies LLC | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvs_UnderwritingCommitmentsPercentage', window );">Sales agent fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=crvs_AtMarketOfferingMember', window );">2024 Sales Agreement | Jefferies LLC | Maximum | Scenario plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvs_UnderwritingCommitmentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of compensation due to broker for  underwriting commitments. Percent is calculated based on proceeds from securities sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvs_UnderwritingCommitmentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=crvs_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=crvs_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=crvs_JefferiesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=crvs_JefferiesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Common Shares Reserved for Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">28,391,273<span></span>
</td>
<td class="nump">25,711,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crvs_PreFundedWarrantEquityMember', window );">Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">8,275,913<span></span>
</td>
<td class="nump">8,275,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crvs_SharesAvailableForFutureOptionGrantsEquityMember', window );">Shares available for future option grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">6,649,034<span></span>
</td>
<td class="nump">3,007,335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crvs_OutstandingOptionsEquityMember', window );">Outstanding options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">13,066,326<span></span>
</td>
<td class="nump">14,028,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crvs_SharesReservedForEmployeeStockPurchasePlanEquityMember', window );">Shares reserved for employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crvs_PreFundedWarrantEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crvs_PreFundedWarrantEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crvs_SharesAvailableForFutureOptionGrantsEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crvs_SharesAvailableForFutureOptionGrantsEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crvs_OutstandingOptionsEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crvs_OutstandingOptionsEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crvs_SharesReservedForEmployeeStockPurchasePlanEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crvs_SharesReservedForEmployeeStockPurchasePlanEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plans - Stock Option Activity (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Feb. 28, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=crvs_EquityIncentiveAwardPlan2014Member', window );">2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Maximum exercise term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Exercise price of common stock grants, percentage of stock fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future option grants</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=crvs_EquityIncentiveAwardPlan2016Member', window );">2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Maximum exercise term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Exercise price of common stock grants, percentage of stock fair value</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=crvs_EquityIncentiveAwardPlan2016Member', window );">2016 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Forfeited or unexercised shares under expired stock plan subject to re-issuance under current stock plan</a></td>
<td class="nump">1,136,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=crvs_EquityIncentiveAwardPlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=crvs_EquityIncentiveAwardPlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=crvs_EquityIncentiveAwardPlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=crvs_EquityIncentiveAwardPlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plans - Stock Options Activity (Details) - Employee Stock Option - 2016 Plan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available for Grant, Opening Balance</a></td>
<td class="nump">3,007,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Shares Available for Grant, Additional Shares Authorized</a></td>
<td class="nump">2,987,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease', window );">Shares Available for Grant, Increase from Options Forfeited</a></td>
<td class="nump">661,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available for Grant, Ending Balance</a></td>
<td class="nump">6,649,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding Options, Opening Balance</a></td>
<td class="nump">14,028,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Outstanding Options, Granted</a></td>
<td class="nump">7,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Outstanding Options, Exercised</a></td>
<td class="num">(308,017)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Outstanding Options, Forfeited</a></td>
<td class="num">(661,334)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding Options, Ending Balance</a></td>
<td class="nump">13,066,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding Options, Weighted Average Exercise Price, Opening Balance | $ / shares</a></td>
<td class="nump">$ 5.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Outstanding Options, Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">14.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Outstanding Options, Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="nump">4.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Outstanding Options, Weighted Average Exercise Price, Forfeited | $ / shares</a></td>
<td class="nump">14.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding Options, Weighted Average Exercise Price, Ending Balance | $ / shares</a></td>
<td class="nump">$ 4.76<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other than shares newly issued, the number of additional shares issued (for example, a stock split) or canceled (for example, to correct a share issuance), during the period under the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=crvs_EquityIncentiveAwardPlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=crvs_EquityIncentiveAwardPlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Expense Allocation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,650<span></span>
</td>
<td class="nump">$ 1,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,077<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,573<span></span>
</td>
<td class="nump">$ 723<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Earning Before Income Taxes and Income Taxes Benefits (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Facility Lease - Lessee Information (Details)<br></strong></div></th>
<th class="th"><div>Feb. 21, 2025</div></th>
<th class="th">
<div>Oct. 22, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid Rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">751,000<span></span>
</td>
<td class="nump">839,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=crvs_OfficeAndLabSpaceLeaseMember', window );">Office and lab space lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased facility | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Option to Extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">27 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals', window );">Sublease initial base monthly rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid Rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 231,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate', window );">Option to terminate</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=crvs_OfficeAndLabSpaceLeaseMember', window );">Office and lab space lease | Third year of sublease | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals', window );">Sublease initial base monthly rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to terminate operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481418/840-10-55-40<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481501/840-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481155/840-10-25-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseMinimumRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=crvs_OfficeAndLabSpaceLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=crvs_OfficeAndLabSpaceLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=crvs_ThirdYearOfSubleaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=crvs_ThirdYearOfSubleaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Facility Lease - Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Costs of operating lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">$ 291<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Other Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows used for operating lease</a></td>
<td class="nump">$ 188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Remaining lease term</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Discount rate</a></td>
<td class="nump">11.70%<span></span>
</td>
<td class="nump">11.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development | Office and lab space lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Costs of operating lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Costs of non-lease components (previously common area maintenance)</a></td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=crvs_OfficeAndLabSpaceLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=crvs_OfficeAndLabSpaceLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Facility Lease - Minimum Rental Commitments San Francisco Lease (Details) - Office and lab space lease - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Minimum Rental Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 358<span></span>
</td>
<td class="nump">$ 486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">566<span></span>
</td>
<td class="nump">566<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">924<span></span>
</td>
<td class="nump">1,052<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(90)<span></span>
</td>
<td class="num">(115)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 834<span></span>
</td>
<td class="nump">$ 937<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=crvs_OfficeAndLabSpaceLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=crvs_OfficeAndLabSpaceLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 23, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,175,000<span></span>
</td>
<td class="nump">$ 7,453,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Support clinical trials | ICON plc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,000<span></span>
</td>
<td class="nump">$ 94,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember', window );">Angel Pharmaceuticals, Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity ownership interest</a></td>
<td class="nump">49.70%<span></span>
</td>
<td class="nump">49.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=crvs_FollowOnPublicOfferingMember', window );">Follow-on Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common shares issued in transaction</a></td>
<td class="nump">9,085,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price of stock issued</a></td>
<td class="nump">$ 22.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=crvs_FollowOnPublicOfferingMember', window );">Follow-on Public Offering | Related party | Puissance Capital Management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common shares issued in transaction</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price of stock issued</a></td>
<td class="nump">$ 22.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=crvs_ServicesSupportClinicalTrialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=crvs_ServicesSupportClinicalTrialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=crvs_IconPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=crvs_IconPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=crvs_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=crvs_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=crvs_PuissanceCapitalManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=crvs_PuissanceCapitalManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>132</ContextCount>
  <ElementCount>239</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995200090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995210101 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureOrganization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995210201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995210301 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995210401 - Disclosure - Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureSegments</Role>
      <ShortName>Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995210501 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995210601 - Disclosure - Equity Method Investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureEquityMethodInvestment</Role>
      <ShortName>Equity Method Investment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995210701 - Disclosure - License and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreements</Role>
      <ShortName>License and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995210801 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995210901 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureWarrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995211001 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995211101 - Disclosure - Stock Option Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureStockOptionPlans</Role>
      <ShortName>Stock Option Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995211201 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995211301 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995211401 - Disclosure - Facility Lease</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureFacilityLease</Role>
      <ShortName>Facility Lease</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995211501 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995211601 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>99930303 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>99930403 - Disclosure - Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureSegmentsTables</Role>
      <ShortName>Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureSegments</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>99930503 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>99930603 - Disclosure - Equity Method Investment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentTables</Role>
      <ShortName>Equity Method Investment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureEquityMethodInvestment</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>99930803 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureBalanceSheetComponents</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>99931003 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureCommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureCommonStock</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>99931103 - Disclosure - Stock Option Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureStockOptionPlansTables</Role>
      <ShortName>Stock Option Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureStockOptionPlans</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>99931203 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>99931403 - Disclosure - Facility Lease (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureFacilityLeaseTables</Role>
      <ShortName>Facility Lease (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureFacilityLease</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>99940101 - Disclosure - Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureOrganizationDetails</Role>
      <ShortName>Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureOrganization</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>99940201 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>99940301 - Disclosure - Net Loss per Share - Calculation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureNetLossPerShareCalculationOfEarningsPerShareDetails</Role>
      <ShortName>Net Loss per Share - Calculation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>99940302 - Disclosure - Net Loss per Share - Anti-Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss per Share - Anti-Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>99940401 - Disclosure - Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureSegmentsDetails</Role>
      <ShortName>Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureSegmentsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>99940501 - Disclosure - Fair Value Measurements - Recurring (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails</Role>
      <ShortName>Fair Value Measurements - Recurring (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>99940502 - Disclosure - Fair Value Measurements - Available For Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsAvailableForSaleDetails</Role>
      <ShortName>Fair Value Measurements - Available For Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>99940503 - Disclosure - Fair Value Measurements - Current Operations and The Remaining Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsCurrentOperationsAndRemainingMaturityDetails</Role>
      <ShortName>Fair Value Measurements - Current Operations and The Remaining Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>99940601 - Disclosure - Equity Method Investment - Investment in Angel Pharmaceuticals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentInvestmentInAngelPharmaceuticalsDetails</Role>
      <ShortName>Equity Method Investment - Investment in Angel Pharmaceuticals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>99940602 - Disclosure - Equity Method Investment - Summary of Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfBalanceSheetInformationDetails</Role>
      <ShortName>Equity Method Investment - Summary of Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>99940603 - Disclosure - Equity Method Investment - Summary of Income Statement Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfIncomeStatementInformationDetails</Role>
      <ShortName>Equity Method Investment - Summary of Income Statement Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>99940701 - Disclosure - License and Collaboration Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails</Role>
      <ShortName>License and Collaboration Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreements</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>99940801 - Disclosure - Balance Sheet Components - Prepaids and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPrepaidsAndOtherCurrentAssetsDetails</Role>
      <ShortName>Balance Sheet Components - Prepaids and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>99940802 - Disclosure - Balance Sheet Components - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails</Role>
      <ShortName>Balance Sheet Components - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>99940803 - Disclosure - Balance Sheet Components - Accruals and Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsAccrualsAndOtherLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Accruals and Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>99940901 - Disclosure - Warrants - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails</Role>
      <ShortName>Warrants - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>99941001 - Disclosure - Common Stock - Stock Issuance Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails</Role>
      <ShortName>Common Stock - Stock Issuance Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>99941002 - Disclosure - Common Stock - Common Shares Reserved for Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureCommonStockCommonSharesReservedForIssuanceDetails</Role>
      <ShortName>Common Stock - Common Shares Reserved for Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>99941101 - Disclosure - Stock Option Plans - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionActivityDetails</Role>
      <ShortName>Stock Option Plans - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>99941102 - Disclosure - Stock Option Plans - Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionsActivityDetails</Role>
      <ShortName>Stock Option Plans - Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>99941201 - Disclosure - Stock-Based Compensation - Expense Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureStockBasedCompensationExpenseAllocationDetails</Role>
      <ShortName>Stock-Based Compensation - Expense Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>99941301 - Disclosure - Income Taxes - Components of Earning Before Income Taxes and Income Taxes Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureIncomeTaxesComponentsOfEarningBeforeIncomeTaxesAndIncomeTaxesBenefitsDetails</Role>
      <ShortName>Income Taxes - Components of Earning Before Income Taxes and Income Taxes Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>99941401 - Disclosure - Facility Lease - Lessee Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails</Role>
      <ShortName>Facility Lease - Lessee Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>99941402 - Disclosure - Facility Lease - Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails</Role>
      <ShortName>Facility Lease - Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>99941403 - Disclosure - Facility Lease - Minimum Rental Commitments San Francisco Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails</Role>
      <ShortName>Facility Lease - Minimum Rental Commitments San Francisco Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="crvs-20260331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>99941601 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>crvs-20260331.xsd</File>
    <File>crvs-20260331_cal.xml</File>
    <File>crvs-20260331_def.xml</File>
    <File>crvs-20260331_lab.xml</File>
    <File>crvs-20260331_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="crvs-20260331x10q.htm">crvs-20260331x10q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>crvs-20260331x10q007.jpg</File>
    <File>crvs-20260331x10q008.jpg</File>
    <File>crvs-20260331x10q009.jpg</File>
    <File>crvs-20260331x10q010.jpg</File>
    <File>crvs-20260331x10q011.jpg</File>
    <File>crvs-20260331x10q012.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2025</BaseTaxonomy>
    <BaseTaxonomy items="471">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>83
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "crvs-20260331x10q.htm": {
   "nsprefix": "crvs",
   "nsuri": "http://www.corvuspharma.com/20260331",
   "dts": {
    "schema": {
     "local": [
      "crvs-20260331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "crvs-20260331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "crvs-20260331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "crvs-20260331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "crvs-20260331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "crvs-20260331x10q.htm"
     ]
    }
   },
   "keyStandard": 217,
   "keyCustom": 22,
   "axisStandard": 21,
   "axisCustom": 0,
   "memberStandard": 22,
   "memberCustom": 24,
   "hidden": {
    "total": 16,
    "http://xbrl.sec.gov/dei/2025": 5,
    "http://fasb.org/us-gaap/2025": 11
   },
   "contextCount": 132,
   "entityCount": 1,
   "segmentCount": 49,
   "elementCount": 503,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 471,
    "http://xbrl.sec.gov/dei/2025": 29,
    "http://xbrl.sec.gov/ecd/2025": 4,
    "http://fasb.org/srt/2025": 1
   },
   "report": {
    "R1": {
     "role": "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation",
     "longName": "995200090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
     "longName": "995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity",
     "longName": "995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QYcmyFRwzk617SCak5HhVg",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QYcmyFRwzk617SCak5HhVg",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "longName": "995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.corvuspharma.com/role/DisclosureOrganization",
     "longName": "995210101 - Disclosure - Organization",
     "shortName": "Organization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995210201 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.corvuspharma.com/role/DisclosureNetLossPerShare",
     "longName": "995210301 - Disclosure - Net Loss per Share",
     "shortName": "Net Loss per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.corvuspharma.com/role/DisclosureSegments",
     "longName": "995210401 - Disclosure - Segments",
     "shortName": "Segments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.corvuspharma.com/role/DisclosureFairValueMeasurements",
     "longName": "995210501 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestment",
     "longName": "995210601 - Disclosure - Equity Method Investment",
     "shortName": "Equity Method Investment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreements",
     "longName": "995210701 - Disclosure - License and Collaboration Agreements",
     "shortName": "License and Collaboration Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponents",
     "longName": "995210801 - Disclosure - Balance Sheet Components",
     "shortName": "Balance Sheet Components",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.corvuspharma.com/role/DisclosureWarrants",
     "longName": "995210901 - Disclosure - Warrants",
     "shortName": "Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "crvs:WarrantsAndRightsNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "crvs:WarrantsAndRightsNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.corvuspharma.com/role/DisclosureCommonStock",
     "longName": "995211001 - Disclosure - Common Stock",
     "shortName": "Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "crvs:CommonStockNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "crvs:CommonStockNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.corvuspharma.com/role/DisclosureStockOptionPlans",
     "longName": "995211101 - Disclosure - Stock Option Plans",
     "shortName": "Stock Option Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "crvs:EquityIncentivePlansDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "crvs:EquityIncentivePlansDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.corvuspharma.com/role/DisclosureStockBasedCompensation",
     "longName": "995211201 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.corvuspharma.com/role/DisclosureIncomeTaxes",
     "longName": "995211301 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.corvuspharma.com/role/DisclosureFacilityLease",
     "longName": "995211401 - Disclosure - Facility Lease",
     "shortName": "Facility Lease",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "995211501 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactions",
     "longName": "995211601 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R24": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.corvuspharma.com/role/DisclosureNetLossPerShareTables",
     "longName": "99930303 - Disclosure - Net Loss per Share (Tables)",
     "shortName": "Net Loss per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.corvuspharma.com/role/DisclosureSegmentsTables",
     "longName": "99930403 - Disclosure - Segments (Tables)",
     "shortName": "Segments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsTables",
     "longName": "99930503 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentTables",
     "longName": "99930603 - Disclosure - Equity Method Investment (Tables)",
     "shortName": "Equity Method Investment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsTables",
     "longName": "99930803 - Disclosure - Balance Sheet Components (Tables)",
     "shortName": "Balance Sheet Components (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.corvuspharma.com/role/DisclosureCommonStockTables",
     "longName": "99931003 - Disclosure - Common Stock (Tables)",
     "shortName": "Common Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:ScheduleOfOptionsIndexedToIssuersEquityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "crvs:CommonStockNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:ScheduleOfOptionsIndexedToIssuersEquityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "crvs:CommonStockNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.corvuspharma.com/role/DisclosureStockOptionPlansTables",
     "longName": "99931103 - Disclosure - Stock Option Plans (Tables)",
     "shortName": "Stock Option Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.corvuspharma.com/role/DisclosureStockBasedCompensationTables",
     "longName": "99931203 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.corvuspharma.com/role/DisclosureFacilityLeaseTables",
     "longName": "99931403 - Disclosure - Facility Lease (Tables)",
     "shortName": "Facility Lease (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.corvuspharma.com/role/DisclosureOrganizationDetails",
     "longName": "99940101 - Disclosure - Organization (Details)",
     "shortName": "Organization (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
     "longName": "99940201 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:ConcentrationRiskCreditRiskUninsuredDeposits",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:ConcentrationRiskCreditRiskUninsuredDeposits",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.corvuspharma.com/role/DisclosureNetLossPerShareCalculationOfEarningsPerShareDetails",
     "longName": "99940301 - Disclosure - Net Loss per Share - Calculation of Earnings Per Share (Details)",
     "shortName": "Net Loss per Share - Calculation of Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.corvuspharma.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails",
     "longName": "99940302 - Disclosure - Net Loss per Share - Anti-Dilutive Securities (Details)",
     "shortName": "Net Loss per Share - Anti-Dilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A",
      "name": "crvs:CommonSharesIssuableUponConversionOfPreFundedWarrants",
      "unitRef": "Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A",
      "name": "crvs:CommonSharesIssuableUponConversionOfPreFundedWarrants",
      "unitRef": "Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.corvuspharma.com/role/DisclosureSegmentsDetails",
     "longName": "99940401 - Disclosure - Segments (Details)",
     "shortName": "Segments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails",
     "longName": "99940501 - Disclosure - Fair Value Measurements - Recurring (Details)",
     "shortName": "Fair Value Measurements - Recurring (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2026_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-i89-0JYT0SuUe9mQLTeMA",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsAvailableForSaleDetails",
     "longName": "99940502 - Disclosure - Fair Value Measurements - Available For Sale (Details)",
     "shortName": "Fair Value Measurements - Available For Sale (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsCurrentOperationsAndRemainingMaturityDetails",
     "longName": "99940503 - Disclosure - Fair Value Measurements - Current Operations and The Remaining Maturity (Details)",
     "shortName": "Fair Value Measurements - Current Operations and The Remaining Maturity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentInvestmentInAngelPharmaceuticalsDetails",
     "longName": "99940601 - Disclosure - Equity Method Investment - Investment in Angel Pharmaceuticals (Details)",
     "shortName": "Equity Method Investment - Investment in Angel Pharmaceuticals (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_dei_LegalEntityAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_IAkd47amHkiAxCCDntS06Q",
      "name": "crvs:EmployeeStockOwnershipPlanEsopEquityReservePercentage",
      "unitRef": "Unit_Standard_pure_zwdjuLpe8Um-MXpoYRfl8Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfBalanceSheetInformationDetails",
     "longName": "99940602 - Disclosure - Equity Method Investment - Summary of Balance Sheet Information (Details)",
     "shortName": "Equity Method Investment - Summary of Balance Sheet Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2026_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_wsU59n8Qhk6UFUREvLUcmQ",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfIncomeStatementInformationDetails",
     "longName": "99940603 - Disclosure - Equity Method Investment - Summary of Income Statement Information (Details)",
     "shortName": "Equity Method Investment - Summary of Income Statement Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_dSaQSn0xTEGxv32ul8LDRw",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails",
     "longName": "99940701 - Disclosure - License and Collaboration Agreements (Details)",
     "shortName": "License and Collaboration Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2015_To_12_31_2015_srt_CounterpartyNameAxis_crvs_ScrippsResearchInstituteMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_XMrt33ULGkeQ_-gbvlHdKA",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPrepaidsAndOtherCurrentAssetsDetails",
     "longName": "99940801 - Disclosure - Balance Sheet Components - Prepaids and Other Current Assets (Details)",
     "shortName": "Balance Sheet Components - Prepaids and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A",
      "name": "us-gaap:InterestReceivable",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A",
      "name": "us-gaap:InterestReceivable",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails",
     "longName": "99940802 - Disclosure - Balance Sheet Components - Property and Equipment (Details)",
     "shortName": "Balance Sheet Components - Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsAccrualsAndOtherLiabilitiesDetails",
     "longName": "99940803 - Disclosure - Balance Sheet Components - Accruals and Other Liabilities (Details)",
     "shortName": "Balance Sheet Components - Accruals and Other Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A",
      "name": "crvs:AccruedLiabilitiesClinicalTrialCurrent",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A",
      "name": "crvs:AccruedLiabilitiesClinicalTrialCurrent",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails",
     "longName": "99940901 - Disclosure - Warrants - Narrative (Details)",
     "shortName": "Warrants - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_MLeYeQx8wE2unDRlLMuIDQ",
      "name": "crvs:ChangeInFairValueOfWarrantLiabilities",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_MLeYeQx8wE2unDRlLMuIDQ",
      "name": "crvs:ChangeInFairValueOfWarrantLiabilities",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails",
     "longName": "99941001 - Disclosure - Common Stock - Stock Issuance Agreement (Details)",
     "shortName": "Common Stock - Stock Issuance Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "crvs:CommonStockNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.corvuspharma.com/role/DisclosureCommonStockCommonSharesReservedForIssuanceDetails",
     "longName": "99941002 - Disclosure - Common Stock - Common Shares Reserved for Issuance (Details)",
     "shortName": "Common Stock - Common Shares Reserved for Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOptionsIndexedToIssuersEquityTextBlock",
       "crvs:CommonStockNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOptionsIndexedToIssuersEquityTextBlock",
       "crvs:CommonStockNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionActivityDetails",
     "longName": "99941101 - Disclosure - Stock Option Plans - Stock Option Activity (Details)",
     "shortName": "Stock Option Plans - Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "Duration_2_1_2014_To_2_28_2014_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2014Member_ZPEqkJZSKkC77f8CpQy3Og",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "crvs:EquityIncentivePlansDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_2_1_2014_To_2_28_2014_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2014Member_ZPEqkJZSKkC77f8CpQy3Og",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "crvs:EquityIncentivePlansDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionsActivityDetails",
     "longName": "99941102 - Disclosure - Stock Option Plans - Stock Options Activity (Details)",
     "shortName": "Stock Option Plans - Stock Options Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_2sdE3FrdcUCS_x2faPApVA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_2sdE3FrdcUCS_x2faPApVA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.corvuspharma.com/role/DisclosureStockBasedCompensationExpenseAllocationDetails",
     "longName": "99941201 - Disclosure - Stock-Based Compensation - Expense Allocation (Details)",
     "shortName": "Stock-Based Compensation - Expense Allocation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.corvuspharma.com/role/DisclosureIncomeTaxesComponentsOfEarningBeforeIncomeTaxesAndIncomeTaxesBenefitsDetails",
     "longName": "99941301 - Disclosure - Income Taxes - Components of Earning Before Income Taxes and Income Taxes Benefits (Details)",
     "shortName": "Income Taxes - Components of Earning Before Income Taxes and Income Taxes Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails",
     "longName": "99941401 - Disclosure - Facility Lease - Lessee Information (Details)",
     "shortName": "Facility Lease - Lessee Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A",
      "name": "us-gaap:PrepaidRent",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_10_22_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_KO4XiJ0y0Eewc683WEweWg",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "unitRef": "Unit_Standard_sqft_HxXZ8IO5D0SV81ta1te2Pw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails",
     "longName": "99941402 - Disclosure - Facility Lease - Lease Cost (Details)",
     "shortName": "Facility Lease - Lease Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:LeaseCost",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:LeaseCost",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.corvuspharma.com/role/DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails",
     "longName": "99941403 - Disclosure - Facility Lease - Minimum Rental Commitments San Francisco Lease (Details)",
     "shortName": "Facility Lease - Minimum Rental Commitments San Francisco Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_v9GABhLy30GLtxZhg92PdA",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_v9GABhLy30GLtxZhg92PdA",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "longName": "99941601 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_IconPlcMember_us-gaap_RelatedPartyTransactionAxis_crvs_ServicesSupportClinicalTrialsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_87RrLXQb50614pVDRnXCIw",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvs-20260331x10q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r737"
     ]
    },
    "us-gaap_AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current, Related Party [Extensible Enumeration]",
        "documentation": "Indicates status and type of related party for accounts receivable, after allowance for credit loss, classified as current."
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Accretion related to marketable securities",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "crvs_AccruedLiabilitiesClinicalTrialCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "AccruedLiabilitiesClinicalTrialCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsAccrualsAndOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsAccrualsAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued liabilities clinical trial current.",
        "label": "Accrued Liabilities Clinical Trial Current",
        "terseLabel": "Accrued clinical trial expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsAccrualsAndOtherLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsAccrualsAndOtherLiabilitiesDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued and other liabilities",
        "totalLabel": "Accrued and other liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "crvs_AccruedLiabilitiesManufacturingCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "AccruedLiabilitiesManufacturingCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsAccrualsAndOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsAccrualsAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued liabilities manufacturing current.",
        "label": "Accrued Liabilities Manufacturing Current",
        "terseLabel": "Accrued manufacturing expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsAccrualsAndOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsAccrualsAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued legal and accounting",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r114",
      "r548"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r52",
      "r120",
      "r544",
      "r568",
      "r569",
      "r965"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "verboseLabel": "Accumulated Other Comprehensive Loss",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r9",
      "r16",
      "r412",
      "r415",
      "r478",
      "r564",
      "r565",
      "r881",
      "r882",
      "r883",
      "r895",
      "r896",
      "r897",
      "r898"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r737",
      "r996"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r583",
      "r895",
      "r896",
      "r897",
      "r898",
      "r966",
      "r999"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital adjustment from warrant issuance",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r26",
      "r70"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "crvs_AggregatePotentialMilestonePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "AggregatePotentialMilestonePaymentsMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The member represent the Aggregate Potential Milestone Payments.",
        "label": "Aggregate Potential Milestone Payments [Member]",
        "terseLabel": "Aggregate potential milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r773",
      "r783",
      "r793",
      "r825"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r776",
      "r786",
      "r796",
      "r828"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r787",
      "r797",
      "r821",
      "r829",
      "r833",
      "r841"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockBasedCompensationExpenseAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r368",
      "r369"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "AngelPharmaceuticalsLtdEquityMethodInvesteeMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentInvestmentInAngelPharmaceuticalsDetails",
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfBalanceSheetInformationDetails",
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfIncomeStatementInformationDetails",
      "http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Angel Pharmaceuticals, Ltd., an equity method investee of Corvus Pharmaceuticals.",
        "label": "Angel Pharmaceuticals LTD Equity Method Investee [Member]",
        "terseLabel": "Angel Pharmaceuticals, Ltd"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Total shares of common stock equivalents",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Excluded from the calculation of diluted net loss per share, due to anti-dilutive effect",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of leased facility",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r79",
      "r116",
      "r142",
      "r143",
      "r144",
      "r191",
      "r204",
      "r212",
      "r215",
      "r260",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r400",
      "r404",
      "r451",
      "r532",
      "r533",
      "r539",
      "r618",
      "r695",
      "r696",
      "r706",
      "r737",
      "r752",
      "r753",
      "r764",
      "r921",
      "r922",
      "r983"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfBalanceSheetInformationDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "verboseLabel": "Current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r122",
      "r142",
      "r143",
      "r144",
      "r260",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r400",
      "r404",
      "r451",
      "r737",
      "r921",
      "r922",
      "r983"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total Assets",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r427",
      "r725"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent",
        "terseLabel": "Non-current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r260",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r400",
      "r404",
      "r451",
      "r921",
      "r922",
      "r983"
     ]
    },
    "crvs_AtMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "AtMarketOfferingMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock through an at-the-market equity offering program under a sales agreement.",
        "label": "At-the-market offering",
        "terseLabel": "2024 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "terseLabel": "Gross Unrealized Losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsCurrentOperationsAndRemainingMaturityDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsCurrentOperationsAndRemainingMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Less than 1 Year",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsAvailableForSaleDetails",
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Marketable securities",
        "verboseLabel": "Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r269"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]",
        "terseLabel": "Fair value of available for sale marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionsActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Components"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails",
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails",
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r112",
      "r673"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r446",
      "r447",
      "r968",
      "r969"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureOrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents and marketable securities",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of the period",
        "periodStartLabel": "Cash and cash equivalents at beginning of the period",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r62",
      "r141"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r62"
     ]
    },
    "crvs_ChangeInFairValueOfWarrantLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "ChangeInFairValueOfWarrantLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Change in fair value of warrant liabilities",
        "terseLabel": "Change in fair value of warrant liability"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockCommonSharesReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r117",
      "r118",
      "r119",
      "r142",
      "r144",
      "r173",
      "r177",
      "r184",
      "r186",
      "r193",
      "r194",
      "r260",
      "r283",
      "r285",
      "r286",
      "r287",
      "r290",
      "r291",
      "r297",
      "r298",
      "r300",
      "r301",
      "r303",
      "r306",
      "r308",
      "r309",
      "r311",
      "r312",
      "r314",
      "r451",
      "r573",
      "r574",
      "r575",
      "r576",
      "r583",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r606",
      "r626",
      "r648",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r851",
      "r891",
      "r892",
      "r899"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockCommonSharesReservedForIssuanceDetails",
      "http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Common Stock",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r193",
      "r300",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r410",
      "r573",
      "r574",
      "r575",
      "r576",
      "r707",
      "r851",
      "r889",
      "r891"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureOrganizationDetails",
      "http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureOrganizationDetails",
      "http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureOrganizationDetails",
      "http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r146",
      "r315"
     ]
    },
    "crvs_ClassOfWarrantOrRightExercisePricePerPrefundedWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "ClassOfWarrantOrRightExercisePricePerPrefundedWarrant",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureOrganizationDetails",
      "http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price expressed as price per unit of pre-funded warrants outstanding.",
        "label": "Class of Warrant or Right, Exercise Price Per Prefunded Warrant",
        "terseLabel": "Exercise price of pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Warrants",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of warrants exercised",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureOrganizationDetails",
      "http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Common Warrants Exercised",
        "terseLabel": "Warrants issued to purchase common shares",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License and Collaboration Agreements",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r397",
      "r398"
     ]
    },
    "crvs_CombinedOfferingPriceForSharesAndWarrants": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "CombinedOfferingPriceForSharesAndWarrants",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureOrganizationDetails",
      "http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Combined price per unit of share and warrants issued.",
        "label": "Combined Offering Price For Shares And Warrants",
        "terseLabel": "Combined offering price per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 15)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r74",
      "r541",
      "r605"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r277",
      "r278",
      "r668",
      "r918",
      "r920"
     ]
    },
    "crvs_CommonSharesIssuableUponConversionOfPreFundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "CommonSharesIssuableUponConversionOfPreFundedWarrants",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common shares issuable upon conversion of pre-funded warrants",
        "label": "Common shares issuable upon conversion of pre-funded warrants",
        "terseLabel": "Common shares issuable upon conversion of pre-funded warrants (included in calculation of basic and diluted EPS)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockCommonSharesReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r755",
      "r756",
      "r758",
      "r759",
      "r760",
      "r761",
      "r895",
      "r896",
      "r898",
      "r966",
      "r995",
      "r999"
     ]
    },
    "crvs_CommonStockNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "CommonStockNoteDisclosureTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for common stock.",
        "label": "Common Stock Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureOrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "verboseLabel": "Public Offerings"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "crvs_CommonStockSharesAndCommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "CommonStockSharesAndCommonStockWarrantsMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureOrganizationDetails",
      "http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The transaction group, which details the sale of common stock equity and the accompanying warrants to purchase common stock in connection with the company's Registered Direct Offering.",
        "label": "Common Stock Shares and Common Stock Warrants [Member]",
        "terseLabel": "Common Stock and Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r606"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r46",
      "r606",
      "r624",
      "r999",
      "r1000"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock: $0.0001 par value; 290,000,000 shares authorized at March 31, 2026 and December 31, 2025; 84,090,424 and 74,696,629 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r298",
      "r305",
      "r543",
      "r737"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Voting rights of common stock",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "crvs_CommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "CommonStockWarrantsMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureOrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to common stock warrants.",
        "label": "Common Stock Warrants [Member]",
        "terseLabel": "Common stock warrants"
       }
      }
     },
     "auth_ref": []
    },
    "crvs_CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "CommonWarrantsMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureOrganizationDetails",
      "http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to common warrants.",
        "label": "Common Warrants [member]",
        "terseLabel": "Common warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationExpenseExcludingCostOfGoodAndServiceSold",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureSegmentsDetails": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Expense, Excluding Cost of Good and Service Sold",
        "terseLabel": "Compensation and benefits, excluding stock-based compensation",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Other employee benefit expense includes, but is not limited to, service component of net periodic benefit cost for defined benefit plan. Excludes compensation cost in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r884"
     ]
    },
    "us-gaap_CompensationRelatedCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationRelatedCostsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive (loss) income",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r127",
      "r129",
      "r133",
      "r530",
      "r555",
      "r556"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment and purchased software",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Other Risks and Uncertainties",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r449"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRiskUninsuredDeposits": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRiskUninsuredDeposits",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Uninsured Deposits",
        "documentation": "Description of credit risk that arises from having significant balances in excess of the Federal Deposit Insurance Corporation or other insurance limits on deposits in financial institutions."
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails",
      "http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails",
      "http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r142",
      "r149",
      "r150",
      "r292",
      "r310",
      "r485",
      "r503",
      "r538",
      "r676",
      "r677",
      "r678",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r961",
      "r962",
      "r963",
      "r964"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsCurrentOperationsAndRemainingMaturityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsAvailableForSaleDetails",
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsCurrentOperationsAndRemainingMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r909"
     ]
    },
    "crvs_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsCurrentOperationsAndRemainingMaturityDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsCurrentOperationsAndRemainingMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Two",
        "terseLabel": "Less than 1-2 Year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsAvailableForSaleDetails",
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsCurrentOperationsAndRemainingMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation expense",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r24"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r136",
      "r191",
      "r205",
      "r215",
      "r679",
      "r695",
      "r696"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r335",
      "r364",
      "r365",
      "r366",
      "r714"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends, Common Stock",
        "terseLabel": "Dividends on common stock",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r70"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureNetLossPerShareCalculationOfEarningsPerShareDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net (loss) income per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r134",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r169",
      "r173",
      "r184",
      "r185",
      "r186",
      "r190",
      "r296",
      "r367",
      "r393",
      "r396",
      "r423",
      "r424",
      "r531",
      "r557",
      "r686"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureNetLossPerShareCalculationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Net Loss Per Share, Basic and Diluted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureNetLossPerShareCalculationOfEarningsPerShareDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r134",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r173",
      "r184",
      "r185",
      "r186",
      "r190",
      "r296",
      "r367",
      "r393",
      "r396",
      "r423",
      "r424",
      "r531",
      "r557",
      "r686"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r187",
      "r188",
      "r189"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsAccrualsAndOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsAccrualsAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Personnel related",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockBasedCompensationExpenseAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Stock-based compensation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails",
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionsActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950"
     ]
    },
    "crvs_EmployeeStockOwnershipPlanEsopEquityReservePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "EmployeeStockOwnershipPlanEsopEquityReservePercentage",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentInvestmentInAngelPharmaceuticalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Percentage of employee stock ownership plan (ESOP), equity reserve.",
        "label": "Employee Stock Ownership Plan (ESOP), Equity Reserve, Percentage",
        "terseLabel": "Equity reserved under employee stock ownership plan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentInvestmentInAngelPharmaceuticalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Entities [Member]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r104",
      "r105",
      "r106",
      "r130",
      "r131",
      "r132",
      "r151",
      "r152",
      "r153",
      "r155",
      "r162",
      "r164",
      "r166",
      "r192",
      "r262",
      "r263",
      "r273",
      "r295",
      "r316",
      "r367",
      "r382",
      "r383",
      "r390",
      "r391",
      "r392",
      "r394",
      "r395",
      "r396",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r463",
      "r478",
      "r553",
      "r564",
      "r565",
      "r566",
      "r583",
      "r648"
     ]
    },
    "crvs_EquityIncentiveAwardPlan2014Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "EquityIncentiveAwardPlan2014Member",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entity's 2014 plan under which it may grant stock-based awards.",
        "label": "2014 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "crvs_EquityIncentiveAwardPlan2016Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "EquityIncentiveAwardPlan2016Member",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionActivityDetails",
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entity's 2016 Equity Incentive Award Plan under which it may grant stock-based awards.",
        "label": "2016 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "crvs_EquityIncentivePlansDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "EquityIncentivePlansDisclosureTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity incentive plans",
        "label": "Equity Incentive Plans Disclosure [Text Block]",
        "terseLabel": "Stock Option Plans"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentInvestmentInAngelPharmaceuticalsDetails",
      "http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "documentation": "Name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r259",
      "r389",
      "r451",
      "r853",
      "r854",
      "r855",
      "r955",
      "r956",
      "r957",
      "r958"
     ]
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfBalanceSheetInformationDetails",
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfIncomeStatementInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r142",
      "r144",
      "r260",
      "r451",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750"
     ]
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfBalanceSheetInformationDetails",
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfIncomeStatementInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r142",
      "r144",
      "r260",
      "r451",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750"
     ]
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfBalanceSheetInformationDetails",
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfIncomeStatementInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]",
        "terseLabel": "Equity method investee",
        "documentation": "Nonconsolidated equity method investee or group of nonconsolidated investees. Excludes information consolidated by reporting entity."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r889",
      "r893",
      "r916",
      "r978"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentInvestmentInAngelPharmaceuticalsDetails",
      "http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Ownership Percentage",
        "verboseLabel": "Equity ownership interest",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r451"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments",
        "terseLabel": "Investment in Angel Pharmaceuticals",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r208",
      "r215",
      "r254",
      "r868",
      "r915"
     ]
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Equity Method Investment",
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r258",
      "r261",
      "r855"
     ]
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsPolicy",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Investments in Equity Securities",
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r257",
      "r451"
     ]
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments [Table Text Block]",
        "terseLabel": "Schedule of financial information of Angel Pharmaceuticals Co.",
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r773",
      "r783",
      "r793",
      "r825"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r770",
      "r780",
      "r790",
      "r822"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "crvs_FacilitiesAndInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "FacilitiesAndInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureSegmentsDetails": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expense in the period incurred with respect to protection provided by facilities and insurance entities against risks other than risks associated with production (which are allocated to cost of sales).",
        "label": "Facilities And Insurance",
        "terseLabel": "Facilities and insurance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Adjustment of Warrants",
        "negatedLabel": "Change in fair value of warrant liability",
        "terseLabel": "Change in fair value of warrant liability",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "verboseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r427",
      "r437",
      "r725"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r427",
      "r437",
      "r725"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of fair value of assets measured at fair value on a recurring basis, by level of fair value hierarchy",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r968",
      "r969"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r326",
      "r425",
      "r427",
      "r428",
      "r429",
      "r430",
      "r436",
      "r437",
      "r439",
      "r445",
      "r490",
      "r491",
      "r492",
      "r672",
      "r704",
      "r705",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r725",
      "r728",
      "r735"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r427",
      "r428",
      "r430",
      "r725",
      "r971",
      "r974"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r432",
      "r434",
      "r435",
      "r436",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r529",
      "r725",
      "r729"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 Inputs",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r318",
      "r323",
      "r325",
      "r427",
      "r437",
      "r445",
      "r490",
      "r672",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r725",
      "r735"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 Inputs",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r318",
      "r323",
      "r325",
      "r327",
      "r427",
      "r428",
      "r437",
      "r445",
      "r491",
      "r672",
      "r704",
      "r705",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r725",
      "r735"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r427",
      "r428",
      "r430",
      "r725",
      "r971",
      "r974"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r326",
      "r425",
      "r427",
      "r428",
      "r429",
      "r430",
      "r436",
      "r437",
      "r439",
      "r445",
      "r490",
      "r491",
      "r492",
      "r672",
      "r704",
      "r705",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r725",
      "r728",
      "r735"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsRecurringDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r725",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r974"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsAvailableForSaleDetails",
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsCurrentOperationsAndRemainingMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r272",
      "r294",
      "r313",
      "r410",
      "r421",
      "r444",
      "r450",
      "r453",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r537",
      "r554",
      "r701",
      "r725",
      "r726",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r738",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r911",
      "r912",
      "r913",
      "r914",
      "r967",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976"
     ]
    },
    "crvs_FollowOnPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "FollowOnPublicOfferingMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureOrganizationDetails",
      "http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secondary offering of stock to the public.",
        "label": "Follow-on Public Offering",
        "terseLabel": "Follow-on Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r787",
      "r797",
      "r829"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r787",
      "r797",
      "r829"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r787",
      "r797",
      "r829"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r787",
      "r797",
      "r829"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r787",
      "r797",
      "r829"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r628"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockBasedCompensationExpenseAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "crvs_IconPlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "IconPlcMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to ICON plc.",
        "label": "Icon Plc [Member]",
        "terseLabel": "ICON plc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before equity method investment",
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r558",
      "r691",
      "r752",
      "r753",
      "r901",
      "r903",
      "r904",
      "r905",
      "r906"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentInvestmentInAngelPharmaceuticalsDetails",
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfIncomeStatementInformationDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Loss from equity method investment",
        "terseLabel": "Share of loss from investments accounted for using the equity method",
        "verboseLabel": "Loss from equity method investment",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r53",
      "r76",
      "r191",
      "r206",
      "r215",
      "r254",
      "r550"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails",
      "http://www.corvuspharma.com/role/DisclosureStockBasedCompensationExpenseAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r406",
      "r407",
      "r408",
      "r409",
      "r431",
      "r433",
      "r438",
      "r452",
      "r453",
      "r454",
      "r561",
      "r563",
      "r633",
      "r671",
      "r672",
      "r717",
      "r718",
      "r723",
      "r724",
      "r727",
      "r735",
      "r959",
      "r960",
      "r994"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails",
      "http://www.corvuspharma.com/role/DisclosureStockBasedCompensationExpenseAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276",
      "r406",
      "r407",
      "r408",
      "r409",
      "r431",
      "r433",
      "r438",
      "r452",
      "r453",
      "r454",
      "r561",
      "r563",
      "r633",
      "r671",
      "r672",
      "r717",
      "r718",
      "r723",
      "r724",
      "r727",
      "r735",
      "r959",
      "r960",
      "r994"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r145",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r384",
      "r386",
      "r387",
      "r388",
      "r536",
      "r571",
      "r578",
      "r716"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureIncomeTaxesComponentsOfEarningBeforeIncomeTaxesAndIncomeTaxesBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax benefits",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r87",
      "r142",
      "r165",
      "r166",
      "r191",
      "r207",
      "r215",
      "r375",
      "r376",
      "r385",
      "r559",
      "r680",
      "r682",
      "r683",
      "r716"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued and other liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r857",
      "r886"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Current Assets",
        "negatedLabel": "Other assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Operating lease right-of-use asset",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureNetLossPerShareCalculationOfEarningsPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureNetLossPerShareCalculationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants",
        "terseLabel": "Weighted average shares issuable upon the exercise of the common warrants",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r186"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r787",
      "r797",
      "r821",
      "r829",
      "r833",
      "r841"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r845"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r845"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r845"
     ]
    },
    "us-gaap_InterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPrepaidsAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPrepaidsAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Receivable",
        "terseLabel": "Interest receivable",
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable."
       }
      }
     },
     "auth_ref": [
      "r869",
      "r1001"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Net",
        "terseLabel": "Interest income and other expense, net",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r60"
     ]
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of remaining maturity by type of security",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "crvs_JefferiesLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "JefferiesLlcMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jefferies LLC [Member]",
        "label": "Jefferies LLC",
        "terseLabel": "Jefferies LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Total operating lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r736"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Costs of operating lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of components of lease expense",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r476"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Facility Lease"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentInvestmentInAngelPharmaceuticalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeDisclosureAbstract",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]",
        "terseLabel": "Lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails",
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails",
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Facility Lease",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r477"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails",
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails",
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r477"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescriptionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseDescriptionAbstract",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Description [Abstract]",
        "verboseLabel": "Other Information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Option to Extend",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToTerminate",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Existence of Option to Terminate [true false]",
        "terseLabel": "Option to terminate",
        "documentation": "Indicates (true false) whether lessee has option to terminate operating lease."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Minimum rental commitments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r890",
      "r894",
      "r992"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r890",
      "r894",
      "r992"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r890",
      "r894",
      "r992"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease extension period",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLease"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Facility Lease",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r142",
      "r143",
      "r144",
      "r260",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r401",
      "r404",
      "r405",
      "r451",
      "r604",
      "r690",
      "r706",
      "r764",
      "r921",
      "r983",
      "r984"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r75",
      "r546",
      "r737",
      "r752",
      "r753",
      "r889",
      "r893",
      "r916",
      "r978"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfBalanceSheetInformationDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "terseLabel": "Current liabilities",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r111",
      "r142",
      "r143",
      "r144",
      "r260",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r401",
      "r404",
      "r405",
      "r451",
      "r737",
      "r921",
      "r983",
      "r984"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent",
        "terseLabel": "Non-current liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r41",
      "r42",
      "r43",
      "r44",
      "r142",
      "r143",
      "r144",
      "r260",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r401",
      "r404",
      "r405",
      "r451",
      "r921",
      "r983",
      "r984"
     ]
    },
    "crvs_LicenseAgreementMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "LicenseAgreementMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount purchased during the period under the license agreement milestone payment.",
        "label": "License Agreement Milestone Payment",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LicenseAgreementTermsMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement Terms [Member]",
        "terseLabel": "Licensing Agreement",
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails",
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails",
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r102",
      "r103",
      "r199",
      "r279",
      "r280",
      "r281",
      "r282",
      "r329",
      "r359",
      "r360",
      "r361",
      "r370",
      "r430",
      "r519",
      "r560",
      "r562",
      "r570",
      "r596",
      "r597",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r664",
      "r665",
      "r666",
      "r667",
      "r669",
      "r670",
      "r700",
      "r707",
      "r713",
      "r717",
      "r719",
      "r720",
      "r728",
      "r729",
      "r733",
      "r734",
      "r751",
      "r923",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "crvs_MonashLicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "MonashLicenseMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Monash License.",
        "label": "Monash University"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureOrganization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Organization",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r196",
      "r687",
      "r688"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r64"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.corvuspharma.com/role/DisclosureSegmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfIncomeStatementInformationDetails",
      "http://www.corvuspharma.com/role/DisclosureSegmentsDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net loss",
        "totalLabel": "Net (loss) income",
        "verboseLabel": "Net income (loss)",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r64",
      "r77",
      "r106",
      "r109",
      "r126",
      "r128",
      "r132",
      "r142",
      "r143",
      "r144",
      "r148",
      "r154",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r165",
      "r166",
      "r182",
      "r260",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r296",
      "r299",
      "r302",
      "r307",
      "r367",
      "r393",
      "r396",
      "r424",
      "r451",
      "r552",
      "r625",
      "r646",
      "r647",
      "r680",
      "r682",
      "r683",
      "r762",
      "r921"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureNetLossPerShareCalculationOfEarningsPerShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureNetLossPerShareCalculationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to common stockholders, basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r135",
      "r158",
      "r159",
      "r160",
      "r161",
      "r169",
      "r170",
      "r183",
      "r186",
      "r299",
      "r302",
      "r307",
      "r396"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureNetLossPerShareCalculationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureNetLossPerShareCalculationOfEarningsPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureNetLossPerShareCalculationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net loss attributable to common stockholders, diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r172",
      "r178",
      "r179",
      "r180",
      "r181",
      "r183",
      "r186"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r787",
      "r797",
      "r821",
      "r829"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "crvs_NonRule10b51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "NonRule10b51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Non Rule 10b5-1 Arr Modified [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Modified"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureSegmentsDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "negatedLabel": "Non-operating income, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "crvs_NumberOfFinancialInstitutionsInWhichCashAndCashEquivalentsAreDeposited": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "NumberOfFinancialInstitutionsInWhichCashAndCashEquivalentsAreDeposited",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of financial institutions in which cash and cash equivalents are deposited.",
        "label": "Number Of Financial Institutions In Which Cash and Cash Equivalents Are Deposited",
        "terseLabel": "Number of financial institutions in which cash and cash equivalents are deposited"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r696",
      "r902"
     ]
    },
    "crvs_OfferingCostsAccruedAndChargedToAdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "OfferingCostsAccruedAndChargedToAdditionalPaidInCapital",
     "crdr": "debit",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents equity issuance costs that have been recognized as a reduction to additional paid-in capital but have not yet been paid in cash as of the reporting period. These amounts are accrued as liabilities and disclosed as non-cash financing activities in the statement of cash flows.",
        "label": "Offering Costs Accrued and Charged to Additional Paid-in Capital",
        "terseLabel": "Offering costs recorded to additional paid-in-capital but not paid"
       }
      }
     },
     "auth_ref": []
    },
    "crvs_OfficeAndLabSpaceLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "OfficeAndLabSpaceLeaseMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails",
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails",
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information related to office and lab space lease.",
        "label": "Office And Lab Space Lease [Member]",
        "terseLabel": "Office and lab space lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.corvuspharma.com/role/DisclosureSegmentsDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureSegmentsDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "terseLabel": "Total segment expense",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r680",
      "r683",
      "r691",
      "r901",
      "r903",
      "r904",
      "r905",
      "r906"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "verboseLabel": "Operating lease costs",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r736"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]",
        "verboseLabel": "Minimum Rental Commitments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "terseLabel": "Total",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows used for operating lease",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r472"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r736"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r736"
     ]
    },
    "us-gaap_OperatingLeasesRentExpenseMinimumRentals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasesRentExpenseMinimumRentals",
     "crdr": "debit",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Rent Expense, Minimum Rentals",
        "terseLabel": "Sublease initial base monthly rent expense",
        "documentation": "This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r82"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization"
       }
      }
     },
     "auth_ref": []
    },
    "crvs_OrganizationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "OrganizationLineItems",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureOrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization [Line Items]",
        "terseLabel": "Organization"
       }
      }
     },
     "auth_ref": []
    },
    "crvs_OrganizationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "OrganizationTable",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureOrganizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Presentation of information about the organization and basis of presentation.",
        "label": "Organization [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsAccrualsAndOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsAccrualsAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPrepaidsAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPrepaidsAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "terseLabel": "Other",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r737"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax",
        "verboseLabel": "Unrealized loss on marketable securities",
        "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized loss on marketable securities",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r553"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Cumulative foreign currency translation adjustment",
        "verboseLabel": "Foreign currency translation adjustment",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r553"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "verboseLabel": "Other comprehensive (loss) income:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureSegmentsDetails": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other General and Administrative Expense",
        "terseLabel": "Outside general and administrative",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r998"
     ]
    },
    "us-gaap_OtherGeneralExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherGeneralExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureSegmentsDetails": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other General Expense",
        "terseLabel": "Other segment items",
        "documentation": "Amount of general expenses not normally included in Other Operating Costs and Expenses."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r695"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPrepaidsAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPrepaidsAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Prepaid research and development manufacturing expenses",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r870",
      "r917"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureSegmentsDetails": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Research and Development Expense",
        "terseLabel": "Clinical trial",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r775",
      "r785",
      "r795",
      "r827"
     ]
    },
    "crvs_OutstandingOptionsEquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "OutstandingOptionsEquityMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockCommonSharesReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Outstanding Options Equity [Member]",
        "terseLabel": "Outstanding options"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r788",
      "r798",
      "r830"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r788",
      "r798",
      "r830"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureOrganizationDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of marketable securities",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r137",
      "r222"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionActivityDetails",
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionActivityDetails",
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "crvs_PreFundedWarrantEquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "PreFundedWarrantEquityMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockCommonSharesReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to share prices.",
        "label": "Pre-funded Warrant Equity [Member]",
        "terseLabel": "Pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r308"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r606"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r308"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r606",
      "r624",
      "r999",
      "r1000"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock: $0.0001 par value; 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; 0 shares issued and outstanding at each of March 31, 2026 and December 31, 2025",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r298",
      "r304",
      "r542",
      "r737"
     ]
    },
    "crvs_PrefundedWarrantsAndCommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "PrefundedWarrantsAndCommonStockWarrantsMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureOrganizationDetails",
      "http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The transaction group, which details the sale of pre-funded warrants, and common warrants, to purchase common stock in connection with the company's Registered Direct Offering.",
        "label": "Prefunded Warrants and Common Stock Warrants [Member]",
        "terseLabel": "Pre-funded and Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "crvs_PrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "PrefundedWarrantsMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureOrganizationDetails",
      "http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to pre-funded warrants.",
        "label": "Prefunded Warrants [member]",
        "terseLabel": "Pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPrepaidsAndOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPrepaidsAndOtherCurrentAssetsDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other current assets",
        "totalLabel": "Prepaid and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPrepaidsAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPrepaidsAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r674",
      "r702",
      "r917"
     ]
    },
    "us-gaap_PrepaidRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidRent",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPrepaidsAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPrepaidsAndOtherCurrentAssetsDetails",
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Rent",
        "terseLabel": "Prepaid facility expenses",
        "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r675",
      "r703",
      "r917"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureOrganizationDetails",
      "http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Registered Direct Offering",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails",
      "http://www.corvuspharma.com/role/DisclosureOrganizationDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock in connection with follow-on public offering, net",
        "verboseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Maturities of marketable securities",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r908"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of common stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureOrganizationDetails",
      "http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from the exercise of common stock warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r109",
      "r126",
      "r128",
      "r139",
      "r142",
      "r143",
      "r144",
      "r148",
      "r154",
      "r162",
      "r165",
      "r166",
      "r260",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r296",
      "r367",
      "r393",
      "r396",
      "r399",
      "r402",
      "r403",
      "r424",
      "r451",
      "r532",
      "r534",
      "r551",
      "r582",
      "r625",
      "r646",
      "r647",
      "r721",
      "r722",
      "r763",
      "r883",
      "r921"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails",
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails",
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails",
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r476"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r113",
      "r549"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and Equipment",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r476",
      "r535",
      "r549",
      "r737"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails",
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails",
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails",
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseMinimumRentalCommitmentsSanFranciscoLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r476"
     ]
    },
    "crvs_PuissanceCapitalManagementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "PuissanceCapitalManagementMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Puissance Capital Management.",
        "label": "Puissance Capital Management [Member]",
        "terseLabel": "Puissance Capital Management"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails",
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails",
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r102",
      "r103",
      "r199",
      "r279",
      "r280",
      "r281",
      "r282",
      "r317",
      "r329",
      "r359",
      "r360",
      "r361",
      "r366",
      "r370",
      "r430",
      "r493",
      "r502",
      "r519",
      "r560",
      "r562",
      "r570",
      "r596",
      "r597",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r664",
      "r665",
      "r666",
      "r667",
      "r669",
      "r670",
      "r700",
      "r707",
      "r713",
      "r717",
      "r719",
      "r720",
      "r728",
      "r729",
      "r733",
      "r734",
      "r751",
      "r756",
      "r919",
      "r923",
      "r971",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails",
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails",
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r102",
      "r103",
      "r199",
      "r279",
      "r280",
      "r281",
      "r282",
      "r317",
      "r329",
      "r359",
      "r360",
      "r361",
      "r366",
      "r370",
      "r430",
      "r493",
      "r502",
      "r519",
      "r560",
      "r562",
      "r570",
      "r596",
      "r597",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r664",
      "r665",
      "r666",
      "r667",
      "r669",
      "r670",
      "r700",
      "r707",
      "r713",
      "r717",
      "r719",
      "r720",
      "r728",
      "r729",
      "r733",
      "r734",
      "r751",
      "r756",
      "r919",
      "r923",
      "r971",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r770",
      "r780",
      "r790",
      "r822"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r147",
      "r148",
      "r221",
      "r324",
      "r328",
      "r482",
      "r483",
      "r540",
      "r547",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r623",
      "r653",
      "r997"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "terseLabel": "Related party",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r147",
      "r148",
      "r482",
      "r483",
      "r484",
      "r485",
      "r540",
      "r547",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r623",
      "r653"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r147",
      "r148",
      "r482",
      "r483",
      "r982"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r147",
      "r148",
      "r982"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r147",
      "r148",
      "r221",
      "r482",
      "r483",
      "r485",
      "r629",
      "r630",
      "r633"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r147",
      "r148",
      "r221",
      "r324",
      "r328",
      "r482",
      "r483",
      "r540",
      "r547",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r623",
      "r653",
      "r982",
      "r997"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r480",
      "r481",
      "r483",
      "r486",
      "r579",
      "r580",
      "r581",
      "r631",
      "r632",
      "r633",
      "r651",
      "r652"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails",
      "http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails",
      "http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r142",
      "r149",
      "r150",
      "r292",
      "r310",
      "r485",
      "r503",
      "r538",
      "r676",
      "r677",
      "r678",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r961",
      "r962",
      "r963",
      "r964"
     ]
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "License and Collaboration Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "crvs_ResearchAndDevelopmentArrangementContractTerminationNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "ResearchAndDevelopmentArrangementContractTerminationNoticePeriod",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of the research and development arrangement contract termination notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Research And Development Arrangement Contract Termination Notice Period",
        "terseLabel": "Early termination notice period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r954"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
     "crdr": "debit",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross",
        "terseLabel": "Annual licensing fee",
        "documentation": "The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "License and Collaboration Agreements",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r954"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r954"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails",
      "http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "R&amp;D expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r671",
      "r680",
      "r681",
      "r695",
      "r991"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails",
      "http://www.corvuspharma.com/role/DisclosureStockBasedCompensationExpenseAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r771",
      "r781",
      "r791",
      "r823"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r782",
      "r792",
      "r824"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r779",
      "r789",
      "r799",
      "r831"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureOrganizationDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r70",
      "r545",
      "r567",
      "r569",
      "r577",
      "r607",
      "r737"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r151",
      "r152",
      "r153",
      "r155",
      "r162",
      "r164",
      "r166",
      "r262",
      "r263",
      "r273",
      "r295",
      "r367",
      "r382",
      "r383",
      "r390",
      "r391",
      "r392",
      "r394",
      "r395",
      "r396",
      "r411",
      "r413",
      "r414",
      "r416",
      "r422",
      "r461",
      "r463",
      "r564",
      "r566",
      "r583",
      "r999"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "crvs_Rule10b51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "Rule10b51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Rule 10b5-1 Arr Modified Flag",
        "terseLabel": "Rule 10b5-1 Arrangement Modified"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails",
      "http://www.corvuspharma.com/role/DisclosureOrganizationDetails",
      "http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureOrganizationDetails",
      "http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Share price of stock issued",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScenarioPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScenarioPlanMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario, Plan [Member]",
        "terseLabel": "Scenario plan",
        "documentation": "The scenario under which facts represent plans as distinct from actual."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails",
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails",
      "http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r107",
      "r108",
      "r167",
      "r330",
      "r852"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of antidilutive securities excluded from calculation of diluted net loss per share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsAvailableForSaleDetails",
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsCurrentOperationsAndRemainingMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Available for sale marketable securities",
        "verboseLabel": "Current operations and the remaining maturity",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of fair value of available for sale marketable securities",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Balance Sheet [Table Text Block]",
        "terseLabel": "Schedule of balance sheet components",
        "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r865",
      "r890",
      "r894",
      "r992"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of net (loss) income per share, basic and diluted",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockBasedCompensationExpenseAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of expenses relating to employee and non-employee stock-based awards",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentInvestmentInAngelPharmaceuticalsDetails",
      "http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r259",
      "r389",
      "r451",
      "r853",
      "r854",
      "r855",
      "r955",
      "r956",
      "r957",
      "r958"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentInvestmentInAngelPharmaceuticalsDetails",
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfBalanceSheetInformationDetails",
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfIncomeStatementInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Equity Method Investment",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r144",
      "r256",
      "r257",
      "r259",
      "r260",
      "r451"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentInvestmentInAngelPharmaceuticalsDetails",
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfBalanceSheetInformationDetails",
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfIncomeStatementInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment [Table]",
        "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r142",
      "r144",
      "r256",
      "r257",
      "r259",
      "r260",
      "r451"
     ]
    },
    "us-gaap_ScheduleOfOptionsIndexedToIssuersEquityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfOptionsIndexedToIssuersEquityTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Options Indexed to Issuer's Equity [Table Text Block]",
        "terseLabel": "Schedule of common stock shares reserved for future issuance",
        "documentation": "Tabular disclosure of the freestanding option contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock. Includes disclosure on the strike price and the number of shares to which the contract is indexed, the settlement date or dates of the contract, and the issuer's accounting for the contract. If the terms of the contract provide settlement alternatives, those settlement alternatives are disclosed, including who controls the settlement alternatives, and the maximum number of shares that could be required to be issued, to net share settle the contract, if applicable. If a contract does not have a fixed or determinable maximum number of shares that could be required to be issued, the fact that a potentially infinite number of shares that may be required to be issued to settle the contract is disclosed. Disclosure also includes the contract's current fair value for each settlement alternative and how changes in the price of the issuer's equity instruments affect those settlement amounts."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r72"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r476"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r147",
      "r148",
      "r482",
      "r483",
      "r485",
      "r629",
      "r630",
      "r633"
     ]
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development, Contract to Perform for Others [Table]",
        "documentation": "Disclosure of information about research and development arrangement accounted for as contract to perform research and development for others. Includes, but is not limited to, royalty arrangement, purchase provision, license agreement, and commitment to provide additional funding."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r954"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureSegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of segment net loss (income) by significant expense category",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionActivityDetails",
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r334",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r366"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r71"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockCommonSharesReservedForIssuanceDetails",
      "http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r68",
      "r69",
      "r70",
      "r117",
      "r118",
      "r119",
      "r193",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r410",
      "r573",
      "r574",
      "r575",
      "r576",
      "r707",
      "r851",
      "r889",
      "r891"
     ]
    },
    "crvs_ScrippsResearchInstituteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "ScrippsResearchInstituteMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the Scripps Research Institute.",
        "label": "Scripps Research Institute"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "crvs_SegmentDrugManufacturingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "SegmentDrugManufacturingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureSegmentsDetails": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred for the operating segment in the production of goods for sale.",
        "label": "Segment drug manufacturing costs",
        "terseLabel": "Drug manufacturing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureSegments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segments",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r191",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r692",
      "r693",
      "r694",
      "r695",
      "r697",
      "r698",
      "r699"
     ]
    },
    "crvs_ServicesSupportClinicalTrialsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "ServicesSupportClinicalTrialsMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to services to support clinical trials.",
        "label": "Services Support Clinical Trials [Member]",
        "terseLabel": "Support clinical trials"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.corvuspharma.com/role/DisclosureSegmentsDetails": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureSegmentsDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionActivityDetails",
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Stock Option Plans",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r334",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionActivityDetails",
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Shares Available for Grant, Additional Shares Authorized",
        "verboseLabel": "Forfeited or unexercised shares under expired stock plan subject to re-issuance under current stock plan",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionActivityDetails",
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Shares Available for Grant, Ending Balance",
        "periodStartLabel": "Shares Available for Grant, Opening Balance",
        "terseLabel": "Shares available for future option grants",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Outstanding Options, Forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Outstanding Options, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding Options, Ending Balance",
        "periodStartLabel": "Outstanding Options, Opening Balance",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding Options, Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Outstanding Options, Weighted Average Exercise Price, Opening Balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Other Share Increase (Decrease)",
        "verboseLabel": "Shares Available for Grant, Increase from Options Forfeited",
        "documentation": "Other than shares newly issued, the number of additional shares issued (for example, a stock split) or canceled (for example, to correct a share issuance), during the period under the plan."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionsActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Outstanding Options, Weighted Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Outstanding Options, Weighted Average Exercise Price, Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Outstanding Options, Weighted Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Maximum exercise term",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Exercise price of common stock grants, percentage of stock fair value",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "crvs_SharesAvailableForFutureOptionGrantsEquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "SharesAvailableForFutureOptionGrantsEquityMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockCommonSharesReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Shares Available for Future Option Grants Equity [Member]",
        "terseLabel": "Shares available for future option grants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureOrganizationDetails",
      "http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "verboseLabel": "Combined offering price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "crvs_SharesReservedForEmployeeStockPurchasePlanEquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "SharesReservedForEmployeeStockPurchasePlanEquityMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockCommonSharesReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Shares Reserved for Employee Stock Purchase Plan Equity [Member]",
        "terseLabel": "Shares reserved for employee stock purchase plan"
       }
      }
     },
     "auth_ref": []
    },
    "crvs_SignificantAccountingPoliciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "SignificantAccountingPoliciesPolicyTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of changes to significant accounting policies.",
        "label": "Significant Accounting Policies [Policy Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockCommonSharesReservedForIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r117",
      "r118",
      "r119",
      "r142",
      "r144",
      "r173",
      "r177",
      "r184",
      "r186",
      "r193",
      "r194",
      "r260",
      "r283",
      "r285",
      "r286",
      "r287",
      "r290",
      "r291",
      "r297",
      "r298",
      "r300",
      "r301",
      "r303",
      "r306",
      "r308",
      "r309",
      "r311",
      "r312",
      "r314",
      "r451",
      "r573",
      "r574",
      "r575",
      "r576",
      "r583",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r606",
      "r626",
      "r648",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r851",
      "r891",
      "r892",
      "r899"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r46",
      "r49",
      "r50",
      "r104",
      "r105",
      "r106",
      "r130",
      "r131",
      "r132",
      "r151",
      "r152",
      "r153",
      "r155",
      "r162",
      "r164",
      "r166",
      "r192",
      "r262",
      "r263",
      "r273",
      "r295",
      "r316",
      "r367",
      "r382",
      "r383",
      "r390",
      "r391",
      "r392",
      "r394",
      "r395",
      "r396",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r422",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r463",
      "r478",
      "r553",
      "r564",
      "r565",
      "r566",
      "r583",
      "r648"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r192",
      "r297",
      "r298",
      "r300",
      "r303",
      "r463",
      "r520",
      "r572",
      "r584",
      "r595",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r606",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r627",
      "r628",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r648",
      "r682",
      "r683",
      "r757",
      "r997"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails",
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails",
      "http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r107",
      "r108",
      "r167",
      "r330",
      "r852",
      "r856"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r192",
      "r221",
      "r297",
      "r298",
      "r300",
      "r303",
      "r463",
      "r520",
      "r572",
      "r584",
      "r595",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r606",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r627",
      "r628",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r648",
      "r682",
      "r683",
      "r757",
      "r997"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r774",
      "r784",
      "r794",
      "r826"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails",
      "http://www.corvuspharma.com/role/DisclosureOrganizationDetails",
      "http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Common shares issued in transaction",
        "verboseLabel": "Common stock issued (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r45",
      "r46",
      "r70",
      "r573",
      "r648",
      "r660"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureStockOptionPlansStockOptionsActivityDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Outstanding Options, Exercised",
        "verboseLabel": "Common stock issued upon exercise of stock options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r45",
      "r46",
      "r70",
      "r344"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails",
      "http://www.corvuspharma.com/role/DisclosureOrganizationDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Gross proceeds from sale of stock",
        "verboseLabel": "Common stock issued",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r45",
      "r46",
      "r70",
      "r583",
      "r648",
      "r660",
      "r763"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Common stock issued upon exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r46",
      "r49",
      "r50",
      "r70"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureEquityMethodInvestmentSummaryOfBalanceSheetInformationDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity",
        "verboseLabel": "Stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r49",
      "r50",
      "r65",
      "r608",
      "r624",
      "r649",
      "r650",
      "r737",
      "r764",
      "r889",
      "r892",
      "r893",
      "r916",
      "r978",
      "r999"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails",
      "http://www.corvuspharma.com/role/DisclosureOrganizationDetails",
      "http://www.corvuspharma.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.corvuspharma.com/role/DisclosureWarrantsNarrativeDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureBalanceSheetComponents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "crvs_ThirdYearOfSubleaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "ThirdYearOfSubleaseMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLesseeInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information related to third year of sublease",
        "label": "Third Year of Sublease [Member]",
        "terseLabel": "Third year of sublease"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.corvuspharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsAvailableForSaleDetails",
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsCurrentOperationsAndRemainingMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r294",
      "r313",
      "r410",
      "r421",
      "r444",
      "r450",
      "r453",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r537",
      "r554",
      "r725",
      "r726",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r738",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r911",
      "r912",
      "r913",
      "r914",
      "r967",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsAvailableForSaleDetails",
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsCurrentOperationsAndRemainingMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "US Government Agencies Securities",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r684",
      "r685",
      "r708",
      "r710",
      "r993"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsAvailableForSaleDetails",
      "http://www.corvuspharma.com/role/DisclosureFairValueMeasurementsCurrentOperationsAndRemainingMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "terseLabel": "US Treasury Securities",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r684",
      "r685",
      "r708",
      "r710",
      "r712",
      "r725",
      "r993"
     ]
    },
    "crvs_UnauditedInterimFinancialInformationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "UnauditedInterimFinancialInformationPolicyTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the presentation of interim (unaudited) financial statements.",
        "label": "Unaudited Interim Financial Information [Policy Text Block]",
        "terseLabel": "Unaudited Interim Financial Information"
       }
      }
     },
     "auth_ref": []
    },
    "crvs_UnderwritingCommitmentsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "UnderwritingCommitmentsPercentage",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureCommonStockStockIssuanceAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of compensation due to broker for  underwriting commitments. Percent is calculated based on proceeds from securities sold.",
        "label": "Underwriting Commitments, Percentage",
        "terseLabel": "Sales agent fee percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureNetLossPerShareCalculationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Undistributed Earnings (Loss) Available to Common Shareholders, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r195",
      "r197",
      "r198",
      "r199",
      "r532",
      "r534",
      "r689"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureFacilityLeaseLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "verboseLabel": "Costs of non-lease components (previously common area maintenance)",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r736"
     ]
    },
    "crvs_VernalisRAndDLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "VernalisRAndDLimitedMember",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureLicenseAndCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Vernalis (R&amp;D) Limited.",
        "label": "Vernalis (R&amp;D) Limited"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureNetLossPerShareCalculationOfEarningsPerShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureNetLossPerShareCalculationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant, Down Round Feature, Decrease in Net Income to Common Shareholder, Amount",
        "negatedLabel": "Gain from change in fair value of warrant liability",
        "documentation": "Amount of decrease in net income available to common shareholder for down round feature triggered for warrant classified as equity."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r186"
     ]
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "crvs_WarrantsAndRightsNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.corvuspharma.com/20260331",
     "localname": "WarrantsAndRightsNoteDisclosureTextBlock",
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for warrants and rights.",
        "label": "Warrants And Rights Note Disclosure [Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureNetLossPerShareCalculationOfEarningsPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureNetLossPerShareCalculationOfEarningsPerShareDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Shares used to compute net loss per share, diluted",
        "totalLabel": "Weighted average common shares and pre-funded warrants outstanding used to compute diluted net (loss) income per share",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r186"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.corvuspharma.com/role/DisclosureNetLossPerShareCalculationOfEarningsPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.corvuspharma.com/role/DisclosureNetLossPerShareCalculationOfEarningsPerShareDetails",
      "http://www.corvuspharma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Shares used to compute net (loss) income per share, basic",
        "verboseLabel": "Weighted average common shares and pre-funded warrants outstanding used to compute basic net (loss) income per share",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r186"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481155/840-10-25-5"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Subparagraph": "(Note 3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481418/840-10-55-40"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481501/840-20-50-1"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "323",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/323/tableOfContent"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "3",
   "Publisher": "SEC"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(1)(iii)",
   "Publisher": "SEC"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-12B"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-26"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-15"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-33"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-35A"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-4"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-12"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-34"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-3"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-7"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0001104659-26-057100-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-26-057100-xbrl.zip
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MV*]ZE[W^89\-:I#4@Z 104J8=(14&0I62*M#LX3FZUCE/ULG*!^5D;6JE24
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M.KOCKY0D:^,R"& H\IDW\MT'OH5!E52?TZ;H7$JTK?G=_P!02P,$%     @
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M.T4+1+6P?XSF(H66.:2_W _I_;;4"=)E@M)R@FMBDNU[<9)O#(DMKV"OB]3
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ME*"EGRRCW;L3HEFD:6, 1H^A]*,IB^!H3+I7<[Z_5R-:#0@* T@K&DKB(A;
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M9*V/O?7\#R)JTXVL34"#E_6U'SJAVU/RK7'C '2DE6]H#!B.?I0G,G9 GN)
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M!":0<'?-0YY"I;K0'0O@:(V0R'LDT@1Y%<AS;S-+3V'!D5A9]?8T3B P:0T
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MQV/*V3'E[)AR!B+E[+AU_$UO'>?+7.6><:T<F)TM0_G5@$ -#S$JM6)"64$
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M7;VZM.AXR3XU$;:X+0!'VWJ5O!@Y'#40D&[DM0U\R%MPQ*VM*(78;,9I'U#
M+@.=.G21_42<,*+$TR:CW:/';6[>_*%^\V;>X2CM<53NDOZXZ_6P;N+<7=0K
MXN?YIO*+UML)1FT-_(Y,\ASYGN^0S:/#2$W?RI $;R7EP81L6PFQ<FVS&*S=
MQW]VU-P[2_IG"9LT@JM3$48 5ZF7%3EIP.HA<GB-@P"_3,)I\ASX[F0V0T04
MF=4H#V )JZ]7VVBB').%FPRW%ZW_E="9^ [%"^S=A&L4I3N%]6\18E!%=TVV
M:@[,.9+6 V)[7@RN"2)RA!=;JBK8O\FN"^4NI*E"V\-P.0[G*)BF#JR+DMAW
MG2"ZC3T>)>(QM$$CEJ_.TU/$[8#: *#E Y0Z(XK$HS1I ,Q%G9VYF";HP<A9
MZF/R"L+P*<U5520I$*D 98(4)Y7K!0%XFV*-$K$=\H!G/L+9&M($ <Z^AS1@
M8YCNDEE1!_3(IC.4#;-4SM]!BAZ3U0J3^(+68)[-$_&I>R/V]K2J 1O*U&MF
M+52#+Y@NTNT'LF(8)$MB?K'A1S%!;+^3I2X?X_#7K*-50MR%$Z'QG* TNV>?
M,N%JUJ"N_86M3/6VM[7K ^IA_+IQ<3@-7/%(M5? ]G7MIIJS'9OV</3 RFGB
M1Y$3NNC"6?FQ$]PYH9.];R[FKKJ.Q120=@Q70X/H,MTJ<C+5U:PE9>HBXK_?
M:32K'%Z^9AK[OXFB!'F7"8OD9Z]1ID],1O?H)?U)N#>H61E NE8C)="$!R=E
MH[2?,R74XZ0$I]2J=P?WB@/(O&HD,2$@.#+BA_(G+R$BT<)?Y6< Z90@$)I!
M?0!95$VD:( 0CEBEE^@))TUI'0"94TW$IT#5(&?JY].,>WZ6(?3/_P]02P,$
M%     @ IH"G7'S$E/JA80  #B8& !4   !C<G9S+3(P,C8P,S,Q7VQA8BYX
M;6SMO6USXT:R)OK]1.Q_J.N]L6Y'4+;;GO%9^\R9#;:D]FB7W=)*LKUS'3<F
M(*!(XA@$> !0$N?7W\HJO!1(%%  "JB$XGZP6Q*K\HV93[UG_N5_O.X"\DSC
MQ(_"?__B_=???D%HZ$:>'V[^_8M#NK[X[U_\C[_^EW_YR_]U<?%_/MROB!>Y
MAQT-4^+&U$FI1U[\=$L>H_W>"<DG&L=^$) /L>]M*"'OWW_]_=???OV>7%S\
ME9/XX"2L2Q023NN[K]_G'UQFU*+P)_+G;_[UF^^^_>X'\OZ[G_[\W4_O_TSN
M/N7M/C')UGY;P\ /__@)_O?$^!&F89C\])KX__[%-DWW/WWSS<O+R]<OWW\=
MQ1O6_]OWW_R?3ZL'=TMWSH4?)JD3NO0+PMK_E/ _KB+72;EYI.ZO3W&0$_C^
MFX*7L@7\=I$WNX _7;S_[N+[]U^_)MX7F8CPL0:3O/GK6?M,I_<__OCC-_S3
MHBDCY*5%6YGNG[\1'W[QUW\AY"]Q%-![NB:\]T_I<4___8O$W^T#X,K_MHWI
MNE[(((Z_@?[?A'0#7R9H^2-H^?X'T/*_9G]>.4\T^() RU_N;Y3Z_EBAE77B
MVFB9Z!NNCG $Z+MB/U6THJ\I#3WJY7H!MP;*7!AN4B ,I".W0B\ +XGB<S,E
MN<$3ZGZ]B9Z_\:@/;OMG^.$"?N#68;_\XS)BD;A\2M+8<=.<$A?_W[^H^[R;
M-4!HH+6,JY([L9OS8C^VV"%K\8T;L2C9IQ=!]L7P[NLXVM5+*MA%-1_^(WCJ
M_L7FJE3TB&D2'6*7=OI&9?%5EBY$9"T %FEX\<M#!YG_>I6#YC+TR'68^NF1
MW(3K*-YQ8/F+$&-$Q\H%D)@^.D]E4$N:-S3%ZVYM^N6>IVJ'TPE;I1WLCQ)E
M\CNG_?]:<4:&SO0FI;M$SPIR\UDYY9F>#8Y9M)V-<YY+;-9!@3[A#";TTD=&
ML4'][&/\7BCK<>IU\!EN+ZM(.-BK@-IT'O2_#TZ<TC@XWM-]%-?-Z]0M\?N5
M0KM3%SMIAMO;5,(.=KR",!&4IW/".QK[D7<=>E=L.=6@^FD[_ Y8J]FI^U4:
MX7:^>E$'NYX@RU8?'@'"XWO>Y2&.&>./?N(ZP=^I$ZN=KZ$I7O]KTZ]8[2K:
MX?3"5FG[.F)&F C*!$A/Z(S%/")VPL2'Z63K8%S3%*\SMNEW-N,[:8?3&5NE
M'3X3+"A/-B*+_9][NO%A=RE,/SN[.DQ4-,/K@DUZY>Y7UP:GZS5*VM?MLJV_
MDBH!LE.YW$WH1C'S<;Z:?D@9[EY&AS"-CY>1I_; ME[8'5)+ZZI_-G;![*YZ
M@@_TW@J3!>%L2!23C!4!7E.Y]$<_H)\/NR<:*VU2:8+=6<_UJ7IF^3EF-ZR1
MLJ_//5#W$+/QF29DZ<+D,:!$D)[*Q1Z=UQN/317\M2^.@5O\3=T>N_.U:%KU
M1$5CS&[9)O) 7&3D297^Q)ZZ]#QFM"3[!S;+WRMM4=\6NX<V:%CUSIJ&F#VS
M2=R!7IG17.0_$*!.;L/)ANB,[R7[\39^C%["-BM46L[$(\^UJ_7'LMD,O+%&
M6%.^"*1AR@C$)_9#/EV]C>_BZ-D/7?6R1]E\)AZIT+/6+4_:SL W51*;<M!B
M49-SF-A+[Z(D=8+_Q]\W+LT5C6?BH;4ZUOIGI>4,O+->7E.^*:@31GZBI3:@
M]3*FCL(73S[&ZWUU>A2'--)G.#VL5L+>AS'<HQBUB5P(KE '=]LH5._6U#3!
MZTHJ?7)W.OT<ITLII>SK5IP@X10G6_MF.T3']]\]/?II[976FB9X74NE3^Y:
MIY_C="VEE'U=BU,AT9J\_^[=TU<DIS^^?SW&#CR&>3CNGJ(Z34\_Q^M9M9KD
M;E7Y$*=/U8O8VZ$$-2+(38=3UZ_NEDE,%<>^BF9XO:I)KU/,DMO@]+%&20<>
M8AQ)3G728]_LXHVXW@#QP]:VA[J+]BW-\;J@CI[5A65]6YPNJ27QP,5E?CFK
M($\$_>FN)J047EKYS_3*29U,'*4QE,VQ^VBSGJ>W$.K:8O;1%HD'WSLHJ,.E
M02=WVBGO&L273DHW47Q4VN"T%7:/K-7J_-)!T02S_]4+.M#M.%&24YW*V1YV
M3A!\."1^2!/U6'W:"KNSU6I5=;9*$\S.5B_H0&?C1$E.=2IGN][1>,,&_9_C
MZ"7=7D:[O1.J$4[5&KOS-6I9=<+:IIB=L5G@@4Z9$R>".LG(3P:%6QH$;4YY
MT@B[+];I=(*#4@O,GE<KYU 4!)I3NQECMX-+LY'[Q\/688:Z/:20"P8VB=2K
MLN9.V-U01^>3A7-##\QNJB7WT$4TYT$XDP41;(C$9S)/9HNBV EN0H^^_B^J
MQLSS=NC]M5ZS$Q>M-D+ME0I1ASJB($LX7<((3_>^KGPW^)']I2F=QWE+O-[7
MHMWIX[J39C@]L$W8P4_KY(>>G/347BA>/.OY8;7M7#RQ1L-Z7Y0:SL$;Z\0U
MY8_9._B)/'+)6'M<L<"IFT:>?H[7\VHUR;VM\B%.#ZL7L:]7%=0(D!OJ1VLG
M>>)<#LG%QG'VPIEHD";Y7TJORO[P#WY%%22X77_T0R=T?18WD7C+K$@AV+$K
M3E_LHS^X:9=^^#RXE_2];P?>?KZZ_OQP?4783P^WJYNKY2/[Y<-RM?Q\>4T>
M_G9]_?A@U>?KDA<J&\W$C\\2%M:WF(%OFDE26) SE9EPD,>M%!D*&QO.Q//.
M=*OUOA7>?(0:LAKPPI6Y](-]7'&9)#1-6H;VLT:X7;!>)]G]JBWPNIY"SM[S
M2TZ._)X3//4X(_JD-$[H:FJE[,5.=F%$*X3.V\XADA0:G@?424/L<:42=Y@G
M+HI[;RCBS+22N7(.I_Z3C;B[=)+M,O3@G^O_//C/3L $2I;II1/'1S_<_.H$
M!]4\7K<O[KCL9 $Y3K4ZXHW;;N+W=G%&GCBA1_@/$J,%<5*2\R*<F97(GM@,
M+OQ 2T96QMIGQP]@P?8QBA^8&&4*GROZE):_U5_R[4\%-P[TM$IEY.Y& B\V
M]%6D]Q$ HTI*L@M2"'"QCN(+$,'.L#^Q'3XY\1\T!88D*8B/H?DSC9\B7+I_
M=/RX=AR8!A-=%[+C)??4I0R;F=J?:=H"@,U=D*.=AKX5:&MHCQC'=*3NO43)
MB).2.IO4K!FHD&401"]0I8RL(>]B3#T_):LH*1<TMH)Z$H/$!74<H;R$+Z7X
M3AB>B6\$OI#BU58 1<SNG#@]0NV):Z@]EOBL[W5XV%&12E/;IN;XS0U$#%NZ
M&8$,,9L3?)E6V0KV+4@F).%2DM]+&8DDI)4]_+N8[AW?NW[=,XDH6QC>IEMF
M<7G[1_%EZ?7$'= =M)=#4Z,;WB#K(GS?<,EXD(P)WPG@;,C)/J>55<Z4%@#-
M(ZZY6]G\'$7Q*'6"F2D^_6&+SHXW>N!JA:B9@)%9WYL"7-IBS*Q&C\!N NC0
M64H95>S2.BC<Q=&>LNG8'=,@95@(N^%[N%?!5HA*_&SL@ALR=/2M3G+4[?$"
MBI;4_<<V07Q!.'D^QA4,%H2QL#2?F4!GKBPME0U'4K9]#H-"V4D@ZG;/EX;A
M9D69>/?^9IO>KG]A,S< 385]VOK@!BDMC664:NR %Z;TQ.[KQ@5UPLDO"&=P
M$:TO& NQ!+,"5%-I'0!Y$N=*'V %6J/T)#$,^)0>/]%T&WDWX3--4H 4U:5=
M=6O<<=NBI1RQBJ9X8[5-X-YO8SE=(@@3B;*5V!Q+RY(6\4.R##<4\O$Z\<YQ
MZ2'U72>P,ON7=CX^,_=NW!I0M<4=DHT:5H;0NH9XP[%9W-Z#1V5WLB1L9YP<
M447;NW"-NPOH@ZJJP_F&&]ZP.9'/Z(WY*7?6#&VIV0N#E>\\^0&_2L26KSPW
MRS8*/(8)8@AN>0S0H3ON4.IJ!SG8=/OB#<?.&O2N@% R*O:KX S:[OL":^K+
MK+[,C&$9!?0> 35VF$VD:SP'4K>>132;?C,CD4;S.FA$=7,-@Y*%E7="^86?
M.^<(EWWT;L:>-<8=E\TZUMU%J[;$&X\M\@Z^!9;1M7N-96PE]X*N_8./'&Z.
MS5'8V@EW-.KIK#[[..V!-SHUY39V^E%PL!NODZDMCC_R$=3*]):!2'R@WOE$
M08UERO:XP[95TY-QM+XQWF!M%WG 0 .42=T,U]: .K*JY:5(:7YK9S,-A:Z6
MEMK:RQKTZ*,'.W/"FQ$\$@W C*!;S7K9"IZ,H%KU[JME$%%,WMK/CC7ZX888
M;<TUEB:S.%_6%GV,!8KMD^<)E4>P3)%0JQW7T$=JC3:*60#>Z*L3TL"X;WM,
M-#086AX$H9Z(+^Z%00JA*(0XIJ&K#I_F'KC#24/;2GHL=7.\X:8C=.^I:4E;
M9,22J=O)?36AMJY,G;S['*64O/_S5W92!G>\8S+C6R7=[I',\>;(B)<E!+D%
M6:9I[#\=1&*F-(*T!0A.G4=4O'HKA'+B5HZ=[Q@9RB;:XDI,4S+*^I:X@[-!
MNY/T"J?-\(9CD[ #WM +FGGI-DYV06Z2Y$ ]2^]_QU4T :(_D?_[VZ^__?;;
M]V3OQ.096/P;>?_M@OT)_B.)J&#G'-)M%/O_A$WFE'QB#K@EW[]?$!9-/_"Q
M]XJZ=/=$X_RO?_XW4G3VN0W%[G19"0\(48?1B=9:!&W-OK.*@8U9:L^;X48%
ME5ZGDVNY#5X\4$HZ9&)9%G'$@ 1CJ:C&@.]^- ("__U/BV\9I3]]]R?>XE__
MM/CAQQ\6/WSW8SLXZ#!8$$9C3]W4?Z:!G6-WS^.%=YS@SO&]F_#2V?NIHSP#
M5+;&#1@M6E8.W.N;XH6/-H%[G\H6= D0AK=X&>E%I4RLG8/W\96&G$073&E7
MD+9T)^:P._!$</PI%I23CND6,L$]TYO0C784TL9]INGM^M%Y51_<=Z2"/)C[
M6>7D5DT7$HB#OZ<B ZYJY/RR]&P5CD2P).^ Z5<\OPG,CQEG6]=SK%DGRV16
ML4[ F-G D7N:.GY(O6LG#MGL))'DO*)KW_55VWI:'7&CA;[N,D"T]\*+"1UD
M[^OH.0N2\R#O9-_/V)QN70_3_$>A>4@WP*,I["<P@*RM)VA:03@4JEHZDM#>
M]$6/46K=FH\>\&)0@ZSC'#6,$7U[7F;[.FP$FQ$T_> $D!UZ/)4>4B=.WXY2
MK=<J1E!'W*Y(:DZ!+&VQC:!CW1D7QOP'"HMH=,,]+.CJW27/ =XA0UMRLWD-
M;-_S&D?7L\M?7&,-N+)P9LT&\-N8URCV^.' '8T?8'-=ZU2QH3/NX.YF _5A
MMZHGWD#O*+^Q(W'&B40Q$;S$L1AAW AG9ZNLP+262(0EBG,R\LX/B1<%@1,G
MA,T-Q:F6E2MG55MPQ9-E<6*G9<":3G/" )7.ZM@_[3&7F%?*;2S6!0=2LD 0
MWR-JG<7UV4$WED 6EP\Z6*GH,+\ KNK:%KRB];P"]T1FTT$[WDV57@%K7-MJ
ML/IUVEH+U-OR#DL'$U5[S2]D:[1NBUNIR[R"MTYPTQ$L\4 3QN/H78WE2*GW
MU-<].ZZI]7KB#NP.VBONB<YO*=U%>#.W2?$MHB>T >+ELV0%S;5S<X_9Q+K.
MJKFA^2QBV_C*L1K3.!;+$^B+:9E\IF[C&EG=>F:!JEX=*YK.*$ -K13K@G/,
M]QM:UQS&4C:[%L!'4A&79F^-=;OW,',MNV.L69?%LK-QIF;[MD9+EYFA;,N&
M1E/[&>&MR25]/>C:WLB80F546QCB4CY?PNW:*QRH6^..UQ8MY5!5-,4;I6T"
M]_;6V\]7UY\?KJ\(^^GA=G5SM7QDOSP\LG\^77]^?""W'\GMW?7]\O&&-2#+
MS]#RT]W]]=]8MYM?K\GJ]N'!:B+ Z]<]#1.VL&GVZJ;VN/VZ5=/:A'^GC?'Z
M=KO(PW/<Y:1MYTZ90E>:D;:2..6>)A2>:"]#[XH^TR#BE9LS;15&:>N#.SRU
M-*Z^@FKH@#=,]<3N__9)4,]>]!?T\\BU] YH,I6]DKZEJ^XC*_O?G-W^WZYR
M<+(!33_3D$%DP/1;>CL_] %X(45$,SBU]\(-3YI:RP#5T@4O1.D*WM>),_H\
M8*L<K,+4E&H[%0XH)OZZ4RWTH:K4K'&"CS<<U:*:F]#CF,6;>OA&-WS.4S](
MFM&M[1'-6+I%9^L3J^!1YJEHLT.EY4P Y%R[6@@IF\T 1&J$'0XCE<PJ=N/-
MH'Y A(!KY%$7A5:B[29\I@G/Q2R4^TS5>\YU+7%'6X-VU;WFLV9XHZU)V+[>
M6-+,PHUG,+(R<(^C'F/+J!)?8$E9;RL;Z!8D/%-WDO#[Z/@QO[&W]/[C(-2^
M7?_FQ+$3IJIAKZT/[I#4TE@.SL8.>,-43^R^'@W4LTNH)7W(.)9SL)2!:%RM
M+[>L'X6$C&O07UQ%94J_" ;* CG3(!=.W2<\O88YS4<6[*):Q(%-F&Z+N<T'
MNH[B+/7<H_-*DT]^&,5,W!R;EZ%7I2(2 GRBZ3;RRD%!!8K32H ;8BU\&^<G
M]Y.PQPO_-HS0?WHDK;#$HJ04F)02DR<N<I8_A A!B"3)(E^L<7U$A39&B!DK
M$"LYH9B51=R<OA"^.,R,+9*5D)TPME]PL0_S0P#Z;4!K;U"<.9Q-"$1*K+$T
MP9T0 +C^FN$_U=I\"N7YA4^8V@:%%4J]$^*X;G0(X1$>PT=R2&!D86OYJJ4L
M'= C]8Y)!H?/-&W=L3]M@QOL:S620;W2P!)XZT-7O;1]G1 RG->D]9YF,F=>
ME7<!'W/$!J$E]#"O5;;?*92S 0IY>N;\0?(')_%=A?JJMKA!HE%#&2QJ&^*=
M\36+VSN7<9XVO7@ZOR"<LI7YS#@ZGL%)^4)^09YJE+42B5=^<$B5SV[5K><5
MC2=:-L5CUG0^$7DJL,F8S&BCB$I3>N8S%CD<O5H])PG(WZB_V3+>2S8S<#;T
M\P$*I-VNSYZ[-0V976G@#MY>%I%#NA,!O('>3XV^89%S(QD[(OC! OP\JY7-
MT7I:LV2Z'Q)FF33B]8P84L ]@6Z#^U2+!TM.XV1.XV9O:K,,(Z%']C&]6!]"
MCS7*SB@KCVS/+,N-UV1?1""=#4FZ;^R[4YDE4+=910.J521F!]:MBDP$US8G
M<E.;I@&R]>9]TVQ>6?,8<UB=F0\;6NO4.KSC"7'8WV/*K'-%Q;]M+]--$,:-
MZ>9L5[G'/I@J7N0WJ%OO6_)=*I&._+!>8XZ*QF+5ZJ05!+/R)+_),,MGQP^@
MYMO'*'YP OI W4,L*N@4]PQ;"B$;)#]?$.MC1UTHZT)[GH#62\/>07IYPV:N
M]"DE)9L%*42X6$?Q!0BQ(#\[?EA G;-F4U+Y/C1,;6R58$9CS%]"AJ !9/L4
MLV V\]LY\1]4U)%,"M;8<(_9ADU<P\M#'-/0/3ZR66G"1@ _"I>AQW\+^+T]
M(R@XB-E\,7&XC741LC^G>>*E 7U'G!1FTI%</"+))U"SE% "5.MU[9%:_%+4
MB09#KS/+NKEE4\F23L$:X03<HOT^]C+:5!E53XW5,LPT]\ ]5FAH>Y).5=4<
M+VKK"#T@LZC.2GS*6MZMVY'3V:/ICMTDP5PDY[Q=GY>>;=D"U.V+.\ [64 .
M=:V.>(.^F_BCIFJ]_-OR\\_7#^3F,_O@]O)__>UV=75]__ EN?[?O]P\_MUJ
M7 A[0-1&(5Q57[[ZJJO<;7UF$@=-&M?Z?UV'&?A]H]B];XZ)YP<E5?([T#W=
M7I[F?F-5P:MHY_BAZH:9HBUNGVW4L'*SL:XA7A]M%M>4;Y+?!6$KSGE9IK/_
M1.&X5ST7.VN'VRF5FBG*+HA&>)U1+:J) @OD=T'43F;K<76S$5=+S_-AD\ )
M[AS?NPDOG;W/ECN-,=;6!W>\:6DLQUYC![QQJ"=V7[\MJ1,@?^&')&-@-T*G
MU?JFT-I*[+JNV#:EGFI;LCF.._1''M-=+5&);]W.B&.]LPJ](^#V\D:Q]S9J
MX&MLS4]HA)(3J3LK6IV_ZIVH+D7*YN?4R]__-$:_LC'N4&_6L5J"HJXEWB!N
MD;=_!09!EA2OU"S'Z4AZRD%Y1=>^ZULY[GHX/"6^YSOQ$>ZE9)NE3;N #>UQ
M1V*KII7=/U5CO/'8+G+O:_:,'G]N(%:TUG;\)+T^.SOVHW1DW;C]I]41N?=J
MZUYQX]9>B/U97W9#CFUQO_ N]I_94' 7."[?O6^<"BD;XW;A9AUEMZUOB==5
M6^3MZYX965+0M;M7,9*6]W3C)Y!OD<V#_)BZ*;E=KVG<KRRK&S\G$%T_?/O]
M]^]YA,%?_O$Q"H+HY3:\.SP%OIO3KPTRG?8XXTQ;4PBUUL9VH\V+V.R8^1B_
M$=;U&QH^+E!F9H_-I-C@( C#*,'+!\/^ 22?VW.^7X\1B'5(,[[.@OA%%!)!
M7A6%XV(-'CVGN0[/UI]+)H_(';X'9V\<^9O:XP0E;4TK]\I5C?%. =I%[GV[
MFU&^*$@30=ON3&!B9<W- Y;I)_X2IGT&H&R),\PTM"M&_?IFR,?[%J&'K@"S
ML7T;1X<-%'\E3GK!AOD+\7 J3[M:S ;V<;2)G1V!%_0Q<4C"R"3$V<24SXRG
MG1:,9)IEQ0*1M=G 2.HQ</@3>>#?VS+_WNQ<Q62>=Y,D!^I='4 _\1Z:UQ7A
MGPD,3*Y?:>SZB3*!7Q\Z.+%LL&6JUS@[$L$[Q>BO2F]TY*@H6!+!DPBF"U&+
M:)%MG66<2<':TEG-]";*+D2)\<,7ECKLV5]HQJ(<7:*]M:)_"KN(U#,&4*:9
MT"QA1L,V&CC30&5V0*.CRZ!,3A<?'$@[!)<3:)AD;U$A.=%&['X^'8G<[LXY
M\C\O7YR8 5(FTZ( H01J9PG1+=6.L&!(*8_4N460P?*8=NB.R^2=GZ?(LI(Y
MO6GL^DQ?^"?JMSEZ?6>)Q/46T)WD%1UGA[<*\4><S#%FHH&=$N[3V.'GF*<&
MC".74B\KJY+(VP"X0-*P]C6XB CLQ(C0$^W..\\2[A0VT)YLSA?P5/*/@7B"
M%U;(,VV)RTH"T&PZQ*8[:7FE!A?JC64 >3IH>;Y7IE5)'B/%.Q!N!M# DQ=%
M][ =G?@I?:#QL^]28;)[ZD:;D%/A8X;"X!.PQ0V[4]F]^B9K7)YXH7XRS7L?
M<]S=7"[J]Q7*K0=>YY;G)>4U""^C)"62)):>CB&W+(?V"\Z=YU\M]G3H*_R,
M+F&T3I)&43*8F2IPDL1?^^Y)AJQDY,2L7?CCAN')OPF3J5VUF>,%YNE-,'%R
MV*R<MIS,4.2+'2F7X<!L?+ALCCF'K)3:Z=))MA^#Z"71S^55UP4W4NKHJ\C<
M==8>+QYI23UNGJ[EP]_(Q]7M;P]V'L/RMX!W3IS*J3B3#T?YDX:7>9T(X/;X
M[K:H/J35[8TW&GKHT/_]A7B$"EF /T<,]\6OP( !O,7G?K*FC<_[:AO.Q\/5
MS_?.6\W#8PT]SVOS3(OO]61M6](6U#2<CV\VI2LX;34/WS3V:JUTQJ/=V_@C
M:K<'FC;BBRUD8!9X%T?/OD>]#\=?$NK=A+=[&K,U3[A9LN'PF:] +J.0_>'
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MF;78.C$]WC$]4V:9:_;7/331'2Z:""!'K,ZV:)P>*7LCQI[N.IB<%.7<&,@
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M>ZTW>':)/O:[VZ+?N@PO&O308<+U%:;MH;%,PK>'Y$TA+,LD, +\!QOFSTY
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M]@S<^11*&&V7&\U)*PU"XI"X,"*L5Q,.YP&4C#VAMO5I#!5EK>"3-%-]=OP
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M_[!7?HJKR=.'>5SUO&"78OAH:H\3_K0UK>1K437&.^%I%WE0OI1$),7S%ED
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M&2ZG4/7L",7*Z/G1\>-?(7OA,DDHKPB[RE(7LGGT)^KP(G>WX3U<2H==?]:
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M0IK3M(,D3!JX&-]Z=';>#CL6*#2K!OM)(\S1K!)UT$QW08"F_8,QT\KQQQX
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MAM.WU!X0.<(@MSC($[YXB#6<AZ?RSL-L"-9V#)8=N-;C EF;D5CY4.#[%?F
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M0;Q"CC?SD,M,UL<L"P4;:J+:$[$2<0!S0,VQ[B(WXB<AWBPGGNW?>3Z*DS!
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M.!@:VB$9U,<]I$Y69D@_.VX>*QCW.R+/\B%W](PB>X[R%9+>AS(_ WB]'U>
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M1E.5HMSRTSG7= A218H#$V$M^>F\7\54CW_]D/(^TRI___]02P,$%     @
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MN__@:Z)[:@EEXLU1=#$N/A'YM#DG8FIWS(P#%VC_G(2&@GC:PUE?$<QB 71
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MKVC;VWGHFFX]RU#AE_C?OWHK\IR)S1N1A&1VK;$_W,U'2.30^YYE0X%_:;'
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M\3?1AY:A MM9[W%CPM2#Y+XU]6=#]0_5/XCJ_[+H)_AZ)E4HM^H2&:/8\T*
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M<AR(1=@^ ^Y63UW]XH@*S &M/(Y&CF4Q_+WZS@&&X!7Y/U'K\XQL.);H;]P
MAB:!D0\8]CR1S]4F"#BG BC[;]P\@>U<.K&2L$\4F@RHHC_/ -N> K:> [::
MQ(6O'?A#,S%W:'GHK)MSCX&% M %2^AR*#]!X_FJ* PJ@OSG)4>Z7>KWJJYI
M6"]Q9"RB<C%:D:(JIT@,H'J23/3[$D'2( H7.(5@>SM+7$.1J'DQ0^>,D4O4
MTR4].Q=9LAT=H OL7K?LD<T&F2B0;2$]$Z3FK&V/^@9JR;YN:30$UIH9"T]O
M9>EZ;6'R>%SF)6J_SW&;GI?L#%\1ZKUE,N]ELT5-'<"6>WWVTNJ 'AC+K)@
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M8Y69J-1(X:D?([BJ68K0"R=GQV'3 [QZBCV)>3)= 8*\F B",O**1@$2*W*
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MYW_QBM''_89^/8E8,24.M'[,TJG)2$KQJ72G.8>3.""=Q<%R+M)3PR(T?#+
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M&&^Z44MJRX<\@(7$LM-I>QDV+7(QU7MJQ-(R0T+GD5X'FE@RO-PVQ(@PT!0
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M><]\^Z^W"1O>)[V\TD@ %7)Y_J2="8B($@H[$XT-G,^(83KPAJ(%/S:@E>@
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M(3/N/\N)TN,)95!SAE-SR;M.?!L;L_4J[]522T#0P%CQE5A!A4*C+H 5*"5
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MRWI7%@>SL:;F"ZE)8[O).4,/,N+0]B"I*)6F+P0;B2_7C]N C7!0B1> C9
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M5_8)EEEVQ*'1ZB<8K;YUFDK!< 8YEQ52B&5.1XE4(II,IG"\[5W'YM_ L.#
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MN-M&UM4*\U%W*::=6?MQA9KN9" H-Q4X7#[Q!)TM79S;X.?NQ:&)@.S7P#I
M9KGDF_//O:$#8BIPA8Z]SZ>HWIVMX5L3[POP328>R#>KVQPX$@?7-^$UQ[JY
MVADGN_<Q1,O]]'W'%1R$W_IL!Z[ZOJDXLDW==<!7>VNOL[CD1YF$X.^[:$VO
MD]0#@:?AJM/P.K%.OID]!,_,M68F]?#F^4H\,=>:& AF"3PS89P9#&9AG9GD
M0PK/S/7M,/(WE>_P-'QR&O[T).)O'940D+;/=_^/^/FSQH&\RVNX<N#+9T<
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ML/]Z2]##])II!"[;[]$]8_&TG,F0"5XD$@RH3V-SVF4%TLL-GOH4M&/B#R-
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MX4""@R9V,%F?GNU!OK*>=]3:B&?,(2"K>:FO3U>?F>V3?8$>);P;?"X@00E
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MF\ H\'^+X!HY*O!=V_'<4SB1K*>MXC[7"/_0?H@46+:QRRAR.H$'7)*D8+E
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M016F=QU5CPB/MVR/\A0B/<:F&A:0YCYI6CQ,FB;^ZY?N4VZG,**A&NB:4<D
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M?E_/)+/S&.I"Q!!_(0$3 B:! I/;."9_ TRT5GV0K]>9A:#2T[#3CS#R9-Y
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M@A[0BV$>HMZDH;+X87A>K*(?LJ<HVTDIGLI8=&NB"/9F6Z'#W5THWHO?>C6
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MK,$H2F[9;8OJ(%E5NYW>9E!H>)N6:KA 23JOC!N@8<P/"L"-90[?[5@N^"Q
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M_(BNVWFX3^XK\+T'Q1Z'L5A>: Q UQ'>+81J*6%T6['9WTS8IFO)N[B>_8?
M6N)[2==1=3A-='_HV@X*1O1CN0_"6&:F G0[Y-]AHJ\C=YR?.(_][-XU2=B+
M 9+F<\N4Y F 7T&WF*N)BF(>=1TG4:@C5990C5#OGN;XUO.-J\T0B@>"JU=G
MD@.>QUOM8XMV=ZU/P4".):' 3'0W "<[M$P-6/]1@*3#-^%K6GL7N&1+<$7P
MG;8*&2U9A]2&Z[=M%W[#CPJRYQ:0%/CQ$!CR!%'@>#3\\US:H%_@JT:2JSOP
M(W,*9.]F:1\O-5%MQ[1P+(4B.1*>HG>-?'*K=6?W%)\5V9G$%SY^>*-2,YI
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M71)^285/E&QJ##$%N0@D"N)8&*QEW;4AUH2HE6GI2AANGV _%^1&D'2=&JE
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M#CME*M$V+C'5^R?JT@[<N*INP0G!><NZ>,!JX<: )E=:L:[4[+R6*6OI]9*
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MIB+!R?CQ9.+/KW9R"@[FCK(L$&:^/!GR.?IJS[?@9.XGS&*!9>;+DR&?F<
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M<\C;B?_\>W13>7;]N@CW%[PU#4K738C!HC7B2%3!E:CH_U6 <K)Y2.N2;%K
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MI0SZH+&.KUC*UC)-M5RQ"YG&!Q D1Z=/>$T"!2T+]ZB#MF@WFX-\=:C#X6G
M!U_$CO1U9YE+Y\L*.R,J<I.MY<8QNO'K#Z2)"V#N 7BDXYZ L@:I%9\3U&9H
M$T64ZXG"3AJ^?8I+E$)_P<)V#3HLU+?2U6IN? JJ\0G\%N34D*J;)EK]NS*;
MHQZ&<$3*3R[R<$;P%]3]4PCZQ"^9 HAUCMU6G,)JJY:;Q0<M P$ T?P*$CS)
M=[VK66K;D8)8(=(4%UY4VUI/7F1*S=4G4-"ZNY%90Y^YD_4,4_,BT1*36&E!
M3H4QF^OQXT2Q3K;Y+23::.3Y@C/K$NT^Y?A0$_CWE@&_JQ*H:#-@E[9CKD:
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MT(Z@J^C#__LK\NN#&T01S\PW:UW@XGS.O::#,CS7*=T?2&V?<-X#]@D)A'9
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M.J_;9WFY':-CU4PX7H%61"3V1!'G$<N0>(C&P?W"5IRG"PYM7H1S[LR)T&6
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ML3*(C,F\EEM9L9M+F6FO8[?"/;NG=".E="XOELN@BBH+QG_](<D;-1Q^C#A
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MO*,L8U1_ 2"]1#T3_D,P@Q]),I%4BF(%>KP>@#T=("M#=MT!X71@F*'86L3
MG9?F=()P!'5K6!B>Q4QZ6&<1)PJ=<7&E!R_<P">ZE4C+>VK76.B\%E/ ['=)
M[ F!RF C=;:2.C;-2I[B2K:-<H58O^0:(4%X82#<7N/?N&&OP0?F2>]PD^>
M[*ED[9M<!A_"X;_]7X>]7S[__N+MY_]\R4^._^<>W<T$BHUV_W[;D>=SZ(".
M?<*;-OH? #X?I82]2CS_Y@)6@C*%Z"4+7O=0:N5C8"/(-F$#T;2UK>LV!9U'
MI!^C4^\_'^- 3#KYG_O_/7P[3'X]'Y:\MQ:J]_H:U\TO:9)]/*9H4T+D]A9P
MW'ANW^5!FB(?/W87R//>N!&8V2@II?=6^8+7$</SI?T)+5SU2&FULWR<!GX
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M%R_??WEYG SCR9_S#_ZGOX\>_=SKM2M"MZB[,7:TN' ^1=,'1*,&NR/A[AC
M ]YHS5E:,N?PXY\NLIIWL_:+-G[C.-Y[%9-ZWW)^$9%(]!H)*74OI(J'>'84
M305H-VARN9[(*=0&Q@M\<CD+P&XK*(BP0U01;V9*7!$MS[R9\'.$/@:A$$G
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M-@N1QY;K?0Z0P(JL$P]J!+V).%/"%6AAQ'9D:'OE58KL5]@MW2BM!:I $F.
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M;@AVV.]9UMVHSN?XUL$!U531-[X &%+K"T_X\K0U4[H[FU6L+WDRH#\_?FV
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M*&;\PF%'?N'0?KHN]M\165IO0 SMJW'4+/0DWR8O&8M*G%<M$VMFKL_FE.W
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M8% S)%+E3]8]0%73NK&L0&+0/5>AG3]G :#;I6D@6MY,45]FQ&." H)&M,:
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M5B @\JQ,,SKX0IR.M1X/"R@2V1U,52=E,F\4BW*D^J\3@WTV?Y@=6LYZSNU
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ME1P<<6EB"\VIO]&OU0>FY\?Y.!0UX?J[:UM>OX/N*$JR?[C[PM6&%NJ!(C=
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MU 79BP8 P&&<IR %T@+Q+H4B8")4$,O)%(A0@C).+/@"9DP20*HD]XAPZ%J
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M2"4,=I)C[CYU8"#E1%!K%"ZL,8D3U!%*$RR/%M%F_ K)*@J139P<G"*5<HD
MP*+!Y@:;UV(S<3W$3,*H/2Z>-5A*;<)D/R>34&=X-%!""I 1>_FBB-OK31M4
MF##I+_ "% =_4;MN#B_^Q;V\E_\_>V_?Y+9Q90]_%=;N/EM)%6<L*8Z3K+92
M)<MVHFP<NV3E\=\@"0YA@0 #@#/F?OI?G_O2?;O1X,PH7INCX(_=6!() HW;
MM^_+N>=X51LZ(7PO7?N&1]&ED%-%AS9R;0,A5M.3@#(/3BXV^GF/09GWR;Q/
MSE:K8E3I@R(,9[4\NW OY)-#&F;.RT8URS2LD2/AI$?-F6+"?2C2B:G->4/,
M&^+<AI!4P4Y$..O[@8PGBOEI3F)A.4.W+@4@PC1G>TT+9*E)<)8!I15-)L06
M[HD&-7]P%V"J2BGZL-WS^.:AJ]:<2FPHRBIGXYZ->SK&Q]PL2[(./(#/FJN(
M3BIE*R6HJU@Y9Z]L7O07N<, J>D: *O.HHJ9Y)4Y$GP\T[1@!QRZLA@",<%0
MKG=-6[<W)X!7!J'0]6G\Z$+A"U4IP*O1/>TQ&.O>4;4A @>WT+RO>8ZOZN)K
MX 2D;WB.PV6*;=3?%FA8B!/C\S)W*[R;G]@Y]&S>J;\D]I?[?"7FX?YQ5#EB
M+'#MA5FVDN%$X_Q1+9<F1<_:61ZA0F[:HV-^!EN\U_0,5N;Y\^L_S,;X,_<&
MAX[)%#C<$%!KORNZTI> (C/T-="=NY8SV=L6()Y:)FN8J0 C*CE&"OZNC&*;
MP54>Q?ZE8(/_Y";Z>>!<AHWY7O:3?O$VB%X!8/U70/K='[_Q<_-_)G&ETW*2
MNN=O94E#O);RXS5/ _]\W&ZC)W^T_.Y,(W )A'>%KPQ?T8CM8E6UAPA[ZV4*
M)$[MD]7:^*7R^JY]49^!(UPO/A_]1F;"G&EWQ)59PAQBFQF8?D4<FXX>6L\5
MM,S 8G.]>-<2*S:]&QXL:]>DI!YD:YU-)65 @D'DBB#Q&-U'07+[Z;,9,SQC
MAG\:S/#/?O[</UZ@[3%R&V?Q$XL/.9KNA%F=>+$8PBI*X\Q^^^+9\T_I/KPB
MXLFE$\&)VC.''"F<*&?D4_T(F7;6'D0X=29/,WHT_U0%::;C*5C@_+=6TOL_
M/GMA!,]QX__A]L.S(($NI^K)+:H*V*KXI5$4=_^?']O]QV^H1WG@7+\^09+D
MX7*X>I'?TF.JQM#H&7YCQ3[=-YK22U'*,[X(SQC?C0B-%DTDIP-1J'5%,V7_
M\>F+SZZ?\>L\)RA*E\JC*SA(N3<P,0,Q.O,F=1GY*I7=O8YE0;5/_SL,M @'
M*<90W?7?3T(<J-:)OI6WI%5Y4S7CQD1\ZE&AGWY:ZS3,"9/;4E\Z^SL7,J7#
M/?<%4-SX6_6ENZ%F4-4H%H1Q!WJKBTRCB"N2]2*@I (T='A?/T6[DE__AE?7
MOC86 VVTG&3$0'U1>.>BVI)9[I[_[B6)R$HC,@L:_)DX@G^2,'UF-;J7U>@B
MM("^&^=(W/S8%S\ =QOH+ 1>&(3,-19N58K,0$EB5[)X.($$^<&5^RQL04DD
M1WN+*$(VD5VYGW>WN3[K(E.GEX6'?8#G.W0E%-?]+V<;1XD?[%E!K.ASQS23
M8P8>RAQ\#=R?\.Z\%M7 ^C_BX\$8+(0 1=^WZXK.)?)F4^_)#T=R^2C/H3(>
M?SC7-2;HAL5D<$W^< !<D&(5(Y:M_\XQ2&W]WN)-X_V&;K=XMIL?E1AX7>;F
M8I;/2QX!)T)G)HLAD:XF98#!;WY"Z._QVU;^&>=N)*?T##13IPW"@([IF ":
MVLLIC"KQ$3^VQ[B)]5XIFD6H(/A;T>LY=X<ISF3"ZL[M/$]?,W4>7XC'8L4M
M.4:5)2/:!*S-SH="] ]R'HG&-]4S/T3"_7YY^*4B+@B?*O)=GA!([RVX+$5$
M&%B2LXOM4<EHP]%"%$%4+RFQ78%8 ILM;L']\.^O%Z]L^SFTR.5F[KD/EIR,
M[Z)DP F?DG1+J@SI&4LL^J-M;EH[X9[C,.$(9R^.(XO-]9QHJ5$GSN!N!PGW
M_/SWCO# 1.F#=>3A1$.^VXH/_U$)U/[CT^<F6\F,S$!M,3 *XS%<! 0J"\:;
M>78J591W5ZU+WOD0KW3_#,<'O@HRN4K8FF]=B,/'E'2*CKUH58;$D=@"B-J"
M&8<-S( '6YJ3TDK'&HQM/^+1MZ</;??>T)H?&\-\[I,*LE $5^2P<#S:0,Y9
M1;_T[^QP7+EEX7ZOVU+.EW%DNY0C9S6$T"^ NA=BA+) !?C[X$EOW*4"71:?
M!]_A$R%\O$LX<38N8J0WA'LU@?82U.Q2>F!:0'<KF(Z /U2S/!0GM@[W$#<A
MH!-R:V<[7<6JI,H5&/'E*,A)B0"[@D?\ MV ;#I=K(F'7!2H1(JGDJ.&0B^&
MVU>-6U%G0:0V2#Q7\*6T1:<@6,$FO.ZG9S;C$D*/=C\"BZ^((K# #L?W%M\X
MLT**[CS,,R+U;L'Y-['KF*QM@;(?J8Q&/:37._?2*$<$LJ"D5/R.__9J18Y]
MNI8L%U:>;?BJCNFT&W<64IE7L9Q[\+?1R(#[%*Z.0 FRE.3=*4Q39(,=H=NX
M=U7T96_!$0*7*(Y#6T$@MPR?XD(RX1#LMRF$=5Z,E$?S:U2(W^#7Z5^=A2Z,
MT7U<[DA*[R9HI#3R^<O''/GZ%?=F;NB%=/*&IDDU..!S3W93MRL24["&]WGG
MUJGQ(A/#J6NQ'Q;OW47=T^J$]^?O_L=/>%?-KEI5 \-K_4D1HMS(W2=.!V_(
M!F'>D8ILPSU9("68SK*2JV+/XLJ:\A"JID+?.%7DU>Y%Y4+TXG0UM%<;N ,_
M^:LX8G(2.7JM"=S* _F&+B(>0]>9PUIE:)+3$"L;A5^2FP^DD%$+^5E2=\H'
MLCXLH&-H4U+VY_Z^.;H/8N^-3[ZE<\4#&48M[=*A_:^/F(N>WM(,DWA (X-*
MQZ>#.]J<^:S@W/MUBS^2E='XKC/;@NC[XOG=V+X?&NVZCUX"C=/B5ZDRMW*2
MNL0RD'#03?_Z,ED^O<,V2_KQ\3!]^GSNJ<X]U9F'Z4F==9?%PQ0*8P\LY-)Y
M-E'XTUDX!O\<CEU_%%IK+D>T+><Q]"]EW)1[><G(Z7\1T[S@,*P16&(@" LQ
MF'0OHF;H,DW7,F;\ 17OK6FUY.R_%"I)=U$4+59%W/;RG=HSM,W"Q,$2:T90
M[*LO7MGJ4JCPWY3-NHKK-LFSRY4?<A6Z?ZE^SUMRWI)GMB1O.UBS=O;0Q*L:
M;?,1@!:R>FL_]EP,OFFBLGN9PK=4BF;SF\WO7O-+$FW?8Z:8(]ABW%Q&6?<1
MSC]6>CQ?,3<L^/%O\N!^1@X$0&3!!\P6/UO\(RV^[/$.JIZ ISF@Q+HX<.G8
M'>ZS?<WV=283-"T&Q=B9!K^,*$J;I"&Q7M#%H;?$L7>U7[G$+NIW!**6@WN)
M72_T#2Z^A.N32]+0F>]HC_WK;+:SV9ZKT*-;=\XMQIB I>^HAL:YB4AAK4W9
MN6\>9L.;#6_*\.YV+"'^H)R:?69O.,G'Z,)0%QB7%0)U^>HTT6Q7Q,1LLK/)
M3IAL'N0+2P2R)JLVRJ!JPQ6"5.=*_2>*8NNY4C1;W7G>BXR[TCF6!X%:\KQ\
ML[>;[>Z<W>EP ,#/[9Y DT)S8'"C'<.WJF;+BG"S/<WV=";3T,&\K?)M 2#C
M2:>4#%>R6H-5FQ.)V:X>6G@9AJX K> .XY!<5Z%) 0(L;RLTZEUVBFF#>K:J
MV:H>9E6^'"(.BALC6NN@9EW785AD[V'OQGV]Q+<NV=:>S:9V$9V))+5<E619
M.N4CTQF7R;KUF$%H$&"P_!"S)@BDG$!/.CSF&=2:H6LY+J@RS,PRIZX3"AA#
M(-+9^@3L2!4/(>APU2KA=@Y3H#EAV)^TT6ET+E9& AG34X'$!+.I1\RWU9&^
M@"Q)F'GXI5@*'D6CAF7]0I1QF''ABWAB'<-WW\I2O?9+]92XTLY(<3O;O"UX
MY(FFB'H>AHNG,& -X%Y@/7L7(WL1>YE[.TO>+5,QIG%^6\G1I:-Q\9YQ%RB4
MBB!;M9)YT,S(_O*<' MN#JI^,N*9<),@8\SRE7?W$Z9O"/G?M_>SFZ-,8MD]
M?T'^-N$HPD@>,>'81SNTG66YUO&G6*HL# L+T#.A>J )*7=PZ M]"!7:O800
MPG\4B+<%?*?=2_%PF58G,PXP TQ,'L-31'2I\R0&2OH0S^E_'/1M+^91@WG4
MX*G2MR6Z*O<(619UVU#4(MA;HU\$NA"PQ=RO@9'0NP#3ZX*RU3&C#A#=PUVI
M,C>A;8W@<N]<DY=M<AL77 )$<U5&XDMYS#[5U_=MPR/D%M71%]M2F*1*_&6Q
M/IUI1%+.R+/1ES)4FK)8Z) OC\!CO"!S(%G>M)31!Z^N=0?3!K*(G@$#QSRI
M_Q*M!AIF,:I L.DY?%\JJH*.6]7W1^VPC42#<A8E=Y:<75&,LCP/39Q'6N=L
M_=_^V)0W3(#0$H]7"^L@1Z+3"01/R.I7YQ),G^8:5V7AL-GNWW*A[G%BM(@#
MJ8S_Z2NW.$4G' * \I1,8HXX#G(I%1$^$$F3)_"Q>G<1-6>9RM81'=MX'*-8
MN3N@U%RFR^?"Z[R_)O:7&.U5)Q6$2%H[' *$Y*&8 KQDS1G5^(?N.J(2/Y$&
M]6VU.>)C1VIN;KHC<^=@9Q4'VH3@3J&65;JE9O3E;.P/-_90X>B/JWTUD ]]
M0R4#(41R-HM?_<+9X.+5P:C.*[_+F[]]T7N"%V;#=-M"*:[<[S6(@2*U>OE5
M]U]*^!EITO&TH)+FF=P<!YL/K7H?/E%(EFPQ+KNB'' H&SU2E-]3F<Q2>L"V
M69?^DO,LQ[QMIH%XBD1AEC$^#0R2-+<)CL.N%69!9\1%Y]DYB)*$]P5*=/YP
MB,^,V1QG<[S7BY=-YUXW%S6$^M4Y]A\H=@''X6Q2LTD]R*3 @>L"S_9PY99Z
MT;&^['9L5;,)S28T84(NTM(Q,>:!QA&GK(W.EL:%-IR:;4, %IK^Y:::I0W%
M=:K2<BJ'0BW7!_*'Y[EZ19J'S28]F_04)%F(,TF[-.(DCQ,)0M/,=C3;T;F
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M8H9;+FGJ\SJ^(E-?E65#A"AM0TLH4O31T;[XP1T?@[V<.UIQX-N?[/4 0)&
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M^'VW-+A-=]2!*D!B[?^NIB?!O%6%D[<"(0[\J_OYH#UF)<>R!=SH+Z/% (\
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M;^KU,:WQJ#2492A>VLY ERL?_=^^ZI^2!.V;_"HE06W85:&UM^00V!!?^EH
M^@>2D5+8CDSOB"84ORC)[CQ!,(73*!^#\-% G:6#P59YBQ"7"P4NWSL,03M
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MYP$8[:LVG+"&4I[*9TZ\71&S\ ],1V3'?1X5DX?^3]I.3(5FS9E GF*IG(G
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M[QBWW93_ +B30;@4M88Z%5393!=SU_8'=,.GVIBARVE ]K[';.H.VH<6EL_
M*6INGGV -LQIN(YFB?<6IE^7+*RN\!; _MUU=.+RH2)R:/46G8?8K-PMN\OW
M'\BK>T][F;DZ>0 JX2J642?_Z,@E>*I!40+7'P>T\;,9VCA#&Y\HM/'Q.*&O
MP@BB%&2)9ESJL=X#GZO  J8U09(.O(Z?D&?0CB#\XEJP) ;#KNW+,,S!*/LU
M] K*]!L9)HQ+0@!]Y[WBPU5M4V0,501OW?LQT+@'O9!L23S%E!H@W8?5OZ\7
M7Q;KW?@?%GWI_N2N5I-R0[4!YH<:Y_Y!JX&?E1Z")5T\.*,7-)A](CK_/52L
MH^BA<39P=+_C=JZ QLX2]D=T!G[IMQ&G_NHTA32DNU7LU?@=T.$_NF&W0M^L
M5";,MCF8RDS?WSV$ WA6H!RO/&7_TK+YJZ!&A0"&9EV^]P.'<I)O+#*6!II[
MFD7>%<X/KEL7OS3MWDBMN$__<.PA,W7.R@0:YD.S,Q]5EQ@ .5[)E.8YHZ_Z
MU8VOX<<N>4/4M.B"_HMBNH<!&/-!:<!X@"J=W>&8&N)Z\2<S56*I*/(!'"-,
MAZ'<'P;_,B"W(HCKU2DPNT1+00Y@3_ALTK5)O6X@W)!H4J:KWC3D,]WUZM,R
M=T=83$,#@YV!JHJA$) 6+XMXL*Z=,Z1R !T4< :D*'!L=+*Q!B$,";;P*N '
MUCN,VC<W@0>"_MG]=7<C6R\S#>2\2D"NRBOPB\);Y 9Y?<STSW->#(F.+,]'
MM:#D:+QMZ<XQB/*-B]YYZFRIMLT*-.UV^<^9RU.!#+^EV2:B^.#9=S.WO<S-
M<A.U14BV7#2&<;^],SWW2:_YQ,<W$RN)DSKY0K)0P9CP8XJ*A;[P0)HL\UK%
MZL1!\&]<6*SP)C?Q3OT:))99CJ6EG(/D6E9EV7AY(%:NDG^60Y8U4'EN;AD!
M;OW;O%6_'6;898Q 2A/F/?>GWOFRE)?S2D!(M.^\#1@%"/>B@M.^+Z!LRKOZ
ME$X!QF.#YD4GL:'/P$\N%D$!.;=[^TO8OH^2*XHG$;_&("I/T+]X]OP9^\%O
M!3WV;=<.9> 5>(42Q(:.Q==X@Z_@-S$@Z]9[$PB7_LS1WVO%1WQ)Y0I<Y"V"
M!(B$\!_=]Q>_0M&R5%8@$H*34$.FIX3#[=7K5TKAYLYI(L)A[R)R,Q"7X^/-
M3"B1:W!_::R.-L1QY>)$KVD$"]5ON*S:?AHD0J2\R$^'C,V$Q$4MHR(<]6JX
MRZAV=\-+@<G[T+>YH6&6E:@6JA'R2"_'M+ [7T;V_0K&3M7M'95[W4.YK_9,
MIH:*\6;C-@GX#1ARM2]=,+'!M4_X&AMG5ZZ8 ^..G\6(Y'3*VX,54#3+X@L<
MY6_I6S $8&#X0"[J-3%^V</7,W!5C3NO$4M5#<@?Z3]H-(3^TYD=(FVF[&UX
M&5YZ[\ZA"M*+_7$?;N2GN/.73#RR*75*A/Y1H#U8=&!T7:ARA" @D]<Q#-)?
MU/UJ@8"#[*+M;ER P^)T[@583'C1--#>V^H@WU#\6!(G8'S;"'5U!L]2H7%;
M*DEF],7*OKQZ3=4G]]??' >4#7OWM#)2_@:K/1P'CI*I,5\&P5?8J@TS-9QG
MK#L[< N*-]T/'5IW1HVA,]YW.E5&>C]'LC+^U*6XN^\J%'E1Z"1_L2?BG>30
M<V?B!O5?EQJ6?@(2J_/:/2<VEA!722#*AYF^O(+FV7J=-W.[WJ5KS>(OQZ9<
M//_=<O'BV8OG9L+[N^,!O##NTL=N0/B+:3(U?&QLF0S76PJ_JB>H^X7%JL/X
MZ(#-H)/A_2!3,6[K'P?EWF)9Q^Y84X>J$:<H)D*/96;E<.^_'$O -PQ--I&$
MA@[A18$5K>UY6)])=P)9'RUO7ZGT)I;)'!/T4NBL6SQ_;M_**Q<*HCB-';1V
MT<VWSD'1P>06!9^BBZ"&3;_DWD%=W.GD7UD3I]L@[\\S>02G0>F0.)MU<5BZ
MQW!/3)G[7YP[ +4 W\VG?&C(1_&;1F+-??. AT8)]]G_Q]!:7#F,KDH09%V,
MI!W*@?KJZV_U_*2U>'6\<<GYXOEG]/,O>#'>--M:3VIMK(>U>.$O]N:M/XQS
MZW/M5G5\[M$/O'VEY81^VB'*D=(RF1W.%'F8IKQIA\J+'#L'I$#,I6:7%*8S
MVQ9SN.AWB-S0$VH46-270NO:^R.&#Q./[OP61+&?&Y"G_MT77C 3*03?G)YB
M\O-N%Z+1B'-0UO17VZIS2[XYTA.Y!?W-KU^J5E]=K*5D)=?W@>U-<?!ILC^P
M).@A*@SY-R:.Y7_^%=NG,S:2&\)O_?;7;&%X \S&S#_W'0JCI"PD7N +E-T&
MI7V16 YW^>>C>V'N\]TMK;':PI__'+AU<8[N1=0!KU<OV@O8NV=>CAVYK\7-
MT470+&OH7O^!=W;@+^5T47)HIH&NF3'C>N%^U$ZS4]*2)BDLV:4_$FY,0SVW
M$M>+UU_SA:B92B<M_LG8C%A4>A\NEF S#7K&Q!((H^5D@I?]LS"9BJB35 W=
MKOMM\F7<.UO'RJ .Y!J_6UH,"]_?C\[%E_2&]%HR\3JF@S6;!F<WSH>;G0F8
M.L;"B!5_',VWW\W-M[GY]D2;;V:_>H<.LE1F^:A/=F^[<"F*3*\7W^^JNE2B
M_8+/;CUY)0"4BGUY9&X1%Y$=0<^M'(ZGDKP0E[M#K7:)=DO5,ZWC2=B33'/_
M4B)^''+?N.#[\^IF\7E9N(=$]^QS^$6J5XC'-16$"N&Z>R2<DDL?$L2X!4^0
M(=&F8?R*4D]Y80CT*1ORWX.;#7+P;6A(DC_WE32F8IM(03E6H (8'2AZ%%.L
MP+EQF$6QY!19=JJHBS@ANBKUSJAB>DDO^EUWW!_2EF2%X[SKB>2\6 QW[=6V
M!66(R@)0B$&K*-V*?NBC+,)SZ,CU68Z 6.X;?GL9'6X70U7;+67ZR0:+XUQN
MD[3<A4(*LU!4M.?B4?(@2@@)\.5^M5&/0!^.V<=</F\Z#:$J8Q]*TD?4D+3)
MPNR0. D/@;J.@LE.F88"'_$>G1$70B6/HY4(I8G>>O(A#_8&NP-3H0;]YA%W
M-OW:*_>=6L*F8?KU<LQ'%"UUL9>_Q1NAT"Z\!Y8:T;F9D@I/\;MQ$5A2"0ZT
M1162_XTRKLOR82FC+ Z.XS><PWW&;,R9UQTMDN<IO](D/2Q16"'3>*>:C<'V
MA8>F:$^ZE3:YH:$,SU"L*X(DH?9YYXMG=--_X+1@:B,1&Y_?3>X?_%5-C=\M
M[@X1D=D9/J*TABVLEB'4OFM#2F_)DYU=?E&N2W**[)63PO"?ZG;%-9H_N8=A
M.E\4:HGT="DIA[TB[Y,H.=GHS3/'Y;[=E'5,8#Y*4%W"?U,AWN#M=:?T,;9#
M?J N!:>3\LXR3/'$6$(*[8Q=Q\< W]-"4C4JK/KFAO'S/N\U-4WI]*ZHGHJR
MX[03F8X6DO7-OB6"Y9A%C\.'1P0.W*KEGT#YE3H4O@XGYZ=?![BAO<)"W,L$
MSV5=W#%$)D]DZWU@XIC[$CPQC$[YN<B9'D-![[<P^N^A0*VUOBS%-:,$L&L%
M45J9+K[(+U!!Q7DZ)J:-&[%1FFQWT*:4*H\!'B3KJ4&$/Z-":T]ZX!Y F_3J
MULS+4A&RUH,"EB-=G5 RYU\J")F1@.FI08*+U"T:,DN;WG8E;3I!TDB!JBN:
M'E0OI/@N+4?R5=0AH_;INB"=";L([N/.:J@^1><,KR'A&)*3E#N.Q_H]/*D+
MUGO:>]^1F(9Y:YE^^0+OCB<$VBL4<ZDBD;0+$-117XX[EZL65'T:()CM0D@%
MQH\83\WK0MW4:(EM!-'KC5[*UOC>=*B94K9G!F<O)<*OX RL( )RQ:5DP2AP
MOQF($ J4-N;HL^E - L^^EE)%)9$'K1P^7OKPJT^E/=44VG)!-1Z&/D.GIJ/
M^7FP^]VQ5W;&3[SZC0G_-'!7G-E60-LI4)"C%?\L3$L[ @#ZI_,L>E%DPJ/Q
MZ5(M>A5ZLE>7AQ.LCW9-%07X;F=J=(&AJ261E PDP-_/Z!WS[2AOX3%B35=,
M5XK[7&)GC-CQ1X3J#T&H7LH>$3S(EW]?^M?A*:27"P_72_ :AHZZM]BF:6S$
MXQ?(4ICJ<2*B5-:D#1!LT@R64<<HNGFAFO[R[ZR61L$D>3$!&\8V:U.Y:*O'
M2@XMD /KVOH/CTVBD0@6G)53J%>"N]K='9?8+;@@O*"8_]0W?AD:"+>B.K;A
M$B']UP*SG:Y-0)9;1O8AO%ER6$]A8?FC^]F>8R7BKH3@#^%F"G[^):!OW,0I
M&KI3*-P$;OKKQ=^*D0Y*;Q!=>I>&[(7..F"XB+$\[4B3D13K78B>QZNW\.[V
MWL<.6&&1%H$1N3U$-LA.H,;4SQW:J,L4HL1$_@5)<?@ !9>BU7.69<U*GHQ-
M2IGDQ[* #WM+#")VAEH$Y/5H*:_11C[4"H+!(UR%< _WAQ_1=VEWN?M1YT+D
MGA %W#EKDPDRV40FJ#*2GL.N4@I6=;!>P"8#N9O$48?0CE'/HB%W  +,?]O0
MX4^CM#[,_?"]@MYU0*E'\YXQ> XVGT"(8[BB'MD,9^NA$I'**JU.$@N*K@-U
MQD)TR.IDBMN0EI.+PZJ:6+F@:*F%@FBFP:"?O="1>^=)4&ZCR:B,+#*17"4C
MJ9ER\%(*06* VZH^_=,F'E(]6\^4;$-4W&D^T98M:!:!NLB_(Y_8E^9:\*+"
MGVO=L*:DYZO6:?:F;I5 *LA!/Y)YLM_/+:VYI771+:U'Q*;?F +?\]\H'N=M
MD '[6TM_]\F+%[]_ 0\@.(1WY7K7,+#Q5>\R\IY<KX<BO NP%,*DPK=]01SV
MB Y?/'ON+OCI)W#IZ/](UL<QFOGMJ%K+*I5H$?FZZ8L7? :X2Q JR?@\QA^9
MC_Y6/>B.ZG%)@N.+=,1O<3J4)F1Q9]9U>;UT_[KF!^8L\);!J.S[3QHP6 1I
MT8NG_2TF$ X(W,Y]ZO>BGEG7RG([_O *S_*;9Z.5JF"?&Y92:3E$#Y$J8U]'
M01)AYO#J\'(DLAGTM29B  QF36]GJ03M.EJ"=:P8HQ'=@$\ ..#'OT,\<P@0
MQ\(;D2EU% B@7)0@: K1+A\]B'MH$D5V\0<,]-TK]S<M.@I1\NYOUKTUREN+
M==?VO8_\[]KN/0=>+M(4X;HMSC,: J=;L2LR>?\:P51-XV(GLO?,XH9J\<[M
M6VH$>;"Q'+?;:,J=?Z^GF7:*0&A\K%;VT#L@*5<^:T1X#]A57Y;O8:O4C4+R
MC=6))@4%D"K#1E1;=U'<S81-4+DJ0%A=WLJM'OL1YP'KD\IF^GSRMJU=F,41
M?+ ,C*?28NNK#K75T6O.##]H5XQ: 51>\0;=M,V5?SN_*J]OKD.J[?+PEF&F
MA.YUH;3[T*\M@C1]=!\OOF?%M[4$3*&$/TXC+J7\\'UY,:*0V4KYTE0'@K*
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M)JP.=1@U"&KHVT!?3VQ\0) W_N1="@ 'IYZFD:%<NYRZ0WU)Q@[!%,<])6^
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MJ(2NT?O28X1_(_(6W\NK6=O&&J8W8,04<Z-NCQ%K8K.\:@".M-0FPW5SY:0
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MYNCIC;!+7#UA#0RHZ#L0$G]?3TS8B]D?M3^::&G$4_VI3O5+<:>3EWS_ON[
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MH+1%3AI  Q;&1]$&\04X:C-2QG@4\P[AB/-JWN&C +AU88QCU/+I0 R'89^
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MRY=WR(5*!?D>#6R;H8(*=<).Z9?TJ970RSTB4--&N%0*NPY9 [!5'"_ F='
ML%82+S#4WAJL,$NH88O!18#WCD><,R"*QQJ!RLRPYMC:&WD!^A*5[?6^!+(B
M$V$<%3-N:L#90JMVK,?'54G=($8"N@K]2W (^+;M2OE!JR^]O/O)<WO30! G
M[=5T8G"S17KJ&==?(8"B H.AJ"?.ABN?"Z*WYAM ?UBAZJRNW*9>^IK&LO)M
M61[@Q*RU 4$E8%Z#5'5?79"&X(AJUSB<#B>V#,B%0!Y4FDK(6RYIL6*8LWX]
M:D\JN5.D8T"QWM*PM8>Q:&S# R;KW)F4-[H&&!.,>9+!EB?8TZ'98Z63>LZH
M-P7C79Y 6#,\ZMR,:D^[&RWBCV*11BS2V-$6\0E[<@(LQ%M.4]8%*JBIUIH1
MQZG>9BB-J387/=@ASN]K6I)4)L1#B]RL\:??KS@T:WT74*^)@[F$!ST5OH6/
M&D2X V?DF3V_WT$*]ZCA%98T02KV&M"9"W>(+<UFY6[WEUU4!34 \')*!_>@
MT_0F>_8"MQ=.G3.5T(8!4T$?,6F9[#\1]W9+_,2E>U/,]:80$[(O7##'-E[K
MV'LUB0,%K?I4FNW @'4;)Z"#%?46GXKZMR#H'! Y^W")9^]+*9''$*=;C=14
MX0]*C-*=ENNZL;'INJCZV!-@+65STU&<P<I.UW ;@?<J)#RH]U[ Z50>G@ #
M((%"R]!  0S@'A6E= SC9U$0L"X8 S_2&_'LY2OIC @ZIW"85=/N(=!%_ULO
M?QC_%L> @K+E>QA!T_TLD@H*8X?[R<_2 Z!1*3";I%&'>]TP.-"@X#Y,66 +
M@$.B(* /C5,"+@@KE(FL$LL5WR%Z;/K C+P:[7F.6.(!H?:G!FJ1ZK7OZ%X;
MJYL)?T0%Y=%5X;]@9$]RR+HM$B8E.)CZJ]/=[F?-B%"R!(+O;+4EHZ.N82O=
M,M?&!9(=7J$55J2&;E2#Y&2OM6KVX#4AG,X)S3:MR/[+4*?Y:(*J]EZ"P=;Q
MP-A - "/<P;HF;G$4:WNLA]:A;7BO6P$NBG-TO1:Q#V<<U\VPM'!*JF0/ S/
M!>JE^$U:*^%R_9,I$YQ'.]'Z!;ZNX>.\*&JBA8"$S'_\V^'IP7>C*1LEF]GP
ME6BS.;'3?OQLRZ9BMRH@BF(5U)4UBGV+':>&7*I"$._VMND$5VVXDJHKMD-Z
MNN4ZJ9;-ZH5!.*'I_-E1P="WJD/:8:GC?DI]0%70IK]6E$BD<ENX).%>L&/-
M.P)%*A9R3: 6A%91N8K6E>]2PJM'&BD [':&!ULB0.[MA&H-F*N-&)%KDY6,
MC1ZD::RR*:_481^[T0@O=*P_UZ.I%VMJ"<2@E'3BK?+8(A5+6[[ZFS^\4(R
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MT'*45D188',.C7568Y6@0U"0^[5YB<.?=<#;+HUQ)\J.'AS$LJ-8=K2C94=
M:L;](6:*-Z_7@8^@F&C.N=8L[//-UA,0ET/.MND<F;R;H%!O="5#=@R*.P*C
M"+69:\:S]L1\7F'7+]6>.M1,N7:E1M7JJ]_M53UG-*PLMW]C!'1BM>?TO.L
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MA>NJSX?^5:7B;CTI@66PSRV: 9ZGM*GS0M!^DA=U2Q0DAW/6R,D9KO%$1Q@
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MS I4M'#F61-F;FW ^5NY@N#?5H+L'ZSJOR4>V!EM-8/&;S4 F,L*K6O?65]
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MIPC\CPV_LU=-;B-_BE]!<A\>O !02P,$%     @ IH"G7&KTX97%FP  2\P
M !@   !C<G9S+3(P,C8P,S,Q>#$P<3 P-RYJ<&?LO =<4VVS+[J0WGLO44"*
M" C2I$54FDA5I(,* @$Q(B ! D$Z2!%04) B73I2I85>1'J33@)2!1)J@)!<
MWO?]]ME[?_O<>_8^Y9Y]S_U6,K^LM6:>F?D_SUKSS*P\"?$G<1%@NJNEJP60
M7   DO,70)P!;@.D%R[\\3[?R,[?Y%3DY&1DY#24E!14=#1T=+0TM+3T#"Q,
M] S,#+2T3!Q,S*QL[.SL=(R<7!QL7"QL[&Q_*"$A/6]#1DY-3D[-1D]+S_8?
MWH@M #,5B2UI'RF)('"!F824F838 8#._20G^7,#_K:17#CWD8*2BIJ&]ER@
MF@FX0$)*>H&,] ^OS[G^YWR C)F<Y9*,!@6K\6-*07<VV=?QGZF$;E6TLIL,
M8X2O/WD91$W#P<G%S7-91%1,_(J<O(*BT@WEVW<TM;1U=._>?V#ZT,S<PM+>
MX:FCDS/$Q</3ZY4WS,<W."0T+#PB,BHA\=W[I.0/'U.RLG-R\_(+OA1^K:RJ
MKJFM^U;?UM[1V=7=T_M]9'1L?&+RY]0T"KVT_&ME=6U] [N[MW]P>(0[/OD#
M%PE 2O)/VW\5%_,YK@MD9*1DE'_@(KG@_8< ,QGY)1D*%@UCRL?NK(*RKZG8
M;L5_KFBE%KIN@F%_\G*8AD-8#G49^P>T/Y']^X %_7<A^R_ _AG7-$!'2G(^
M>*3, !@XNY6^\>#CF *@_FZPIO^," S=?XY<0AN6:&H($P&WU%,BD)F]58E
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MT:NVP<L8ULP\LCKD6(EICH,HO*9+.KGS=DJK)/_.$L-;)O"K8J5++ZA*$Z*
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MO%83],_>/B94GR<=>T?GG1)W##+Y.RO:_\H']MTY-D31L3?^%&]W'/X/E/]
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M-!@B(;UX^-1C$\=S[LN?TU1,YK_0'/B'OW_^E,!45U[%.<?!A^JIDA"$"-!
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M[ M$"7QNAZ\M5X+1A,P'Q7$XPF&.O;FV\L,?\X]^Q$@;FY"MQWR)6TJJO#X
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M_. )%Q**.;L@@$YXR  )X8[<[D.&@2=9R<#NHA<9"+(BBFSW!R(5I?:)*V3
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ME5Q-S[/OJA8I4J@R_I/'%_P7[:\L/\7%#G^33]MTQW$E1CGMO/W9H5L7"\@
M1G0(N2)B3P9>723)X@^[GAKC=3L^%:4<Y(PB1V3*I/OTMR1.=T061/"R]V0=
M]8ST4VO0CBN(V?M3!N]S>ZJV E?)P$6'LXA,S4J"2*./SR4Q_F EA=3"")=1
MB[ +1\ZGG62@18/;$NF)W$XR1Y::0)=[SX+!A2NGE=#?1/UFZ#]2((-LL_A(
M!GZ:]I&!<TQ$UP6T&+0>??@]]_\F0X@,6!8A!U,/R4 K:#.*# AB__?P:QV/
M&9,0Y6@2@'RF?P1EVM8GZ,K CB]-(A?N(./ N#0G]![+E[.GOR8#[ 2)?\6Z
M,W)RA@ 1#1TO0NW^"20#.,J3)\@> LK_/Y+[5X9RU5F4F5V:3CHO2)CX%O2O
M6--0,["3WX:DFH=G0:[(-AD(!D\SD?0[3D;^D5HM(G^&Q.F%9VC<#6A7"^V_
M8854D[!G02M/PGY1/O$(AB0"I%^HG2#!^0/%FK1"]$;Z<^N-KFT!U5_'"V,-
M!-UO+9*C"-K2SD+G%S1G'G3D:4]*0\46-#4P;@$4R>[1(79%H@3VM#BLOM9N
MMXT4,?WSL#RWMRK#+P[#WR<[TK"C#.%65"CW7A7OUM=@-AO*RO[OB=Y9L]Y.
M"+H!]\5$1/!/-!D76SDUW#728IJ=E1MEV&!A73,/IF[VRI#?I,<M=W SC1)U
M'R_2"R]KC/#'<ZSGO7\R^=M>>US5SZB_ETKK-C98^6JTJMJVIE8I(,;\CKOZ
MJ<&Y(>LVX@-<**&>8(+0_R0?%2&HQ3IT6N*)VK>J>[F<YSZSEN;CFY96-:M.
M_V/ZUG0[WRO;)T46(:%]E[-3XMN"Q0PM; 7QIDD+S0S+YA.RM($2NK73RS8S
M]=J+,]]8^?;Z;B44EMY/L 0L101U\*8I92X- YF/D?1C!PF*EO/?..Q+\^#)
M)EI<4?%W/7(OP4"$?!V\2?/,\8,<JAR6TIEQZ2:&:UJ0!T;F@[DBYV@VG"A-
MHWO'B8:?""_<Q,4>D&AORNIV5GRQ>'\S"Y/ZP4[?5#C>D]13-!413U3.L]#R
M\RZ9U' 5R,XPZG>P^;SYYXHH&[CKJ9+/_B S1;.& &9-A-H,OQWQDDM@UQ@]
M7E):(KJ5W+N$6;9)'-A**KGOU7XUB0IT^_&Z*L?>7_G(B4H_SPU96)*!:!D4
MK8:]0"F2*BN][ODOJ^HM9EU/$;=XV7T'",5<S2UE)PJGD@1F>.-=W(/DX_Q(
MV0 Q)KT[+%O[M*]#^ 6S13L87&^3!.&&+S<I#6"75X=_K1]&Y:_Z2LZ(=/L]
M[]VH[.K5=N"15P#/RE",&IH?JH@/;4(,[3 ]-32\$Q)N#LUUE0ZG&Q4=W[\H
M<+6]N\Q$^EFD(DQXAY&@M+68@L=T3#T(\_;W=&/(#> $20VHJ/;3>G4S4XR<
MB5)T"P_!JK7M.R&FP]+VM02JKT8Q[O=SO\WNWLS(&3\N96>(%1[<ED41,N[!
M2$BY]_-&HUO:CHM94NL7E(:XICYO'O#RI9DR%A89Q(ISC_,H=IWC&=YS$U\H
MZ@Q ^G%*?C>WO]-XF4&+EZ7J<8&52ZV!K<6,AK>SXD6>+%:&Y)ML=)^>JW%U
M N;_U9^ZSR71G<&/[NT?Y) 6 T5VR[_!V)OL%O3CD354J%RB$EZK@U:'J%8]
MLRJ=G_[H0A7])^UV]Q=6?_:R04,W/*],GG0>$6R##H??#Q36>5)ZM@YZP3+1
M5;YQ3VMQZ1O*;@'Y4VN'[,7PQ-J\H-WF'X5Q FY#5ZX;F2/R^\T6Z.Q*3294
M;A-U">O@C<7%30L9/<%6$@\ASRG#)/[M;A[QBH8,[O77)]/\#+P^"K0AN:&-
MP:#A-9%%?4K2*)@)H?X1X8I_D.>[H$S;UD(SX>T!,I]Q&;:V.DJ_/,@XW;0A
M?R'.\+N2FC-7L,';Y3=5IRU$,TPY!?%YR]AFM0?S/.%JMW;CB"R]8MNZ7@B^
M_)=F,1]3,L;P%U<KL6^$F>(P_VWC@3L'_KUOIR(:@B'D+6Z_1M4X=H"9$?<"
M14S'($HXMWTO9TQWAHC2A_3&-WXOI)\%3MZ9A  SCD[S!+T3#\)AQZ)Y@DGU
M4$U8^K?T%KYJ]+!,YKJY3-_WQ[=B1$*A3.?J>>[:]QA)?9>A./2X]_3%I^]<
MUQ2S8O.O3_Q5?P#J,A\])X0W^];GP6X.-ZR6B,IB&Y55,M][76\5H^/F-F[J
MS/:KT((2E*35]]Y=H0</"H=>">)?:V$[3;1J/4X+6PCDZ/!5[!?[:*7N<Q '
M,;:6"7\T4J7#II?WL-;TSH_WEP'J-<5[R:PT:YT,X\ R]<^1]04G%65X'>8@
M]$1U/>@BSA:EDO\8KU;=V%>LJ]N(%ACM"K&Y [^JZ6P!6)=84=]N76I).'T?
M).("8R>!;%V-")GMEC\(]5^K8TQQ,U[=YS8-*S_7U9_3YN=XY?2V5N%&I S%
MQKK,LS^4(>T%@SPHV#OP^6K:P1#H51*G)=$TH8MT#;^46]I<!%]KMW+35\>[
M]F[^F1Y@B^ZLES0QR(YE?.X?0$<&:N7CGQ!,\@F1EBOS4TQ$FS,CQC8ZK5-A
M'IB'G:%^AY)W2<A4&,3]I)X:-?O6 CFM)$D0GO0MFL6(5I^97FNX$B8]1C/5
MRQ7B2QL8Z#1\)],P=$,+)B.WFSC9-53W03\:7 /K/(5V0[G%B& WC 1!JX5M
MM<&G'EFS4"\O+[<S>?I96[.;TH^B8IGB.=7X@"KU]*A9CRFRICMR?YL17NU\
MH!C8DN",2YONGGKIU;%Y:U:/HSY>DX[R.H4F0%TN.T"0/L@CU.'!7; +3;=S
MU#!6?D3[!6VB<9'UVM7=S;K$!Q]A_"8]O XF!EDE%Y_170;5K";?2_R\[*TQ
M<*O[7(L0<IJW<Q4_V$[BJAE'L&'IJ3NX^1MPO^6.Q?)^E^<G<;RU3]ZO;1<)
M-URZ&QJO:C<*CX4RJ=P0W$C 9UK@][?B%D]TP9&%>=,6:Q=]SK_XG'NI+]PB
M]36ET)/8*W74/@N>JN!"9K/.N=NG94V!&!LOK."KQS5#F=VU68K#$"5,=8 %
MW:U?:]=UZ;[DOTNWC[Y]>"N5S;"U((@O:#)(& ?M"E 6'S3]JZ[@,CXN/2Q_
M:*_/]6NYV.*'6IDJ6\_S7L4O'GV[[MDH0W%0K)A](1)X[W7G>UPC'<,<J 8Q
M<G)OS8S[^NE'I",,\-MISW-A[\K!<NQ':^HK.(^W/)6J!?5_UJ%D@7#ERNZ6
MAZC($OJ^@:^0 1<;:1V"+S:!:U(/&S.F&)[^/.M!%B2-0SOIE6UCB^THQ3'$
M,5:33_P<&#O(W.+R^ $F?"%@8DD\:@'*C= Z344Z--MVM1OAST2I>IUV$J&Q
MT$?ON7>RJ?LREN>=M6)UB^VUC=G5->T5;WTVIP-4Q8_#6"(3%GQU=AXABT^M
MS>-*B+&_6;!JU.U]2?=SO]K1XI4'Z^%BB83-8(IC4"FA6 OW2]!D=//E@MB?
M1H$E^UB:)]-+VCHKQ<TO_.G;QPL(7ECY<(@-RZ<,E<;'!:63J8].(&M=FC$>
M;[/]R_Y\7[LE\B.(IS.0NJ-Q]@Z8%G4M,X&ZCSLS]QZ>S\PK;TJIS1*6Y$L=
MG#R;RT=9^W6;EH TC[' 01JR4I'YA'(#O-MX8W&?%^>]V-#[:6SL-YB3+[RF
MJ@U3KUVLOOI[*5@E_F/BR[SL<XE[,O]R_$$TZ189Z#'"2YP&@DZOIG:9.?['
M;!$T;1<9:#8A \QHN:! &&%D'_G64(.EZ]'_]&2ZKPOS;"ZV5./8T;T>'^TF
M':; 'N.&BCV2282&M:"PD7%HE8;F _I[XC_ SPF46*I,/.U=W77626&,8ZW7
MO[I[95DM2@2.?'CR=E>%'N90DL_\Y.GPN<<[5;WU6_J/)R 3OU)/J/3C"Q/:
M ^XE55G"<G=AA0>_1.]6RGS]7$(&_JI</JO\W]G"1;E</AWB.HU\/76^P:W:
M-R,:/M(>Y^8A,W=/5VCLNE L08E"X4+%<X;GKMUH9XD(6YEF''5G0A2W:.UP
MDUB!2X-I1/:4L[_84/-4Q5JAX)1C:J[JCGNF2]GPN;*+MSL#<[$2M,XJ8E4A
M$^8C"Z-N"PWA!T);3,]U<CSYC$ 'J:.2*A\3F A6.OBL*,_<]8S EL+/ULRW
MIF8^$V9RB\NTJH23MBX B!HLBJ4'Q]0-OKK7-\]&*%ML3R)(ZX^;8IW'2<?C
MQ]B=M='F\K=R-U]48&AVVNDPFAI><E/="3)Q =BZ5WO;S+,$1;N%326CBGH\
M+))WU+;MP.KK@H,\5/)U;U%,G2A+])?XYT'-XRU<<+N.](R\\>+L7R[2:QG^
MJV8_O,_U'&1J.-J'?<,DRL1[KG55RJ""40Q[2DKK5E JIR&K^4EZ13S]Q_JO
M=0P#O.D^OG$#W4N#L#P 45B*>( 7?$7BAK>WRS&=K1.\J"(9B"B1Y; )L([>
M?]EG<P<I],.U\/%WG;ONC7D]4?$^!:WE+TXS-A$6']=;%(80ZH7M*IG._._'
MV9_.72?]0H_T)Z$SJNY_+Z_LS<U&9,'>/P*I_E2Y" >U<[.>V>S/!'V=NB%O
MZ].6OHW>5=\N:$ C/TZ!(ZIU-7H()]@.HR7>&A&HP-5&V'^T')1 W;+4J.X3
M &8VQ^(!-KX%0/$2<-1H2PC @#G@[3IG *7<XPHR(%9U+(P1WEG).S6;-S'U
MJ38>\V5G]MYO7D [6O!&Y<Z-%:33_/E?A/2#" (E_Q]2L0/8:.S&C_ \V0*.
MEY-_KOUJI[NWD-1C7?B=S\S;^82?>*-B-'=4K(DR]YLO)QEPUK&+>Q/EZSX?
M_&M@RVO=9CZ6!#[3&"RI>?F1>ZYZ3VAUWS35614<7G.PWDP"F3RZR$:=PWNV
MD..).D6$M,&%[FXD.YB-$*[W8*3+MT'N T4SSUS;F&R,-RTCQ6A(7WU*&+\F
MM16L>KZCU';<(^I,A\>78B.W$$R^]D_=,TW#!^]5-1B>+S]G>;K^95UQ^]9-
ML,+#1QJ!CIZX]K9T?X;2CWK9YCJ?UNH2"F 6U:K=GL]WHBS-N'Y]+^HX?F6A
M(D"@QFUW6?XA5942I#7'9)4(IK3%F9DF/N_,*'S]*P!@'DX1BPU6*'\5"\7X
MDGX6HS))C(&0165TY3.1+IGMR_#,SN/\5WLZ$)LRYY\N*!:B1=[LH)WO%[.J
M<&6-W%!/:AK()\K8,@KKRS3'!X.MQU0H[*QZY]4&O5)TI.PUWMJF49Z$9W57
MN@\IDPYK]\[OQC*DFHY@TL.>B9>4N>UQ7'/\,NKN'>#'>)W.+/V<&F1]98L_
MQ7.[Z2=U;PL''A8E4SS(0'A)2#=K^3*B(FM-\+E9[AY;Q[BZJ)?E'6*A_T/(
M+(CV*<:,;U'V!X'V7@H&W6ZCN7AG0K9^JXPD_SGUA;BW3IFT.^3.4&I[Y;<D
MSJ.X\?M_HLJKS# )84:K[F9JE4QE95.XQ+NW)/H=>+W(@,TEQL9F^H=0JJ;+
MWF[ZQF<6R4Z/=2KUM*S03S*84GFV<3O$AXLN<E[RF2/D_4_J/C"3"O]:'[8/
MQ4: F>"5IB81JB-$N4/YXR9)YPY:PK.M#4P%9^_[OI-N@Y,Z2;<BD:R1:C\5
M+H048;O$R7*ISJVH&_]@1']6H%BF/JQ&65)JJE]S6<?" O_US<+[)RW-S82+
MN&U#/,M<L]?"#W8WV[4ED<FRJ2'?F@[WLI0 ;;;+6YP?<OG&BLE J K-F*R;
MG7$#KBM3]J!B?,>%28977O]\%)_8=4YIWDXV.K\CUBPARC^HJ"Q)/%=WA(H*
M\8[*K7$9?28XI75RG^J0VS:D\0;S92L=NA?3+]_/RO1?1+S7SKF4^ID(:\8K
M'Q)ER$ 4#QX5]3( ==YJTH6=&_4XZ$E==;T-#VWX3/ 3#4<^&;<WM^UBWR<4
M>0^&VE+C)6+%("9%!+-[:#Q]H?K5',]GI4(W^Y^BL$)^1B_,:H7WR4 [DLXE
MD9#%T<S0"R?>?R6;"O\B,7KWQCG8=M#FG< +@%_YYD6LFYD>;K[M))-CM<0>
MC:]]Y?'";:8\DZX.T&';-Z4^[V_V>M[%5K .UQV'0$ \L.I%3JBK\4F/[0YV
M1.TJ Y_,36[.<3ZY*]6[X-YC*[?9#75T56$<(JI[Y*L5.M<>5JQ.&,Q;\O74
MJT,$I;1;8O,3 TQ?HN@0-\53 C^KO'HR%7B0?UKIY?Z$@[]I-\U#.<)W]PI,
MI8@>\"0#W& ,*8HUG&B\&,-;-.<TD8Q\[!Q9"JGS'>YZ\C!\^M,(BRCK]8T^
MN8?GM'[82A"<L1[GX!*8JJDXP?8Y ;Q\%]_$PG!MX.=N3>=-\5JK*TQ""-''
MJ,? ]RVU;L'UA$CT!>(5O(N>+!&&*:8/TI/O/^&8N^$0VC^]].QZB/PSZU/A
MN@@52@)EFV5@:GP*1D^Q=[C/V,9ABB\VB07;96<QP8=ID[(^9E+EYOUD =\:
M/!C&7<.WE&:O?:D+E1W\\H%6/V/((+!8?[9)1S0SZL@SUHYZO(8$76D!I71P
M"PR]A-&;$QJQW7%[82-QS22!\*X>ED6KF'!$C.M39[9(:YGRMG!WE*HUW$R[
M <^/BN0?64BQK*I-&Y@[2CFL5.?EU8X.H)+*X3U-LH;&D &'A'!N9;S8=J0W
M&;BPZI]5$U!A/:_'X?=E0S6J/D0ZS(#ZLQ!E6Q/_ HC>"<H.,<3 N/OLRU?G
MP 2SC\[C\O[#Q1=+$F>[ R5!B?(RGJR\J*\IPY4D%A=NKI^D\T3P^/X@/8B3
M:#N.N.*<ZW0LMGC1-L! /B)1YTT(IR*;XZ-;YT+K-XWW!B.ACF=&3D5X:$],
MP@+GD%!D[N09*;/BOGDW9$X2V!G-\N&D*^3CI LU(3J?*!!E"!&EW<6$B&\9
MIH6%W<_2G+UE[BJVODZ-9>']<SZ9^AYPI-4^3T,TP>UB_Q)GP,H6;F?Y]6<0
MQY%_X'9TLD5)\N]Y^6F]$L#^U\VZ6$2OD5BS[Q68-NG[\7Y\(\ZHP_GX0D(X
MIF+46TQVX^4[2RN0'.UD;IJNJ?M]\;6!4 "85FTM2S$^1;5PN:J 1B!BR(53
MX5VUX<FLK@$G>;$J*?[89P_^##QX[C<H.[FB2)6)">0>U!G:$*MN%A^0HF_^
M\%Z7V2![I:@(H%Q595WY3WL^_JW=D3^G[-J/H#^!KG!3X 4[2EVZMD@!*&[;
MF$T-<;9+=[#2W#QM(5373C=V;5$: !P<"K6#T<!YYA=^RUEF50H3)>0W/QWM
MW T:.JAHTX?22,=U<_B<+'V=Y3T <"JAI02'K>Z.+-$$7=Q$%&M'@TKP!+X6
M92?IDY2KW>_WJ[]C1Y>BE5<,E5^0#0(:3F.:KB!QW5CPJRV/FJB7@^R$:"2S
MS<S%(<>:IF3S/U17+P87X6]2A/H.N)0@*T&A'J4DWFZLF%='D&A*]Y1W%JID
MQF7"D TT^>5)VJVD DTZ=8JX[(+6==1'IVS0!^*-$T:"5ON<X'C-#]B9E.-+
MYVHPOKBTCRV\S3KC 0+/.Q %>=J T/2KT9V.RN:%\DG6>[B@U*+5%_#=;O:#
M5.\<7<RT'M1T['7:^-7X,*@O(T^Q=I%/%!]=*YU9LZ$J]PW,X*1$6PM;(T'/
MTZU@K8P,T.]ESO+J,NJP,75Z7>KDU7O])Z2 UWTH*WO\0L2&_,(I+Z:\'7G1
M.8,,1.[U("C\E+>B2J>L.^HJJP<VA2NEWM@_^J,]_1.$..4ZF_HGI)X,ECQ4
M7(HNWBSZI<@\,_P]X8N;N@[:RF^SK'?SUVN!\1@NNT0%Y=W.E_,T2,=M!@08
MEQ\I8W5[>[\6?Z:$BUS/K%,QW^&A=(&%S8%PP86']$79E_:FA"B7/*B"6ENH
M<!Z1""D?B 9V$Z:&JR$#!Y_#,('&#YF<&[R_\Z?=U7LU,*QCT.^9,B$H91O4
MJD+3,%$FD7[&W0A])(O6XK67&J.7?TVOG=.7FN25^AT!X>I(O#@=FP+3-U0%
M7X%K'=S(Q(+B6Z1_X*F6._RUPKVW.5J*&1+L"C5K%6<S(N=X(8^D .WF:*EK
MU-F=<>H'LJ,MPD%#\US[(*8Y0D([]R4\GZ5L<TD&=PZSU-H!?FJC/N3AC8'6
M.V7//YU3Y6,4V;QO& T<'7:3@4JM$(07UBK0=MX4SQK61G@.-UKJ5D5?Q=DZ
M]]+$LZF9*EB3@8ML &72^PV$RNF;)C'<<F?+>3P5JL E998 ;5MN\Y&:T6'3
M$=,-GQ>XS"2@9:!Z4.[Z,5C%%5>WP;] !FC6YICKO^#EHS-U<67- NA<IY2Y
MN^.FR=]M/IP[4GNGJ]TMVAG^G*:G/V-P0V+AAU4[\C)$L6$[LA0!7>1RE[@\
MLUHYT_%S<DX4ZQL0.)3\4=.$[EH=8,>R%\9,L1C$?YH& 6-14[SM9.#:-A\:
M=F5E_..<DO9O0T=IX?[*'SQN?=HQ2F&WKV'KI]&_H-\FV$<G# FH3M,I8W@M
ME%TK1\./]=?'T;L?M1Y]%OMC$7'C[>*'>LC$\*@!=1@BD&!?[@J[JG*)<*:U
M3,%39EE,$X)UHV(=A6RD'\W![9[79S07V:ZT#/4 V 80)6F !,;Q'W;T-8KT
M'7W"'^2(YQ5>G*4)U^&52F)@?OP</INQ;WDF0:OHQS JK87RB ;Q=U@PLQ-[
M^2NWI9HAHM:G>3[Y=>82R[N)&T)KD[P7D.\&)?#J!RIZO N<L(M$:C=DT12A
MKC/-=TYX0M9J+'EU87<XH/&K]>;<QO6[EW*3V^,_MWS]&,Q>Q*(* (J@>]9&
M0_\C==,9I*X*9B':DX'D/"SL^/BOLRABR^87N:H'\>H=L97:O>[A-,:A)]5E
M\AMG/M[@1>AV*"S<SOAX#(;7W75<WA\YJ-I'OF-AD?BU3 :R&)'S5 F5@V0
MPD<&6N@])P\DJW@^YIV<!0.[;?HG"T,'M\G \FO4X;>/@Q46289&I_'((XS@
M*<[IWX<X_A+]7E 8U TEXE)(!)G ?QM1M7'UZ<.':#L4":Y#!A#L*O\VPN*
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M"^7+KX3G5%?V>(NS[[]TS]1>>M@8LZD7<C%*MU:2,X70\H56DG9NJH#B1_2
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M4N&/.Z?M6X$D2FN7V)1&"?R;YIG$JC7-9U<.8OI+@!)[DKW,QDNGE?T ;OO
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M7X#_UTF8F*%C6':S[][-SL_%P<7_[]X8]0#O'J9"YC?,3$> 7;Q,S+Q,C&8
M!LUS-]-O&_#7C6D7-$=6MCWL>SF@7RC;!^QB8F;>Q<+\:];03T.AGP,LO+OY
M#I\^S[K?V('MB __F?M)K_=(7"AN$##I)DF>O7DGC'VOH)#P 9&CQZ2DCY]0
M4%12/J>BJGU11U?ODOYET^MFYA:65M:.3LXNKF[N'KY^_@&!0<$AX0\B(J.B
M'\8\3G[R-"7UV?.TS*SLG-R\-_EO/Y24EI57?*RL:FQJ;FEM^]3^N:>WKW^
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M_8A27+-1^/B!#0TA.[+RPSH8R*7PR>(\^5@R<<3NPMC.>J[M:/M)5^: .TG
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M_J%[K/H:OUHZ"_:Q[^]V0Y]7=C%X/Y-OK+OY]TAGQ@"_'R0>T#SC*%11MQA
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M[J&KV1XM5[D7(+IK)?*?U3YATK-C (^.0;?:?A4S?PS/BUVI&,![^8]O[_*
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M0)*;I;497!A-D?D_7)A5-;LQ7MOIRD4Q?5E^F3)D-_SS<ZZGD]'5EC#?#W*
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MSSGP5?(A*!I9BVQ13\-I^;,#;K<;DYQA$TY.D==;+/QK9']6Q+ZX^YDU("
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MZ+$U[;6 /=BMW7O-F6%)\TV+L:+]!R58'N'8=XC!'.ES0!!Z&:$]C%FQ-+E
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M?Z!LWIH.[(E#^5B9U8]3B5061[] V3+_V-<)6</:&IQW?%O^UV P8_IP@U(
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MAHR:#4&T9G3<MTT((*3<-@3[?M,]#J.NU3#7NJSW](A\:;S+K5R+O>%5:5-
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M7+%)_O,;0/3SRWZK-Y57GP1JD)MEG; B(_H5$(CLA1.!R&C]_>9'.\D+%\E
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MQK_@UZTZ8"6>J&SJA![COK<$PGF\S-C4FR_[>O+YL3ZVF+#B\,LHX-%=>65
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MW1N &T@\00)';I0WO/A\"J97X(K\;,?^99=R/&947=KU)T&1\(Y\J+R:UR2
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M?:?VV*$1+7$D\C+E::"$R[S>/]><AZE4%>+\L%J6&*J4@+(E<%!WLIGAVG@
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MTO02KYE;/@X[QFQX%YS2,?+&SBCM,,[@A7&+&W8I2(WA\@T[^I_0G%&DP:-
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M_-J.[O24C;W >3I4>P%.LHF4C:-<]GSX189L3*Y%>C%X*$4GCOX)TJ'>C+Q
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MSVG$3XXN<NHW32L(+)JULC99L"6%OQ'(2W3[O[]<^;\N61[/_3]02P,$%
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MLJ+0N >UZ^668[%VC2/=ONF*2:/ =6Y? :8I'E 3 P#7!HYC_@E6UFR;MC
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M+T6DA )U0NKN/[H9&OVY!O<VJ5!?$Q_GVT\4A-F17F9/GPCV,:N0$OQNV]?
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M/VO[T7R04CIHXN:L"1KZ HDXZW.]$\S?A%'2'[#*-U5CU==@M=YVR$L9$_U
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M.]55Y'B1=K93XXQE/9*6=<WT0FCVXWC.!6<_B=^S-<^:!8?!7,*-8J+R P2
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MF;#E74XRANP)(YCT^]CW"W<*07@3_Z3\-(EUO<4[$-R'U66,8903OL%X.(<
M!&X1&5^EH?- )P&@FG"3BO;T H<<2,/..U3/TOKSVN%+VNL53S)$O^.MN8=K
MT)D1#OA<M>%W/8<2 J 3"1#Z->@(2P#0G 1@AQB$:"KPW@0@"('77,K'+LQI
MSC["2)1^6275$L&'%+PF +0-[4_<Z([#/FW^=/!FR,*Y-T0ZGZ\A^QPBZD8
ME!8,\#<+9V9G7/N_K2W&.%X-1 H0@,^A$XLECE=AA\P07.GN(;;/LH<]DQ=C
ML/7<5U$I&G*M2QDL[%@CE@$#?#)5)K]J6A* ;WGEZ*3G23#NV_>/Q\Z(37=
M<?>3<76JZ_)":!1B_2*D[^7N:N/C^9B*2#S7M-QIH"-[$:3LKD^C>3$H"S40
MGDW5-),=#\/T?GD>+EI:&-6N:SQ7W (EIBO%5!S]X]?M:6@T&JJ8A?NPH]7(
M,!_SM9D=+5$><'M+XW2GY$'6W':42WS@**I,G  ,IY0-]BQ+^*FQ=8F$^CTJ
M(@!S12VG%S77X4Q6Q03@S.#)+/[ECX54 D"&TXZE];_94$, ;+^.%($.1\(K
M_0/0+)W'V^&"5=68,GS=4U[S)_L2Q;0+4W94PTI&]7^)B^:OQ/T_'G]#A.=J
M2TJNC127-?%G30UZ8K.N%AK*UN5,F>.I Q/U,$HQ* (0TGP%WZ_H_'8JBN(P
M/$]"=O'M:Z?:3?,@\YWN(/!EDFFN\U8)3K/^8I@:T[&]R/U;Z/?8".W ='B8
M%_76M^-0EHU$3?PJ%P)Z[R77'N(RQJAUTD$VJE%MKDE=CQS[#N\@^>2N;!EJ
MK[8&(@8_"#\W4\)UR7C4UU)L-.7,1^\EBST0-E=(!/00<N)=/&HDWV&[Z]%_
M45T6-*&51P Z<[8)@*O?+,HO;:/Y.E;1=VCFY&Z:2KT'7,"D.NE+\%Y?4$N9
M-W=@B4V)RO+#Z39?!MQ>3:(UM)_%0H.CJ^;;EN4WL(2]X;%@I5S:V8]1RRN'
M$=E'WT%"\$/KGK%Z'40('_6HX(E7_*OZ![NB7@V#DGS?$IY?WGEU\7B^4>D.
MK6RK[":K"$>E4;33IW)/(E:?;/CZO!'FCK$8U*;9&"WD6!F76II8+UY1R$?(
M0L[B'K\KPK=B@WVE+QPY(T\>;K/";ZZQ$0">(0+0KH$147T9I]&>[AIYG@P<
M& '[V7)Z\HIAL"1F?2@"4_09'/,:]K,&]EP#-)(+F1N-;8**$;E0:?/2@%9.
MXPP$SDV10#M/RVO5_M&.3M89?"L6=+SR+IGOJ+Q'%1,8,6]-G[=VH)C0#1N4
M9+Y)]8UG;,_MN^-VZMM;LT[KARX>HVV6]I*.+R?,-PMG*Q!JP@Y.50N_I:&>
M\7UZRXY/^,]#%T;)[/IW7<$#E<,@ 3O9"EU8O9-"UV>)BZ9?3/=U RD3DF*3
M'?%WB#SN]H*2V((>H\_K1[5@[I"QKN4D+F'%5\]TXWM[[.&9#P[+Q^H8PK)V
M+C(<GS81@*'78HCRVPQ*']!OM>H4!/=K7 7CWUB^</K*.I^3[*1SN/N$F'.W
MY4/^$UGO;T] P"-;=L1U\<=$WUQ=?X4EL@K^SMEMQ&XV@\ _JA[^"2'K;7%T
M/1(D+N7WF\,$0/V,Z-]FVFR&VK\V\%HQ&\]V?*Z:G%@T0<+*#,<TTDRJ7U](
M^O3 NI^W36V"TKT5?@_*XT0 &/=!48C\/JJHS4;W9L9&_" 2 WU1E5+75&7,
M[^,]NU))]^6<0+,P4EG=P(BRN0K;@UJ'L.$D,>#D(@>3\!H[;RM!]^\.DL7>
MEQ;RA'JAEZW$DF.#+2C0B/FL=BDZ;/U)9Z8H=N8X*Y:YU4'7=:%8PM.I27%*
M4]!>MR:%9,:,M+\M:N*RVPC9*,PVCJ7C.31(2LI?;K[7WS&]NQ!<""LQU6"]
MTC09QLS?QDE*_XZ1LW?JK(Y-E.RZP2+H+%@!*S /BBH8QH,FO\R?4\C4B=/H
MY-9-G996N!F\.Y50(E,6Q@GW!?R_ T8EW_X=Q7 HJZ9E[,N;SQ!"&MG%;&S@
MM?>G .N_]1[N;'@_5F/59_RSFN;^[]%/]_=N5Y#RZ6\EU<BO7V7<I3#7TZD<
M*Q7^V((,/_CJ]4.BJ?/Q8,^[^VT(@0R41A28H_^PA0YY_MA6IP]%;VGH=VW_
M1*E0@NSY62.1;(1M3A.=I&(UF[S&0^5Y8M5M?B)K6R_C_;@"^?13MV+7-D<I
M]/WVCQ+9P=RO.'H,0@-C6^ IH3ZSW#XC'FNK2VM$J@!OU#VTM0#OL.RQK00X
MI6/&.^!G<9K#%/$M!3W/([U5Y2[*,/Q82'B<&%$DNUR+C4 [%4Z A7QN0K+'
MG@SOF29 J(['74?1M9M/X4FP3R)$0^FR%L7 0\G7 Q'AW>MA_LEX+640UIH
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M"X'0?86YC?[1QQ8E=F7?50(*IU7][!0CHN=G;JRL^87S<-=8J!;C6)K1\>_
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M!%K>(K:DRF^YG8;,79QU$Y#Z:C4A+U"\T"PV[M0?3J)#H\Y9;R)?4)>6ND8
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M(>$JA]!P]Z'0!Q>)B&)> J8'B&A.C'O][$MG8E0@M4*9D'V'&1N6WJ$Y*Z@
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MN)^"Z=K:J^3#2]=FR@G[U)^Y+Z#!5:7>JN@; &C*KX$^H_99.<&E]*O0/GD
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M0!3U:A$!-R'._?)WVL8KZN:\6V5=62]6"+_^V<47/O^Y:"9B^*@^WON5X*K
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M.JZR]] PG+Q<#4.\^'-I^V\5RIP9(.*/L.UIDZR'";:E1E+XZN8P^;%UJE]
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MCF9CE\R\L%-H4/0-3$0Y/$2D5=9:=K.QN3&>_V/%?9/;G@1-_PO>&R.3320
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M0'NE;*6)!T,/"O>L),LM,<@N'[<+]9AO<9>IH^JU5O9NQ9A4BRP6BYQZBI(
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MX,X*3@(%MJ_^?]-#^9^[O_+?O5/X/^W45RBQU4N;2$SVFESS<+S1K7)C $2
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M3S\RT1=*'KY8&"KN,3?D'"J5D:*F$FTF5?BR<(M<LM(S[9M6*'WP:":]+=*
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M4KR9LJY2HK&Q"X8:BLCJ=Y&CS3)?U0>2"Y5'&M6*QQ&<K;E/1Y._! FQ/8]
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M&\1EFGF_SI(0EE7V2_*GI4^]GW#UCRZJ,ZV/_.GCDI,.;4BX)'W3]X$3U[W
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M)2$+3NR1/#CRNV';#Q]'*Y 6)/W@]55"'38R231;E94CRE3PL+!<%.1&V$:
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M6JA>*WK;L(BG2<^,Y(7B0=A=PQ\ZJ)KJ)9AGOO^PV_Z;%/-PG?S/)I'M;OQ
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M,3(^P;1HE&S[;VME'OK8/P%02P,$%     @ IH"G7&/=/@5-H   Y\(  !@
M  !C<G9S+3(P,C8P,S,Q>#$P<3 Q,"YJ<&?LNG<T7&_;+[Y%[[V7T1(2$=&%
MT2((@B!ZD$0$$42TP3!*#-%+D) 871"$Z#6,DA!$CVYF1"\SHDP8,S_?]SF_
M\Y[U/,_[.^?]K7/..NNLYYZY_MG[VGO=U[ZO_;D^GVO?I)^D98#%4,] #R"[
M  !DYS^ - ?H .07+OSU/Q\4YW]*&DI*"@I*.FIJ*AH&.@8&>CIZ>D8F-A9&
M)E8F>GH6+A96=@Y.3DX&9FX>+@X>-@Y.CK]N0D9^?@T%)2TE)2T'(STCQW]Z
MD+X K#1DQ>0?R,E$@0NL9.2L9*0> '0^3TJR?QO ?QED%\[G2$5-0TM'?^Y0
MSP)<(",GOT!!_M>LS\^&GI\'*%@IV41DM:G8S1Y2B_IPR$6DYM.(W:SIXC0?
MQ8K+/WH124O'Q<W#RW?QDH3DY2L*BDK**C=4=6[IZNG?-C"TN&=I96UC:^?\
MV.6)JYO[4U\__X! 2%!PU,MH>$SLJ[BT]-<9F5EOWF87%!85EY1^*"NO_5Q7
MW]#8U-S2C>SI[>O_^FU@;'QB<FKZY\PL"HU9^;6ZMKZQB=O_?7!X=(S_<_)7
M7&0 .=G_._YI7*SG<5V@H""GH/XK+K(+@7\YL%)0BLA2L6F;43_T81>5BZ#A
MN)F:7]-%*R9OCN5\]&*4CDM< 741]U=H_Q;9_UA@D?^_(ONO@?U[7+,  SG9
M^>*1LP*:P)E%=9JF.V*V&FV-A,U*="W1$ODA8GJX@!JTM)"Q">?$7N[/W<22
M:ZVU'$!*^K<5W(:3_?2:YLZKY6]@& F@!.$5\WO1"]9?1GQ11K6*"URH!RV-
MLS+V-#M?%AH?'C+H L')$9K/O..$!/ X% CNQ-?!.0M1Q?1N28[6&X/N<:>T
MI2;4JOYJ6J>E%GN!U?YZRB,0'NJQ/]U'Y/*><3V:PE_\J(MC@B5F(UY=(P$U
M0N.]%I6K^47(JZF]1[&"M*PXJ>4=D'^_<%IGF4XQ(,UAID7Y']J,@%["=ZV[
M<@8[3CQ09A(0&07KGCFKJ-^#6[@U-#CRR#G,KO--/#$^_CW'NAIILRT<ON))
M ERGPC5&"SI@.-@.YT=\X%'5J 8GLOBG49$3_L6:7<@,GVG=U=08$8#::_Q3
MP,BEDK-XF)NZ\U$67I8$T"8UE]AL*"_-6BLYN8[/?+=WGHOZG?8BD \X+I="
M.\4ZU<?T>W3.6O3!Z(F<!'5L?QPWL@&[8'"M-.QH[,W"W97,#([W(PET!S(S
M@4?=L 0^ZZ1G1&&W@"5FL-ER2*IWE8[Z9GW14YTPK.%/.@V+=VFJ+"9NY!MQ
M4H-MZJ>FT"LX>'+EIAUU,D']XYS;U)XOU%-1\A5<4>#SXP09SX4; M/)Z["&
M'A+ 20*>#'F@99!;(*:NJIFGM$\58&Q;G^;Z&?1<M([9N+7YY7:O%"VGAAL#
MH<ZZ0</MN/%N$!-8+.]I)PO4(@]B%6JR>.G"VEW=. -;CD^O7OV98$<R)#Q8
MRU[?[1"'F/3?&O>/1["['9V8% UD6H\MW?IT_W/H*'\F,CTJG'9#2U"0<S4;
MMB.!1=K5XB[VI6,ZF3>1R!KP;)KMYMWF1LM-^]4OO!AU^3Z/C#,$"?#HI(*^
MP%N'8LID#O88?MH:7UFP7WKJ(S][J_)EFF^*V$*D%CB874MH2_?Y$F/'#:@F
M'GE4C;_9YER ?U\9]%YAL.<MAK?/5ONK$+Y7'F/=2X$W6E:K]+PZ7%IF(!X0
M'/"NE&IWUXJ6PW8G4TSBTQ 0^-HZ$H_ N/:HM+ER1[2!ED-E>CHD/XWE3_BW
M[NA8ABH;1R,B.!A_&>[+/EC0 IPELGL;SFJ&/V-_&[2/$D2DEY+]I<.<Z/51
M0=Z1NER%7'>Z=F^RKI0G$A^8Z#_#:8$,S9PTW$A _2VB0$R_%8@=K,P=#35
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M^F;,0Z?=<BKW<SU,3'G6K^.S99@ZZDM+8R^&S_<7*X[1E\0*\%+8SENKX^*
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M.@V8]7[GRS 6"#_J;*=W#0X6S,,'[*]D9F.,QA\VIMT,WGU\UQ@(>T(<K?6
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M*K%7.924/FQR^F[5!=/Y.7*.YD_96R<;U!A;?F[YXYEB\N*Z[R5E/TPE$!8
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MD:K,L3+,K_1C*NM#BGD[:H4+'?07,"["18,3UX5S,WR/X"0@13^*!&R[UI"
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M'S42312>.<OJR:9"5/9H[,UY3NDEG!2R-INVI'@4%J0;&GY?,R[U"V+%\U9
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M(Q/\> [ K0$\A[YY2UY ?WC;<X5B@.^;-EE#WT2KX4>PKH(/QHC7\54#%7^
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M#5$,$1PFJ_^$ED"+ZS-%UM_5H3MYDT["'"2 @W;GN1'WR7+G-J(S0?O@Y4.
M2I>TY=.A+:]2$+;C]%)MY9]<M^M^2<$7Z39?V-.Z7;$*8!CJ R* ];M4G+91
M\NV$$]M;)  B6H$;RS4WX/^*!'"-R2#>GCWK01=MS :O?!XR'!-?Z.7?KH3V
M_$:)JK= +9TX*5.[H[2N:HK<\U!IU;Z:.\R.ZLN.;MY-B_7L8?R HE,]+X@S
M.Z^;ZZE<P/NRE*Y3&@K=<->;)]NP?^(._OF2>; L<SW5_)YW&BO@J*NK]]4]
M&]],@I;,^XGPY"IAL[+'H?KIHK73V@O]"]M>QT=E+;4]\).[IN3_F::*!!C$
M#'@-I.8HW\04Z1=M>WH:J%'S_+T_C>'"#\+_6NZ?\^<8AW>SD=Q'%YK(OP)4
M _B,+,ZB F<T-M<6CG_-B:4*@M0Z$SO4?;H3OX-WWJE<07.,E8PA ^'U#=_P
MTMB332DH[)KU'>2=:=!>S]8W3;DIB]F29E/QI7A+M\'NST#1\T]*TK!<?(?E
M>P+O;ODC;\RT[LJ;P\[&NL!*!R?UZH3K',^KMK-\EYN2_ZS/>&$)N>($9F::
M_9&Q$Q$8D-^?]?,T[5N>[[-6_72=#_9O-:[75(3SMTWFWJ'N*7]'[YYQBGU]
M]6X)C-FW7G<7%"%37HSZ:=;R5+ZR(F/[\;<?;2]S:A>/;!0'J-H!(?YC/]GZ
MM]0SCK<XYS+9=7 T3C;L"09U&(&A@F\9PG&&WE^3'B6V)88D\B$L[LY5I M<
M#56 7PPTQOHUJ.WN& TWF!?BWP3Z9$&<,\(_^#^3.0T<E!)!.A@_L'NT;W$C
M]Q,AE_ CZ<)ZTW^[LYJQ$Y],U :^!<_4D3]VI_[JO%?"Q8U3!-JUL!-;7L&N
MD5B:S>;B<DTAE2=IW UH<U?.W=GMBJJ814%>G=1II5==1U0!/E0_H]/H>^B3
M[^]=DV:6[ZVV3G$)D_7N+4V;#>7Y2H@7K'*MAXRJMJMYM0!<[_1[VC?IEXX8
M5V4D]"D_24SU'Q6'/>'ZXXTL8L5Q[:"8@=&43J^Q@-_)QT)Z'Y)6>"0'!Q+,
M,+##NP=!SA,++3,\;LQZ(_>:R'PS_WY"D@%QK?\+X^2H3Z22;!Z^6#=9?U1$
M])!='G0@*Q%A=1I[ %I(M-(@W.82W@7VS^L^WJC3AO^BMGJ?KG80LI$&L7]W
M[Y@A5A[' L>*^1Y#F/N4@^S*'1'):NY-K/B"W(V)R"'8C2"*-I[ "?6B;,&/
MPQT>5<;'JO"KFX69E<5&Y5S.K^J(E4'(=V1)9_^'45'QHZV8Z.&X^='I@Z9Y
MZD,&4(T2=T=!=K*I"9NWC]R6;+-_$[*H-S#0P$-2[TE?G . GEF.0YQ37WO3
M,?M;GCK#S2?HWNJ3*JA)Y8;4"BQ)9T_S;G;T5-M?FSO#_[G7*R+6TQ<J?]$5
M@VK:\T7()BK%5'.&?-\W#Z8;]&JD&A(6/NL%K0_QWZ)#-20V:0DD];5RG)HR
M?&JJ8/ZY]:(\#P7M[]J,3AA9K$W=SD0UI>_M*SC?S:[7^T>U1?YWX4(30.$Z
M\*%>]FMY3M-Y_7!IG1QOJ7;,SNEY]6/ORH^@/*R0UNDRV26V\&.GZ2IR?+^N
M7XM/0_!4W0SF\@S@"-*$==07"8>8L='MJRN5-U@FS$(A*QYU<A-KKWY:]50F
MI4\'3"Z^S.D@\@ZJL.V\%<N-\Y7U9^CQXQ[K47S.'9(Q- BZ@[>#U)Q)EY5?
MM#F0\3&O_L1]NL)C<B[\I:07VFJA'R5*B#/510T_VZQ^4O+^]+D[WO#(+ -.
MJ6<_H7,85WHL<68EK1^/%,=#5G?@C6SF97;_T4&9%\P_98/TSO=ZF.RN<7M?
M%E,ZLR4!7%Y,?0X0$^XERD-G;P1RSL=XQBLK0JJ2YB\THKXGOE"]+,1UK]U/
MCI5ZEW%E 5?1.N^LW2@ 5;9S$A\D 1:K%'?EY)Y)/%U0+:J':@64'T+B^JK_
M"5LRL3P[U\?NM$PVZHUM*KR=T#WKAY$ 2E/9STU1IO57!-MUO92TVEOTQ#\;
M/J=?R#@I/@H[+Y)" _&R!I@&B6)KQ].#-8\;ZQGQ"3ZT,L$6-_J:GO-HMLT;
ML5[ZM'*QIF<VJHD/AXS8#E0I\-TPPLSO[H2+2%L:5TCD6J3L75^6;FEX7H<P
M<IRX(,\Q\BX@_9_-/,"AXV2_.]O0X>$^]]^F!<%U4X>]1<HTSZ'CS-O1 (N_
M]IK^Q(F';S:8YO070#IL6.\9#\\ON/^LX_H%Y!DM96"^\O-3RMSF8!M>MBV]
MRB(9#VD3H__F]G&K#(>"S7%<81[L5+?I1(17$R!DX2XC>W ;LMM<I2KV[6FY
MAZ_6U22,5@R+(ON^-\6<VS?DY "?^%\?B!?.K,9Y3O2'!3[,<QXH38^L/)-G
M6I_B3FU^6&5V;E"7H*>R:*1LUB*]Q*'&_R)CV1HU[0=N7JO0@.; N^[T$VO%
M]QB]"QUG]ZZ0X5R9#B',.M?/"#_[A:S<U_YF/4V".B,]Z[40K(?"FO8/P[4$
MU&P/+XW40[_ _C O7=+"NIEH_KZ/S&)@FK];C,HB P^5OU6I62VA"2G"), 9
MY21\=6TCI^S5+%&;D00X#]E"'W@><$H%LR&010H*=[-#W_^]P[O0><+"^>C%
M]$IMM6%S]83> )I[2Y":@9'AHZD_!ZQSGP1@^O>9$%;Z"5(>),!5 :S:05U:
MH8^(A=NWBWDC!TD:WTR,K0KE^ #RV:$6!R-"\5=F9GFGH3_0+C!FB".2%D7'
M&2B+5=;7&BT1<UT>#92X4E.+$:-06^06U$YB]XP(?IG/<UEQ8Q::@B]86 4Q
M$\"C! -WQ^/N_,D/8=\UOYW$:AH;;NU]%FD5\S5(\G_RAY_&#W%&_*P9+JB]
M(!(%9W!F$GZ^S6RQRS-XV^DA#W EXA:2LND!U2M]=NBJ$([[+9KSL)_9]WM/
M*X)O]PB9-VO57GQ!+/V+=(O(1-!NU0?O!L<.F1N/>N[(*PZ'M:Q,?@'D\DI5
M/J%RRYKOE349/FA4W^M3C)D6,\WXZ=#MR+G@^"%]*J?NG&4,/,\=VG1UESE2
M6AG62F3#'&2:&DP??2QVK*J@\N"],/Y07D1UCFDQ!/K]_ZS<]3]9M/";OAH:
MN+1/+EZE"G2JLXJI]C8&Z(;2$<NI:U RYWP+[P@&G%2R+V"W6.'+-TMTJ_;X
M#\(7STD ^Q3XC^(AQ\\+Q6$%)C:# 17;E?#%L61=/X[T,-"=U2:A!E<YJ0F;
M6I9?=: "[D1/Q+P^/7KK%N],W40+#A(BI<]NGM=44=#IRZN8G9Z:QD0\>"7&
M"JQ+M$H_@L<1N3T*IK@Y5J$D@)A/V;?U)^5G-U\F!W$(PRN=6,XL\/ %C0QP
M+V-YGR)A ?[(WYCQEZ\.%A2Q(&A?55$3X&IXX6.<T*DDY13WSJ.IA?.L=P%L
M:VN9E4684B[_5[I^E Q/F<>@MD[2K1HBQ6QI@I=>:+AX&W,D;]Z5<N7WUE=S
M/X6WTTD:#5MT<"I:G:G>+XD^56N)/ X::BL#S.T%"7_]_#/5V2O9<Q'Y^=^<
M[']<C*E8]CB;B5]:.9/F5K^NB%57-&@S<T;G/"<R)LY9P]NX^+Z3F8 AYF!2
M6# Q.BAM3^MYU[-[#]5S./P'/.IP<<;:?3O=DSN_-\A:1?_ZK^E[LG\0[ Q'
M$NM;28 <2L_#'@(93R4ZH3>PP',6X61FXH[18*:9_D+K"$?Z?VW4A=>G/%<-
MO:J1RK./[%UA[7F_7&D'02]76VD+?H>HN4_L_)B]X)NQKUXWHB1: +%R7$TT
M5QI\WA;]JGAL^<D#'ID'2F->_QA*<SG+$TX- %"T'<E1$"?^G#_#N 2NE"6$
M*)%WLU-.( Z7F_S'O/M_7,+=)(!C)M#X8W,2%,11E8@ZN_94ETJIO^+>;6.>
MW8WXE_Y>C!N,B5@2X(31*^%T/YT$>"#%B;^Z XPN,!0Z@FI4;".3E1;FQ]J
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M+Q\QGQT+Q!]%F4@94IFE*5W83-TWW5S!F1KB"A+*7<2)_%/XHN%Q?>6WS#9
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M%06"IE]J-[FRWEW GA!P\Z_L6SB;_C]02P,$%     @ IH"G7(QT ;A>FP
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M\+\M9V#I/*Z8"/PU4"(9^'EEV6/ YBE$PYP2^1A^I""73 8.@+-10PS0<(Q
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M\2 G;H?I.<],0JFOVN+]IN1@@8=-GS)U?_>!*^ZP]XI_B=AZ3[P^!-5<] U
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M#^ BS3JP3C103B?:XEWO#[5I+M+#Z-?RK+.= WXWI?%M_!39<: 1?8L&SG,
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MX.]&(>E9&*4QWP7:<22&D($')CQD0'\>70Q^3? @&<^GDX'-"T6PU>GCO61
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M0RU.\P(SR@685ZO*[01A2LNCMP-MK_1J/9+Z_KT[Z/H'H5:PUXD.K$^YP^E
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M^3/21[A9["'L"^%N?O$FT#]',Y$C)R6G838[-_';NT:!9I>A"OBF9SJY>9!
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ME4D;(/J1#AE08TJT\2)$C"V++PQ(G+U-)/+;$SC\J8BQLWQG;Z&G%[$%\*Q
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MU=WJ3A6A=U4'>"01;)GZ\R3KR;19NR,P3;*8VI9NY(Y.TFB2[F16H"FNK%D
MMYR4_Z5S?!\QQI3?J,M4XE/\\O8ENK>9V@L&^P_Q%U_62U.UE[N&[[#JR/6.
M+D^_-@2'"P^GB'EB?M)G./*_1#1M!T^9]NWFAKU;[U+/T:SQW$/-?2'&53D9
MA'M<JGOWD],J1E6&LLL]9K_;J=+R_CJ(&\\6X;I_<5QRT;EH&GM0PWKX"#O@
MM\Q[&*8U+N^>M1QU+.E9AKOV>Y&Y;N'GI$KPII<&@F2W^,V]3:H'9'M<ZFV>
ML4W@,?QOO!D$EL?H3[AY&5PE0 P-9"$#;)122:'\_B6GPQ;Z?RN\9094_2>9
MR]+IF]5V6.]6-,N'&RD:OW-Q^:V\]=@5;U#BN4-+G(+GIL._. 868*EAV. Q
M43WFL_EP_ *4V=BW\JEIK[1=^[65$)UJ(SZ@'W? G?*H107M!><IT:>$^/:'
MO!/GWWJ\['8Q>6=#,!WNQB'G?=<1"Q#FWX1*S1-]&&'F6J=B5;M+]0Y#8US3
M^W*GD>AX1#Z.)'0 S<5BLU]'U4AZ$V/3!?/Z7[/3*/&+_F\U);!T&$%['">A
M&^<*R8!UI65OG_,&(0\OW'SZ?,.1^7MX-\4;9>4 6\,O*%_Q;FF2:-UD5D<P
MT&_+]?KW1,:<I\Q\NJKSQ2<Z-^+3VS_'7;23GS'F4)[PL<\[<WB+/_VU,UZ7
MYR,B&:UQJJTY^A1E\%$JNJF%QN;UMU?: A[G[^_ES2 XQO":_Q"ORT;_4##,
M":0BQ!9@01S1VM69[8:-,@D8]P&V_ET^_5_,7,26JYM*]AKS2H-H^^'],Q6#
MD*Y<N-]\%>-/%16HX;@ W]QSEA>";::O6]CQ0/K/A]C&7-J]/N\RDT@EM<&R
M!.4$<?D.=EK<PM6\#[Q:XB 7G)MGZL3ZNAM-H[9U,U$^_QU3\]/W^JD]&+5K
M-B9IF?(G=\@ :R<R@ ,AW\_04:\T\T[:Y]#[PV\'-@.F.14?#^8D24.FDFXO
M>Y:VWF5)4YR V;<?XOO[@9,XX$$0_O!-H_Z\,Y(%2V(?\X13$G2AM(Y#:REL
M=S1OJTY$]'WL%88]J+)@IC<Z,1SY^._ID142.QF0>+B(/#GO,'<L36JZV?CW
MKK&_=V986"T" 9A,'CSMK!3NMG+]V!NHDP/L1'3_TV2!]I,O*M.II/._N15!
M41-?5#1G B<]9%N?&T!QW?+S$.YUZ!5)G2+'.(Q.GXQT*LUW](C=R;!Z1++[
M^ER(Q"6I?+&F_';>O/2P'#DNB:HUZJS'_:\LKP0#G5+2A_'PMRAA2^:.MVX;
M=J[5J YA,D"DH%N%:R.U))/^>8)9\!>8KPQ:)98(]&&-MW$.=A._,5;5>Z*:
MLC6[]* S-UFUQV6'X<9;"B8ZKY(K19_GY\3154U9:P/V)J^J^)&KZ\>YL]G)
M I&VD1.JO^R,Z1_R=.AAA)T=RN;C+MU4M8IQ55U\5I([=*ZEV'EP3_[17]M#
MDLI%F<_]\+71^([ PR-70T8NV2=MG"S'W2G[;3"@NK3',FF#/9J4^@K],8/6
M/CD[P4,6]4Z+;7S%5:G&T/6GV$YIS*TYU;.E(OA4=UC)FROD"H-.>KETJKU[
MEO3$Y7NGA#$RX*Y!4=Y(0';!1-?3S*O#_+)!-UL'3PPJLM9U@!2$H/HU?\?C
MWV=$WC$QPQ*=K;9]\9!7WZ($I;TM>P0"^EKH[!(@JM##,NLS5>+T>>YR(\LK
MJ-^")CMRLPN,@WV/ZE^XLT,H[B0FY'2B>1'*S2[HP5;H^:MDP,WPZ#-UHT9B
MAK:EX1Z<-+./YI !,!T7TA-#1R7[?5H!XE$\Z3SRQRCV%_+H1)QXF0Q(6^6Y
M06"<WS14:D1PN*1DNCS-T0A(>V@A]\:HF/@09K\ ;M5;@%QJE0Y%?S'5;*A[
MF?CHB6[+$A/E6IK[5-'UD\G*&3*@NPJYE;5LE'D&O F/M<@ +^2>-.SRLB^X
MO,T]+TG''^ZU55_*C>NKB*81E(N%V>6.NYQ,=\ID@H;>LG%X)Z,SO!:#8@I^
MSL=;BFG^T";2ZN42FG),Y#IAIA@>MD]?OCH=E#/;GCQMR 4?COM(]MQ4RW68
M81D.I_[V@W?:$#*.U2/1&:[S]S6?\A]6NP=9QVJC1RPJ N'[\=,)%MTZWR=<
M.@Y\[EB:_+B?<IGUB=4^.V69$NVKKF*.VS=C+CX# -67I!C>9;(WUCDW.%,.
MP^/!SL,K ;)J^[<D+@"+I$Q)C'#V-<TOPIU7L%?H4U"G1:)[N]DH*%,Y87BS
M@ID,B%0GN3N2Z >78#Q=8=H+XS4?DY$L7KO>\F4,ZG<4A<-Y0!-[+K'0UD/\
M=:Q/[AUD!!;A_9.*")BH#L5SMEOP?V@OQ$I_GV%H<N8]TH-/R+0S_*P*EV&0
M%?0PT<YMM)S>^)%)W\@[V.LUX]2\[^GI>SZ&0?V>AGGAGP3J.:X4O/K:-H?\
MC9^5@OS:17LP%?1YS(%!.!F@/0GSQ*\HL7WX\&A]][[NZQ]:?ONPGW70]\@=
MT:SCH] ST!!UM^$]B:Q">3?'PG]LM*F/SZ=K6Q2#^Q:\G(4S&.)!YZ*PSS+T
M4D_ NJ# M?>_.@*MF!E&FJ+^EH:'U78J"<)W9>T$!+S/*$5'X"-I*&N'#F=X
M&LMJ>4R;C"D]5/(SW#R[W:[/783^&C[3[E][+$J0GL_.#_]U-C8W.HO:XF$Q
MM$UEX?L'K$.V?;5'M>BCNV<0,O>'&-TBHC;^E6<]5%9_P_J*>CIGKC6SX,VS
MHCT7/5QXV',\6/KS_E!E_!^J//6/REW</-^N-R2^!7,E]D8'J#W5A=@)>B<E
MA,B/0UE\M3:];J#%Z;\_A#_)M@L;^(6XU$VL3!J.P"%U]@K4T+W:K+Z<)ND7
M P(^N19$80;<JTT=SW/EQG7/97-%;;X3O3_Q=08&G_$#BPW"BTL,G)Y-[4@'
MBGXU<JB^=&" IDR7=+STTK6;9VEB7'^$#%CB="8#S%*/J!%F+/Q"_77RE:Q3
M/E9*S ;6_ZN]E^S"<ATK4O3S3"5:$@&T!S 3(#,V$;/CN-J.%QGNY-J"5C&_
MB>O+!0H(+$%&ZG^NEB.7@L>@&YRN9$"N/:Q$H3I54N_[[E:#I".G\0PW';..
M68'5/^OGRR3]MTT;%LXGJK[Q.KC4EFUV)Y16H71"L:GCUL2A][=(>T,^0(60
M 8^-O5/B)=J?JBUP=;CT:>YV5>P9L\3>FJQ:]PJZOOY=Q<..9=$X+?E;PU/,
MP[#7[9ZA6S!M)P":=*$YCR3Z<7:-#&#=6Y;6TO#%'(\$7)]*6M:A'0B<K;W?
M=<%CI.F@V8K MF"NO0#IG (S$-Z(=FZ59T];&&L4$KH-QU]$W<]_:ZLFNIW_
M2L).,PEN#KMDMKNW?Z9XGGM]\=#";8;..=4<U+LF7N%![]A%2?'-VWUZ(^%P
M?I]E(;U[DX%_L&OP,L&RO5VS&=?9V3^>4EY:U?IKNCPF]6XK!/%-/4PY8>#!
M;!3(VGN4 ,9'= 7?FB0"P>^GE%(?XYN3O4K6O5%>915FCK-ZRCW,WR5C;LTP
M?TVA_N1U_?RE%JJ_EU@)_[TAY9]KM1W+S8LG$F8$,N @'!<?686\"K6:U<IX
M[1K8%;DYGF>@R^Z1^>XJ87(B>:7Y!FXPSDN<S1&%*&OF4?7\?4L:WW\0NP4+
M UG?I[B0*3S4:I#)D_N9+ZG2Y"@WFDU=ZFON_3G]HX\JG4'0%H$>0NS"KO/+
M0B N<>WVH9P?<#8%9%=#?"Q(.O4WB(:MS_*.6HU)EIZXJK=9U<MGJ!D83?]I
MHM)X4:-I=0EYY13^8K<QYBB@87-F (1814VVG,I*"2&R+CFQ@2@G\UUWM//>
M'CBGD $%!_TG=:!:.M*XG;^49#!V9SQH"IY\2H,P<MT6[R9F+6#\]5F6%M'0
MR&9@EC":(:)W'>-.!ER6B> -B'X*]?>536%X+0,_>=0$?(!G3467BW%KJ(RY
M>FE<#K>IJTJVC44R=@65"@U_D>H[V*HF(:\:Z<?,I)S6ITOJ*%D[_?N)O;A>
MRYIX^N')I+QVRBV^&VZ_>06 ZIE1FN9&CK^GT9ZQPIW5)ILS&_BU N&N^'ZC
ME8S7%RG<DY=VYUBF=)2LE*-R/NM!)OM0"'OC@A&+MTK,A@_?_+6/BVZ.&*!!
M6B?I1\XS'#%+;A^:D@&/G1K0- U8T[L'=)(87=#SKU]NHNY.BDY4$"F\,D2E
MY[3&JJ#?R@2AP6*)SSHJ[K>L-KWZZ6AM7780Q(UP+B_S[J);R-NJ,=<_"!+W
M*,N)$JY%_T$)IN]>VY?6F@4C>L>K2A655!Y[4-=9OE+] 9J?:&*Y^NZV2HH3
MMJ]6Z_ER/Y7]TBLDKC1#G1VW^GX_B ;H_6OPH,%J<[F_X<)O(]TS90E<,SI1
MSL@G9$Z[KQ@]==FZM+^S-/WNE"N896;8#*Q3R##?TSZ\?B8[&KIQ\J &62B[
MT'$Y%,?O&"S  .S<9)I0BC8]8Z/VJU=CG%G+F?T./KX\N]6##"VMBDV<JK'N
M=EYTTW0C1GSTA7BNYR-/DFZH/%MKOVADR[@'>W2R(!#NYF:"&>FL,IT@ U++
M>5Y6)H$*>Z_+H.E8N_1^=SFOLAUBLJ9#".H9A50[B:<<)[]_&XKCV4A*E62
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M@T6_"C6O=F; <B^<5,R(;R=-^7Q2+%K*U5M(%=XX.)G$-%NOE#)$FOM!4XG
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M=I!'$7=>YW$KBW31:R9R.[A121V*6'F+>XS=]36U2-LRG7K#8!KR^C.CS/-
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M:H6>+N@C:9]J)<HD-/4)YM&%.G_DT5 VIAH'H6>MY<^HP<PP=&8VSDT-47T
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MF<*/8 <)P*W"20) ,PS#RX+OF=RM3<_(Q#&K69;-G:B=RJ^ SECBC'!BX@0
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MT[H^1(>]^?%"2E)V7D&GZ&;;0/:RA_RI<+<\_M*X1%C3=$."Z+K5YM,F+UK
MXZ,OQ7C3%8L47;M^/3Y2DDFH(C:Z&&>,3J]YX0MKT'&3'J9+MO\X9FLSPIK
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MQT7$ L?O_J04N*$6J\HQJ^RR7+' TXL7S.ZQCISO2:B ]_$&/-@W_W)IE%9
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M.$I%(EC$5#[MSE7QGZ2R# ^5]-+>R/.)CA]:V]G@R.:-/IT!OQ\Q"6MKSTL
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M,THKO^]'9.C0+H2=:O9;C0JWF>:9+_;P5<$L(;[X(D"C^\=C+6C<J6B_(!C
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M\LJ0-Q%M3H'Z!.1'6>K# H=>=&\+!=E^E@2XMD+L&=H9R)YJ ? WS*G/GVZ
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MU^^QN7N,Y&G1C@&,2A3 :QOD=,]RQEZ/+(\B)8?3#H-F*M+2/IU._>4/Z.@
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MWA\3A9_AG$O_\?=TY@]02B%H?&5<-_I&&DO.J]7"V2?A79+%[]YGLSP /VJ
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M&5C8OB)>?LRXSSLHJ1"]%:0$[;5N11S1UQ,!H]I.Z3G[F+%.O0*M\21'<:1
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M#]9(=G-O'W$&+H&TMDE@C6 P#'I%)L[C-C9N);7J<K66DKI  9\LO<XJJ^2
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MM#3J#'3]XRC2R3=#TZJQ)?AT3I,@-60S,VKM$+B:PI@*,<Z5L+33 QX= XD
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M0^I@O0\3V58,7;:&V1!FM!8&BIEK>HB H6+HXALB8,5.[S3S,]1_;RZH6H@
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M)+]'%;A4#.L4!\>7ZZK&1DEO=."7I#UWA*.1]"GJ]')4N9$[<MZ5"\/CU+\
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M,@P LA3<[Y8S3I^(FY0EF9J;!G9:3*6QFF,A3HU>;V@9M-!C&F7N:;L'T :
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M98342D4S24DV.6_,!V6%8.F%ILS]=",I;'JZBB>D71Y#*B]Y5P>*>DV'-(B
MHU&TRX-+]05QT5-]0+S^-#DFQ(V\LI/QR&:W@I=U\'[?[.PN3TQYGY55O/,G
MSZWLQ?0_4$L! A0#%     @ IH"G7-@*"&(@$   H*8  !$
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M4$L! A0#%     @ IH"G7(.!3D001   H@ % !4              ( !C;,
M &-R=G,M,C R-C S,S%?<')E+GAM;%!+ 0(4 Q0    ( *: IUP87+=_L;X"
M +_M&@ 5              "  =#W  !C<G9S+3(P,C8P,S,Q>#$P<2YH=&U0
M2P$"% ,4    " "F@*=<:O3AE<6;  !+S   &               @ &TM@,
M8W)V<RTR,#(V,#,S,7@Q,'$P,#<N:G!G4$L! A0#%     @ IH"G7(0IE]G=
MW@  W_X  !@              ( !KU($ &-R=G,M,C R-C S,S%X,3!Q,# X
M+FIP9U!+ 0(4 Q0    ( *: IUSO VI((:(  *S/   8              "
M <(Q!0!C<G9S+3(P,C8P,S,Q>#$P<3 P.2YJ<&=02P$"% ,4    " "F@*=<
M8]T^!4V@  #GP@  &               @ $9U 4 8W)V<RTR,#(V,#,S,7@Q
M,'$P,3 N:G!G4$L! A0#%     @ IH"G7(QT ;A>FP  @;T  !@
M     ( !G'0& &-R=G,M,C R-C S,S%X,3!Q,#$Q+FIP9U!+ 0(4 Q0    (
M *: IUS&]S[PL=0  %H( 0 8              "  3 0!P!C<G9S+3(P,C8P
M,S,Q>#$P<3 Q,BYJ<&=02P$"% ,4    " "F@*=<Q4X=&2((  "Y+0  &
M            @ $7Y0< 8W)V<RTR,#(V,#,S,7AE>#,Q9#$N:'1M4$L! A0#
M%     @ IH"G7%>Q+),-"   >RT  !@              ( !;^T' &-R=G,M
M,C R-C S,S%X97@S,60R+FAT;5!+ 0(4 Q0    ( *: IUP#JE9]H08  + M
M   8              "  ;+U!P!C<G9S+3(P,C8P,S,Q>&5X,S)D,2YH=&U0
52P4&      \ #P $!   B?P'

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>crvs-20260331x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:crvs="http://www.corvuspharma.com/20260331"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="crvs-20260331.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_FFOllL2fhkyBY8izLXeb2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_2G3cA69Y60Kut3dIpiEj-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0I7JIIL4bUeBisCBXAmQJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rHbcLVDNhk-yPYw6tJnvKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_23_2026_To_1_23_2026_srt_CounterpartyNameAxis_crvs_PuissanceCapitalManagementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_vaIDQou6BEeDZj4w0IamBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:PuissanceCapitalManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-23</startDate>
            <endDate>2026-01-23</endDate>
        </period>
    </context>
    <context id="Duration_1_23_2026_To_1_23_2026_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_lGZZMu3Hk0q46YOWfhYujg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-23</startDate>
            <endDate>2026-01-23</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_-EcyvuEUt0iqD5CMwxh5TA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_JefferiesLlcMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_AtMarketOfferingMember_xtxU8hDdr0aP8Izzn0-FoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:JefferiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_5_6_2024_To_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonStockSharesAndCommonStockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_qes8akhL1UOvGAi6lmbg1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvs:CommonStockSharesAndCommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-06</startDate>
            <endDate>2024-05-06</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7NENmaw0i0-q2C5PDhSUwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FLIZWim2CEmiyA6jK8gsKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0whMsvUI40mL2d3_7eOvsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IY-IxZUYbEqP1aoewvItXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1-iFrDRj3UuxNy56xcRv_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bjsu6eUjm0mYlqMaqNdetA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zBkc-2BhYEWNDNtaR_EzxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AWAcFg_V-k6IIf18aUHL0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_tctkN7xylEqaixLGu7rKQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Cb6CWZHa8U-FLgwfn7_C_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MPfkm448p0mSNurWEEYd7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_z2-y6giFRkGYS5lYBANhoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsAndCommonStockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Tlt-RbPRSUqh-Yw0_LG3kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvs:PrefundedWarrantsAndCommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-06</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_OZWZ5jrEbUGvUd0flVPW_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvs:EquityIncentiveAwardPlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_2sdE3FrdcUCS_x2faPApVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvs:EquityIncentiveAwardPlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2016_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2014Member_HBYSs8y8e0q-y5FdS0ZbgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvs:EquityIncentiveAwardPlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_9SSsEi9c802Zz5UyJSFtsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvs:EquityIncentiveAwardPlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2016_To_3_31_2016_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_i1V10D_o5EOltzgKO-ZZrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvs:EquityIncentiveAwardPlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2016_To_3_31_2016_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_nSKTEU2cHUaYGFDps5DZNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvs:EquityIncentiveAwardPlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2014_To_2_28_2014_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2014Member_ZPEqkJZSKkC77f8CpQy3Og">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvs:EquityIncentiveAwardPlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-02-01</startDate>
            <endDate>2014-02-28</endDate>
        </period>
    </context>
    <context id="As_Of_1_23_2026_srt_CounterpartyNameAxis_crvs_PuissanceCapitalManagementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_hqg4T-aXuUSSmEgLg3oLVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:PuissanceCapitalManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-23</instant>
        </period>
    </context>
    <context id="As_Of_1_23_2026_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_EBLWg8HfXUaxzZXp3DlZnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-23</instant>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_IconPlcMember_us-gaap_RelatedPartyTransactionAxis_crvs_ServicesSupportClinicalTrialsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_87RrLXQb50614pVDRnXCIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:IconPlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">crvs:ServicesSupportClinicalTrialsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_crvs_IconPlcMember_us-gaap_RelatedPartyTransactionAxis_crvs_ServicesSupportClinicalTrialsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_m6-TI6NhC0ODOujZoxCV1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:IconPlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">crvs:ServicesSupportClinicalTrialsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_11_5_2015_To_11_5_2015_srt_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_cxY8H5-g_EGIH2ELcc-HaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:VernalisRAndDLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-11-05</startDate>
            <endDate>2015-11-05</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2015_To_12_31_2015_srt_CounterpartyNameAxis_crvs_ScrippsResearchInstituteMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_XMrt33ULGkeQ_-gbvlHdKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:ScrippsResearchInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2017_To_4_30_2017_srt_CounterpartyNameAxis_crvs_MonashLicenseMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_a9cCB_fmJ0qXM_jhei5r1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:MonashLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-04-30</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_R_4AduDylk-cunlIwrPmxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_6C25sOE9Ikmp0oeoupptOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_1OU2yiImZUyepALNkZ8rTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_YgSDQjrssE-QgSvTIuicjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_AIlQrJQUYUCBdCBov2bs-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_66ZNx4o7xE6nChx728HdAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_HK6hD7pbIEy_GhLi3vMwpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_uu4IdM0C2U-qNTnXiqDKRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvs:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_6_30_2025_To_6_30_2025_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_sAkMcg3a40yNfpBDpGFwVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvs:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="Duration_3_13_2026_To_3_13_2026_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_AtMarketOfferingMember_JM0TXSQCVEWG7UWlAYRf6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-13</startDate>
            <endDate>2026-03-13</endDate>
        </period>
    </context>
    <context id="Duration_1_23_2026_To_1_23_2026_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_C6QNxTSO-0mAbUm6YypDqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-23</startDate>
            <endDate>2026-01-23</endDate>
        </period>
    </context>
    <context id="Duration_1_20_2026_To_1_20_2026_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_AtMarketOfferingMember_pLGqywBb50amw3DDckyXMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-20</startDate>
            <endDate>2026-01-20</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_JefferiesLlcMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_AtMarketOfferingMember_Hon6YB2UOE6cicnSMk7KpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:JefferiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_8_6_2024_To_8_6_2024_srt_CounterpartyNameAxis_crvs_JefferiesLlcMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_AtMarketOfferingMember_eoj_eqi2mkWRVEknHEdLaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:JefferiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-06</startDate>
            <endDate>2024-08-06</endDate>
        </period>
    </context>
    <context id="Duration_5_6_2024_To_5_6_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Q6hXsJygPUicAUk5ciCrwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-06</startDate>
            <endDate>2024-05-06</endDate>
        </period>
    </context>
    <context id="As_Of_11_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_D946TWJ6zkKBuSKvEfvEWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvs:OfficeAndLabSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_n-FcguAxykeAUv9IniliJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7MVQIs275UufJ7lWOSw2jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_10_22_2024_To_10_22_2024_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_crvs_ThirdYearOfSubleaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_frW_QJfWakWrSN17Dz5hfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">crvs:ThirdYearOfSubleaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvs:OfficeAndLabSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-22</startDate>
            <endDate>2024-10-22</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_XaSINNDlBEGGXLQ8_-a_rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvs:OfficeAndLabSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_-5vxilaEUEie4f1HnGwt7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvs:OfficeAndLabSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2wktLQL_MEyMYi3EnlM2xA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_dSaQSn0xTEGxv32ul8LDRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">crvs:AngelPharmaceuticalsLtdEquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__i-TBaMyv0a9A7f3NWezNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_Tb3DXUa7E0uzOGfwD0V8eA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">crvs:AngelPharmaceuticalsLtdEquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_v9GABhLy30GLtxZhg92PdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvs:OfficeAndLabSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_Jyih6nVRJku2Wn342lRYIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvs:OfficeAndLabSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="Duration_2_21_2025_To_2_21_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_N8S53sDar0yqd8bB4rnoJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvs:OfficeAndLabSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-21</startDate>
            <endDate>2025-02-21</endDate>
        </period>
    </context>
    <context id="Duration_10_22_2024_To_10_22_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_VpJmf9leeki0mF9gdl0L2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvs:OfficeAndLabSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-22</startDate>
            <endDate>2024-10-22</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_YLkw7MG8HEKDEWIWiE4lUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_W8_lVfV_5UW3wioprmLFCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_6ofbkjgS-0e4rwuNdfqWaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">crvs:AngelPharmaceuticalsLtdEquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_2y33YWXdnkGW7dFGwtYxNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">crvs:AngelPharmaceuticalsLtdEquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2026_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_ZE_QhKexwEy9f39wgI86gQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">crvs:AngelPharmaceuticalsLtdEquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_1_23_2026_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_H7SnitH0TUet8vSGLhtCmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">crvs:AngelPharmaceuticalsLtdEquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-23</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_R50vtT-u40OjHn3pS5rzEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">crvs:AngelPharmaceuticalsLtdEquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_N1dSKssguEigxjFAegIoIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tU01KvpBW0K_zhL4h7OiVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bzThaTIaykCefde4hKplUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QYcmyFRwzk617SCak5HhVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_StatementClassOfStockAxis_crvs_SharesReservedForEmployeeStockPurchasePlanEquityMember_ANdQEPEp4UGpxOwiSjtfYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:SharesReservedForEmployeeStockPurchasePlanEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_StatementClassOfStockAxis_crvs_SharesAvailableForFutureOptionGrantsEquityMember_laFqZToHYU-XM4gSwg61WA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:SharesAvailableForFutureOptionGrantsEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_StatementClassOfStockAxis_crvs_PreFundedWarrantEquityMember_pG3Yboioek6oDxPenlOLwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:PreFundedWarrantEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_StatementClassOfStockAxis_crvs_OutstandingOptionsEquityMember_-jXcOLXdRUmPSJboXwLFAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:OutstandingOptionsEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_crvs_SharesReservedForEmployeeStockPurchasePlanEquityMember_Nx9PKFTI5ku9GkWFXfmECQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:SharesReservedForEmployeeStockPurchasePlanEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_crvs_SharesAvailableForFutureOptionGrantsEquityMember_uY3rsda1GkefIVaYZOCIXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:SharesAvailableForFutureOptionGrantsEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_crvs_PreFundedWarrantEquityMember_WYZ3KbAX40KHkOolRICzyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:PreFundedWarrantEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_crvs_OutstandingOptionsEquityMember_b0UFSQtEOEulbCh_kct75A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crvs:OutstandingOptionsEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2025_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_54_yHogU40CKupBljfogmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvs:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-31</instant>
        </period>
    </context>
    <context id="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonStockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_YFKxpTiNbU6oZe1MFcXljw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvs:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-06</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_t-6dI_GLqkWg5FN5nJrFAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvs:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Jot-50-Yk0qa7VxZIMl1Sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvs:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-06</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_g8cU3m0E20Wpgrbgr6r3kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_by6XIl09fUeHMa27xYEX5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2TM0kzCyaUqmRGhHtqiKBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1UFe9j-ZmEGRYjbAX_HTFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vIybyFvfXUWOpF0Ttuei1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-i89-0JYT0SuUe9mQLTeMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_XWrNNuJp9kmcv0K4YI0__w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_umpLEYrKtUW8udWfgt4FUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_d-ggcYb3f0OK5oH3EAR0_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_wsU59n8Qhk6UFUREvLUcmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">crvs:AngelPharmaceuticalsLtdEquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_dBO40tK2nky99I0IgRgeFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">crvs:AngelPharmaceuticalsLtdEquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_22_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_KO4XiJ0y0Eewc683WEweWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvs:OfficeAndLabSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-22</instant>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_fyY1JRXZxEybfcmX0J6BsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_uG2y5xP9jkqJqpWj4ONRlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_SydJ5hNnoUqd8ueH3lWPpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_eVV0R68k0kqMD0Z_2saoiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_cVDT7uqBXEWvbTkAOn4YWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_0ugRH7hZ0kaz47JCeRx9MQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_5_6_2024_To_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_xxahbdsvrUmf_bB3pjxXsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvs:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-06</startDate>
            <endDate>2024-05-06</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QuMDHAkYtUGRRN-xmfw_9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JiFN9ck9y06tFohjtNzoVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_5_7_2026_d2WHpuKgfkqb3D159XpVkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
        </entity>
        <period>
            <instant>2026-05-07</instant>
        </period>
    </context>
    <context id="Duration_8_6_2024_To_8_6_2024_srt_CounterpartyNameAxis_crvs_JefferiesLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_AtMarketOfferingMember_C9TVVV5bD06kEd2FNfIBfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:JefferiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvs:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-06</startDate>
            <endDate>2024-08-06</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_srt_StatementScenarioAxis_crvs_AggregatePotentialMilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_aJ4OIsSntUiP4dLNeBCv1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:VernalisRAndDLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">crvs:AggregatePotentialMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_ScrippsResearchInstituteMember_srt_StatementScenarioAxis_crvs_AggregatePotentialMilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_dD5UP8Q5v06xhOLdtmqxlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:ScrippsResearchInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">crvs:AggregatePotentialMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_MonashLicenseMember_srt_StatementScenarioAxis_crvs_AggregatePotentialMilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_6utRsh2k0ky_UVcLFS0XMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:MonashLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">crvs:AggregatePotentialMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_zptfIK_qa0ys8kZeVc8ECg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:VernalisRAndDLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_ScrippsResearchInstituteMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_po2cXNmYykeJqOGtUERulg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:ScrippsResearchInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_MonashLicenseMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_11uvkiG9bE23RyZq6u2HDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:MonashLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_yZROy1gbRU-l_b7CkxhgEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:VernalisRAndDLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_crvs_MonashLicenseMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_qMLGaFcjDk6SK_FVkFPddA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:MonashLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_53gyr3oPf0-E7oFQOdHZ2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvs:VernalisRAndDLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-01</startDate>
            <endDate>2017-02-28</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_dei_LegalEntityAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_IAkd47amHkiAxCCDntS06Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">crvs:AngelPharmaceuticalsLtdEquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_dei_LegalEntityAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_v9ThojvBS0yKLcEp5NgIDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">crvs:AngelPharmaceuticalsLtdEquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_Z1ifIYrZk0K3l2sseW4akQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_xEp_Nqn3VkmF6ubCOIKCDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2025_tNZXFjlgt0COhU24eHoxGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonStockSharesAndCommonStockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_oZTsrk4nrkiHDAAiKkO7Zw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvs:CommonStockSharesAndCommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-06</instant>
        </period>
    </context>
    <context id="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_4BVj8xmMz0KGnw09dZm4mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvs:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-06</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_MLeYeQx8wE2unDRlLMuIDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvs:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <unit id="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_pure_zwdjuLpe8Um-MXpoYRfl8Q">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_Institution_zA7d4X9tZU-Zo_s_3W3SSg">
        <measure>crvs:Institution</measure>
    </unit>
    <unit id="Unit_Standard_sqft_HxXZ8IO5D0SV81ta1te2Pw">
        <measure>utr:sqft</measure>
    </unit>
    <us-gaap:AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      id="Hidden_mkKD2jkV_kmgGThlOZM9jA">http://fasb.org/us-gaap/2025#RelatedPartyMember</us-gaap:AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      id="Hidden_IJ6KV1ib5UaSDg1-LEzK6g"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      id="Hidden__smBmUS0R0e8VdwDFfJpRA"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="INF"
      id="Hidden_f8lQR0w4Tky013YtD5Xtrw"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="INF"
      id="Hidden_Ggjt4LQL406hrMZNS22yKA"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">0</us-gaap:PreferredStockSharesOutstanding>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tc_4fsmTbNo0Ua9Zq3nEaLmvA_2_1">0001626971</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tc_hVbF8Ubt7ky3tkVE8s4O_g_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tc_6XZg3WUwoUmjvS2mwhgVAw_4_1">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tc_0cJgo-HWAkuCAuL0ETt4XQ_5_1">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tc_GaCJY-61e0OrGUF4Skhkbg_6_1">false</dei:AmendmentFlag>
    <us-gaap:AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      id="Hidden_y97SYRsuwU6VBvyrhRYUYw">http://fasb.org/us-gaap/2025#RelatedPartyMember</us-gaap:AccountsReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="INF"
      id="Hidden_FgprKYhvx0GT34f5BC1wWw"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      id="Hidden_eNKIckLa0UyHrLM1g_0mcg"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      id="Hidden_gYog-BNdUE-FBM0D6OXi_w"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="INF"
      id="Hidden_bQBBXjHiDkurSgRMYzw24g"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">84090424</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="INF"
      id="Hidden_jqJW3JRuLEelbaPw9XFCKw"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">74696629</us-gaap:CommonStockSharesOutstanding>
    <dei:DocumentType
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Narr_QmMkpakvWkOK_z6yyNdX3A">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tc_Q6EcA9-fKUeMVJJ11Z04IA_3_0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Narr_kmBjEOs5nU-h-ihhQJedyA">2026-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tc_dtL9lwJ7nUm3C8Cy_rGpdA_1_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Narr_1DYlsFYzFkyveTS4BnbutQ">001-37719</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Narr_InsPClEHl0yWCXaNWH3BBA">Corvus Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tc_4r3WJxNLTEGeSTF7_pTtMw_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tc_7DIJrrGBAkOuVsGAa6_bgg_1_2">46-4670809</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Narr_1OxT6xJwT0SgdFbA4U-FDg">901 Gateway Boulevard, Third Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Narr_r3ZXzakQS0C4LR2GkeE5hA">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Narr_4fKGyWBuL0GvFWh2wpGRsQ">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tc_eD_aWmr33k6Lo1fJtW5yPg_1_1">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Narr_hWXDwZQT1EW6VjjvSbkKKg">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Narr_ZdpUZuTjHUyw8yAxbHlwNA">900-4520</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tc_aM5pJYGkq0uoci3pct2brA_2_0">Common Stock, Par Value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tc_T19lmEd7oUWdXndptY75dA_2_1">CRVS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tc_gbXFjBLKb0KkkmMGgA1gBA_2_2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Narr_JAz0H8gHxUevlzSepAUpGA">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Narr_Co0yrJYexkWSKKPkCYO8TQ">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Narr_E67gVUULUE-cbHDnmXHh9w">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Narr_hTXFkqr9eEGShFkvKKWrXw">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Narr_61TWvdqYS0moEKPbHbX4bQ">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Narr_Y0iFVQmAnkeYf7qpC84tGQ">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_5_7_2026_d2WHpuKgfkqb3D159XpVkw"
      decimals="INF"
      id="Narr_wkVYWw1NMUiAJ_C-02FX1g"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">84090424</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_QIgkJjmSA0mnWeITRncenA_5_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">40102000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_sA_OT-40uUOKRJFdl6338A_5_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">4576000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_PK_JiTnJMkeCp6wIZmltlg_6_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">196612000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_MmyBSMv0VUqVin_waOwoOQ_6_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">52174000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_MVVEoD7okkiYh34GXGkK5A_7_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">43000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_ogLlwAwRlk2pYKchwvCIPA_7_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">37000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_PRushlV8Ok6d4Vyols61Xg_8_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">3189000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_xAeDdx5aHkmHDS9CeEtFQQ_8_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1427000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_XTFwl3VHR02j_jDyj9mtzA_9_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">239946000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_czuy3jO-kESlgKE9kydFeA_9_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">58214000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_8nzQW7AEK0S_-hTHcWBBRg_10_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">282000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_THgc1ieULky27qChUxJcVg_10_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">220000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_t_D02v3ALku-5PwlhcguGg_11_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">751000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_d7LsGOpSeke59IEsg3Lvxg_11_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">839000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:EquityMethodInvestments
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_phZ-euys5EqE8rkIwZSskQ_12_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">10496000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_QA-5G4TONU-yDooJdFHFGA_12_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">10991000</us-gaap:EquityMethodInvestments>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_VozUM2ygbkKDwzm7krYRuQ_13_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1720000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_pgvtl9kUj0yqrNp9zwJkWQ_13_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">855000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_kJtaoTk-vk24ttSvYjn_7g_14_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">253195000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_Zf5Sb7IhXUOamGqZ-fB5QQ_14_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">71119000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_9AyP_PbeAkyvqLQrBCFzdA_18_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">4697000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_BSwaHnn_2k-R3p4ROvd0Kw_18_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">2491000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_iT2Bn43fn0aE8xAfYhgKPg_19_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">428000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_qoAGfsJL3k2TodTJF0LMKw_19_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">403000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_bJl-P-eANkyVar7RsX1WKA_20_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">6985000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_eKzB6yc0ukm9jNFhhz_-qg_20_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">6486000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_Bz5wqi3ShE-YjJVYIatFiw_21_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">12110000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_cfGBqoD4fEy9WzJvd50Zzw_21_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">9380000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_dPTXn3qgtkyT-ghMpNx9Ag_22_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">406000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_vJvHYBML_ESPTgPXmUxJWg_22_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">534000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_0yYYXuH5GU69duzT9Ga41w_23_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">12516000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_fnKrL8n7yEWqT2I-YbwMTw_23_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">9914000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="INF"
      id="Narr_97qWHT-SeUGZas4xtKlQ_g"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="INF"
      id="Narr_mcxfi4FZikGTDfChVxYFGA"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="INF"
      id="Narr_pdTEdBhqAEGb9RnqQjIMFg"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="INF"
      id="Narr_xwHsemi7W0iA4JnbeRRoKg"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="INF"
      id="Narr_1PyRHJ07RkeP0kguEFbudQ"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="INF"
      id="Narr_MwARpLx_g0SfphgAkobVtQ"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="INF"
      id="Narr_yzr1rdroLE-chWM3xpeqTw"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="INF"
      id="Narr_Z_Ce0cpys0mA_A48FBBqcw"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">290000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="INF"
      id="Narr_t1pNlhEu1kisoitEMAkvJA"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">290000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="INF"
      id="Narr_7KExFM3VokyPu-49vC04Tw"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">84090424</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="INF"
      id="Narr_Am-Hc3EjoEedkGbvxhmjhg"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">74696629</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_uqH6ohbfGEyvW6dIXz_ibA_27_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">8000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_3yEceTBoWEWW6kUnblWRUQ_27_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">7000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_XHZXinOxfEKWf-MfFjIs7Q_28_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">667782000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_GPVC888F7EmWLLd1q0OdWQ_28_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">474387000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_pIRMygWa6UmEGOuUbGQMPw_29_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-1126000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_zvbxxQtz_Emcju1YiN-XwQ_29_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-896000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_tITkOCNvm0C6kmBwR4zY1Q_30_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-425985000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_sOTvL2aJr0ieqBAVvR2COg_30_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-412293000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_jI9kTlBsvEiND0gXCq9rZA_31_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">240679000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_4ueeLew8aUW3xLpHR3GR0A_31_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">61205000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_1xDfZl6iokKrex0I2bzkQA_32_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">253195000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_LgmUmRN24Ua7U69ngv-Ozw_32_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">71119000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_MUcTyuQnekaOlPA_6OSFlg_5_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">11175000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_oW-fMJV6Y02aQZ543Nvrbg_5_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">7453000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_IjpMX6FEBkaSBgyM56gQYA_6_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">3702000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_YCV-kTGwOUGKesO4w5CYRQ_6_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">2469000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_FHKyp3oYn0KwKIh5OLKZrA_7_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">14877000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_6rq65DiPV0y3ZudU40l5wg_7_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">9922000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_B9YFMOBya0-wB6qH3f3-7A_8_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-14877000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_WlfqJORz2UWlVEtt9ZN-Og_8_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-9922000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_imWBMhvWh0GpeI-V3EerCQ_9_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1784000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_Y8RE9mIQ6U-GXzZ2agFXww_9_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">525000</us-gaap:InvestmentIncomeNet>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_HOdjW1UUPEecjEE4G7XQ4g_10_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-25129000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_xI6SC8Q5RkC_HtskZh7BDw_11_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-13093000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_HgdDjGvLHU2UNzX8rvFxIg_11_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">15732000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_OIDW4H8cj06CAuiHg_6OQQ_12_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-599000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_Xs8p2ldfZUuM_U2g8WwefA_12_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-539000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_HnLwfTcZRkSzl5aebtlywg_13_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-13692000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_D16ZpxRgAE6-l7mrJiON8A_13_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">15193000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="2"
      id="Tc_WE-_zGkbOUiwLHT4xN8nKA_14_3"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">-0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="2"
      id="Tc_9WdbN8FlKEOMRiLjzRq03A_14_6"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="2"
      id="Tc_bAZlC6Ml8UWNVtgFiKjcTg_15_3"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">-0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="2"
      id="Tc_AQnvnmHHbUWwoViBO13kEA_15_6"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="0"
      id="Tc_IprbQlR0CUO1cBxeaBbiug_16_3"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">89996728</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="0"
      id="Tc_DXb6H_g9tk-k3AEJWnm8uQ_16_6"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">72126496</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="0"
      id="Tc_PTwvFW1F5UmiU8dxtbU_aA_17_3"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">89996728</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="0"
      id="Tc_9Il6cbQvZkO41GZXdFiysg_17_6"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">75152514</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_JW6cVIAkkkuM6824vncZeQ_19_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-334000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_dz1ZMlCPYEaCPbE4UUnccg_19_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-23000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_mFaFZ8DgKEeZ6bbs6ym4zA_20_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">104000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_3xkpqaKq00WopGYsSirfhA_20_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">57000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_Gt8ApF8KGU2UoTsARzg4YQ_21_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-13922000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_uGN7TAMUhUiR7MZ7sJAq9A_21_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">15227000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tU01KvpBW0K_zhL4h7OiVQ"
      decimals="INF"
      id="Tc_S6kqRMsK-EKLI2T-kmbXyA_6_2"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">74696629</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tU01KvpBW0K_zhL4h7OiVQ"
      decimals="-3"
      id="Tc_5gYNtZjovUut4z-fAOMUcw_6_5"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1-iFrDRj3UuxNy56xcRv_Q"
      decimals="-3"
      id="Tc_palI6zhwTEeYP1u5mQ6D2Q_6_8"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">474387000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bjsu6eUjm0mYlqMaqNdetA"
      decimals="-3"
      id="Tc_EOxRBy6oeU2dPU7wOg6fyQ_6_11"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-896000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IY-IxZUYbEqP1aoewvItXw"
      decimals="-3"
      id="Tc_EvOVdaYmfkiFG8hPzyDtZQ_6_14"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-412293000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_HHsWCvzYU0ybDKMndUF_PA_6_17"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">61205000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0I7JIIL4bUeBisCBXAmQJA"
      decimals="INF"
      id="Tc_E1BwUgvWZk-q0NTioaeDqg_7_2"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">308017</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QuMDHAkYtUGRRN-xmfw_9A"
      decimals="-3"
      id="Tc_RTHwq1o8NkWNR4EVZPJ95A_7_8"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1339000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_IXtkScxvNkWrk2JFWmM0sQ_7_17"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1339000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_-EcyvuEUt0iqD5CMwxh5TA"
      decimals="INF"
      id="Tc_dtaZnRX56kOztQgGntYDuA_8_2"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">9085778</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_-EcyvuEUt0iqD5CMwxh5TA"
      decimals="-3"
      id="Tc_DZ7RDMAG9EK7GmpWbw2sbQ_8_5"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_FFOllL2fhkyBY8izLXeb2Q"
      decimals="-3"
      id="Tc_jooWYD8CbkyOydWzeQt4dQ_8_8"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">189406000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_2G3cA69Y60Kut3dIpiEj-Q"
      decimals="-3"
      id="Tc_V--JetzT9keYO6rrHhSZzA_8_17"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">189407000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QuMDHAkYtUGRRN-xmfw_9A"
      decimals="-3"
      id="Tc_qrVwRGhEmUOCq2cMEppWRg_9_8"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">2650000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_AbbS-zmnZkqju_rywFO4dw_9_17"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">2650000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_n-FcguAxykeAUv9IniliJQ"
      decimals="-3"
      id="Tc_z0K61lGVL0-IDjL0fVRc9A_10_11"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-334000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_uOGhfh1P9E2HEusoadHERA_10_17"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-334000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_n-FcguAxykeAUv9IniliJQ"
      decimals="-3"
      id="Tc_vxMFFATzSkyEHnZVkLdvXQ_11_11"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">104000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_NmUxfk74zEa0uADe5eOJ5g_11_17"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">104000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2wktLQL_MEyMYi3EnlM2xA"
      decimals="-3"
      id="Tc_BaEnWM2C9kK4xag7hENHnw_12_14"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-13692000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_FsPUBfCWBkmPKFD16gLB6w_12_17"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-13692000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_N1dSKssguEigxjFAegIoIg"
      decimals="INF"
      id="Tc_ba0ZaKKIA0ukH6kRvG_O3Q_13_2"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">84090424</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_N1dSKssguEigxjFAegIoIg"
      decimals="-3"
      id="Tc_AMH5KLEDHUCOZ1yYS_zn8g_13_5"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FLIZWim2CEmiyA6jK8gsKQ"
      decimals="-3"
      id="Tc_UEI5NEU-tE2i53le7q9ppQ_13_8"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">667782000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0whMsvUI40mL2d3_7eOvsQ"
      decimals="-3"
      id="Tc_vU_X3bOE60GUD9tnW2sPDA_13_11"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-1126000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2026_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7NENmaw0i0-q2C5PDhSUwA"
      decimals="-3"
      id="Tc_rUu9UB-RKUucMMFwMKL0UQ_13_14"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-425985000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_0E2Dy3JgYU2Q3aFZPuTlrA_13_17"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">240679000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QYcmyFRwzk617SCak5HhVg"
      decimals="INF"
      id="Tc_G1YuOKN3o0S0NNDY2FjnsQ_6_2"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">67899779</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QYcmyFRwzk617SCak5HhVg"
      decimals="-3"
      id="Tc_JoZZJhaOTk6RcKQ9eiBciA_6_5"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MPfkm448p0mSNurWEEYd7A"
      decimals="-3"
      id="Tc_ET8eh2ZQG0264JQFktIqZg_6_8"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">430859000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_z2-y6giFRkGYS5lYBANhoA"
      decimals="-3"
      id="Tc_afN8U9R2E0G3MrbiuNB0Sw_6_11"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-1288000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Cb6CWZHa8U-FLgwfn7_C_g"
      decimals="-3"
      id="Tc_vV8nlpF_80CKX_hS85B4Pw_6_14"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-397010000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_g8cU3m0E20Wpgrbgr6r3kw"
      decimals="-3"
      id="Tc_2b9yzD1hQ0mZAtxyrCMlMw_6_17"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">32568000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rHbcLVDNhk-yPYw6tJnvKw"
      decimals="INF"
      id="Tc_pGEcfaM6NUaJ9K7DnPEIPA_7_2"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">269682</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JiFN9ck9y06tFohjtNzoVg"
      decimals="-3"
      id="Tc_omuUKTtIWk6tydHUfVqNig_7_8"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">279000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_P8M_iyluSEu33rl85tqHAw_7_17"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">279000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JiFN9ck9y06tFohjtNzoVg"
      decimals="-3"
      id="Tc_Ogcilocdl0WXnA6tXLAIVA_8_8"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1251000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_Pg-vCIR9SUOruO1YRLedZQ_8_17"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1251000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7MVQIs275UufJ7lWOSw2jw"
      decimals="-3"
      id="Tc_MJLkvTP9dUmWh8g12Nt19g_9_11"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-23000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_fVwA2BB48U6gblSLR3MHtQ_9_17"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-23000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7MVQIs275UufJ7lWOSw2jw"
      decimals="-3"
      id="Tc_VCiel5YdcEevTK2oGs3KQg_10_11"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">57000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_grb5P4eMaU692JrQDGsqJw_10_17"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">57000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__i-TBaMyv0a9A7f3NWezNg"
      decimals="-3"
      id="Tc_5q1lGXBazkazsh03YBH1zg_11_14"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">15193000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_fKWRUMFDAEO-4Q-d1UYkWA_11_17"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">15193000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bzThaTIaykCefde4hKplUA"
      decimals="INF"
      id="Tc_cDm-OjsOy0ma50EVAaDXUA_12_2"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">68169461</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bzThaTIaykCefde4hKplUA"
      decimals="-3"
      id="Tc_8q4C4X5aak2vjy1njwt2fQ_12_5"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AWAcFg_V-k6IIf18aUHL0w"
      decimals="-3"
      id="Tc_VKhe9rQBgU6R2sxJSimHzQ_12_8"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">432389000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_tctkN7xylEqaixLGu7rKQg"
      decimals="-3"
      id="Tc_uMWSPxvhr0mOzIzMvmo7iA_12_11"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-1254000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zBkc-2BhYEWNDNtaR_EzxA"
      decimals="-3"
      id="Tc_NxgtJfV9tk-ZP-n6nSBMKw_12_14"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-381817000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_tNZXFjlgt0COhU24eHoxGQ"
      decimals="-3"
      id="Tc_GuJ9XY0a7EiHKCews4l1hA_12_17"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">49325000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_SpxC6GTOykyhseGlmn2iUg_5_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-13692000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_ulWJk-ZVW0uzJtAaDoBcuA_5_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">15193000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_OxvSId_M5UWzwsX4XE80QQ_7_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">29000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_FOJ3MAI6_ESlJjznwjtDZw_7_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">22000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_WbWjv5q8wUelqfpUzVzYBA_8_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">17000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_pqjI9xu1Ck2RuaYPiTMT5A_8_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">291000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_rqhM5tQAtUSn9Ghj9oGQ2A_9_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">2650000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_80li2zeatk-VPhcDbu6I9A_9_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1251000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_rc0TFg4pjkeUl1jHnzB3pQ_10_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-25129000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_a1gPDd8nsECizNUoEoISGQ_11_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-599000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_Crd41qQ0uECf1YeGXy3x2g_11_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-539000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_YLkw7MG8HEKDEWIWiE4lUA"
      decimals="-3"
      id="Tc_kWL6Lcx0UkeWuzi-44I0sA_13_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">6000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_W8_lVfV_5UW3wioprmLFCQ"
      decimals="-3"
      id="Tc_USzV-y-kQUmV7A_HGJp1DQ_13_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">4000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_QP7VGRtfB0q6J6flCFNqbQ_14_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1762000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_Ng74OPE_2kKhJI3QpXJf-g_14_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-1168000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_BrU3dBB15Ua056eOj-p3uA_15_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-88000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_YSi2iTg7a0KEYTEVjWzafg_15_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-82000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_CcKmx_SIjEyiN6RFHFD1NQ_16_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">865000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_IIcZ_BnlfkKsl2ZyBd4d-Q_16_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-3000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_HyRxQfvJBUedIZfbqhQaUw_17_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">2206000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_kB8Rj__OIE-w8eZ7aYXWag_17_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-1274000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_NFnPuTSar0etr7ode3TzQQ_18_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">499000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_PyYvV9BMDk2fuwAT47Ahtg_18_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">146000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_i8NxHzIxq0-0M1a8HaTJSw_19_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-103000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_Rw1nb5hMI0ag97HDR1AnDg_19_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">31000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_93kLG_3Qn0ufCCxOcS-iFA_20_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-10374000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_z2vbpIJK5UCHheMlFz8G0w_20_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-8263000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_h40T4wH4wUyTCJfCsJAOBw_22_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">161737000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_98eQZMmxx0qvBShPBclV-Q_22_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">7708000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_eVAmBdJ6sEWYcJU0kOBjDA_23_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">16982000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_wwOKRG94c0-lzTXwhvw5fg_23_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">11987000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_bIVXPyZpR0WG-M5KoDcWyg_24_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">91000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_JbFSzbstikGwxgTy-4PzIQ_24_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">36000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_u6BHfllZB0-zUArewTwzeg_25_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-144846000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_hMo3TBYILUact8IX5JbiqQ_25_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">4243000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_ohMRA9eoFUu33302TR7hKA_27_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">189407000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_FxwkPLcSKkGpvsS5LJOQtA_28_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1339000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_5qUFGQHDo0SkVYkDYbugJA_28_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">279000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_vuAJ4lzlrk6Pk1hE8TIq0w_29_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">190746000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_xLLfXWMoK0a1d31BxGyhQA_29_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">279000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_GQBqclM2REq0LT_mmgw22A_30_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">35526000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_RpljB1n4gkqM9Y-81C_kmw_30_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-3741000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_r2oW3TOloEOV-Hb6ogjIKg_31_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">4576000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_g8cU3m0E20Wpgrbgr6r3kw"
      decimals="-3"
      id="Tc_kuwQztmwwk6xv0FHeOCI3Q_31_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">8740000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_N9xc-g7RwUGJiqQIRuedkg_32_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">40102000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2025_tNZXFjlgt0COhU24eHoxGQ"
      decimals="-3"
      id="Tc_WX18eRiPBEidKWEX3Shl7A_32_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">4999000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <crvs:OfferingCostsAccruedAndChargedToAdditionalPaidInCapital
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_9PH00SmYYE2DCX-TSppzXQ_34_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">553000</crvs:OfferingCostsAccruedAndChargedToAdditionalPaidInCapital>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_K7pXwM7pD0O0A3g2kmfbsQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1. Organization&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Corvus Pharmaceuticals, Inc. (&#x201c;Corvus&#x201d; or the &#x201c;Company&#x201d;) was incorporated in Delaware on January 27, 2014 and commenced operations in November 2014. Corvus is a clinical-stage biopharmaceutical company. The Company&#x2019;s operations are located in South San Francisco, California.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Corvus Biopharmaceuticals, Ltd. and Corvus Hong Kong Limited. All intercompany accounts and transactions have been eliminated from the condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Registered Direct Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;On May 6, 2024, the Company completed a registered direct offering which resulted in gross proceeds of approximately $30.6 million. The financing consisted of the sale of 13,512,699 shares of common stock and accompanying common stock warrants to purchase 13,078,509 shares of common stock (or pre-funded warrants in lieu thereof) at a combined offering price of $1.7312 per share, and the sale of pre-funded warrants to purchase 4,144,085 shares of common stock and accompanying common warrants to purchase 4,010,927 shares of common stock (or pre-funded warrants in lieu thereof) at a combined offering price of $1.7311 per share. The common warrants had an exercise price of $3.50 per share of common stock (or $3.4999 per pre-funded warrant in lieu thereof), were exercisable at any time after the date of issuance, subject to certain ownership limitations, and expired on June 30, 2025. The pre-funded warrants have an exercise price of $0.0001 and are exercisable any time after the date of the issuance, subject to certain ownership limitations. As of June 30, 2025, the expiration date of the common warrants, all of the common warrants had been exercised, resulting in proceeds of $54.3 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Follow-on Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;On January 23, 2026, the Company completed a follow-on public offering in which the Company sold 9,085,778 shares of common stock at a price of $22.15 per share, which included 1,185,101 shares issued pursuant to the underwriters&#x2019; exercise of their option to purchase additional shares of common stock. The aggregate net proceeds received by the Company from the offering were approximately $189.4 million, net of underwriting discounts and commissions and offering expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, contract manufacturer and contract research organizations, compliance with government regulations and the need to obtain additional financing to fund operations. Since commencing operations in 2014, the majority of the Company&#x2019;s efforts have been focused on the research and development of soquelitinib, ciforadenant and mupadolimab. The Company believes that it will continue to expend substantial resources for the foreseeable future as it continues clinical development of, seek regulatory approval for and, if approved, prepare for the commercialization of soquelitinib, as well as product candidates under the Company&#x2019;s other development programs. These expenditures will include costs associated with research and development, conducting preclinical studies and clinical trials, obtaining regulatory approvals, manufacturing and supply, sales and marketing and general operations. In addition, other unanticipated costs may arise. Because the outcome of any clinical trial and/or regulatory approval process is highly uncertain, the Company may not be able to accurately estimate the actual amounts necessary to successfully complete the development, regulatory approval process and commercialization of soquelitinib, or any other product candidates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has incurred significant losses and negative cash flows from operations in all periods since inception and had an accumulated deficit of $426.0 million as of March 31, 2026. To date, none of the Company&#x2019;s product candidates have been approved for sale and therefore the Company has not generated any revenue from sales of commercial products. Management expects operating losses to continue for the foreseeable future. The Company has funded its operations to date primarily through the sale of redeemable convertible preferred stock, common stock, pre-funded warrants and common stock warrants. As of March 31, 2026, the Company had cash, cash equivalents and marketable securities of $236.7 million. Management believes that the Company&#x2019;s current cash, cash equivalents and short-term marketable securities will be sufficient to fund its planned operations for at least the next 12 months from the date of the issuance of these condensed consolidated financial statements. To fund all of the Company's ongoing and planned development programs through commercialization, the Company will need to raise additional capital in the future. The Company intends to raise additional capital through private and public equity offerings, debt financings and license and development agreements. However, there can be no assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its operations or on terms acceptable to the Company or at all. If the Company is unsuccessful in its efforts to raise additional capital or if sufficient funds on acceptable terms are not available when needed, the Company could be required to significantly reduce operating expenses and delay, reduce the scope of or eliminate one or more of its development programs, out-license intellectual property rights to its product candidates, sell unsecured assets, or a combination of the above, any of which may have a material adverse effect on the Company&#x2019;s business, results of operations, financial condition and/or its ability to fund its obligations on a timely basis or at all. Failure to manage discretionary spending or raise additional capital, as needed, may adversely impact the Company&#x2019;s ability to achieve its intended business objectives.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_5_6_2024_To_5_6_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Q6hXsJygPUicAUk5ciCrwA"
      decimals="-5"
      id="Narr_BrxUMvYe70yqS2pNTQ3gpw"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">30600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_5_6_2024_To_5_6_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Q6hXsJygPUicAUk5ciCrwA"
      decimals="INF"
      id="Narr_qiMKwCtxIEKXbaBSlIKs3g"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">13512699</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonStockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_YFKxpTiNbU6oZe1MFcXljw"
      decimals="INF"
      id="Narr_CfXn287k50OclXeuh5vHlg"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">13078509</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <crvs:CombinedOfferingPriceForSharesAndWarrants
      contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonStockSharesAndCommonStockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_oZTsrk4nrkiHDAAiKkO7Zw"
      decimals="4"
      id="Narr_UUOBs1xqIUOJJcF8iC0MLw"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">1.7312</crvs:CombinedOfferingPriceForSharesAndWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Jot-50-Yk0qa7VxZIMl1Sg"
      decimals="INF"
      id="Narr_ih3TouhekEeQ3h8vlG7X8w"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">4144085</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_4BVj8xmMz0KGnw09dZm4mg"
      decimals="INF"
      id="Narr_88uTQ9FSwU6pFTgw8oSVsg"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">4010927</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsAndCommonStockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Tlt-RbPRSUqh-Yw0_LG3kg"
      decimals="4"
      id="Narr_xvVuU1h6F0OBXPzd84LkqA"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">1.7311</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_4BVj8xmMz0KGnw09dZm4mg"
      decimals="2"
      id="Narr_4irDIRc8dUCNELCwjYiCpA"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">3.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <crvs:ClassOfWarrantOrRightExercisePricePerPrefundedWarrant
      contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_4BVj8xmMz0KGnw09dZm4mg"
      decimals="4"
      id="Narr_5hRFOvAokUqZOMzJopXaIw"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">3.4999</crvs:ClassOfWarrantOrRightExercisePricePerPrefundedWarrant>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Jot-50-Yk0qa7VxZIMl1Sg"
      decimals="4"
      id="Narr_KC5W23BpbUSofJU5PbTPyg"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_6_30_2025_To_6_30_2025_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_sAkMcg3a40yNfpBDpGFwVQ"
      decimals="-5"
      id="Narr_dYS_FiKqt0SWfup1bmAMHA"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">54300000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_23_2026_To_1_23_2026_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_C6QNxTSO-0mAbUm6YypDqg"
      decimals="INF"
      id="Narr_MlIQFGqugUWiAhdLax5F7w"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">9085778</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_1_23_2026_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_EBLWg8HfXUaxzZXp3DlZnw"
      decimals="2"
      id="Narr_PhH0e0jnvESvdHwNvs9s_A"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">22.15</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_23_2026_To_1_23_2026_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_lGZZMu3Hk0q46YOWfhYujg"
      decimals="INF"
      id="Narr_MNO-dFV4x0y2-j4ThnKwJg"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">1185101</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_23_2026_To_1_23_2026_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_C6QNxTSO-0mAbUm6YypDqg"
      decimals="-5"
      id="Narr_R_RtpjgSYU60UCKYCxcyAw"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">189400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-5"
      id="Narr_KvFQFB1Ek0SSbHhXVPHxOQ"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-426000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-5"
      id="Narr_FPHNJyCKL0ir9EEXG_QXmQ"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">236700000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_h7iQmvYOiUSo94M_cpWjzQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2. Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). The Company&#x2019;s functional and reporting currency is the U.S. dollar, except for its investment in its equity method investee which is the Chinese renminbi (RMB). The accompanying condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and discharge of liabilities in the normal course of business.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The accompanying interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for fair statement of the condensed consolidated financial statements presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The condensed consolidated balance sheet as of December 31, 2025 was derived from audited financial statements, but does not include all disclosures required by GAAP. The condensed consolidated results of operations for the three months ended March 31, 2026 are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements and the related notes for the year ended December 31, 2025 included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on March 12, 2026.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The preparation of the Company&#x2019;s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from such estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Investments in Equity Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;The Company uses the equity method of accounting for its equity investment if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;The Company&#x2019;s proportionate share of the net income (loss) resulting from the equity method investment is reported under the line item captioned &#x201c;income (loss) from equity method investment&#x201d; in the condensed consolidated statements of operations and comprehensive loss and the carrying value of the equity method investments is reported under the line captioned &#x201c;Investment in Angel Pharmaceuticals&#x201d; in the condensed consolidated balance sheets. The Company&#x2019;s equity method investments are reported at cost and adjusted each period for the Company&#x2019;s share of the investee&#x2019;s income or loss and the foreign currency translation adjustment as applicable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;For equity method investees with a functional currency different than the Company&#x2019;s reporting currency, the Company follows the guidance under Accounting Standards Codification (&#x201c;ASC&#x201d;) 830-10-15-5, pursuant to which, the foreign currency financial statements of a foreign investee accounted for by the equity method should be translated to the reporting entity&#x2019;s reporting currency.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;The Company evaluates equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable. Factors considered by the Company when reviewing an equity method investment for impairment include the length of time (duration) and the extent (severity) to which the fair value of the equity method investment has been less than cost, the investee&#x2019;s financial condition and near-term prospects and the intent and ability to hold the investment for a period of time sufficient to allow for anticipated recovery. An impairment that is other-than-temporary is recognized in the period identified.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;See Note 6, &#x201c;Equity Method Investment,&#x201d; for further information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Concentrations of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Substantially all of the Company&#x2019;s cash and cash equivalents are deposited in accounts with two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company maintains its cash with an accredited financial institution and accordingly, such funds are subject to minimal credit risk. The Company&#x2019;s marketable securities consist of investments in U.S. Treasury securities and U.S. government agency securities, which can be subject to certain credit risks. However, the Company mitigates the risks by investing in high-grade instruments, limiting its exposure to any one issuer, and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The Company is subject to a number of risks similar to other early stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#x2019;s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, and protection of proprietary technology. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;There have been no material changes to the Company&#x2019;s significant accounting policies during the three months ended March 31, 2026 from those discussed in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on March 12, 2026.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In October 2023, the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative, which modifies the disclosure or presentation requirements related to variety of FASB Accounting Standard Codification topics. The effective date for each amendment will be the date on which the SEC&#x2019;s removal of that related disclosure from Regulation S-X or Regulation S-K is effective. If by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the associated amendment will be removed from the Codification and will not become effective for any entities. The Company is currently evaluating the effect of adopting this ASU.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expense. This update requires entities to disaggregate operating expenses into specific categories, such as salaries and wages, depreciation, and amortization, to provide enhanced transparency into the nature and function of expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, with early adoption permitted. ASU 2024-03 may be applied retrospectively or prospectively. The Company is currently evaluating the impact of ASU 2024-03 on its financial statement presentation and disclosures.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_f38xxQgX-0msnp6fb4AzLA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). The Company&#x2019;s functional and reporting currency is the U.S. dollar, except for its investment in its equity method investee which is the Chinese renminbi (RMB). The accompanying condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and discharge of liabilities in the normal course of business.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <crvs:UnauditedInterimFinancialInformationPolicyTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_GPO6XF_bgki77M62gF958g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The accompanying interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for fair statement of the condensed consolidated financial statements presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The condensed consolidated balance sheet as of December 31, 2025 was derived from audited financial statements, but does not include all disclosures required by GAAP. The condensed consolidated results of operations for the three months ended March 31, 2026 are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements and the related notes for the year ended December 31, 2025 included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on March 12, 2026.&lt;/p&gt;</crvs:UnauditedInterimFinancialInformationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_ejveAPN5q0Og2t6U2I0Dnw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The preparation of the Company&#x2019;s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from such estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_6jarc9NDR0GL0Ivevq1Mqg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Investments in Equity Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;The Company uses the equity method of accounting for its equity investment if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;The Company&#x2019;s proportionate share of the net income (loss) resulting from the equity method investment is reported under the line item captioned &#x201c;income (loss) from equity method investment&#x201d; in the condensed consolidated statements of operations and comprehensive loss and the carrying value of the equity method investments is reported under the line captioned &#x201c;Investment in Angel Pharmaceuticals&#x201d; in the condensed consolidated balance sheets. The Company&#x2019;s equity method investments are reported at cost and adjusted each period for the Company&#x2019;s share of the investee&#x2019;s income or loss and the foreign currency translation adjustment as applicable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;For equity method investees with a functional currency different than the Company&#x2019;s reporting currency, the Company follows the guidance under Accounting Standards Codification (&#x201c;ASC&#x201d;) 830-10-15-5, pursuant to which, the foreign currency financial statements of a foreign investee accounted for by the equity method should be translated to the reporting entity&#x2019;s reporting currency.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;The Company evaluates equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable. Factors considered by the Company when reviewing an equity method investment for impairment include the length of time (duration) and the extent (severity) to which the fair value of the equity method investment has been less than cost, the investee&#x2019;s financial condition and near-term prospects and the intent and ability to hold the investment for a period of time sufficient to allow for anticipated recovery. An impairment that is other-than-temporary is recognized in the period identified.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;See Note 6, &#x201c;Equity Method Investment,&#x201d; for further information.&lt;/p&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_FKX-fjYIwUWxSvJ-atF5ew">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Concentrations of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Substantially all of the Company&#x2019;s cash and cash equivalents are deposited in accounts with two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company maintains its cash with an accredited financial institution and accordingly, such funds are subject to minimal credit risk. The Company&#x2019;s marketable securities consist of investments in U.S. Treasury securities and U.S. government agency securities, which can be subject to certain credit risks. However, the Company mitigates the risks by investing in high-grade instruments, limiting its exposure to any one issuer, and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The Company is subject to a number of risks similar to other early stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#x2019;s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, and protection of proprietary technology. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskCreditRiskUninsuredDeposits
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Narr_Ex-1AP7yMEyzeyV19zfazw">Substantially all of the Company&#x2019;s cash and cash equivalents are deposited in accounts with two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company maintains its cash with an accredited financial institution and accordingly, such funds are subject to minimal credit risk. The Company&#x2019;s marketable securities consist of investments in U.S. Treasury securities and U.S. government agency securities, which can be subject to certain credit risks. However, the Company mitigates the risks by investing in high-grade instruments, limiting its exposure to any one issuer, and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities.</us-gaap:ConcentrationRiskCreditRiskUninsuredDeposits>
    <crvs:NumberOfFinancialInstitutionsInWhichCashAndCashEquivalentsAreDeposited
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="INF"
      id="Narr_FdqbESBG5Ey2HML_D3jDBQ"
      unitRef="Unit_Standard_Institution_zA7d4X9tZU-Zo_s_3W3SSg">2</crvs:NumberOfFinancialInstitutionsInWhichCashAndCashEquivalentsAreDeposited>
    <crvs:SignificantAccountingPoliciesPolicyTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_tI-6DrE1eEaFO-JLCprdXQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;There have been no material changes to the Company&#x2019;s significant accounting policies during the three months ended March 31, 2026 from those discussed in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on March 12, 2026.&lt;/p&gt;</crvs:SignificantAccountingPoliciesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_IG5Edo71tkOurSKulJeN7A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In October 2023, the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative, which modifies the disclosure or presentation requirements related to variety of FASB Accounting Standard Codification topics. The effective date for each amendment will be the date on which the SEC&#x2019;s removal of that related disclosure from Regulation S-X or Regulation S-K is effective. If by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the associated amendment will be removed from the Codification and will not become effective for any entities. The Company is currently evaluating the effect of adopting this ASU.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expense. This update requires entities to disaggregate operating expenses into specific categories, such as salaries and wages, depreciation, and amortization, to provide enhanced transparency into the nature and function of expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, with early adoption permitted. ASU 2024-03 may be applied retrospectively or prospectively. The Company is currently evaluating the impact of ASU 2024-03 on its financial statement presentation and disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_ddzhK8BDr0ShdEsyzM0-XA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;3. Net Loss per Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The following table shows the calculation of net (loss) income per share (in thousands, except share and per share data):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:25.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:25.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Net loss attributable to common stockholders, basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (13,692)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,193&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Gain from change in fair value of warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (25,129)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Net loss - basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (13,692)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (9,936)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Weighted average common shares and pre-funded warrants outstanding used to compute basic and diluted net (loss) income per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 89,996,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72,126,496&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Weighted average shares issuable upon the exercise of common warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,026,018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Weighted average common shares and prefunded warrants outstanding used to compute diluted net loss per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 89,996,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 75,152,514&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Net (loss) income per share, basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (0.15)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Net loss per share, diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (0.15)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (0.13)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Weighted average common shares outstanding used in the calculation of basic and diluted net loss per share for the three months ended March 31, 2026 and 2025 includes 8,275,913 and 4,144,085 shares of common stock issuable upon conversion of pre-funded warrants, respectively. Refer to Note 9, &#x201c;Warrants&#x201d; for further details.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Shares issuable upon exercise of common warrants used in the calculation of diluted net loss per share for the three months ended March 31, 2025 were calculated using the treasury stock method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The amounts in the table below were excluded from the calculation of diluted net loss per share, due to their anti-dilutive effect:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Outstanding options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,066,326&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,575,683&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_tPJfTkf__UC-Z4ODGxeb1A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The following table shows the calculation of net (loss) income per share (in thousands, except share and per share data):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:25.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:25.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Net loss attributable to common stockholders, basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (13,692)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,193&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Gain from change in fair value of warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (25,129)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Net loss - basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (13,692)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (9,936)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Weighted average common shares and pre-funded warrants outstanding used to compute basic and diluted net (loss) income per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 89,996,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72,126,496&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Weighted average shares issuable upon the exercise of common warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,026,018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Weighted average common shares and prefunded warrants outstanding used to compute diluted net loss per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 89,996,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 75,152,514&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Net (loss) income per share, basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (0.15)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Net loss per share, diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (0.15)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (0.13)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_N9CRsXxzI0iNZGm01mZL_Q_5_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-13692000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_2cMHUAvc4kCOrXEhgmwdXg_5_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">15193000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_i0Lsn-7fZkifj6KxZPApOw_6_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">25129000</us-gaap:WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_EN6opVegE0G5CrcPKJPVSA_7_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-13692000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_5AIdsTF43kapsl2YkI3c1g_7_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-9936000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="0"
      id="Tc_iAy2e8vu_0miiGH1unHi8w_9_3"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">89996728</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="0"
      id="Tc_KeXriQ3dOkm8HzhRW5xVrQ_9_6"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">72126496</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="0"
      id="Tc_6UBGDvhmFUmiAPgPdyDfiw_10_6"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">3026018</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="0"
      id="Tc_9Lkt4zIV-UeAZZlDAFp7Hg_11_3"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">89996728</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="0"
      id="Tc_kSP_HPP1qEi0j-tZ41chpQ_11_6"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">75152514</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="2"
      id="Tc_qnCYTm0xjUqjf9eiY-ccCg_13_3"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">-0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="2"
      id="Tc_M6A-fSjdi0iGHqCRYkhxRw_13_6"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="2"
      id="Tc_baz_FUXSsEeaIdmJB3lH7g_14_3"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">-0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="2"
      id="Tc_MPXE6wLwDEekbGinsJATig_14_6"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">-0.13</us-gaap:EarningsPerShareDiluted>
    <crvs:CommonSharesIssuableUponConversionOfPreFundedWarrants
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="INF"
      id="Narr_9AIQhUI0OUCIGr3WGc2wxA"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">8275913</crvs:CommonSharesIssuableUponConversionOfPreFundedWarrants>
    <crvs:CommonSharesIssuableUponConversionOfPreFundedWarrants
      contextRef="As_Of_3_31_2025_tNZXFjlgt0COhU24eHoxGQ"
      decimals="INF"
      id="Narr_yC4LgAP7Kk--pXOeCGAuPw"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">4144085</crvs:CommonSharesIssuableUponConversionOfPreFundedWarrants>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_R5jv-1evA0SIX8FkuNJHeA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Outstanding options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,066,326&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,575,683&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_fyY1JRXZxEybfcmX0J6BsQ"
      decimals="INF"
      id="Tc_ST2pr1JHCU-MnHAG_K8YRg_4_2"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">13066326</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_uG2y5xP9jkqJqpWj4ONRlg"
      decimals="INF"
      id="Tc_l4VcjCA7I0uGSllOwrTo2A_4_4"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">11575683</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_6fS73Z3ViEqTUSilWO-LQA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;4. Segments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;The Company views its operations and manages its business in one operating segment, that of the development and commercialization of drugs and antibodies that target critical elements of the immune system. The Company&#x2019;s Chief Operating Decision Maker (&#x201c;CODM&#x201d;) is made up of the Chief Executive Officer and Chief Financial Officer. The CODM assesses performance for the segment and decides how to allocate resources based on consolidated net loss that is reported on the consolidated statement of operations and comprehensive loss. The measure of segment assets is reported on the balance sheet as total consolidated assets. Managing and allocating resources on a consolidated basis enables the CODM to assess the overall level of resources available and how to best deploy these resources across functions and programs that are in line with the Company&#x2019;s long-term company-wide strategic goals.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The following table presents reportable segment net loss, including significant expense categories, attributable to the Company&#x2019;s reportable segment for the three months ended March 31, 2026 and 2025 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Compensation and benefits, excluding stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,239&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,650&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Drug manufacturing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 431&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,830&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Clinical trials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,043&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,927&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Outside general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,244&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 946&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Facilities and insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 558&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 780&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Other segment items (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,924&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 949&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total segment expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,877&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,922&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Non-operating income, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (1,185)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (25,115)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,692&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (15,193)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;Includes consulting, non-clinical research and laboratory supplies.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:3pt;"&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="INF"
      id="Narr_lhMdfOQ3uE6f38VtrLF9FQ"
      unitRef="Unit_Standard_pure_zwdjuLpe8Um-MXpoYRfl8Q">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="INF"
      id="Narr_jL9F7RkRIk-1O1uM0fPcAA"
      unitRef="Unit_Standard_pure_zwdjuLpe8Um-MXpoYRfl8Q">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_qaUfeIKQM0uZqXw3Lti1cw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The following table presents reportable segment net loss, including significant expense categories, attributable to the Company&#x2019;s reportable segment for the three months ended March 31, 2026 and 2025 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Compensation and benefits, excluding stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,239&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,650&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Drug manufacturing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 431&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,830&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Clinical trials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,043&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,927&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Outside general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,244&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 946&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Facilities and insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 558&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 780&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Other segment items (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,924&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 949&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total segment expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,877&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,922&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Non-operating income, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (1,185)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (25,115)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,692&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (15,193)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;Includes consulting, non-clinical research and laboratory supplies.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:3pt;"&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_13QLE4--qkSLAG4eDqDZOw_4_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">3027000</us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold>
    <us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_HhgmmlQf7EWW8vrLMCqlbg_4_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">2239000</us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_IE3j77P_3ESSlg1PuFpLOA_5_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">2650000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_BzlRanmm4EiTKdkeIEWvQg_5_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1251000</us-gaap:ShareBasedCompensation>
    <crvs:SegmentDrugManufacturingCosts
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_kjSkT5SgqU2oQrO9qXYGeQ_6_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">431000</crvs:SegmentDrugManufacturingCosts>
    <crvs:SegmentDrugManufacturingCosts
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_sMrKbVv7nUeMvk7adJ1rpg_6_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1830000</crvs:SegmentDrugManufacturingCosts>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_7lSreRP70USRpQuNR9fgoA_7_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">5043000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_MXM7_wrcZ02O_qy786zIAQ_7_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1927000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_7gJ4JSLVIUSmA_tArmjgyg_8_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1244000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_gR2D5niWjkOlrlmFL_uGcw_8_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">946000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <crvs:FacilitiesAndInsurance
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_XB2jVlvoaEi09Fycb-Kmcw_9_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">558000</crvs:FacilitiesAndInsurance>
    <crvs:FacilitiesAndInsurance
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_0ShVXZxySUy0blkGtdHwvA_9_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">780000</crvs:FacilitiesAndInsurance>
    <us-gaap:OtherGeneralExpense
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_vHRpbb1WI02RfLwX9x1D2w_10_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1924000</us-gaap:OtherGeneralExpense>
    <us-gaap:OtherGeneralExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_UrLEZK7KZ0SqofqqshXHZQ_10_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">949000</us-gaap:OtherGeneralExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_oj_57xTYYUGnpyD_FRW5YA_11_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">14877000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_xZKHCL8_fEevR-8_2yJSjQ_11_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">9922000</us-gaap:OperatingExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_XQDJZr-Uw0CsYH-AUv_jjg_12_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1185000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_qy_Yt9Z9rEOwaMPIYcH_ng_12_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">25115000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_6APwYmHgY0Wv9zRWrJDqVA_13_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-13692000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_5yZL0ulBeE-pItxNMcPwuA_13_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">15193000</us-gaap:NetIncomeLoss>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_mQ1ddGvXTUi_ANiXWYy_IQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;5. Fair Value Measurements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Financial assets and liabilities are measured and recorded at fair value. The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;1&#x2014;Quoted prices in active markets for identical assets or liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;2&#x2014;Inputs other than quoted prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;3&#x2014;Unobservable inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants would use in pricing the asset or liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;There have been no transfers of assets and liabilities between levels of hierarchy.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The Company&#x2019;s Level 2 investments are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar investments, issuer credit spreads, benchmark investments, prepayment/default projections based on historical data and other observable inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The following tables present information as of March 31, 2026 and December 31, 2025 about the Company&#x2019;s assets that are measured at fair value on a recurring basis and indicate the level of the fair value hierarchy the Company utilized to determine such fair values (in&#160;thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;width:43.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;width:32.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measured&#160;Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,106&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,106&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 196,612&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 196,612&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,106&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 196,612&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 235,718&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:normal;width:43.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:normal;width:32.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measured&#160;Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,163&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,163&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,174&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,174&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,163&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,174&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 56,337&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;As of March 31, 2026 and December 31, 2025, the fair value of available for sale marketable securities by type of security were as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:38.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:59.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;U.S. Treasury securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164,862&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (237)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164,678&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;U.S. Government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (88)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,934&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 196,883&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 54&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (325)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 196,612&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:36.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;U.S. Treasury securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,622&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,675&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;U.S. Government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,489&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,499&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,111&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,174&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="color:#ee0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;As of March 31, 2026, all of the Company&#x2019;s marketable securities are considered available for current operations and the remaining maturity by type of security is as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="color:#ee0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Maturities&#160;by&#160;Period at Amortized Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Less&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;than&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1 Year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1-2 years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;U.S. Treasury securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164,862&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 95,749&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69,113&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;U.S. Government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,943&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,078&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 196,883&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 108,692&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88,191&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="color:#ee0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_3bF2iaIDb0G23EF4PmuJRQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The following tables present information as of March 31, 2026 and December 31, 2025 about the Company&#x2019;s assets that are measured at fair value on a recurring basis and indicate the level of the fair value hierarchy the Company utilized to determine such fair values (in&#160;thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;width:43.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;width:32.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measured&#160;Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,106&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,106&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 196,612&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 196,612&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,106&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 196,612&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 235,718&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:normal;width:43.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:normal;width:32.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measured&#160;Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:normal;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&#160;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,163&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,163&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,174&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,174&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:54.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,163&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,174&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:8.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 56,337&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_3_31_2026_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vIybyFvfXUWOpF0Ttuei1g"
      decimals="-3"
      id="Tc_tAVOJvg6jUycRAmQn3RK8w_5_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">39106000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_3_31_2026_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-i89-0JYT0SuUe9mQLTeMA"
      decimals="-3"
      id="Tc_bQj9ROKoTU6BcLEAsLhJoA_5_12"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">39106000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="As_Of_3_31_2026_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1UFe9j-ZmEGRYjbAX_HTFw"
      decimals="-3"
      id="Tc_5rQxo2wcEkeGRBxz6wfP-A_6_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">196612000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="As_Of_3_31_2026_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-i89-0JYT0SuUe9mQLTeMA"
      decimals="-3"
      id="Tc_rdC3Tu6r-EiBi0cU6YzclQ_6_12"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">196612000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_3_31_2026_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_vIybyFvfXUWOpF0Ttuei1g"
      decimals="-3"
      id="Tc__t3jOBzLEkSehAtzRU0bDQ_7_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">39106000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_3_31_2026_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1UFe9j-ZmEGRYjbAX_HTFw"
      decimals="-3"
      id="Tc_597XN0Oob0uevEqwNODN1w_7_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">196612000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_3_31_2026_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-i89-0JYT0SuUe9mQLTeMA"
      decimals="-3"
      id="Tc_d9jv0iLhREijn3nrIiGOjA_7_12"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">235718000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_umpLEYrKtUW8udWfgt4FUQ"
      decimals="-3"
      id="Tc_IaN0v6gVrUK1r2PLr-kQog_5_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">4163000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_d-ggcYb3f0OK5oH3EAR0_w"
      decimals="-3"
      id="Tc_ukXVyuvJGE2kk_gSGjWJvg_5_12"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">4163000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_XWrNNuJp9kmcv0K4YI0__w"
      decimals="-3"
      id="Tc_mqBqwx3WmU-efGYpmh1-7w_6_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">52174000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_d-ggcYb3f0OK5oH3EAR0_w"
      decimals="-3"
      id="Tc_5JVOYhJTVkyCCI-3xd6JiA_6_12"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">52174000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_umpLEYrKtUW8udWfgt4FUQ"
      decimals="-3"
      id="Tc_WL88Q_ATxUqh2hzmKtWAxA_7_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">4163000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_XWrNNuJp9kmcv0K4YI0__w"
      decimals="-3"
      id="Tc_2fwr-Xyc5kWt2roXYHIMGw_7_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">52174000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_d-ggcYb3f0OK5oH3EAR0_w"
      decimals="-3"
      id="Tc_awpN79pkBkCm6CS800vp9A_7_12"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">56337000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_fHMEMrdCkEKRBtHksSF2bQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;As of March 31, 2026 and December 31, 2025, the fair value of available for sale marketable securities by type of security were as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:38.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:59.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;U.S. Treasury securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164,862&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (237)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164,678&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:59.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;U.S. Government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (88)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,934&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 196,883&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 54&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (325)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 196,612&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:36.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;U.S. Treasury securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,622&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38,675&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:61.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;U.S. Government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,489&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,499&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,111&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,174&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_Z1ifIYrZk0K3l2sseW4akQ"
      decimals="-3"
      id="Tc_qO5vfv6ulEG_yydGlyTrJQ_5_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">164862000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_Z1ifIYrZk0K3l2sseW4akQ"
      decimals="-3"
      id="Tc_rlP-bz2CsE2CQlUPs1d2bQ_5_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">53000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_Z1ifIYrZk0K3l2sseW4akQ"
      decimals="-3"
      id="Tc_WjWDc7szqUaNdfG04nCpwA_5_9"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">237000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_Z1ifIYrZk0K3l2sseW4akQ"
      decimals="-3"
      id="Tc_29JvD2edjUOfiJfT1RQEdg_5_12"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">164678000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_xEp_Nqn3VkmF6ubCOIKCDQ"
      decimals="-3"
      id="Tc_TQvMk84POU2l9HiA4M1L1g_6_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">32021000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_xEp_Nqn3VkmF6ubCOIKCDQ"
      decimals="-3"
      id="Tc_Tk6vWkgod0OLdd7xEuefQQ_6_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_xEp_Nqn3VkmF6ubCOIKCDQ"
      decimals="-3"
      id="Tc_bkIM-LBEE0utuws9gc5jvA_6_9"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">88000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_xEp_Nqn3VkmF6ubCOIKCDQ"
      decimals="-3"
      id="Tc__110bAL6Bk-SH51U_sMuPQ_6_12"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">31934000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_yXYJaMF0sEOc03a0yq_HcA_7_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">196883000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_DedKCjtgFkmUQmdgxTaeRw_7_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">54000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_AEtsalyPW0m2nZpHY-H9hA_7_9"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">325000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_oC1x32-OdU6hmLT3bm4BbQ_7_12"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">196612000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="As_Of_12_31_2025_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_by6XIl09fUeHMa27xYEX5w"
      decimals="-3"
      id="Tc_D6mb8zgQLECgolQzmDojDA_5_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">38622000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2025_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_by6XIl09fUeHMa27xYEX5w"
      decimals="-3"
      id="Tc_c05Y99AmG0avBSt9Clt9oQ_5_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">53000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="As_Of_12_31_2025_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_by6XIl09fUeHMa27xYEX5w"
      decimals="-3"
      id="Tc_VLlxmRUZz06iwEaiHerMxQ_5_12"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">38675000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="As_Of_12_31_2025_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2TM0kzCyaUqmRGhHtqiKBw"
      decimals="-3"
      id="Tc_yhuNG8LwlEuyJxvGd6K6rg_6_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">13489000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2025_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2TM0kzCyaUqmRGhHtqiKBw"
      decimals="-3"
      id="Tc_2B5KhP6Uq0Cq63_M-R4OcA_6_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="As_Of_12_31_2025_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2TM0kzCyaUqmRGhHtqiKBw"
      decimals="-3"
      id="Tc_h9Ltn6t-CUGMLUkZDYoBiA_6_12"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">13499000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_jSXltk0uUUKH2H2ojUbj8w_7_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">52111000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_LIhH3nm_uEaDaB6wQvLwGQ_7_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">63000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_uq6hFWBubU28wF_OK6oIZw_7_12"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">52174000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_XqD0Ux5HkkGM5XQGwTmiAw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;As of March 31, 2026, all of the Company&#x2019;s marketable securities are considered available for current operations and the remaining maturity by type of security is as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="color:#ee0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Maturities&#160;by&#160;Period at Amortized Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Less&lt;/b&gt;&lt;b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;than&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1 Year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1-2 years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;U.S. Treasury securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164,862&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 95,749&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69,113&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;U.S. Government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,943&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,078&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 196,883&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 108,692&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88,191&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="color:#ee0000;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_Z1ifIYrZk0K3l2sseW4akQ"
      decimals="-3"
      id="Tc_vHImPEEtPUW-WtB7rHlEgg_4_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">164862000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_Z1ifIYrZk0K3l2sseW4akQ"
      decimals="-3"
      id="Tc_AuEVHbo8hkOT4wpNn1U2FQ_4_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">95749000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <crvs:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo
      contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_Z1ifIYrZk0K3l2sseW4akQ"
      decimals="-3"
      id="Tc_q_iyV2vKpU6d3D5uuDyViw_4_9"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">69113000</crvs:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_xEp_Nqn3VkmF6ubCOIKCDQ"
      decimals="-3"
      id="Tc_RAoUpbN-2UeCx6yqH7qAKQ_5_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">32021000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_xEp_Nqn3VkmF6ubCOIKCDQ"
      decimals="-3"
      id="Tc_mLKqi7pprUqu0kAAq9BjVA_5_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">12943000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <crvs:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo
      contextRef="As_Of_3_31_2026_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_xEp_Nqn3VkmF6ubCOIKCDQ"
      decimals="-3"
      id="Tc_BeZDG692nE6fqrhMWS_JBw_5_9"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">19078000</crvs:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_Wrzyl4v2TEqduVKksqGb_w_6_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">196883000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_aYlgYm_8O0uesJJwQ4_7cg_6_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">108692000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <crvs:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_wA6Whjw9tECsy5lKzmL8Qg_6_9"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">88191000</crvs:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_fGD6W6BlB0mCyqFS_nsb-g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;6. Equity Method Investment&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Angel Pharmaceuticals Co. Ltd. (&#x201c;Angel Pharmaceuticals&#x201d;) is a corporate venture in the People&#x2019;s Republic of China designed to develop, manufacture, and commercialize soquelitinib, ciforadenant and mupadolimab compounds for distribution within the countries of China, Taiwan, Macao, and Hong Kong based on intellectual property licenses contributed to Angel Pharmaceuticals by the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of March 31, 2026 and December 31, 2025, the Company&#x2019;s ownership interest in Angel Pharmaceuticals was approximately 49.7%, excluding 7% of Angel Pharmaceuticals&#x2019; equity reserved for issuance under the Angel Pharmaceuticals Employee Stock Ownership Plan, and is accounted for as an equity method investment. The Company recognized its share of loss in Angel Pharmaceuticals for the total amount of $0.6 million and $0.5 million as loss from equity method investment in the condensed consolidated statement of operations for the three months ended March 31, 2026 and 2025, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Summary Financial Information&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Summary financial information for Angel Pharmaceuticals is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance Sheet Data&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31, 2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,286&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,033&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Non-current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 798&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 904&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 863&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,049&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Non-current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 143&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 229&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Stockholders' equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,078&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,659&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statement&#160;of&#160;Operations&#160;Data&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Gross profit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (768)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (686)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Share of loss from investments accounted for using the equity method&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (599)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (539)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="As_Of_3_31_2026_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_ZE_QhKexwEy9f39wgI86gQ"
      decimals="3"
      id="Narr_vv-i-Z4Hnkm9hSKru9v99g"
      unitRef="Unit_Standard_pure_zwdjuLpe8Um-MXpoYRfl8Q">0.497</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="As_Of_12_31_2025_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_R50vtT-u40OjHn3pS5rzEA"
      decimals="3"
      id="Narr_DGWIIlsTmUqbgfemg9-VEQ"
      unitRef="Unit_Standard_pure_zwdjuLpe8Um-MXpoYRfl8Q">0.497</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <crvs:EmployeeStockOwnershipPlanEsopEquityReservePercentage
      contextRef="Duration_1_1_2026_To_3_31_2026_dei_LegalEntityAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_IAkd47amHkiAxCCDntS06Q"
      decimals="2"
      id="Narr_vbbyFlGkYkGiHei4myBLeA"
      unitRef="Unit_Standard_pure_zwdjuLpe8Um-MXpoYRfl8Q">0.07</crvs:EmployeeStockOwnershipPlanEsopEquityReservePercentage>
    <crvs:EmployeeStockOwnershipPlanEsopEquityReservePercentage
      contextRef="Duration_1_1_2025_To_12_31_2025_dei_LegalEntityAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_v9ThojvBS0yKLcEp5NgIDw"
      decimals="2"
      id="Narr_GukjNznNM0SaYT2jsMC93w"
      unitRef="Unit_Standard_pure_zwdjuLpe8Um-MXpoYRfl8Q">0.07</crvs:EmployeeStockOwnershipPlanEsopEquityReservePercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="Duration_1_1_2026_To_3_31_2026_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_6ofbkjgS-0e4rwuNdfqWaw"
      decimals="-5"
      id="Narr_TeiI_sT-a0iXgYJBqa9S7g"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-600000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_2y33YWXdnkGW7dFGwtYxNQ"
      decimals="-5"
      id="Narr_nCLTmD7c8EWjCRrQbVtJeA"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Group_kvemLDOiikSQ8whOQalung">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance Sheet Data&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31, 2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="7" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,286&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,033&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Non-current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 798&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 904&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 863&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,049&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Non-current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 143&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 229&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:67.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Stockholders' equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,078&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,659&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statement&#160;of&#160;Operations&#160;Data&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Gross profit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (768)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (686)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:71.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Share of loss from investments accounted for using the equity method&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (599)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (539)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_3_31_2026_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_wsU59n8Qhk6UFUREvLUcmQ"
      decimals="-3"
      id="Tc_CXA-8YPfoEWEofDBmU4fOg_4_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">10286000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2025_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_dBO40tK2nky99I0IgRgeFA"
      decimals="-3"
      id="Tc_4OdPE57CHE61jHWJ3k676Q_4_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">11033000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_3_31_2026_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_wsU59n8Qhk6UFUREvLUcmQ"
      decimals="-3"
      id="Tc_QvdlZaF6REeOsd2p7B0B7g_5_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">798000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_12_31_2025_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_dBO40tK2nky99I0IgRgeFA"
      decimals="-3"
      id="Tc_SmcwGMXPz0SQPuCyjbYdDg_5_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">904000</us-gaap:AssetsNoncurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_3_31_2026_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_wsU59n8Qhk6UFUREvLUcmQ"
      decimals="-3"
      id="Tc_cGLy5fiCBEuqkwWHotkQPg_6_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">863000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2025_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_dBO40tK2nky99I0IgRgeFA"
      decimals="-3"
      id="Tc_w2kVPvn_FEup3tFbIVClaA_6_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1049000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_3_31_2026_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_wsU59n8Qhk6UFUREvLUcmQ"
      decimals="-3"
      id="Tc_VbYNOE2zS0KV1mK7VgUtwg_7_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">143000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2025_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_dBO40tK2nky99I0IgRgeFA"
      decimals="-3"
      id="Tc_AapER5xAJEOdRV8DdC2HKg_7_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">229000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2026_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_wsU59n8Qhk6UFUREvLUcmQ"
      decimals="-3"
      id="Tc_0bEJWhMDWEi80DqbZ93-hA_8_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">10078000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_dBO40tK2nky99I0IgRgeFA"
      decimals="-3"
      id="Tc_tf4kjobaJUGzdvUthIqsBg_8_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">10659000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_dSaQSn0xTEGxv32ul8LDRw"
      decimals="-3"
      id="Tc_xh1t7Ej4Dkq_3kBJNQCGEw_7_4"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-768000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_Tb3DXUa7E0uzOGfwD0V8eA"
      decimals="-3"
      id="Tc_3u4lo_NUE0espasGKSqsUA_7_7"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-686000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_YYrR8dYMUkeFvmgdZDyUHg_8_4"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-599000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_Ew65Xl5-Bk6kvk30OdGv9Q_8_7"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-539000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_-NwrlrjdG0Wu8bS84vI-1w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;7. License and Collaboration Agreements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Scripps Licensing Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2014, the Company entered into a license agreement with The Scripps Research Institute (&#x201c;Scripps&#x201d;), pursuant to which it was granted a non-exclusive, world-wide license for all fields of use under Scripps&#x2019; rights in certain know-how and technology related to a mouse hybridoma clone expressing an anti-human CD73 antibody, and to progeny, mutants or unmodified derivatives of such hybridoma and any antibodies expressed by such hybridoma, from which we developed CPI-006. Scripps also granted the Company the right to grant sublicenses in conjunction with other proprietary rights the Company holds, or to others collaborating with or performing services for the Company. Under this license agreement, Scripps has agreed not to grant any additional commercial licenses with respect to such materials, other than march-in rights granted to the U.S. government.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Upon execution of the agreement, the Company made a one time cash payment to Scripps of $10,000 in 2015 and is also obligated to pay a minimum annual fee to Scripps of $25,000. The one time cash payment was recorded as research and development expense as technological feasibility of the asset had not been established and there was no alternative future use. A minimum annual fee payment is due on each anniversary of the effective date of the agreement &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;for the term of the agreement. The Company is also required to make performance based cash payments upon successful completion of clinical and sales milestones. The aggregate potential milestone payments are $2.5 million as of March 31, 2026. The Company is also required to pay royalties on net sales of licensed products (including CPI-006) sold by it, its affiliates and its sublicensees at a rate in the low single digits. In addition, should the Company sublicense the rights licensed under the agreement, it has agreed to pay a percentage of sublicense revenue received at specified rates that start at double digit percentages and decrease to single digit percentages based on the elapsed time from the effective date of the agreement and the time of entry into such sublicense. To date, no milestone payments have been made.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s license agreement with Scripps will terminate upon expiration of its obligation to pay royalties to Scripps under the license agreement. The Company&#x2019;s license agreement with Scripps is terminable by the consent of the parties, at will by the Company upon providing 90 days written notice to Scripps, or by Scripps for certain material breaches, or if the Company undergoes a bankruptcy event. In addition, Scripps may terminate the license on a product by product basis, or the entire agreement, if the Company fails to meet specified diligence obligations related to the development and commercialization of licensed products. Scripps may also terminate the agreement after the third anniversary of the effective date of the agreement if it reasonably believes, based on reports the Company provides to Scripps, that the Company has not used commercially reasonable efforts as required under the agreement, subject to a specified notice and cure period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Vernalis Licensing Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;In February 2015, the Company entered into a license agreement with Vernalis (R&amp;amp;D) Limited (&#x201c;Vernalis&#x201d;), which was subsequently amended as of November 5, 2015, and, pursuant to which the Company was granted an exclusive, worldwide license under certain patent rights and know-how, including a limited right to grant sublicenses, for all fields of use to develop, manufacture and commercialize products containing certain adenosine receptor antagonists, including ciforadenant. Pursuant to this agreement, the Company made a one-time cash payment to Vernalis in the amount of $1.0 million, which was recorded as research and development expense as technological feasibility of the asset had not been established and there was no alternative future use. The Company is also required to make cash milestone payments to Vernalis upon the successful completion of clinical and regulatory milestones for licensed products depending on the indications for which such licensed products are developed and upon achievement of certain sales milestones. In February 2017, the Company made a milestone payment of $3.0 million to Vernalis following the expansion of a cohort of patients with renal cell cancer treated with single agent ciforadenant in the Company&#x2019;s Phase 1/1b clinical trial. During the three months ended March 31, 2026 and 2025, no clinical or regulatory milestones were completed or paid to Vernalis, and the aggregate potential milestone payments were approximately $220 million for all indications as of March 31, 2026. The Company has also agreed to pay Vernalis tiered incremental royalties based on the annual net sales of licensed products containing ciforadenant on a product by product and country by country basis, subject to certain offsets and reductions. The tiered royalty rates for products containing ciforadenant range from the mid single digits up to the low double digits on a country by country net sales basis. The royalties on other licensed products that do not include ciforadenant also increase with the amount of net sales on a product-by-product and country by country basis and range from the low single digits up to the mid single digits on a country by country net sales basis. The Company is also obligated to pay to Vernalis certain sales milestones as indicated above when worldwide net sales reach specified levels over an agreed upon time period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The agreement will expire on a product-by-product and country-by-country basis upon the expiration of the Company&#x2019;s payment obligations to Vernalis in respect of a particular product and country. Both parties have the right to terminate the agreement for an uncured material breach by the other party. The Company may also terminate the agreement at its convenience by providing 90 days written notice, provided that the Company has not received notice of its own default under the agreement at the time the Company exercises such termination right. Vernalis may also terminate the agreement if the Company challenges a licensed patent or undergoes a bankruptcy event.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Monash License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In April&#160;2017, the Company entered into a license agreement with Monash University (&#x201c;Monash&#x201d;), pursuant to which the Company was granted an exclusive, sublicensable worldwide license under certain know-how, patent rights and other intellectual property rights controlled by Monash to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon execution of the agreement, the Company made a one time cash payment to Monash of $275,000 and reimbursed Monash for certain patent prosecution costs incurred prior to execution of the agreement. The Company recorded these payments as research and development expenses for the year ended December 31, 2017. The Company is also obligated to pay an annual license maintenance fee to Monash of $25,000 until a certain development milestone is met with respect to the licensed product, after which no further maintenance fee will be due. The Company is also required to make development and sales milestone payments to Monash with respect to the licensed products. During the three months ended March 31, 2026 and 2025, no development or sales milestones were completed or paid to Monash, and the aggregate potential milestones were $45.1 million as of March 31, 2026. The Company is also required to pay to Monash tiered royalties on net sales of licensed products sold by it, its affiliates and its sublicensees at a rate ranging in the low single digits. In addition, should the Company sublicense its rights under the agreement, the Company has agreed to pay a percentage of sublicense revenue received at specified rates that are currently at low double digit percentages and decrease to single digit percentages based on the achievement of development milestones.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The term of the Company&#x2019;s agreement with Monash continues until the expiration of its obligation to pay royalties to Monash thereunder. The license agreement is terminable at will by the Company upon providing 30 days written notice to Monash, or by either party for material breaches by the other party. In addition, Monash may terminate the entire agreement or convert the license to a non-exclusive license if the Company has materially breached its obligation to use commercially reasonable efforts to develop and commercialize a licensed product, subject to a specified notice and cure mechanism.&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2015_To_12_31_2015_srt_CounterpartyNameAxis_crvs_ScrippsResearchInstituteMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_XMrt33ULGkeQ_-gbvlHdKA"
      decimals="0"
      id="Narr_RdoLPSx-O0KdWZKWx9mHSg"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">10000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_ScrippsResearchInstituteMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_po2cXNmYykeJqOGtUERulg"
      decimals="0"
      id="Narr_UJcEY2LP-k-036Jjj97gig"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">25000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <crvs:LicenseAgreementMilestonePayment
      contextRef="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_ScrippsResearchInstituteMember_srt_StatementScenarioAxis_crvs_AggregatePotentialMilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_dD5UP8Q5v06xhOLdtmqxlA"
      decimals="-5"
      id="Narr_uaPOhfflsUWjvQTdDLlyOQ"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">2500000</crvs:LicenseAgreementMilestonePayment>
    <crvs:LicenseAgreementMilestonePayment
      contextRef="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_ScrippsResearchInstituteMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_po2cXNmYykeJqOGtUERulg"
      decimals="0"
      id="Narr_bcA1Fi0nnkGAiMMS8Ho43A"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">0</crvs:LicenseAgreementMilestonePayment>
    <crvs:ResearchAndDevelopmentArrangementContractTerminationNoticePeriod
      contextRef="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_ScrippsResearchInstituteMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_po2cXNmYykeJqOGtUERulg"
      id="Narr_-QZ31wnJPkOuHnDLnCxv0Q">P90D</crvs:ResearchAndDevelopmentArrangementContractTerminationNoticePeriod>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_11_5_2015_To_11_5_2015_srt_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_cxY8H5-g_EGIH2ELcc-HaQ"
      decimals="-5"
      id="Narr_KYwUiagBwEylwfdh5F56Qw"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1000000</us-gaap:ResearchAndDevelopmentExpense>
    <crvs:LicenseAgreementMilestonePayment
      contextRef="Duration_2_1_2017_To_2_28_2017_srt_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_53gyr3oPf0-E7oFQOdHZ2A"
      decimals="-5"
      id="Narr_oH2NyYNmoU2MUUMnvehc0A"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">3000000</crvs:LicenseAgreementMilestonePayment>
    <crvs:LicenseAgreementMilestonePayment
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_yZROy1gbRU-l_b7CkxhgEg"
      decimals="0"
      id="Narr_vEjqAyv4WEaZ2toQeOc5ug"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">0</crvs:LicenseAgreementMilestonePayment>
    <crvs:LicenseAgreementMilestonePayment
      contextRef="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_zptfIK_qa0ys8kZeVc8ECg"
      decimals="0"
      id="Narr_ELLoI-U-2EKl4jTTUHE0bQ"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">0</crvs:LicenseAgreementMilestonePayment>
    <crvs:LicenseAgreementMilestonePayment
      contextRef="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_srt_StatementScenarioAxis_crvs_AggregatePotentialMilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_aJ4OIsSntUiP4dLNeBCv1A"
      decimals="-6"
      id="Narr_TxJxpRSILUGesoU4MeYugw"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">220000000</crvs:LicenseAgreementMilestonePayment>
    <crvs:ResearchAndDevelopmentArrangementContractTerminationNoticePeriod
      contextRef="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_VernalisRAndDLimitedMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_zptfIK_qa0ys8kZeVc8ECg"
      id="Narr_1UJ1fluf-EqiE0hxNWEIHA">P90D</crvs:ResearchAndDevelopmentArrangementContractTerminationNoticePeriod>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2017_To_4_30_2017_srt_CounterpartyNameAxis_crvs_MonashLicenseMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_a9cCB_fmJ0qXM_jhei5r1Q"
      decimals="0"
      id="Narr_6KKaQ4RB30WGO4V_CfoNhw"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">275000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="Duration_4_1_2017_To_4_30_2017_srt_CounterpartyNameAxis_crvs_MonashLicenseMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_a9cCB_fmJ0qXM_jhei5r1Q"
      decimals="0"
      id="Narr_LLHmbctO70mAdxgSs9zfoQ"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">25000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <crvs:LicenseAgreementMilestonePayment
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_crvs_MonashLicenseMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_qMLGaFcjDk6SK_FVkFPddA"
      decimals="0"
      id="Narr_zrLkubgCfEy1AwmFFd4a7Q"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">0</crvs:LicenseAgreementMilestonePayment>
    <crvs:LicenseAgreementMilestonePayment
      contextRef="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_MonashLicenseMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_11uvkiG9bE23RyZq6u2HDA"
      decimals="0"
      id="Narr_SwCxs_ifV0KpxwattsviRA"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">0</crvs:LicenseAgreementMilestonePayment>
    <crvs:LicenseAgreementMilestonePayment
      contextRef="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_MonashLicenseMember_srt_StatementScenarioAxis_crvs_AggregatePotentialMilestonePaymentsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_6utRsh2k0ky_UVcLFS0XMg"
      decimals="-5"
      id="Narr_zgj72-EnmU27vTz8WA_rXg"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">45100000</crvs:LicenseAgreementMilestonePayment>
    <crvs:ResearchAndDevelopmentArrangementContractTerminationNoticePeriod
      contextRef="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_MonashLicenseMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_LicenseAgreementTermsMember_11uvkiG9bE23RyZq6u2HDA"
      id="Narr_i9zqJIY7gUa2qDj-6pKmBQ">P30D</crvs:ResearchAndDevelopmentArrangementContractTerminationNoticePeriod>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_he-nVDrEc0O05UX4ZwJB0w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;8. Balance Sheet Components (in thousands)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Prepaid and Other Current Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Interest receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 337&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Prepaid research and development manufacturing expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,564&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 599&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Prepaid facility expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 138&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 367&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 318&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,189&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,427&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,713&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,646&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Computer equipment and purchased software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 190&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 190&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,959&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,869&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (2,677)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (2,649)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 282&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 220&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accrued and Other Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Accrued clinical trial expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,566&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Accrued manufacturing expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,794&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,812&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Personnel related &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,381&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 641&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Accrued legal and accounting&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 304&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 229&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 206&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 238&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,985&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,486&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the three months ended March 31, 2026 and 2025, the Company recorded approximately $29,000 and $22,000 in depreciation expense, respectively.&lt;/p&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <srt:ScheduleOfCondensedBalanceSheetTableTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_z0LYv6qH8ECL1x1LTXtXaQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Prepaid and Other Current Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Interest receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 337&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Prepaid research and development manufacturing expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,564&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 599&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Prepaid facility expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 138&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 367&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 318&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,189&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,427&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,713&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,646&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Computer equipment and purchased software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 190&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 190&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,959&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,869&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (2,677)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (2,649)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 282&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 220&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Accrued and Other Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Accrued clinical trial expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,566&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Accrued manufacturing expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,794&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,812&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Personnel related &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,381&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 641&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Accrued legal and accounting&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 304&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 229&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 206&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 238&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,985&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,486&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</srt:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <us-gaap:InterestReceivable
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_LDKDLWzqlUiT9mtzkkjMyg_4_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1155000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_YwkhEkZrh0GILWTmOa9FQw_4_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">337000</us-gaap:InterestReceivable>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_wZcNB6eEYEudHFkOkkdC2Q_5_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1564000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_vP06TTqYn0ahhnPUZrFqyw_5_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">599000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidRent
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_IL6qsoXxIEe4bNLfKvCwfA_6_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">34000</us-gaap:PrepaidRent>
    <us-gaap:PrepaidRent
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_gEm1bjhG4UOLyoRUSi0B3A_6_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">35000</us-gaap:PrepaidRent>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_rwFvDe4DD0KGNignKXduwQ_7_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">69000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_YpJPcxIqf0C9EnI0n8VDRg_7_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">138000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_NZBLIRttk0CABSNlVF-tgA_8_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">367000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_Zdsdb4JXvkSNaEgR2jQmgw_8_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">318000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_H_jsvud-D02jJXXBAVxLAA_9_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">3189000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_wMfoOD19G0-Gvyew6QKjSw_9_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1427000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_6C25sOE9Ikmp0oeoupptOQ"
      decimals="-3"
      id="Tc_gWDj3ZicDEyNOVuUkaJb2w_11_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">2713000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_66ZNx4o7xE6nChx728HdAQ"
      decimals="-3"
      id="Tc_RYIDSZFym0e1SviuC2qLww_11_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">2646000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_YgSDQjrssE-QgSvTIuicjQ"
      decimals="-3"
      id="Tc_7kuQEhbFcE-eVWfEQlgiaA_12_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">190000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_HK6hD7pbIEy_GhLi3vMwpg"
      decimals="-3"
      id="Tc_k7eCc1K9ZE2Jkkkrl4EIIQ_12_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">190000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_R_4AduDylk-cunlIwrPmxA"
      decimals="-3"
      id="Tc_9WG1A-2yn0aNn2ruP7db9g_13_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">33000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_AIlQrJQUYUCBdCBov2bs-A"
      decimals="-3"
      id="Tc_hhfK1dwVTEahimnbjA7RmQ_13_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">33000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_1OU2yiImZUyepALNkZ8rTQ"
      decimals="-3"
      id="Tc_YDOuo_dzo0GXAqCm72cxIg_14_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">23000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_YGOEOFj7DkyNAO7Sd2giyA_15_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">2959000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_y9qKYDRFWUGJCDoi2H0odA_15_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">2869000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_7IUiJhxLIkWaPYQ4nAFfbw_16_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">2677000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_WBFOH6660UeM296x9fUp2g_16_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">2649000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_yffE4Z5EHkiXvt7g0pyryw_17_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">282000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_X1-DN8HXBEGNbUKh-Jckpw_17_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">220000</us-gaap:PropertyPlantAndEquipmentNet>
    <crvs:AccruedLiabilitiesClinicalTrialCurrent
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_ozcNd_EPMku6d0SJh37tpA_19_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">3300000</crvs:AccruedLiabilitiesClinicalTrialCurrent>
    <crvs:AccruedLiabilitiesClinicalTrialCurrent
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_bgWIDAIJk0m7hnsRXzHyCQ_19_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">3566000</crvs:AccruedLiabilitiesClinicalTrialCurrent>
    <crvs:AccruedLiabilitiesManufacturingCurrent
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_UaU0fnFUMUSjYfXs0G4nJg_20_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1794000</crvs:AccruedLiabilitiesManufacturingCurrent>
    <crvs:AccruedLiabilitiesManufacturingCurrent
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_WTxzARpeqEq0RiU2BtgKiw_20_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1812000</crvs:AccruedLiabilitiesManufacturingCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_uN1nQXAguUKHydRgy5E5nw_21_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1381000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_08GRs6yphkagieXXcZGM_g_21_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">641000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_wqTawbwlqEajHI1j0E1iIA_22_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">304000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc__Law-VZCE0S_NcD3V4kCTg_22_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">229000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_ZLteTAu6VECsO7rw4wqICQ_23_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">206000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_8I8kPn4FXEalrwurwjxowA_23_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">238000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-3"
      id="Tc_nx6UBmIg_EWXm6B4Oric9g_24_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">6985000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="-3"
      id="Tc_jogQwegC3ECtVSpU8oKcQQ_24_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">6486000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="0"
      id="Narr_V6FDhVf-9UGGmP6j9Gqj5A"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">29000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="0"
      id="Narr_g9SgpGbI7UqVt0e9Zmk27A"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">22000</us-gaap:DepreciationAndAmortization>
    <crvs:WarrantsAndRightsNoteDisclosureTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_uvGRnerGKkO4d-BgLvKH6Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;9. Warrants&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On May 6, 2024, the company completed a registered direct offering in which the Company sold an aggregate of 13,512,699 shares of common stock and common warrants to purchase up to 13,078,509 shares of common stock (or pre-funded warrants in lieu thereof) at a combined offering price of $1.7312 per share and common warrant, and pre-funded warrants to purchase up to 4,144,085 shares of common stock and common warrants to purchase up to 4,010,927 shares of common stock (or pre-funded warrants in lieu thereof), at a combined offering price of $1.7311 per share underlying each pre-funded warrant and common warrant, which equals the offering price per share and common warrant less the $0.0001 exercise price per share of the pre-funded warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The pre-funded warrants have an exercise price per share of common stock equal to $0.0001 per share. The exercise price and the number of shares of common stock issuable upon exercise of the pre-funded warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. The pre-funded warrants are exercisable at any time after the date of issuance. In accordance with accounting guidance discussed in Note 2, the Company recorded $5.0 million to additional paid-in capital upon issuance of the pre-funded warrants on May 6, 2024. In May 2025, an additional 4,131,828 pre-funded warrants were issued in connection with the exercise of common warrants. As of March 31, 2026, none of the pre-funded warrants have been exercised and 8,275,913 pre-funded warrants remain outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The common warrants had an exercise price per share of common stock equal to $3.50 per share (or $3.4999 per pre-funded warrant). The exercise price and the number of shares of common stock (or pre-funded warrants in lieu thereof) issuable upon exercise of the common warrants were subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;common stock. The common warrants were exercisable at any time after the date of issuance and had an expiration date of June 30, 2025. In accordance with accounting guidance discussed in Note 2, &#x201c;Summary of Significant Accounting Policies,&#x201d; the Company recorded a decrease in fair value of warrant liability of $25.1 million to other income in its condensed consolidated statement of operations and comprehensive loss for the three months ended March 31, 2025. As of June 30, 2025, the expiration date of the common warrants, all of the common warrants had been exercised, resulting in proceeds of $54.3 million.&lt;/p&gt;</crvs:WarrantsAndRightsNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_5_6_2024_To_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonStockSharesAndCommonStockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_qes8akhL1UOvGAi6lmbg1w"
      decimals="INF"
      id="Narr_fdVAkSsN1UCo9car9emC-A"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">13512699</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonStockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_YFKxpTiNbU6oZe1MFcXljw"
      decimals="INF"
      id="Narr_YyZusWQNXE-Y769gihKLAA"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">13078509</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <crvs:CombinedOfferingPriceForSharesAndWarrants
      contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonStockSharesAndCommonStockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_oZTsrk4nrkiHDAAiKkO7Zw"
      decimals="4"
      id="Narr_maNDEkBM2k-8H67FJyJD0g"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">1.7312</crvs:CombinedOfferingPriceForSharesAndWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Jot-50-Yk0qa7VxZIMl1Sg"
      decimals="INF"
      id="Narr_pVRBaOx8n0yZzwzrDOwAOg"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">4144085</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_4BVj8xmMz0KGnw09dZm4mg"
      decimals="INF"
      id="Narr_oj1-87WAEEG6FUKtPBc0sQ"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">4010927</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsAndCommonStockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Tlt-RbPRSUqh-Yw0_LG3kg"
      decimals="4"
      id="Narr_Di-yWYaTekCMGxAN_d44IA"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">1.7311</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Jot-50-Yk0qa7VxZIMl1Sg"
      decimals="4"
      id="Narr_WdN3FMLi2k6zOjbidvttPw"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Jot-50-Yk0qa7VxZIMl1Sg"
      decimals="4"
      id="Narr_tyn0PzBbBE6iJ_zQxOz72A"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_5_6_2024_To_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_xxahbdsvrUmf_bB3pjxXsA"
      decimals="-5"
      id="Narr_zdnbrQOJ2UmDMOQVgYLQ9A"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">5000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_5_31_2025_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_54_yHogU40CKupBljfogmQ"
      decimals="INF"
      id="Narr_349YLcAIcEiiXEPV7ziHTA"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">4131828</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_t-6dI_GLqkWg5FN5nJrFAw"
      decimals="INF"
      id="Narr_2o9zY-31gkm7sYCZU58b_w"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_crvs_PrefundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_t-6dI_GLqkWg5FN5nJrFAw"
      decimals="INF"
      id="Narr_5OH4GnI0h06BY5FBEEe3oA"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">8275913</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_4BVj8xmMz0KGnw09dZm4mg"
      decimals="2"
      id="Narr_seeesWTIk0WeOU6pJMxarg"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">3.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <crvs:ClassOfWarrantOrRightExercisePricePerPrefundedWarrant
      contextRef="As_Of_5_6_2024_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_4BVj8xmMz0KGnw09dZm4mg"
      decimals="4"
      id="Narr_q4E_D5ipjkK5d9a9KYxeCA"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">3.4999</crvs:ClassOfWarrantOrRightExercisePricePerPrefundedWarrant>
    <crvs:ChangeInFairValueOfWarrantLiabilities
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_MLeYeQx8wE2unDRlLMuIDQ"
      decimals="-5"
      id="Narr_oxVvGCHLkEm0MiREOGf73Q"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">-25100000</crvs:ChangeInFairValueOfWarrantLiabilities>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_crvs_CommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_uu4IdM0C2U-qNTnXiqDKRw"
      decimals="-5"
      id="Narr_0h7Kq1jcfEGXaf9JP1TazQ"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">54300000</us-gaap:ProceedsFromWarrantExercises>
    <crvs:CommonStockNoteDisclosureTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_yPKfRt0vgkO76gAGqrLetA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;10. Common Stock&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;As of March 31, 2026, the amended and restated certificate of incorporation authorizes the Company to issue 290&#160;million shares of common stock and 10 million shares of preferred stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Each share of common stock is entitled to one vote. Common stockholders are entitled to dividends if and when declared by the board of directors. As of March 31, 2026, no dividends on common stock had been declared.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;On August 6, 2024, the Company entered into an Open Market Sale Agreement&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; (the &#x201c;2024 Sales Agreement&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;) to sell shares of the Company&#x2019;s common stock, from time-to-time, with aggregate gross sales proceeds of up to $100.0 million, through an at-the-market equity offering program under which Jefferies will act as its sales agent. The issuance and sale of shares of common stock by the Company pursuant to the 2024 Sales Agreement are deemed an &#x201c;at-the-market&#x201d; offering under the Securities Act of 1933, as amended. Jefferies is entitled to compensation for its services up to 3.0% of the gross proceeds of any shares of common stock sold through Jefferies under the 2024 Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;On January 20, 2026, in connection with the January 2026 financing, as further described in Note 1, the Company suspended the offering of any shares of its common stock under the 2024 Sales Agreement and, on March 13, 2026, the Company entered into an Amended and Restated Open Market Sale Agreement&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt;, dated March 13, 2026 (the &#x201c;Amended Sales Agreement&#x201d;), with Jefferies, which amends and restates the 2024 Sales Agreement to increase the maximum aggregate offering price of shares of the Company&#x2019;s common stock from $100.0 million to $200.0 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;During the three months ended March 31, 2026, the Company did not sell any shares of common stock under its at-the-market offering program. As of March 31, 2026, $200.0 million remained available for sale under the Amended Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The Company has reserved shares of common stock for issuance as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Pre-funded warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,275,913&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,275,913&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Shares available for future option grants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,649,034&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,007,335&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Outstanding options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,066,326&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,028,177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Shares reserved for employee stock purchase plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 400,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 400,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,391,273&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,711,425&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</crvs:CommonStockNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-6"
      id="Narr_3G6cbrMSkEyvzaQG4hFLvQ"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">290000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="-6"
      id="Narr_mjjD3d93qEGI3uNm_MvfVQ"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockVotingRights
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Narr_S5zsYkhN-U6fJDcHXDDYyQ">Each share of common stock is entitled to one vote.</us-gaap:CommonStockVotingRights>
    <us-gaap:DividendsCommonStock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="0"
      id="Narr_l95CgOqVI0qiSqH_K1pOQQ"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">0</us-gaap:DividendsCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_8_6_2024_To_8_6_2024_srt_CounterpartyNameAxis_crvs_JefferiesLlcMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_AtMarketOfferingMember_eoj_eqi2mkWRVEknHEdLaA"
      decimals="-5"
      id="Narr_Lp0GJvbZP0yzJIVkfjPy7w"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">100000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <crvs:UnderwritingCommitmentsPercentage
      contextRef="Duration_8_6_2024_To_8_6_2024_srt_CounterpartyNameAxis_crvs_JefferiesLlcMember_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_AtMarketOfferingMember_C9TVVV5bD06kEd2FNfIBfg"
      decimals="INF"
      id="Narr_PkvSjdGyCUq15LOcDGFmkw"
      unitRef="Unit_Standard_pure_zwdjuLpe8Um-MXpoYRfl8Q">0.03</crvs:UnderwritingCommitmentsPercentage>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_20_2026_To_1_20_2026_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_AtMarketOfferingMember_pLGqywBb50amw3DDckyXMA"
      decimals="-5"
      id="Narr_ujK5RNTHakqtMu0c-d__jA"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">100000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_3_13_2026_To_3_13_2026_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_AtMarketOfferingMember_JM0TXSQCVEWG7UWlAYRf6Q"
      decimals="-5"
      id="Narr_FHMsq1g6tkGS-1w1GmYmLg"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">200000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_JefferiesLlcMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_AtMarketOfferingMember_xtxU8hDdr0aP8Izzn0-FoA"
      decimals="INF"
      id="Narr_SK8glwjhEUaFePxsVQZBjw"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_JefferiesLlcMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_AtMarketOfferingMember_Hon6YB2UOE6cicnSMk7KpA"
      decimals="-5"
      id="Narr_M0qAmS3GdUChKEsFbp1cxg"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">200000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ScheduleOfOptionsIndexedToIssuersEquityTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_TwMQk7VKk0eIbEu_A6DHdQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Pre-funded warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,275,913&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,275,913&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Shares available for future option grants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,649,034&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,007,335&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Outstanding options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,066,326&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,028,177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Shares reserved for employee stock purchase plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 400,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 400,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,391,273&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,711,425&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfOptionsIndexedToIssuersEquityTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_3_31_2026_us-gaap_StatementClassOfStockAxis_crvs_PreFundedWarrantEquityMember_pG3Yboioek6oDxPenlOLwA"
      decimals="INF"
      id="Tc_ww1SOYCha06aGaojTFgguQ_3_2"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">8275913</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_crvs_PreFundedWarrantEquityMember_WYZ3KbAX40KHkOolRICzyw"
      decimals="INF"
      id="Tc_qkH3bfJUzEKj-Zw2MlM0sw_3_4"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">8275913</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_3_31_2026_us-gaap_StatementClassOfStockAxis_crvs_SharesAvailableForFutureOptionGrantsEquityMember_laFqZToHYU-XM4gSwg61WA"
      decimals="INF"
      id="Tc__8WXJMKv30ep7kB0GspBJg_4_2"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">6649034</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_crvs_SharesAvailableForFutureOptionGrantsEquityMember_uY3rsda1GkefIVaYZOCIXg"
      decimals="INF"
      id="Tc_lfqMUretn0WhLGwE-KT63g_4_4"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">3007335</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_3_31_2026_us-gaap_StatementClassOfStockAxis_crvs_OutstandingOptionsEquityMember_-jXcOLXdRUmPSJboXwLFAQ"
      decimals="INF"
      id="Tc_dHa3EJUrC0eP2SQL9lYBFA_5_2"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">13066326</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_crvs_OutstandingOptionsEquityMember_b0UFSQtEOEulbCh_kct75A"
      decimals="INF"
      id="Tc_q95zmSmnhEKe5VZaO10hSw_5_4"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">14028177</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_3_31_2026_us-gaap_StatementClassOfStockAxis_crvs_SharesReservedForEmployeeStockPurchasePlanEquityMember_ANdQEPEp4UGpxOwiSjtfYw"
      decimals="INF"
      id="Tc_wSTFWyv3EEGZFv1NpUAb4Q_6_2"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">400000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2025_us-gaap_StatementClassOfStockAxis_crvs_SharesReservedForEmployeeStockPurchasePlanEquityMember_Nx9PKFTI5ku9GkWFXfmECQ"
      decimals="INF"
      id="Tc_rOwF70OnqE6WeEYQOeWjZQ_6_4"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">400000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="INF"
      id="Tc_5XxIGd1KcEquEjcsBr5AnA_7_2"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">28391273</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2025_xtJZyrXDfkObqdpgkz7UpQ"
      decimals="INF"
      id="Tc_ILWdQ9aChESRB6k7ebDwcg_7_4"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">25711425</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <crvs:EquityIncentivePlansDisclosureTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_PFNCk9BR3Eqd4eRW32RFbg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;11. Stock Option Plans&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;In February 2014, the Company adopted the 2014 Equity Incentive Plan (the &#x201c;2014 Plan&#x201d;), which was subsequently amended in November 2014, July 2015 and September 2015, under which it granted incentive stock options (&#x201c;ISOs&#x201d;) or non-qualified stock options (&#x201c;NSOs&#x201d;). Terms of stock agreements, including vesting requirements, are determined by the board of directors or a committee authorized by the board of directors, subject to the provisions of the 2014 Plan. In general, awards granted by the Company vest over four years and have a maximum exercise term of 10 years. The 2014 Plan provides that grants must be at an exercise price of 100% of fair market value of the Company&#x2019;s common stock as determined by the board of directors on the date of the grant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;In connection with the consummation of the IPO in March 2016, the 2016 Equity Incentive Award Plan (the &#x201c;2016 Plan&#x201d;) became effective. Under the 2016 Plan, ISOs, NSOs, stock purchase rights and other stock-based awards &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;may be granted. Terms of stock agreements, including vesting requirements, are determined by the board of directors or a committee authorized by the board of directors, subject to the provisions of the 2016 Plan. In general, awards granted by the Company vest over four years and have a maximum exercise term of 10 years. The 2016 Plan provides that grants must be at an exercise price of 100% of fair market value of the Company&#x2019;s common stock as determined by the board of directors on the date of the grant. In conjunction with adopting the 2016 Plan, the 2014 Plan was terminated and no further awards will be granted under the 2014 Plan. Options outstanding under the 2014 Plan as of the effective date of the 2016 Plan that are forfeited or lapse unexercised may be re-issued under the 2016 Plan, up to a maximum of 1,136,229 shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Activity under the Company&#x2019;s stock option plans is set forth below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Available&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for&#160;Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Balance at December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,007,335&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,028,177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Additional shares authorized&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,987,865&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (7,500)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14.63&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Options exercised &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (308,017)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 661,334&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (661,334)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14.23&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Balance at March&#160;31,&#160;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,649,034&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,066,326&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.76&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</crvs:EquityIncentivePlansDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_2_1_2014_To_2_28_2014_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2014Member_ZPEqkJZSKkC77f8CpQy3Og"
      id="Narr_B1ssn0d0pkK0Mg1aQu8pAg">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_2_1_2014_To_2_28_2014_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2014Member_ZPEqkJZSKkC77f8CpQy3Og"
      id="Narr_5h9js8hNjE-dDcP-Jutj6g">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_2_1_2014_To_2_28_2014_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2014Member_ZPEqkJZSKkC77f8CpQy3Og"
      decimals="INF"
      id="Narr_ZVRZc_lrEUSBkhmaiSIAjQ"
      unitRef="Unit_Standard_pure_zwdjuLpe8Um-MXpoYRfl8Q">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_3_1_2016_To_3_31_2016_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_nSKTEU2cHUaYGFDps5DZNw"
      id="Narr_-8If3gMCu02g1O5scG11lg">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_3_1_2016_To_3_31_2016_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_nSKTEU2cHUaYGFDps5DZNw"
      id="Narr_j8hL_PDqJEGuN0gsuf1OGg">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_3_1_2016_To_3_31_2016_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_nSKTEU2cHUaYGFDps5DZNw"
      decimals="INF"
      id="Narr_mYb_7J3ViUm65NpScdFALg"
      unitRef="Unit_Standard_pure_zwdjuLpe8Um-MXpoYRfl8Q">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_3_31_2016_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2014Member_HBYSs8y8e0q-y5FdS0ZbgA"
      decimals="INF"
      id="Narr_MCiLk-dTr02VbfM4XQoMIw"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_3_1_2016_To_3_31_2016_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_i1V10D_o5EOltzgKO-ZZrA"
      decimals="INF"
      id="Narr_nV0gB67ZDUii-Q10VTfsSA"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">1136229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_eqRaYtCxSkq4FIiQXxrLBw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Available&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for&#160;Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Balance at December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,007,335&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,028,177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Additional shares authorized&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,987,865&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (7,500)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14.63&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Options exercised &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (308,017)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 661,334&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (661,334)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14.23&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Balance at March&#160;31,&#160;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,649,034&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,066,326&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.76&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_2sdE3FrdcUCS_x2faPApVA"
      decimals="INF"
      id="Tc_XucXXvAhJ0qYH5gQUlFgzg_6_2"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">3007335</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_2sdE3FrdcUCS_x2faPApVA"
      decimals="INF"
      id="Tc_18tJ_BReEkW-JlvgLeWBZw_6_4"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">14028177</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_2sdE3FrdcUCS_x2faPApVA"
      decimals="2"
      id="Tc_HPxSVl0lb0enDjzg-0ccEA_6_7"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">5.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_9SSsEi9c802Zz5UyJSFtsQ"
      decimals="INF"
      id="Tc_J878ekErQkWruMoXsIFFqw_7_2"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">2987865</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_9SSsEi9c802Zz5UyJSFtsQ"
      decimals="INF"
      id="Tc_EJ1CZkuDUkaSkBhjasY1Sw_8_2"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">7500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_9SSsEi9c802Zz5UyJSFtsQ"
      decimals="INF"
      id="Tc_XVcw-VRJqU-0QRr-_F11Tg_8_4"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">7500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_9SSsEi9c802Zz5UyJSFtsQ"
      decimals="2"
      id="Tc_TSOnx3zA6EG2p6FTme1aqg_8_7"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">14.63</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_9SSsEi9c802Zz5UyJSFtsQ"
      decimals="INF"
      id="Tc_gCQIp1cj506kQ5NjWo6aMw_9_4"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">308017</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_9SSsEi9c802Zz5UyJSFtsQ"
      decimals="2"
      id="Tc_HWHNkr3xQkGjDU0yNFss9Q_9_7"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">4.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_9SSsEi9c802Zz5UyJSFtsQ"
      decimals="INF"
      id="Tc_8ZieV-T-vky9xkYca6r8ag_10_2"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">661334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_9SSsEi9c802Zz5UyJSFtsQ"
      decimals="INF"
      id="Tc_4Ht0047oi0iI4dhUcCfCDw_10_4"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">661334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_9SSsEi9c802Zz5UyJSFtsQ"
      decimals="2"
      id="Tc_f3SI2He0EUCbfc7obklqqg_10_7"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">14.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_OZWZ5jrEbUGvUd0flVPW_Q"
      decimals="INF"
      id="Tc_B1kz28NarEWO7CNZshJxLg_11_2"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">6649034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_OZWZ5jrEbUGvUd0flVPW_Q"
      decimals="INF"
      id="Tc_Z9qZdO4eykq-7Im1DpR0_A_11_4"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">13066326</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_3_31_2026_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_crvs_EquityIncentiveAwardPlan2016Member_OZWZ5jrEbUGvUd0flVPW_Q"
      decimals="2"
      id="Tc_8Wb13jCbQUiMV46h5n_vbA_11_7"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">4.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_5p7aRHOMK06a8bAMREhKKA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;12. Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The Company&#x2019;s results of operations include expenses relating to employee and non-employee stock-based awards as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:21.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:21.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,077&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 528&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,573&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 723&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,650&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_KK5pPa0UCkmvnKubU2Qd2Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The Company&#x2019;s results of operations include expenses relating to employee and non-employee stock-based awards as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:21.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:21.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,077&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 528&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,573&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 723&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:74.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,650&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_SydJ5hNnoUqd8ueH3lWPpQ"
      decimals="-3"
      id="Tc_ibt-7FWSuUSe2oCYyR2bIA_4_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1077000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_cVDT7uqBXEWvbTkAOn4YWw"
      decimals="-3"
      id="Tc_BtAb-t0HdEugA7IL7h4olw_4_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">528000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_eVV0R68k0kqMD0Z_2saoiw"
      decimals="-3"
      id="Tc_PRqJAaAhZ0KCZ_DEt_bRvA_5_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1573000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_0ugRH7hZ0kaz47JCeRx9MQ"
      decimals="-3"
      id="Tc_bzX9dou-Y02ePO3nyG9tRA_5_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">723000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_CKbHJNYZeEaJ7t5WaypU3Q_6_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">2650000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_7w7SxUvoTkS2fi6BP7Su1A_6_6"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1251000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_a5w46kUsqkW9gKqOyZaEcA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;13. Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the three months ended March 31, 2026 and 2025, the Company recorded no income tax benefits for the net operating losses (NOLs) incurred due to the uncertainty of realizing a benefit from those items. The Company continues to maintain a full valuation allowance against its net deferred tax assets.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="0"
      id="Narr_Z90yJyin5Eq8vCgYea5Q3Q"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="0"
      id="Narr_k1IXwJweXkG2h9s6yZeKUg"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_5yYVSILaxUqA0TLXOcgGeg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;14. Facility Lease&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;On October 22, 2024, the Company entered into an operating sub-sublease agreement, pursuant to which the Company sub-leased approximately 20,916 square feet of office and lab space. The sub-sublease has a term of three years commencing on February 21, 2025 with an option to extend at fair market value for an additional 27 months. The Company records rent expense on a straight-line basis over the effective term of the lease, including any free rent periods and incentives. As the interest rate implicit in lease arrangements is typically not readily available, in calculating the present value of the lease payments, the Company has utilized its incremental borrowing rate, which is determined based on the prevailing market rates for collateralized debt with maturity dates commensurate with the term of its lease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The Company&#x2019;s obligation for the payment of base rent for the premises began on the commencement date and is initially $33,833 per month, up to monthly base rent of $47,200 during the third year of the sub-sublease. In addition &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;to base rent, the Company is obligated to pay its proportionate share of taxes, insurance and operating expenses. In November 2024, the Company paid the sublandlord $231,235 in prepaid rent, which was applied to the monthly base rent and the Company&#x2019;s proportionate share of additional expenses for the first three months of the term of the sub-sublease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Although the non-cancellable lease term commenced on February 21, 2025, for purposes of determining the right-of-use asset balance, in accordance with ASC Topic 842, the Company used November 25, 2024 as the commencement date, the date on which the sublandlord granted the Company access to the premises. The sub-sublease is a net lease, as the non-lease components (i.e., common area maintenance) are paid separately from rent based on actual costs incurred. Therefore, the non-lease components were not included in the right-of-use asset and liability and are reflected as an expense in the period incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;As of March 31, 2026 and December 31, 2025, the right-of-use asset under the operating lease was approximately $0.8 million. The elements of lease expense under the operating lease for the three months ended March 31, 2026 were as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:20.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statements of operations and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:20.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;comprehensive loss location&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:41.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Costs of operating lease&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:33.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Operating lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Research and development,&lt;br/&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 230&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 113&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:41.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Costs of non-lease components (previously common area maintenance)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:33.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Research and development,&lt;br/&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 291&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 135&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:41.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other Information&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:33.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Operating cash flows used for operating lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 188&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:41.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Remaining lease term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:33.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1.9 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2.9 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;11.7%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;11.7%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"&gt;As of March 31, 2026, minimum rental commitments under this lease were as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31 (in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2026*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 358&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 566&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 924&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (90)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 834&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;* Remainder of the year&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;As of December 31, 2025, minimum rental commitments under this lease were as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31 (in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 486&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 566&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,052&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (115)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 937&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_10_22_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_KO4XiJ0y0Eewc683WEweWg"
      decimals="0"
      id="Narr_F_m755rbaEyT31bSNwTO7w"
      unitRef="Unit_Standard_sqft_HxXZ8IO5D0SV81ta1te2Pw">20916</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_10_22_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_KO4XiJ0y0Eewc683WEweWg"
      id="Narr_CF3Mch_56EiO04wBtCtYCw">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_10_22_2024_To_10_22_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_VpJmf9leeki0mF9gdl0L2g"
      id="Narr_SXPGXk-11E20t9k950tC_A">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_10_22_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_KO4XiJ0y0Eewc683WEweWg"
      id="Narr_CVMH7A6daEC6qR5pSy9lKg">P27M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeasesRentExpenseMinimumRentals
      contextRef="Duration_10_22_2024_To_10_22_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_VpJmf9leeki0mF9gdl0L2g"
      decimals="0"
      id="Narr_Lf0g-YQqkEucyqciZ1YvQw"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">33833</us-gaap:OperatingLeasesRentExpenseMinimumRentals>
    <us-gaap:OperatingLeasesRentExpenseMinimumRentals
      contextRef="Duration_10_22_2024_To_10_22_2024_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_crvs_ThirdYearOfSubleaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_frW_QJfWakWrSN17Dz5hfg"
      decimals="0"
      id="Narr_VXf59lKWYEaiT737ND-8MA"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">47200</us-gaap:OperatingLeasesRentExpenseMinimumRentals>
    <us-gaap:PrepaidRent
      contextRef="As_Of_11_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_D946TWJ6zkKBuSKvEfvEWw"
      decimals="0"
      id="Narr_1waq8hRybEKZ-QYyN-ygSw"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">231235</us-gaap:PrepaidRent>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate
      contextRef="Duration_2_21_2025_To_2_21_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_N8S53sDar0yqd8bB4rnoJA"
      id="Narr_0d8-nOAH5U-HJ28BolLZvw">false</us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_v9GABhLy30GLtxZhg92PdA"
      decimals="-5"
      id="Narr_eXKcsXWm1kiPUv847jdqjg"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_Jyih6nVRJku2Wn342lRYIg"
      decimals="-5"
      id="Narr_oDj7pP1Ia0OJlFvaBomOTA"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Group_m-yHoJ5Rc0K0bbIp3V7eRw">The elements of lease expense under the operating lease for the three months ended March 31, 2026 were as follows (in thousands):&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:20.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statements of operations and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;width:20.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;comprehensive loss location&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2026&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:41.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Costs of operating lease&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:33.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Operating lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Research and development,&lt;br/&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 230&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 113&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:41.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Costs of non-lease components (previously common area maintenance)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:33.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Research and development,&lt;br/&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 291&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 135&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:41.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other Information&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:33.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="color:#ff0000;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Operating cash flows used for operating lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 188&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:41.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Remaining lease term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:33.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1.9 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2.9 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:33.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;11.7%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;11.7%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_XaSINNDlBEGGXLQ8_-a_rg"
      decimals="-3"
      id="Tc_urUsWM_V_UWjF4LBq7aKgA_5_5"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">230000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_-5vxilaEUEie4f1HnGwt7g"
      decimals="-3"
      id="Tc_jXVuS-XuXkW4KCGHdLLeNw_5_8"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">113000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2026_To_3_31_2026_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_XaSINNDlBEGGXLQ8_-a_rg"
      decimals="-3"
      id="Tc_7-ilndUgtEmcE0jbzpJkZQ_6_5"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">61000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_-5vxilaEUEie4f1HnGwt7g"
      decimals="-3"
      id="Tc_R1hzGoVAQEyi-oNZrH97tw_6_8"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">22000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_JDukXNyxm06nzJDZ39Lg0A_7_5"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">291000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2025_To_3_31_2025_t2Dw6mdwIky0Uj4ZIkjYEg"
      decimals="-3"
      id="Tc_NCWyg6YHY0-OtAyyb_pZsg_7_8"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">135000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      decimals="-3"
      id="Tc_MgIbfgVG7ESzfe9__siezw_9_5"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">188000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      id="Narr_BPkEpNjp8kypI_XS45Mkng">P1Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_3_31_2025_tNZXFjlgt0COhU24eHoxGQ"
      id="Narr_Wurams_i20WWl23yncWhew">P2Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_3_31_2026_q9MzBqUXF0KMPcGhDT4d2A"
      decimals="3"
      id="Tc_FNex6-USUEerbLB-cWkX6Q_11_5"
      unitRef="Unit_Standard_pure_zwdjuLpe8Um-MXpoYRfl8Q">0.117</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_3_31_2025_tNZXFjlgt0COhU24eHoxGQ"
      decimals="3"
      id="Tc_exjzWNVVBEaVegoUCSGZTQ_11_8"
      unitRef="Unit_Standard_pure_zwdjuLpe8Um-MXpoYRfl8Q">0.117</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Group__eZ4x-Z1yEON54GRI2FMkA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31 (in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2026*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 358&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 566&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 924&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (90)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 834&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;* Remainder of the year&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31 (in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 486&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 566&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,052&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (115)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 937&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_v9GABhLy30GLtxZhg92PdA"
      decimals="-3"
      id="Tc_khD_GQgeF0eHRfSVtSPJ6A_2_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">358000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_v9GABhLy30GLtxZhg92PdA"
      decimals="-3"
      id="Tc_rNb1ggyBp0OXX2daauTrgw_3_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">566000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_v9GABhLy30GLtxZhg92PdA"
      decimals="-3"
      id="Tc_PWexeEYjVkiJl9pvZog4vw_4_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">924000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_v9GABhLy30GLtxZhg92PdA"
      decimals="-3"
      id="Tc_Hhh4k7UIyUGZxVQ6P9R17A_5_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">90000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_3_31_2026_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_v9GABhLy30GLtxZhg92PdA"
      decimals="-3"
      id="Tc_HJSIogXRoUO2qNn7XKzxig_6_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">834000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_Jyih6nVRJku2Wn342lRYIg"
      decimals="-3"
      id="Tc_MGn23iz04Ei5DmmgkEyT4A_2_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">486000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_Jyih6nVRJku2Wn342lRYIg"
      decimals="-3"
      id="Tc_qmvYwm5Q3E2McwpMUZ-UOQ_3_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">566000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_Jyih6nVRJku2Wn342lRYIg"
      decimals="-3"
      id="Tc_nTusVZDj1EO5B9KFxXbL1w_4_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">1052000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_Jyih6nVRJku2Wn342lRYIg"
      decimals="-3"
      id="Tc_9RvOrQ0YhE64fdCe39rNhA_5_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">115000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_crvs_OfficeAndLabSpaceLeaseMember_Jyih6nVRJku2Wn342lRYIg"
      decimals="-3"
      id="Tc_Qry10sec9UuSf9DK67Wr4A_6_3"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">937000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_qXXbgcH18U-N-Qm4ymfeDA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;15. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Pursuant to the Company&#x2019;s license agreements with each of Vernalis, Scripps and Monash, it has obligations to make future milestone and royalty payments to the respective parties. However, because these amounts are contingent, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;they have not been included on the Company&#x2019;s balance sheet. For further discussion of the Vernalis, Scripps and Monash licensing agreements, see Note 7, &#x201c;License and Collaboration Agreements.&#x201d;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Indemnifications&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware law. There have been no claims to date and the Company has a directors and officers insurance policy that may enable it to recover a portion of any amounts paid for future claims.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Legal Proceedings&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is not a party to any material legal proceedings.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Tb_Rl5VdH52GkKDNkXxuICZaA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;16. Related Party Transactions&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As part of the January 2026 follow-on public offering, 30,000 shares of common stock, at the public offering price of $22.15 per share, were sold to Puissance Capital Management, a related party. Ted Wang, Ph.D., a Co-Founder, General Manager and Director of Angel Pharmaceuticals, of which the Company holds a 49.7% ownership interest, is the founder of Puissance Capital Management.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In July 2021, Linda S. Grais, M.D., J.D., a member of the Company&#x2019;s Board of Directors, was appointed as a non-executive member of the Board of Directors of ICON plc (&#x201c;ICON&#x201d;), effective upon completion of ICON&#x2019;s acquisition of PRA Health Sciences, Inc. ICON is a clinical research organization and provides services to support the Company&#x2019;s clinical trials. During the three months ended March 31, 2026 and 2025, the Company recorded approximately $123,000 and $94,000, respectively, in clinical trial expenses under its agreements with ICON.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_23_2026_To_1_23_2026_srt_CounterpartyNameAxis_crvs_PuissanceCapitalManagementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_vaIDQou6BEeDZj4w0IamBw"
      decimals="INF"
      id="Narr_7zaZ0NNyf0CZU3iDUIB-5g"
      unitRef="Unit_Standard_shares_nOcX_oief0uW6Y9N5rHT5A">30000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_1_23_2026_srt_CounterpartyNameAxis_crvs_PuissanceCapitalManagementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_crvs_FollowOnPublicOfferingMember_hqg4T-aXuUSSmEgLg3oLVg"
      decimals="2"
      id="Narr_5dXadeEQxECr5ofWmRdjzA"
      unitRef="Unit_Divide_USD_shares_Hj7WEUoBnk6luvvaIYpAjA">22.15</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="As_Of_1_23_2026_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_crvs_AngelPharmaceuticalsLtdEquityMethodInvesteeMember_H7SnitH0TUet8vSGLhtCmw"
      decimals="3"
      id="Narr_DJcIMMDCZEqF6p43mfatYw"
      unitRef="Unit_Standard_pure_zwdjuLpe8Um-MXpoYRfl8Q">0.497</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2026_To_3_31_2026_srt_CounterpartyNameAxis_crvs_IconPlcMember_us-gaap_RelatedPartyTransactionAxis_crvs_ServicesSupportClinicalTrialsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_87RrLXQb50614pVDRnXCIw"
      decimals="0"
      id="Narr_AfM23MdmNkqs4QdcaEPhqQ"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">123000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_CounterpartyNameAxis_crvs_IconPlcMember_us-gaap_RelatedPartyTransactionAxis_crvs_ServicesSupportClinicalTrialsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_m6-TI6NhC0ODOujZoxCV1Q"
      decimals="0"
      id="Narr_FT3NAOM9tEumBZ-kvblsSw"
      unitRef="Unit_Standard_USD_xcU3Gr5AMkSGMKqkqLH6VA">94000</us-gaap:ResearchAndDevelopmentExpense>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Narr_fNNH7WRRRkq7CeF6UDCPzg">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Narr_thvp3Z72Ek-7-0NN5uf_Iw">false</ecd:Rule10b51ArrAdoptedFlag>
    <crvs:Rule10b51ArrModifiedFlag
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Narr_ohvm1PZ5fESAxV_aCHSQrw">false</crvs:Rule10b51ArrModifiedFlag>
    <crvs:NonRule10b51ArrModifiedFlag
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Narr_zMpd8GlMMEe5k0V-GTbxNA">false</crvs:NonRule10b51ArrModifiedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Narr_MXS14G6hKEGjkhMXEQmuVQ">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_1_1_2026_To_3_31_2026_GzZ0A9HXdEu5tHEUEoRd1g"
      id="Narr_FZKx0mOflE-cWWpWb1WC_w">false</ecd:Rule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
